PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Patton, BL; Chiu, AY; Sanes, JR				Patton, BL; Chiu, AY; Sanes, JR			Synaptic laminin prevents glial entry into the synaptic cleft	NATURE			English	Article							PROTEIN S-LAMININ; NEUROMUSCULAR-JUNCTIONS; SKELETAL-MUSCLE; NEURONS; REGENERATION; AXOTOMY	Presynaptic and postsynaptic membranes directly oppose each other at chemical synapses, minimizing the delay in transmitting information across the synaptic cleft. Extrasynaptic neuronal surfaces, in contrast, are almost entirely covered by processes from glial cells(1). The exclusion of glial cells from the synaptic deft, and the long-term stability of synapses, presumably result in large part from the tight adhesion between presynaptic and postsynaptic elements(2,3). Here we show that there is another requirement for synaptic maintenance: glial cells of the skeletal neuromuscular synapse, Schwann cells, are actively inhibited from entering the synaptic deft between the motor nerve terminal and the muscle fibre. One inhibitory component is laminin 11, a heterotrimeric glycoprotein that is concentrated in the synaptic cleft(4). Regulation of an inhibitory interaction between glial cells and synaptic deft components may contribute to synaptic rearrangements, and loss of this inhibition may underlie the loss of synapses that results from injury to the postsynaptic cell(5-12).	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Neurosci, Duarte, CA 91010 USA	Washington University (WUSTL); City of Hope; Beckman Research Institute of City of Hope	Sanes, JR (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid Ave,Box 8108, St Louis, MO 63110 USA.							ANTON ES, 1994, DEV BIOL, V164, P133, DOI 10.1006/dbio.1994.1186; Bargmann C, 1998, NATURE, V391, P435, DOI 10.1038/35020; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Colman DR, 1997, MOL CELL NEUROSCI, V10, P1, DOI 10.1006/mcne.1997.0648; COVAULT J, 1987, J CELL BIOL, V105, P2479, DOI 10.1083/jcb.105.6.2479; DUCHEN LW, 1974, J NEUROL SCI, V21, P391, DOI 10.1016/0022-510X(74)90041-0; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; JIRMANOVA I, 1975, J NEUROCYTOL, V4, P141, DOI 10.1007/BF01098779; Kreutzberg Georg W., 1995, P355; MATTHEWS MR, 1975, J PHYSIOL-LONDON, V245, P91, DOI 10.1113/jphysiol.1975.sp010837; MILEDI R, 1968, PROC R SOC SER B-BIO, V169, P289, DOI 10.1098/rspb.1968.0012; Milner R, 1997, DEV BIOL, V185, P215, DOI 10.1006/dbio.1997.8547; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Peters A., 1991, FINE STRUCTURE NERVO; Pfrieger FW, 1996, CURR OPIN NEUROBIOL, V6, P615, DOI 10.1016/S0959-4388(96)80093-6; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; PORTER BE, 1995, NEURON, V14, P549, DOI 10.1016/0896-6273(95)90311-9; PURVES D, 1975, J PHYSIOL-LONDON, V252, P429, DOI 10.1113/jphysiol.1975.sp011151; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; Son YJ, 1996, TRENDS NEUROSCI, V19, P280, DOI 10.1016/S0166-2236(96)10032-1; SVENSSON M, 1993, EXP NEUROL, V120, P123, DOI 10.1006/exnr.1993.1046; TITMUS MJ, 1990, PROG NEUROBIOL, V35, P1, DOI 10.1016/0301-0082(90)90039-J; VAUGHN JE, 1989, SYNAPSE, V3, P255, DOI 10.1002/syn.890030312; WINLOW W, 1975, J NEUROCYTOL, V4, P377, DOI 10.1007/BF01261371	29	114	116	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1998	393	6686					698	701		10.1038/31502	http://dx.doi.org/10.1038/31502			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641682				2022-12-28	WOS:000074289600057
J	Karjalainen, J; Kujala, UM; Kaprio, J; Sarna, S; Viitasalo, M				Karjalainen, J; Kujala, UM; Kaprio, J; Sarna, S; Viitasalo, M			Lone atrial fibrillation in vigorously exercising middle aged men: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; PREVALENCE		Cent Mil Hosp, Helsinki 00301, Finland; Univ Helsinki, Inst Biomed, Unit Sports & Exercise Med, Helsinki 00250, Finland; Univ Helsinki, Dept Publ Hlth, FIN-00290 Helsinki, Finland; Helsinki Univ Hosp, Dept Med 1, Helsinki 00290, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Karjalainen, J (corresponding author), Cent Mil Hosp, Box 50, Helsinki 00301, Finland.	jouko.kajalainen@pp.inet.fi	Kaprio, Jaakko/A-1820-2008; Kujala, Urho/AAP-2547-2020	Kaprio, Jaakko/0000-0002-3716-2455; Sarna, Seppo/0000-0003-3458-1627; Kujala, Urho/0000-0002-9262-1992				COUMEL P, 1994, EUR HEART J, V15, P9, DOI 10.1093/eurheartj/15.suppl_A.9; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; KRAHN AD, 1995, AM J MED, V98, P476, DOI 10.1016/S0002-9343(99)80348-9; KUJALA UM, 1994, METABOLISM, V43, P1255, DOI 10.1016/0026-0495(94)90219-4; MORRIS JN, 1980, LANCET, V2, P1207	5	220	224	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	1998	316	7147					1784	+		10.1136/bmj.316.7147.1784	http://dx.doi.org/10.1136/bmj.316.7147.1784			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624065	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000074286300025
J	Cachero, TG; Morielli, AD; Peralta, EG				Cachero, TG; Morielli, AD; Peralta, EG			The small GTP-binding protein RhoA regulates a delayed rectifier potassium channel	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; C3 ADP-RIBOSYLTRANSFERASE; SERINE-THREONINE KINASE; TYROSINE KINASE; ACETYLCHOLINE-RECEPTOR; PUTATIVE TARGET; FOCAL ADHESIONS; FAMILY GTPASES; K+ CHANNELS; CELLS	Tyrosine kinases activated by G protein-coupled receptors can phosphorylate and thereby suppress the activity of the delayed rectifier potassium channel Kv1.2. Using a yeast two-hybrid screen, we identified the small GTP-binding protein RhoA as a necessary component in this process. Coimmunoprecipitation experiments confirmed that RhoA associates with Kv1.2. Electrophysiological analyses revealed that overexpression of RhoA markedly reduced the basal current generated by Kv1.2 expressed in Xenopus oocytes. Furthermore, in 293 cells expressing Kv1.2 and m1 muscarinic acetylcholine receptors, inactivating RhoA using C3 exoenzyme blocked the ability of mi receptors to suppress Kv1.2 current. Therefore, these results demonstrate that RhoA regulates Kv1.2 activity and is a central component in the mechanism of receptor-mediated tyrosine kinase-dependent suppression of Kv1.2.	Harvard Univ, Dept Cellular & Mol Biol, Cambridge, MA 02138 USA	Harvard University	Peralta, EG (corresponding author), Harvard Univ, Dept Cellular & Mol Biol, Cambridge, MA 02138 USA.							AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BARRY ST, 1994, J CELL SCI, V107, P2033; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brill S, 1996, MOL CELL BIOL, V16, P4869; CARROLL RC, 1995, CURR BIOL, V5, P536, DOI 10.1016/S0960-9822(95)00106-0; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FITZGERALD EM, 1995, BIOCHEM SOC T, V23, pS193, DOI 10.1042/bst023193s; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hille B., 1992, IONIC CHANNELS EXCIT; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUANG XY, 1994, P NATL ACAD SCI USA, V91, P624, DOI 10.1073/pnas.91.2.624; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; Keller J, 1997, FEBS LETT, V403, P299, DOI 10.1016/S0014-5793(97)00067-7; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Meiri N, 1997, P NATL ACAD SCI USA, V94, P4430, DOI 10.1073/pnas.94.9.4430; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOHR C, 1990, FEBS LETT, V275, P168, DOI 10.1016/0014-5793(90)81464-Y; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PAULMICHL M, 1991, P NATL ACAD SCI USA, V88, P7892, DOI 10.1073/pnas.88.17.7892; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; SUGAI M, 1992, J BIOL CHEM, V267, P2600; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VEH RW, 1995, EUR J NEUROSCI, V7, P2189, DOI 10.1111/j.1460-9568.1995.tb00641.x; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WilkBlaszczak MA, 1997, J NEUROSCI, V17, P4094; YAMAGISHI T, 1995, EUR J PHARMACOL, V281, P151, DOI 10.1016/0014-2999(95)00240-L; YATANI A, 1991, J BIOL CHEM, V266, P22222; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHONG Y, 1995, NATURE, V375, P588, DOI 10.1038/375588a0	57	82	90	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					1077	1085		10.1016/S0092-8674(00)81212-X	http://dx.doi.org/10.1016/S0092-8674(00)81212-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635436	Bronze			2022-12-28	WOS:000074205700018
J	Yost, C; Farr, GH; Pierce, SB; Ferkey, DM; Chen, MM; Kimelman, D				Yost, C; Farr, GH; Pierce, SB; Ferkey, DM; Chen, MM; Kimelman, D			GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis	CELL			English	Article							GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR LEF-1; BETA-CATENIN; DORSOVENTRAL AXIS; SPEMANN ORGANIZER; WINGLESS SIGNAL; LAEVIS EMBRYOS; PROTEIN; LITHIUM; TAU	Dorsal accumulation of beta-catenin in early Xenopus embryos is required for body axis formation. Recent evidence indicates that beta-catenin is dorsally stabilized by the localized inhibition of the kinase Xgsk-3, utilizing a novel Wnt ligand-independent mechanism. Using a two-hybrid screen, we identified GBP, a maternal Xgsk-3-binding protein that is homologous to a T cell protooncogene in three well-conserved domains. GBP inhibits in vivo phosphorylation by Xgsk-3, and ectopic GBP expression induces an axis by stabilizing beta-catenin within Xenopus embryos. Importantly, antisense oligonucleotide depletion of the maternal GBP mRNA demonstrates that GBP is required for the establishment of the dorsal-ventral axis in Xenopus embryos. Our results define a family of GSK-3-binding proteins with roles in development and cell proliferation.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Fred Hutchinson Canc Ctr, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Kimelman, D (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.			Pierce, Sarah/0000-0001-6739-7135	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007183] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NICHD NIH HHS [T32-HDO7183, HD27262] Funding Source: Medline; NIGMS NIH HHS [T32-GM07270] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brannon M, 1996, DEV BIOL, V180, P344, DOI 10.1006/dbio.1996.0306; BYSTROFF C, 1998, IN PRESS J MOL BIOL; Carnac G, 1996, DEVELOPMENT, V122, P3055; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORNELL RA, 1994, DEVELOPMENT, V120, P453; CUI YZ, 1995, DEVELOPMENT, V121, P2177; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fagotto F, 1997, DEVELOPMENT, V124, P453; Fan MJ, 1997, DEVELOPMENT, V124, P2581; GERHART J, 1991, BOD MAR LAB, P57; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1991, METHOD CELL BIOL, V36, P213; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KUCHARZ EJ, 1988, INT J IMMUNOPHARMACO, V10, P253, DOI 10.1016/0192-0561(88)90056-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Larabell CA, 1997, J CELL BIOL, V136, P1123, DOI 10.1083/jcb.136.5.1123; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOON RT, 1998, IN PRESS BIOESSAYS; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336; PIERCE SB, 1995, DEVELOPMENT, V121, P755; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Sorensen AB, 1996, J VIROL, V70, P4063; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Vleminckx K, 1997, J CELL BIOL, V136, P411, DOI 10.1083/jcb.136.2.411; WU YY, 1991, P SOC EXP BIOL MED, V198, P620; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; [No title captured]	66	283	292	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					1031	1041		10.1016/S0092-8674(00)81208-8	http://dx.doi.org/10.1016/S0092-8674(00)81208-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635432	Bronze			2022-12-28	WOS:000074205700014
J	Costanzi, C; Pehrson, JR				Costanzi, C; Pehrson, JR			Histone macroH2A1 is concentrated in the inactive X chromosome of female mammals	NATURE			English	Article							DOSAGE COMPENSATION; XIST GENE; MOUSE; MAINTENANCE; EXPRESSION; NUCLEUS; REGION; RNA	In female mammals one of the X chromosomes is rendered almost completely transcriptionally inactive(1,2) to equalize expression of X-linked genes in males and females. The inactive X chromosome is distinguished from its active counterpart by its condensed appearance in interphase nuclei(3), late replication(4), altered DNA methylation(2), hypoacetylation of histone H4 (ref. 5), and by transcription of a large cis-acting nuclear RNA called Xist(6-10). Although it is believed that the inactivation process involves the association of specific protein(s) with the chromatin of the inactive X, no such proteins have been identified(11). We discovered a new gene family encoding a core histone which we called macroH2A (mH2A)(12,13). The amino-terminal third of mH2A proteins is similar to a full-length histone H2A, but the remaining two-thirds is unrelated to any known histones. Here we show that an mH2A1 subtype is preferentially concentrated in the inactive X chromosome of female mammals. Our results link X inactivation with a major alteration of the nucleosome, the primary structural unit of chromatin.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Pehrson, JR (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.							BARR ML, 1949, NATURE, V163, P676, DOI 10.1038/163676a0; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BRENEMAN JW, 1993, CHROMOSOMA, V102, P591, DOI 10.1007/BF00352306; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1994, NATURE, V368, P154, DOI 10.1038/368154a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; EVANS EP, 1982, NATURE, V300, P433; Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; HWA TC, 1965, HEREDITAS, V52, P320; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KASLOW DC, 1987, P NATL ACAD SCI USA, V84, P6210, DOI 10.1073/pnas.84.17.6210; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MIGEON BR, 1985, P NATL ACAD SCI USA, V82, P3390, DOI 10.1073/pnas.82.10.3390; MONESTIER M, 1994, J IMMUNOL, V152, P667; PEHRSON JR, 1992, SCIENCE, V257, P1398; Pehrson JR, 1997, J CELL BIOCHEM, V65, P107, DOI 10.1002/(SICI)1097-4644(199704)65:1<107::AID-JCB11>3.0.CO;2-H; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; Willard H, 1997, NATURE, V386, P228, DOI 10.1038/386228a0	25	463	477	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1998	393	6685					599	601		10.1038/31275	http://dx.doi.org/10.1038/31275			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634239				2022-12-28	WOS:000074150100058
J	Beecham, L				Beecham, L			King's Fund launches quality service	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1754	1754						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614048				2022-12-28	WOS:000074129500086
J	Abbate, E; Albianelli, A; Azzaroli, A; Benvenuti, M; Tesfamariam, B; Bruni, P; Cipriani, N; Clarke, RJ; Ficcarelli, G; Macchiarelli, R; Napoleone, G; Papini, M; Rook, L; Sagri, M; Tecle, TM; Torre, D; Villa, I				Abbate, E; Albianelli, A; Azzaroli, A; Benvenuti, M; Tesfamariam, B; Bruni, P; Cipriani, N; Clarke, RJ; Ficcarelli, G; Macchiarelli, R; Napoleone, G; Papini, M; Rook, L; Sagri, M; Tecle, TM; Torre, D; Villa, I			A one-million-year-old Homo cranium from the Danakil (Afar) Depression of Eritrea	NATURE			English	Article							MIDDLE-AWASH VALLEY; ETHIOPIA	One of the most contentious topics in the study of human evolution is that of the time, place and mode of origin of Homo sapiens(1-3). The discovery in the Northern Danakil (Afar) Depression, Eritrea, of a well-preserved Homo cranium with a mixture of characters typical of H. erectus and H. sapiens contributes significantly to this debate. The cranium was found in a succession of fluvio-deltaic and lacustrine deposits and is associated with a rich mammalian fauna of early to early-middle Pleistocene age. A magnetostratigraphic survey indicates two reversed and two normal magnetozones. The layer in which the cranium was found is near the top of the lower normal magnetozone, which is identified as the Jaramillo subchron. Consequently, the human remains can be dated at similar to 1 million years before present.	Univ Florence, Dipartimento Sci Terra, I-50121 Florence, Italy; Univ Florence, Sez Geol & Paleontol, Museo Storia Nat, I-50121 Florence, Italy; Eritrea Natl Museum, Asmara, Eritrea; Univ Witwatersrand, Sch Med, Dept Anat Sci, Palaeoanthropol Res Unit, ZA-2193 Johannesburg, South Africa; Museo Nazl Preistor Etnog L Pigorini, Sez Antropol, I-00144 Rome, Italy; Minist Energy Water & Mineral Resources, Dept Mines, Asmara, Eritrea; Univ Bern, Inst Mineral, Abt Isotopengeol, CH-3012 Bern, Switzerland	University of Florence; University of Florence; University of Witwatersrand; University of Bern	Abbate, E (corresponding author), Univ Florence, Dipartimento Sci Terra, I-50121 Florence, Italy.	abbate@cesitl.unifi.it	Rook, Lorenzo/D-9675-2011; Benvenuti, Marco/G-9229-2011; Rook, Lorenzo/AAA-5014-2019	Rook, Lorenzo/0000-0001-8923-5428; Rook, Lorenzo/0000-0001-8923-5428; Tecle, Tesfaldet/0000-0002-3558-5673				BANNERT D, 1970, GEOL RUNDSCH, V59, P409; BARBERI F, 1977, GEOL SOC AM BULL, V88, P1251, DOI 10.1130/0016-7606(1977)88<1251:VOASPT>2.0.CO;2; Berggren W. A., 1995, GEOCHRONOLOGY TIME S, P129, DOI DOI 10.2110/PEC.95.04.0129; Brauer G, 1997, NATURE, V386, P337, DOI 10.1038/386337a0; Brinckmann J., 1970, GEOLOGICAL SKETCHMAP; CLARK JD, 1994, SCIENCE, V264, P1907, DOI 10.1126/science.8009220; deCastro JMB, 1997, SCIENCE, V276, P1392; GARLAND CR, 1980, GEOLOGICAL SURVEY ET, V1; KALB JE, 1982, NATURE, V298, P17, DOI 10.1038/298017a0; Merla G., 1979, GEOLOGICAL MAP ETHIO; TOBIAS PVOLDUVATI, 1991, WOLP, V4, pCH5; Ward R, 1997, NATURE, V388, P225, DOI 10.1038/40746; WOLPOFF MH, HUMAN EVOLUTION, P97; Wood B., 1991, HOMINID CRANIAL REMA, V4	14	107	109	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					458	460		10.1038/30954	http://dx.doi.org/10.1038/30954			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9623999				2022-12-28	WOS:000074020000041
J	Jonsson, PV				Jonsson, PV			Letter from Reykjavik	ANNALS OF INTERNAL MEDICINE			English	Article								Medical care in Iceland can be viewed as an experiment of nature. This small island society has combined the Nordic social and welfare structures with advanced international medicine. The Vikings settled Ireland in the ninth century, and the population has remained biologically homogeneous because of its remote isolation. This homogeneity may provide a unique opportunity to contribute to the understanding of the genetics of common disorders. Iceland's isolation has also limited the resources that are available for clinical training. Therefore, it has been necessary for most physicians who graduate from the medical school at the University of Iceland to obtain postgraduate training abroad. This has been of enormous benefit to Icelandic medicine. Fewer opportunities for foreign medical graduates to train in the United States would have a substantial effect on the future practice of Icelandic medicine. The Icelandic health care system faces many challenges. Because health care spending has been reined in, priorities must be set more clearly than in the past, and heated discussions have erupted about gatekeeping and merging of hospitals. These have been "interesting times" for Icelandic medicine. Other countries may learn lessons from our medical situation: a microcosm, to be sure, but no longer an isolated one.	Reykjavik Hosp, IS-108 Reykjavik, Iceland	Landspitali National University Hospital	Jonsson, PV (corresponding author), Reykjavik Hosp, Fossvogi, IS-108 Reykjavik, Iceland.							Berrino F, 1995, IARC SCI PUBLICATION, V132; BYOCK JL, 1995, SCI AM, V272, P82, DOI 10.1038/scientificamerican0195-82; Carpenter GI, 1997, AGE AGEING, V26, P1; ENGELAND A, 1995, APMIS S, V103; *GOV COMM CHOIC HL, 1992, CHOIC HLTH CAR REP Z; Hardarson T, 1996, BRIT MED J, V313, P1613, DOI 10.1136/bmj.313.7072.1613; *HLTH CAR MED PRIO, 1995, PRIOR HEALTHC ETH EC; JOHANNESDOTTIR GB, 1994, AGR MED RES S2, V53, P512; JOHANNSSON KB, 1996, ICELANDIC MED J S34, V82, P29; LANNYTON C, 1996, POETIC EDDA; LAXNESS H, 1996, GLACIER; LAXNESS H, 1982, ATOMIC STATION; Laxness Halldor, 1997, INDEPENDENT PEOPLE; MAGNUSSON M, 1996, NJALS SAGA; *MIN HLTH, 1997, REP PRIOR HLTH CAR I; MOORE SD, 1997, WALL STREET J   0710, pB7; MOORE SD, 1997, WALL STREET J   0710, pB1; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; Palsson Hermann, 1976, EGILS SAGA; Steel K, 1996, AGING-CLIN EXP RES, V8, P295, DOI 10.1007/BF03339585; Steffensen J., 1975, MENNING MEINSEMDIR R	21	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					941	945		10.7326/0003-4819-128-11-199806010-00014	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00014			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634434				2022-12-28	WOS:000073808600010
J	Santoro, B; Liu, DT; Yao, H; Bartsch, D; Kandel, ER; Siegelbaum, SA; Tibbs, GR				Santoro, B; Liu, DT; Yao, H; Bartsch, D; Kandel, ER; Siegelbaum, SA; Tibbs, GR			Identification of a gene encoding a hyperpolarization-activated pacemaker channel of brain	CELL			English	Article							RABBIT SINOATRIAL NODE; CALF PURKINJE-FIBERS; VOLTAGE-CLAMP ANALYSIS; PACE-MAKER CURRENT; SINO-ATRIAL NODE; CURRENT I-H; VENTRICULAR MYOCYTES; XENOPUS OOCYTES; CATION CURRENT; INWARD CURRENT	The generation of pacemaker activity in heart and brain is mediated by hyperpolarization-activated cation channels that are directly regulated by cyclic nucleotides. We previously cloned a novel member of the voltage-gated K channel family from mouse brain (mBCNG-1) that contained a carboxy-terminal cyclic nucleotide-binding domain (Santoro et al., 1997) and hence proposed it to be a candidate gene for pacemaker channels. Heterologous expression of mBCNG-1 demonstrates that it does indeed code for a channel with properties indistinguishable from pacemaker channels in brain and similar to those in heart. Three additional mouse genes and two human genes closely related to mBCNG-1 display unique patterns of mRNA expression in different tissues, including brain and heart, demonstrating that these channels constitute a widely expressed gene family.	Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA; Columbia Univ, Integrated Program Cellular Mol & Biophys Studies, New York, NY 10032 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ, Dept Physiol, New York, NY 10032 USA; Columbia Univ, Dept Biochem & Biophys, New York, NY 10032 USA; Columbia Univ, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute	Tibbs, GR (corresponding author), Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA.			Santoro, Bina/0000-0002-4277-1992	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036658] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 36658-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATTWELL D, 1980, J PHYSIOL-LONDON, V309, P287, DOI 10.1113/jphysiol.1980.sp013509; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BIGGER JT, 1979, ANNU REV MED, V30, P91, DOI 10.1146/annurev.me.30.020179.000515; BROWN H, 1980, J PHYSIOL-LONDON, V308, P331, DOI 10.1113/jphysiol.1980.sp013474; BROWN HF, 1979, NATURE, V280, P235, DOI 10.1038/280235a0; CERBAI E, 1994, J PHYSIOL-LONDON, V481, P585, DOI 10.1113/jphysiol.1994.sp020465; Cerbai E, 1997, CIRCULATION, V95, P568, DOI 10.1161/01.CIR.95.3.568; CHANG F, 1991, J PHYSIOL-LONDON, V440, P367, DOI 10.1113/jphysiol.1991.sp018713; DEKIN MS, 1993, J NEUROPHYSIOL, V70, P590, DOI 10.1152/jn.1993.70.2.590; DIFRANCESCO D, 1989, SCIENCE, V243, P669, DOI 10.1126/science.2916119; DIFRANCESCO D, 1984, J PHYSIOL-LONDON, V348, P341, DOI 10.1113/jphysiol.1984.sp015114; DIFRANCESCO D, 1986, NATURE, V324, P470, DOI 10.1038/324470a0; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DIFRANCESCO D, 1981, J PHYSIOL-LONDON, V314, P359, DOI 10.1113/jphysiol.1981.sp013713; DIFRANCESCO D, 1982, J PHYSIOL-LONDON, V329, P485, DOI 10.1113/jphysiol.1982.sp014315; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FAIN GL, 1978, NATURE, V272, P467, DOI 10.1038/272467a0; FRACE AM, 1992, J PHYSIOL-LONDON, V453, P307, DOI 10.1113/jphysiol.1992.sp019230; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; HALLIWELL JV, 1982, BRAIN RES, V250, P71, DOI 10.1016/0006-8993(82)90954-4; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; Ingram SL, 1996, J PHYSIOL-LONDON, V492, P97, DOI 10.1113/jphysiol.1996.sp021292; IRISAWA H, 1993, PHYSIOL REV, V73, P197, DOI 10.1152/physrev.1993.73.1.197; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; JOHNSON SM, 1991, J NEUROPHYSIOL, V66, P744, DOI 10.1152/jn.1991.66.3.744; MACCAFERRI G, 1993, J NEUROPHYSIOL, V69, P2129, DOI 10.1152/jn.1993.69.6.2129; Maccaferri G, 1996, J PHYSIOL-LONDON, V497, P119, DOI 10.1113/jphysiol.1996.sp021754; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MAYER ML, 1983, J PHYSIOL-LONDON, V340, P19, DOI 10.1113/jphysiol.1983.sp014747; McCormick DA, 1997, ANNU REV NEUROSCI, V20, P185, DOI 10.1146/annurev.neuro.20.1.185; Miller AG, 1996, NEURON, V16, P853, DOI 10.1016/S0896-6273(00)80105-1; NOMA A, 1983, PFLUG ARCH EUR J PHY, V397, P190, DOI 10.1007/BF00584356; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; PAPE HC, 1989, NATURE, V340, P715, DOI 10.1038/340715a0; PEDARZANI P, 1995, P NATL ACAD SCI USA, V92, P11716, DOI 10.1073/pnas.92.25.11716; Robinson RB, 1997, PFLUG ARCH EUR J PHY, V433, P533, DOI 10.1007/s004240050309; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SPELLBERG RD, 1971, CHEST, V60, P246, DOI 10.1378/chest.60.3.246; Strata F, 1997, J NEUROSCI, V17, P1435; THURINGER D, 1992, J MOL CELL CARDIOL, V24, P451, DOI 10.1016/0022-2828(92)91833-Q; TSIEN RW, 1974, J GEN PHYSIOL, V64, P293, DOI 10.1085/jgp.64.3.293; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; WOLLMUTH LP, 1992, J GEN PHYSIOL, V100, P749, DOI 10.1085/jgp.100.5.749; YANAGIHARA K, 1980, PFLUG ARCH EUR J PHY, V385, P11, DOI 10.1007/BF00583909; YANG XC, 1990, J PHYSIOL-LONDON, V431, P103, DOI 10.1113/jphysiol.1990.sp018322; YU HG, 1993, CIRC RES, V72, P232, DOI 10.1161/01.RES.72.1.232; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; Zaza A, 1996, J PHYSIOL-LONDON, V491, P347, DOI 10.1113/jphysiol.1996.sp021220; ZHOU ZF, 1992, J PHYSIOL-LONDON, V453, P503, DOI 10.1113/jphysiol.1992.sp019242	54	574	605	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1998	93	5					717	729		10.1016/S0092-8674(00)81434-8	http://dx.doi.org/10.1016/S0092-8674(00)81434-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630217	hybrid			2022-12-28	WOS:000073956700009
J	Rothenberg, ME				Rothenberg, ME			Mechanisms of disease - Eosinophilia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; CATIONIC PROTEIN; 5-LIPOXYGENASE INHIBITOR; PULMONARY EOSINOPHILIA; FUNCTIONAL-PROPERTIES; AIRWAY INFLAMMATION; INTERFERON-ALPHA; HEAVY-CHAIN; ASTHMA; INTERLEUKIN-5		Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.							ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; Aldebert D, 1996, BLOOD, V87, P2354, DOI 10.1182/blood.V87.6.2354.bloodjournal8762354; BARNES PJ, 1995, QJM-MON J ASSOC PHYS, V88, P455; BARNES PJ, 1995, ANN MED, V27, P531, DOI 10.3109/07853899509002464; BEEKEN W, 1987, GUT, V28, P976, DOI 10.1136/gut.28.8.976; BOYCE JA, 1995, J EXP MED, V182, P49, DOI 10.1084/jem.182.1.49; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; CAPRON M, 1991, Annales de Parasitologie Humaine et Comparee, V66, P41; COGAN E, 1994, NEW ENGL J MED, V330, P535, DOI 10.1056/NEJM199402243300804; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; COUTANT G, 1993, ANN MED INTERNE, V144, P243; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DAVISON RA, 1985, MED CLIN N AM, V69, P751, DOI 10.1016/S0025-7125(16)31017-3; Dent G, 1996, THORAX, V51, P647, DOI 10.1136/thx.51.6.647; EGAN RW, 1995, INT ARCH ALLERGY IMM, V107, P321, DOI 10.1159/000237014; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GADDY JN, 1992, AM REV RESPIR DIS, V146, P358, DOI 10.1164/ajrccm/146.2.358; Galli SJ, 1997, J EXP MED, V186, P343, DOI 10.1084/jem.186.3.343; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; GRIMALDI JC, 1989, BLOOD, V73, P2081; Hamelmann E, 1997, P NATL ACAD SCI USA, V94, P1350, DOI 10.1073/pnas.94.4.1350; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; Hunt LW, 1996, MAYO CLIN PROC, V71, P361, DOI 10.4065/71.4.361; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kane GC, 1996, J ALLERGY CLIN IMMUN, V97, P646, DOI 10.1016/S0091-6749(96)70310-X; KANE GC, 1995, PROSTAGLANDINS, V50, P1, DOI 10.1016/0090-6980(95)00088-R; KAY AB, 1995, INT ARCH ALLERGY IMM, V107, P208, DOI 10.1159/000236979; KIPS JC, 1995, INT ARCH ALLERGY IMM, V107, P115, DOI 10.1159/000236947; Kita H, 1996, J ALLERGY CLIN IMMUN, V97, P889, DOI 10.1016/S0091-6749(96)80061-3; Kita H, 1996, J EXP MED, V183, P2421, DOI 10.1084/jem.183.6.2421; KUIJPERS TW, 1993, J EXP MED, V178, P279, DOI 10.1084/jem.178.1.279; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467, DOI 10.1164/ajrccm.152.2.7633694; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; MOQBEL R, 1994, J ALLERGY CLIN IMMUN, V94, P1183, DOI 10.1016/0091-6749(94)90330-1; MORLEY J, 1992, J AUTOIMMUN, V5, P265, DOI 10.1016/0896-8411(92)90042-O; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; PARRILLO JE, 1978, ANN INTERN MED, V89, P167, DOI 10.7326/0003-4819-89-2-167; RAND TH, 1988, INT ARCH ALLER A IMM, V87, P151, DOI 10.1159/000234665; REDIER H, 1992, J ALLERGY CLIN IMMUN, V90, P215, DOI 10.1016/0091-6749(92)90074-C; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; ROTHENBERG ME, 1987, SCIENCE, V237, P645, DOI 10.1126/science.3110954; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Rothenberg ME, 1996, MOL MED, V2, P334, DOI 10.1007/BF03401631; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHLEIMER RP, 1994, J ALLERGY CLIN IMMUN, V94, P1202, DOI 10.1016/0091-6749(94)90333-6; SHER A, 1990, J IMMUNOL, V145, P3911; Simon HU, 1997, J IMMUNOL, V158, P3902; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SNYMAN JR, 1992, EUR J CLIN PHARMACOL, V42, P359, DOI 10.1007/BF00280118; SPRY CJF, 1988, EOSINOPHILS GUIDE SC; Sternberg EM, 1996, ADV EXP MED BIOL, V398, P325; Sullivan S, 1996, J ALLERGY CLIN IMMUN, V97, P966, DOI 10.1016/S0091-6749(96)80072-8; SYMON FA, 1994, J EXP MED, V180, P371, DOI 10.1084/jem.180.1.371; VANHERWERDEN L, 1995, LANCET, V346, P1262, DOI 10.1016/S0140-6736(95)91863-9; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; WEG VB, 1993, J EXP MED, V177, P561, DOI 10.1084/jem.177.2.561; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WEIN M, 1995, AM J RESP CELL MOL, V12, P315, DOI 10.1165/ajrcmb.12.3.7532979; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; WELLER PF, 1994, BLOOD, V83, P2759, DOI 10.1182/blood.V83.10.2759.2759; YOUNG JD, 1986, NATURE, V321, P613, DOI 10.1038/321613a0	72	788	818	1	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1998	338	22					1592	1600		10.1056/NEJM199805283382206	http://dx.doi.org/10.1056/NEJM199805283382206			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ350	9603798				2022-12-28	WOS:000073852400006
J	Wachter, RM; Katz, P; Showstack, J; Bindman, AB; Goldman, L				Wachter, RM; Katz, P; Showstack, J; Bindman, AB; Goldman, L			Reorganizing an academic medical service - Impact on cost, quality, patient satisfaction, and education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TEST-ORDERING BEHAVIOR; MANAGED CARE; INTERNAL-MEDICINE; CONTROLLED TRIAL; HEALTH-CARE; PHYSICIAN; STUDENTS; SEVERITY; ILLNESS; SYSTEM	Context.-Academic medical centers are under enormous pressure to improve quality and cut costs while preserving education. Objective.-To determine whether a reorganized academic medical service, led by faculty members who attended more often and became involved earlier and more intensively in care, would lower costs without compromising quality and education, Design.-Alternate-day controlled trial. Setting.-Inpatient academic general medical service. Patients.-The 1623 patients discharged from the Moffitt-Long medical service between July 1, 1995, and June 30, 1996. Interventions.-We divided our 4-team inpatient general medical service into 2 managed care service (MCS) teams and 2 traditional service (TS) teams. The MCS faculty served as attending physicians more often and were required to provide early input into clinical decisions, Patients were assigned to teams based on alternate days of admission. Main Outcome Measures.-Outcome measures included resource use and outcomes for MCS vs TS patients, and for MCS patients vs patients seen the previous year, adjusted for demographic characteristics and case mix. Satisfaction of patients, house staff, and faculty was also assessed, as was educational emphasis. Results.-A total of 806 patients were admitted to the MCS and 817 to the TS, Demographic characteristics and case mix were similar. Clinical outcomes, including mortality and readmission rates, were also similar, as was patient satisfaction. Resident and faculty satisfaction were high on both services, The average adjusted length of stay of patients on the MCS was 4.3 days vs 4.9 days on the TS and 5 days in 1994-1995 (adjusted P=.01 for MCS vs TS; MCS vs 1994-1995, P<.001). Average adjusted hospital costs were $7007 on the MCS vs $7777 on the TS and $8078 in 1994-1995 (adjusted P=.05 for MCS vs TS; MCS vs 1994-1995, P=.002). Conclusions.-A reorganized academic medical service, led by faculty members who attended more often and became involved earlier and more intensively, resulted in significant resource savings with no changes in clinical outcomes or patient, faculty, and house staff satisfaction.	Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA; San Francisco Gen Hosp, Primary Care Res Ctr, San Francisco, CA 94110 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center	Wachter, RM (corresponding author), Univ Calif San Francisco, Sch Med, Dept Med, POB 0120, San Francisco, CA 94143 USA.		Showstack, Jonathan/L-6556-2013	Showstack, Jonathan/0000-0002-1367-419X				BAKER LC, 1993, HEALTH AFFAIR, V12, P258, DOI 10.1377/hlthaff.12.suppl_1.258; BERMAN RA, 1986, J MED EDUC, V61, P1; BERNARD AM, 1995, MED CARE, V33, P663, DOI 10.1097/00005650-199507000-00003; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BILLI JE, 1987, J GEN INTERN MED, V2, P306, DOI 10.1007/BF02596163; BRANDNER J, 1995, MANAGED CARE     JUL, P19; Cashman S B, 1990, Health Care Manage Rev, V15, P47; CEBUL RD, 1991, MED CARE, V29, pJS9; COHEN JJ, 1995, ACAD MED, V70, P381, DOI 10.1097/00001888-199505000-00013; CUMMINGS KM, 1982, MED CARE, V20, P293, DOI 10.1097/00005650-198203000-00006; Dunn D, 1996, J Health Care Finance, V22, P23; FRANKL SE, 1991, AM J MED, V90, P667; Genet C A, 1995, Nurse Pract, V20, P47; Genet C.A., 1995, NURSE PRACT, V20, P54; GIPE B, 1996, COST QUALITY, V2, P6; HORN SD, 1985, NEW ENGL J MED, V313, P20, DOI 10.1056/NEJM198507043130105; LICHTENSTEIN R, 1984, MED CARE, V22, P56, DOI 10.1097/00005650-198401000-00005; LINN LS, 1985, MED CARE, V23, P1171, DOI 10.1097/00005650-198510000-00006; MANNHEIM LM, 1990, MED CARE, V28, P29; MARTIN AR, 1980, NEW ENGL J MED, V303, P1330, DOI 10.1056/NEJM198012043032304; Moore J D Jr, 1997, Mod Healthc, V27, P54; Robinson JC, 1996, JAMA-J AM MED ASSOC, V276, P1060, DOI 10.1001/jama.276.13.1060; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P225, DOI 10.1001/jama.252.2.225; Shea S, 1996, NEW ENGL J MED, V334, P162, DOI 10.1056/NEJM199601183340307; SIMMER TL, 1991, MED CARE, V29, pJS31; Speer TL, 1997, HOSP HEALTH NETWORK, V71, P44; WACHTER R, 1997, MED PRACT MANAGE NOV, P123; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; WARTMAN SA, 1994, ARCH INTERN MED, V154, P2539, DOI 10.1001/archinte.154.22.2539; Weingarten SR, 1996, AM J RESP CRIT CARE, V153, P1110, DOI 10.1164/ajrccm.153.3.8630553; WILLIAMS SV, 1984, MED CARE, V22, P535, DOI 10.1097/00005650-198406000-00004; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1432, DOI 10.1097/00003246-199310000-00009	32	210	210	1	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1560	1565		10.1001/jama.279.19.1560	http://dx.doi.org/10.1001/jama.279.19.1560			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZN087	9605901				2022-12-28	WOS:000073608100035
J	Cavalli, G; Paro, R				Cavalli, G; Paro, R			The Drosophila Fab-7 chromosomal element conveys epigenetic inheritance during mitosis and meiosis	CELL			English	Article							POSITION-EFFECT VARIEGATION; BITHORAX COMPLEX; REGULATORY SEQUENCES; RESPONSE ELEMENT; GENE ENCODES; GAGA FACTOR; WHITE GENE; POLYCOMB; MELANOGASTER; CHROMATIN	Polycomb group (PcG) and trithorax group (trxG) gene products are responsible for the maintenance of repressed and active expression patterns of many developmentally important regulatory genes including the homeotic genes. In Drosophila embryos, Polycomb protein and the trxG protein GAGA factor colocalize at the Fab-7 DNA element of the bithorax complex. In transgenic lines, the Fab-7 element induces extensive silencing on a flanking GAL4-driven lacZ reporter and mini-white genes. However, a short single pulse of GAL4 during embryogenesis is sufficient to release PcG-dependent silencing from the transgene. Such an activated state of Fab-7 is mitotically inheritable through development and can be transmitted in a GAL4-independent manner to the subsequent generations through female meiosis. Thus, Fab-7 is a switchable chromosomal element, which can convey memory of epigenetically determined active and repressed chromatin states.	Univ Heidelberg, ZMBH, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Paro, R (corresponding author), Univ Heidelberg, ZMBH, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.		Cavalli, Giacomo/A-7958-2008; cavalli, giacomo/Z-2754-2019	Cavalli, Giacomo/0000-0003-3709-3469; cavalli, giacomo/0000-0003-3709-3469				Ahmad K, 1996, GENETICS, V144, P657; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BAKER WK, 1963, AM ZOOL, V3, P57; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CAMPBELL SD, 1991, GENETICS, V127, P367; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; CHANG YL, 1995, MOL CELL BIOL, V15, P6601; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; DORN R, 1993, GENETICS, V133, P279; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FAUVARQUE MO, 1993, GENE DEV, V7, P1508, DOI 10.1101/gad.7.8.1508; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GINDHART JG, 1995, GENETICS, V139, P797; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; GRANOK H, 1995, CURR BIOL, V5, P238, DOI 10.1016/S0960-9822(95)00048-0; Grewal SIS, 1996, CELL, V86, P95, DOI 10.1016/S0092-8674(00)80080-X; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; Hagstrom K, 1997, GENETICS, V146, P1365; Hollick JB, 1997, TRENDS GENET, V13, P302, DOI 10.1016/S0168-9525(97)01184-0; KARCH F, 1994, NUCLEIC ACIDS RES, V22, P3138, DOI 10.1093/nar/22.15.3138; KASSIS JA, 1994, GENETICS, V136, P1025; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KUZIORA MA, 1988, EMBO J, V7, P3233, DOI 10.1002/j.1460-2075.1988.tb03190.x; LEVIS R, 1985, EMBO J, V4, P3489, DOI 10.1002/j.1460-2075.1985.tb04108.x; Lyko F, 1997, NAT GENET, V16, P171, DOI 10.1038/ng0697-171; MARTIN CH, 1995, P NATL ACAD SCI USA, V92, P8398, DOI 10.1073/pnas.92.18.8398; Mihaly J, 1997, DEVELOPMENT, V124, P1809; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Paro R., 1996, EPIGENETIC MECH GENE, P507; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; PIRROTTA V, 1995, GENETICS, V141, P1429; Poux S, 1996, EMBO J, V15, P4713, DOI 10.1002/j.1460-2075.1996.tb00848.x; REIJNEN MJ, 1995, MECH DEVELOP, V53, P35, DOI 10.1016/0925-4773(95)00422-X; REUTER G, 1981, MOL GEN GENET, V182, P516, DOI 10.1007/BF00293947; REUTER G, 1985, CHROMOSOMA, V93, P132, DOI 10.1007/BF00293160; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; SIMON J, 1993, DEV BIOL, V158, P131, DOI 10.1006/dbio.1993.1174; STELLER H, 1985, EMBO J, V4, P3765, DOI 10.1002/j.1460-2075.1985.tb04146.x; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; Strutt H, 1997, MOL CELL BIOL, V17, P6773, DOI 10.1128/MCB.17.12.6773; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; Zhou JM, 1996, GENE DEV, V10, P3195, DOI 10.1101/gad.10.24.3195; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x; ZINK D, 1994, THESIS U HEIDELBERG	51	299	311	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					505	518		10.1016/S0092-8674(00)81181-2	http://dx.doi.org/10.1016/S0092-8674(00)81181-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604927	Bronze			2022-12-28	WOS:000073722200005
J	Roberts, DL; Weix, DJ; Dahms, NM; Kim, JJP				Roberts, DL; Weix, DJ; Dahms, NM; Kim, JJP			Molecular basis of lysosomal enzyme recognition: Three-dimensional structure of the cation-dependent mannose 6-phosphate receptor	CELL			English	Article							GROWTH FACTOR-II; HUMAN BETA-GLUCURONIDASE; LIGAND-BINDING; ARGININE RESIDUES; BOVINE LIVER; CLONING; EXPRESSION; SITES; GLYCOSYLATION; PURIFICATION	Targeting of newly synthesized lysosomal hydrolases to the lysosome is mediated by the cation-dependent mannose 6-phosphate receptor (CD-MPR) and the insulin-like growth factor II/cation-independent mannose 6-phosphate receptor (IGF-II/CI-MPR). The two receptors, which share sequence similarities, constitute the P-type family of animal lectins. We now report the three-dimensional structure of a glycosylation-deficient, yet fully functional form of the extracytoplasmic domain of the bovine CD-MPR (residues 3-154) complexed with mannose 6-phosphate at 1.8 Angstrom resolution. The extracytoplasmic domain of the CD-MPR crystallizes as a dimer, and each monomer folds into a nine-stranded flattened beta barrel, which bears a striking resemblance to avidin. The distance of 40 Angstrom between the two ligand-binding sites of the dimer provides a structural basis for the observed differences in binding affinity exhibited by the CD-MPR toward various lysosomal enzymes.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Dahms, NM (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.			Weix, Daniel/0000-0002-9552-3378	NIDDK NIH HHS [DK-42667] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042667, R29DK042667, R56DK042667] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARTER C, 1979, J BIOL CHEM, V246, P12219; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DAHMS NM, 1995, ARCH BIOCHEM BIOPHYS, V317, P497, DOI 10.1006/abbi.1995.1193; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DISTLER JJ, 1991, J BIOL CHEM, V266, P21687; DRICKAMER K, 1995, NAT STRUCT BIOL, V2, P437, DOI 10.1038/nsb0695-437; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; FUREY W, 1997, MACROMOLECULAR CRYST; HOFLACK B, 1987, J BIOL CHEM, V262, P123; HOFLACK B, 1985, P NATL ACAD SCI USA, V82, P4428, DOI 10.1073/pnas.82.13.4428; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOSTER A, 1991, BIOL CHEM H-S, V372, P297, DOI 10.1515/bchm3.1991.372.1.297; LI M, 1990, ARCH BIOCHEM BIOPHYS, V283, P150, DOI 10.1016/0003-9861(90)90625-9; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MA ZM, 1992, J BIOL CHEM, V267, P19017; MA ZM, 1991, J BIOL CHEM, V266, P10589; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McPherson A, 1982, PREPARATION ANAL PRO; MunierLehmann H, 1996, J BIOL CHEM, V271, P15166, DOI 10.1074/jbc.271.25.15166; MunierLehmann H, 1996, BIOCHEM SOC T, V24, P133, DOI 10.1042/bst0240133; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; OTOWINSKI Z, 1996, METHOD ENZYMOL, V276, P307; Punnonen EL, 1996, EUR J BIOCHEM, V237, P809, DOI 10.1111/j.1432-1033.1996.0809p.x; READ RA, 1986, ACTA CRYSTALLOGR D, V5, P760; ROUSSEL A, 1994, TURBOFRODO MANUAL VE; SHIPLEY JM, 1993, J BIOL CHEM, V268, P12193; Sleat DE, 1997, J BIOL CHEM, V272, P731, DOI 10.1074/jbc.272.2.731; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; TERWILLIGER T, 1994, HEAVY VERSION 3 0 MA; TONG PY, 1988, J BIOL CHEM, V263, P2585; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1988, BIOCHEM BIOPH RES CO, V152, P1248, DOI 10.1016/S0006-291X(88)80419-4; WAHEED A, 1990, BIOCHEMISTRY-US, V29, P2449, DOI 10.1021/bi00462a003; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WENDLAND M, 1989, BIOCHEM J, V260, P201, DOI 10.1042/bj2600201; WENDLAND M, 1991, J BIOL CHEM, V266, P7132; WENDLAND M, 1991, J BIOL CHEM, V266, P2917; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; ZHANG Y, 1993, BIOCHEM J, V295, P841, DOI 10.1042/bj2950841	50	92	97	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					639	648		10.1016/S0092-8674(00)81192-7	http://dx.doi.org/10.1016/S0092-8674(00)81192-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604938	Bronze			2022-12-28	WOS:000073722200016
J	Hansson, L; Zanchetti, A; Carruthers, SG; Dahlof, B; Elmfeldt, D; Julius, S; Menard, J; Rahn, KH; Wedel, H; Westerling, S				Hansson, L; Zanchetti, A; Carruthers, SG; Dahlof, B; Elmfeldt, D; Julius, S; Menard, J; Rahn, KH; Wedel, H; Westerling, S		HOT Study Grp	Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial	LANCET			English	Article							CARDIOVASCULAR MORBIDITY; MYOCARDIAL-INFARCTION; PRIMARY PREVENTION; MORTALITY; REDUCTION; BENEFITS; DISEASE; RISK	Background Despite treatment, there is often a higher incidence of cardiovascular complications in patients with hypertension than in normotensive individuals. Inadequate reduction of their blood pressure is a likely cause, but the optimum target blood pressure is not known. The impact of acetylsalicylic acid (aspirin) has never been investigated in patients with hypertension. We aimed to assess the optimum target diastolic blood pressure and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension. Methods 18 790 patients, from 26 countries, aged 50-80 years (mean 61.5 years) with hypertension and diastolic blood pressure between 100 mm Hg and 115 mm Hg (mean 105 mm Hg) were randomly assigned a target diastolic blood pressure. 6264 patients were allocated to the target pressure less than or equal to 90 mm Hg, 6264 to less than or equal to 85 mm Hg, and 6262 to less than or equal to 80 mm Hg. Felodipine was given as baseline therapy with the addition of other agents, according to a five-step regimen. In addition, 9399 patients were randomly assigned 75 mg/day acetylsalicylic acid (Bamycor, Astra) and 9391 patients were assigned placebo. Findings Diastolic blood pressure was reduced by 20.3 mm Hg, 22.3 mm Hg, and 24.3 mm Hg, in the less than or equal to 90 mm Hg, less than or equal to 85 mm Hg, and less than or equal to 80 mm Hg target groups, respectively. The lowest incidence of major cardiovascular events occurred at a mean achieved diastolic blood pressure of 82.6 mm Hg; the lowest risk of cardiovascular mortality occurred at 86.5 mm Hg. Further reduction below these blood pressures was safe. In patients with diabetes mellitus there was a 51% reduction in major cardiovascular events in target group less than or equal to 80 mm Hg compared with target group less than or equal to 90 mm Hg (p for trend=0.005). Acetylsalicylic acid reduced major cardiovascular events by 15% (p=0.03) and all myocardial infarction by 36% (p=0.002), with no effect on stroke. There were seven fatal bleeds in the acetylsalicylic acid group and eight in the placebo group, and 129 versus 70 non-fatal major bleeds in the two groups, respectively (p<0.001). Interpretation Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events. The HOT Study shows the benefits of lowering the diastolic blood pressure down to 82.6 mm Hg. Acetylsalicylic acid significantly reduced major cardiovascular events with the greatest benefit seen in all myocardial infarction. There was no effect on the incidence of stroke or fatal bleeds, but non-fatal major bleeds were twice as common.	Uppsala Univ, Dept Publ Hlth & Social Sci, S-75125 Uppsala, Sweden; Univ Milan, Osped Maggiore Milano, Ctr Fisiol Clin & Ipertens, Milan, Italy; Ist Auxol, Milan, Italy; Univ Western Ontario, London Hlth Sci Ctr, London, ON N6A 3K7, Canada; Sahlgrens Univ Hosp, Dept Med, Gothenburg, Sweden; Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden; Astra Hassle AB, Molndal, Sweden; Univ Michigan, Med Ctr, Dept Internal Med, Div Hypertens,Ctr Taubman, Ann Arbor, MI USA; Direct Gen Sante, Paris, France; Univ Munster, Med Poliklin, D-4400 Munster, Germany; Nord Sch Publ Hlth, Gothenburg, Sweden	Uppsala University; University of Milan; IRCCS Istituto Auxologico Italiano; London Health Sciences Centre; Western University (University of Western Ontario); Sahlgrenska University Hospital; Uppsala University; University of Michigan System; University of Michigan; University of Munster	Hansson, L (corresponding author), Uppsala Univ, Dept Publ Hlth & Social Sci, POB 609, S-75125 Uppsala, Sweden.		Portaluppi, Francesco/H-2206-2012	Portaluppi, Francesco/0000-0002-2948-1579; zanchetti, alberto/0000-0003-4796-7959; Tourne-Garcia, Carlos/0000-0002-4440-9268				ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1991, Lancet, V338, P1345; [Anonymous], 1993, Blood Press, V2, P62; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Breslow NE., 1987, STAT METHODS CANC RE, P81; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COLLINS R, 1994, TXB HYPERTENSION, P1156; CRUICKSHANK JM, 1987, LANCET, V1, P581; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Hansson L, 1996, J HYPERTENS, V14, P537, DOI 10.1097/00004872-199605000-00001; Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502; Hansson L., 1995, Blood Pressure, V4, P313, DOI 10.3109/08037059509077613; HANSSON L, 1990, AM J HYPERTENS, V3, P726, DOI 10.1093/ajh/3.9.726; Hansson L., 1997, Blood Pressure, V6, P313, DOI 10.3109/08037059709062088; Hansson L, 1994, Blood Press, V3, P322, DOI 10.3109/08037059409102281; HENNEKENS CH, 1989, CIRCULATION, V80, P749, DOI 10.1161/01.CIR.80.4.749; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; *IPPPSH COLL GROUP, 1985, J HYPERTENS, V36, P379; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; LINDHOLM L, 1984, ACTA MED SCAND, V216, P251; LITHELL H, IN PRESS BLOOD PRESS; Mancia G, 1997, LANCET, V349, P454, DOI 10.1016/S0140-6736(96)07099-7; O'Brien E, 1993, J HYPERTENS S2, V11, pS43; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; ROSE GA, 1982, CARDIOVASCULAR SURVE, P123; SAMUELSSON O, 1987, JAMA-J AM MED ASSOC, V258, P1768; STEWART IMG, 1979, LANCET, V1, P861; STRASSER T, 1987, MILD HYPERTENSION DR, P9; Wiklund Ingela, 1997, Blood Pressure, V6, P357, DOI 10.3109/08037059709062095; ZANCHETTI A, 1989, J HYPERTENS, V7, pS338, DOI 10.1097/00004872-198900076-00165; ZANCHETTI A, 1992, HIGH BLOOD PRESSURE, V1, P197	33	4266	4503	8	253	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 13	1998	351	9118					1755	1762		10.1016/S0140-6736(98)04311-6	http://dx.doi.org/10.1016/S0140-6736(98)04311-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635947	Green Submitted			2022-12-28	WOS:000074197600008
J	Conroy, GC; Weber, GW; Seidler, H; Tobias, PV; Kane, A; Brunsden, B				Conroy, GC; Weber, GW; Seidler, H; Tobias, PV; Kane, A; Brunsden, B			Endocranial capacity in an early hominid cranium from Sterkfontein, South Africa	SCIENCE			English	Article								Two- and three-dimensional computer imaging shows that endocranial capacity in an similar to 2.8- to 2.6-million-year-old early hominid cranium (Stw 505) from Sterkfontein, South Africa, tentatively assigned to Australopithecus africanus, is similar to 515 cubic centimeters. Although this is the largest endocranial capacity recorded for this species, it is still markedly less than anecdotal reports of endocranial capacity exceeding 600 cubic centimeters. No australopithecine has an endocranial capacity approaching, let alone exceeding, 600 cubic centimeters. Some currently accepted estimates of early hominid endocranial capacity may be inflated, suggesting that the tempo and mode of early hominid brain evolution may need reevaluation.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anthropol, St Louis, MO 63110 USA; Univ Vienna, Inst Human Biol, A-1090 Vienna, Austria; Univ Witwatersrand, Sch Med, Dept Anat Sci, Johannesburg, South Africa; Washington Univ, Sch Med, Div Plast Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); University of Vienna; University of Witwatersrand; Washington University (WUSTL); Washington University (WUSTL)	Conroy, GC (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, Box 8108, St Louis, MO 63110 USA.		Weber, Gerhard W/F-2583-2010	Weber, Gerhard W/0000-0002-8542-6259; Kane, Alex/0000-0002-1219-6536				Clarke RJ, 1994, INTEGRATIVE PATHS ES, P205; CONROY GC, 1990, SCIENCE, V247, P838, DOI 10.1126/science.2305255; Holloway R., 1983, CANADIAN J ANTHR, V3, P215; Johanson D., 1996, LUCY LANGUAGE; LOCKWOOD CS, 1997, THESIS U WITWATERSRA; Seidler H, 1997, J HUM EVOL, V33, P691, DOI 10.1006/jhev.1997.0163; Tobias P., 1994, INTEGRATIVE PATHS PA, P185; Tobias P.V., 1991, OLDUVAI GORGE, V4; TOBIAS PV, 1989, 23 ANN REPORT PALAEO; Weber G., 1998, AM J PHYS ANTHROPOL, V26, P228	10	83	92	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1730	1731		10.1126/science.280.5370.1730	http://dx.doi.org/10.1126/science.280.5370.1730			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624045				2022-12-28	WOS:000074197800034
J	McGarry, TJ; Kirschner, MW				McGarry, TJ; Kirschner, MW			Geminin, an inhibitor of DNA replication, is degraded during mitosis	CELL			English	Article							SISTER-CHROMATID SEPARATION; CELL-FREE-EXTRACTS; S-PHASE; LICENSING SYSTEM; MITOTIC CYCLINS; FISSION YEAST; XENOPUS; PROTEOLYSIS; PROTEIN; DESTRUCTION	We describe a novel 25 kDa protein, geminin, which inhibits DNA replication and is degraded during the mitotic phase of the cell cycle. Geminin has a destruction box sequence and is ubiquitinated anaphase-promoting complex (APC) in vitro. In synchronized HeLa cells, geminin is absent during G1 phase, accumulates during S, G2, and M phases, and disappears at the time of the metaphase-anaphase transition. Geminin inhibits DNA replication by preventing the incorporation of MCM complex into prereplication complex (preRC). We propose that geminin inhibits DNA replication during S, G2, and M phases and that geminin destruction at the metaphase-anaphase transition permits replication in the succeeding cell cycle.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.							AMON A, 1994, CELL, V77, P4037; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUTCHISON CJ, 1993, CELL CYCLE PRACTICAL, P177; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; Kay BK., 1991, XENOPUS LAEVIS PRACT, V36; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LENO GH, 1991, METHOD CELL BIOL, V36, P561; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUSTIG A, 1997, SCIENCE, V283, P83; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; MECHALI M, 1982, CELL, V30, P93, DOI 10.1016/0092-8674(82)90015-0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Rowles A, 1997, CURR OPIN GENET DEV, V7, P152, DOI 10.1016/S0959-437X(97)80123-2; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Stern B, 1996, TRENDS GENET, V12, P345; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4	42	708	725	1	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					1043	1053		10.1016/S0092-8674(00)81209-X	http://dx.doi.org/10.1016/S0092-8674(00)81209-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635433	Bronze			2022-12-28	WOS:000074205700015
J	Lave, JR; Keane, CR; Lin, CCJ; Ricci, EM; Amersbach, G; Lavallee, CP				Lave, JR; Keane, CR; Lin, CCJ; Ricci, EM; Amersbach, G; Lavallee, CP			Impact of a children's health insurance program on newly enrolled children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE	Context.-Although there is considerable interest in decreasing the number of US children who do not have health insurance, there is little information on the effect that health insurance has on children and their families. Objective.-To determine the impact of children's health insurance programs on access to health care and on other aspects of the lives of the children and their families. Design.-A before-after design with a control group, The families of newly enrolled children were interviewed by telephone using an identical survey instrument at baseline, at 6 months, and at 12 months after enrollment into the program. A second group of families of newly enrolled children were interviewed 12 months after the initial interviews to form a comparison sample. Setting.-The 29 counties of western Pennsylvania, an area with a population of 4.1 million people. Subjects.-A total of 887 families of newly enrolled children were randomly selected to be interviewed; 88.3% agreed to participate. Of these, 659 (84%) responded to all 3 interviews. The study population consists of 1031 newly enrolled children. The children were further classified into those who were continuously enrolled in the programs, The 330 comparison families had 460 newly enrolled children, Main Outcome Measures.-The following access measures were examined: whether the child had a usual source of medical or dental care; the number of physician visits, emergency department visits, and dentist visits; and whether the child had experienced unmet need, delayed care, or both for 6 types of care. Other indicators were restrictions on the child's usual activities and the impact of being insured or uninsured on the families. Results.-Access to health care services after enrollment in the program improved: at 12 months after enrollment, 99% of the children had a regular source of medical care, and 85% had a regular dentist, up from 89% and 60%, respectively, at baseline. The proportion of children reporting any unmet need or delayed care in the past 6 months decreased from 57% at baseline to 16% at 12 months. The proportion of children seeing a physician increased from 59% to 64%, while the proportion visiting an emergency department decreased from 22% to 17%, Since the comparison children were similar to the newly enrolled children at enrollment into the insurance programs, these findings can be attributed to the program. Restrictions on childhood activities because of lack of health insurance were eliminated. Parents reported that having health insurance reduced the amount of family stress, enabled children to get the care they needed, and eased family burdens. Conclusions.-Extending health insurance to uninsured children had a major positive impact on children and their families. In western Pennsylvania, health insurance did not lead to excessive utilization but to more appropriate utilization.	Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Serv Adm, Pittsburgh, PA 15261 USA; Western Penn Caring Fdn Children, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lave, JR (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Econ, 130 DeSoto St, Pittsburgh, PA 15261 USA.	Lave@pop.pitt.edu		Lin, Chyongchiou/0000-0001-9441-3508				ADAY L, 1989, DESIGNING CONDUCTING; BENNEFIELD RL, 1996, CURRENT POPULATION R, P60; Campbell D. T., 1966, EXPT QUASIEXPERIMENT; Cook T.C., 1979, QUASIEXPERIMENTATION; Cunningham P J, 1994, Future Child, V4, P24, DOI 10.2307/1602433; Currie J., 1994, 4644 NAT BUR EC RES; Cutler DM, 1996, Q J ECON, V111, P391, DOI 10.2307/2946683; Dubay LC, 1996, FUTURE CHILD, V6, P152, DOI 10.2307/1602499; EDWARDS AL, 1985, EXPT DESIG PSYCHOL R; *EMPL BEN RES I, 1997, EBRI NOTES, V18, P1; Gibbon D, CLASS NOTES; Hill IT, 1992, FUTURE CHILD, V2, P134; KOGAN MD, 1995, JAMA-J AM MED ASSOC, V274, P1429, DOI 10.1001/jama.274.18.1429; LAVE JR, IN PRESS J HLTH SOC; LEIBOWITZ A, 1985, PEDIATRICS, V75, P942; Lohr K N, 1986, Med Care, V24, pS1; MANNING WG, 1987, AM ECON REV, V77, P251; Martin DP, 1997, INQUIRY-J HEALTH CAR, V34, P129; MONHEIT AC, 1992, FUTURE CHILD, V2, P54; *NAT CTR HLTH STAT, VIT HLTH STAT, V10; Newacheck PW, 1996, PEDIATRICS, V97, P26; Newhouse JP, 1993, FREE ALL LESSONS RAN; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; *SPSS INC, 1996, STAT PACK SOC SCI; STODDARD JJ, 1994, NEW ENGL J MED, V330, P1421, DOI 10.1056/NEJM199405193302006; ULLRICH S, 1991, EVALUATION STUDY INN; VALDEZ R, 1986, RAND HLTH INSURANCE	27	118	118	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1820	1825		10.1001/jama.279.22.1820	http://dx.doi.org/10.1001/jama.279.22.1820			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZR635	9628715	Bronze			2022-12-28	WOS:000073998500036
J	Borg-Graham, LJ; Monier, C; Fregnac, Y				Borg-Graham, LJ; Monier, C; Fregnac, Y			Visual input evokes transient and strong shunting inhibition in visual cortical neurons	NATURE			English	Article							ORIENTATION SELECTIVITY; PYRAMIDAL CELLS; STRIATE CORTEX; CAT; MECHANISMS; EXCITATION; POTENTIALS; RESPONSES; SUMMATION; RAT	The function and nature of inhibition of neurons in the visual cortex have been the focus of both experimental and theoretical investigations(1-7), There are two ways in which inhibition can suppress synaptic excitation(2,8). In hyperpolarizing inhibition, negative and positive currents sum linearly to produce a net change in membrane potential. In contrast, shunting inhibition acts nonlinearly by causing an increase in membrane conductance; this divides the amplitude of the excitatory response. Visually evoked changes in membrane conductance have been reported to be nonsignificant or weak, supporting the hyperpolarization mode of inhibition(3,9-12). Here we present a new approach to studying inhibition that is based on in vivo whole-cell voltage clamping. This technique allows the continuous measurement of conductance dynamics during visual activation. We show, in neurons of cat primary visual cortex, that the response to optimally orientated flashed bars can increase the somatic input conductance to more than three times that of the resting state. The short latency of the visually evoked peak of conductance, and its apparent reversal potential suggest a dominant contribution from gamma-aminobutyric acid ((GABA)(A)) receptor-mediated synapses. We propose that nonlinear shunting inhibition may act during the initial stage of visual cortical processing, setting the balance between opponent 'On' and 'Off' responses in different locations of the visual receptive field.	CNRS, Inst Alfred Fessard, Equipe Cognisci, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Fregnac, Y (corresponding author), CNRS, Inst Alfred Fessard, Equipe Cognisci, Ave Terrasse, F-91198 Gif Sur Yvette, France.	fregnac@iaf.cnrs-gif.fr						ANDERSON JC, 1994, J COMP NEUROL, V341, P25, DOI 10.1002/cne.903410104; BARKER JL, 1988, J PHYSIOL-LONDON, V403, P41, DOI 10.1113/jphysiol.1988.sp017237; BERMAN NJ, 1991, J PHYSIOL-LONDON, V440, P697, DOI 10.1113/jphysiol.1991.sp018731; BERMAN NJ, 1989, J PHYSIOL-LONDON, V418, pP107; Bringuier V, 1997, J PHYSIOL-LONDON, V500, P751, DOI 10.1113/jphysiol.1997.sp022056; BUSH PC, 1994, J NEUROPHYSIOL, V71, P2183, DOI 10.1152/jn.1994.71.6.2183; Carandini M, 1997, SCIENCE, V276, P949, DOI 10.1126/science.276.5314.949; CARANDINI M, 1994, SCIENCE, V264, P1333, DOI 10.1126/science.8191289; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; DEBANNE D, 1998, J PHYSL, V500, P523; DOUGLAS RJ, 1988, NATURE, V332, P642, DOI 10.1038/332642a0; DREIFUSS JJ, 1969, EXP BRAIN RES, V9, P137, DOI 10.1007/BF00238327; Eccles, 2013, PHYSL SYNAPSES; FERSTER D, 1988, J NEUROSCI, V8, P1172; FERSTER D, 1992, J NEUROSCI, V12, P1262; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JAGADEESH B, 1993, SCIENCE, V262, P1901, DOI 10.1126/science.8266083; KOCH C, 1990, J NEUROSCI, V10, P1728; KOCH C, 1985, MODELS VISUAL CORTEX, P408; NEHER E, 1992, METHOD ENZYMOL, V207, P123; NELSON S, 1994, SCIENCE, V265, P774, DOI 10.1126/science.8047882; Orban GA, 1984, STUDIES BRAIN FUNCTI; PALMER LA, 1981, J NEUROPHYSIOL, V46, P260, DOI 10.1152/jn.1981.46.2.260; Rall W, 1964, NEURAL THEORY MODELI, P73; SHULZ D, 1993, SOC NEUR ABSTR, V19, P638; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P305, DOI 10.1113/jphysiol.1975.sp011056; SPRUSTON N, 1993, J NEUROPHYSIOL, V70, P781, DOI 10.1152/jn.1993.70.2.781; VOLGUSHEV M, 1993, VISUAL NEUROSCI, V10, P1151, DOI 10.1017/S0952523800010257; XING P, 1991, NEUROREPORT, V2, P485	29	506	515	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 28	1998	393	6683					369	373		10.1038/30735	http://dx.doi.org/10.1038/30735			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620800				2022-12-28	WOS:000073883600055
J	McLatchie, LM; Fraser, NJ; Main, MJ; Wise, A; Brown, J; Thompson, N; Solari, R; Lee, MG; Foord, SM				McLatchie, LM; Fraser, NJ; Main, MJ; Wise, A; Brown, J; Thompson, N; Solari, R; Lee, MG; Foord, SM			RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor	NATURE			English	Article							GENE-RELATED-PEPTIDE; XENOPUS-OOCYTES; ADRENOMEDULLIN; IDENTIFICATION; CLONING; CELLS; EXPRESSION; BRAIN	Calcitonin-gene-related peptide (CORP) and adrenomedullin are related peptides with distinct pharmacological profiles. Here we show that a receptor with seven transmembrane domains, the calcitonin-receptor-like receptor (CRLR), can function as either a CORP receptor or an adrenomedullin receptor, depending on which members of a new family of single-transmembrane-domain proteins, which we have called receptor-activity-modifying proteins or RAMPs, are expressed. RAMPs are required to transport CRLR to the plasma membrane. RAMP1 presents the receptor at the cell surface as a mature glycoprotein and a CORP receptor. RAMP2-transported receptors are core-glycosylated and are adrenomedullin receptors.	Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Receptor Syst Unit, Stevenage SG1 2NY, Herts, England; Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Cell Biol Unit, Stevenage SG1 2NY, Herts, England	GlaxoSmithKline; GlaxoSmithKline	Foord, SM (corresponding author), Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Receptor Syst Unit, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.							Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; Chen WJ, 1997, MOL PHARMACOL, V52, P1164, DOI 10.1124/mol.52.6.1164; FLUHMANN B, 1995, BIOCHEM BIOPH RES CO, V206, P341, DOI 10.1006/bbrc.1995.1047; FOORD SM, 1987, EUR J BIOCHEM, V170, P373, DOI 10.1111/j.1432-1033.1987.tb13710.x; GUILLEMARE E, 1994, PFLUG ARCH EUR J PHY, V428, P604, DOI 10.1007/BF00374584; Han ZQ, 1997, J MOL ENDOCRINOL, V18, P267, DOI 10.1677/jme.0.0180267; Kapas S, 1995, BIOCHEM BIOPH RES CO, V217, P832, DOI 10.1006/bbrc.1995.2847; KAPAS S, 1995, J BIOL CHEM, V270, P25344, DOI 10.1074/jbc.270.43.25344; KATO J, 1995, EUR J PHARM-MOLEC PH, V289, P383, DOI 10.1016/0922-4106(95)90117-5; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; Luebke AE, 1996, P NATL ACAD SCI USA, V93, P3455, DOI 10.1073/pnas.93.8.3455; MUFF R, 1995, EUR J ENDOCRINOL, V133, P17, DOI 10.1530/eje.0.1330017; NJUKI F, 1993, CLIN SCI, V85, P385, DOI 10.1042/cs0850385; Osajima A, 1996, EUR J PHARMACOL, V315, P319, DOI 10.1016/S0014-2999(96)00557-2; Owji AA, 1996, J NEUROCHEM, V67, P2172; Perry KJ, 1997, ENDOCRINOLOGY, V138, P3486, DOI 10.1210/en.138.8.3486; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POYNER DR, 1992, PHARMACOL THERAPEUT, V56, P23, DOI 10.1016/0163-7258(92)90036-Y; SIMMONS D, 1988, J IMMUNOL, V141, P2797; STANGL D, 1991, BIOCHEMISTRY-US, V30, P8605, DOI 10.1021/bi00099a016; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; UEZONO Y, 1993, RECEPTOR CHANNEL, V1, P233; WANG XK, 1995, P NATL ACAD SCI USA, V92, P11480, DOI 10.1073/pnas.92.25.11480; ZIMMERMANN U, 1995, PEPTIDES, V16, P421, DOI 10.1016/0196-9781(94)00195-C; Zimmermann U, 1996, BRAIN RES, V724, P238, DOI 10.1016/0006-8993(96)00337-X; ZIMMERMANN U, 1990, NEUROSCI LETT, V119, P195	27	1770	1863	0	68	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1998	393	6683					333	339		10.1038/30666	http://dx.doi.org/10.1038/30666			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620797				2022-12-28	WOS:000073883600044
J	Marshall, SW; Runyan, CW; Bangdiwala, SI; Linzer, MA; Sacks, JJ; Butts, JD				Marshall, SW; Runyan, CW; Bangdiwala, SI; Linzer, MA; Sacks, JJ; Butts, JD			Fatal residential fires - Who dies and who survives?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INJURIES; POPULATION; PREVENTION; ALCOHOL; DEATHS	Context.-The United States has one of the highest fire fatality rates in the developed world, and three quarters of these deaths are in residential fires. Objective.-To compare characteristics of those who die and those who survive in the same residential fire. Design.-Data on fatal residential fires were collected from the medical examiner and interviews with local fire officials. Setting.-North Carolina. Subjects.-Persons in residential fires with at least 1 fatality in a 1-year period. Main Outcome Measure.-Dying vs surviving a fatal residential fire that occurred with more than 1 person at home. Results.-Of the 190 decedents, 124 (65%) were male, 78 (41%) were home alone, and 69 (53%) of 130 adults who had blood alcohol measured were intoxicated (blood alcohol content >22 mmol/L [100 mg/dL]). Of the 254 persons present during fires in which more than 1 person was at home, 112 died. Individuals more likely to die thigh-vulnerability group) were younger than 5 years or 64 years or older, had a physical or cognitive disability, or were impaired by alcohol or other drugs (risk of death for group, odds ratio [OR], 4.01; 95% confidence interval [CI], 2.29-7.03). The presence of an adult with no physical or cognitive disabilities who was unimpaired by alcohol or other drugs (a potential rescuer) reduced the risk of death in the high-vulnerability group (OR, 0.49; 95% CI, 0.24-0.99) but not the low-vulnerability group. Overall, a functioning smoke detector lowered the risk of death (OR, 0.39; 95% CI, 0.18-0.83). Conclusions.-Smoke detectors were equally effective in both low-and high-vulnerability populations. The high-vulnerability group was more likely to survive if, in addition to a smoke detector, a potential rescuer was present. Further research should seek to identify prompts that facilitate speedy egress from a burning structure and that can be incorporated into residential fire alarm systems.	Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Hlth Behav & Hlth Educ, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Ctr Dis Control & Prevent, US PHS, Atlanta, GA 30333 USA; N Carolina Off Chief Med Examiner, Chapel Hill, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Centers for Disease Control & Prevention - USA; United States Public Health Service	Marshall, SW (corresponding author), Univ N Carolina, Injury Prevent Res Ctr, 204 Chase Hall,CB7505, Chapel Hill, NC 27599 USA.	smarshall@unc.edu		Marshall, Stephen/0000-0002-2664-9233	PHS HHS [R49/CCR402444] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHRENS M, 1997, US EXPERIENCE SMOKE; BAKER SP, 1992, NEW ENGL J MED, V327, P887, DOI 10.1056/NEJM199209173271213; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; BALLARD JE, 1992, AM J EPIDEMIOL, V135, P26, DOI 10.1093/oxfordjournals.aje.a116198; Barillo DJ, 1996, BURNS, V22, P85, DOI 10.1016/0305-4179(95)00095-X; CLARKE FB, 1981, B NEW YORK ACAD MED, V57, P1047; *FED EM MAN AG, 1997, FIR US 1985 1994; Gulaid J A, 1988, MMWR CDC Surveill Summ, V37, P39; GULAID JA, 1989, J AM GERIATR SOC, V37, P331, DOI 10.1111/j.1532-5415.1989.tb05500.x; HALL JR, 1985, FIRE J           SEP, P78; HALL JR, 1985, FIRE J           SEP, P37; HENDEE WR, 1987, JAMA-J AM MED ASSOC, V257, P1618; HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012; HOSMER DW, 1989, APPL LOGISTIC REGRES; HOWLAND J, 1987, PUBLIC HEALTH REP, V102, P475; KARTR MJ, 1997, NFPA J           SEP, P77; Mallonee S, 1996, NEW ENGL J MED, V335, P27, DOI 10.1056/NEJM199607043350106; MCLOUGHLIN E, 1990, AM J DIS CHILD, V144, P677, DOI 10.1001/archpedi.1990.02150300075020; MIERLEY MC, 1983, JAMA-J AM MED ASSOC, V249, P1466, DOI 10.1001/jama.249.11.1466; PATETTA MJ, 1990, AM J PUBLIC HEALTH, V80, P1116, DOI 10.2105/AJPH.80.9.1116; ROHR KD, 1997, US EXPERIENCE SPRINK; Rothman K, 1986, MODERN EPIDEMIOLOGY; RUNYAN CW, 1992, NEW ENGL J MED, V327, P859, DOI 10.1056/NEJM199209173271207; Shah BV, 1996, SUDAAN USERS MANUAL	24	135	137	0	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1998	279	20					1633	1637		10.1001/jama.279.20.1633	http://dx.doi.org/10.1001/jama.279.20.1633			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP489	9613913				2022-12-28	WOS:000073758600033
J	Schneider, EC; Epstein, AM				Schneider, EC; Epstein, AM			Use of public performance reports - A survey of patients undergoing cardiac surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BYPASS GRAFT-SURGERY; QUALITY; MORTALITY; CARE	Context.-Publicly released performance reports ("report cards") are expected to foster competition on the basis of quality. Proponents frequently cite the need to inform patient choice of physicians and hospitals as a central element of this strategy. Objective.-To examine the awareness and use of a statewide consumer guide that provides risk-adjusted, in-hospital mortality ratings of hospitals that provide cardiac surgery. Design.-Telephone survey conducted in 1996. Setting.-Pennsylvania, where since 1992, the Pennsylvania Consumer Guide to Coronary Artery Bypass Graft [CABG] Surgery has provided risk-adjusted mortality ratings of all cardiac surgeons and hospitals in the state. Participants.-A total of 474 (70%) of 673 eligible patients who had undergone CABG surgery during the previous year at 1 of 4 hospitals listed in the Consumer Guide as having average mortality rates between 1% and 5% were successfully contacted. Main Outcome Measures.-Patients' awareness of the Consumer Guide, their knowledge of its ratings, their degree of interest in the report, and barriers to its use. Results.-Ninety-three patients (20%) were aware of the Consumer Guide, but only 56 (12%) knew about it before surgery. Among these 56 patients, 18 reported knowing the hospital rating and 7 reported knowing the surgeon rating, 11 said hospital and/or surgeon ratings had a moderate or major impact on their decision making, but only 4 were able to specify either or both correctly. When the Consumer Guide was described to all patients, 264 (56%) were "very" or "somewhat" interested in seeing a copy, and 273 (58%) reported that they probably or definitely would change surgeons if they learned that their surgeon had a higher than expected mortality rate in the previous year. A short time window for decision making and a limited awareness of alternative hospitals within a reasonable distance of home were identified as important barriers to use. Conclusions.-Only 12% of patients surveyed reported awareness of a prominent report on cardiac surgery mortality before undergoing cardiac surgery. Fewer than 1% knew the correct rating of their surgeon or hospital and reported that it had a moderate or major impact on their selection of provider. Efforts to aid patient decision making with performance reports are unlikely to succeed without a tailored and intensive program for dissemination and patient education.	Harvard Univ, Sch Publ Hlth,Dept Hlth Policy & Management, Brigham & Womens Hosp, Div Gen Intern Med,Sect Hlth Serv & Pol Res, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard T.H. Chan School of Public Health	Epstein, AM (corresponding author), Harvard Univ, Sch Publ Hlth,Dept Hlth Policy & Management, Brigham & Womens Hosp, Div Gen Intern Med,Sect Hlth Serv & Pol Res, 677 Huntington Ave, Boston, MA 02115 USA.			Schneider, Eric/0000-0002-1132-5084	BHP HRSA HHS [5T 32 PE 11001-8] Funding Source: Medline	BHP HRSA HHS		*AG HLTH CAR POL R, 1995, AHCPR PUBL; Bentley J M, 1998, Jt Comm J Qual Improv, V24, P40; BLAU SP, 1997, CONSUMERS DIGEST, V36, P40; *CA OFF STAT HLTH, 1993, ANN REP CAL HOSP OUT, V1; Comarow A, 1997, US News World Rep, V123, P68; EdgmanLevitan S, 1996, HEALTH AFFAIR, V15, P42, DOI 10.1377/hlthaff.15.4.42; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; Hannan EL, 1997, AM HEART J, V134, P55, DOI 10.1016/S0002-8703(97)70106-6; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; Hibbard JH, 1997, HEALTH AFFAIR, V16, P218, DOI 10.1377/hlthaff.16.3.218; Localio AR, 1997, MED CARE, V35, P272, DOI 10.1097/00005650-199703000-00007; LOHR KN, 1990, NEW ENGL J MED, V322, P707, DOI 10.1056/NEJM199003083221031; Longo DR, 1997, JAMA-J AM MED ASSOC, V278, P1579, DOI 10.1001/jama.278.19.1579; LUFT HS, 1993, JAMA-J AM MED ASSOC, V270, P331, DOI 10.1001/jama.270.3.331; LUFT HS, 1986, JAMA-J AM MED ASSOC, V255, P2780, DOI 10.1001/jama.255.20.2780; McMullan M, 1996, HEALTH CARE FINANC R, V18, P9; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; *PA HLTH CAR COST, 1994, CONS GUID COR ART BY, V3; *PA HLTH CAR COST, 1992, CONS GUID COR ART BY, V1; *PA HLTH CAR COST, 1995, CONS GUID COR ART BY, V4; *PA HLTH CAR COST, 1994, CONS GUID COR ART BY, V2; Podolsky D, 1993, US News World Rep, V115, P66; Quinn J B, 1994, Newsweek, V124, P57; Rainwater J A, 1998, Jt Comm J Qual Improv, V24, P31; Robinson S, 1997, JOINT COMM J QUAL IM, V23, P239, DOI 10.1016/S1070-3241(16)30313-3; Schneider EC, 1996, NEW ENGL J MED, V335, P251, DOI 10.1056/NEJM199607253350406; SILBER JH, 1995, JAMA-J AM MED ASSOC, V274, P317, DOI 10.1001/jama.274.4.317; THOMAS JW, 1993, INQUIRY-J HEALTH CAR, V30, P6; *US GEN ACC OFF, 1994, PUBL HEHS; *US GEN ACC OFF, 1995, PUBL HEHS	32	313	315	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1998	279	20					1638	1642		10.1001/jama.279.20.1638	http://dx.doi.org/10.1001/jama.279.20.1638			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP489	9613914	Bronze			2022-12-28	WOS:000073758600034
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Zeptomolar damage	SCIENCE			English	Editorial Material																		Le XC, 1998, SCIENCE, V280, P1066, DOI 10.1126/science.280.5366.1066	1	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1101	1102						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9616083				2022-12-28	WOS:000073663600054
J	Nuorti, JP; Butler, JC; Crutcher, JM; Guevara, R; Welch, D; Holder, P; Elliott, JA				Nuorti, JP; Butler, JC; Crutcher, JM; Guevara, R; Welch, D; Holder, P; Elliott, JA			An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	35th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 15-18, 1996	NEW ORLEANS, LOUISIANA				TERM-CARE FACILITIES; STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE; UNITED-STATES; RISK-FACTORS; POLYSACCHARIDE VACCINE; ANTIBIOTIC-THERAPY; HOSPITAL OUTBREAK; CHILDREN; INFECTIONS	Background Outbreaks of pneumococcal disease are uncommon and have occurred mainly in institutional settings. Epidemic, invasive, drug-resistant pneumococcal disease has not been seen among adults in the United States. In February 1996, there was an outbreak of multidrug-resistant pneumococcal pneumonia among the residents of a nursing home in rural Oklahoma. Methods We obtained nasopharyngeai swabs for culture from residents and employees. Streptococcus pneumoniae isolates were serotyped and compared by pulsed-field gel electrophoresis. A retrospective cohort study was conducted to identify factors associated with colonization and disease. Results Pneumonia developed in 11 of 84 residents (13 percent), 3 of whom died. Multidrug-resistant S. pneumoniae, serotype 23F, was isolated from blood and sputum from 7 of the 11 residents with pneumonia (64 percent) and from nasopharyngeal specimens from 17 of the 74 residents tested (23 percent) and 2 of the 69 employees tested (3 percent). All the serotype 23F isolates were identical according to pulsed-field gel electrophoresis. Recent use of antibiotics was associated with both colonization (relative risk, 2.3; 95 percent confidence interval, 1.3 to 4.2) and disease (relative risk, 3.6; 95 percent confidence interval, 1.2 to 10.8). Only three residents (4 percent) had undergone pneumococcal vaccination. After residents received pneumococcal vaccine and prophylactic antibiotics, there were no additional cases of pneumonia, and the rates of carriage decreased substantially. Conclusions In this outbreak a single pneumococcal strain was disseminated among the residents and employees of a nursing home. The high prevalence of colonization with a virulent organism in an unvaccinated population contributed to the high attack rate. Clusters of pneumococcal disease may be underrecognized in nursing homes, and wider use of pneumococcal vaccine is important to prevent institutional outbreaks of drug-resistant S. pneumoniae infection. (N Engl J Med 1998;338:1861-8.) (C) 1998, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Resp Dis Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Epidem Intelligence Serv, Atlanta, GA 30333 USA; Oklahoma State Dept Hlth, Oklahoma City, OK USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Oklahoma System; University of Oklahoma Health Sciences Center	Butler, JC (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Resp Dis Branch, MS C-23,1600 Clifton Rd, Atlanta, GA 30333 USA.							[Anonymous], 1997, MMWR MORB MORTAL WKL, V46, P1; Arnold KE, 1996, J PEDIATR-US, V128, P757, DOI 10.1016/S0022-3476(96)70326-8; AUSTRIAN R, 1986, J ANTIMICROB CHEMOTH, V18, P35, DOI 10.1093/jac/18.Supplement_A.35; BARNES DM, 1995, J INFECT DIS, V171, P890, DOI 10.1093/infdis/171.4.890; BECKSAGUE C, 1994, INFECT CONT HOSP EP, V15, P494; BERK SL, 1985, SOUTHERN MED J, V78, P159, DOI 10.1097/00007611-198502000-00010; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; Butler JC, 1996, J INFECT DIS, V174, P986, DOI 10.1093/infdis/174.5.986; CAPUTO GM, 1993, ARCH INTERN MED, V153, P1301, DOI 10.1001/archinte.153.11.1301; CARTER R, 1997, 37 INT C ANT AG CHEM, P55; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; CRAIG AS, 1997, 35 ANNM SAN FRANC SE, P77; Dean A.G., 1994, EPI INFO VERSION 6 W; DEMARIA A, 1980, JAMA-J AM MED ASSOC, V244, P1446, DOI 10.1001/jama.244.13.1446; DOUGLAS RM, 1986, AM J DIS CHILD, V140, P1183, DOI 10.1001/archpedi.1986.02140250109044; DUCHIN JS, 1995, PEDIATR INFECT DIS J, V14, P745, DOI 10.1097/00006454-199509000-00004; Facklam RR, 1991, MANUAL CLIN MICROBIO, P238; FENOLL A, 1991, REV INFECT DIS, V13, P56; Finland M, 1942, MEDICINE, V21, P307, DOI 10.1097/00005792-194209010-00003; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607; GARDNER P, 1993, NEW ENGL J MED, V328, P1252, DOI 10.1056/NEJM199304293281708; GARIBALDI RA, 1981, NEW ENGL J MED, V305, P731, DOI 10.1056/NEJM198109243051304; GESLIN P, 1992, CLIN INFECT DIS, V15, P95, DOI 10.1093/clinids/15.1.95; GOULD FK, 1987, J INFECTION, V15, P77, DOI 10.1016/S0163-4453(87)91576-3; GRAY GC, 1994, AM J EPIDEMIOL, V139, P793, DOI 10.1093/oxfordjournals.aje.a117076; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HAGLUND LA, 1993, J INFECT DIS, V168, P1532, DOI 10.1093/infdis/168.6.1532; HENDERSON FW, 1988, J INFECT DIS, V157, P256, DOI 10.1093/infdis/157.2.256; Herrmann KL, 1995, DIAGNOSTIC PROCEDURE, V7th, P121; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; HOGE CW, 1994, NEW ENGL J MED, V331, P643, DOI 10.1056/NEJM199409083311004; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; JONES SR, 1987, AM J MED, V83, P499, DOI 10.1016/0002-9343(87)90761-3; KATZ PR, 1990, ARCH INTERN MED, V150, P1465, DOI 10.1001/archinte.150.7.1465; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P320; KOORNHOF HJ, 1992, CLIN INFECT DIS, V15, P84, DOI 10.1093/clinids/15.1.84; MACLEOD CM, 1945, J EXP MED, V82, P445, DOI 10.1084/jem.82.6.445; MANDIGERS CMPW, 1994, EUR RESPIR J, V7, P1635, DOI 10.1183/09031936.94.07091635; Mannheimer SB, 1996, J INFECT DIS, V174, P513, DOI 10.1093/infdis/174.3.513; Marrie TJ, 1996, DRUG AGING, V8, P338, DOI 10.2165/00002512-199608050-00003; MCDOUGAL LK, 1995, ANTIMICROB AGENTS CH, V39, P2282, DOI 10.1128/AAC.39.10.2282; MCDOUGAL LK, 1992, ANTIMICROB AGENTS CH, V36, P2176, DOI 10.1128/AAC.36.10.2176; MERCAT A, 1991, CHEST, V99, P147, DOI 10.1378/chest.99.1.147; MILLAR MR, 1994, J HOSP INFECT, V27, P99, DOI 10.1016/0195-6701(94)90002-7; MOORE EP, 1988, J INFECTION, V16, P199, DOI 10.1016/S0163-4453(88)94147-3; MUSHER DM, 1993, CLIN INFECT DIS, V17, P66, DOI 10.1093/clinids/17.1.66; Musher DM, 1997, CLIN INFECT DIS, V24, P441, DOI 10.1093/clinids/24.3.441; *NCCLS, 1993, M7A3 NCCLS; Nicolle LE, 1996, INFECT CONT HOSP EP, V17, P119; Ortqvist A, 1998, LANCET, V351, P399, DOI 10.1016/S0140-6736(97)07358-3; PALLARES R, 1987, NEW ENGL J MED, V317, P18, DOI 10.1056/NEJM198707023170104; Plouffe JF, 1996, JAMA-J AM MED ASSOC, V275, P194, DOI 10.1001/jama.275.3.194; QUICK RE, 1993, AM J MED, V94, P149, DOI 10.1016/0002-9343(93)90176-P; RADETSKY MS, 1981, LANCET, V2, P771; RAUCH AM, 1990, AM J DIS CHILD, V144, P923, DOI 10.1001/archpedi.1990.02150320087033; REICHLER MR, 1995, J INFECT DIS, V171, P1491, DOI 10.1093/infdis/171.6.1491; Reichler MR, 1996, J INFECT DIS, V173, P374, DOI 10.1093/infdis/173.2.374; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; SCHARTZ JS, 1988, ANN INTERN MED, V109, P762; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SIMBERKOFF MS, 1986, NEW ENGL J MED, V315, P1318, DOI 10.1056/NEJM198611203152104; SIMS RV, 1988, ANN INTERN MED, V108, P653, DOI 10.7326/0003-4819-108-5-653; Sisk JE, 1997, JAMA-J AM MED ASSOC, V278, P1333, DOI 10.1001/jama.278.16.1333; Smillie WG, 1938, AM J PUBLIC HEALTH N, V28, P293, DOI 10.2105/AJPH.28.3.293; Snow R, 1995, PUBLIC HEALTH REP, V110, P720; STRAHAN GW, 1997, ADV DATA VITAL HLTH, V280; Strausbaugh LJ, 1996, INFECT CONT HOSP EP, V17, P129; TAN TQ, 1993, PEDIATRICS, V92, P761; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; ZIMMER JG, 1986, J AM GERIATR SOC, V34, P703, DOI 10.1111/j.1532-5415.1986.tb04301.x; 1996, MMWR MORB MORTAL WKL, V45, P853; 1997, MMWR MORB MORTAL WKL, V46, P60; 1995, MMWR MORB MORTAL WKL, V43, P949; 1996, MMWR MORTAL WKLY REP, V45, P1; 1994, MMWR MORB MORTAL WKL, V43, P23; 1995, MMWR MORB MORTAL WKL, V44, P97	78	190	193	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1998	338	26					1861	1868		10.1056/NEJM199806253382601	http://dx.doi.org/10.1056/NEJM199806253382601			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV898	9637804	Bronze			2022-12-28	WOS:000074352800001
J	Bellen, HJ				Bellen, HJ			The fruit fly: A model organism to study the genetics of alcohol abuse and addiction?	CELL			English	Review							DROSOPHILA-MELANOGASTER		Baylor Coll Med, Howard Hughes Med Inst, Dept Mol & Human Genet, Program Dev Biol, Houston, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute	Bellen, HJ (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, Dept Mol & Human Genet, Program Dev Biol, Houston, TX 77030 USA.			Bellen, Hugo/0000-0001-5992-5989				BELLEN HJ, 1987, GENETICS, V115, P153; CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604; COHAN FM, 1986, GENETICS, V114, P145; COHAN FM, 1985, EVOLUTION, V39, P278, DOI 10.1111/j.1558-5646.1985.tb05666.x; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; FEANY MB, 1995, SCIENCE, V268, P869, DOI 10.1126/science.7754370; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45; LOOMIS WF, 1998, IN PRESS MICROBIOL M; McClung C, 1998, CURR BIOL, V8, P109, DOI 10.1016/S0960-9822(98)70041-7; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66; SCHUCKIT MA, 1994, AM J PSYCHIAT, V151, P184; Tabakoff B, 1996, NEURON, V16, P909, DOI 10.1016/S0896-6273(00)80113-0; ZHONG Y, 1995, NATURE, V375, P588, DOI 10.1038/375588a0	18	29	34	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					909	912		10.1016/S0092-8674(00)81195-2	http://dx.doi.org/10.1016/S0092-8674(00)81195-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635419	Bronze			2022-12-28	WOS:000074205700001
J	Stipe, BC; Rezaei, MA; Ho, W				Stipe, BC; Rezaei, MA; Ho, W			Single-molecule vibrational spectroscopy and microscopy	SCIENCE			English	Article							ELECTRON-TUNNELING SPECTROSCOPY; CRYSTAL SURFACES; METAL TIP; ACETYLENE; CU(100); SENSITIVITY; ADSORPTION	Vibrational spectra for a single molecule adsorbed on a solid surface have been obtained with a scanning tunneling microscope (STM). Inelastic electron tunneling spectra for an isolated acetylene (C2H2) molecule adsorbed on the copper (100) surface showed an increase in the tunneling conductance at 358 millivolts, resulting from excitation of the C-H stretch mode. An isotopic shift to 266 millivolts was observed for deuterated acetylene (C2D2). Vibrational microscopy from spatial imaging of the inelastic tunneling channels yielded additional data to further distinguish and characterize the two isotopes. Single-molecule vibrational analysis should lead to better understanding and control of surface chemistry at the atomic level.	Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA; Cornell Univ, Ctr Mat Res, Ithaca, NY 14853 USA	Cornell University; Cornell University	Ho, W (corresponding author), Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA.							ARVANITIS D, 1986, SURF SCI, V178, P686, DOI 10.1016/0039-6028(86)90344-4; AVERY NR, 1985, J AM CHEM SOC, V107, P6711, DOI 10.1021/ja00309a050; BANDY BJ, 1984, SURF SCI, V139, P87, DOI 10.1016/0039-6028(84)90010-4; BINNIG G, 1985, PHYS REV B, V32, P1336, DOI 10.1103/PhysRevB.32.1336; GATA MA, 1993, PHYS REV B, V47, P13797, DOI 10.1103/PhysRevB.47.13797; GREGORY S, 1990, PHYS REV LETT, V64, P689, DOI 10.1103/PhysRevLett.64.689; HAMMERS RJ, 1986, PHYS REV LETT, V56, P1972; Hansma P. K., 1982, TUNNELING SPECTROSCO; HANSMA PK, 1977, PHYS REP, V30, P145, DOI 10.1016/0370-1573(77)90054-0; Hu XF, 1996, SURF SCI, V365, P319, DOI 10.1016/0039-6028(96)00725-X; Ibach H., 1982, ELECT ENERGY LOSS SP; JAKLEVIC RC, 1966, PHYS REV LETT, V17, P1139, DOI 10.1103/PhysRevLett.17.1139; KROEKER RM, 1977, SURF SCI, V67, P362, DOI 10.1016/0039-6028(77)90391-0; MARINOVA TS, 1987, SURF SCI, V191, P66, DOI 10.1016/S0039-6028(87)81048-8; PERSSON BNJ, 1987, PHYS REV LETT, V59, P339, DOI 10.1103/PhysRevLett.59.339; PERSSON BNJ, 1986, SOLID STATE COMMUN, V57, P769, DOI 10.1016/0038-1098(86)90856-2; SHEPPARD N, 1986, J ELECTRON SPECTROSC, V38, P175, DOI 10.1016/0368-2048(86)85087-3; SMITH DPE, 1987, J CHEM PHYS, V86, P6034, DOI 10.1063/1.452491; Stipe BC, 1997, J CHEM PHYS, V107, P6443, DOI 10.1063/1.474304; WEINBERG WH, 1978, ANNU REV PHYS CHEM, V29, P115, DOI 10.1146/annurev.pc.29.100178.000555; Wolfram T., 1978, INELASTIC ELECT TUNN	21	1034	1048	11	392	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1732	1735		10.1126/science.280.5370.1732	http://dx.doi.org/10.1126/science.280.5370.1732			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624046				2022-12-28	WOS:000074197800035
J	Salit, SA; Kuhn, EM; Hartz, AJ; Vu, JM; Mosso, AL				Salit, SA; Kuhn, EM; Hartz, AJ; Vu, JM; Mosso, AL			Hospitalization costs associated with homelessness in New York City	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOCIOECONOMIC-STATUS; PHYSICAL HEALTH; ADULTS	Background Homelessness is believed to be a cause of health problems and high medical costs, but data supporting this association have been difficult to obtain. We compared lengths of stay and reasons for hospital admission among homeless and other low-income persons in New York City to estimate the hospitalization costs associated with homelessness. Methods We obtained hospital-discharge data on 18,864 admissions of homeless adults to New York City's public general hospitals (excluding admissions for childbirth) and 383,986 nonmaternity admissions of other low-income adults to all general hospitals in New York City during 1992 and 1993. The differences in length of stay were adjusted for diagnosis-related group, principal diagnosis, selected coexisting illnesses, and demographic characteristics. Results Of the admissions of homeless people, 51.5 percent were for treatment of substance abuse or mental illness, as compared with 22.8 percent for I the other low-income patients, and another 19.7 percent of the admissions of homeless people were for trauma, respiratory disorders, skin disorders, and infectious diseases (excluding the acquired immunodeficiency syndrome [AIDS]), many of which are potentially preventable medical conditions. For the homeless, 80.6 percent of the admissions involved either a principal or a secondary diagnosis of substance abuse or mental illness - roughly twice the rates for the other patients. The homeless patients stayed 4.1 days, or 36 percent, longer per admission on average than the other patients, even after adjustments were made for differences in the rates of substance abuse and mental illness and other clinical and demographic characteristics. The costs of the additional days per discharge averaged $4,094 for psychiatric patients, $3,370 for patients with AIDS, and $2,414 for all types of patients. Conclusions Homelessness is associated with substantial excess costs per hospital stay in New York City. Decisions to fund housing and supportive services for the homeless should take into account the potential of these services to reduce the high costs of hospitalization in this population. (C) 1998, Massachusetts Medical Society.	New York City Hlth & Hosp Corp, New York, NY USA; Med Coll Wisconsin, Dept Emergency Med, Milwaukee, WI 53226 USA; Univ Iowa, Dept Family Med, Iowa City, IA USA; Univ Iowa, Publ Policy Ctr, Iowa City, IA USA	Medical College of Wisconsin; University of Iowa; University of Iowa	Salit, SA (corresponding author), United Hosp Fund, Empire State Bldg,350 5th Ave,23rd Fl, New York, NY 10118 USA.							[Anonymous], AM STAT; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BREAKEY WR, 1989, JAMA-J AM MED ASSOC, V262, P1352, DOI 10.1001/jama.262.10.1352; BRICKNER PW, 1990, SAFETY NET HLTH SOCI; BRICKNER PW, 1987, HLTH CARE HOMELESS P; Committee on Health Care for Homeless People, 1988, HOM HLTH HUM NEEDS; EPSTEIN AM, 1990, NEW ENGL J MED, V322, P1122, DOI 10.1056/NEJM199004193221606; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P1973, DOI 10.1001/jama.262.14.1973; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P3132; HIBBS JR, 1994, NEW ENGL J MED, V331, P304, DOI 10.1056/NEJM199408043310506; HOLLOWAY L, 1996, NY TIMES        0831, pA1; Jencks Christopher, 1994, HOMELESS; Kennedy Randy, 1997, NEW YORK TIMES  1210, pB1; *NY CIT HUM RES AD, 1995, HRA FACTS AUG 1995; ROPERS RH, 1987, SOC SCI MED, V24, P669, DOI 10.1016/0277-9536(87)90310-8; ROSENHECK R, 1993, HOSP COMMUNITY PSYCH, V44, P1166; ROSSI P, 1989, DOWN OUT AM ORIGINS; *SAS I, 1989, SAS STAT US GUID VER, V2; STRUENING EL, 1990, J SOC ISSUES, V46, P65, DOI 10.1111/j.1540-4560.1990.tb01799.x; WRIGHT JD, 1987, HOMELESSNESS HLTH	20	218	218	3	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1998	338	24					1734	1740		10.1056/NEJM199806113382406	http://dx.doi.org/10.1056/NEJM199806113382406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZT654	9624194				2022-12-28	WOS:000074109800006
J	Rayman, RB				Rayman, RB			Aerospace medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Aerosp Med Assoc, Alexandria, VA 22314 USA		Rayman, RB (corresponding author), Aerosp Med Assoc, 320 S Henry St, Alexandria, VA 22314 USA.							Aerosp Med Assoc, 1998, AVIAT SPACE ENVIR MD, V69, P427; *AIR TRANSP ASS AM, 1997, 97MED42 AIR TRANSP A; Bashshur R L, 1997, Telemed J, V3, P113, DOI 10.1089/tmj.1.1997.3.113; Doarn CR, 1998, TELEMED J, V4, P19, DOI 10.1089/tmj.1.1998.4.19; Houtchens BA, 1993, PREHOSP DISASTER MED, V8, P57; McKenas DK, 1997, AVIAT SPACE ENVIR MD, V68, P365; NewsonSmith MS, 1997, AVIAT SPACE ENVIR MD, V68, P1134; ORourke MF, 1997, CIRCULATION, V96, P2849, DOI 10.1161/01.CIR.96.9.2849; ORourke RA, 1997, CIRCULATION, V96, P2775, DOI 10.1161/01.CIR.96.9.2775; *WHIT HOUS COMM AV, 1997, FIN REP PRES CLINT; 1998, TELEMEDICINE SPACEBR	11	6	6	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1777	1778		10.1001/jama.279.22.1777	http://dx.doi.org/10.1001/jama.279.22.1777			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR635	9628700				2022-12-28	WOS:000073998500015
J	Beecham, L				Beecham, L			GMC tells Privy Council about exam concerns	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1754	1754						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614048				2022-12-28	WOS:000074129500085
J	Gekakis, N; Staknis, D; Nguyen, HB; Davis, FC; Wilsbacher, LD; King, DP; Takahashi, JS; Weitz, CJ				Gekakis, N; Staknis, D; Nguyen, HB; Davis, FC; Wilsbacher, LD; King, DP; Takahashi, JS; Weitz, CJ			Role of the CLOCK protein in the mammalian circadian mechanism	SCIENCE			English	Article							DNA-BINDING; SACCHAROMYCES-CEREVISIAE; EXPRESSION; CLONING; RETINA; SYSTEM	The mouse Clock gene encodes a bHLH-PAS protein that regulates circadian rhythms and is related to transcription factors that act as heterodimers. Potential partners of CLOCK were isolated in a two-hybrid screen, and one, BMAL1, was coexpressed with CLOCK and PER1 at known circadian clock sites in brain and retina. CLOCK-BMAL1 heterodimers activated transcription from E-box elements, a type of transcription factor-binding site, found adjacent to the mouse per1 gene and from an identical E-box known to be important for per gene expression in Drosophila. Mutant CLOCK from the dominant-negative Clock allele and BMAL1 formed heterodimers that bound DNA but failed to activate transcription, Thus, CLOCK-BMAL1 heterodimers appear to drive the positive component of per transcriptional oscillations, which are thought to underlie circadian rhythmicity.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Northeastern Univ, Dept Biol, Boston, MA 02115 USA; Northwestern Univ, Dept Neurobiol & Physiol, Howard Hughes Med Inst, Evanston, IL 60208 USA; Northwestern Univ, Natl Sci Fdn, Ctr Biol Timing, Evanston, IL 60208 USA	Harvard University; Harvard Medical School; Northeastern University; Howard Hughes Medical Institute; Northwestern University; National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University	Weitz, CJ (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.		Takahashi, Joseph S./Y-2781-2019; Takahashi, Joseph S/E-8482-2012; Jansen, Heiko T./A-5770-2008	Takahashi, Joseph S./0000-0003-0384-8878; Takahashi, Joseph S/0000-0003-0384-8878; Jansen, Heiko T./0000-0003-0178-396X				Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BESHARSE JC, 1983, NATURE, V305, P133, DOI 10.1038/305133a0; Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1117; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Edmunds LN, 1988, CELLULAR MOL BASES B; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GEKAKIS N, UNPUB; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; Hirose K, 1996, MOL CELL BIOL, V16, P1706; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Inouye S, 1997, BIOCHEM BIOPH RES CO, V233, P349, DOI 10.1006/bbrc.1997.6452; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; King DP, 1997, GENETICS, V146, P1049; Klein D.C., 1991, SUPRACHIASMATIC NUCL; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Moffett P, 1997, MOL CELL BIOL, V17, P4933, DOI 10.1128/MCB.17.9.4933; Morris ME, 1998, SCIENCE, V279, P1544, DOI 10.1126/science.279.5356.1544; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P291, DOI 10.1007/BF01417859; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLOVYEV V, 1997, ISMB, V5, P294; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; Stanewsky R, 1997, EMBO J, V16, P5006, DOI 10.1093/emboj/16.16.5006; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VITATERNA MH, UNPUB; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; ZELAER E, 1997, GENE DEV, V11, P2079; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZYLKA MJ, IN PRESS NEURON	43	1489	1549	8	183	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	1998	280	5369					1564	1569		10.1126/science.280.5369.1564	http://dx.doi.org/10.1126/science.280.5369.1564			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616112				2022-12-28	WOS:000074061200030
J	Steel, KP; Brown, SDM				Steel, KP; Brown, SDM			More deafness genes	SCIENCE			English	Editorial Material							HAIR-CELLS		Univ Nottingham, Inst Hearing Res, MRC, Nottingham NG7 2RD, England; MRC, Mammalian Genet Unit, Harwell OX11 ORD, Berks, England	University of Nottingham	Steel, KP (corresponding author), Univ Nottingham, Inst Hearing Res, MRC, Univ Pk, Nottingham NG7 2RD, England.	karen@ihr.mrc.ac.uk						AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; HUDSPETH AJ, 1994, NEURON, V12, P1, DOI 10.1016/0896-6273(94)90147-3; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Probst FJ, 1998, SCIENCE, V280, P1444, DOI 10.1126/science.280.5368.1444; Self T, 1998, DEVELOPMENT, V125, P557; Steel KP, 1998, SCIENCE, V279, P1870, DOI 10.1126/science.279.5358.1870; Verhoeven K, 1998, NAT GENET, V19, P60, DOI 10.1038/ng0598-60; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0	10	9	10	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 29	1998	280	5368					1403	1403		10.1126/science.280.5368.1403	http://dx.doi.org/10.1126/science.280.5368.1403			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9634418				2022-12-28	WOS:000073883400046
J	Teglund, S; McKay, C; Schuetz, E; van Deursen, JM; Stravopodis, D; Wang, DM; Brown, M; Bodner, S; Grosveld, G; Ihle, JN				Teglund, S; McKay, C; Schuetz, E; van Deursen, JM; Stravopodis, D; Wang, DM; Brown, M; Bodner, S; Grosveld, G; Ihle, JN			Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses	CELL			English	Article							COLONY-STIMULATING FACTOR; DNA-BINDING ACTIVITY; GROWTH FACTOR-I; MICE LACKING; ERYTHROPOIETIN RECEPTOR; TRANSCRIPTIONAL ACTIVATION; TYROSINE PHOSPHORYLATION; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION	A variety of cytokines mediate the activation of Janus protein tyrosine kinases (Jaks). The Jaks then phosphorylate cellular substrates, including members of the signal transducers and activators of transcription (Stat) family of transcription factors. Among the Stats, the two highly related proteins, Stat5a and Stat5b, are activated by a variety of cytokines. To assess the role of the Stat5 proteins, mutant mice were derived that have the genes deleted individually or together. The phenotypes of the mice demonstrate an essential, and often redundant, role for the two Stat5 proteins in a spectrum of physiological responses associated with growth hormone and prolactin. Conversely, the responses to a variety of cytokines that activate the Stat5 proteins, including erythropoietin, are largely unaffected.	St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Tennessee, Sch Med, Dept Biochem, Memphis, TN 38105 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Ihle, JN (corresponding author), St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA.		Schuetz, Erin/N-8087-2018; Wang, Demin/AAX-4449-2020; Brown, Michael/C-2081-2014	Wang, Demin/0000-0001-5549-3795; Brown, Michael/0000-0002-5796-1932; Stravopodis, Dimitrios/0000-0002-9535-2134	NCI NIH HHS [CA21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angerer L.M., 1992, IN SITU HYBRIDIZATIO, P15; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DONAHUE LR, 1993, J ENDOCRINOL, V136, P91, DOI 10.1677/joe.0.1360091; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Hogan B, 1994, MANIPULATING MOUSE E; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nishinakamura R, 1996, BLOOD, V88, P2458, DOI 10.1182/blood.V88.7.2458.bloodjournal8872458; NORSTEDT G, 1984, CELL, V36, P805, DOI 10.1016/0092-8674(84)90030-8; Ogawa S, 1996, ONCOGENE, V13, P183; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; PARMER TG, 1991, ENDOCRINOLOGY, V129, P2924, DOI 10.1210/endo-129-6-2924; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shuai K, 1996, ONCOGENE, V13, P247; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SQUIRES EJ, 1988, J BIOL CHEM, V263, P4166; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; TIAN SS, 1994, BLOOD, V84, P1760; TWEARDY DJ, 1995, BLOOD, V86, P4409, DOI 10.1182/blood.V86.12.4409.bloodjournal86124409; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VANDEURSEN J, 1991, NUCLEIC ACIDS RES, V19, P2637, DOI 10.1093/nar/19.10.2637; Wakao H, 1997, BIOCHEM BIOPH RES CO, V234, P198, DOI 10.1006/bbrc.1997.6486; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Woldman I, 1997, J IMMUNOL, V159, P877; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; Zhong L, 1997, BIOCHEM BIOPH RES CO, V235, P587, DOI 10.1006/bbrc.1997.6833; ZHOU Y, 1994, P NATL ACAD SCI USA, V94, P13215	62	1041	1061	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1998	93	5					841	850		10.1016/S0092-8674(00)81444-0	http://dx.doi.org/10.1016/S0092-8674(00)81444-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630227	Bronze			2022-12-28	WOS:000073956700019
J	Kuttner, R				Kuttner, R			Must good HMOs go bad? Second of two parts - The search for checks and balances	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							QUALITY-ASSURANCE		Amer Prospect, Cambridge, MA 02138 USA		Kuttner, R (corresponding author), Amer Prospect, 6 Univ Rd, Cambridge, MA 02138 USA.							*ADV COMM CONS, 1998, FIN REP; *AM ASS HLTH PLANS, 1997, HLTH CAR CHOIC; *AM ASS HLTH PLANS, 1997, ISS BRIEF MAST LENGT; *AM SOC INT MED, 1995, MON SER; ARTHUR WB, 1989, ECON J, V99, P116, DOI 10.2307/2234208; DAVID PA, 1985, AM ECON REV, V75, P332; DAVIS K, 1996, MANAGED CARE PATIENT; Declercq E, 1997, MILBANK Q, V75, P175, DOI 10.1111/1468-0009.00051; Deming EW., 1986, OUT CRISIS; Enthoven AC, 1980, HLTH PLAN ONLY PRACT; Gabel J, 1997, HEALTH AFFAIR, V16, P134, DOI 10.1377/hlthaff.16.3.134; GOLDFIELD N, 1996, PHYSCIAN PROFILING R, P120; HERZLINGER R, 1997, MARKET DRIVEN HLTH C; Iglehart JK, 1996, NEW ENGL J MED, V335, P995, DOI 10.1056/NEJM199609263351322; Ignagni K, 1998, HEALTH AFFAIR, V17, P26, DOI 10.1377/hlthaff.17.1.26; KAISER HJ, 1996, AM HLTH CARE CONSUME; Kerr EA, 1996, JAMA-J AM MED ASSOC, V276, P1236, DOI 10.1001/jama.276.15.1236; KRANE D, 1997, BNA MANAGED CAR 0917, P882; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; SCHIFF GD, 1994, INT J HEALTH SERV, V24, P655, DOI 10.2190/VE9L-W378-55G3-L0R3; SCHLESINGER M, 1993, HEALTH AFFAIR, V12, P123, DOI 10.1377/hlthaff.12.suppl_1.123; Starr P, 1997, HEALTH AFFAIR, V16, P91, DOI 10.1377/hlthaff.16.3.91; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; White Joseph, 1995, COMPETING SOLUTIONS; WOOLHANDLER S, 1995, NEW ENGL J MED, V333, P1706, DOI 10.1056/NEJM199512213332510; 1995, NY TIMES        1221, pA1; 1998, BOSTON GLOBE    0225, pA11; 1996, NY TIMES        1115; 1997, N ENGL J MED, V335, P1146; 1997, N ENGL J MED, V335, P1227; 1997, N ENGL J MED, V335, P891; 1996, HUMANA PHYSICIAN B; 1997, N ENGL J MED, V335, P1328; 1997, GAOHEHS97175; 1997, N ENGL J MED, V335, P966; 1997, N ENGL J MED, V335, P1060; 1998, NY TIMES        0401	37	32	32	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1998	338	22					1635	1639		10.1056/NEJM199805283382221	http://dx.doi.org/10.1056/NEJM199805283382221			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZQ350	9603803				2022-12-28	WOS:000073852400027
J	Pearson, TA				Pearson, TA			Lipid-lowering therapy in low-risk patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORONARY HEART-DISEASE; COST-EFFECTIVENESS; TASK-FORCE; CHOLESTEROL LEVELS; ARTERY DISEASE; ATHEROSCLEROSIS; PRAVASTATIN; PROGRESSION; PREVENTION; HYPERCHOLESTEROLEMIA		Univ Rochester, Sch Med, Dept Community & Prevent Med, Rochester, NY 14642 USA	University of Rochester	Pearson, TA (corresponding author), Univ Rochester, Sch Med, Dept Community & Prevent Med, 601 Elmwood Ave,Box 644, Rochester, NY 14642 USA.							ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; Califf RM, 1996, J AM COLL CARDIOL, V27, P1007, DOI 10.1016/0735-1097(96)87733-3; Campeau L, 1997, NEW ENGL J MED, V336, P153; COBBES S, 1997, AM J CARDIOL, V121, P293; COHEN DJ, 1995, LOWERING CHOLESTEROL, P311; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; Goldman L, 1996, J AM COLL CARDIOL, V27, P1020, DOI 10.1016/0735-1097(96)87734-5; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HAMILTON VH, 1995, JAMA-J AM MED ASSOC, V273, P1032, DOI 10.1001/jama.273.13.1032; HAY JW, 1991, AM J CARDIOL, V67, P789, DOI 10.1016/0002-9149(91)90609-O; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; OLIVER MF, 1994, LANCET, V344, P633; Pearson TA, 1996, J AM COLL CARDIOL, V27, P961; PEDERSEN TR, 1994, LANCET, V344, P1383; PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0; PYORALA K, 1994, EUR HEART J, V15, P1300; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; TONKIN A, 1997, 70 SCI SESS AM HEART; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959	27	24	26	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1998	279	20					1659	1661		10.1001/jama.279.20.1659	http://dx.doi.org/10.1001/jama.279.20.1659			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP489	9613918				2022-12-28	WOS:000073758600038
J	Farrell, L				Farrell, L			Soundings - My role model	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1998	316	7148					1913	1913						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632434				2022-12-28	WOS:000074686500081
J	Fiebig, M; Miyano, K; Tomioka, Y; Tokura, Y				Fiebig, M; Miyano, K; Tomioka, Y; Tokura, Y			Visualization of the local insulator-metal transition in Pr0.7Ca0.3MnO3	SCIENCE			English	Article							NEUTRON-DIFFRACTION; PR1-XCAXMNO3	The light-induced insulator-metal transition in the "colossal magnetoresistance" compound Pr0.7Ca0.3MnO3 is shown to generate a well-localized conducting path while the bulk of the sample remains insulating. The path can be visualized through a change of reflectivity that accompanies the phase transition. Its visibility provides a tool for gaining insight into electronic transport in materials with strong magnetic correlations. For example, a conducting path can be generated or removed at an arbitrary position just because of the presence of another path. Such manipulation may be useful in the construction of optical switches.	Univ Tokyo, Dept Appl Phys, Tokyo 1138656, Japan; Japan Sci & Technol Corp, Tokyo 1710031, Japan; Joint Res Ctr Atom Technol, Tsukuba, Ibaraki 3050046, Japan	University of Tokyo; Japan Science & Technology Agency (JST); National Institute of Advanced Industrial Science & Technology (AIST)	Fiebig, M (corresponding author), Univ Tokyo, Dept Appl Phys, Tokyo 1138656, Japan.		Miyano, Kenjiro/G-7534-2014; Tokura, Yoshinori/C-7352-2009	Miyano, Kenjiro/0000-0002-5869-3087; Tokura, Yoshinori/0000-0002-2732-4983				Asamitsu A, 1997, NATURE, V388, P50, DOI 10.1038/40363; BALKAN N, 1992, NATO ASI SERIES; Eberle W, 1996, APPL PHYS LETT, V68, P3329, DOI 10.1063/1.116047; JIRAK Z, 1985, J MAGN MAGN MATER, V53, P153, DOI 10.1016/0304-8853(85)90144-1; Kiryukhin V, 1997, NATURE, V386, P813, DOI 10.1038/386813a0; Millis AJ, 1998, NATURE, V392, P147, DOI 10.1038/32348; Miyano K, 1997, PHYS REV LETT, V78, P4257, DOI 10.1103/PhysRevLett.78.4257; Mori T, 1997, J PHYS SOC JPN, V66, P3570, DOI 10.1143/JPSJ.66.3570; Moritomo Y, 1997, PHYS REV B, V55, P7549, DOI 10.1103/PhysRevB.55.7549; OGAWA K, IN PRESS PHYS REV B; OKIMOTO Y, IN PRESS PHYS REV B; Prettl W., 1996, Nonlinear physics of complex systems. Current status and future trends, P341; Tomioka Y, 1996, PHYS REV B, V53, pR1689, DOI 10.1103/PhysRevB.53.R1689; TOMIOKA Y, 1995, J PHYS SOC JPN, V64, P3626, DOI 10.1143/JPSJ.64.3626; YOSHIZAWA H, 1995, PHYS REV B, V52, P13145, DOI 10.1103/PhysRevB.52.R13145	15	330	338	4	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1925	1928		10.1126/science.280.5371.1925	http://dx.doi.org/10.1126/science.280.5371.1925			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632388				2022-12-28	WOS:000074323800060
J	Ganopolski, A; Kubatzki, C; Claussen, M; Brovkin, V; Petoukhov, V				Ganopolski, A; Kubatzki, C; Claussen, M; Brovkin, V; Petoukhov, V			The influence of vegetation-atmosphere-ocean interaction on climate during the mid-Holocene	SCIENCE			English	Article							SENSITIVITY; CIRCULATION; INSOLATION; FEEDBACKS; BP	Simulations with a synchronously coupled atmosphere-ocean-vegetation model show that changes in vegetation cover during the mid-Holocene, some 6000 years ago, modify and amplify the climate system response to an enhanced seasonal cycle of solar insolation in the Northern Hemisphere both directly (primarily through the changes in surface albedo) and indirectly (through changes in oceanic temperature, sea-ice cover, and oceanic circulation). The model results indicate strong synergistic effects of changes in vegetation cover, ocean temperature, and sea ice at boreal latitudes, but in the subtropics, the atmosphere-vegetation feedback is most important. Moreover, a reduction of the thermohaline circulation in the Atlantic Ocean leads to a warming of the Southern Hemisphere.	Potsdam Inst Klimafolgenforsch, D-14412 Potsdam, Germany; FU Berlin, Inst Meteorol, D-12165 Berlin, Germany; Oboukhov Inst Atmospher Phys, Moscow 109017, Russia	Potsdam Institut fur Klimafolgenforschung; Free University of Berlin; Russian Academy of Sciences; Obukhov Institute of Atmospheric Physics of Russian Academy of Sciences	Kubatzki, C (corresponding author), Potsdam Inst Klimafolgenforsch, Postfach 601203, D-14412 Potsdam, Germany.	kubi@pik-potsdam.de	Brovkin, Victor/C-2803-2016; Brovkin, Victor/I-7450-2012; Ganopolski, Andrey/F-6811-2013	Brovkin, Victor/0000-0001-6420-3198; 				BERGER AL, 1978, J ATMOS SCI, V35, P2362, DOI 10.1016/0033-5894(78)90064-9; Brovkin V, 1997, ECOL MODEL, V101, P251, DOI 10.1016/S0304-3800(97)00049-5; Cheddadi R., 1997, CLIM DYNAM, V13, P1, DOI DOI 10.1007/S003820050148; Claussen M, 1997, GLOBAL ECOL BIOGEOGR, V6, P369, DOI 10.2307/2997337; Coe MT, 1997, J GEOPHYS RES-ATMOS, V102, P11087, DOI 10.1029/97JD00343; deNoblet N, 1996, CLIM DYNAM, V12, P589, DOI 10.1007/s003820050130; FOLEY JA, 1994, NATURE, V371, P52, DOI 10.1038/371052a0; Ganopolski A, 1998, NATURE, V391, P351, DOI 10.1038/34839; Hall NMJ, 1997, J CLIMATE, V10, P3, DOI 10.1175/1520-0442(1997)010<0003:AGSOTC>2.0.CO;2; HAYS JD, 1976, SCIENCE, V194, P1121, DOI 10.1126/science.194.4270.1121; Hewitt CD, 1996, J CLIMATE, V9, P3505, DOI 10.1175/1520-0442(1996)009<3505:GSOTCO>2.0.CO;2; Hewitt CD, 1998, GEOPHYS RES LETT, V25, P361, DOI 10.1029/97GL03721; Hoelzmann P, 1998, GLOBAL BIOGEOCHEM CY, V12, P35, DOI 10.1029/97GB02733; JOLLY D, IN PRESS QUAT SCI RE; JOUZEL J, 1987, NATURE, V329, P403, DOI 10.1038/329403a0; KLIMANOV VA, 1992, ATLAS PALEOCLIMATES; Kutzbach J, 1996, NATURE, V384, P623, DOI 10.1038/384623a0; KUTZBACH JE, 1988, SCIENCE, V241, P1043, DOI 10.1126/science.241.4869.1043; Kutzbach JE, 1996, GLOBAL BIOGEOCHEM CY, V10, P727; Kutzbach JE, 1997, SCIENCE, V278, P440, DOI 10.1126/science.278.5337.440; Lorenz S, 1996, GEOL RUNDSCH, V85, P513, DOI 10.1007/s005310050092; Monserud Robert A., 1993, Climate Research, V3, P143, DOI 10.3354/cr003143; PETOUKHOV V, 1998, 35 PIK POTSD I KLIM; Prentice IC, 1996, CLIM DYNAM, V12, P185, DOI 10.1007/BF00211617; Rahmstorf S, 1996, CLIM DYNAM, V12, P799, DOI 10.1007/s003820050144; STREET FA, 1979, QUATERNARY RES, V12, P83, DOI 10.1016/0033-5894(79)90092-9; Texier D, 1997, CLIM DYNAM, V13, P865, DOI 10.1007/s003820050202; WEBB T, 1993, GLOBAL CLIMATES LAST, pCH17; Yu G, 1996, CLIM DYNAM, V12, P723, DOI 10.1007/s003820050139	29	302	315	2	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1998	280	5371					1916	1919		10.1126/science.280.5371.1916	http://dx.doi.org/10.1126/science.280.5371.1916			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632385	Green Submitted			2022-12-28	WOS:000074323800057
J	Brizel, DM; Albers, ME; Fisher, SR; Scher, RL; Richtsmeier, WJ; Hars, V; George, SL; Huang, AT; Prosnitz, LR				Brizel, DM; Albers, ME; Fisher, SR; Scher, RL; Richtsmeier, WJ; Hars, V; George, SL; Huang, AT; Prosnitz, LR			Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; RADIATION-THERAPY; RANDOMIZED TRIAL; RADIOTHERAPY; RECURRENCE; SURVIVAL; LARYNX	Background Radiotherapy is often the primary treatment for advanced head and neck cancer, but the rates of locoregional recurrence are high and survival is poor. We investigated whether hyperfractionated irradiation plus concurrent chemotherapy (combined treatment) is superior to hyperfractionated irradiation alone. Methods Patients with advanced head and neck cancer who were treated only with hyperfractionated irradiation received 125 cGy twice daily, for a total of 7500 cGy. Patients in the combined-treatment group received 125 cGy twice daily, for a total of 7000 cGy, and five days of treatment with 12 mg of cisplatin per square meter of body-surface area per day and 600 mg of fluorouracil per square meter per day during weeks 1 and 6 of irradiation. Two cycles of cisplatin and fluorouracil were given to most patients after the completion of radiotherapy. Results of 122 patients who underwent randomization, 116 were included in the analysis. Most patients in both treatment groups had unresectable disease. The median follow-up was 41 months (range, 19 to 86). At three years the rate of overall survival was 55 percent in the combined-therapy group and 34 percent in the hyperfractionation group (P=0.07). The relapse-free survival rate was higher in the combined-treatment group (61 percent vs. 41 percent, P=0.08). The rate of locoregional control of disease at three years was 70 percent in the combined-treatment group and 44 percent in the hyperfractionation group (P=0.01). Confluent mucositis developed in 77 percent and 75 percent of the two groups, respectively. Severe complications occurred in three patients in the hyperfractionation group and five patients in the combined-treatment group. Conclusions Combined treatment for advanced head and neck cancer is more efficacious and not more toxic than hyperfractionated irradiation alone. (C) 1998, Massachusetts Medical Society.	Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Community & Family Med, Div Biometry, Durham, NC 27710 USA; Duke Univ, Med Ctr, Duke Comprehens Canc Ctr, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University	Brizel, DM (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Box 3085, Durham, NC 27710 USA.			Brizel, David/0000-0001-9828-4790	NATIONAL CANCER INSTITUTE [P30CA014236] Funding Source: NIH RePORTER; NCI NIH HHS [CA14236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Beahrs OH, 1988, MANUAL STAGING CANC; Bourhis J, 1996, ANTICANCER RES, V16, P2397; BRIZEL DM, 1994, INT J RADIAT ONCOL, V28, P213, DOI 10.1016/0360-3016(94)90160-0; CAPLAN RJ, 1994, INT J RADIAT ONCOL, V29, P1183, DOI 10.1016/0360-3016(94)90416-2; Dubray B, 1996, RADIOLOGY, V201, P553, DOI 10.1148/radiology.201.2.8888257; FU KK, 1987, J CLIN ONCOL, V5, P1410, DOI 10.1200/JCO.1987.5.9.1410; GATENBY RA, 1988, INT J RADIAT ONCOL, V14, P831, DOI 10.1016/0360-3016(88)90002-8; GELMAN R, 1990, J CLIN ONCOL, V8, P548, DOI 10.1200/JCO.1990.8.3.548; GRIEM KL, 1996, 4 INT C HEAD NECK CA, P118; Harari PM, 1997, J CLIN ONCOL, V15, P2050, DOI 10.1200/JCO.1997.15.5.2050; HORIOT JC, 1992, RADIOTHER ONCOL, V25, P231, DOI 10.1016/0167-8140(92)90242-M; Horiot JC, 1997, RADIOTHER ONCOL, V44, P111, DOI 10.1016/S0167-8140(97)00079-0; HORIOT JC, 1995, EUR J CANCER, V31, P69; HORIOT JC, 1996, RADIOTHER ONCOL S1, V40, P106; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNEE R, 1985, RADIOTHER ONCOL, V4, P1, DOI 10.1016/S0167-8140(85)80055-4; LARAMORE GE, 1992, INT J RADIAT ONCOL, V23, P705, DOI 10.1016/0360-3016(92)90642-U; Lefebvre JL, 1996, J NATL CANCER I, V88, P890, DOI 10.1093/jnci/88.13.890; MUNRO AJ, 1995, BRIT J CANCER, V71, P83, DOI 10.1038/bjc.1995.17; NG CE, 1987, BRIT J CANCER, V56, P301, DOI 10.1038/bjc.1987.193; OVERGAARD J, 1986, INT J RADIAT ONCOL, V12, P515, DOI 10.1016/0360-3016(86)90058-1; PARSONS JT, 1989, HEAD NECK-J SCI SPEC, V11, P400, DOI 10.1002/hed.2880110504; PARSONS JT, 1988, INT J RADIAT ONCOL, V14, P649, DOI 10.1016/0360-3016(88)90085-5; PETERS LJ, 1992, PRINCIPLES PRACTICE, P97; WANG CC, 1986, INT J RADIAT ONCOL, V12, P3, DOI 10.1016/0360-3016(86)90407-4; WITHERS HR, 1988, ACTA ONCOL, V27, P131, DOI 10.3109/02841868809090333; WOLF GT, 1991, NEW ENGL J MED, V324, P1685, DOI 10.1056/nejm199106133242402	28	900	922	1	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1998	338	25					1798	1804		10.1056/NEJM199806183382503	http://dx.doi.org/10.1056/NEJM199806183382503			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU443	9632446	Bronze			2022-12-28	WOS:000074197500003
J	Sayegh, MH; Turka, LA				Sayegh, MH; Turka, LA			The role of T-cell costimulatory activation pathways in transplant rejection	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CARDIAC ALLOGRAFT-REJECTION; LONG-TERM ACCEPTANCE; RENAL-ALLOGRAFT; CD28 RECEPTOR; CD40 LIGAND; BLOCKADE; MECHANISMS; SURVIVAL; CTLA4IG; TOLERANCE		Univ Penn, Dept Med, Stellar Chance Labs 901, Philadelphia, PA 19104 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Renal Div,Lab Immunogenet & Transplantat, Boston, MA 02115 USA	University of Pennsylvania; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Turka, LA (corresponding author), Univ Penn, Dept Med, Stellar Chance Labs 901, 422 Curie Blvd, Philadelphia, PA 19104 USA.				NIAID NIH HHS [AI41521, AI34965, AI37691] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI041521, R01AI034965, R29AI034965, R01AI037691] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Azuma H, 1996, P NATL ACAD SCI USA, V93, P12439, DOI 10.1073/pnas.93.22.12439; Brazelton TR, 1996, CURR OPIN IMMUNOL, V8, P710, DOI 10.1016/S0952-7915(96)80090-2; Cecka J M, 1996, Clin Transpl, P1; Chandraker A, 1997, TRANSPLANTATION, V63, P1053, DOI 10.1097/00007890-199704270-00002; CHANG AC, 1997, 23 AM SOC TRANSPL SU, pA41; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Ciubotariu R, 1998, J CLIN INVEST, V101, P398, DOI 10.1172/JCI1117; DURIE FH, 1994, IMMUNOL TODAY, V15, P406, DOI 10.1016/0167-5699(94)90269-0; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; Guo Y, 1996, J EXP MED, V184, P955, DOI 10.1084/jem.184.3.955; Hancock WW, 1996, P NATL ACAD SCI USA, V93, P13967, DOI 10.1073/pnas.93.24.13967; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; KRENSKY AM, 1990, NEW ENGL J MED, V322, P510, DOI 10.1056/NEJM199002223220805; Krieger NR, 1996, J EXP MED, V184, P2013, DOI 10.1084/jem.184.5.2013; Larsen CP, 1996, TRANSPLANTATION, V61, P4, DOI 10.1097/00007890-199601150-00002; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Lebwohl Mark, 1997, Journal of Investigative Dermatology, V108, P570; LECHLER RI, 1990, IMMUNOL TODAY, V11, P83, DOI 10.1016/0167-5699(90)90033-6; LENSCHOW DJ, 1995, J EXP MED, V181, P1145, DOI 10.1084/jem.181.3.1145; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; Levisetti MG, 1997, J IMMUNOL, V159, P5187; LIN H, 1993, J EXP MED, V178, P1801, DOI 10.1084/jem.178.5.1801; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; Noel PJ, 1996, J IMMUNOL, V157, P636; NORMAN DJ, 1995, THER DRUG MONIT, V17, P615, DOI 10.1097/00007691-199512000-00012; PARKER DC, 1995, P NATL ACAD SCI USA, V92, P9560, DOI 10.1073/pnas.92.21.9560; Paul Leendert C., 1996, P567; Pearson TC, 1996, TRANSPLANTATION, V61, P997, DOI 10.1097/00007890-199604150-00002; PEARSON TC, 1997, 17 AM SOC TRANSPL PH, P85; Perez VL, 1997, IMMUNITY, V6, P411, DOI 10.1016/S1074-7613(00)80284-8; Perico N, 1996, TRANSPLANTATION, V61, P1320, DOI 10.1097/00007890-199605150-00006; PORT FK, 1993, JAMA-J AM MED ASSOC, V270, P1339, DOI 10.1001/jama.270.11.1339; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; RANHEIM EA, 1993, J EXP MED, V177, P925, DOI 10.1084/jem.177.4.925; Reiser H, 1996, NEW ENGL J MED, V335, P1369, DOI 10.1056/NEJM199610313351807; Reul RM, 1997, TRANSPLANTATION, V64, P1765, DOI 10.1097/00007890-199712270-00025; Russell ME, 1996, J CLIN INVEST, V97, P833, DOI 10.1172/JCI118483; SAYEGH MH, 1994, TRANSPLANTATION, V57, P1295, DOI 10.1097/00007890-199405150-00001; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; Sayegh MH, 1997, TRANSPLANTATION, V64, P1646, DOI 10.1097/00007890-199712270-00003; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; STEURER W, 1995, J IMMUNOL, V155, P1165; SUTHANTHIRAN M, 1994, NEW ENGL J MED, V331, P365, DOI 10.1056/NEJM199408113310606; Takada M, 1997, J CLIN INVEST, V100, P1199, DOI 10.1172/JCI119632; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; Tilney Nicholas L., 1996, P629; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; Vella JP, 1997, TRANSPLANTATION, V64, P795, DOI 10.1097/00007890-199709270-00001; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541; Woodward JE, 1996, TRANSPLANTATION, V62, P1011, DOI 10.1097/00007890-199610150-00021; YIN DP, 1995, J IMMUNOL, V155, P1655; Zheng XX, 1997, J IMMUNOL, V159, P1169	55	430	458	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1998	338	25					1813	1821		10.1056/NEJM199806183382506	http://dx.doi.org/10.1056/NEJM199806183382506			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU443	9632449				2022-12-28	WOS:000074197500006
J	Dehlendorf, CE; Wolfe, SM				Dehlendorf, CE; Wolfe, SM			Physicians disciplined for sex-related offenses	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTACT; MISCONDUCT; PREVALENCE	Context.-Physicians who abuse their patients sexually cause immense harm, and, therefore, the discipline of physicians who commit any sex-related offenses is an important public health issue that should be examined. Objectives.-To determine the frequency and severity of discipline against physicians who commit sex-related offenses and to describe the characteristics of these physicians. Design and Setting.-Analysis of sex-related orders from a national database of disciplinary orders taken by state medical boards and federal agencies. Subjects.-A total of 761 physicians disciplined for sex-related offenses from 1981 through 1996. Main Outcome Measures.-Rate and severity of discipline over time for sex-related offenses and specialty, age, and board certification status of disciplined physicians. Results.-The number of physicians disciplined per year for sex-related offenses increased from 42 in 1989 to 147 in 1996, and the proportion of all disciplinary orders that were sex related increased from 2.1% in 1989 to 4.4% in 1996 (P<.001 for trend). Discipline for sex-related offenses was significantly more severe (P<.001) than for non-sex-related offenses, with 71.9% of sex-related orders involving revocation, surrender, or suspension of medical license. Of 761 physicians disciplined, the offenses committed by 567 (75%) involved patients, including sexual intercourse, rape, sexual molestation, and sexual favors for drugs. As of March 1997, 216 physicians (39.9%) disciplined for sex-related offenses between 1981 and 1994 were licensed to practice. Compared with all physicians, physicians disciplined for sex-related offenses were more likely to practice in the specialties of psychiatry, child psychiatry, obstetrics and gynecology, and family and general practice tall P<.001) than in other specialties and were older than the national physician population, but were no different in terms of board certification status. Conclusions.-Discipline against physicians for sex-related offenses is increasing over time and is relatively severe, although few physicians are disciplined for sexual offenses each year. In addition, a substantial proportion of physicians disciplined for these offenses are allowed to either continue to practice or return to practice.	Publ Citizens Hlth Res Grp, Washington, DC 20009 USA		Wolfe, SM (corresponding author), Publ Citizens Hlth Res Grp, 1600 20th St NW, Washington, DC 20009 USA.							*AM MED ASS, 1996, PHYS CHAR DISTR US 1; *AM MED ASS, 1993, PHYS CHAR DISTR US 1; *AM OST ASS, 1991, YB DIR OST PHYS; *AM PSYCH ASS, 1993, PRINC MED ETH ANN ES; American Psychiatric Association, 1973, PRINC MED ETH ANN ES; BOUHOUTSOS J, 1983, PROF PSYCHOL-RES PR, V14, P185, DOI 10.1037/0735-7028.14.2.185; BURGESS AW, 1981, AM J PSYCHIAT, V138, P1335; CAMPBELL ML, 1989, PERSPECT BIOL MED, V32, P300; *COUNC ETH JUD AFF, 1989, CURR OP; *COUNC ETH JUD AFF, 1996, COD MED ETH CURR OP; DEHLENDORF CE, 1997, PHYSICIANS DISCIPLIN; DREIBLATT IS, 1992, FED B            JAN, P8; ENBORN JA, 1997, AM J OBSTET GYNECOL, V76, P1340; FELDMANSUMMERS S, 1984, J CONSULT CLIN PSYCH, V52, P1054, DOI 10.1037/0022-006X.52.6.1054; GARTRELL N, 1986, AM J PSYCHIAT, V143, P1126; GARTRELL N, 1987, AM J ORTHOPSYCHIAT, V57, P287, DOI 10.1111/j.1939-0025.1987.tb03539.x; GARTRELL NK, 1992, WESTERN J MED, V157, P139; *PHYS COMM SEX MIS, 1992, CROSS BOUND, V32, P32; Pope, 1994, SEXUAL INVOLVEMENT T; POPE KS, 1991, PSYCHOTHER, V28, P429, DOI 10.1037/0033-3204.28.3.429; *TASK FORC SEX AB, 1991, FIN REP, P58; Walzer Robert S, 1994, FEDERATION B, V81, P79; WINN JR, 1993, FED B            SUM, P90; [No title captured]	24	74	74	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1998	279	23					1883	1888		10.1001/jama.279.23.1883	http://dx.doi.org/10.1001/jama.279.23.1883			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZT653	9634259	Bronze			2022-12-28	WOS:000074109700035
J	Gauss, R; Seifert, R; Kaupp, UB				Gauss, R; Seifert, R; Kaupp, UB			Molecular identification of a hyperpolarization-activated channel in sea urchin sperm	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; GATED CHANNEL; CAMP; DROSOPHILA; FAMILY; ROD; SEQUENCE; GENES	Sea urchin eggs attract sperm through chemotactic peptides, which evoke complex changes in membrane voltage and in the concentrations of cyclic AMP, cyclic GMP and Ca2+ ions (see ref. 1 for a review). The intracellular signalling pathways and their cellular targets are largely unknown. We have now cloned, from sea urchin testis, the complementary DNA encoding a channel polypeptide, SPIH, Functional expression of SPIH gives rise to weakly K+-selective hyperpolarization-activated channels, whose activity is enhanced by the direct action of cAMP. Thus, SPIH is under the dual control of voltage and cAMP. The SPIH channel, which is confined to the sperm flagellum, may be involved in the control of flagellar beating. SPM currents exhibit all the hallmarks of hyperpolarization-activated currents (I-h)(2,3), which participate in the rhythmic firing of central neurons, control pacemaking in the heart, and curtail saturation by bright light in retinal photoreceptors(2,3). Because of their sequence(4) and functional properties, I-h channels form a class of their own within the superfamily of voltage-gated and cyclic-nucleotide-gated channels.	Forschungszentrum Julich, Inst Biol Informat Verarbeitung, D-52425 Julich, Germany	Helmholtz Association; Research Center Julich	Kaupp, UB (corresponding author), Forschungszentrum Julich, Inst Biol Informat Verarbeitung, Postfach 1913, D-52425 Julich, Germany.	a.eckert@fz-juelich.de						AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BABCOCK DE, 1992, P NATL ACAD SCI USA, V86, P6001; BAUMANN A, 1994, EMBO J, V13, P5040, DOI 10.1002/j.1460-2075.1994.tb06833.x; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; Darszon A., 1994, Methods (Orlando), V6, P37, DOI 10.1006/meth.1994.1006; DIFRANCESCO D, 1984, J PHYSIOL-LONDON, V348, P341, DOI 10.1113/jphysiol.1984.sp015114; DIFRANCESCO D, 1994, J PHYSIOL-LONDON, V474, P473, DOI 10.1113/jphysiol.1994.sp020038; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; FINN JT, ANN REV PHYSL, V58, P395; Hagen V, 1996, BIOCHEMISTRY-US, V35, P7762, DOI 10.1021/bi952895b; HANSBROUGH JR, 1981, J BIOL CHEM, V256, P1447; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Labarca P, 1996, DEV BIOL, V174, P271, DOI 10.1006/dbio.1996.0072; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; WARD CR, 1993, DEV BIOL, V158, P9, DOI 10.1006/dbio.1993.1165; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; WOLLMUTH LP, 1992, J GEN PHYSIOL, V100, P749, DOI 10.1085/jgp.100.5.749	30	364	374	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					583	587		10.1038/31248	http://dx.doi.org/10.1038/31248			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634235				2022-12-28	WOS:000074150100054
J	Johnson, KS; Thywissen, JH; Dekker, NH; Berggren, KK; Chu, AP; Younkin, R; Prentiss, M				Johnson, KS; Thywissen, JH; Dekker, NH; Berggren, KK; Chu, AP; Younkin, R; Prentiss, M			Localization of metastable atom beams with optical standing waves: Nanolithography at the Heisenberg limit	SCIENCE			English	Article							DEPOSITION; LITHOGRAPHY	The spatially dependent de-excitation of a beam of metastable argon atoms, traveling through an optical standing wave, produced a periodic array of localized metastable atoms with position and momentum spreads approaching the limit stated by the Heisenberg uncertainty principle. Silicon and silicon dioxide substrates placed in the path of the atom beam were patterned by the metastable atoms. The de-excitation of metastable atoms upon collision with the surface promoted the deposition of a carbonaceous film from a vapor-phase hydrocarbon precursor, The resulting patterns were imaged both directly and after chemical etching. Thus, quantum-mechanical steady-state atom distributions can be used for sub-0.1-micrometer lithography.	Harvard Univ, Dept Phys, Cambridge, MA 02138 USA	Harvard University	Johnson, KS (corresponding author), Igen Int Inc, 16020 Ind Dr, Gaithersburg, MD 20877 USA.		Thywissen, Joseph H/E-8235-2010; Prentiss, Mara/AAU-2940-2021	Thywissen, Joseph H/0000-0002-7007-8204; Dekker, Nynke/0000-0003-4029-0973				Abfalterer R, 1997, PHYS REV A, V56, pR4365, DOI 10.1103/PhysRevA.56.R4365; Behringer RE, 1996, APPL PHYS LETT, V68, P1034, DOI 10.1063/1.116239; BERGGREN KK, 1995, SCIENCE, V269, P1255, DOI 10.1126/science.7652572; BERGGREN KK, 1997, THESIS HARVARD U; Chu AP, 1996, QUANTUM SEMICL OPT, V8, P521, DOI 10.1088/1355-5111/8/3/015; Cohen-Tannoudji C., 1998, ATOM PHOTON INTERACT; Drodofsky U, 1997, APPL PHYS B-LASERS O, V65, P755, DOI 10.1007/s003400050342; GUPTA R, 1995, APPL PHYS LETT, V67, P1378, DOI 10.1063/1.115539; Harada Y, 1997, CHEM REV, V97, P1897, DOI 10.1021/cr940315v; JESSEN PS, 1992, PHYS REV LETT, V69, P49, DOI 10.1103/PhysRevLett.69.49; Johnson KS, 1996, APPL PHYS LETT, V69, P2773, DOI 10.1063/1.117671; MCCLELLAND JJ, 1993, SCIENCE, V262, P877, DOI 10.1126/science.262.5135.877; MullerSeydlitz T, 1997, PHYS REV LETT, V78, P1038, DOI 10.1103/PhysRevLett.78.1038; Nowak S, 1996, APPL PHYS B-LASERS O, V63, P203, DOI 10.1007/BF01095274; RAAB EL, 1987, PHYS REV LETT, V59, P2631, DOI 10.1103/PhysRevLett.59.2631; Rehse SJ, 1997, APPL PHYS LETT, V71, P1427, DOI 10.1063/1.119914; SALOMON C, 1987, PHYS REV LETT, V59, P1969; THOMAS JE, 1995, PHYS REP, V262, P311, DOI 10.1016/0370-1573(95)00050-Q; Thywissen JH, 1998, J VAC SCI TECHNOL B, V16, P1155, DOI 10.1116/1.590026	20	244	250	3	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1583	1586		10.1126/science.280.5369.1583	http://dx.doi.org/10.1126/science.280.5369.1583			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616117				2022-12-28	WOS:000074061200035
J	Tamura, M; Gu, JG; Matsumoto, K; Aota, S; Parsons, R; Yamada, KM				Tamura, M; Gu, JG; Matsumoto, K; Aota, S; Parsons, R; Yamada, KM			Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN	SCIENCE			English	Article							INTEGRINS; KINASE	The tumor suppressor PTEN is a phosphatase with sequence similarity to the cytoskeletal protein tensin. Here the cellular roles of PTEN were investigated. Overexpression of PTEN inhibited cell migration, whereas antisense PTEN enhanced migration. Integrin-mediated cell spreading and the formation of focal adhesions were down-regulated by wild-type PTEN but not by PTEN with an inactive phosphatase domain. PTEN interacted with the focal adhesion kinase FAK and reduced its tyrosine phosphorylation. Overexpression of FAK partially antagonized the effects of PTEN. Thus, PTEN phosphatase may function as a tumor suppressor by negatively regulating cell interactions with the extracellular matrix.	NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Columbia University; Columbia University	Tamura, M (corresponding author), NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bldg 30,Room 421,30 Convent Dr MSC 4370, Bethesda, MD 20892 USA.	mtamura@yoda.nidr.nih.gov; kyamada@yoda.nidr.nih.gov	Gu, Jianguo/ABC-9257-2020	Parsons, Ramon/0000-0002-6656-3514; Yamada, Kenneth/0000-0003-1512-6805				AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Arregui Carlos O., 1997, Molecular Biology of the Cell, V8, p290A; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Guldberg P, 1997, CANCER RES, V57, P3660; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Lin Shin, 1993, P240; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Okami K, 1998, CANCER RES, V58, P509; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TAMURA M, UNPUB; Teng DHF, 1997, CANCER RES, V57, P5221; Wang SI, 1997, CANCER RES, V57, P4183; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X	25	1019	1142	4	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	1998	280	5369					1614	1617		10.1126/science.280.5369.1614	http://dx.doi.org/10.1126/science.280.5369.1614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616126				2022-12-28	WOS:000074061200044
J	Kozyrskyj, AL; Hildes-Ripstein, GE; Longstaffe, SEA; Wincott, JL; Sitar, DS; Klassen, TP; Moffatt, MEK				Kozyrskyj, AL; Hildes-Ripstein, GE; Longstaffe, SEA; Wincott, JL; Sitar, DS; Klassen, TP; Moffatt, MEK			Treatment of acute otitis media with a shortened course of antibiotics - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PLACEBO-CONTROLLED TRIAL; PEDIATRIC-PATIENTS; CLINICAL-TRIALS; CO-AMOXICLAV; ANTIMICROBIAL TREATMENT; PENICILLIN TREATMENT; AMOXICILLIN THERAPY; GENERAL-PRACTICE; CHILDREN; AZITHROMYCIN	Objective.-To conduct a meta-analysis of randomized controlled trials of antibiotic treatment of acute otitis media in children to determine whether outcomes were comparable in children treated with antibiotics for less than 7 days or at least 7 days or more. Data Sources.-MEDLINE (1966-1997), EMBASE (1974-1997), Current Contents, and Science Citation Index searches were conducted to identify randomized controlled trials of the treatment of acute otitis media in children with antibiotics of different durations, Study Selection.-Studies were included if they met the following criteria: subjects aged 4 weeks to 18 years, clinical diagnosis of acute otitis media, no antimicrobial therapy at time of diagnosis, and randomization to less than 7 days of antibiotic treatment vs 7 days or more of antibiotic treatment, Data Extraction.-Trial methodological quality was assessed independently by 7 reviewers; outcomes were extracted as the number of treatment failures, relapses, or reinfections. Data Synthesis.-Included trials were grouped by antibiotic used in the short course: (1) 15 short-acting oral antibiotic trials (penicillin V potassium, amoxicillin [-clavulanate], cefaclor, cefixime, cefuroxime, cefpodoxime proxetil, cefprozil), (2)4 intramuscular ceftriaxone sodium trials, and (3) 1 1 oral azithromycin trials. The summary odds ratio for treatment outcomes at 8 to 19 days in children treated with short-acting antibiotics for 5 days vs 8 to 10 days was 1.52 (95% confidence interval [CI], 1.17-1.98) but by 20 to 30 days outcomes between treatment groups were comparable (odds ratio, 1.22; 95% CI, 0.98 to 1.54). The risk difference (2.3%; 95% CI, -0.2% to 4.9%) at 20 to 30 days suggests that 44 children would need to be treated with the long course of short-acting antibiotics to avoid 1 treatment failure. This similarity in later outcomes was observed for up to 3 months following therapy (odds ratio, 1.16; 95% CI, 0.90-1.50), Comparable outcomes were shown between treatment with ceftriaxone or azithromycin, and at least 7 days of other antibiotics, Conclusion. This meta-analysis suggests that 5 days of short-acting antibiotic use is effective treatment for uncomplicated acute otitis media in children.	Univ Manitoba, Fac Med, Dept Community Hlth Sci, Manitoba Ctr Hlth Policy & Evaluat, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Clin Pharmacol Sect, Winnipeg, MB R3E 0W3, Canada; Univ Ottawa, Childrens Hosp Eastern Ontario, Res Inst, Dept Pediat, Ottawa, ON, Canada	University of Manitoba; University of Manitoba; University of Manitoba; University of Ottawa; Children's Hospital of Eastern Ontario	Moffatt, MEK (corresponding author), Univ Manitoba, Fac Med, Dept Community Hlth Sci, Manitoba Ctr Hlth Policy & Evaluat, 750 Bannatyne Ave, Winnipeg, MB R3E 0W3, Canada.		Sitar, Daniel/T-8777-2018	Sitar, Daniel/0000-0003-4294-7940				Adam D, 1995, INFECTION, V23, P398, DOI 10.1007/BF01713583; APPELMAN CLM, 1991, BMJ-BRIT MED J, V303, P1450, DOI 10.1136/bmj.303.6815.1450; Arguedas A, 1996, INT J ANTIMICROB AG, V6, P233, DOI 10.1016/0924-8579(95)00066-6; Arguedas A, 1997, J CHEMOTHERAPY, V9, P44, DOI 10.1179/joc.1997.9.1.44; Aronovitz G, 1996, PEDIATR INFECT DIS J, V15, pS15, DOI 10.1097/00006454-199609009-00003; BAIN J, 1985, BRIT MED J, V291, P1243, DOI 10.1136/bmj.291.6504.1243; Barnett ED, 1997, PEDIATRICS, V99, P23, DOI 10.1542/peds.99.1.23; BERLIN JA, 1995, PEDIATR INFECT DIS J, V14, pS30; BERMAN S, 1995, PEDIATRICS, V96, P126; Berman S, 1997, PEDIATRICS, V100, P585, DOI 10.1542/peds.100.4.585; BORZAK S, 1995, ANN INTERN MED, V123, P873, DOI 10.7326/0003-4819-123-11-199512010-00010; Boswell JB, 1996, ANN OTO RHINOL LARYN, V105, P893, DOI 10.1177/000348949610501110; BOULESTEIX J, 1995, MED MALADIES INFECT, V25, P534, DOI 10.1016/S0399-077X(05)80739-5; BURKE P, 1991, BRIT MED J, V303, P558, DOI 10.1136/bmj.303.6802.558; CANAFAX DM, 1991, OTOLARYNG CLIN N AM, V24, P859; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; CHAMBERLAIN JM, 1994, CLIN PEDIATR, V33, P642, DOI 10.1177/000992289403301101; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; Cohen R, 1997, MED MALADIES INFECT, V27, P596, DOI 10.1016/S0399-077X(97)80091-1; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P161; DANIEL RR, 1993, J ANTIMICROB CHEMOTH, V31, P65, DOI 10.1093/jac/31.suppl_E.65; DelMar C, 1997, BRIT MED J, V314, P1526, DOI 10.1136/bmj.314.7093.1526; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DESAINTONGE DMC, 1982, BRIT MED J, V284, P1078; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Eppes SC, 1997, PEDIATRICS, V100, P157, DOI 10.1542/peds.100.1.157; FADEN H, 1992, ANN OTO RHINOL LARYN, V101, P87, DOI 10.1177/000348949210100119; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; GEHANNO P, 1990, J ANTIMICROB CHEMOTH, V26, P29, DOI 10.1093/jac/26.suppl_A.29; Gooch WM, 1996, PEDIATR INFECT DIS J, V15, P157, DOI 10.1097/00006454-199602000-00013; GREEN SM, 1993, PEDIATRICS, V91, P23; GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B; Guillemot D, 1998, JAMA-J AM MED ASSOC, V279, P365, DOI 10.1001/jama.279.5.365; HARRISON CJ, 1985, PEDIATR INFECT DIS J, V4, P641, DOI 10.1097/00006454-198511000-00009; HARRISON CJ, 1993, PEDIATR INFECT DIS J, V12, P62, DOI 10.1097/00006454-199301000-00013; HENDRICKSE WA, 1988, PEDIATR INFECT DIS J, V7, P14, DOI 10.1097/00006454-198801000-00005; Hoberman A, 1997, PEDIATR INFECT DIS J, V16, P463, DOI 10.1097/00006454-199705000-00002; HOWIE VM, 1969, PEDIATRICS, V44, P940; INGVARSSON L, 1982, ACTA OTO-LARYNGOL, V94, P283, DOI 10.3109/00016488209128915; JACOBSON JA, 1979, POSTGRAD MED J, V55, P39; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JENNER PN, 1987, BRIT J CLIN PRACT, V41, P820; JOHNSON CE, 1991, J PEDIATR-US, V119, P117, DOI 10.1016/S0022-3476(05)81051-0; JONES R, 1986, J ROY COLL GEN PRACT, V36, P356; Kafetzis DA, 1997, EUR J CLIN MICROBIOL, V16, P283, DOI 10.1007/BF01695632; KALEIDA PH, 1991, PEDIATRICS, V87, P466; Khurana CM, 1996, PEDIATR INFECT DIS J, V15, pS24, DOI 10.1097/00006454-199609009-00005; KLEIN JO, 1988, RECENT ADV OTITIS ME, P6; KURBASCI M, 1996, ARCH PEDIAT ADOLESC, V150, P19; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; MacLoughlin GJF, 1996, J ANTIMICROB CHEMOTH, V37, P565, DOI 10.1093/jac/37.3.565; MANDEL EM, 1995, PEDIATRICS, V96, P5; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; McLinn S, 1996, PEDIATR INFECT DIS J, V15, pS20; MEISTRUPLARSEN KI, 1983, ACTA OTO-LARYNGOL, V96, P99, DOI 10.3109/00016488309132879; MILLS R, 1984, J ROY SOC MED, V77, P754, DOI 10.1177/014107688407700909; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; MOHS E, 1993, J ANTIMICROB CHEMOTH, V31, P73; MURPH JR, 1993, CLIN PEDIATR, V32, P528, DOI 10.1177/000992289303200904; MURRAY BE, 1994, NEW ENGL J MED, V330, P1229, DOI 10.1056/NEJM199404283301710; MYGIND N, 1981, CLIN OTOLARYNGOL, V6, P5, DOI 10.1111/j.1365-2273.1981.tb01781.x; ODoherty B, 1996, J ANTIMICROB CHEMOTH, V37, P71, DOI 10.1093/jac/37.suppl_C.71; Oxman A, 1995, COCHRANE COLLABORATI; PARADISE JL, 1995, PEDIATRICS, V96, P712; Paradise JL, 1997, JAMA-J AM MED ASSOC, V278, P1640, DOI 10.1001/jama.278.20.1640; PETALOZZA G, 1992, SCAND J INFECT DIS, V83, P22; Pichichero ME, 1997, PEDIATR INFECT DIS J, V16, P680, DOI 10.1097/00006454-199707000-00011; PLOUSSARD JH, 1984, CURR THER RES CLIN E, V36, P641; PRINCIPI N, 1995, EUR J CLIN MICROBIOL, V14, P669, DOI 10.1007/BF01690872; PUCZYNSKI MS, 1987, LARYNGOSCOPE, V97, P16; Rodriguez AF, 1996, J ANTIMICROB CHEMOTH, V37, P63, DOI 10.1093/jac/37.suppl_C.63; Rosenfeld RM, 1996, PEDIATR CLIN N AM, V43, P1165, DOI 10.1016/S0031-3955(05)70512-5; ROSENFELD RM, 1994, J PEDIATR-US, V124, P355, DOI 10.1016/S0022-3476(94)70356-6; RUBENSTEIN MM, 1965, AJDC, V100, P308; SCHAAD UB, 1993, J ANTIMICROB CHEMOTH, V31, P81, DOI 10.1093/jac/31.suppl_E.81; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SCOTT HV, 1990, NEW ZEAL MED J, V103, P25; SPENCER RC, 1993, 18 INT C CHEM JUN 27; STICKLER GB, 1967, AM J DIS CHILD, V114, P123, DOI 10.1001/archpedi.1967.02090230053002; STICKLER GB, 1964, JAMA-J AM MED ASSOC, V187, P85; STOOL SE, 1989, PEDIATR INFECT DIS J, V8, pS11; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; VANBUCHEM FL, 1981, LANCET, V2, P883; VARSANO I, 1988, CHEMOTHERAPY, V34, P39, DOI 10.1159/000238646; VARSANO I, 1994, 6 INT C INF DIS SESS	87	104	106	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1736	1742		10.1001/jama.279.21.1736	http://dx.doi.org/10.1001/jama.279.21.1736			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624028				2022-12-28	WOS:000073878700036
J	Gonzalez, CH; Marques-Dias, MJ; Kim, CA; Sugayama, SMM; Da Paz, JA; Huson, SM; Holmes, LB				Gonzalez, CH; Marques-Dias, MJ; Kim, CA; Sugayama, SMM; Da Paz, JA; Huson, SM; Holmes, LB			Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy	LANCET			English	Article							PARAPLEGIA; ABORTION; SEQUENCE	Background Misoprostol is commonly used to induce abortion in Brazil, and in other countries in South and Central America where abortions are illegal. However, misoprostol is not very effective in inducing abortions, and exposure to the drug in utero can cause abnormalities in the fetus. We aimed to define the common phenotypical effects of exposure to the drug. Methods We studied 42 infants from Sao Paulo, Brazil, who were exposed to misoprostol during the first 3 months of gestation, and then born with congenital abnormalities. We interviewed each of the infants' mothers to find out about misoprostol exposure and dosage. Each infant was physically examined by a geneticist or a neuropaediatrician. Findings 17 of the infants had equinovarus with cranial-nerve defects. Ten children had equinovarus as part of more extensive arthrogryposis. The most distinctive phenotypes were arthrogryposis confined to the legs (five cases) and terminal transverse-limb defects (nine cases) with or without Mobius sequence. The most common dose of misoprostol taken was 800 mu g (range 200-16 000 mu g). Interpretation Deformities attributed to vascular disruption were found in these children. We suggest that the uterine contractions induced by misoprostol cause vascular disruption in the fetus, including brain-stem ischaemia. Information on the effects of taking misoprostol during pregnancy should be made more widely available, to dissuade women from misusing the drug.	Massachusetts Gen Hosp, Genet & Teratol Univ, Boston, MA 02115 USA; Univ Sao Paulo, Fac Med, Inst Crianca, Sao Paulo, Brazil; Oxford Radcliffe Hosp, Dept Clin Genet, Oxford, England	Harvard University; Massachusetts General Hospital; Universidade de Sao Paulo; University of Oxford	Holmes, LB (corresponding author), Massachusetts Gen Hosp, Genet & Teratol Univ, Warren 801,55 Fruit St, Boston, MA 02115 USA.			Kim, Chong/0000-0002-1754-1300	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033222] Funding Source: NIH RePORTER; NICHD NIH HHS [R0I HD 33222] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOUWESBAVINCK JN, 1986, AM J MED GENET, V23, P903, DOI 10.1002/ajmg.1320230405; Bugalho A, 1996, CONTRACEPTION, V53, P243, DOI 10.1016/0010-7824(96)00044-3; CLEMENS GR, 1997, TOXICOLOGIST, V36, P260; COELHO HLL, 1991, LANCET, V338, P247, DOI 10.1016/0140-6736(91)90379-4; COSTA SH, 1993, LANCET, V341, P1258, DOI 10.1016/0140-6736(93)91156-G; DOWNIE WW, 1991, LANCET, V338, P247; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; FONSECA W, 1991, LANCET, V338, P56, DOI 10.1016/0140-6736(91)90046-R; GONZALEZ CH, 1993, AM J MED GENET, V47, P59, DOI 10.1002/ajmg.1320470113; GOVAERT P, 1989, PEDIATRICS, V84, P570; Hall JG, 1996, AM J MED GENET, V63, P293, DOI 10.1002/(SICI)1096-8628(19960503)63:1<293::AID-AJMG48>3.0.CO;2-G; HOLMES LB, 1995, J PEDIATR-US, V126, P131, DOI 10.1016/S0022-3476(95)70516-3; KOTSONIS FN, 1985, DIGEST DIS SCI, V30, pS142, DOI 10.1007/BF01309401; LIPSON AH, 1989, TERATOLOGY, V40, P339, DOI 10.1002/tera.1420400406; ORNOY A, 1982, ISRAEL J MED SCI, V18, P235; Pastuszak A. L., 1997, Teratology, V55, P36; PERSAUD TVN, 1979, ADV STUDY BIRTH DEFE, P161; RINGEL RE, 1983, J PEDIATR-US, V103, P251, DOI 10.1016/S0022-3476(83)80358-8; Schonhofar P S, 1991, Lancet, V337, P1534, DOI 10.1016/0140-6736(91)93212-R; Schuler L., 1997, Teratology, V55, P36; SHEPARD TH, 1995, LANCET, V346, P780, DOI 10.1016/S0140-6736(95)91540-0; SODRE H, 1990, J PEDIATR ORTHOPED, V10, P101; VERLOES A, 1990, J MED GENET, V27, P213, DOI 10.1136/jmg.27.3.213-b; WEYERTS LK, 1992, AM J MED GENET, V43, P751, DOI 10.1002/ajmg.1320430420	24	161	173	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1624	1627		10.1016/S0140-6736(97)12363-7	http://dx.doi.org/10.1016/S0140-6736(97)12363-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620717				2022-12-28	WOS:000074026600010
J	Van Damme, W; De Brouwere, V; Boelaert, M; Van Lerberghe, W				Van Damme, W; De Brouwere, V; Boelaert, M; Van Lerberghe, W			Effects of a refugee-assistance programme on host population in Guinea as measured by obstetric interventions	LANCET			English	Article							SPATIAL-ANALYSIS; HEALTH; MORTALITY; AFRICA	Background Since 1990, 500 000 people have fled from Liberia and Sierra Leone to Guinea, west Africa, where the government allowed them to settle freely, and provided medical assistance. We assessed whether the host population gained better access to hospital care during 1988-96. Methods In Gueckedou prefecture, we used data on major obstetric interventions performed in the district hospital between January, 1988, and August, 1996, and estimated the expected number of births to calculate the rate of major obstetric interventions for the host population. We calculated rates for 1988-90, 1991-93, and 1994-96 for three rural areas with different numbers of refugees. Findings Rates of major obstetric interventions for the host population increased from 0.03% (95% CI 0-0.09) to 1.06% (0.74-1.38) in the area with high numbers of refugees, from 0.34% (0.22-0.45) to 0.92% (0.74-1.11) in the area with medium numbers, and from 0.07% (0-0.17) to 0.27% (0.08-0.46) in the area with low numbers. The rate ratio over time was 4.35 (2.64-7.15), 1.70 (1.40-2.07), and 1.94 (0.97-3.87) for these areas, respectively. The rates of major obstetric interventions increased significantly more in the area with high numbers of refugees than in the other two areas. Interpretation In areas with high numbers of refugees, the refugee-assistance programme improved the health system and transport infrastructure. The presence of refugees also led to economic changes and a "refugee-induced demand". The non-directive refugee policy in Guinea made such changes possible and may be a cost-effective alternative to camps.	Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium	Institute of Tropical Medicine (ITM)	Van Damme, W (corresponding author), Inst Trop Med, Dept Publ Hlth, Nat Str 155, B-2000 Antwerp, Belgium.	wvdamme@itg.be	Van Damme, Wim/F-7404-2011; Boelaert, Marleen/E-2698-2012	Van Damme, Wim/0000-0002-6344-3007; Boelaert, Marleen/0000-0001-8051-6776; Van Lerberghe, Wim/0000-0001-9966-6563				[Anonymous], 1995, Lancet, V345, P339; CHAMBERS R, 1986, INT MIGR REV, V20, P245, DOI 10.2307/2546034; COLLINS S, 1996, IGNORING HOST IMPACT, P1; DALVA FRM, 1997, ANAL PROGRAMME REDUC, P1; DeBrouwere V, 1996, REV EPIDEMIOL SANTE, V44, P111; DEBROUWERE V, 1997, BESOINS OBSTET COUVE, P1; DRAME ML, 1992, RAPPORT ANN 199U, P1; Goyens P., 1996, Journal of Refugee Studies, V9, P268, DOI 10.1093/jrs/9.3.268; KOUROUMA K, 1997, ANAL TAUX CESARIENNE, P1; MCGOVERN M, 1996, IDENTITIES NEGOTIATI, P1; MCPAKE B, 1993, SOC SCI MED, V36, P1383, DOI 10.1016/0277-9536(93)90381-D; NORDBERG E, 1995, E AFR MED J, V72, P127; NORDBERG EM, 1984, BRIT MED J, V289, P92, DOI 10.1136/bmj.289.6437.92; PORIGNON D, 1995, DISASTERS, V19, P356, DOI 10.1111/j.1467-7717.1995.tb00356.x; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; Toole MJ, 1996, LANCET, V348, P840, DOI 10.1016/S0140-6736(05)64732-0; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; VANDAMME W, 1995, LANCET, V346, P360; VANDAMME W, 1997, DEV SANTE, V127, P23; VANDENBROEK N, 1989, INT J GYNECOL OBSTET, V28, P337, DOI 10.1016/0020-7292(89)90605-X; VANLERBERGHE W, 1988, SOC SCI MED, V26, P949, DOI 10.1016/0277-9536(88)90415-7; VANLERBERGHE W, 1988, HEALTH POLICY PLANN, V3, P308; YANSANE ML, 1996, COMITE TECHNIQUE PRE, P1	24	46	46	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	1998	351	9116					1609	1613		10.1016/S0140-6736(97)10348-8	http://dx.doi.org/10.1016/S0140-6736(97)10348-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZR900	9620714				2022-12-28	WOS:000074026600007
J	Storey, A; Thomas, M; Kalita, A; Harwood, C; Gardiol, D; Mantovani, F; Breuer, J; Leigh, IM; Matlashewski, G; Banks, L				Storey, A; Thomas, M; Kalita, A; Harwood, C; Gardiol, D; Mantovani, F; Breuer, J; Leigh, IM; Matlashewski, G; Banks, L			Role of a p53 polymorphism in the development of human papillomavirus-associated cancer	NATURE			English	Article							CARCINOMA CELL-LINES; RENAL-TRANSPLANT RECIPIENTS; LUNG-CANCER; BROAD-SPECTRUM; GENE-PRODUCT; E6; DEGRADATION; PROTEIN; TYPE-16; BINDING	The E6 oncoprotein derived from tumour-associated human papillomaviruses (HPVs) binds to and induces the degradation of the cellular tumour-suppressor protein p53. A common polymorphism that occurs in the p53 amino-acid sequence results In the presence of either a proline or an arginine at position 72, The effect of this polymorphism on the susceptibility of p53 to EG-mediated degradation has been Investigated and the arginine form of p53 was found to be significantly more susceptible than the proline form. Moreover, allelic analysis of patients with HPV-associated tumours revealed a striking overrepresentation of homozygous arginine-72 p53 compared with the normal population, which indicated that individuals homozygous for arginine 72 are about seven times more susceptible to HPV-associated tumorigenesis than heterozygotes. The arginine-encoding allele therefore represents a significant risk factor in the development of HPV-associated cancers.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Imperial Canc Res Fund, Skin Tumour Lab, London E1 2AT, England; McGill Univ, Inst Parasitol, St Anne De Bellevue, PQ H9X 3V9, Canada; McGill Univ, McGill Canc Ctr, St Anne De Bellevue, PQ H9X 3V9, Canada; St Bartholomews & Royal London Hosp, Sch Med & Dent, Queen Mary & Westfield Coll, Dept Med Microbiol, London E1 1BB, England	International Center for Genetic Engineering & Biotechnology (ICGEB); Cancer Research UK; McGill University; McGill University; Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.			Storey, Alan/0000-0003-2001-9772; Breuer, Judith/0000-0001-8246-0534; Harwood, Catherine/0000-0002-1375-0965				ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228; BENTON EC, 1989, IMMUNODEFICIENCY SKI, P168; BERKHOUT RJM, 1995, J CLIN MICROBIOL, V33, P690, DOI 10.1128/JCM.33.3.690-695.1995; BIRGANDER R, 1995, CARCINOGENESIS, V16, P2233, DOI 10.1093/carcin/16.9.2233; BLESSING K, 1989, HISTOPATHOLOGY, V14, P129, DOI 10.1111/j.1365-2559.1989.tb02123.x; BOYLE J, 1993, CANCER RES, V53, P5328; BUTZ K, 1995, ONCOGENE, V10, P927; CHAN SY, 1995, J VIROL, V69, P3074, DOI 10.1128/JVI.69.5.3074-3083.1995; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; CROOK T, 1991, ONCOGENE, V6, P873; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Glover Mary T., 1993, Cancer Bulletin (Houston), V45, P220; GOLDBERG A, 1992, EUR J BIOCHEM, V203, P285; HERSHKO D, 1992, ANNU REV BIOCHEM, V61, P761; JIN XM, 1995, CARCINOGENESIS, V16, P2205, DOI 10.1093/carcin/16.9.2205; KAWAJIRI K, 1993, CARCINOGENESIS, V14, P1085, DOI 10.1093/carcin/14.6.1085; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; MANOS MM, 1989, CANCER CEL, V7, P209; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOREAU F, 1992, BIOCHEM CELL BIOL, V70, P1014, DOI 10.1139/o92-145; Murata M, 1996, CARCINOGENESIS, V17, P261, DOI 10.1093/carcin/17.2.261; PURDIE KJ, 1993, CANCER RES, V53, P5328; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shamanin V, 1996, JNCI-J NATL CANCER I, V88, P802, DOI 10.1093/jnci/88.12.802; SHAMANIN V, 1994, J GEN VIROL, V75, P1149, DOI 10.1099/0022-1317-75-5-1149; SHAMANIN V, 1994, CANCER RES, V54, P4610; SNIJDERS PJF, 1990, J GEN VIROL, V71, P173, DOI 10.1099/0022-1317-71-1-173; Sun XF, 1996, ONCOGENE, V13, P407; THOMAS M, 1995, ONCOGENE, V10, P261; VOGAN K, 1993, CANCER RES, V53, P5269; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WESTON A, 1994, CARCINOGENESIS, V15, P583, DOI 10.1093/carcin/15.4.583; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG W, 1992, GENE, V117, P271, DOI 10.1016/0378-1119(92)90738-B; ZURHAUSEN H, 1987, PAPOVAVIRIDAE PAPILL, P245	48	810	854	3	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					229	234		10.1038/30400	http://dx.doi.org/10.1038/30400			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607760				2022-12-28	WOS:000073761000041
J	Moore, TJ; Psaty, BM; Furberg, CD				Moore, TJ; Psaty, BM; Furberg, CD			Time to act on drug safety	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ADVERSE		Ctr Hlth Policy Res, Washington, DC 20006 USA; George Washington Univ, Med Ctr, Washington, DC 20037 USA; Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA	George Washington University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Wake Forest University; Wake Forest Baptist Medical Center	Moore, TJ (corresponding author), Ctr Hlth Policy Res, 2021 K St NW,Suite 800, Washington, DC 20006 USA.							ALBENGRES E, 1990, INT J CLIN PHARM TH, V28, P312; AXELRAD JA, 1993, PROGRAM REV DIVISION; *DRUG RES BOARD NA, 1971, INT C ADV REACT REP; *FOOD DRUG ADM, 1997, REP HALC TASK FORC M, P35; *FOOD DRUG ADM, 1997, FDA AN CARD VALV DYS; *FOOD DRUG ADM PRE, 1997, FDA APPR ALL D MAN W; GRAHAM D, 1997, NEWS PIKE, V3, P1; HINE LK, 1990, AM J MED, V88, P151, DOI 10.1016/0002-9343(90)90465-P; JICK H, 1977, NEW ENGL J MED, V296, P481, DOI 10.1056/NEJM197703032960904; *JOINT COMM PRESCR, 1980, FIN REP JOINT COMM P; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LUMPKIN MM, 1993, FINAL REPORT PHASE 2; Miwa LJ, 1997, ARCH INTERN MED, V157, P2129, DOI 10.1001/archinte.157.18.2129; REIFFEL JA, 1990, AM J CARDIOL, V66, P1262, DOI 10.1016/0002-9149(90)91115-M; REINSTEIN PF, ANN ADVERSE DRUG EXP; SOUMERAI SB, 1987, AM J PUBLIC HEALTH, V77, P1518, DOI 10.2105/AJPH.77.12.1518; STROM BL, 1992, ARCH INTERN MED, V152, P1475, DOI 10.1001/archinte.152.7.1475; *US GEN ACC OFF, 1990, GAOPEMD9015; WARREN JL, 1994, ARCH INTERN MED, V154, P1482, DOI 10.1001/archinte.154.13.1482	20	73	77	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1571	1573		10.1001/jama.279.19.1571	http://dx.doi.org/10.1001/jama.279.19.1571			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN087	9605903				2022-12-28	WOS:000073608100037
J	Waters, DJ				Waters, DJ			Holding the heart	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1520	1520		10.1001/jama.279.19.1520	http://dx.doi.org/10.1001/jama.279.19.1520			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN087	9605884				2022-12-28	WOS:000073608100012
J	Emanuel, EJ; Emanuel, LL				Emanuel, EJ; Emanuel, LL			The promise of a good death	LANCET			English	Article							PHYSICIAN-ASSISTED SUICIDE; OF-LIFE QUESTIONNAIRE; ADVANCE DIRECTIVES; TERMINAL CARE; CANCER PAIN; EUTHANASIA; ATTITUDES; ILLNESS; HOSPICE; NEEDS		NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Amer Med Assoc, Div Eth Stand, Chicago, IL 60610 USA	National Institutes of Health (NIH) - USA; American Medical Association	Emanuel, EJ (corresponding author), NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bldg 10 Room 1C118, Bethesda, MD 20892 USA.	eemanuel@nih.gov						*AG HLTH CAR POL R, 1994, AHCPR PUBL; ALLEBECK P, 1989, J CLIN EPIDEMIOL, V42, P611, DOI 10.1016/0895-4356(89)90003-6; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; Aries P, 1981, HOUR OUR DEATH; *ASS PALL MED ROYA, 1993, PALL MED CURR; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BERWICK DM, 1991, MED CARE, V29, P169, DOI 10.1097/00005650-199102000-00008; Billings JA, 1997, JAMA-J AM MED ASSOC, V278, P733, DOI 10.1001/jama.278.9.733; BREITBART W, 1995, J PAIN SYMPTOM MANAG, V10, P131, DOI 10.1016/0885-3924(94)00075-V; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; BROOK DB, IN PRESS HOSPICE J; Bruera E, 1991, J Palliat Care, V7, P6; Cassel, 1991, NATURE SUFFERING GOA; Cleeland CS, 1989, ADV PAIN RES THER, P391, DOI DOI 10.1093/BRAIN/113.5.1589; COHEN SR, 1995, PALLIATIVE MED, V9, P207, DOI 10.1177/026921639500900306; Cohen SR, 1996, CANCER-AM CANCER SOC, V77, P576, DOI 10.1002/(SICI)1097-0142(19960201)77:3<576::AID-CNCR22>3.0.CO;2-0; Cohen SR, 1997, PALLIATIVE MED, V11, P3; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DONNELLY S, 1995, SEMIN ONCOL, V22, pS67; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2067; EMANUEL EJ, 1998, J CLIN ONCOL, V17, P1628; EMANUEL LL, 1995, J AM GERIATR SOC, V43, P440, DOI 10.1111/j.1532-5415.1995.tb05821.x; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EMANUEL LL, 1991, JAMA-J AM MED ASSOC, V325, P3288; FaberLangendoen K, 1996, ARCH INTERN MED, V156, P2130, DOI 10.1001/archinte.156.18.2130; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; HOUTS PS, 1988, CANCER, V62, P627, DOI 10.1002/1097-0142(19880801)62:3<627::AID-CNCR2820620331>3.0.CO;2-1; *I MED, 1997, APPR DEATH IMPR CAR; KANE RL, 1984, LANCET, V1, P890; KINSELLA TD, 1994, BRIT MED J, V308, P1332; Kohout F J, 1993, J Aging Health, V5, P179, DOI 10.1177/089826439300500202; Kubler-Ross E., 1970, DEATH DYING; KUTNER L, 1969, INDIANA LAW J, V44, P539; Mount B M, 1994, J Palliat Care, V10, P24; MOUNT BM, 1983, J CHRON DIS, V36, P731, DOI 10.1016/0021-9681(83)90068-1; *NAT HOSP ORG, 1997, HOSP FACT SHEET; PATRICK C, 1992, GEN HOSP PSYCHIAT, V14, P219, DOI 10.1016/0163-8343(92)90091-N; PHILLIPS DP, 1988, LANCET, V2, P728; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; PORTENOY RK, 1994, QUAL LIFE RES, V3, P183, DOI 10.1007/BF00435383; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; QUILL TE, 1996, MIDWIFE DYING PROCES, P202; SCHULBERG HC, 1985, ARCH GEN PSYCHIAT, V42, P1164; SEAL C, 1994, YEAR DEATH; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; SIEGEL K, 1991, CANCER, V68, P1131, DOI 10.1002/1097-0142(19910901)68:5<1131::AID-CNCR2820680541>3.0.CO;2-N; STODDARD S, 1974, HOSPICE MOVEMENT BET; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERMAAS PJ, 1996, NEW ENGL J MED, V335, P1691; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; *VTTAS HEALTHC, 1995, MISS VITAS QUAL IND; WEEKS JC, IN PRESS JAMA; Welch T., 1985, OUTPATIENT MANAGEMEN; World Health Organization, 1990, CANC PAIN REL PALL C; [No title captured]	60	323	329	2	30	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY	1998	351			2			21	29		10.1016/S0140-6736(98)90329-4	http://dx.doi.org/10.1016/S0140-6736(98)90329-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZP168	9606363				2022-12-28	WOS:000073724100005
J	Cooper, PJ; Murray, L				Cooper, PJ; Murray, L			Fortnightly review - Postnatal depression	BMJ-BRITISH MEDICAL JOURNAL			English	Review							POSTPARTUM MOOD DISORDERS; IMPACT; PROPHYLAXIS; PREVALENCE; VALIDATION; MOTHERS; SAMPLE; SCALE		Univ Reading, Dept Psychol, Winnicott Res Unit, Reading RG6 6AL, Berks, England	University of Reading	Cooper, PJ (corresponding author), Univ Reading, Dept Psychol, Winnicott Res Unit, Reading RG6 6AL, Berks, England.	P.J.Cooper@reading.ac.uk						Appleby L, 1997, BRIT MED J, V314, P932, DOI 10.1136/bmj.314.7085.932; BRISCOE ME, 1985, HLTH VISITOR, V58, P197; COGILL SR, 1986, BMJ-BRIT MED J, V292, P1165, DOI 10.1136/bmj.292.6529.1165; Cooper P. J., 1991, EUROPEAN HDB PSYCHIA, P1255; Cooper Peter J., 1997, P201; Cooper PJ, 1996, PSYCHOL MED, V26, P627, DOI 10.1017/S0033291700035698; COOPER PJ, 1995, BRIT J PSYCHIAT, V166, P191, DOI 10.1192/bjp.166.2.191; COOPER PJ, 1988, BRIT J PSYCHIAT, V152, P799, DOI 10.1192/bjp.152.6.799; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; COX JL, 1993, BRIT J PSYCHIAT, V163, P27, DOI 10.1192/bjp.163.1.27; DALTON K, 1985, PRACTITIONER, V229, P507; Gregoire AJP, 1996, LANCET, V347, P930, DOI 10.1016/S0140-6736(96)91414-2; HARRIS B, 1994, BRIT J PSYCHIAT, V164, P288, DOI 10.1192/bjp.164.3.288; HARRIS B, 1993, BRIT J PSYCHIAT, V163, P403, DOI 10.1192/bjp.163.3.403; HOLDEN JM, 1989, BRIT MED J, V298, P223, DOI 10.1136/bmj.298.6668.223; LYONSRUTH K, 1996, MATERNAL DEPRESSION, P34; Murray L, 1996, DEV MED CHILD NEUROL, V38, P109; MURRAY L, 1992, J CHILD PSYCHOL PSYC, V33, P543, DOI 10.1111/j.1469-7610.1992.tb00890.x; MURRAY L, 1990, BRIT J PSYCHIAT, V157, P288, DOI 10.1192/bjp.157.2.288; Murray L, 1997, ARCH DIS CHILD, V77, P99, DOI 10.1136/adc.77.2.99; Murray L, 1996, CHILD DEV, V67, P2512, DOI 10.2307/1131637; MURRAY L, 1993, J REPROD INFANT PSYC, V11, P215, DOI DOI 10.1080/02646839308403221; O'hara MW, 1997, POSTPARTUM DEPRESSIO, P3; OHARA MW, 1991, J ABNORM PSYCHOL, V100, P63, DOI 10.1037/0021-843X.100.1.63; OHARA MW, 1990, J ABNORM PSYCHOL, V99, P3, DOI 10.1037/0021-843X.99.1.3; Sharp D, 1995, J CHILD PSYCHOL PSYC, V36, P1315, DOI 10.1111/j.1469-7610.1995.tb01666.x; Sinclair D, 1998, BRIT J PSYCHIAT, V172, P58, DOI 10.1192/bjp.172.1.58; TETI DM, 1995, DEV PSYCHOL, V31, P364, DOI 10.1037/0012-1649.31.3.364; TROUTMAN BR, 1990, J ABNORM PSYCHOL, V99, P69, DOI 10.1037/0021-843X.99.1.69; Wickberg B, 1996, J AFFECT DISORDERS, V39, P209, DOI 10.1016/0165-0327(96)00034-1; [No title captured]	31	279	290	1	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 20	1998	316	7148					1884	1886						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZZ013	9632411				2022-12-28	WOS:000074686500028
J	[Anonymous]				[Anonymous]			Junior doctors conference	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 20	1998	316	7148					1910	1911						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632433				2022-12-28	WOS:000074686500077
J	Benigni, A; Remuzzi, G				Benigni, A; Remuzzi, G			Transplant tolerance: will genes protect the graft?	LANCET			English	Editorial Material									Osped Riuniti Bergamo, Ist Ric Farmacol Mario Negri, Dept Transplant Immunol & Innovat Antireject The, I-24100 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo	Benigni, A (corresponding author), Osped Riuniti Bergamo, Ist Ric Farmacol Mario Negri, Dept Transplant Immunol & Innovat Antireject The, I-24100 Bergamo, Italy.		Ariela, Benigni/ABH-3492-2020; Remuzzi, Giuseppe/V-9766-2017	Ariela, Benigni/0000-0002-4721-5485; Remuzzi, Giuseppe/0000-0002-6194-3446				CHAHINE AA, 1995, TRANSPLANTATION, V59, P1313, DOI 10.1097/00007890-199505150-00016; Deng S, 1997, TRANSPL P, V29, P770, DOI 10.1016/S0041-1345(96)00477-0; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Knechtle SJ, 1997, J IMMUNOL, V159, P152; LONDON NJ, 1995, LANCET, V346, P403, DOI 10.1016/S0140-6736(95)92780-8; LUTZ J, 1997, J AM SOC NEPHROL S, V8, pA502; Nashan B, 1997, LANCET, V350, P1193, DOI 10.1016/S0140-6736(97)09278-7; Olthoff KM, 1998, NAT MED, V4, P194, DOI 10.1038/nm0298-194; Perico N, 1997, DRUGS, V54, P533, DOI 10.2165/00003495-199754040-00003; Perico N, 1997, INT J CLIN LAB RES, V27, P165, DOI 10.1007/BF02912453; QIN LH, 1995, TRANSPLANTATION, V59, P809, DOI 10.1097/00007890-199503270-00002; SAYEGH MH, 1997, KIDNEY INT S58, V51, pS11; Swenson KM, 1998, TRANSPLANTATION, V65, P155	13	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1749	1751		10.1016/S0140-6736(05)78739-0	http://dx.doi.org/10.1016/S0140-6736(05)78739-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635942				2022-12-28	WOS:000074197600003
J	Boshuizen, HC; Izaks, GJ; van Buuren, S; Ligthart, GJ				Boshuizen, HC; Izaks, GJ; van Buuren, S; Ligthart, GJ			Blood pressure and mortality in elderly people aged 85 and older: community based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SURVIVAL; SEX	Objective: To determine whether the inverse relation between blood pressure and all cause mortality in elderly people over 85 years of age can be explained by adjusting for health status, and to determine whether high blood pressure is a risk factor for mortality when the effects of poor health are accounted for. Design: 5 to 7 year follow up of community residents aged 85 years and older. Setting: Leiden, the Netherlands. Subjects: 835 subjects whose blood pressure was recorded between 1987 and 1989. Main outcome measure: All cause mortality. Results: An inverse relation between blood pressure and all cause mortality was observed. For diastolic blood pressure crude year all cause mortality decreased from 88% (52/59) (95% confidence interval 79% to 95%) in those with diastolic blood pressures < 65 mm Hg to 59% (27/46) (44% to 72%) in those with diastolic pressures > 100 mm Hg. For systolic blood pressure crude 5 year all cause mortality decreased from 85% (95/112) (78% to 91%) in those with systolic pressures < 125 mm Hg to 59% (13/22) (38% to 78%) in those with systolic pressures > 200 min Hg. This decrease was no longer significant after adjustment for indicators of poor health. No relation existed between blood pressure and mortality from cardiovascular causes or stroke after adjustment for age and sex, but after adjustment for age, sex, and indicators of poor health there was a positive relation between diastolic blood pressure and mortality from both cardiovascular causes and stroke. Conclusion: The inverse relation between blood pressure and all cause mortality in elderly people over 85 is associated with health status.	TNO Prevent & Hlth, Div Publ Hlth & Prevent, Leiden, Netherlands; Leiden Univ, Dept Gen Internal Med, Sect Gerontol & Geriatr, Med Ctr, Leiden, Netherlands	Netherlands Organization Applied Science Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Boshuizen, HC (corresponding author), TNO Prevent & Hlth, Div Publ Hlth & Prevent, Leiden, Netherlands.	HC.Boshuizen@PG.TNO.NL	Izaks, Gerbrand/F-5089-2014; Boshuizen, Hendriek/M-3415-2014; Boshuizen, Hendriek C/B-3718-2014	Izaks, Gerbrand/0000-0003-3213-7637; Boshuizen, Hendriek/0000-0002-3916-9095; van Buuren, Stef/0000-0003-1098-2119	NATIONAL INSTITUTE ON AGING [R01AG006354] Funding Source: NIH RePORTER; NIA NIH HHS [AG 06354] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMERY A, 1986, LANCET, V2, P589; [Anonymous], 1991, JAMA, V265, P3255; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GLYNN RJ, 1995, LANCET, V345, P825, DOI 10.1016/S0140-6736(95)92964-9; Guo ZC, 1997, AM J PUBLIC HEALTH, V87, P623, DOI 10.2105/AJPH.87.4.623; HEIKINHEIMO RJ, 1990, J HYPERTENS, V8, P361, DOI 10.1097/00004872-199004000-00010; HOLME I, 1976, ACTA MED SCAND, V200, P229; Izaks GJ, 1997, J AM GERIATR SOC, V45, P56, DOI 10.1111/j.1532-5415.1997.tb00978.x; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; LAGAAY AM, 1992, BRIT MED J, V304, P1091, DOI 10.1136/bmj.304.6834.1091; LANGER RD, 1991, AM J EPIDEMIOL, V134, P29, DOI 10.1093/oxfordjournals.aje.a115990; LIGTHART GJ, 1984, MECH AGEING DEV, V28, P47, DOI 10.1016/0047-6374(84)90152-0; MATTILA K, 1988, BRIT MED J, V296, P887, DOI 10.1136/bmj.296.6626.887; RAJALA S, 1983, LANCET, V2, P520; WeverlingRijnsburger AWE, 1997, LANCET, V350, P1119, DOI 10.1016/S0140-6736(97)04430-9	16	152	158	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	1998	316	7147					1780	+		10.1136/bmj.316.7147.1780	http://dx.doi.org/10.1136/bmj.316.7147.1780			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624064	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000074286300024
J	Brown, P; Marsden, CD				Brown, P; Marsden, CD			What do the basal ganglia do?	LANCET			English	Article							PRIMATE SUBTHALAMIC NUCLEUS; MPTP MODEL; PARKINSONIAN-PATIENTS; NEURONAL-ACTIVITY; GLOBUS-PALLIDUS; MOTOR BEHAVIOR; OSCILLATIONS; DISEASE; SYNCHRONIZATION; HUMANS	We propose that the basal ganglia support a basic attentional mechanism operating to bind input to output in the executive forebrain, Such focused attention provides the automatic link between voluntary effort, sensory input, and the ceiling up and operation of a sequence of motor programmes or thoughts. The physiological basis for this attentional mechanism may lie in the tendency of distributed, but related, cortical activities to synchronise in the gamma (30 to 50 Hz) band, as occurs in the visual cortex,(1) Coherent and synchronised elements are more effective when convergence occurs during successive stages of processing, and in this way may come together to give the one gestalt or action. We suggest that the basal ganglia have a major role in facilitating this aspect of neuronal processing in the forebrain, and that loss of this function contributes to parkinsonism and abulia.	UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; Inst Neurol, MRC, Human Movement & Balance Unit, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London	Brown, P (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Queen Sq, London WC1N 3BG, England.		Brown, Peter/J-4307-2016	Brown, Peter/0000-0002-5201-3044				Adrian ED, 1934, BRAIN, V57, P355, DOI 10.1093/brain/57.4.355; ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; BROWN P, IN PRESS J PHYSL; Defebvre Luc, 1994, Brain Topography, V6, P237, DOI 10.1007/BF01187715; DEFRANCE J, 1988, EEG MENTAL ACTIVITIE, P153; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DIECKMANN G, 1968, J NEUROL SCI, V7, P385, DOI 10.1016/0022-510X(68)90157-3; ENGLAND AC, 1959, ELECTROEN CLIN NEURO, V11, P723, DOI 10.1016/0013-4694(59)90111-7; FILION M, 1991, BRAIN RES, V547, P142; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HASSLER R., 1967, BRAIN RES, V5, P504, DOI 10.1016/0006-8993(67)90021-2; HILL AV, 1921, J PHYSL, V55, pP14; HOOVER JE, 1993, SCIENCE, V259, P819, DOI 10.1126/science.7679223; Kennard MA, 1942, J NEUROPHYSIOL, V5, P335, DOI 10.1152/jn.1942.5.5.335; LLINAS R, 1993, P NATL ACAD SCI USA, V90, P2078, DOI 10.1073/pnas.90.5.2078; MARSDEN CD, 1994, BRAIN, V117, P877, DOI 10.1093/brain/117.4.877; MERTON PA, 1981, J NEUROL NEUROSUR PS, V44, P861, DOI 10.1136/jnnp.44.10.861; Munk MHJ, 1996, SCIENCE, V272, P271, DOI 10.1126/science.272.5259.271; NEUFELD MY, 1994, DEMENTIA, V5, P23, DOI 10.1159/000106690; NEUFELD MY, 1988, ACTA NEUROL SCAND, V78, P1, DOI 10.1111/j.1600-0404.1988.tb03609.x; NICOLELIS MAL, 1995, SCIENCE, V268, P1353, DOI 10.1126/science.7761855; NINI A, 1995, J NEUROPHYSIOL, V74, P1800, DOI 10.1152/jn.1995.74.4.1800; PFURTSCHELLER G, 1993, NEUROSCI LETT, V164, P179, DOI 10.1016/0304-3940(93)90886-P; Piper H.E., 1912, ELEKTROPHYSIOLOGIE M; REINER A, 1988, P NATL ACAD SCI USA, V85, P5733, DOI 10.1073/pnas.85.15.5733; Salenius S, 1996, NEUROSCI LETT, V213, P75, DOI 10.1016/0304-3940(96)12796-8; SEMJACOBSEN CW, 1956, ELECTROEN CLIN NEURO, V8, P263, DOI 10.1016/0013-4694(56)90118-3; SINGER W, 1993, PROG BRAIN RES, V95, P461, DOI 10.1016/S0079-6123(08)60388-X; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; STERIADE M, 1991, P NATL ACAD SCI USA, V88, P4396, DOI 10.1073/pnas.88.10.4396; THOMPSON PD, 1994, MOVEMENT DISORD, V9, P633, DOI 10.1002/mds.870090609; TIITINEN H, 1993, NATURE, V364, P59, DOI 10.1038/364059a0; WICHMANN T, 1994, J NEUROPHYSIOL, V72, P521, DOI 10.1152/jn.1994.72.2.521; YAAR I, 1977, ELECTROEN CLIN NEURO, V43, P111, DOI 10.1016/0013-4694(77)90203-6	35	281	290	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1801	1804		10.1016/S0140-6736(97)11225-9	http://dx.doi.org/10.1016/S0140-6736(97)11225-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635969				2022-12-28	WOS:000074197600045
J	Mahadeva, R; Webb, K; Westerbeek, RC; Carroll, NR; Dodd, ME; Bilton, D; Lomas, DA				Mahadeva, R; Webb, K; Westerbeek, RC; Carroll, NR; Dodd, ME; Bilton, D; Lomas, DA			Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PSEUDOMONAS-AERUGINOSA; SURVIVAL; MORTALITY	Objectives: To assess the effect on clinical outcome of managing paediatric and adult patients with cystic fibrosis at specialised cystic fibrosis centres. Design: Gross sectional study. Setting: Two adult cystic fibrosis centres in the United Kingdom. Subjects: Patients from an adult cystic fibrosis centre in Manchester were subdivided into those who had received continuous care from paediatric and adult cystic fibrosis centres (group A), and those who had received paediatric care in a centre not specialising in cystic fibrosis followed by adult care in a cystic fibrosis centre (group B). Group C were referrals to the new adult cystic fibrosis centre in Cambridge who had received neither paediatric nor adult centre care for their cystic fibrosis. Main outcome measures: Body mass index (weight (kg)/height (m(2))), lung function (forced expiratory volume in one second (FEV1 percentage of predicted)), the Northern chest x ray film score, and age at colonisation with Pseudomonas aeruginosa. Results: A prominent stepwise increase in body mass index was associated with increasing amounts of care at a cystic fibrosis centre; 18.3, 20.2, and 21.3 for groups C, B, and A respectively (P < 0.001). Improved nutritional status was correlated with a higher FEV1 and better (lower) chest a ray film scores; r=0.52 and -0.45 respectively (P < 0.001 for both). Conclusion: These findings provide the first direct evidence that management of cystic fibrosis in paediatric and adult cystic fibrosis centres results in a better clinical outcome, and strongly supports the provision of these specialist services.	Papworth Hosp NHS Trust, Cyst Fibrosis Unit, Cambridge CB3 8RE, England; Univ Cambridge, Dept Haematol, MRC Ctr, Cambridge CB2 2QH, England; Wythenshawe Hosp NHS Trust, Bradbury Cyst Fibrosis Unit, Manchester M23 9LT, Lancs, England; Univ Cambridge, MRC, Biostat Unit, Cambridge CB2 2QQ, England; Addenbrookes Hosp NHS Trust, Cambridge CB2 2QQ, England	Papworth Hospital; MRC Laboratory Molecular Biology; University of Cambridge; Wythenshawe Hospital NHS Foundation Trust; MRC Biostatistics Unit; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital	Bilton, D (corresponding author), Papworth Hosp NHS Trust, Cyst Fibrosis Unit, Cambridge CB3 8RE, England.			Bilton, Diana/0000-0002-1913-9171				Andersen DH, 1938, AM J DIS CHILD, V56, P344, DOI 10.1001/archpedi.1938.01980140114013; Bell SC, 1996, THORAX, V51, P126, DOI 10.1136/thx.51.2.126; Cheng K, 1996, LANCET, V348, P639, DOI 10.1016/S0140-6736(96)05169-0; CONWAY SP, 1994, THORAX, V49, P860, DOI 10.1136/thx.49.9.860; COREY M, 1988, J CLIN EPIDEMIOL, V41, P583, DOI 10.1016/0895-4356(88)90063-7; *CYST FIBR TRUST, 1996, CLIN GUID CYST FIBR; DODGE JA, 1988, BRIT MED J, V297, P1599; DURIE PR, 1992, BRIT MED BULL, V48, P823, DOI 10.1093/oxfordjournals.bmb.a072580; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; HENRY RL, 1992, PEDIATR PULM, V12, P158, DOI 10.1002/ppul.1950120306; HOOGKAMPKORSTANJE JAA, 1980, A VAN LEEUW J MICROB, V46, P100, DOI 10.1007/BF00422237; KEREM E, 1992, NEW ENGL J MED, V326, P1187, DOI 10.1056/NEJM199204303261804; KRAEMER R, 1978, ACTA PAEDIATR SCAND, V67, P33, DOI 10.1111/j.1651-2227.1978.tb16273.x; Mahadeva R, 1998, EUR RESPIR J, V11, P873, DOI 10.1183/09031936.98.11040873; Moorcroft AJ, 1997, THORAX, V52, P291, DOI 10.1136/thx.52.3.291; NEIJENS HJ, 1985, ACTA PAEDIATR SCAND, P38; NIELSEN OH, 1982, ACTA PAEDIATR SCAND, P107; PHELAN P, 1984, ARCH DIS CHILD, V59, P71, DOI 10.1136/adc.59.1.71; Royal College of Physicians, 1990, CYST FIBR AD REC CAR; SPEERT DP, 1987, J HOSP INFECT, V9, P11, DOI 10.1016/0195-6701(87)90089-2; SPEERT DP, 1982, J PEDIATR-US, V101, P227, DOI 10.1016/S0022-3476(82)80127-3; SUN L, 1995, NAT MED, V1, P661, DOI 10.1038/nm0795-661; Thomassen M J, 1985, Pediatr Pulmonol, V1, P40, DOI 10.1002/ppul.1950010110; WALTERS S, 1994, THORAX, V49, P300, DOI 10.1136/thx.49.4.300; WIENTZEN R, 1980, AM J DIS CHILD, V134, P1134, DOI 10.1001/archpedi.1980.02130240018007	25	179	180	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	1998	316	7147					1771	+		10.1136/bmj.316.7147.1771	http://dx.doi.org/10.1136/bmj.316.7147.1771			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624062	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000074286300020
J	Richards, SH; Coast, J; Gunnell, DJ; Peters, TJ; Pounsford, J; Darlow, MA				Richards, SH; Coast, J; Gunnell, DJ; Peters, TJ; Pounsford, J; Darlow, MA			Randomised controlled trial comparing effectiveness and acceptability of an early discharge, hospital at home scheme with acute hospital care	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; STATE	Objective: to compare effectiveness and acceptability of early discharge to a hospital at home scheme with that of routine discharge from acute hospital. Design: Pragmatic randomised controlled trial. Setting: Acute hospital wards and community in north of Bristol, with a catchment population of about 224 000 people. Subjects: 241 hospitalised but medically stable elderly patients who fulfilled criteria for early discharge to hospital at home scheme and who consented to participate. Interventions: Patients' received hospital at home care or routine hospital care. Main outcome measures: Patients' quality of life, satisfaction, and physical functioning assessed at 4 weeks and 3 months after randomisation to treatment; length of stay in hospital and in hospital at home scheme after randomisation; mortality at 3 months. Results: There were no significant differences in patient mortality, quality of life, and physical functioning between the two arms of the trial at 4 weeks or 3 months. Only one of 11 measures of patient satisfaction was significantly different: hospital at home patients perceived higher levels of involvement in decisions. Length of stay for those receiving routine hospital care was 62% (95% confidence interval 51% to 75%) of length of stay in hospital at home scheme. Conclusions: The early discharge hospital at home scheme was similar to routine hospital discharge in terms of effectiveness and acceptability. Increased length of stay associated with the scheme must be interpreted with caution because of different organisational characteristics of the services.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Frenchay Hosp, Day Hosp, Bristol BS16 1LE, Avon, England; Hosp Home, Downend Clin, Bristol BS16 5TW, Avon, England	University of Bristol	Richards, SH (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	suzanne.richards@bris.ac.uk	Gunnell, David/ABE-6653-2020	Gunnell, David/0000-0002-0829-6470; Richards, Suzanne/0000-0003-1416-0569; Peters, Tim/0000-0003-2881-4180; Coast, Joanna/0000-0002-3537-5166				Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Closset J, 1995, ACTA GASTRO-ENT BELG, V58, P373; Coast J, 1998, BRIT MED J, V316, P1802, DOI 10.1136/bmj.316.7147.1802; Coast J, 1996, BRIT MED J, V312, P162; Collin C, 1988, Int Disabil Stud, V10, P61; COSTAIN D, 1992, HOSP HOME CARE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fulop NJ, 1997, J ROY SOC MED, V90, P212, DOI 10.1177/014107689709000408; GOULD MM, 1995, BR J HLTH CARE MANAG, V1, P809; HENDEE WR, 1990, JAMA-J AM MED ASSOC, V263, P1241; Hensher M, 1996, J ROY SOC MED, V89, P548, DOI 10.1177/014107689608901003; KNOWELDEN J, 1991, J PUBLIC HEALTH MED, V13, P182, DOI 10.1093/oxfordjournals.pubmed.a042616; MAHONEY F I, 1965, Md State Med J, V14, P61; Marks L, 1990, HOME HOSP CARE REDRA; OCATHAIN A, 1994, J PUBLIC HEALTH MED, V16, P205, DOI 10.1093/oxfordjournals.pubmed.a042958; *OFF POP CENS SURV, 1994, GEN HOUS SURV RES 19; Peters TJ, 1998, J EPIDEMIOL COMMUN H, V52, P59, DOI 10.1136/jech.52.1.59; PRYOR GA, 1989, J BONE JOINT SURG BR, V71, P471, DOI 10.1302/0301-620X.71B3.2722942; SCHULTEN JHG, 1992, FUNCTIONAL STATUS AS	19	100	102	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1796	1801		10.1136/bmj.316.7147.1796	http://dx.doi.org/10.1136/bmj.316.7147.1796			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624070	Green Published			2022-12-28	WOS:000074286300029
J	Balsalobre, A; Damiola, F; Schibler, U				Balsalobre, A; Damiola, F; Schibler, U			A serum shock induces circadian gene expression in mammalian tissue culture cells	CELL			English	Article							LEUCINE-ZIPPER PROTEINS; C-FOS; RHYTHMS; CLOCK; TRANSCRIPTION; ENTRAINMENT; LIGHT; TEF; DBP	The treatment of cultured rat-1 fibroblasts or H35 hepatoma cells with high concentrations of serum induces the circadian expression of various genes whose transcription also oscillates in living animals. Oscillating genes include rper1 and rper2 (rat homologs of the Drosophila clock gene period), and the genes encoding the transcription factors Rev-Erb alpha, DBP, and TEF. In rat-1 fibroblasts, up to three consecutive daily oscillations with an average period length of 22.5 hr could be recorded. The temporal sequence of the various mRNA accumulation cycles is the same in cultured cells and in vivo. The serum shock of rat-1 fibroblasts also results in a transient stimulation of c-fos and rper expression and thus mimics light-induced immediate-early gene expression in the suprachiasmatic nucleus.	Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland	University of Geneva	Schibler, U (corresponding author), Univ Geneva, Dept Mol Biol, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Damiola, Francesca/0000-0002-0238-1252				Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chrousos GP, 1998, ENDOCRINOLOGY, V139, P437, DOI 10.1210/endo.139.2.5857; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; EWER J, 1992, J NEUROSCI, V12, P3321; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; Gwinner E, 1997, BRAIN RES BULL, V44, P439, DOI 10.1016/S0361-9230(97)00224-4; HASTINGS HM, 1997, CURR BIOL, V7, P670; Honrado GI, 1996, J COMP PHYSIOL A, V178, P563; Kaneko M, 1997, J NEUROSCI, V17, P6745; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; Kornhauser JM, 1996, BEHAV GENET, V26, P221, DOI 10.1007/BF02359382; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; MOORE RY, 1992, CIRCADIAN RHYTHMS, P26; Morris ME, 1998, SCIENCE, V279, P1544, DOI 10.1126/science.279.5356.1544; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; Okano T, 1997, J PINEAL RES, V22, P145, DOI 10.1111/j.1600-079X.1997.tb00316.x; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Portaluppi F, 1996, ANN NY ACAD SCI, V783, P113, DOI 10.1111/j.1749-6632.1996.tb26711.x; Rabinowitz L, 1996, KIDNEY INT, V49, P1738, DOI 10.1038/ki.1996.258; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; ROBERTSON LM, 1988, J NEUROSCI, V8, P22; Rosato E, 1997, BIOESSAYS, V19, P1075, DOI 10.1002/bies.950191206; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; RUSAK B, 1979, PHYSIOL REV, V59, P449, DOI 10.1152/physrev.1979.59.3.449; SCHMIDT EE, 1995, DEVELOPMENT, V121, P2373; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; TAKAHASHI JS, 1993, CURR OPIN GENET DEV, V3, P301, DOI 10.1016/0959-437X(93)90038-Q; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Tosini G, 1998, J NEUROSCI, V18, P1105; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Young MW, 1996, COLD SPRING HARB SYM, V61, P279; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	49	1464	1498	7	113	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					929	937		10.1016/S0092-8674(00)81199-X	http://dx.doi.org/10.1016/S0092-8674(00)81199-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635423	Bronze			2022-12-28	WOS:000074205700005
J	Rizzuto, R; Pinton, P; Carrington, W; Fay, FS; Fogarty, KE; Lifshitz, LM; Tuft, RA; Pozzan, T				Rizzuto, R; Pinton, P; Carrington, W; Fay, FS; Fogarty, KE; Lifshitz, LM; Tuft, RA; Pozzan, T			Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses	SCIENCE			English	Article							CALCIUM LOADS; INTACT-CELLS; LIVING CELLS; HOMEOSTASIS; AEQUORIN; NEURONS	The spatial relation between mitochondria and endoplasmic reticulum (ER) in living HeLa cells was analyzed at high resolution in three dimensions with two differently colored, specifically targeted green fluorescent proteins. Numerous close contacts were observed between these organelles, and mitochondria in situ formed a largely interconnected, dynamic network. A Ca2+-sensitive photoprotein targeted to the outer face of the inner mitochondrial membrane showed that, upon opening of the inositol 1,4,5-triphosphate (IP3)-gated channels of the ER, the mitochondrial surface was exposed to a higher concentration of Ca2+ than was the bulk cytosol. These results emphasize the importance of cell architecture and the distribution of organelles in regulation of Ca2+ signaling.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Natl Res Council, Ctr Study Biomembranes, I-35121 Padua, Italy; Univ Massachusetts, Med Ctr, Biomed Imaging Grp, Worcester, MA 01605 USA	University of Padua; University of Padua; University of Massachusetts System; University of Massachusetts Worcester	Rizzuto, R (corresponding author), Univ Padua, Dept Biomed Sci, Via Colombo 3, I-35121 Padua, Italy.	rizzuto@civ.bio.unipd.it	Pinton, Paolo/J-8025-2012; Rizzuto, Rosario/B-6312-2008	Pinton, Paolo/0000-0001-7108-6508; Rizzuto, Rosario/0000-0001-7044-5097	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009799] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014523, R37HL014523] Funding Source: NIH RePORTER; NCRR NIH HHS [RR09799] Funding Source: Medline; NHLBI NIH HHS [HL14523] Funding Source: Medline; Telethon [845, 850] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon)		BAKEEVA LE, 1978, BIOCHIM BIOPHYS ACTA, V501, P349, DOI 10.1016/0005-2728(78)90104-4; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; BROWN LJ, 1994, J BIOL CHEM, V269, P14363; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; CAMPBELL CL, 1994, MOL BIOL CELL, V5, P899, DOI 10.1091/mbc.5.8.899; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; DAVISON MT, 1977, J GEN MICROBIOL, V98, P147, DOI 10.1099/00221287-98-1-147; Drummond RM, 1996, PFLUG ARCH EUR J PHY, V431, P473, DOI 10.1007/s004240050025; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KIEDROWSKI L, 1995, MOL PHARMACOL, V47, P140; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; MacDonald MJ, 1996, ARCH BIOCHEM BIOPHYS, V326, P79, DOI 10.1006/abbi.1996.0049; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Rizzuto R, 1995, METHOD ENZYMOL, V260, P417, DOI 10.1016/0076-6879(95)60155-4; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; RIZZUTO R, IN PRESS TRENDS CELL; ROBBGASPERS LD, UNPUB; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; WERTH JL, 1994, J NEUROSCI, V14, P348; WHITE RJ, 1995, J NEUROSCI, V15, P1318	35	1728	1771	6	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	1998	280	5370					1763	1766		10.1126/science.280.5370.1763	http://dx.doi.org/10.1126/science.280.5370.1763			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624056				2022-12-28	WOS:000074197800045
J	Botkin, JR; McMahon, WM; Smith, KR; Nash, JE				Botkin, JR; McMahon, WM; Smith, KR; Nash, JE			Privacy and confidentiality in the publication of pedigrees - A survey of investigators and biomedical journals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Pedigree diagrams efficiently communicate family information to genetics investigators; however, the publication of pedigrees poses a risk to the privacy and confidentiality of individuals depicted in the diagrams. Two sets of authoritative guidelines have been published to protect the privacy and confidentiality of subjects, but the influence of these guidelines on publication practices for pedigrees is unknown. Objective.-To determine the attitudes, practices, and experiences of investigators and journals with respect to privacy and confidentiality concerns in the publication of pedigrees. Design.-Investigators who have published pedigrees and editors of 26 biomedical journals were surveyed. Journals were reviewed for content in their "information for authors" sections and for documentation of informed consent in articles containing pedigrees. Outcome Measures.-Practices regarding confidentiality and privacy reported by investigators and editors. Results.-Of 226 surveys sent to investigators, 177 were returned (78% response rate). Sixty-one investigators (36%) stated that family members were not informed that their pedigree would be published; 131 (78%) do not obtain informed consent specifically for pedigree publication and only 12 (28%) of the 43 who obtained consent obtained consent from all family members depicted. Thirty-two individuals (19%) reported having altered published pedigrees and 14 (45%) of 31 who had altered pedigrees stated that alterations were not disclosed to journals. Of the 14 journals that responded (54% response rate), only 3 reported written policies for managing potentially identifying information. Two journals reported having asked authors to alter pedigrees and 3 stated they had permitted alterations. A review of 5 genetics journals over a 2-year period revealed no documentation of consent for pedigree publication. Conclusions.-Current practices in the publication of pedigrees do not conform with established recommendations and risk the privacy and confidentiality of subjects, often without informed consent. Attempts to address this problem through the alteration of data are being used, although this practice impairs the integrity of scientific communication.	Univ Utah, Dept Pediat, Salt Lake City, UT USA; Univ Utah, Dept Psychiat, Div Med Eth, Salt Lake City, UT USA; Univ Utah, Dept Family & Consumer Studies, Salt Lake City, UT USA; Univ Utah, Dept Human Genet, Salt Lake City, UT USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Botkin, JR (corresponding author), Primary Childrens Med Ctr, Dept Pediat, 100 N Med Dr, Salt Lake City, UT 84113 USA.	botkin@howard.med.utah.edu	Smith, Ken/B-6451-2011	Smith, Ken/0000-0003-0682-3705	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG000199, R13HG001651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K07MH000980] Funding Source: NIH RePORTER; NHGRI NIH HHS [R13 HG01651, P50 HG00199] Funding Source: Medline; NIMH NIH HHS [K07MH00980] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Clever LH, 1997, JAMA-J AM MED ASSOC, V278, P628, DOI 10.1001/jama.278.8.628; DAVIDOFF F, 1995, BRIT MED J, V311, P1272; Fontanarosa PB, 1997, JAMA-J AM MED ASSOC, V278, P682, DOI 10.1001/jama.278.8.682; FRANKEL MS, 1993, ETHICAL LEGAL ISSUES, P33; JORDE LB, 1995, MED GENETICS, P61; MURRAY JC, 1984, CLIN RES, V32, P404; NYLENNA M, 1991, BRIT MED J, V302, P1182, DOI 10.1136/bmj.302.6786.1182; *OFF PROT RES RISK, 1993, PROT HUM RES SUBJ I; Powers Madison, 1993, IRB, V15, P7, DOI 10.2307/3564322; Snider DE, 1997, JAMA-J AM MED ASSOC, V278, P624, DOI 10.1001/jama.278.8.624	10	29	30	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1808	1812		10.1001/jama.279.22.1808	http://dx.doi.org/10.1001/jama.279.22.1808			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR635	9628712	Bronze			2022-12-28	WOS:000073998500033
J	Klein, R				Klein, R			Competence, professional self regulation, and the public interest	BRITISH MEDICAL JOURNAL			English	Article									Univ Bath, Ctr Anal Social Policy, Bath BA2 7AY, Avon, England	University of Bath	Klein, R (corresponding author), Univ Bath, Ctr Anal Social Policy, Bath BA2 7AY, Avon, England.							BOSELEY S, 1998, GUARDIAN        0218, P2; CALMAN K, 1995, MAINTAINING MED EXCE; *GEN MED COUNC, 1995, GOOD MED PRACT; Irvine D, 1997, BRIT MED J, V314, P1613, DOI 10.1136/bmj.314.7094.1613; STACEY M, 1992, BRIT MED J, V305, P1085, DOI 10.1136/bmj.305.6861.1085; Wells W, 1997, REV CERVICAL SCREENI	6	39	39	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1740	1742		10.1136/bmj.316.7146.1740	http://dx.doi.org/10.1136/bmj.316.7146.1740			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614032	Green Published			2022-12-28	WOS:000074129500041
J	Serpell, MG; Haldane, GJ; Jamieson, DRS; Carson, D				Serpell, MG; Haldane, GJ; Jamieson, DRS; Carson, D			Prevention of headache after lumbar puncture: questionnaire survey of neurologists and neurosurgeons in United Kingdom	BRITISH MEDICAL JOURNAL			English	Article							NEEDLE		Univ Glasgow, Western Infirm, Dept Anaesthesia, Glasgow G11 6NT, Lanark, Scotland; So Gen Hosp NHS Trust, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland; Ulster Hosp, Dept Anaesthesia, Belfast BT16 0RH, Antrim, North Ireland	University of Glasgow; University of Glasgow	Serpell, MG (corresponding author), Univ Glasgow, Western Infirm, Dept Anaesthesia, Glasgow G11 6NT, Lanark, Scotland.							CARBAAT PAT, 1981, LANCET, V2, P1133; Carson D, 1996, NEUROLOGY, V47, P33, DOI 10.1212/WNL.47.1.33; KUNTZ KM, 1992, NEUROLOGY, V42, P1884, DOI 10.1212/WNL.42.10.1884; MIHIC D N, 1986, Regional-Anaesthesie, V9, P54; TOURTELLOTTE WW, 1972, HEADACHE, V12, P73, DOI 10.1111/j.1526-4610.1972.hed1202073.x	5	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1709	1710		10.1136/bmj.316.7146.1709	http://dx.doi.org/10.1136/bmj.316.7146.1709			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614018	Green Accepted, Green Submitted, Bronze, Green Published			2022-12-28	WOS:000074129500020
J	Cooper, MK; Porter, JA; Young, KE; Beachy, PA				Cooper, MK; Porter, JA; Young, KE; Beachy, PA			Teratogen-mediated inhibition of target tissue response to Shh signaling	SCIENCE			English	Article							MOTOR-NEURON INDUCTION; A REDUCTASE-ACTIVITY; SONIC-HEDGEHOG; CHOLESTEROL-BIOSYNTHESIS; FLOOR PLATE; GENE; CELLS; PROGESTERONE; HOMEOSTASIS; AUTOPROTEOLYSIS	Veratrum alkaloids and distal inhibitors of cholesterol biosynthesis have been studied for more than 30 years as potent teratogens capable of inducing cyclopia and other birth defects. Here, it is shown that these compounds specifically block the Sonic hedgehog (Shh) signaling pathway. These teratogens did not prevent the sterol modification of Shh during autoprocessing but rather inhibited the response of target tissues to Shh, possibly acting through the sterol sensing domain within the Patched protein regulator of Shh response.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University	Beachy, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA.							ALTABA AR, 1995, DEV BIOL, V170, P299; AUFENANGER J, 1986, BIOCHEM PHARMACOL, V35, P911, DOI 10.1016/0006-2952(86)90076-6; Beachy PA, 1997, COLD SPRING HARB SYM, V62, P191; BELL JJ, 1976, J BIOL CHEM, V251, P1745; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; BINNS W, 1963, AM J VET RES, V24, P1164; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CAPDEVILA J, 1994, DEVELOPMENT, V120, P987; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COHEN MM, 1992, J CRAN GENET DEV BIO, V12, P196; COOPER MD, UNPUB; Dehart DB, 1997, AM J MED GENET, V68, P328, DOI 10.1002/(SICI)1096-8628(19970131)68:3<328::AID-AJMG15>3.0.CO;2-V; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; Gaffield W, 1996, J NAT TOXINS, V5, P25; GIBSON KM, 1990, J LIPID RES, V31, P515; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KEELER RF, 1968, TERATOLOGY, V1, P5, DOI 10.1002/tera.1420010103; Kelley RI, 1996, AM J MED GENET, V66, P478, DOI 10.1002/(SICI)1096-8628(19961230)66:4<478::AID-AJMG22>3.0.CO;2-Q; KRAML M, 1964, BIOCHEM BIOPH RES CO, V15, P455, DOI 10.1016/0006-291X(64)90485-1; Lange Y, 1996, J LIPID RES, V37, P534; Lange Y, 1996, TRENDS CELL BIOL, V6, P205, DOI 10.1016/0962-8924(96)20016-9; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MARTI E, 1995, DEVELOPMENT, V121, P2537; Metherall JE, 1996, J BIOL CHEM, V271, P2627, DOI 10.1074/jbc.271.5.2627; MILLER SC, 1984, J LIPID RES, V25, P991; POPJAK G, 1989, J BIOL CHEM, V264, P6230; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; ROUX C, 1966, CR SOC BIOL, V160, P1353; ROUX CHARLES, 1964, ARCH FRANC PEDIAT, V21, P451; Rubenstein JLR, 1998, CURR OPIN NEUROBIOL, V8, P18, DOI 10.1016/S0959-4388(98)80004-4; STEFANSSON S, 1995, J BIOL CHEM, V270, P19417, DOI 10.1074/jbc.270.33.19417; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; Wang B., UNPUB; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YOSHIKAWA H, 1991, BRAIN DEV-JPN, V13, P115, DOI 10.1016/S0387-7604(12)80118-5	47	729	771	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1603	1607		10.1126/science.280.5369.1603	http://dx.doi.org/10.1126/science.280.5369.1603			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616123				2022-12-28	WOS:000074061200041
J	Schreiber-Agus, N; Meng, Y; Hoang, T; Hou, H; Chen, K; Greenberg, R; Cordon-Cardo, C; Lee, HW; DePinho, RA				Schreiber-Agus, N; Meng, Y; Hoang, T; Hou, H; Chen, K; Greenberg, R; Cordon-Cardo, C; Lee, HW; DePinho, RA			Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth	NATURE			English	Article							TRANSGENIC MICE; PROSTATE-CANCER; C-MYC; REPRESSOR SIN3; MAX; MODELS; MOUSE; GENE; DIFFERENTIATION; TRANSFORMATION	Mxi1 belongs to the Mad (Mxi1) family of proteins, which function as potent antagonists of Myc oncoproteins(1-4). This antagonism relates partly to their ability to compete with Myc for the protein Max and for consensus DNA binding sites and to recruit transcriptional co-repressors(4-6). Mad(Mxi1) proteins have been suggested to be essential in cellular growth control and/or in the induction and maintenance of the differentiated state(6-7) Consistent with these roles, mxi1 may be the tumour-suppressor gene that resides at region 24-26 of the long arm of chromosome 10. This region is a cancer hotspot, and mutations here may be involved in several cancers, including prostate adenocarcinoma(8-10). Here we show that mice lacking Mxi1 exhibit progressive, multisystem abnormalities. These mice also show increased susceptibility to tumorigenesis either following carcinogen treatment or when also deficient in Ink4a. This cancer-prone phenotype may correlate with the enhanced ability of several mxi1-deficient cell types, including prostatic epithelium, to proliferate. Our results show that Mxi1 is involved in the homeostasis of differentiated organ systems, acts as a tumour suppressor in vivo and engages the Myc network in functionally relevant manner.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center	DePinho, RA (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	depinho@aecom.yu.edu		DePinho, Ronald/0000-0002-5625-577X				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; COWLEY BD, 1991, J AM SOC NEPHROL, V1, P1048; Dedeoglu IO, 1996, PEDIATR PATHOL LAB M, V16, P941, DOI 10.1080/15513819609168717; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; EDELHOFF S, 1994, ONCOGENE, V9, P665; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Gerlach C, 1997, LAB INVEST, V77, P697; GRAY IC, 1995, CANCER RES, V55, P4800; HARRIS AW, 1988, CURR TOP MICROBIOL, V141, P82; HECKER E, 1992, J CANCER RES CLIN, V118, P321, DOI 10.1007/BF01208624; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Jenkins RB, 1997, CANCER RES, V57, P524; Kawamata N, 1996, PROSTATE, V29, P191, DOI 10.1002/1097-0045(199609)29:3<191::AID-PROS2990290305>3.0.CO;2-1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; PROCHOWNIK EV, IN PRESS GENES CHROM; RAIMONDI SC, 1988, BLOOD, V72, P1560; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHREIBERAGUS N, IN PRESS BIOESSAYS; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAPIRO DN, 1994, GENOMICS, V23, P282, DOI 10.1006/geno.1994.1496; THOMPSON TC, 1993, CANCER, V71, P1165, DOI 10.1002/1097-0142(19930201)71:3+<1165::AID-CNCR2820711440>3.0.CO;2-U; TRUDEL M, 1991, KIDNEY INT, V39, P665, DOI 10.1038/ki.1991.80; WECHSLER DS, 1994, GENOMICS, V21, P669, DOI 10.1006/geno.1994.1336; YUKAWA K, 1989, J EXP MED, V170, P711, DOI 10.1084/jem.170.3.711; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	30	164	170	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 4	1998	393	6684					483	487		10.1038/31008	http://dx.doi.org/10.1038/31008			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624006				2022-12-28	WOS:000074020000049
J	Cleland, JGF; Swedberg, K				Cleland, JGF; Swedberg, K		Int Ecadotril Multictr Dose-Ranging Study I	Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure	LANCET			English	Letter									Univ Glasgow, Glasgow Clin Res Initiat Heart Failure, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Cleland, JGF (corresponding author), Univ Glasgow, Glasgow Clin Res Initiat Heart Failure, Glasgow G12 8QQ, Lanark, Scotland.		Cleland, John G./AAZ-4185-2020; Swedberg, Karl/B-2475-2008	Cleland, John G./0000-0002-1471-7016; 				GOOD JM, 1995, J AM COLL CARDIOL, V25, P1273, DOI 10.1016/0735-1097(94)00561-4; KAUFMAN DW, 1991, ANONYMOUS MONOGRAPHS, P159; KIM CR, 1989, ANN INTERN MED, V111, P187, DOI 10.7326/0003-4819-111-2-187_2; NORTHRIDGE DB, 1989, LANCET, V2, P591; Young NS, 1997, NEW ENGL J MED, V336, P1365, DOI 10.1056/NEJM199705083361906	5	82	84	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1657	1658		10.1016/S0140-6736(05)77712-6	http://dx.doi.org/10.1016/S0140-6736(05)77712-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620738				2022-12-28	WOS:000074026600043
J	Schneeweiss, B; Greul, R; Zauner, C; Oberhuber, G				Schneeweiss, B; Greul, R; Zauner, C; Oberhuber, G			A man with a leg-vein clot and colonic ulcers	LANCET			English	Article							ACTIVATED PROTEIN-C; RESISTANCE; MUTATION		LKH Kirchdorf, Dept Internal Med, A-4560 Kirchdorf Krems, Austria; Univ Vienna, Dept Internal Med 4, Vienna, Austria; Univ Vienna, Dept Clin Pathol, Vienna, Austria	University of Vienna; University of Vienna	Schneeweiss, B (corresponding author), LKH Kirchdorf, Dept Internal Med, A-4560 Kirchdorf Krems, Austria.							BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Fickert P, 1996, GASTROENTEROLOGY, V111, P1670, DOI 10.1016/S0016-5085(96)70031-8; Heresbach D, 1997, GASTROENTEROLOGY, V113, P322, DOI 10.1016/S0016-5085(97)70110-0; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; ZOLLER B, 1995, BLOOD, V85, P3524, DOI 10.1182/blood.V85.12.3524.bloodjournal85123524	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1628	1628		10.1016/S0140-6736(98)03128-6	http://dx.doi.org/10.1016/S0140-6736(98)03128-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620718				2022-12-28	WOS:000074026600011
J	Cullen, BR				Cullen, BR			HIV-1 auxiliary proteins: Making connections in a dying cell	CELL			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; DOWN-REGULATION; NUCLEAR EXPORT; SURFACE CD4; NEF; VIF; VPR; REQUIREMENT; REPLICATION; LYMPHOCYTES		Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Genet, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Cullen, BR (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.							AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; ALONSO A, 1992, J VIROL, V66, P4617, DOI 10.1128/JVI.66.7.4617-4621.1992; BENSON RE, 1993, J EXP MED, V177, P1561, DOI 10.1084/jem.177.6.1561; Camaur D, 1996, J VIROL, V70, P6106, DOI 10.1128/JVI.70.9.6106-6111.1996; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; CULLEN BR, 1995, AIDS SA, V9, P19; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Greenberg ME, 1998, EMBO J, V17, P2777, DOI 10.1093/emboj/17.10.2777; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KLIMKAIT T, 1990, J VIROL, V64, P621, DOI 10.1128/JVI.64.2.621-629.1990; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Piguet V, 1998, EMBO J, V17, P2472, DOI 10.1093/emboj/17.9.2472; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; Simon JHM, 1998, EMBO J, V17, P1259, DOI 10.1093/emboj/17.5.1259; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Swingler S, 1997, J VIROL, V71, P4372, DOI 10.1128/JVI.71.6.4372-4377.1997; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	37	278	289	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					685	692		10.1016/S0092-8674(00)81431-2	http://dx.doi.org/10.1016/S0092-8674(00)81431-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630214	Bronze			2022-12-28	WOS:000073956700006
J	Horton, R				Horton, R			Tobacco tactics: not so passive about smoking after all	LANCET			English	Editorial Material									Lancet, London, England		Horton, R (corresponding author), Lancet, London, England.								0	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1450	1450		10.1016/S0140-6736(05)78867-X	http://dx.doi.org/10.1016/S0140-6736(05)78867-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605799				2022-12-28	WOS:000073707300005
J	Lagos, R; Valenzuela, MT; Levine, OS; Losonsky, GA; Erazo, A; Wasserman, SS; Levine, MM				Lagos, R; Valenzuela, MT; Levine, OS; Losonsky, GA; Erazo, A; Wasserman, SS; Levine, MM			Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunoaffinity of fractional-dose and two-dose regimens	LANCET			English	Article							TETANUS TOXOID CONJUGATE; CAPSULAR POLYSACCHARIDE; NEONATAL IMMUNIZATION; ANTIBODY-RESPONSES; SERUM ANTIBODIES; BINDING ASSAY; INFANTS; VACCINES; DIPHTHERIA; SANTIAGO	Background. The cost of Haemophilus influenzae type b (Hib) conjugate vaccines has limited their use in non-industrialised countries. To identify more economical vaccination schedules, we carried out a randomised trial of the immunogenicity of alternative regimens to the standard three-dose series. Methods. 627 Chilean infants were randomly allocated to one of four regimens with either Hib polysaccharide-tetanus toroid conjugate vaccine (PRP-T) or Hib oligosaccharide-diphtheria mutant toroid conjugate vaccine (PRP-CRM197), for a total of eight groups. All infants receive diphtheria-tetanus-pertussis (DTP) vaccine at ages 2, 4, and 6 months. The regimens included three full doses, three fractional doses consisting of one half or one third of the full dose, and a regimen of two full doses (at age 4 and 6 months). The primary outcome was the proportion of infants with serum anti-polyribosyl ribitol phosphate (PRP, the type b capsular polysaccharide) concentrations of 0.15 mu g/mL or more at age 8 months. Findings 93% (95% CI 85-98) of infants vaccinated with three full doses of PRP-T or PRP-CRM197 (95% CI 84-98) achieved anti-PRP concentrations of 0.15 mu g/mL or more at age 8 months, compared with 91% (83-96) to 100% (95-100) of infants immunised with any fractional-dose regimen. Of the infants vaccinated with two doses of PRP-T or PRP-CRM197, 99% (93-100) and 87% (77-93) developed anti-PRP concentrations of 0.15 mu g/mL or more, respectively. Interpretation. 91% (83-96) to 100% (95-100) of infants immunised with one-half or one-third of a full dose of Hib conjugate developed protective antibody concentrations. Carrier priming with DTP may make two-dose schedules an option in some places. These alternative regimens could bring the cost of Hib vaccines within reach of countries that currently cannot afford them.	Serv Salud Metropolitano Norte, Santiago, Chile; CVD, Chile Hosp Roberto Del Rio Avendla Zanartu 1085, Independencia Santiago, Chile; Minist Salud, Santiago, Chile; Ctr Dis Control & Prevent, Atlanta, GA USA; Univ Maryland, Ctr Vaccine Dev, Baltimore, MD 21201 USA	Centers for Disease Control & Prevention - USA; University System of Maryland; University of Maryland Baltimore	Lagos, R (corresponding author), Serv Salud Metropolitano Norte, Santiago, Chile.			Valenzuela, M Teresa/0000-0002-9433-6423	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035948] Funding Source: NIH RePORTER; NIAID NIH HHS [UO1-AI35948] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON P, 1987, J PEDIATR-US, V111, P644, DOI 10.1016/S0022-3476(87)80237-8; AVENDANO A, 1993, PEDIATR INFECT DIS J, V12, P638, DOI 10.1097/00006454-199308000-00003; Booy R, 1997, LANCET, V349, P1197, DOI 10.1016/S0140-6736(96)06392-1; CLAESSON BA, 1989, J PEDIATR-US, V114, P97, DOI 10.1016/S0022-3476(89)80611-0; DECKER MD, 1992, J PEDIATR-US, V120, P184, DOI 10.1016/S0022-3476(05)80424-X; DEFEBRES OC, 1994, PEDIATR INFECT DIS J, V13, P635, DOI 10.1097/00006454-199407000-00010; DUPUY JM, 1990, LANCET, V336, P733, DOI 10.1016/0140-6736(90)92216-5; FERRECCIO C, 1991, PEDIATR INFECT DIS J, V10, P764, DOI 10.1097/00006454-199110000-00009; FERRECCIO C, 1990, PEDIATR INFECT DIS J, V9, P488, DOI 10.1097/00006454-199007000-00007; FRITZELL B, 1992, J PEDIATR-US, V121, P355, DOI 10.1016/S0022-3476(05)81786-X; GRANOFF DM, 1994, JAMA-J AM MED ASSOC, V272, P1116, DOI 10.1001/jama.272.14.1116; HOPPENBROUWERS K, 1998, IN PRESS VACCINE; KAYHTY H, 1983, J INFECT DIS, V147, P1100; KAYHTY H, 1992, J INFECT DIS S1, V165, P165; KUO JSC, 1981, J IMMUNOL METHODS, V43, P35, DOI 10.1016/0022-1759(81)90034-X; KURIKKA S, 1995, PEDIATRICS, V95, P815; LAGOS R, 1909, IN PRESS PEDIAT INFE; Levine MM, 1997, LANCET, V350, P1386, DOI 10.1016/S0140-6736(97)03253-4; LEVINE OS, 1993, AM J EPIDEMIOL, V137, P1221, DOI 10.1093/oxfordjournals.aje.a116624; Levine OS, 1997, VACCINE, V15, P325, DOI 10.1016/S0264-410X(96)00161-2; LIEBERMAN JM, 1995, J PEDIATR-US, V126, P198, DOI 10.1016/S0022-3476(95)70545-7; MITCHISON NA, 1995, J EXP MED, V161, P275; Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7; PARKE JC, 1991, J PEDIATR-US, V118, P184, DOI 10.1016/S0022-3476(05)80480-9; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; PHIPPS DC, 1990, J IMMUNOL METHODS, V135, P121, DOI 10.1016/0022-1759(90)90264-V; WARD J, 1994, VACCINES, P337; WENGER JD, 1997, NEW GENERATION VACCI, P489	28	48	56	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1472	1476		10.1016/S0140-6736(97)07456-4	http://dx.doi.org/10.1016/S0140-6736(97)07456-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605803				2022-12-28	WOS:000073707300009
J	Butler, CC; Pill, R; Stott, NCH				Butler, CC; Pill, R; Stott, NCH			Qualitative study of patients' perceptions of doctors' advice to quit smoking: implications for opportunistic health promotion	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VIEWS	Objectives: To determine the effectiveness and acceptability of general practitioners' opportunistic antismoking interventions by examining detailed accounts of smokers' experiences of these. Design: Qualitative semistructured interview study. Setting: South Wales. Subjects: 42 participants in the Welsh smoking intervention study were asked about initial smoking, attempts to quit, thoughts about future smoking, past experiences with the health services, and the most appropriate way for health services to help them and other smokers. Results: Main emerging themes were that subjects already made their own evaluations about smoking, did not believe doctors' words could influence their smoking, believed that quitting was down to the individual, and felt that doctors who took the opportunity to talk about smoking should focus on the individual patient Smokers anticipated that they would be given antismoking advice by doctors when attending: for health care; they reacted by shrugging this off, feeling guilty, or becoming annoyed. These reactions affected the help seeking behaviour of some respondents, Smokers were categorised as "contrary;" "matter of fact" and "self blaming" depending on their reported reaction to antismoking advice. Conclusions: Doctor-patient relationships can be damaged if doctors routinely advise all smokers to quit. Where doctors intervene, a patient centred approach-one that considers how individual patients view themselves as smokers and how they are likely to react to different styles of intervention-is the most acceptable.	Cardiff Univ, Dept Gen Practice, Cardiff CF3 7PN, S Glam, Wales	Cardiff University	Butler, CC (corresponding author), Cardiff Univ, Dept Gen Practice, Cardiff CF3 7PN, S Glam, Wales.	butlercc@cf.ac.uk	Butler, Christopher C/B-5048-2009	Butler, Christopher/0000-0002-0102-3453				BARTECCHI CE, 1994, NEW ENGL J MED, V330, P907, DOI 10.1056/NEJM199403313301307; BRITTEN N, 1995, BRIT MED J, V311, P251, DOI 10.1136/bmj.311.6999.251; BRUCE N, 1991, FAM PRACT, V8, P373, DOI 10.1093/fampra/8.4.373; Butler C, 1996, CAN MED ASSOC J, V154, P1357; ELDER NC, 1995, J FAM PRACTICE, V41, P279; Fitzpatrick R, 1994, Qual Health Care, V3, P107; Glaser B.G., 1965, AWARENESS DYING; GoldbeckWood S, 1997, BRIT MED J, V315, P1252; GRAHAM H, 1987, SOC SCI MED, V25, P47, DOI 10.1016/0277-9536(87)90206-1; *HLTH ED AUTH, 1993, SMOK EP PRESCR CHANG; Hoddinott P, 1997, FAM PRACT, V14, P307, DOI 10.1093/fampra/14.4.307; Hoddinott P, 1997, FAM PRACT, V14, P313, DOI 10.1093/fampra/14.4.313; KARANCI NA, 1987, INT J ADDICT, V22, P289, DOI 10.3109/10826088709027431; Miles M.B., 1994, ANAL DONNEES QUALITA, V2nd; Mullen K., 1993, HLTH BALANCE GLASWEG; PROCHASKA JO, 1995, CAN J CARDIOL, V11, pA20; Rollnick S, 1997, PATIENT EDUC COUNS, V31, P191, DOI 10.1016/S0738-3991(97)01004-5; RUSSELL MAH, 1974, J ROY STAT SOC A STA, V137, P313, DOI 10.2307/2344953; Sesney JW, 1997, J FAM PRACTICE, V44, P578; SILAGY C, 1996, TOBACCO MODULE COCHR; SILVERMAN D, 1993, INTERPRETIANG QUALIT; Stewart M J, 1996, Can J Nurs Res, V28, P41; STOTT NCH, 1990, FAM PRACT, V7, P125, DOI 10.1093/fampra/7.2.125; WILLMS DG, 1991, AM J PREV MED, V7, P95, DOI 10.1016/S0749-3797(18)30944-9; 1989, GUIDE CLINICAL PREVE	25	109	110	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 20	1998	316	7148					1878	1881						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632409				2022-12-28	WOS:000074686500025
J	Masiello, CA; Druffel, ERM				Masiello, CA; Druffel, ERM			Black carbon in deep-sea sediments	SCIENCE			English	Article							LONG-RANGE TRANSPORT; NORTH PACIFIC-OCEAN; ELEMENTAL CARBON; ORGANIC-MATTER; MARINE-SEDIMENTS; SOOT CARBON; RADIOCARBON; AEROSOL; ATMOSPHERE; CHARCOAL	Black carbon (BC) enters the ocean through aerosol and river deposition. BC makes up 12 to 31 percent of the sedimentary organic carbon (SOC) at two deep ocean sites, and it is 2400 to 13,900 carbon-14 years older than non-BC SOC deposited concurrently. BC is likely older because it is stored in an intermediate reservoir before sedimentary deposition. Possible intermediate pools are oceanic dissolved organic carbon (DOC) and terrestrial soils. If DOC is the intermediate reservoir, then BC is 4 to 22 percent of the DOC pool. If soils are the intermediate reservoir, then the importance of riverine carbon in the ocean carbon cycle has been underestimated.	Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA	University of California System; University of California Irvine	Masiello, CA (corresponding author), Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA.		Masiello, Caroline/A-2653-2011	Masiello, Caroline/0000-0003-2102-6229				ANDREAE MO, 1983, SCIENCE, V220, P1148, DOI 10.1126/science.220.4602.1148; ANDREAE MO, 1984, SCI TOTAL ENVIRON, V36, P73, DOI 10.1016/0048-9697(84)90249-3; BACON MP, 1982, J GEOPHYS RES-OCEANS, V87, P2045, DOI 10.1029/JC087iC03p02045; BAUER JE, 1995, NATURE, V373, P686, DOI 10.1038/373686a0; BLONG RJ, 1978, NATURE, V271, P739, DOI 10.1038/271739a0; CACHIER H, 1985, J ATMOS CHEM, V3, P469, DOI 10.1007/BF00053872; Cooke WF, 1996, J GEOPHYS RES-ATMOS, V101, P19395, DOI 10.1029/96JD00671; Druffel ERM, 1996, J GEOPHYS RES-OCEANS, V101, P20543, DOI 10.1029/96JC01850; DRUFFEL ERM, 1992, J GEOPHYS RES-OCEANS, V97, P15639, DOI 10.1029/92JC01511; DRUFFEL ERM, UNPUB; Goldberg E. D., 1985, Black carbon in the environment. Properties and distribution; HEDGES JI, 1979, GEOCHIM COSMOCHIM AC, V43, P1809, DOI 10.1016/0016-7037(79)90029-2; HEDGES JI, 1995, MAR CHEM, V49, P81, DOI 10.1016/0304-4203(95)00008-F; Hedges JI, 1997, ORG GEOCHEM, V27, P195, DOI 10.1016/S0146-6380(97)00066-1; HERRING JR, 1985, CARBON CYCLE ATMOSPH, P419; Jennings SG, 1996, J GEOPHYS RES-ATMOS, V101, P19447, DOI 10.1029/96JD00614; KUHLBUSCH TAJ, 1995, GLOBAL BIOGEOCHEM CY, V9, P491, DOI 10.1029/95GB02742; Liousse C, 1996, J GEOPHYS RES-ATMOS, V101, P19411, DOI 10.1029/95JD03426; OGREN JA, 1983, TELLUS B, V35, P241, DOI 10.1111/j.1600-0889.1983.tb00027.x; PENNER JE, 1993, ATMOS ENVIRON A-GEN, V27, P1277, DOI 10.1016/0960-1686(93)90255-W; RAU JA, 1993, ATMOS ENVIRON A-GEN, V27, P1297, DOI 10.1016/0960-1686(93)90256-X; Reeburgh W.S., 1997, B ECOL SOC AM, V78, P260; SMITH DM, 1973, NATURE, V241, P268, DOI 10.1038/241268a0; SMITH KL, 1994, LIMNOL OCEANOGR, V39, P1101, DOI 10.4319/lo.1994.39.5.1101; STUIVER M, 1986, RADIOCARBON, V28, P980, DOI 10.1017/S0033822200060264; Suman D. O., 1983, THESIS U CALIFORNIA; Trumbore SE, 1995, DAHL WS ENV, V16, P7; Verardo DJ, 1996, GEOLOGY, V24, P855, DOI 10.1130/0091-7613(1996)024<0855:LPCITA>2.3.CO;2; WILLIAMS PM, 1987, NATURE, V330, P246, DOI 10.1038/330246a0; WOLBACH WS, 1985, SCIENCE, V230, P167, DOI 10.1126/science.230.4722.167; WOLBACH WS, 1989, GEOCHIM COSMOCHIM AC, V53, P1637, DOI 10.1016/0016-7037(89)90245-7; [No title captured]	32	355	398	12	150	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1911	1913		10.1126/science.280.5371.1911	http://dx.doi.org/10.1126/science.280.5371.1911			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632383	Green Submitted			2022-12-28	WOS:000074323800055
J	Shibata, M; Morizane, T; Uchida, T; Yamagami, T; Onozuka, Y; Nakano, M; Mitamura, K; Ueno, Y				Shibata, M; Morizane, T; Uchida, T; Yamagami, T; Onozuka, Y; Nakano, M; Mitamura, K; Ueno, Y			Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection	LANCET			English	Article							LIVER-CELL DYSPLASIA; DISEASE; HCV	Background Hepatocellular carcinoma (HCC) commonly develops in patients with chronic hepatitis br cirrhosis of the liver caused by hepatitis-C-virus (HCV) infection. We prospectively studied whether irregular regeneration of hepatocytes is a risk factor for HCC in these patients. Methods 242 patients were enrolled after liver biopsy and followed up by ultrasonographic scanning every 3 months. We examined age, sex, platelet count, the diagnosis of cirrhosis or chronic hepatitis, liver-cell dysplasia, and irregular regeneration, We classified irregular regeneration as slight or severe, based on histological expression of pleiomorphism, anisocytosis, bulging, and map-like distribution of hepatocytes. Findings 37 of 63 patients with cirrhosis and 26 of 179 with chronic hepatitis were judged to have severe irregular regeneration. HCC was diagnosed in 33 of 63 patients with cirrhosis (29 had severe irregular regeneration) and 12 of 179 patients with chronic hepatitis (11 had severe irregular regeneration) during mean follow-up of 5.5 years (SD 4.1; range 1-16), Multivariate analysis with a proportional-hazards model showed severe irregular regeneration (relative risk 15.1 [95% CI 5.6-40.7], p<0.0001) and a diagnosis of cirrhosis (3.8 [1.7-8.2], p=0.0008) to be significant risk factors for HCC, Within the diagnostic categories, irregular regeneration was also significant (cirrhosis 6.8 [2.1-21.9], p=0.0014; chronic hepatitis 28.5 [2.9-276.4], p=0.0038). Interpretation We recommend that liver biopsy to look for irregular regeneration should be done in patients with HCV-related chronic liver diseases. Those with severe irregular regeneration should be followed up carefully.	Kanagawa Dent Coll, Dept Med, Yokosuka, Kanagawa 238, Japan; Kawasaki Chuo Hosp, Dept Med, Kanagawa, Japan; Nihon Univ, Sch Med, Dept Pathol, Tokyo, Japan; Chiba Univ, Univ Hosp, Sch Med, Div Pathol, Chiba, Japan; Showa Univ, Sch Med, Dept Internal Med 2, Tokyo 142, Japan	Kanagawa Dental College; Nihon University; Chiba University; Showa University	Morizane, T (corresponding author), Kanagawa Dent Coll, Dept Med, 82 Inaoka Chou, Yokosuka, Kanagawa 238, Japan.							ANTHONY PP, 1973, J CLIN PATHOL, V26, P217, DOI 10.1136/jcp.26.3.217; BORZIO M, 1995, GASTROENTEROLOGY, V108, P812, DOI 10.1016/0016-5085(95)90455-7; BRUIX J, 1989, LANCET, V2, P1004; DEMITRI MS, 1995, LANCET, V345, P413, DOI 10.1016/S0140-6736(95)90400-X; GanneCarrie N, 1996, HEPATOLOGY, V23, P1112; GIBSON JB, 1978, INT HISTOLOGICAL CLA, V20, P12; HADENGUE A, 1990, LIVER, V10, P147; HENMI A, 1985, CANCER, V55, P2594, DOI 10.1002/1097-0142(19850601)55:11<2594::AID-CNCR2820551111>3.0.CO;2-7; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; KATO Y, 1994, CANCER, V74, P2234, DOI 10.1002/1097-0142(19941015)74:8<2234::AID-CNCR2820740805>3.0.CO;2-6; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Kuwana K, 1997, J GASTROEN HEPATOL, V12, P149, DOI 10.1111/j.1440-1746.1997.tb00398.x; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEFKOWITCH JH, 1980, AM J CLIN PATHOL, V74, P432; MOHAMED AE, 1992, INT J CANCER, V51, P537, DOI 10.1002/ijc.2910510406; NALPAS B, 1991, J HEPATOL, V12, P70, DOI 10.1016/0168-8278(91)90912-U; Peters R. L., 1986, LIVER PATHOLOGY CONT, P73; SIMONETTI RG, 1992, ANN INTERN MED, V116, P97, DOI 10.7326/0003-4819-116-2-97; TAKANO S, 1995, HEPATOLOGY, V21, P650; TOZUKA S, 1989, ARCH PATHOL LAB MED, V113, P20; UCHIDA T, 1995, PATHOL INT, V45, P175, DOI 10.1111/j.1440-1827.1995.tb03440.x; UCHIDA T, 1994, INTERVIROLOGY, V37, P126, DOI 10.1159/000150367; UCHIDA T, 1984, HUM PATHOL, V15, P267, DOI 10.1016/S0046-8177(84)80190-2; ZANMAN SN, 1985, LANCET, V2, P1357	25	105	108	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1773	1777		10.1016/S0140-6736(97)08002-1	http://dx.doi.org/10.1016/S0140-6736(97)08002-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635950				2022-12-28	WOS:000074197600011
J	Marzuk, PM; Tardiff, K; Leon, AC; Hirsch, CS; Portera, L; Iqbal, I; Nock, MK; Hartwell, N				Marzuk, PM; Tardiff, K; Leon, AC; Hirsch, CS; Portera, L; Iqbal, I; Nock, MK; Hartwell, N			Ambient temperature and mortality from unintentional cocaine overdose	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEUROLEPTIC MALIGNANT SYNDROME; 1980 HEAT-WAVE; RECREATIONAL COCAINE; CONSCIOUS DOG; ABUSE; HYPERTHERMIA; DEATH; INTOXICATION; RHABDOMYOLYSIS; LETHALITY	Context.-Hot weather taxes cardiovascular function and is associated with increased deaths from heart disease. Cocaine can cause hypertension, tachycardia, coronary vasospasm, arrhythmias, and increased core temperature. Objective.-To determine the association between mortality from cocaine overdose and hot weather. Setting.-New York, NY. Design.-Retrospective review of medical examiner cases from 1990 through 1995. Subjects.-All fatal unintentional cocaine overdoses from 1990 through 1992 (n=1382) and all hyperthermia deaths of cocaine users (n = 10) were used to identify a maximum daily temperature threshold above which mortality from cocaine intoxication increased. The study population consisted of all fatal unintentional cocaine overdoses from 1993 through 1995 (n = 2008) and 4 contemporaneous comparison groups that included fatal unintentional opiate overdoses (n = 793), all other fatal unintentional overdoses (n = 85), and a subset of homicides (n = 4638) and fatalities from motor vehicle crashes (n = 815). Main Outcome Measures.-The number of overdose deaths and the proportion of homicides and traffic fatalities with a positive cocaine toxicology test result on days with a maximum temperature above or below the temperature threshold. Results.-A threshold temperature of 31.1 degrees C (88 degrees F) was identified, above which the mean daily number of fatal cocaine overdoses increased steadily. On days with a maximum daily temperature of 31.1 degrees C (88 degrees F) or higher ("hot days"), the mean daily number of cocaine overdose deaths was 2.34 (SD = 1.68), which was 33% higher than the mean on days with a maximum temperature of less than 31.1 degrees C (88 degrees F) (mean=1.76 [SD=1.37] (P<.001). In contrast, the mean number of opiate overdose deaths per day was 0.81 (SD = 0.94) on hot days and 0.71 (SD = 0.86) on other days (P=.28). For other drug overdose deaths, the mean number of deaths per day was 0.08 (SD = 0.28) on hot days and 0.08 (SD = 0.28) on other days (P=.69). Among homicides, the proportion with a positive cocaine toxicology test result was 18.9% on hot days and 19.5% on other days (P=.69), and among traffic fatalities, the proportions with positive cocaine toxicology test results were 9.5% on hot days and 10.3% on other days (P=.91). Conclusions.-High ambient temperature is associated with a significant increase in mortality from cocaine overdose. Based on our comparison groups, the increase is not explained by changes in cocaine use among the general population. Although cocaine use is dangerous on all days, it appears to be even more dangerous on hot days.	Cornell Univ Med Coll, Dept Psychiat, Epidemiol Sect, New York, NY USA; Cornell Univ Med Coll, Dept Publ Hlth, New York, NY USA; Off Chief Med Examiner, New York, NY USA; NYU, Sch Med, Dept Forens Med, New York, NY USA	Cornell University; Cornell University; New York University	Marzuk, PM (corresponding author), Cornell Univ, Med Ctr, New York Hosp, Dept Psychiat, 525 E 68th St, New York, NY 10021 USA.		Nock, Matthew/AAE-8330-2019		NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006534] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 06534] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ANDERS C, 1995, MMWR-MORBID MORTAL W, V44, P465; APPLEGATE WB, 1981, J AM GERIATR SOC, V29, P337, DOI 10.1111/j.1532-5415.1981.tb01238.x; BAUWENS JE, 1989, WESTERN J MED, V150, P210; BUECHLEY RW, 1972, ENVIRON RES, V5, P85, DOI 10.1016/0013-9351(72)90022-9; CALLAWAY CW, 1994, ANN EMERG MED, V24, P68, DOI 10.1016/S0196-0644(94)70165-2; CATRAVAS JD, 1978, ARCH INT PHARMACOD T, V235, P328; CATRAVAS JD, 1981, J PHARMACOL EXP THER, V217, P350; CLARKE JF, 1972, ENVIRON RES, V5, P93, DOI 10.1016/0013-9351(72)90023-0; COX B, 1978, J PHYSIOL-LONDON, V282, P471, DOI 10.1113/jphysiol.1978.sp012476; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; DARAS M, 1995, ACTA NEUROL SCAND, V92, P161; ELLIS FP, 1972, ENVIRON RES, V5, P1, DOI 10.1016/0013-9351(72)90019-9; FISCHMAN MW, 1976, ARCH GEN PSYCHIAT, V33, P983; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; JONES TS, 1982, JAMA-J AM MED ASSOC, V247, P3327, DOI 10.1001/jama.247.24.3327; KALKSTEIN LS, 1993, LANCET, V342, P1397, DOI 10.1016/0140-6736(93)92757-K; KALKSTEIN LS, 1989, ANN ASSOC AM GEOGR, V79, P44, DOI 10.1111/j.1467-8306.1989.tb00249.x; KALKSTEIN LS, 1988, IMPACT PREDICTED CLI, V41; KOSTEN TR, 1988, AM J DRUG ALCOHOL AB, V14, P335, DOI 10.3109/00952998809001555; LOGHMANEE F, 1986, AM J FOREN MED PATH, V7, P246, DOI 10.1097/00000433-198607030-00012; MARZUK PM, 1995, NEW ENGL J MED, V332, P1753, DOI 10.1056/NEJM199506293322606; Marzuk PM, 1997, AM J DRUG ALCOHOL AB, V23, P221, DOI 10.3109/00952999709040943; *OFF APPL STUD, 1993, SMA PUBL; *OFF APPL STUD, 1996, SMA PUBL; *OFF APPL STUD, 1994, ANN EM ROOM DAT 19 1, pA12; ROBERTS JR, 1984, AM J EMERG MED, V2, P373, DOI 10.1016/0735-6757(84)90178-5; ROTH D, 1988, NEW ENGL J MED, V319, P673, DOI 10.1056/NEJM198809153191103; SEMANZA JC, 1996, NEW ENGL J MED, V335, P84; SPRANG CL, 1979, CHEST, V75, P362; WETLI CV, 1985, J FORENSIC SCI, V30, P873	31	75	77	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1795	1800		10.1001/jama.279.22.1795	http://dx.doi.org/10.1001/jama.279.22.1795			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR635	9628710	Green Published, Bronze			2022-12-28	WOS:000073998500031
J	Beecham, L				Beecham, L			Junior doctors call for more consultants	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1754	1754						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614048				2022-12-28	WOS:000074129500083
J	Bridger, S; Henderson, K; Glucksman, E; Ellis, AJ; Henry, JA; Williams, R				Bridger, S; Henderson, K; Glucksman, E; Ellis, AJ; Henry, JA; Williams, R			Lesson of the week - Deaths from low dose paracetamol poisoning	BRITISH MEDICAL JOURNAL			English	Article							FULMINANT HEPATIC-FAILURE; INTRAVENOUS N-ACETYLCYSTEINE; ACETAMINOPHEN OVERDOSE		St Marys Hosp, Dept Accid & Emergency, London W2 1NY, England; Univ London Kings Coll, Sch Med, Dept Med, London SE5 9PJ, England; Univ London Kings Coll Hosp, Dept Accid & Emergency, London SE5 9RS, England; Univ London Kings Coll Hosp, Inst Liver Studies, London SE5 9RS, England	Imperial College London; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Henry, JA (corresponding author), St Marys Hosp, Dept Accid & Emergency, Praed St, London W2 1NY, England.			opoku, anita/0000-0001-7243-8157				BRAY GP, 1992, HUM EXP TOXICOL, V11, P265, DOI 10.1177/096032719201100405; BRAY GP, 1993, BRIT MED J, V306, P157, DOI 10.1136/bmj.306.6871.157; BRAY GP, 1991, HUM EXP TOXICOL, V10, P435, DOI 10.1177/096032719101000612; CRITCHLEY JAJH, 1986, BRIT J CLIN PHARMACO, V22, P649, DOI 10.1111/j.1365-2125.1986.tb02953.x; ERIKSSON LS, 1992, J INTERN MED, V231, P567, DOI 10.1111/j.1365-2796.1992.tb00976.x; Fagan E, 1996, BRIT MED J, V313, P1417, DOI 10.1136/bmj.313.7070.1417; HARRISON PM, 1990, LANCET, V335, P1572, DOI 10.1016/0140-6736(90)91388-Q; KEAYS R, 1991, BRIT MED J, V303, P1026, DOI 10.1136/bmj.303.6809.1026; LITOVITZ TL, 1993, AM J EMERG MED, V12, P546; MEREDITH TJ, 1986, BRIT MED J, V293, P345, DOI 10.1136/bmj.293.6543.345; MEREDITH TJ, 1981, ARCH INTERN MED, V141, P395; NEUVONEN PJ, 1983, EUR J CLIN PHARMACOL, V24, P557, DOI 10.1007/BF00609903; PRESCOTT LF, 1979, BRIT MED J, V2, P1097, DOI 10.1136/bmj.2.6198.1097; READ RB, 1986, HUM TOXICOL, V5, P201, DOI 10.1177/096032718600500309; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; SMILKSTEIN MJ, 1991, ANN EMERG MED, V20, P1058, DOI 10.1016/S0196-0644(05)81352-6; TIGHE TV, 1994, J TOXICOL-CLIN TOXIC, V32, P431, DOI 10.3109/15563659409011045; VALE JA, 1995, LANCET, V346, P547, DOI 10.1016/S0140-6736(95)91385-8; VALE JA, 1981, ARCH INTERN MED, V141, P394, DOI 10.1001/archinte.141.3.394	19	59	64	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1724	1725		10.1136/bmj.316.7146.1724	http://dx.doi.org/10.1136/bmj.316.7146.1724			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614027	Green Published			2022-12-28	WOS:000074129500027
J	Avarvari, N; Mezailles, N; Ricard, L; Le Floch, P; Mathey, F				Avarvari, N; Mezailles, N; Ricard, L; Le Floch, P; Mathey, F			Silacalix-[n]-phosphaarenes: Macrocyclic ligands based on dicoordinate phosphorus centers	SCIENCE			English	Article							METAL-COMPLEXES; HETEROARENES	The synthesis of polyphosphinine macrocycles, which consist of a 16-membered ring with four phosphorus atoms (P-4) and a 12-membered ring with three phosphorus atoms (P-3), is described. Their high coordination ability is demonstrated by the quantitative synthesis of the rhodium and iridium cation complexes of the P-4 macrocycle and by quantitative synthesis of the W(CO)(3) complex of the P-3 compound. Unlike the other available macrocyclic ligands bearing oxygen, sulfur, di- or tricoordinate nitrogen, and even tricoordinate phosphorus as ligating atoms, which are all essentially a donors, these dicoordinate phosphorus-based macrocycles have strong pi-acceptor properties. Their use can be envisaged for the stabilization of negative oxidation states of transition metals or in reductive catalysis.	Ecole Polytech, CNRS, Unite Mixte Rech 7653, Lab Heteroelements & Coordinat, F-91128 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris	Le Floch, P (corresponding author), Ecole Polytech, CNRS, Unite Mixte Rech 7653, Lab Heteroelements & Coordinat, F-91128 Palaiseau, France.	dcph@poly.polytechnique.fr						Avarvari N, 1997, ORGANOMETALLICS, V16, P4089, DOI 10.1021/om970414+; Avarvari N, 1996, J AM CHEM SOC, V118, P11978, DOI 10.1021/ja962736v; BALDRIDGE KK, 1988, J AM CHEM SOC, V110, P4204, DOI 10.1021/ja00221a018; BATICH C, 1973, J AM CHEM SOC, V95, P929; BOWMANJONES K, 1994, ENCY INORGANIC CHEM, P1999; Breit B, 1997, J CHEM SOC PERK T 1, P2681, DOI 10.1039/a705249i; Chatt J., 1953, J CHEM SOC, P2929; COTTON FA, 1988, ADV INORG CHEM, P255; DAPPRICH S, 1995, J PHYS CHEM-US, V99, P9352, DOI 10.1021/j100023a009; Dewar M. J. S., 1951, B SOC CHIM FR, pC79; Ehlers AW, 1996, ORGANOMETALLICS, V15, P105, DOI 10.1021/om950697a; ELSCHENBROICH C, 1994, J AM CHEM SOC, V116, P6217, DOI 10.1021/ja00093a022; ELSCHENBROICH C, 1992, ANGEW CHEM INT EDIT, V31, P1343, DOI 10.1002/anie.199213431; ELSCHENBROICH C, 1993, J ORGANOMET CHEM, V459, P157, DOI 10.1016/0022-328X(93)86068-S; ELSCHENBROICH C, 1991, ANGEW CHEM INT EDIT, V30, P547, DOI 10.1002/anie.199105471; LAPORTE F, 1994, J AM CHEM SOC, V116, P3306, DOI 10.1021/ja00087a017; LEFLOCH P, 1995, INORG CHEM, V34, P11, DOI 10.1021/ic00105a006; LEFLOCH P, 1990, POLYHEDRON, V9, P991, DOI 10.1016/S0277-5387(00)84303-X; SOROKIN A, 1995, SCIENCE, V268, P1163, DOI 10.1126/science.268.5214.1163; WALKER FA, 1994, ENCY INORGANIC CHEM, V4, P1785; WALUK J, 1989, ORGANOMETALLICS, V8, P2804, DOI 10.1021/om00114a011; Willner H, 1997, ANGEW CHEM INT EDIT, V36, P2403	22	91	91	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	1998	280	5369					1587	1589		10.1126/science.280.5369.1587	http://dx.doi.org/10.1126/science.280.5369.1587			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616118				2022-12-28	WOS:000074061200036
J	Rosenmund, C; Stern-Bach, Y; Stevens, CF				Rosenmund, C; Stern-Bach, Y; Stevens, CF			The tetrameric structure of a glutamate receptor channel	SCIENCE			English	Article							HIPPOCAMPAL-NEURONS; ACID RECEPTORS; BINDING-SITES; RAT-BRAIN; DESENSITIZATION; CONDUCTANCE; LOCALIZATION; ACTIVATION; KINETICS; GLYCINE	The subunit stoichiometry of several ligand-gated ion channel receptors is still unknown. A counting method was developed to determine the number of subunits in one family of brain glutamate receptors, Successful application of this method in an HEK cell line provides evidence that ionotropic glutamate receptors share a tetrameric structure with the voltage-gated potassium channels. The average conductance of these channels depends on how many subunits are occupied by an agonist.	Salk Inst, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Max Planck Inst Biophys Chem, Workgrp Cellular Neurobiol, Gottingen, Germany; Hebrew Univ Jerusalem, Haddassah Dent Sch, Dept Anat & Embryol, Jerusalem, Israel	Howard Hughes Medical Institute; Salk Institute; Max Planck Society; Hebrew University of Jerusalem	Stevens, CF (corresponding author), Salk Inst, Howard Hughes Med Inst, La Jolla, CA 92093 USA.		Rosenmund, Christian/AAC-3596-2020	Rosenmund, Christian/0000-0002-3905-2444	NINDS NIH HHS [NS 12961] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS012961] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENVENISTE M, 1991, BIOPHYS J, V59, P560, DOI 10.1016/S0006-3495(91)82272-X; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BROSE N, 1993, J BIOL CHEM, V268, P22663; CHAPMAN L, 1997, BIOPHYS J, V72, P708; Clements JD, 1998, J NEUROSCI, V18, P119; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; DUDEL J, 1990, BIOPHYS J, V57, P533, DOI 10.1016/S0006-3495(90)82569-8; FerrerMontiel AV, 1996, P NATL ACAD SCI USA, V93, P2741, DOI 10.1073/pnas.93.7.2741; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KISKIN NI, 1986, NEUROSCI LETT, V63, P225, DOI 10.1016/0304-3940(86)90360-5; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; Mano I, 1998, NEUROREPORT, V9, P327, DOI 10.1097/00001756-199801260-00027; Mano I., 1996, Society for Neuroscience Abstracts, V22, P726; PARTIN KM, 1994, MOL PHARMACOL, V46, P129; PREMKUMAR LS, 1997, J GEN PHYSIOL, V110, P48; RAFTERY MA, 1980, SCIENCE, V208, P1454, DOI 10.1126/science.7384786; ROSENMUND C, 1995, J NEUROSCI, V15, P2788; Rosenmund C., 1996, Biophysical Journal, V70, pA251; RUIZ L, 1997, NATURE, V389, P389; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Sutcliffe MJ, 1996, BIOPHYS J, V70, P1575, DOI 10.1016/S0006-3495(96)79724-2; SWANSON T, 1997, J NEUROSCI, V17, P58; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TAYLOR WR, 1995, J PHYSIOL-LONDON, V483, P567, DOI 10.1113/jphysiol.1995.sp020607; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882; WU TY, 1994, BIOCHEM J, V300, P365, DOI 10.1042/bj3000365; YAMADA KA, 1993, J NEUROSCI, V13, P3904	35	608	626	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1596	1599		10.1126/science.280.5369.1596	http://dx.doi.org/10.1126/science.280.5369.1596			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616121	Green Published			2022-12-28	WOS:000074061200039
J	Ridge, JP; Di Rosa, F; Matzinger, P				Ridge, JP; Di Rosa, F; Matzinger, P			A conditioned dendritic cell can be a temporal bridge between a CD4(+) T-helper and a T-killer cell	NATURE			English	Article							ANTIGEN-PRESENTING CELLS; INVIVO; TOLERANCE; INDUCTION; RESPONSES; ABSENCE; REQUIREMENTS; GENERATION; ACTIVATION; MECHANISM	To generate an immune response, antigen-specific T-helper and T-killer cells must find each other and, because they cannot detect each other's presence, they are brought together by an antigen-loaded dendritic cell that displays antigens to both(1-3). This three-cell interaction, however, seems nearly impossible because all three cell types are rare and migratory. Here we provide a potential solution to this conundrum, We found that the three cells need not meet simultaneously but that the helper cell can first engage and 'condition' the dendritic cell, which then becomes empowered to stimulate a killer cell. The first step (help) can be bypassed by modulation of the surface molecule CD40, or by viral infection of dendritic cells. These results may explain the longstanding paradoxical observation that responses to some viruses are helper-independent, and they evoke the possibility that dendritic cells may take on different functions in response to different conditioning signals.	NIAID, Ghost Lab, Sect T Cell Tolerance & Memory, Lab Cellular & Mol Immunol,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Ridge, JP (corresponding author), NIAID, Ghost Lab, Sect T Cell Tolerance & Memory, Lab Cellular & Mol Immunol,NIH, Bldg 4 Room 111,9000 Rockville Pike, Bethesda, MD 20892 USA.	jridge@atlas.niaid.nih.gov	Di Rosa, Francesca/J-8116-2014; Di Rosa, Francesca/AAW-8612-2020	Di Rosa, Francesca/0000-0003-0252-9138				AHMED R, 1988, J VIROL, V62, P2102, DOI 10.1128/JVI.62.6.2102-2106.1988; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Bennett SRM, 1997, J EXP MED, V186, P65, DOI 10.1084/jem.186.1.65; BOOG CJP, 1985, NATURE, V318, P59, DOI 10.1038/318059a0; BULLER RML, 1987, NATURE, V328, P77, DOI 10.1038/328077a0; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GUERDER S, 1992, J EXP MED, V176, P553, DOI 10.1084/jem.176.2.553; GUERDER S, 1989, COLD SPRING HARB SYM, V54, P799; HOU S, 1995, J VIROL, V69, P1429, DOI 10.1128/JVI.69.3.1429-1434.1995; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; KATONA IM, 1991, J IMMUNOL, V146, P4215; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; Liu LM, 1997, ADV EXP MED BIOL, V417, P375; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MITCHISON NA, 1987, EUR J IMMUNOL, V17, P1579, DOI 10.1002/eji.1830171109; NONACS R, 1992, J EXP MED, V176, P519, DOI 10.1084/jem.176.2.519; PALIARD X, 1988, J IMMUNOL, V141, P849; REES MA, 1990, P NATL ACAD SCI USA, V87, P2765, DOI 10.1073/pnas.87.7.2765; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; SAELAND S, 1993, J EXP MED, V178, P113, DOI 10.1084/jem.178.1.113; SIMPSON E, 1977, IMMUNOL REV, V35, P59, DOI 10.1111/j.1600-065X.1977.tb00235.x; STAVNEZER J, 1995, J IMMUNOL, V155, P1647; TRIPP RA, 1995, J IMMUNOL, V155, P2955; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P1031, DOI 10.1002/eji.1830220423; WU Y, 1994, CURR BIOL, V4, P499, DOI 10.1016/S0960-9822(00)00110-X; Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862; YONG JL, 1995, IMMUNITY, V2, P239	30	1947	2102	1	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					474	478		10.1038/30989	http://dx.doi.org/10.1038/30989			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624003				2022-12-28	WOS:000074020000046
J	Weeks, JC; Cook, EF; O'Day, SJ; Petersen, LM; Wenger, N; Reding, D; Harrell, FE; Kussin, P; Dawson, NV; Connors, AF; Lynn, J; Phillips, RS				Weeks, JC; Cook, EF; O'Day, SJ; Petersen, LM; Wenger, N; Reding, D; Harrell, FE; Kussin, P; Dawson, NV; Connors, AF; Lynn, J; Phillips, RS			Relationship between cancer patients' predictions of prognosis and their treatment preferences	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVANCE DIRECTIVES; CARDIOPULMONARY-RESUSCITATION; BREAST-CANCER; SURVIVAL; LIFE; CARE; DECISIONS; DOCTORS; TRUTH	Context.-Previous studies have documented that cancer patients tend to overestimate the probability of long-term survival. If patient preferences about the trade-offs between the risks and benefits associated with alternative treatment strategies are based on inaccurate perceptions of prognosis, then treatment choices may not reflect each patient's true values. Objective.-To test the hypothesis that among terminally ill cancer patients an accurate understanding of prognosis is associated with a preference for therapy that focuses on comfort over attempts at life extension. Design.-Prospective cohort study. Setting.-Five teaching hospitals in the United States. Patients.-A total of 917 adults hospitalized with stage III or IV non-small cell lung cancer or colon cancer metastatic to liver in phases 1 and 2 of the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT), Main Outcome Measures.-Proportion of patients favoring life-extending therapy over therapy focusing on relief of pain and discomfort, patient and physician estimates of the probability of 6-month survival, and actual 6-month survival, Results.-Patients who thought they were going to live for at least 6 months were more likely (odds ratio [OR], 2.6; 95% confidence interval [CI], 1.8-3.7) to favor life-extending therapy over comfort care compared with patients who thought there was at least a 10% chance that they would not live 6 months. This OR was highest (8.5; 95% CI, 3.0-24.0) among patients who estimated their 6-month survival probability at greater than 90% but whose physicians estimated it at 10% or less. Patients overestimated their chances of surviving 6 months, while physicians estimated prognosis quite accurately. Patients who preferred life-extending therapy were more likely to undergo aggressive treatment, but controlling for known prognostic factors, their 6-month survival was no better. Conclusions.-Patients with metastatic colon and lung cancer overestimate their survival probabilities and these estimates may influence their preferences about medical therapies.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Med, Clin Epidemiol Sect, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Univ Calif Los Angeles, Med Ctr, Dept Med, Los Angeles, CA 90024 USA; Marshfield Clin Fdn Med Res & Educ, Marshfield, WI 54449 USA; Univ Virginia, Sch Med, Dept Hlth Evaluat Sci, Div Biostat & Epidemiol, Charlottesville, VA 22908 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Case Western Reserve Univ, Dept Med, Metrohlth Med Ctr, Cleveland, OH 44106 USA; George Washington Univ, Ctr Improve Care Dying, Washington, DC USA; Beth Israel Hosp, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Marshfield Clinic; University of Virginia; Duke University; Case Western Reserve University; MetroHealth System; George Washington University; Harvard University; Beth Israel Deaconess Medical Center	Weeks, JC (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	jane_weeks@dci.harvard.edu		Connors, Alfred F./0000-0001-7123-3360				Bernheim JL, 1987, MONOGR SER EUR ORGAN, V17, P285; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; Dawson N. V., 1995, JGIM, V10, P41; EIDINGER RN, 1984, CANCER, V53, P2736, DOI 10.1002/1097-0142(19840615)53:12<2736::AID-CNCR2820531233>3.0.CO;2-W; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FORROW L, 1988, JAMA-J AM MED ASSOC, V259, P3161, DOI 10.1001/jama.259.21.3161; GOODMAN LA, 1972, J AM STAT ASSOC, V67, P415, DOI 10.2307/2284396; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HOLCOMBE RF, 1994, NEW ENGL J MED, V331, P811; HOSMER DW, 1989, APPL LOGISTIC REGRES; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KATZ S, 1976, INT J HEALTH SERV, V6, P493, DOI 10.2190/UURL-2RYU-WRYD-EY3K; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; MCQUELLON RP, 1995, J CLIN ONCOL, V13, P858, DOI 10.1200/JCO.1995.13.4.858; Mezey M, 1996, J AM GERIATR SOC, V44, P144, DOI 10.1111/j.1532-5415.1996.tb02430.x; MIYAJI NT, 1993, SOC SCI MED, V36, P249, DOI 10.1016/0277-9536(93)90008-R; MIYAJI NT, 1994, NEW ENGL J MED, V331, P810; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; MURPHY DJ, 1990, J CLIN EPIDEMIOL S, V43, pS1; Phillips RS, 1996, J GEN INTERN MED, V11, P387, DOI 10.1007/BF02600183; PRONZATO P, 1994, SUPPORT CARE CANCER, V2, P242, DOI 10.1007/BF00365729; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; SIMINOFF LA, 1989, J CLIN ONCOL, V7, P1192, DOI 10.1200/JCO.1989.7.9.1192; SINGER PA, 1995, SOC SCI MED, V41, P1517, DOI 10.1016/0277-9536(95)00057-E; SINGER PA, 1991, J CLIN ONCOL, V9, P328, DOI 10.1200/JCO.1991.9.2.328; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; STEELE GD, 1994, CANCER, V74, P1979, DOI 10.1002/1097-0142(19941001)74:7<1979::AID-CNCR2820740725>3.0.CO;2-J; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; YELLEN SB, 1996, 4 INT SOC BEH MED MA	31	892	894	1	34	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1709	1714		10.1001/jama.279.21.1709	http://dx.doi.org/10.1001/jama.279.21.1709			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624023	Bronze			2022-12-28	WOS:000073878700031
J	Fradin, MS				Fradin, MS			Mosquitoes and mosquito repellents: A clinician's guide	ANNALS OF INTERNAL MEDICINE			English	Review							3 CLIMATIC REGIMENS; INSECT-REPELLENT; N,N-DIETHYL-M-TOLUAMIDE DEET; TOXIC ENCEPHALOPATHY; HUMAN VOLUNTEERS; AEDES-AEGYPTI; LABORATORY EVALUATION; PERSONAL PROTECTION; DERMAL APPLICATION; ANOPHELES-GAMBIAE	This paper is intended to provide the clinician with the detailed and scientific information needed to advise patients who seek safe and effective ways of preventing mosquito bites. For this review, clinical and analytical data were selected from peer-reviewed research studies and review articles, case reports, entomology texts and journals, and government and industry publications. Relevant information was identified through a search of the MEDLINE database, the World Wide Web, the Mosquito-L electronic mailing list, and the Extension Toxicology Network database; selected U.S. Army, U.S. Environmental Protection Agency, and U.S. Department of Agriculture publications were also reviewed. N,N-diethyl-3-methylbenzamide (DEET) is the most effective, and best studied, insect repellent currently on the market. This substance has a remarkable safety profile after 40 years of worldwide use, but toxic reactions can occur (usually when the product is misused). When DEET-based repellents are applied in combination with permethrin-treated clothing, protection against bites of nearly 100% can be achieved. Plant-based repellents are generally less effective than DEET-based products. Ultrasonic devices, outdoor bug "zappers," and bat houses are not effective against mosquitoes. Highly sensitive persons may want to take oral antihistamines to minimize cutaneous reactions to mosquito bites.	Chapel Hill Dermatol, Chapel Hill, NC 27514 USA		Fradin, MS (corresponding author), Chapel Hill Dermatol, 891 Willow Dr,Suite 2, Chapel Hill, NC 27514 USA.							AMICHAI B, 1994, CONTACT DERMATITIS, V30, P188, DOI 10.1111/j.1600-0536.1994.tb00715.x; ANNIS B, 1990, J AM MOSQUITO CONTR, V6, P430; [Anonymous], 1989, MMWR MORB MORTAL WKL, V38, P678; BELTON P, 1981, MOSQ NEWS, V41, P751; Bock G. R., 1996, OLFACTION MOSQUITO H; BOWEN MF, 1991, ANNU REV ENTOMOL, V36, P139, DOI 10.1146/annurev.en.36.010191.001035; Brown M, 1997, J AM ACAD DERMATOL, V36, P243, DOI 10.1016/S0190-9622(97)70289-5; BrummerKorvenkontio H, 1997, INT ARCH ALLERGY IMM, V112, P169, DOI 10.1159/000237450; BRUMMERKORVENKONTIO H, 1990, INT ARCH ALLER A IMM, V93, P14, DOI 10.1159/000235273; BUESCHER MD, 1982, MOSQ NEWS, V42, P428; BUESCHER MD, 1983, MOSQ NEWS, V43, P364; Casida J.E., 1995, PYRETHRUM FLOWERS PR; *CHEM SPEC MAN ASS, 1996, COMPL STUD DEET TOX; CILEK JE, 1994, J AM MOSQUITO CONTR, V10, P473; CLEM JR, 1993, ANN PHARMACOTHER, V27, P289, DOI 10.1177/106002809302700305; Clements A. N., 1963, PHYSL MOSQUITOES; CURTIS CF, 1987, MED VET ENTOMOL, V1, P109, DOI 10.1111/j.1365-2915.1987.tb00331.x; CURTIS CF, 1986, PARASITOL TODAY, V2, P316, DOI 10.1016/0169-4758(86)90129-8; DAVIS EE, 1976, J COMP PHYSIOL, V105, P43, DOI 10.1007/BF01380052; DAVIS EE, 1994, J AM MOSQUITO CONTR, V10, P316; DAVIS EE, 1985, J MED ENTOMOL, V22, P237, DOI 10.1093/jmedent/22.3.237; DEGARBINO JP, 1983, VET HUM TOXICOL, V25, P422; deJong R, 1996, CIBA F SYMP, V200, P89; DOME AJ, 1995, J AM MOSQUITO CONTR, V11, P29; DUKE J, USDA AGR RES SERVICE; EDWARDS DL, 1987, CLIN PHARMACY, V6, P496; Foster A., 1994, Business Information Review, V10, P2; FOSTER WA, 1985, J AM MOSQUITO CONTR, V1, P199; FRICK TB, 1996, ENTOMOL NEWS, V2, P77; GABEL ML, 1976, MOSQ NEWS, V36, P141; Garrettson L, 1997, J TOXICOL-CLIN TOXIC, V35, P443, DOI 10.3109/15563659709001225; Geier M, 1996, CIBA F SYMP, V200, P132; GILBERT IRWIN H., 1966, FLORIDA ENTOMOL, V49, P53, DOI 10.2307/3493317; GILLIES MT, 1980, B ENTOMOL RES, V70, P525, DOI 10.1017/S0007485300007811; GILLIES MT, 1972, B ENTOMOL RES, V61, P389, DOI 10.1017/S0007485300047295; GJULLIN CM, 1947, J ECON ENTOMOL, V40, P326, DOI 10.1093/jee/40.3.326; GRAINGER J, 1991, NATURAL INSECT REPEL; GRYBOSKI J, 1961, NEW ENGL J MED, V264, P289, DOI 10.1056/NEJM196102092640608; GUPTA RK, 1987, J AM MOSQUITO CONTR, V3, P556; GUPTA RK, 1991, J AM MOSQUITO CONTR, V7, P490; GUPTA RK, 1989, J AM MOSQUITO CONTR, V5, P52; HEICK HMC, 1988, PEDIATRICS, V82, P373; HEICK HMC, 1980, J PEDIATR-US, V97, P471; Jacobson M., 2008, GLOSSARY PLANT DERIV, V40; Keystone JS, 1996, LANCET, V347, P1423, DOI 10.1016/S0140-6736(96)91678-5; KHAN A A, 1969, Transactions of the St. John's Hospital Dermatological Society, V55, P99; KHAN AA, 1973, J ECON ENTOMOL, V66, P437, DOI 10.1093/jee/66.2.437; Khan AA, 1977, CHEM CONTROL INSECT, P305; KING WV, 1954, USDA AGR HDB, V69, P1; KNOLS BGJ, 1994, MED VET ENTOMOL, V8, P386, DOI 10.1111/j.1365-2915.1994.tb00104.x; LAMBERG SI, 1969, ARCH DERMATOL, V100, P582, DOI 10.1001/archderm.100.5.582; LEACH GJ, 1988, J TOXICOL ENV HEALTH, V25, P217, DOI 10.1080/15287398809531203; LEWIS DJ, 1982, CAN ENTOMOL, V114, P699, DOI 10.4039/Ent114699-8; LILLIE TH, 1988, J MED ENTOMOL, V25, P475, DOI 10.1093/jmedent/25.6.475; Lindsay LR, 1996, J AM MOSQUITO CONTR, V12, P293; Lindsay R. L., 1996, COMP EVALUATION EFFI; LINDSAY RL, 1996, EVALUATION BITE BLOC; LINES JD, 1987, MED VET ENTOMOL, V1, P37, DOI 10.1111/j.1365-2915.1987.tb00321.x; LIPSCOMB JW, 1992, ANN EMERG MED, V21, P315, DOI 10.1016/S0196-0644(05)80896-0; MAIBACH HI, 1966, J AMER MED ASSOC, V196, P263, DOI 10.1001/jama.196.3.263; MAIBACH HI, 1974, ARCH DERMATOL, V109, P32, DOI 10.1001/archderm.109.1.32; MAIBACH HI, 1975, ARCH DERMATOL, V111, P726, DOI 10.1001/archderm.111.6.726; MAIBACH HI, 1974, CLIN PHARMACOL THER, V16, P970, DOI 10.1002/cpt1974165part2970; Matsuda BM, 1996, J AM MOSQUITO CONTR, V12, P69; MCCORMACK DR, 1995, ANN ALLERG ASTHMA IM, V74, P39; MCHUGH CP, 1994, LAB MED, V25, P429, DOI 10.1093/labmed/25.7.429; MEHR ZA, 1985, J AM MOSQUITO CONTR, V1, P143; MIIKE L, 1987, DO INSECTS TRANSMIT; MILLER JD, 1982, NEW ENGL J MED, V307, P1341; MITCHELL M, 1992, WING BEATS, V3, P18; Montemarano AD, 1997, LANCET, V349, P1670, DOI 10.1016/S0140-6736(05)62637-2; MUIRHEADTHOMSON RC, 1951, BRIT MED J, V1, P1114, DOI 10.1136/bmj.1.4715.1114; NASCI RS, 1983, MOSQ NEWS, V43, P180; OSIMITZ TG, 1995, J AM MOSQUITO CONTR, V11, P274; Osimitz TG, 1997, J TOXICOL-CLIN TOXIC, V35, P435, DOI 10.3109/15563659709001224; Peng ZK, 1996, ANN ALLERG ASTHMA IM, V77, P238, DOI 10.1016/S1081-1206(10)63262-0; PORT GR, 1980, B ENTOMOL RES, V70, P133, DOI 10.1017/S0007485300009834; Qiu HC, 1997, J PHARM SCI-US, V86, P514, DOI 10.1021/js960283m; QUARLES W, 1996, COMMON SENSE PEST CO, V12, P5; QUARLES W, 1996, COMMON SENSE PEST CO, V12, P12; REIFENRATH W, 1986, CONTROLLED RELEASE P; REUNALA T, 1994, ANN MED, V26, P301, DOI 10.3109/07853899409147906; REUNALA T, 1993, CLIN EXP ALLERGY, V23, P72, DOI 10.1111/j.1365-2222.1993.tb02487.x; REUNALA T, 1990, CLIN EXP ALLERGY, V20, P19, DOI 10.1111/j.1365-2222.1990.tb02472.x; REUNALA T, 1991, CLIN EXP ALLERGY, V21, P617, DOI 10.1111/j.1365-2222.1991.tb00855.x; REUVENI H, 1982, ARCH DERMATOL, V118, P582, DOI 10.1001/archderm.118.8.582; ROBBINS PJ, 1986, J TOXICOL ENV HEALTH, V18, P503, DOI 10.1080/15287398609530891; ROLAND EH, 1985, CAN MED ASSOC J, V132, P155; RUTLEDGE LC, 1985, J AM MOSQUITO CONTR, V1, P56; RUTLEDGE LC, 1983, J MED ENTOMOL, V20, P506, DOI 10.1093/jmedent/20.5.506; RUTLEDGE LC, 1988, J AM MOSQUITO CONTR, V4, P414; Schoenig GP, 1996, DRUG METAB DISPOS, V24, P156; Schreck C, 1995, WILDERNESS MED MANAG, P813; SCHRECK CE, 1989, J AM MOSQUITO CONTR, V5, P247; SCHRECK CE, 1980, J ECON ENTOMOL, V73, P451, DOI 10.1093/jee/73.3.451; SCHRECK CE, 1978, J ECON ENTOMOL, V71, P397, DOI 10.1093/jee/71.3.397; SCHRECK CE, 1989, J AM MOSQUITO CONTR, V5, P91; SCHRECK CE, 1991, J AM MOSQUITO CONTR, V7, P533; SCHRECK CE, 1989, J AM MOSQUITO CONTR, V5, P77; SCHRECK CE, 1990, J AM MOSQUITO CONTR, V6, P406; SELIM S, 1995, FUND APPL TOXICOL, V25, P95, DOI 10.1006/faat.1995.1043; Shell E.R., 1997, ATLANTIC MONTHLY, P45; SHELOV SP, 1991, CARING YOUR BABY YOU, P639; SHOLDT LL, 1988, J AM MOSQUITO CONTR, V4, P233; SNOW WF, 1970, B ENTOMOL RES, V60, P43, DOI 10.1017/S0007485300034131; SNYDER JW, 1986, J TOXICOL-CLIN TOXIC, V24, P429, DOI 10.3109/15563658608992605; SPERO NC, 1993, REPELLENT TESTING AU; STRAUSS WG, 1968, AM J TROP MED HYG, V17, P461, DOI 10.4269/ajtmh.1968.17.461; SUKUMAR K, 1991, J AM MOSQUITO CONTR, V7, P210; SURGEONER GA, 1995, EFFICACY BUZZ AWAY O; TAUBES G, 1977, NY TIMES MAGAZI 0824, P40; TENENBEIN M, 1987, JAMA-J AM MED ASSOC, V258, P1509, DOI 10.1001/jama.258.11.1509; *U CAL BERK, 1997, U CAL BERK WELLN LET, V13, P2; *US EPA, 1996, EPA735F93052R; *US EPA, 1980, EPA540RS81004; *USDA, 1967, USDA AGR HDB, V340, P1; VELTRI JC, 1994, J TOXICOL-CLIN TOXIC, V32, P1, DOI 10.3109/15563659409000426; VONMAYENBURG J, 1983, CONTACT DERMATITIS, V9, P171, DOI 10.1111/j.1600-0536.1983.tb04350.x; Wantke F, 1996, CONTACT DERMATITIS, V35, P186, DOI 10.1111/j.1600-0536.1996.tb02349.x; WRIGHT RH, 1975, SCI AM, V233, P104, DOI 10.1038/scientificamerican0775-104; ZADIKOFF CM, 1979, J PEDIATR-US, V95, P140, DOI 10.1016/S0022-3476(79)80109-2; 1989, MED LETT DRUGS THER, V31, P45	122	286	314	0	93	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					931	940		10.7326/0003-4819-128-11-199806010-00013	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00013			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634433				2022-12-28	WOS:000073808600009
J	Yancopoulos, GD; Klagsbrun, M; Folkman, J				Yancopoulos, GD; Klagsbrun, M; Folkman, J			Vasculogenesis, angiogenesis, and growth factors: Ephrins enter the fray at the border	CELL			English	Review							RECEPTOR TYROSINE KINASES; LETHALITY; MEMBRANE; LIGANDS		Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Regeneron; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Yancopoulos, GD (corresponding author), Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA.							Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HOLLENBERG NK, 1993, COLLATERAL CIRCULATI, P1; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; NGUYEN M, 1994, MICROVASC RES, V47, P31, DOI 10.1006/mvre.1994.1003; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Thurston G, 1996, AM J PHYSIOL-HEART C, V271, pH2547, DOI 10.1152/ajpheart.1996.271.6.H2547; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1	20	305	343	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					661	664		10.1016/S0092-8674(00)81426-9	http://dx.doi.org/10.1016/S0092-8674(00)81426-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630209	Bronze			2022-12-28	WOS:000073956700001
J	Young, ED				Young, ED			Neuroscience - What's the best sound?	SCIENCE			English	Article							NEURONS; CORTEX		Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Ctr Hearing Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Young, ED (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA.	eyoung@bme.jhu.edu		Young, Eric/0000-0003-0334-408X				DEBOER E, 1968, IEEE T BIO-MED ENG, VBM15, P169, DOI 10.1109/TBME.1968.4502561; deCharms RC, 1998, SCIENCE, V280, P1439, DOI 10.1126/science.280.5368.1439; DiCarlo JJ, 1998, J NEUROSCI, V18, P2626; EGGERMONT JJ, 1981, HEARING RES, V5, P109, DOI 10.1016/0378-5955(81)90030-7; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; HUBEL DH, 1979, SCI AM, V241, P150, DOI 10.1038/scientificamerican0979-150; Kowalski N, 1996, J NEUROPHYSIOL, V76, P3524, DOI 10.1152/jn.1996.76.5.3524; Marr D., 1982, VISION COMPUTATIONAL, DOI [10.7551/mitpress/9780262514620.001.0001, DOI 10.7551/MITPRESS/9780262514620.001.0001]; Nelken I, 1997, J NEUROPHYSIOL, V78, P800, DOI 10.1152/jn.1997.78.2.800; Ringach DL, 1997, VISION RES, V37, P2455, DOI 10.1016/S0042-6989(96)00247-7; Suga N, 1997, TRENDS COGN SCI, V1, P14, DOI 10.1016/S1364-6613(97)01002-4	11	5	5	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 29	1998	280	5368					1402	1403		10.1126/science.280.5368.1402	http://dx.doi.org/10.1126/science.280.5368.1402			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9634417				2022-12-28	WOS:000073883400045
J	Badham, G				Badham, G			Norman John Badham - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1998	316	7148					1908	1908						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632432				2022-12-28	WOS:000074686500072
J	Lumer, ED; Friston, KJ; Rees, G				Lumer, ED; Friston, KJ; Rees, G			Neural correlates of perceptual rivalry in the human brain	SCIENCE			English	Article							BINOCULAR-RIVALRY; VISUAL-PERCEPTION; ATTENTION; CORTEX; MECHANISMS; NEGLECT; FMRI; LOBE	When dissimilar images are presented to the two eyes, perception alternates spontaneously between each monocular view, a phenomenon called binocular rivalry. Functional brain imaging in humans was used to study the neural basis of these subjective perceptual changes. Cortical regions whose activity reflected perceptual transitions included extrastriate areas of the ventral visual pathway, and parietal and frontal regions that have been implicated in spatial attention; whereas the extrastriate areas were also engaged by nonrivalrous perceptual changes, activity in the frontoparietal cortex was specifically associated with perceptual alternation only during rivalry. These results suggest that frontoparietal areas play a central role in conscious perception, biasing the content of visual awareness toward abstract internal representations of visual scenes, rather than simply toward space.	UCL, Inst Neurol, Wellcome Dept Cognit Neurol, London WC1N 3BG, England	University of London; University College London	Lumer, ED (corresponding author), UCL, Inst Neurol, Wellcome Dept Cognit Neurol, Queen Sq, London WC1N 3BG, England.	elumer@fil.ion.ucl.ac.uk	Friston, Karl/D-9230-2011; Rees, Geraint/C-1493-2008	Friston, Karl/0000-0001-7984-8909; Rees, Geraint/0000-0002-9623-7007	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andrews TJ, 1997, P NATL ACAD SCI USA, V94, P9905, DOI 10.1073/pnas.94.18.9905; BLAKE R, 1989, PSYCHOL REV, V96, P145, DOI 10.1037/0033-295X.96.1.145; BORSELLINO A, 1972, KYBERNETIK, V10, P139, DOI 10.1007/BF00290512; CORBETTA M, 1995, SCIENCE, V270, P802, DOI 10.1126/science.270.5237.802; Corbetta M, 1998, P NATL ACAD SCI USA, V95, P831, DOI 10.1073/pnas.95.3.831; CORBETTA M, 1991, J NEUROSCI, V11, P2383; CORBETTA M, 1993, J NEUROSCI, V13, P1202; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; Crick F, 1996, NATURE, V379, P485, DOI 10.1038/379485a0; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; Fink GR, 1996, NATURE, V382, P626, DOI 10.1038/382626a0; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; FRISTON KJ, 1995, NEUROIMAGE, V2, P157, DOI 10.1006/nimg.1995.1018; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; HEILMAN KM, 1980, NEUROLOGY, V30, P327, DOI 10.1212/WNL.30.3.327; HEINZE HJ, 1994, NATURE, V372, P543, DOI 10.1038/372543a0; HELMHOLTZ, 1911, TREATISE PHYSL OPTIC; Holmes AP, 1997, NEUROIMAGE, V5, pS480; HUMPHREYS GW, 1994, NATURE, V372, P357, DOI 10.1038/372357a0; Husain M, 1996, J NEUROL, V243, P652, DOI 10.1007/BF00878662; Josephs O, 1997, HUM BRAIN MAPP, V5, P243, DOI 10.1002/(SICI)1097-0193(1997)5:4<243::AID-HBM7>3.0.CO;2-3; Kanwisher N, 1997, J NEUROSCI, V17, P4302; LANSING RW, 1964, SCIENCE, V146, P1325, DOI 10.1126/science.146.3649.1325; Leopold DA, 1996, NATURE, V379, P549, DOI 10.1038/379549a0; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; Logothetis NK, 1996, NATURE, V380, P621, DOI 10.1038/380621a0; LOGOTHETIS NK, 1996, ANNU REV NEUROSCI, V19, P557; MALACH R, 1995, P NATL ACAD SCI USA, V92, P8135, DOI 10.1073/pnas.92.18.8135; MAUNSELL JHR, 1995, SCIENCE, V270, P764, DOI 10.1126/science.270.5237.764; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; POGGIO GF, 1988, J NEUROSCI, V8, P4531; Rees G, 1997, SCIENCE, V278, P1616, DOI 10.1126/science.278.5343.1616; Rosen BR, 1998, P NATL ACAD SCI USA, V95, P773, DOI 10.1073/pnas.95.3.773; SCALAIDHE SPO, 1997, SCIENCE, V278; Talairach J., 1988, COPLANAR STEREOTAXIC; Ungerleider Leslie G., 1994, Current Opinion in Neurobiology, V4, P157, DOI 10.1016/0959-4388(94)90066-3; VANESSEN DC, 1994, NEURON, V13, P1, DOI 10.1016/0896-6273(94)90455-3; WALKER P, 1978, PSYCHOL BULL, V85, P376, DOI 10.1037/0033-2909.85.2.376; Wolfe JM, 1996, NATURE, V380, P587, DOI 10.1038/380587a0	41	546	552	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1930	1934		10.1126/science.280.5371.1930	http://dx.doi.org/10.1126/science.280.5371.1930			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632390				2022-12-28	WOS:000074323800062
J	Kwong, PD; Wyatt, R; Robinson, J; Sweet, RW; Sodroski, J; Hendrickson, WA				Kwong, PD; Wyatt, R; Robinson, J; Sweet, RW; Sodroski, J; Hendrickson, WA			Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CRYSTAL-STRUCTURE; TRANSMEMBRANE GLYCOPROTEIN; VARIABLE REGIONS; ATOMIC-STRUCTURE; BINDING; RESOLUTION; FRAGMENT; AIDS; HEMAGGLUTININ	The entry of human Immunodeficiency virus (HIV) into cells requires the sequential interaction of the viral exterior envelope glycoprotein, gp120, with the CD4 glycoprotein and a chemokine receptor on the cell surface. These interactions initiate a fusion of the viral and cellular membranes. Although gp120 can elicit virus-neutralizing antibodies, HIV eludes the Immune system. We have solved the X-ray crystal structure at 2.5 Angstrom resolution of an HIV-1 gp120 core complexed with a two-domain fragment of human con and an antigen-binding fragment of a neutralizing antibody that blocks chemokine-receptor binding. The structure reveals a cavity-laden CD4-gp120 interface, a conserved binding site for the chemokine receptor, evidence for a conformational change upon CD4 binding, the nature of a CD4-induced antibody epitope, and specific mechanisms for immune evasion. Our results provide a framework for understanding the complex biology of HIV entry into cells and should guide efforts to Intervene.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Tulane Univ, Med Ctr, Dept Pediat, New Orleans, LA 70112 USA; SmithKline Beecham Pharmaceut, Dept Immunol, King Of Prussia, PA 19406 USA	Columbia University; Columbia University; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Tulane University; GlaxoSmithKline	Hendrickson, WA (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.	wayne@convex.hhmi.columbia.edu			NIGMS NIH HHS [R01 GM034102] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034102] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Binley JM, 1998, AIDS RES HUM RETROV, V14, P191, DOI 10.1089/aid.1998.14.191; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CORDONNIER A, 1989, NATURE, V340, P571, DOI 10.1038/340571a0; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Dumonceaux J, 1998, J VIROL, V72, P512, DOI 10.1128/JVI.72.1.512-519.1998; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Fass D, 1997, SCIENCE, V277, P1662, DOI 10.1126/science.277.5332.1662; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; KWONG PD, UNPUB J BIOL CHEM; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; MOEBIUS U, 1992, J EXP MED, V176, P507, DOI 10.1084/jem.176.2.507; Moir S, 1996, J VIROL, V70, P8019, DOI 10.1128/JVI.70.11.8019-8028.1996; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLSHEVSKY U, 1990, J VIROL, V64; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PROFY AT, 1990, J IMMUNOL, V144, P4641; RIZZUTO C, IN PRESS SCIENCE; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; RYU SE, 1994, STRUCTURE, V2, P59, DOI 10.1016/S0969-2126(00)00008-3; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; Speck RF, 1997, J VIROL, V71, P7136, DOI 10.1128/JVI.71.9.7136-7139.1997; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; SWEET RW, 1991, CURR OPIN BIOTECH, V2, P622, DOI 10.1016/0958-1669(91)90089-N; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Wu H, 1996, P NATL ACAD SCI USA, V93, P15030, DOI 10.1073/pnas.93.26.15030; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1997, J VIROL, V71, P9722, DOI 10.1128/JVI.71.12.9722-9731.1997; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	50	2391	2568	3	322	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1998	393	6686					648	659		10.1038/31405	http://dx.doi.org/10.1038/31405			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641677	Green Accepted			2022-12-28	WOS:000074289600043
J	Martinelli, I; Sacchi, E; Landi, G; Taioli, E; Duca, F; Mannucci, PM				Martinelli, I; Sacchi, E; Landi, G; Taioli, E; Duca, F; Mannucci, PM			High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVATED PROTEIN-C; FACTOR-V LEIDEN; VENOUS THROMBOSIS; RESISTANCE; PLASMA; THROMBOPHILIA; COAGULATION	Background Idiopathic cerebral-vein thrombosis can cause serious neurologic disability. We evaluated risk factors for this disorder, including genetic risk factors (mutations in the genes encoding factor V and prothrombin) and nongenetic risk factors (such as the use of oral contraceptive agents). Methods We compared the prevalence of these risk factors in 40 patients with cerebral-vein thrombosis, 80 patients with deep-vein thrombosis of the lower extremities, and 120 healthy controls. The G1691A mutation in the factor V gene and the G20210A prothrombin-gene mutation, which are established genetic risk factors for venous thrombosis, were studied. We also assessed the use of oral contraceptives and other risk factors for thrombosis. Results The prevalence of the prothrombin-gene mutation was higher in patients with cerebral-vein thrombosis (20 percent) than in healthy controls (3 percent; odds ratio, 10.2; 95 percent confidence interval, 2.3 to 31.0) and was similar to that in patients with deep-vein thrombosis (18 percent). Similar results were obtained for the mutation in the factor V gene. The use of oral contraceptives was more frequent among women with cerebral-vein thrombosis (96 percent) than among controls (32 percent; odds ratio, 22.1; 95 percent confidence interval, 5.9 to 84.2) and among those with deep-vein thrombosis (61 percent; odds ratio, 4.4; 95 percent confidence interval, 1.1 to 17.8). For women who were taking oral contraceptives and who also had the prothrombin-gene mutation (seven patients with cerebral-vein thrombosis but only one control), the odds ratio for cerebral-vein thrombosis rose to 149.3 (95 percent confidence interval, 31.0 to 711.0). Conclusions Mutations in the prothrombin gene and the factor V gene are associated with cerebral-vein thrombosis. The use of oral contraceptives is also strongly and independently associated with the disorder. The presence of both the prothrombin-gene mutation and oral-contraceptive use raises the risk of cerebral-vein thrombosis further. (C) 1998, Massachusetts Medical Society.	Univ Milan, Maggiore Hosp, IRCCS, Hemophila & Thrombosis Ctr, I-20122 Milan, Italy; Univ Milan, Maggiore Hosp, IRCCS, Epidemiol Unit, I-20122 Milan, Italy; Univ Milan, Maggiore Hosp, IRCCS, Dept Neurol, I-20122 Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Martinelli, I (corresponding author), Univ Milan, Maggiore Hosp, IRCCS, Hemophila & Thrombosis Ctr, Via Pave 9, I-20122 Milan, Italy.		Martinelli, ida/J-2287-2015	Martinelli, ida/0000-0001-9218-3622				AMERI A, 1992, NEUROL CLIN, V10, P87, DOI 10.1016/S0733-8619(18)30235-4; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOUSSER MG, 1985, STROKE, V16, P199, DOI 10.1161/01.STR.16.2.199; Brey RL, 1996, STROKE, V27, P1719, DOI 10.1161/01.STR.27.10.1719; BUONANNO FS, 1978, J COMPUT ASSIST TOMO, V2, P281, DOI 10.1097/00004728-197807000-00008; COMP PC, 1986, BLOOD, V67, P504; de Bruijn SFTM, 1998, BRIT MED J, V316, P589, DOI 10.1136/bmj.316.7131.589; DERONDE H, 1994, THROMB HAEMOSTASIS, V72, P880; Deschiens MA, 1996, STROKE, V27, P1724, DOI 10.1161/01.STR.27.10.1724; DeStefano V, 1996, BLOOD, V87, P3531, DOI 10.1182/blood.V87.9.3531.bloodjournal8793531; Dulli DA, 1996, STROKE, V27, P1731, DOI 10.1161/01.STR.27.10.1731; EINHAUPL KM, 1991, LANCET, V338, P958; EINHAUPL KM, 1991, LANCET, V338, P597, DOI 10.1016/0140-6736(91)90607-Q; Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257; KIERKEGAARD A, 1980, ACTA CHIR SCAND, V146, P267; Kluft C, 1997, THROMB HAEMOSTASIS, V78, P315; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; Martinelli I, 1996, THROMB HAEMOSTASIS, V76, P477; Martinelli I, 1996, THROMB HAEMOSTASIS, V75, P393; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Poort SR, 1997, THROMB HAEMOSTASIS, V78, P1157; Preter M, 1996, STROKE, V27, P243, DOI 10.1161/01.STR.27.2.243; Rosendaal FR, 1997, BLOOD, V89, P2817, DOI 10.1182/blood.V89.8.2817; Rosendaal FR, 1997, BLOOD, V90, P1747, DOI 10.1182/blood.V90.5.1747; SAS G, 1975, THROMB RES, V6, P87, DOI 10.1016/0049-3848(75)90153-X; *SAS I, 1990, SAS US GUID VERS 6; Taioli E, 1998, AM J EPIDEMIOL, V147, P605; Vandenbroucke JP, 1996, BRIT MED J, V313, P1127, DOI 10.1136/bmj.313.7065.1127; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; Zuber M, 1996, STROKE, V27, P1721, DOI 10.1161/01.STR.27.10.1721	31	468	484	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1998	338	25					1793	1797		10.1056/NEJM199806183382502	http://dx.doi.org/10.1056/NEJM199806183382502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU443	9632445				2022-12-28	WOS:000074197500002
J	Klein, MDS				Klein, MDS			The knight of faith	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Klein, MDS (corresponding author), 103 S High St,Bldg B, Bridgton, ME 04009 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				1040	1042		10.7326/0003-4819-128-12_Part_1-199806150-00018	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00018			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625669				2022-12-28	WOS:000074201300013
J	Coast, J; Richards, SH; Peters, TJ; Gunnell, DJ; Darlow, MA; Pounsford, J				Coast, J; Richards, SH; Peters, TJ; Gunnell, DJ; Darlow, MA; Pounsford, J			Hospital at home or acute hospital care? A cost minimisation analysis	BRITISH MEDICAL JOURNAL			English	Article							EARLY DISCHARGE; HIP	Objective: To compare, from the viewpoints of the NHS and social services and of patients, the costs associated with early discharge to a hospital at home scheme and those associated with continued care in an acute hospital. Design: Cost minimisation analysis. Setting: Acute hospital wards and the community in the north of Bristol (population about 224 000). Subjects: 241 hospitalised but medically stable elderly patients who fulfilled the criteria for early discharge to a hospital at home scheme and who consented to participate. Main outcome measures: Costs to the NHS, social services, and patients over the 3 months after randomisation. Results: The mean cost for hospital at home patients over the 3 months was pound 2516, whereas that for hospital patients was pound 3292. Under all the assumptions used in the sensitivity analysis, the cost of hospital at home care was less than that of hospital care. Only when hospital costs were assumed to be less than 50% of those used in the initial analysis was the difference equivocal. Conclusions: The hospital at home scheme is less costly than care in the acute hospital. These results may be generalisable to schemes of similar size and scope, operating in a similar context of rising acute admissions.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Frenchay Hosp, Day Hosp, Bristol BS16 1LE, Avon, England; Hosp Home, Downend Clin, Bristol BS16 5TW, Avon, England	University of Bristol	Coast, J (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.		Gunnell, David/ABE-6653-2020	Gunnell, David/0000-0002-0829-6470; Richards, Suzanne/0000-0003-1416-0569; Peters, Tim/0000-0003-2881-4180; Coast, Joanna/0000-0002-3537-5166				CRAIL M, 1996, HLTH SURV J     0404, P16; Donaldson C, 1996, HEALTH ECON, V5, P267, DOI 10.1002/(SICI)1099-1050(199605)5:3<267::AID-HEC209>3.0.CO;2-X; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; FARNWORTH MG, 1994, AGE AGEING, V23, P190, DOI 10.1093/ageing/23.3.190; Hensher M, 1996, J ROY SOC MED, V89, P548, DOI 10.1177/014107689608901003; HOLLINGWORTH W, 1993, BRIT MED J, V307, P903, DOI 10.1136/bmj.307.6909.903; HUSAIN O, 1996, HOSP DOCTOR     0222, P40; HUSAIN O, 1996, HOSP DOCTOR     0201, P6; NETTEN A, 1996, UNIT COSTS HLTH SOCI; OCATHAIN A, 1994, J PUBLIC HEALTH MED, V16, P205, DOI 10.1093/oxfordjournals.pubmed.a042958; Richards SH, 1998, BRIT MED J, V316, P1796, DOI 10.1136/bmj.316.7147.1796; SIKORSKI JM, 1993, MED J AUSTRALIA, V159, P23, DOI 10.5694/j.1326-5377.1993.tb137698.x; SMITH K, 1994, HEALTH ECON, V3, P137, DOI 10.1002/hec.4730030303	13	87	88	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1802	1806		10.1136/bmj.316.7147.1802	http://dx.doi.org/10.1136/bmj.316.7147.1802			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624074	Green Published			2022-12-28	WOS:000074286300031
J	Dowsett, M				Dowsett, M			Improved prognosis for biomarkers in breast cancer	LANCET			English	Editorial Material							EXPRESSION		Royal Marsden NHS Trust, Acad Dept Biochem, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust	Dowsett, M (corresponding author), Royal Marsden NHS Trust, Acad Dept Biochem, London SW3 6JJ, England.							Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; ABE O, 1992, LANCET, V339, P71; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BARTLETT K, 1993, LANCET, V341, P1293; Bast RC, 1998, J CLIN ONCOL, V16, P793; DRESSLER LG, 1992, J NATL CANCER I MONO, V11, P167; *EARL BREAST CANC, 1992, LANCET, V339, P1; ELLEDGE RM, 1993, ANNU REV MED, V44, P201, DOI 10.1146/annurev.me.44.020193.001221; Elledge RM, 1997, J CLIN ONCOL, V15, P1916, DOI 10.1200/JCO.1997.15.5.1916; Ellis PA, 1997, LANCET, V349, P849, DOI 10.1016/S0140-6736(05)61752-7; FOEKENS JA, 1994, J CLIN ONCOL, V12, P1648, DOI 10.1200/JCO.1994.12.8.1648; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; Makris A, 1998, BREAST CANCER RES TR, V48, P11, DOI 10.1023/A:1005973529921; NICHOLSON RI, 1994, BREAST CANCER RES TR, V29, P117, DOI 10.1007/BF00666187; TIETILAINEN T, 1996, J CANC RES ONCOL, V122, P687	16	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1753	1754		10.1016/S0140-6736(05)78743-2	http://dx.doi.org/10.1016/S0140-6736(05)78743-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635946				2022-12-28	WOS:000074197600007
J	Rogers, A; Entwistle, V; Pencheon, D				Rogers, A; Entwistle, V; Pencheon, D			Managing demand - A patient led NHS: Managing demand at the interface between lay and primary care	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; MEDICATION; SERVICES; ILLNESS		Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Univ York, NHS Ctr Reviews & Disseminat, York YO1 5DD, N Yorkshire, England; Univ Forvie Site, Inst Publ Hlth, Cambridge CB2 2SR, England	University of Manchester; University of York - UK; University of Cambridge	Rogers, A (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.		Entwistle, Vikki Ann/I-9266-2019	Entwistle, Vikki Ann/0000-0002-0856-4025				ALONZO AA, 1984, SOC SCI MED, V19, P499, DOI 10.1016/0277-9536(84)90045-5; ANCTIL B, 1996, JOINT COMMISSION J Q, V2, P345; BALXTER M, 1986, J ROY COLL GEN PRACT, V33, P256; Blenkinsopp A, 1996, BRIT MED J, V312, P629; Coulter A, 1997, J Health Serv Res Policy, V2, P112; DEAN K, 1986, SOC SCI MED, V22, P275, DOI 10.1016/0277-9536(86)90076-6; DEAN K, 1986, HLTH PROMOTION, V2, P133; EYLES J, 1990, SOCIAL EFFECTS HLTH; FLEMING GV, 1984, MED CARE, V22, P950, DOI 10.1097/00005650-198410000-00007; Free C, 1998, BRIT MED J, V316, P380, DOI 10.1136/bmj.316.7128.380; FREWER LJ, 1994, PUBLIC UNDERST SCI, V2, P112; Gurwitz JH, 1995, HEALTH SERV RES, V30, P672; Hassell K, 1997, FAM PRACT, V14, P498, DOI 10.1093/fampra/14.6.498; HOPTON JL, 1995, BRIT MED J, V310, P1369, DOI 10.1136/bmj.310.6991.1369; JESSON J, 1994, ETHNIC MINORITY CONS, P66; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Macfarlane JT, 1997, BRIT J GEN PRACT, V47, P719; PEARSON M, 1993, HEALTH SOC CARE COMM, V1, P11; ROGERS A, IN PRESS HLTH PLACE; ROGERS A, IN PRESS DEMANDING P; *SECR STAT HLTH, 1998, NEW NHS; Shipman C, 1997, FAM PRACT, V14, P503, DOI 10.1093/fampra/14.6.503; STACEY M, 1984, ECON IND DEMOCRACY, V5, P157, DOI 10.1177/0143831X8452002	24	37	37	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1816	+		10.1136/bmj.316.7147.1816	http://dx.doi.org/10.1136/bmj.316.7147.1816			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZV258	9624078	Green Published			2022-12-28	WOS:000074286300035
J	Shepperd, S; Harwood, D; Jenkinson, C; Gray, A; Vessey, M; Morgan, P				Shepperd, S; Harwood, D; Jenkinson, C; Gray, A; Vessey, M; Morgan, P			Randomised controlled trial comparing hospital at home care with inpatient hospital care. I: three month follow up of health outcomes	BRITISH MEDICAL JOURNAL			English	Article							SF-36	Objectives: To compare hospital at home care with inpatient hospital care in terms of patient outcomes. Design: Randomised controlled trial with three month follow up. Setting: District general hospital and catchment area of neighbouring community trust. Subjects: Patients recovering from hip replacement (n = 86), knee replacement (n = 86), and hysterectomy (n = 238); elderly medical patients (n = 96); and patients with chronic obstructive airways disease (n = 32). Interventions: Hospital at home care or inpatient hospital care. Main outcome measures: Dartmouth COOP chart to measure patients' general health status; SF-36 to measure possible limitations in physical functioning of patients with hysterectomy; disease specific measures-chronic respiratory disease questionnaire, Barthel index for elderly medical patients, Oxford hip score, and Bristol knee score; hospital readmission and mortality data; carer strain index to measure burden on carers; patients' and carers' preferred form of care. Results: At follow up, there were no major differences in outcome between hospital at home care and hospital care for any of the patient groups except that those recovering from hip replacement reported a significantly greater improvement in quality of life with hospital at home care (difference in change from baseline value 0.50, 95% confidence interval 0.13 to 0.88). Hospital at home did not seem suitable for patients recovering from a knee replacement, as 14 (30%) of patients allocated to hospital at home remained in hospital. Patients in all groups preferred hospital at home care except chose with chronic obstructive airways disease. No differences were detected for carer burden. Carers of patients recovering from knee replacement preferred hospital at home care, while carers of patients recovering from a hysterectomy preferred hospital care. Conclusions: Few differences in outcome were detected. Thus, the cost of hospital at home compared with hospital care becomes a primary concern.	Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Hlth Serv Res Unit, Oxford OX3 7LF, England; Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Hlth Econ Res Ctr, Oxford OX3 7LF, England; Northamptonshire Hlth Author, Northampton NN1 5DN, England	University of Oxford; University of Oxford	Shepperd, S (corresponding author), Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Hlth Serv Res Unit, Oxford OX3 7LF, England.	Sasha.Shepperd@dphpc.ox.ac.uk		Shepperd, Sasha/0000-0001-6384-8322				ADLER MW, 1978, J EPIDEMIOL COMMUN H, V32, P136, DOI 10.1136/jech.32.2.136; Audit Commission, 1997, COM AG IMPR CAR SERV; Dawson J, 1996, J BONE JOINT SURG BR, V78B, P185, DOI 10.1302/0301-620X.78B2.0780185; DONALD IP, 1995, AGE AGEING, V24, P434, DOI 10.1093/ageing/24.5.434; GALASKO D, 1990, ARCH NEUROL-CHICAGO, V47, P49, DOI 10.1001/archneur.1990.00530010061020; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; HALL JA, 1990, MED CARE, V28, P261, DOI 10.1097/00005650-199003000-00006; HUGHES SL, 1992, HEALTH SERV RES, V26, P801; Iliffe S, 1997, J ROY SOC MED, V90, P181, DOI 10.1177/014107689709000401; JENKINSON C, 1995, QUAL LIFE RES, V4, P47, DOI 10.1007/BF00434383; MACKINNON J, 1988, J BONE JOINT SURG BR, V70, P217, DOI 10.1302/0301-620X.70B2.3346291; MAHONEY F I, 1965, Md State Med J, V14, P61; MARKS L, 1991, HOME HOSP CARE REDRA; MARTIN F, 1994, AGE AGEING, V23, P28; Nelson EC, 1987, J CHRON DIS, V40, P55; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; RUCKLEY CV, 1978, BRIT J SURG, V65, P456, DOI 10.1002/bjs.1800650704; Shepperd S, 1998, BRIT MED J, V316, P1791, DOI 10.1136/bmj.316.7147.1791; SHEPPERD S, 1998, COCHRANE LIB; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	20	142	145	1	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1786	+		10.1136/bmj.316.7147.1786	http://dx.doi.org/10.1136/bmj.316.7147.1786			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZV258	9624068	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000074286300027
J	Davies-Hhumphreys, J				Davies-Hhumphreys, J			Elizabeth Timgwilian Davies-Humphreys - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1752	1752		10.1136/bmj.316.7146.1752	http://dx.doi.org/10.1136/bmj.316.7146.1752			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614047	Green Published			2022-12-28	WOS:000074129500074
J	Cullum, CM; Rosenberg, RN				Cullum, CM; Rosenberg, RN			Memory loss - When is it Alzheimer disease?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINI-MENTAL-STATE		Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Alzheimers Dis Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cullum, CM (corresponding author), Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Cullum, C. Munro/AAC-2496-2019	Cullum, C. Munro/0000-0001-9706-5465	NIA NIH HHS [P30-AG-12300-05] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG012300] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1996, Neurology, V47, P592; Bonte FJ, 1997, RADIOLOGY, V202, P793, DOI 10.1148/radiology.202.3.9051035; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Cullum C M, 1995, J Int Neuropsychol Soc, V1, P100; CULLUM CM, 1993, J CLIN EXP NEUROPSYC, V15, P321, DOI 10.1080/01688639308402566; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Geldmacher DS, 1997, NEUROLOGY, V48, pS2, DOI 10.1212/WNL.48.5_Suppl_6.2S; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; MORRISONBOGORAD M, 1997, MOL GENETIC BASIS NE, P581; NAUGLE RI, 1998, INTRO CLIN NEUROPSYC; Rosenberg RN, 1997, JAMA-J AM MED ASSOC, V278, P1282, DOI 10.1001/jama.278.15.1282; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Small GW, 1997, JAMA-J AM MED ASSOC, V278, P1363, DOI 10.1001/jama.278.16.1363	13	8	8	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1689	1690		10.1001/jama.279.21.1689	http://dx.doi.org/10.1001/jama.279.21.1689			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624014				2022-12-28	WOS:000073878700010
J	Charon, R; Montello, M				Charon, R; Montello, M			Literature and medicine: An on-line guide	ANNALS OF INTERNAL MEDICINE			English	Article									Columbia Univ, Coll Phys & Surg, Div Gen Med, New York, NY 10032 USA; Univ Kansas, Sch Med, Med Ctr, Kansas City, KS 66160 USA	Columbia University; University of Kansas; University of Kansas Medical Center	Charon, R (corresponding author), Columbia Univ, Coll Phys & Surg, Div Gen Med, 630 W 168th St,PH 9 E,Room 105, New York, NY 10032 USA.	rac5@columbia.edu						CHAMBERS TS, 1994, LIT MED, V13, P60, DOI 10.1353/lm.2011.0160; CHARON R, 1995, ANN INTERN MED, V122, P599, DOI 10.7326/0003-4819-122-8-199504150-00008; Coles R, 1989, CALL STORIES TEACHIN; DITTRICH L, 1995, ACAD MED, V70, P36; Montgomery Hunter K, 1991, DOCTORS STORIES NARR; TRAUTMANN J, 1975, LIT MED TOPICS TITLE; Weinstein A, 1997, LIT MED, V16, P1, DOI 10.1353/lm.1997.0009	7	3	3	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					959	962		10.7326/0003-4819-128-11-199806010-00030	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00030			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634447				2022-12-28	WOS:000073808600025
J	Cadigan, KM; Fish, MP; Rulifson, EJ; Nusse, R				Cadigan, KM; Fish, MP; Rulifson, EJ; Nusse, R			Wingless repression of Drosophila frizzled 2 expression shapes the wingless morphogen gradient in the wing	CELL			English	Article							IMAGINAL DISKS; SIGNALING PATHWAY; NERVOUS-SYSTEM; BODY PATTERN; CELL FATE; HEDGEHOG; PROTEIN; POLARITY; RECEPTOR; ENCODES	In Drosophila wing imaginal discs, the Wingless (Wg) protein acts as a morphogen, emanating from the dorsal/ventral (D/V) boundary of the disc to directly define cell identities along the D/V axis at short and long range. Here, we show that high levels of a Wg receptor, Drosophila frizzled 2 (Dfz2), stabilize Wg, allowing it to reach cells far from its site of synthesis. Wg signaling represses Dfz2 expression, creating a gradient of decreasing Wg stability moving toward the D/V boundary. This repression of Dfz2 is crucial for the normal shape of Wg morphogen gradient as well as the response of cells to the Wg signal. In contrast to other ligand-receptor relationships where the receptor limits diffusion of the ligand, Dfz2 broadens the range of Wg action by protecting it from degradation.	Stanford Univ, Med Ctr, Dept Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Nusse, R (corresponding author), Stanford Univ, Med Ctr, Dept Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA.			Cadigan, Ken/0000-0003-2431-1703				BAKER NE, 1988, DEVELOPMENT, V102, P489; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BLAIR SS, 1994, DEV BIOL, V162, P229, DOI 10.1006/dbio.1994.1081; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadigan KM, 1996, DEVELOPMENT, V122, P2801; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CASANOVA J, 1995, GENE DEV, V9, P2539, DOI 10.1101/gad.9.20.2539; CASANOVA J, 1993, NATURE, V362, P152, DOI 10.1038/362152a0; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; COUSO JP, 1994, DEVELOPMENT, V120, P621; Freeman M, 1997, DEVELOPMENT, V124, P261; Golembo M, 1996, DEVELOPMENT, V122, P223; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hajnal A, 1997, GENE DEV, V11, P2715, DOI 10.1101/gad.11.20.2715; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOPPLER S, 1995, EMBO J, V14, P5016, DOI 10.1002/j.1460-2075.1995.tb00184.x; Hulme E. C., 1992, RECEPTOR LIGAND INTE, P63; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Kozopas KM, 1998, GENE DEV, V12, P1155, DOI 10.1101/gad.12.8.1155; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lawrence PA, 1996, DEVELOPMENT, V122, P4095; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Neumann CJ, 1996, DEVELOPMENT, V122, P1781; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; Pai LM, 1997, DEVELOPMENT, V124, P2255; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; Pignoni F, 1997, DEVELOPMENT, V124, P271; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Rulifson EJ, 1996, NATURE, V384, P72, DOI 10.1038/384072a0; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SLACK JMW, 1987, TRENDS BIOCHEM SCI, V12, P200, DOI 10.1016/0968-0004(87)90094-6; SLACK JMW, 1987, EGG EMBRYO REGIONAL; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; VINCENT JP, 1994, CELL, V77, P909, DOI 10.1016/0092-8674(94)90139-2; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; XU T, 1993, DEVELOPMENT, V117, P1223; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	58	265	268	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					767	777		10.1016/S0092-8674(00)81438-5	http://dx.doi.org/10.1016/S0092-8674(00)81438-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630221	Bronze			2022-12-28	WOS:000073956700013
J	Chen, XM; Vinkemeier, U; Zhao, YX; Jeruzalmi, D; Darnell, JE; Kuriyan, J				Chen, XM; Vinkemeier, U; Zhao, YX; Jeruzalmi, D; Darnell, JE; Kuriyan, J			Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA	CELL			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; INTERFERON-ALPHA; SIGNAL-TRANSDUCTION; BINDING; PROTEINS; DOMAIN; ACTIVATION; COMPLEX; ISGF-3	The crystal structure of the DNA complex of a STAT-1 homodimer has been determined at 2.9 Angstrom resolution. STAT-1 utilizes a DNA-binding domain with an immunoglobulin ford, similar to that of NF kappa B and the p53 tumor suppressor protein. The STAT-1 dimer forms a contiguous C-shaped clamp around DNA that is stabilized by reciprocal and highly specific interactions between the SH2 domain of one monomer and the C-terminal segment, phosphorylated on tyrosine, of the other. The phosphotyrosine-binding site of the SH2 domain in each monomer is coupled structurally to the DNA-binding domain, suggesting a potential role for the SH2-phosphotyrosine interaction in the stabilization of DNA interacting elements.	Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute	Kuriyan, J (corresponding author), Rockefeller Univ, New York, NY 10021 USA.			Zhao, Yanxiang/0000-0002-9408-9979; Vinkemeier, Uwe/0000-0001-6924-1783				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Briscoe J, 1996, PHILOS T ROY SOC B, V351, P167, DOI 10.1098/rstb.1996.0013; BRUNGER AT, 1998, IN PRESS ACTA CRYS D; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Darnell JE, 1997, P NATL ACAD SCI USA, V94, P11767, DOI 10.1073/pnas.94.22.11767; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LEVY D, 1990, New Biologist, V2, P923; MartinezMoczygemba M, 1997, J BIOL CHEM, V272, P20070, DOI 10.1074/jbc.272.32.20070; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	45	522	550	3	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1998	93	5					827	839		10.1016/S0092-8674(00)81443-9	http://dx.doi.org/10.1016/S0092-8674(00)81443-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630226	Bronze			2022-12-28	WOS:000073956700018
J	Wheeler, GL; Jones, MA; Smirnoff, N				Wheeler, GL; Jones, MA; Smirnoff, N			The biosynthetic pathway of vitamin C in higher plants	NATURE			English	Article							ASCORBIC-ACID BIOSYNTHESIS; L-SORBOSONE; L-FUCOSE; DEHYDROGENASE; METABOLISM; GALACTOSE; MANNOSE; ENZYME; ROOTS; LEAF	Vitamin C (L-ascorbic acid) has important antioxidant and metabolic functions in both plants and animals, but humans, and a few other animal species, have lost the capacity to synthesize it(1). Plant-derived ascorbate is thus the major source of vitamin C in the human diet. Although the biosynthetic pathway of L-ascorbic acid in animals is well understood(2), the plant pathway has remained unknown(3)-one of the few primary plant metabolic pathways for which this is the case. L-ascorbate is abundant in plants (found at concentrations of 1-5 mM in leaves and 25 mM in chloroplasts(3,4)) and may have roles in photosynthesis and transmembrane electron transport(3-5). We found that D-mannose and I.-galactose are efficient precursors for ascorbate synthesis and are interconverted by GDP-D-mannose-3,5-epimerase. We have identified an enzyme in pea and Arabidopsis thaliana, L-galactose dehydrogenase, that catalyses oxidation of L-galactose to L-galactono-1,4-lactone. We propose an ascorbate biosynthesis pathway involving GDP-D-mannose, GDP-L-galactose, L-galactose and L-galactono-1,4-lactone, and have synthesized ascorbate from GDP-D-mannose by way of these intermediates in vitro. The definition of this biosynthetic pathway should allow engineering of plants for increased ascorbate production, thus increasing their nutritional value and stress tolerance.	Univ Exeter, Sch Biol Sci, Hatherly Labs, Exeter EX4 4PS, Devon, England	University of Exeter	Smirnoff, N (corresponding author), Univ Exeter, Sch Biol Sci, Hatherly Labs, Prince Wales Rd, Exeter EX4 4PS, Devon, England.	N.Smirnoff@exeter.ac.uk	Smirnoff, Nicholas/GZN-1978-2022; Wheeler, Glen L/E-5034-2011	Smirnoff, Nicholas/0000-0001-5630-5602; 				ANDREWS MA, 1989, CARBOHYD RES, V194, P1, DOI 10.1016/0008-6215(89)85001-3; BARBER GA, 1971, ARCH BIOCHEM BIOPHYS, V147, P619, DOI 10.1016/0003-9861(71)90420-6; BARBER GA, 1979, J BIOL CHEM, V254, P7600; BAYDOUN EAH, 1988, J PLANT PHYSIOL, V132, P484, DOI 10.1016/S0176-1617(88)80068-3; BURNS J. J., 1967, Metabolic Pathways, V1, P394; CHEN YT, 1953, BIOCHEM J, V55, P821, DOI 10.1042/bj0550821; Conklin PL, 1996, P NATL ACAD SCI USA, V93, P9970, DOI 10.1073/pnas.93.18.9970; Conklin PL, 1997, PLANT PHYSIOL, V115, P1277, DOI 10.1104/pp.115.3.1277; CONTER PF, 1984, CAN J MICROBIOL, V30, P753, DOI 10.1139/m84-115; Dawson R. M. C., 1991, DATA BIOCH RES, V3rd, P363; Feingold D. S., 1982, ENCY PLANT PHYSL A, V13A, P3; Foyer C. H., 1993, ANTIOXIDANTS HIGHER, P31; GHEBREGZABHER M, 1976, J CHROMATOGR, V127, P133, DOI 10.1016/S0021-9673(00)80168-5; HARRIS GC, 1986, PLANT PHYSIOL, V82, P1081, DOI 10.1104/pp.82.4.1081; HOREMANS N, 1994, PLANT PHYSIOL, V104, P1455, DOI 10.1104/pp.104.4.1455; Kim ST, 1996, BBA-PROTEIN STRUCT M, V1297, P1, DOI 10.1016/0167-4838(96)00077-5; LOEWUS FA, 1987, CRC CR REV PLANT SCI, V5, P101, DOI 10.1080/07352688709382235; LOEWUS FA, 1963, PHYTOCHEMISTRY, V2, P109, DOI 10.1016/S0031-9422(00)82971-4; LOEWUS MW, 1990, PLANT PHYSIOL, V94, P1492, DOI 10.1104/pp.94.3.1492; MAIER E, 1982, METHOD ENZYMOL, V89, P176; MAPSON LW, 1956, BIOCHEM J, V64, P13, DOI 10.1042/bj0640013; MAPSON LW, 1958, BIOCHEM J, V68, P395, DOI 10.1042/bj0680395; NISHIKIMI M, 1994, J BIOL CHEM, V269, P13685; OBA K, 1995, J BIOCHEM, V117, P120, DOI 10.1093/oxfordjournals.jbchem.a124697; ROBERTS RM, 1973, PHYTOCHEMISTRY, V12, P2679, DOI 10.1016/0031-9422(73)85079-4; ROBERTS RM, 1971, ARCH BIOCHEM BIOPHYS, V145, P685, DOI 10.1016/S0003-9861(71)80029-2; SAITO K, 1990, PLANT PHYSIOL, V94, P1496, DOI 10.1104/pp.94.3.1496; SCHACHTER H, 1969, J BIOL CHEM, V244, P4785; Smirnoff N, 1996, ANN BOT-LONDON, V78, P661, DOI 10.1006/anbo.1996.0175	29	772	918	8	168	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 28	1998	393	6683					365	369		10.1038/30728	http://dx.doi.org/10.1038/30728			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620799				2022-12-28	WOS:000073883600054
J	Cook, DJ; Kollef, MH				Cook, DJ; Kollef, MH			Risk factors for ICU-acquired pneumonia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTILATOR-ASSOCIATED PNEUMONIA; CRITICALLY ILL PATIENTS; INTENSIVE-CARE UNITS; NOSOCOMIAL PNEUMONIA; INFECTION		McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol, Hamilton, ON L8S 4L8, Canada; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	McMaster University; McMaster University; Washington University (WUSTL)	Cook, DJ (corresponding author), St Josephs Hosp, Dept Med, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	debcook@fhs.csu.mcmaster.ca						Baraibar J, 1997, CHEST, V112, P1050, DOI 10.1378/chest.112.4.1050; CHEVRET S, 1993, INTENS CARE MED, V19, P256, DOI 10.1007/BF01690545; Cook, 1997, Crit Care, V1, P3, DOI 10.1186/cc1; Cook D, 1998, JAMA-J AM MED ASSOC, V279, P781, DOI 10.1001/jama.279.10.781; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; Elatrous S, 1996, CLIN INTENSIVE CARE, V7, P276, DOI DOI 10.3109/TCIC.7.6.276.281; Joiner G A, 1996, Am J Med Qual, V11, P100, DOI 10.1177/0885713X9601100208; JOSHI N, 1992, AM J MED, V93, P135, DOI 10.1016/0002-9343(92)90042-A; KELLEGHAN SI, 1993, AM J INFECT CONTROL, V21, P322, DOI 10.1016/0196-6553(93)90390-P; Kollef MH, 1997, CHEST, V112, P765, DOI 10.1378/chest.112.3.765; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; Kropec A, 1996, INTENS CARE MED, V22, P1155, DOI 10.1007/BF01709329; LIBERATI A, 1998, ANTIBIOTIC PROPHYLAX; MOSCONI P, 1991, EUR J EPIDEMIOL, V7, P320, DOI 10.1007/BF00144995; RELLO J, 1994, INTENS CARE MED, V20, P193, DOI 10.1007/BF01704699; Rello J, 1996, AM J RESP CRIT CARE, V154, P111, DOI 10.1164/ajrccm.154.1.8680665; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639	19	115	129	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1998	279	20					1605	1606		10.1001/jama.279.20.1605	http://dx.doi.org/10.1001/jama.279.20.1605			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP489	9613899				2022-12-28	WOS:000073758600013
J	Koven, SJ				Koven, SJ			The ungifted physician	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1998	279	20					1607	1607		10.1001/jama.279.20.1607	http://dx.doi.org/10.1001/jama.279.20.1607			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP489	9613900				2022-12-28	WOS:000073758600014
J	Astiz, ME; Rackow, EC				Astiz, ME; Rackow, EC			Septic shock	LANCET			English	Editorial Material							DISSEMINATED INTRAVASCULAR COAGULATION; SYSTEMIC INFLAMMATORY RESPONSE; MULTICENTER CLINICAL-TRIAL; GRAM-NEGATIVE BACTEREMIA; GASTRIC INTRAMUCOSAL PH; CRITICALLY ILL PATIENTS; NECROSIS-FACTOR-ALPHA; BLOOD LACTATE LEVELS; SEVERE SEPSIS; DOUBLE-BLIND		New York Med Coll, St Vincents Hosp & Med Ctr, Dept Med, New York, NY 10011 USA	New York Medical College; Saint Vincents Hospital Manhattan	Astiz, ME (corresponding author), New York Med Coll, St Vincents Hosp & Med Ctr, Dept Med, New York, NY 10011 USA.							ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; Abraham E, 1996, New Horiz, V4, P184; Abraham E, 1997, JAMA-J AM MED ASSOC, V277, P1531, DOI 10.1001/jama.277.19.1531; ADAMS DH, 1994, LANCET, V343, P831, DOI 10.1016/S0140-6736(94)92029-X; Astiz M, 1996, J LAB CLIN MED, V128, P594, DOI 10.1016/S0022-2143(96)90132-8; ASTIZ M, 1988, CIRC SHOCK, V26, P311; ASTIZ ME, 1995, CRIT CARE MED, V23, P265, DOI 10.1097/00003246-199502000-00011; BAKKER J, 1991, CHEST, V99, P956, DOI 10.1378/chest.99.4.956; Bakker J, 1996, AM J SURG, V171, P221, DOI 10.1016/S0002-9610(97)89552-9; BEAL AL, 1994, JAMA-J AM MED ASSOC, V271, P226, DOI 10.1001/jama.271.3.226; Bernard GR, 1997, NEW ENGL J MED, V336, P912, DOI 10.1056/NEJM199703273361303; BERSTEN AD, 1992, SURGERY, V112, P549; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Bone RC, 1996, JAMA-J AM MED ASSOC, V276, P565, DOI 10.1001/jama.276.7.565; BONE RC, 1994, ARCH INTERN MED, V154, P26, DOI 10.1001/archinte.154.1.26; Bone RC, 1996, ANN INTERN MED, V125, P680, DOI 10.7326/0003-4819-125-8-199610150-00009; Brandtzaeg P, 1996, J EXP MED, V184, P51, DOI 10.1084/jem.184.1.51; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; CALANDRA T, 1990, J INFECT DIS, V161, P982, DOI 10.1093/infdis/161.5.982; CLEMMER T, 1990, CRIT CARE MED, V20, P1395; Cobb JP, 1996, JAMA-J AM MED ASSOC, V275, P1192, DOI 10.1001/jama.275.15.1192; COWLEY HC, 1994, CRIT CARE MED, V22, P651, DOI 10.1097/00003246-199404000-00022; CUNHA B, 1997, SEPSIS MULTIORGAN FA, P483; CUNNION RE, 1986, CIRCULATION, V73, P637, DOI 10.1161/01.CIR.73.4.637; DAHN MS, 1987, SURGERY, V101, P69; DHAINAUT JFA, 1994, CRIT CARE MED, V22, P1720, DOI 10.1097/00003246-199422110-00005; Dinarello CA, 1996, CURR TOP MICROBIOL, V216, P133; FOURRIER F, 1993, CHEST, V104, P882, DOI 10.1378/chest.104.3.882; FRIEDMAN G, 1995, CRIT CARE MED, V23, P1184, DOI 10.1097/00003246-199507000-00006; GROENEVELD ABJ, 1986, SURGERY, V99, P140; Gutierrez G, 1996, INTENS CARE MED, V22, P6, DOI 10.1007/BF01728325; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; HACK CE, 1989, BLOOD, V74, P1704; HARRIS RL, 1987, ARCH INTERN MED, V147, P1895, DOI 10.1001/archinte.147.11.1895; Hayes MA, 1997, CRIT CARE MED, V25, P926, DOI 10.1097/00003246-199706000-00007; Heyland DK, 1996, CRIT CARE MED, V24, P517, DOI 10.1097/00003246-199603000-00025; HOTCHKISS RS, 1992, JAMA-J AM MED ASSOC, V267, P1503, DOI 10.1001/jama.267.11.1503; JAVA R, 1997, SEPSIS MULTIORGAN FA, P74; KREGER BE, 1980, AM J MED, V68, P344, DOI 10.1016/0002-9343(80)90102-3; Kumar A, 1996, J EXP MED, V183, P949, DOI 10.1084/jem.183.3.949; LAM C, 1994, J CLIN INVEST, V94, P2077, DOI 10.1172/JCI117562; LEVI M, 1993, JAMA-J AM MED ASSOC, V270, P975, DOI 10.1001/jama.270.8.975; Levy B, 1997, CRIT CARE MED, V25, P1649, DOI 10.1097/00003246-199710000-00013; Liu M, 1997, INTENS CARE MED, V23, P718, DOI 10.1007/s001340050400; LORENTE JA, 1993, CHEST, V103, P1536, DOI 10.1378/chest.103.5.1536; LORENTE JA, 1993, CRIT CARE MED, V21, P1287, DOI 10.1097/00003246-199309000-00010; LYNN WA, 1995, CLIN INFECT DIS, V20, P143, DOI 10.1093/clinids/20.1.143; MARIK PE, 1994, JAMA-J AM MED ASSOC, V272, P1354, DOI 10.1001/jama.272.17.1354; MUNOZ C, 1991, J CLIN INVEST, V88, P1747, DOI 10.1172/JCI115493; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; NELSON DP, 1988, J APPL PHYSIOL, V64, P2410, DOI 10.1152/jappl.1988.64.6.2410; Neviere R, 1996, AM J RESP CRIT CARE, V154, P1684, DOI 10.1164/ajrccm.154.6.8970355; NISHIJIMA H, 1973, MEDICINE, V52, P287, DOI 10.1097/00005792-197307000-00007; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; Opal SM, 1997, CRIT CARE MED, V25, P1115, DOI 10.1097/00003246-199707000-00010; PACKMAN MI, 1983, CRIT CARE MED, V11, P165, DOI 10.1097/00003246-198303000-00003; PARRILLO JE, 1985, J CLIN INVEST, V76, P1539, DOI 10.1172/JCI112135; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; PRINS JM, 1995, J INFECT DIS, V172, P886, DOI 10.1093/infdis/172.3.886; RACKOW EC, 1983, CRIT CARE MED, V11, P839, DOI 10.1097/00003246-198311000-00001; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; Rudis MI, 1996, CRIT CARE MED, V24, P525, DOI 10.1097/00003246-199603000-00026; SCHAEFER CF, 1991, J SURG RES, V51, P382, DOI 10.1016/0022-4804(91)90138-C; SILVERMAN HJ, 1993, CRIT CARE MED, V21, P31, DOI 10.1097/00003246-199301000-00010; SILVERMAN HJ, 1992, CHEST, V102, P184, DOI 10.1378/chest.102.1.184; SPRUNG CL, 1990, CRIT CARE MED, V18, P801, DOI 10.1097/00003246-199008000-00001; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; Thijs LG, 1996, CURR TOP MICROBIOL, V216, P209; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; Yodice PC, 1997, AM J RESP CRIT CARE, V155, P38, DOI 10.1164/ajrccm.155.1.9001286; Zeni F, 1997, CRIT CARE MED, V25, P1095, DOI 10.1097/00003246-199707000-00001	71	238	259	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 16	1998	351	9114					1501	1505		10.1016/S0140-6736(98)01134-9	http://dx.doi.org/10.1016/S0140-6736(98)01134-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605819				2022-12-28	WOS:000073707300042
J	Colasanti, J; Yuan, Z; Sundaresan, V				Colasanti, J; Yuan, Z; Sundaresan, V			The indeterminate gene encodes a zinc finger protein and regulates a leaf-generated signal required for the transition to flowering in maize	CELL			English	Article							FLORAL MERISTEM IDENTITY; SHOOT APICAL MERISTEM; NICOTIANA-TABACUM; ARABIDOPSIS; TIME; MORPHOGENESIS; PATTERNS; HOMOLOG; CLONING; PLANTS	Flowering in plants is a consequence of the transition of the shoot apex from vegetative to reproductive growth in response to environmental and internal signals. The indeterminate 1 gene (id1) controls the transition to flowering in maize. We show by cloning the id1 gene that it encodes a protein with zinc finger motifs, suggesting that the id1 gene product functions as a transcriptional regulator of the floral transition, id1 mRNA expression studies and analyses of transposon-induced chimeric plants indicate that id1 acts non-cell-autonomously to regulate the production of a transmissible signal in the leaf that elicits the transformation of the shoot apex to reproductive development. These results provide molecular and genetic data consistent with the florigen hypothesis derived from classical plant physiology studies.	Univ Calif Berkeley, USDA, Ctr Plant Gene Express, Albany, CA 94710 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Natl Univ Singapore, Inst Mol Agrobiol, Singapore 117604, Singapore	United States Department of Agriculture (USDA); University of California System; University of California Berkeley; Cold Spring Harbor Laboratory; National University of Singapore	Colasanti, J (corresponding author), Univ Calif Berkeley, USDA, Ctr Plant Gene Express, Albany, CA 94710 USA.			Sundaresan, Venkatesan/0000-0002-4670-0630				Aukerman MJ, 1996, SEMIN CELL DEV BIOL, V7, P427, DOI 10.1006/scdb.1996.0053; BATTEY NH, 1990, BOT REV, V56, P162, DOI 10.1007/BF02858534; BERNIER G, 1988, ANNU REV PLANT PHYS, V39, P175, DOI 10.1146/annurev.arplant.39.1.175; Blazquez MA, 1997, DEVELOPMENT, V124, P3835; Chen J., 1994, MAIZE HDB, P526, DOI [10.1007/978-1-4612-2694-9_85, DOI 10.1007/978-1-4612-2694-9_85]; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COLASANTI J, 1991, P NATL ACAD SCI USA, V88, P3377, DOI 10.1073/pnas.88.8.3377; COLASANTI J, 1992, MAIZE GENET COOP NEW, V66, P30; COUPLAND G, 1995, TRENDS GENET, V11, P393, DOI 10.1016/S0168-9525(00)89122-2; DAWE RK, 1990, DEV BIOL, V142, P233, DOI 10.1016/0012-1606(90)90167-H; FISHER JE, 1972, BOT GAZ, V133, P78, DOI 10.1086/336618; GALINAT WC, 1951, AM J BOT, V38, P38, DOI 10.2307/2437990; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; HAKE S, 1989, EMBO J, V8, P15, DOI 10.1002/j.1460-2075.1989.tb03343.x; Irish E, 1997, PLANT J, V11, P63, DOI 10.1046/j.1365-313X.1997.11010063.x; IRISH EE, 1991, DEVELOPMENT, V112, P891; IRISH EE, 1988, PLANTA, V175, P9, DOI 10.1007/BF00402876; JACKSON D, 1994, DEVELOPMENT, V120, P405; Jackson DP, 1991, MOL PLANT PATHOL, P163; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; KUHN C, 1995, MOL GEN GENET, V247, P759, DOI 10.1007/BF00290408; Lang A., 1965, ENCYCL PLANT PHYSIOL, VVolume XV/1, P1380; LEE I, 1994, PLANT CELL, V6, P75, DOI 10.1105/tpc.6.1.75; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; MARTIENSSEN RA, 1989, EMBO J, V8, P1633, DOI 10.1002/j.1460-2075.1989.tb03553.x; Martinez-Zapater JM, 1994, ARABIDOPSIS, P403; McClintock B., 1949, CARNEGIE I WASHINGTO, V48, P142; MCCLINTOCK B, 1955, CARNEGIE I WASH YB, V54, P242; MCDANIEL CN, 1988, PLANTA, V175, P13, DOI 10.1007/BF00402877; McDaniel CN, 1996, PLANT J, V9, P55, DOI 10.1046/j.1365-313X.1996.09010055.x; Okamuro JK, 1996, P NATL ACAD SCI USA, V93, P13831, DOI 10.1073/pnas.93.24.13831; ONEILL SD, 1992, PHOTOCHEM PHOTOBIOL, V56, P789, DOI 10.1111/j.1751-1097.1992.tb02235.x; Pouteau S, 1997, DEVELOPMENT, V124, P3343; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; RAIKHEL N, 1992, PLANT PHYSIOL, V100, P1627, DOI 10.1104/pp.100.4.1627; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scott L, 1996, GENETICS, V142, P237; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; SINGER SR, 1986, DEV BIOL, V118, P587, DOI 10.1016/0012-1606(86)90028-X; SINGLETON WR, 1946, J HERED, V37, P61, DOI 10.1093/oxfordjournals.jhered.a105582; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; Weller JL, 1997, TRENDS PLANT SCI, V2, P412, DOI 10.1016/S1360-1385(97)85580-X	43	223	257	2	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1998	93	4					593	603		10.1016/S0092-8674(00)81188-5	http://dx.doi.org/10.1016/S0092-8674(00)81188-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604934	Bronze			2022-12-28	WOS:000073722200012
J	Fauman, EB; Cogswell, JP; Lovejoy, B; Rocque, WJ; Holmes, W; Montana, VG; Piwnica-Worms, H; Rink, MJ; Saper, MA				Fauman, EB; Cogswell, JP; Lovejoy, B; Rocque, WJ; Holmes, W; Montana, VG; Piwnica-Worms, H; Rink, MJ; Saper, MA			Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A	CELL			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; KINASE ACTIVATION; PHOSPHORYLATION; DEPHOSPHORYLATION; P34CDC2; TRANSITION; P34(CDC2); MECHANISM; RHODANESE; MITOSIS	Cdc25 phosphatases activate the cell division kinases throughout the cell cycle. The 2.3 Angstrom structure of the human Cdc25A catalytic domain reveals a small alpha/beta domain with a fold unlike previously described phosphatase structures but identical to rhodanese, a sulfur-transfer protein. Only the active-site loop, containing the Cys-(X)(5)-Arg motif, shows similarity to the tyrosine phosphatases. In some crystals, the catalytic Cys-430 forms a disulfide bond with the invariant Cys-384, suggesting that Cdc25 may be self-inhibited during oxidative stress. Asp-383, previously proposed to be the general acid, instead serves a structural role, forming a conserved buried salt-bridge. We propose that Glu-431 may act as a general acid. Structure-based alignments suggest that the noncatalytic domain of the MAP kinase phosphatases will share this topology, as will ACR2, a eukaryotic arsenical resistance protein.	Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Glaxo Wellcome Inc, Dept Funct Genet, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Struct Chem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Mol Sci, Res Triangle Pk, NC 27709 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, Howard Hughes Med Inst, St Louis, MO 63110 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Howard Hughes Medical Institute; Washington University (WUSTL)	Fauman, EB (corresponding author), Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA.		Fauman, Eric/AAC-8275-2020; Piwnica-Worms, Helen/C-5214-2012	Fauman, Eric/0000-0002-9739-0249	NIAID NIH HHS [AI34095] Funding Source: Medline; NIGMS NIH HHS [GM47017] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047017] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Bobrowicz P, 1997, YEAST, V13, P819, DOI 10.1002/(SICI)1097-0061(199707)13:9<819::AID-YEA142>3.0.CO;2-Y; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Collaborative Computational Project, 1994, ACTA CRYST D, V50, P760; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Eckstein JW, 1996, PROTEIN SCI, V5, P5; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Gladysheva T, 1996, J BIOL CHEM, V271, P33256, DOI 10.1074/jbc.271.52.33256; Gliubich F, 1996, J BIOL CHEM, V271, P21054, DOI 10.1074/jbc.271.35.21054; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; Ramponi G, 1997, BBA-PROTEIN STRUCT M, V1341, P137, DOI 10.1016/S0167-4838(97)00087-3; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Wysocki R, 1997, J BIOL CHEM, V272, P30061, DOI 10.1074/jbc.272.48.30061; Xu X, 1996, J BIOL CHEM, V271, P5118; Yamauchi A, 1997, BLOOD, V89, P4092, DOI 10.1182/blood.V89.11.4092; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	51	262	268	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					617	625		10.1016/S0092-8674(00)81190-3	http://dx.doi.org/10.1016/S0092-8674(00)81190-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604936	Bronze			2022-12-28	WOS:000073722200014
J	Fisk, GJ; Thummel, CS				Fisk, GJ; Thummel, CS			The DHR78 nuclear receptor is required for ecdysteroid signaling during the onset of Drosophila metamorphosis	CELL			English	Article							STEROID-HORMONE ECDYSONE; RETINOID-X-RECEPTOR; BROAD-COMPLEX; GENE-EXPRESSION; MANDUCA-SEXTA; MOLECULAR ANALYSIS; PUPAL DEVELOPMENT; TOBACCO HORNWORM; SALIVARY-GLANDS; INDUCIBLE GENE	Pulses of ecdysteroids direct Drosophila through its life cycle by activating stage- and tissue-specific genetic regulatory hierarchies. Here we show that an orphan nuclear receptor, DHR78, functions at the top of the ecdysteroid regulatory hierarchies. Null mutations in DHR78 lead to lethality during the third larval instar with defects in ecdysteroid-triggered developmental responses. Consistent with these phenotypes, DHR78 mutants fail to activate the mid-third instar regulatory hierarchy that prepares the animal for metamorphosis. DHR78 protein is bound to many ecdysteroid-regulated puff loci, suggesting that DHR78 directly regulates puff gene expression. In addition, ectopic expression of DHR78 has no effects on development, indicating that its activity is regulated posttranslationally. We propose that DHR78 is a ligand-activated receptor that plays a central role in directing the onset of Drosophila metamorphosis.	Univ Utah, Dept Human Genet, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Thummel, CS (corresponding author), Univ Utah, Dept Human Genet, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA.				NIGMS NIH HHS [5T32GM07464] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007464] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRES AJ, 1994, METHOD CELL BIOL, V44, P565, DOI 10.1016/S0091-679X(08)60932-2; ANDRES AJ, 1993, DEV BIOL, V160, P388, DOI 10.1006/dbio.1993.1315; ANDREW DJ, 1994, DROSOPHILA MELANOGAS, P354; Arias A.M., 1993, DEV DROSOPHILA, P609; Ashburner M, 1972, Results Probl Cell Differ, V4, P101; ASHBURNER M, 1974, DEV BIOL, V39, P141, DOI 10.1016/S0012-1606(74)80016-3; BELYAEVA ES, 1980, CHROMOSOMA, V81, P281, DOI 10.1007/BF00285954; Bender M, 1997, CELL, V91, P777, DOI 10.1016/S0092-8674(00)80466-3; BERREUR P, 1984, GEN COMP ENDOCR, V54, P76, DOI 10.1016/0016-6480(84)90201-6; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BOLLENBACHER WE, 1975, DEV BIOL, V44, P46, DOI 10.1016/0012-1606(75)90375-9; BOYD L, 1991, DEVELOPMENT, V112, P981; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CALVEZ B, 1976, FEBS LETT, V71, P57, DOI 10.1016/0014-5793(76)80898-8; Champlin DT, 1998, DEVELOPMENT, V125, P269; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; CLEVER U, 1964, SCIENCE, V146, P794, DOI 10.1126/science.146.3645.794; Crossgrove K, 1996, DEV BIOL, V180, P745, DOI 10.1006/dbio.1996.0343; DAVIES MJ, 1995, CARDIOL ELDER, V3, P161; DIBELLO PR, 1991, GENETICS, V129, P385; DOMINICK OS, 1985, J EXP BIOL, V117, P45; FISK GJ, 1995, P NATL ACAD SCI USA, V92, P10604, DOI 10.1073/pnas.92.23.10604; FLETCHER JC, 1995, GENETICS, V141, P1025; FLETCHER JC, 1995, DEVELOPMENT, V121, P1455; FLETCHER JC, 1995, DEVELOPMENT, V121, P1411; Gilbert Lawrence I., 1996, P59; GUAY PS, 1991, GENETICS, V129, P169; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; HENRICH VC, 1994, DEV BIOL, V165, P38, DOI 10.1006/dbio.1994.1232; HIROMI Y, 1993, DEVELOPMENT, V118, P1123; Horner M., 1997, DROS INF SERV, V80, P35; IMAM F, 1996, THESIS STANFORD U ST; KARIM FD, 1992, EMBO J, V11, P4083, DOI 10.1002/j.1460-2075.1992.tb05501.x; KARIM FD, 1991, GENE DEV, V5, P1067, DOI 10.1101/gad.5.6.1067; KARIM FD, 1993, DEVELOPMENT, V118, P977; Karim FD, 1996, GENETICS, V143, P315; KARLSON P, 1984, BIOSYNTHESIS METABOL, P162; KISS I, 1988, GENETICS, V118, P247; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOELLE MR, 1992, P NATL ACAD SCI USA, V89, P6167, DOI 10.1073/pnas.89.13.6167; KOELLE MR, 1992, THESIS STANFORD U ST; KOOLMAN J, 1980, PROGR ECDYSONE RES, V7, P187; KOZLOVA T, 1998, IN PRESS GENETICS; Lam GT, 1997, DEVELOPMENT, V124, P1757; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MEYEROWITZ EM, 1987, TRENDS GENET, V3, P288, DOI 10.1016/0168-9525(87)90270-8; MOUGNEAU E, 1993, MOL CELL BIOL, V13, P184, DOI 10.1128/MCB.13.1.184; NAKANISHI Y, 1983, P NATL ACAD SCI-BIOL, V80, P2971, DOI 10.1073/pnas.80.10.2971; NOIROT C, 1982, INSECT ULTRASTRUCTUR, V1, P351; OHTAKI T, 1986, J INSECT PHYSIOL, V32, P635, DOI 10.1016/0022-1910(86)90093-4; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; ORO AE, 1992, DEVELOPMENT, V115, P449; RESTIFO LL, 1992, ROUX ARCH DEV BIOL, V201, P221, DOI 10.1007/BF00188753; RICHARDS G, 1981, BIOL REV, V56, P501, DOI 10.1111/j.1469-185X.1981.tb00358.x; RICHARDS G, 1981, MOL CELL ENDOCRINOL, V21, P181, DOI 10.1016/0303-7207(81)90013-7; Riddiford L., 1993, DEV DROSOPHILA MELAN, V2, P899; RIDDIFORD LM, 1978, GEN COMP ENDOCR, V34, P438, DOI 10.1016/0016-6480(78)90284-8; RIDDIFORD LM, 1986, DEV BIOL, V118, P82, DOI 10.1016/0012-1606(86)90075-8; Russell SRH, 1996, GENETICS, V144, P159; RYERSE JS, 1978, J INSECT PHYSIOL, V24, P541, DOI 10.1016/0022-1910(78)90056-2; SCHWARTZ MB, 1984, DEV BIOL, V103, P85, DOI 10.1016/0012-1606(84)90010-1; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SLATIS HM, 1959, GENETICS, V44, P536; SLITER TJ, 1992, GENETICS, V130, P555; SMITH WA, 1982, J INSECT PHYSIOL, V28, P797, DOI 10.1016/0022-1910(82)90141-X; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; SUTHERLAND JD, 1995, P NATL ACAD SCI USA, V92, P7966, DOI 10.1073/pnas.92.17.7966; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; TALBOT WS, 1993, THESIS STANFORD U ST; Thummel CS, 1996, TRENDS GENET, V12, P306, DOI 10.1016/0168-9525(96)10032-9; Thummel CS, 1992, DROS INF SERV, V71, P150; Urness LD, 1995, EMBO J, V14, P6239, DOI 10.1002/j.1460-2075.1995.tb00314.x; VONKALM L, 1994, EMBO J, V13, P3505, DOI 10.1002/j.1460-2075.1994.tb06657.x; Wassarman P., 1997, ADV DEV BIO, P81; White KP, 1997, SCIENCE, V276, P114, DOI 10.1126/science.276.5309.114; WIGGLESWORTH VB, 1976, INSECT DEV, V8, P186; WOODARD CT, 1994, CELL, V79, P607, DOI 10.1016/0092-8674(94)90546-0; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; ZELHOF AC, 1995, MOL CELL BIOL, V15, P6736; ZELHOF AC, 1995, P NATL ACAD SCI USA, V92, P10477, DOI 10.1073/pnas.92.23.10477	86	49	49	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1998	93	4					543	555		10.1016/S0092-8674(00)81184-8	http://dx.doi.org/10.1016/S0092-8674(00)81184-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604930	Bronze			2022-12-28	WOS:000073722200008
J	Dreifus, FE; Rosman, NP; Cloyd, JC; Pellock, JM; Kuzniecky, RI; Lo, WD; Matsuo, F; Sharp, GB; Conry, JA; Bergen, DC; Bell, WE				Dreifus, FE; Rosman, NP; Cloyd, JC; Pellock, JM; Kuzniecky, RI; Lo, WD; Matsuo, F; Sharp, GB; Conry, JA; Bergen, DC; Bell, WE			A comparison of rectal diazepam gel and placebo for acute repetitive seizures	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADULT EPILEPTIC PATIENTS; N-DESMETHYLDIAZEPAM; HOME USE; CHILDREN; INFANTS; BIOAVAILABILITY; CONVULSIONS; LORAZEPAM; EEG	Background Acute repetitive seizures are readily recognizable episodes involving increased seizure frequency. Urgent treatment is often required. Rectal diazepam gel is a promising therapy. Methods We conducted a randomized, double-blind, parallel-group, placebo-controlled study of home-based treatment for acute repetitive seizures. Patients were randomly assigned to receive either rectal diazepam gel, at doses ranging from 0.2 to 0.5 mg per kilogram of body weight on the basis of age, or placebo. Children received one dose at the onset of acute repetitive seizures and a second dose four hours later. Adults received three doses - one dose at onset, and two more doses 4 and 12 hours after onset. Treatment was administered by a care giver, such as a parent, who had received special training. The number of seizures after the first dose was counted for 12 hours in children and for 24 hours in adults. Results Of 125 study patients (64 assigned to diazepam and 61 to placebo) with a history of acute repetitive seizures, 91 (47 children and 44 adults) were treated for an exacerbation of seizures during the study period. Diazepam treatment was superior to placebo with regard to the outcome variables related to efficacy: reduced seizure frequency (P<0.001) and improved global assessment of treatment outcome by the care giver (frequency and severity of seizures and drug toxicity) (P<0.001). Post hoc analysis showed diazepam to be superior to placebo in reducing seizure frequency in both children (P<0.001) and adults (P=0.02), but only in children was it superior with regard to improvement in global outcome (P<0.001). The time to the first recurrence of seizures after initial treatment was longer for the patients receiving diazepam (P<0.001). Thirty-five patients reported at least one adverse effect of treatment; somnolence was the most frequent. Respiratory depression was not reported. Conclusions Rectal diazepam gel, administered at home by trained care givers, is an effective and well-tolerated treatment for acute repetitive seizures. (N Engl J Med 1998;338:1869-75.) (C) 1998, Massachusetts Medical Society.	Univ Virginia, Dept Neurol, Charlottesville, VA USA; New England Med Ctr, Div Pediat Neurol, Boston, MA 02111 USA; Univ Minnesota, Coll Pharm, Minneapolis, MN 55455 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurol, Richmond, VA 23298 USA; Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA; Childrens Hosp, Dept Pediat, Columbus, OH 43205 USA; Univ Utah, Dept Neurol, Salt Lake City, UT 84112 USA; Arkansas Childrens Hosp, Dept Neurol, Little Rock, AR 72202 USA; Childrens Natl Med Ctr, Dept Neurol, Washington, DC 20010 USA; Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA; NIH, Bethesda, MD 20892 USA	University of Virginia; Tufts Medical Center; University of Minnesota System; University of Minnesota Twin Cities; Virginia Commonwealth University; University of Alabama System; University of Alabama Birmingham; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Utah System of Higher Education; University of Utah; Arkansas Children's Hospital; Children's National Health System; Rush University; National Institutes of Health (NIH) - USA	Rosman, NP (corresponding author), Floating Hosp Children, NEMC 330, Div Pediat Neurol, 750 Washington St, Boston, MA 02111 USA.		Patterson, Marc C./H-5331-2019; Patterson, Marc/AAI-5056-2020	Rosman, N./0000-0002-7702-8015				AGURELL S, 1975, EPILEPSIA, V16, P277, DOI 10.1111/j.1528-1157.1975.tb06058.x; AICARDI J, 1994, EPILEPSY, P284; ALBANO A, 1989, AM J EMERG MED, V70, P168; ALLDREDGE BK, 1995, PEDIATR NEUROL, V12, P213, DOI 10.1016/0887-8994(95)00044-G; BROWNE TR, 1990, NEUROLOGY, V40, P28; CAMFIELD CS, 1989, J CHILD NEUROL, V4, P125, DOI 10.1177/088307388900400210; CLOYD J, 1993, EPILEPSIA S2, V34, P123; *CTR DRUG EV RES, 1989, COSTART COD SYMB THE; DENEGRI M, 1991, BRAIN DEV-JPN, V13, P21, DOI 10.1016/S0387-7604(12)80291-9; DHILLON S, 1982, BRIT J CLIN PHARMACO, V13, P427, DOI 10.1111/j.1365-2125.1982.tb01397.x; DODSON WE, 1993, JAMA-J AM MED ASSOC, V270, P854; FISHER LD, 1993, BIOSTATISTICS METHOD, P611; FISHER LD, 1993, BIOSTATISTICS METHOD, P385; FRANZONI E, 1983, EPILEPSIA, V24, P35, DOI 10.1111/j.1528-1157.1983.tb04863.x; GAROFALO EA, 1989, CLEVE CLIN J MED S, V56, pS277; GRAVES NM, 1987, CLIN NEUROPHARMACOL, V10, P555, DOI 10.1097/00002826-198712000-00007; GREENBLATT DJ, 1982, J PHARM SCI, V71, P248, DOI 10.1002/jps.2600710227; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HOPPU K, 1981, ACTA PAEDIATR SCAND, V70, P369, DOI 10.1111/j.1651-2227.1981.tb16565.x; KNUDSEN FU, 1979, ARCH DIS CHILD, V54, P855, DOI 10.1136/adc.54.11.855; KNUDSEN FU, 1977, ACTA PAEDIATR SCAND, V66, P563, DOI 10.1111/j.1651-2227.1977.tb07947.x; KRAMER LD, 1993, EPILEPSIA, V34, P1075, DOI 10.1111/j.1528-1157.1993.tb02136.x; KRIEL RL, 1991, PEDIATR NEUROL, V7, P13, DOI 10.1016/0887-8994(91)90099-7; LANGSLET A, 1978, ACTA PAEDIATR SCAND, V67, P699, DOI 10.1111/j.1651-2227.1978.tb16246.x; Lehmann E.L., 1975, NONPARAMETRICS STAT, P5; LOMBROSO CT, 1989, EPILEPSIA, V30, pS11, DOI 10.1111/j.1528-1157.1989.tb05819.x; MARUBINI E, 1994, ANAL SURVIVAL DATA C, P42; MEBERG A, 1978, EUR J CLIN PHARMACOL, V14, P273, DOI 10.1007/BF00560461; MILLIGAN N, 1981, J NEUROL NEUROSUR PS, V44, P914, DOI 10.1136/jnnp.44.10.914; MILLIGAN N, 1982, EPILEPSIA, V23, P323, DOI 10.1111/j.1528-1157.1982.tb06198.x; MILLIGAN NM, 1984, J NEUROL NEUROSUR PS, V47, P235, DOI 10.1136/jnnp.47.3.235; Mitchell WG, 1996, EPILEPSIA, V37, pS74, DOI 10.1111/j.1528-1157.1996.tb06025.x; MOOLENAAR F, 1980, INT J PHARM, V5, P127, DOI 10.1016/0378-5173(80)90017-4; MOSES LE, 1992, MED USES STAT, P259; NEWMARK ME, 1990, CHRONOPHARMACOLOGY IN THERAPY OF THE EPILEPSIES, P89; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; REMY C, 1992, EPILEPSIA, V33, P353, DOI 10.1111/j.1528-1157.1992.tb02327.x; Schmidt Dieter, 1995, P705; SCHROEDER MC, 1996, EPILIPSIA, V37, pS154; SMOLENSKY MH, 1990, CHRONOPHARMACOLOGY IN THERAPY OF THE EPILEPSIES, P71; SYKES RM, 1988, ANN TROP PAEDIATR, V8, P259, DOI 10.1080/02724936.1988.11748583; WOODY RC, 1989, J PEDIATR SURG, V24, P474, DOI 10.1016/S0022-3468(89)80405-1; YAGER JY, 1988, AM J DIS CHILD, V142, P931, DOI 10.1001/archpedi.1988.02150090029016	43	189	192	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1998	338	26					1869	1875		10.1056/NEJM199806253382602	http://dx.doi.org/10.1056/NEJM199806253382602			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV898	9637805	Green Published, Bronze			2022-12-28	WOS:000074352800002
J	Berger, A				Berger, A			Action on clinical audit: progress report	BMJ-BRITISH MEDICAL JOURNAL			English	Article																		Miller E, 1998, BRIT MED J, V316, P875, DOI 10.1136/bmj.316.7135.875	1	7	7	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 20	1998	316	7148					1893	1894						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632415				2022-12-28	WOS:000074686500035
J	Rizzuto, CD; Wyatt, R; Hernandez-Ramos, N; Sun, Y; Kwong, PD; Hendrickson, WA; Sodroski, J				Rizzuto, CD; Wyatt, R; Hernandez-Ramos, N; Sun, Y; Kwong, PD; Hendrickson, WA; Sodroski, J			A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; AMINO-ACID CHANGES; ENVELOPE GLYCOPROTEIN; INFLUENZA HEMAGGLUTININ; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; VARIABLE LOOP; FUSION; INFECTION; PEPTIDE	The entry of primate immunodeficiency viruses into target cells depends on a sequential interaction of the gp120 envelope glycoprotein with the cellular receptors, CD4 and members of the chemokine receptor family. The gp120 third variable (V3) loop has been implicated in chemokine receptor binding, but the use of the CCR5 chemokine receptor by diverse primate immunodeficiency viruses suggests the involvement of an additional, conserved gp120 element. Through the use of gp120 mutants, a highly conserved gp120 structure was shown to be critical for CCR5 binding. This structure is located adjacent to the V3 loop and contains neutralization epitopes induced by CD4 binding. This conserved element may be a useful target for pharmacologic or prophylactic intervention in human immunodeficiency virus (HIV) infections.	Harvard Univ, Sch Med, Dept Pathol, Dana Farber Canc Inst,Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Columbia University; Howard Hughes Medical Institute; Harvard University; Harvard T.H. Chan School of Public Health	Sodroski, J (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Dana Farber Canc Inst,Dept Canc Immunol & AIDS, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040895, R01AI041851] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 41851, AI 40895] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARILLO A, 1996, J VIROL, V70, P1301; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; CONNOLLY ML, 1987, J MOL GRAPHICS, V5, P103; CORDONNIER A, 1989, NATURE, V340, P571, DOI 10.1038/340571a0; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FUJITA K, 1992, J VIROL, V66, P4445, DOI 10.1128/JVI.66.7.4445-4451.1992; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; JIANG SB, 1993, BIOCHEM BIOPH RES CO, V195, P533, DOI 10.1006/bbrc.1993.2078; KELLER R, 1993, J VIROL, V67, P6253, DOI 10.1128/JVI.67.10.6253-6258.1993; KIRCHHOFF F, 1995, VIROLOGY, V213, P179, DOI 10.1006/viro.1995.1558; KWONG P, IN PRESS NATURE; KWONG P, UNPUB; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; Martin KA, 1997, SCIENCE, V278, P1470, DOI 10.1126/science.278.5342.1470; MOORE JP, 1993, J VIROL, V67, P4785, DOI 10.1128/JVI.67.8.4785-4796.1993; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; MORRISON HG, 1993, VIROLOGY, V195, P167, DOI 10.1006/viro.1993.1357; MYERS G, 1996, HUMAN RETROVIRUSES A; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; POSNER MR, 1991, J IMMUNOL, V146, P4325; Rabut GEE, 1998, J VIROL, V72, P3464, DOI 10.1128/JVI.72.4.3464-3468.1998; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; RIZZUTO C, UNPUB; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Speck RF, 1997, J VIROL, V71, P7136, DOI 10.1128/JVI.71.9.7136-7139.1997; Sullivan N, 1998, J VIROL, V72, P4694, DOI 10.1128/JVI.72.6.4694-4703.1998; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; WYATT R, 1992, J VIROL, V66, P6997, DOI 10.1128/JVI.66.12.6997-7004.1992; WYATT R, IN PRESS NATURE	49	737	776	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1949	1953		10.1126/science.280.5371.1949	http://dx.doi.org/10.1126/science.280.5371.1949			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632396				2022-12-28	WOS:000074323800068
J	Bancewicz, J				Bancewicz, J			Charles Douglas Anderson - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1832	1832		10.1136/bmj.316.7147.1832	http://dx.doi.org/10.1136/bmj.316.7147.1832			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624095	Green Published			2022-12-28	WOS:000074286300069
J	Kernick, DP				Kernick, DP			Lies, damned lies, and evidence-based medicine	LANCET			English	Editorial Material																			0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1824	1824		10.1016/S0140-6736(05)78797-3	http://dx.doi.org/10.1016/S0140-6736(05)78797-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635992				2022-12-28	WOS:000074197600072
J	Kuijpers, TW; Tjia, KL; de Jager, F; Peters, M; Lam, J				Kuijpers, TW; Tjia, KL; de Jager, F; Peters, M; Lam, J			A boy with chickenpox whose fingers peeled	LANCET			English	Article							KAWASAKI SYNDROME; CHILDREN; DISEASE		Univ Amsterdam, Acad Med Ctr, Dept Pediat, NL-1105 AZ Amsterdam, Netherlands; Zuiderzee Hosp, Dept Pediat, Lelystad, Netherlands; Flevo Hosp, Dept Pediat, Almere, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Kuijpers, TW (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Pediat, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.							LEUNG DYM, 1993, LANCET, V342, P1385, DOI 10.1016/0140-6736(93)92752-F; NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305; NGUYEN P, 1994, EUR J PEDIATR, V153, P646, DOI 10.1007/BF02190684; NIGRO G, 1994, LANCET, V343, P1260, DOI 10.1016/S0140-6736(94)92154-7; SHULMAN ST, 1995, PEDIATR CLIN N AM, V42, P1205	5	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1782	1782		10.1016/S0140-6736(98)04021-5	http://dx.doi.org/10.1016/S0140-6736(98)04021-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635952				2022-12-28	WOS:000074197600013
J	Oldach, DW; Borza, EN; Benitez, RM				Oldach, DW; Borza, EN; Benitez, RM			A mysterious death	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Penn State Univ, University Pk, PA 16802 USA	University System of Maryland; University of Maryland Baltimore; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Benitez, RM (corresponding author), 22 S Greene St,Rm S3B06, Baltimore, MD 21201 USA.			Oldach, David/0000-0002-8811-2562				Arrian, 1983, ANABASIS ALEXANDER; ASHTON NG, 1990, MACEDONIAN HELLENISM, P27; BEGER HG, 1986, GASTROENTEROLOGY, V91, P433, DOI 10.1016/0016-5085(86)90579-2; BENNETT IL, 1953, MEDICINE, V32, P431, DOI 10.1097/00005792-195312000-00002; BOLLIGER CT, 1992, RESPIRATION, V59, P57; Borza E., 1979, AJAH, V4, P102; Borza E. N., 1983, ANCIENT MACEDONIA, V3, P45; BORZA EN, 1987, ANCIENT HIST B, V1, P36; Bosworth A. B., 1988, CONQUEST EMPIRE REIG, P171; BOSWORTH AB, 1971, CLASSICAL Q, V21, P114; BRUCE D, 1888, PRACTITIONER, V40, P241; COULOMB, 1984, HIST SCI MED, V18, P137; CULLEN MR, 1983, MEDICINE, V62, P221, DOI 10.1097/00005792-198307000-00003; ENGELS D, 1978, CLASSICAL PHILOL, V73, P224, DOI 10.1086/366434; FORD M, 1994, GOLDFRANKS TOXICOLOG, P1015; GERHARDT RE, 1980, ARCH ENVIRON HEALTH, V35, P332, DOI 10.1080/00039896.1980.10667515; GILFILLAN S C, 1965, J Occup Med, V7, P53; GREEN DW, 1985, SOUTHERN MED J, V78, P48, DOI 10.1097/00007611-198501000-00013; GREEN P, 1991, ALEXANDER MACEDON 35, P476; HOFFMAN TA, 1975, AM J MED, V59, P481, DOI 10.1016/0002-9343(75)90255-7; HOLMSTEDT B, 1981, READINGS PHARM, P281; KINI MM, 1962, J NEUROCHEM, V9, P119, DOI 10.1111/j.1471-4159.1962.tb11853.x; LEE CY, 1975, ANAL CHEM, V47, P747, DOI 10.1021/ac60354a048; Mendenhall CL, 1993, DIS LIVER, V2, P856; Osler W., 1907, PRINCIPLES PRACTICE, V6th; PERSHAGEN G, 1983, BIOL ENV EFFECTS ARS, P199; PLUTARCH, 1994, LIVES ALEXANDER; REES JH, 1995, NEW ENGL J MED, V333, P1374, DOI 10.1056/NEJM199511233332102; Sbarounis CN, 1997, J CLIN GASTROENTEROL, V24, P294, DOI 10.1097/00004836-199706000-00031; SCHOOLMEESTER WL, 1980, SOUTH MED J, V73, P198, DOI 10.1097/00007611-198002000-00021; SQUIBB KS, 1983, BIOL ENV EFFECTS ARS, P232; Waldron H A, 1973, Med Hist, V17, P391; 1985, GENUINE WORKS HIPPOC, V1, P791	33	30	30	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1998	338	24					1764	1769		10.1056/NEJM199806113382411	http://dx.doi.org/10.1056/NEJM199806113382411			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT654	9625631				2022-12-28	WOS:000074109800011
J	Pablos-Mendez, A; Raviglione, MC; Laszlo, A; Binkin, N; Rieder, HL; Bustreo, F; Cohn, DL; Lambregts-van Weezenbeek, CSB; Kim, SJ; Chaulet, P; Nunn, P				Pablos-Mendez, A; Raviglione, MC; Laszlo, A; Binkin, N; Rieder, HL; Bustreo, F; Cohn, DL; Lambregts-van Weezenbeek, CSB; Kim, SJ; Chaulet, P; Nunn, P		World Hlth Org Int Union TB Lung Dis Working G	Global surveillance for antituberculosis-drug resistance, 1994-1997	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEW-YORK-CITY; DIRECTLY OBSERVED THERAPY; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; HIV-INFECTION; OUTBREAK; TRANSMISSION; EPIDEMIOLOGY; EMERGENCE; MORTALITY	Background Drug-resistant tuberculosis threatens efforts to control the disease. This report describes the prevalence of resistance to four first-line drugs in 35 countries participating in the World Health Organization-lnternational Union against Tuberculosis and Lung Disease Global Project on Anti-Tuberculosis Drug Resistance Surveillance between 1994 and 1997. Methods The data are from cross-sectional surveys and surveillance reports. Participating countries followed guidelines to ensure the use of representative samples, accurate histories of treatment, standardized laboratory methods, and common definitions. A network of reference laboratories provided quality assurance. The median number of patients studied in each country or region was 555 (range, 59 to 14,344). Results Among patients with no prior treatment, a median of 9.9 percent of Mycobacterium tuberculosis strains were resistant to at least one drug (range, 2 to 41 percent); resistance to isoniazid (7.3 percent) or streptomycin (6.5 percent) was more common than resistance to rifampin (1.8 percent) or ethambutol (1.0 percent). The prevalence of primary multidrug resistance was 1.4 percent (range, 0 to 14.4 percent). Among patients with histories of treatment for one month or less, the prevalence of resistance to any of the four drugs was 36.0 percent (range, 5.3 to 100 percent), and the prevalence of multidrug resistance was 13 percent (range, 0 to 54 percent). The overall prevalences were 12.6 percent for single-drug resistance (range, 2.3 to 42.4 percent) and 2.2 percent for multidrug resistance (range, 0 to 22.1 percent). Particularly high prevalences of multidrug resistance were found in the former Soviet Union, Asia, the Dominican Republic, and Argentina. Conclusions Resistance to antituberculosis drugs was found in all 35 countries and regions surveyed, suggesting that it is a global problem. (C) 1998, Massachusetts Medical Society.	Columbia Univ Coll Phys & Surg, Div Gen Med, New York, NY 10032 USA; Columbia Univ, Div Epidemiol, New York, NY 10032 USA; WHO, Global TB Program, CH-1211 Geneva, Switzerland; Lab Ctr Dis Control, Ottawa, ON K1A 0L2, Canada; Int Union TB & Lung Dis, Paris, France; Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA; Denver Publ Hlth Dept, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Royal Netherlands TB Assoc, The Hague, Netherlands; Korean Inst TB, Seoul, South Korea	Columbia University; Columbia University; World Health Organization; Centers for Disease Control & Prevention - USA; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Pablos-Mendez, A (corresponding author), Columbia Univ Coll Phys & Surg, Div Gen Med, 622 W 168th St,PH-9E-105, New York, NY 10032 USA.			RAVIGLIONE, Mario/0000-0002-9331-2067				ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BARNES PF, 1987, AM REV RESPIR DIS, V136, P325, DOI 10.1164/ajrccm/136.2.325; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Boulahbal F, 1989, Bull Int Union Tuberc Lung Dis, V64, P23; BOUVET E, 1991, B EPIDEMIOLOGIQUE HE, V45, P196; CANETTI G, 1965, AM REV RESPIR DIS, V92, P687; CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21; Chaulet P, 1995, TUBERCLE LUNG DIS, V76, P487, DOI 10.1016/0962-8479(95)90523-5; CHAULET P, 1993, ANN I PASTEUR, V4, P181; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; Cohn DL, 1997, CLIN INFECT DIS, V24, pS121, DOI 10.1093/clinids/24.Supplement_1.S121; COHN ML, 1959, J CLIN INVEST, V38, P1349, DOI 10.1172/JCI103910; CONINX R, 1997, INT J TUBERC LUNG S1, V1, pS43; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; CROFTON J, 1948, BMJ-BRIT MED J, V2, P1009, DOI 10.1136/bmj.2.4588.1009; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; FRIEDEN TR, 1993, NEW ENGL J MED, V329, P148; Fujiwara PI, 1997, CLIN CHEST MED, V18, P135, DOI 10.1016/S0272-5231(05)70363-4; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; *HONG KONG GOV TUB, 1964, TUBERCLE, V45, P77; KENNEDY N, 1993, BRIT MED J, V306, P514, DOI 10.1136/bmj.306.6876.514; KIM SJ, 1992, TUBERCLE LUNG DIS, V73, P219, DOI 10.1016/0962-8479(92)90090-7; Kim SJ, 1997, INT J TUBERC LUNG D, V1, P302; KOCHI A, 1993, RES MICROBIOL, V144, P104, DOI 10.1016/0923-2508(93)90023-U; LAMBREGTSVANWEC.CS, 1997, EUR RESP MONOGR, V2, P298; Laszlo A, 1997, INT J TUBERC LUNG D, V1, P231; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; MONNO L, 1991, LANCET, V337, P852, DOI 10.1016/0140-6736(91)92559-K; Morcillo N, 1996, MEDICINA-BUENOS AIRE, V56, P45; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PablosMendez A, 1996, JAMA-J AM MED ASSOC, V276, P1223, DOI 10.1001/jama.276.15.1223; PABLOSMENDEZ A, 1997, PUBLICATION WHO GTB; *PHS COOP INV, 1964, AM RESP DIS, V89, P327; RAVIGLIONE MC, 1994, TUBERCLE LUNG DIS, V75, P400, DOI 10.1016/0962-8479(94)90113-9; Raviglione MC, 1997, LANCET, V350, P624, DOI 10.1016/S0140-6736(97)04146-9; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; SIDDIQI SH, 1989, BACTECT TB SYSTEM PR; SKINNER C, 1994, THORAX, V49, P1193, DOI 10.1136/thx.49.12.1193; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; STYBLO K, 1967, B WORLD HEALTH ORGAN, V37, P819; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; *WHO, 1961, WHO TECH REP SER, V210, P3; *WHO, 1994, WHO PUBL; WHO, 1997, OBESITY PREVENTING M; *WHO, 1983, MAN BACT TUB; Zhao FZ, 1996, LANCET, V347, P358, DOI 10.1016/S0140-6736(96)90537-1; 1991, MMWR MORB MORTAL WKL, V40, P585; 1996, MMWR MORB MORTAL WKL, V45, P330	56	684	719	0	55	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1998	338	23					1641	1649		10.1056/NEJM199806043382301	http://dx.doi.org/10.1056/NEJM199806043382301			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR451	9614254	Bronze			2022-12-28	WOS:000073978000001
J	Minkoff, H; O'Sullivan, MJ				Minkoff, H; O'Sullivan, MJ			The case for rapid HIV testing during labor	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; MOTHER-TO-INFANT; COCAINE USE; ZIDOVUDINE TREATMENT; TRANSMISSION; TYPE-1; INFECTION; CITY; WOMEN; ASSOCIATION		Maimonides Hosp, Dept Obstet & Gynecol, Brooklyn, NY 11219 USA; SUNY, Hlth Sci Ctr, Brooklyn, NY USA; Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA	Maimonides Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; SUNY Maritime College; University of Miami	Minkoff, H (corresponding author), Maimonides Hosp, Dept Obstet & Gynecol, 4800 10th Ave, Brooklyn, NY 11219 USA.	hminkoff@maimonidesmed.org						BIRKHEAD GS, 1998, 5 C RETR FEBR 1 5 19; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; Centers for Disease Control, 1994, MMWR, V43, P1; Centers for Disease Control and Prevention, 1995, MMWR-MORBID MORTAL W, V44, P1; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 1996, J INFECT DIS, V174, P1207, DOI 10.1093/infdis/174.6.1207; *CTR DIS CONTR, 1991, MMWR-MORBID MORTAL W, V40, P1; *CTR DIS CONTR PRE, 1996, MMWR-MORBID MORTAL W, V46, P468; DEROSSI A, 1993, AIDS, V7, P1528, DOI 10.1097/00002030-199311000-00020; DULIEGE AM, 1995, J PEDIATR-US, V126, P625, DOI 10.1016/S0022-3476(95)70365-9; DUNN DT, 1995, AIDS, V9, pF9; Fiscus Susan A., 1996, JAMA (Journal of the American Medical Association), V275, P1483, DOI 10.1001/jama.275.19.1483; GOEDERT JJ, 1989, LANCET, V2, P1351; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; Irwin K, 1996, ANN INTERN MED, V125, P471, DOI 10.7326/0003-4819-125-6-199609150-00007; Mayaux MJ, 1996, JAMA-J AM MED ASSOC, V275, P606, DOI 10.1001/jama.275.8.606; MAYERS MM, 1991, PEDIATRICS, V88, P1248; McCalla S, 1995, AM J PUBLIC HEALTH, V85, P1695, DOI 10.2105/AJPH.85.12.1695; MINKOFF HL, 1990, AM J OBSTET GYNECOL, V163, P521, DOI 10.1016/0002-9378(90)91188-I; NANDA D, 1990, NEW YORK STATE J MED, V90, P488; Rouzioux C, 1995, AM J EPIDEMIOL, V142, P1330, DOI 10.1093/oxfordjournals.aje.a117601; SIMMONDS RJ, 1996, P 11 INT C AIDS JUL; SPEILBERG F, 1996, ANN INTERN MED, V125, P509; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Stetler HC, 1997, AIDS, V11, P369, DOI 10.1097/00002030-199703110-00015	25	41	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1743	1744		10.1001/jama.279.21.1743	http://dx.doi.org/10.1001/jama.279.21.1743			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624029				2022-12-28	WOS:000073878700037
J	Takahashi, N; Nishida, H; Kato, H; Imanishi, K; Sakata, Y; Uchiyama, T				Takahashi, N; Nishida, H; Kato, H; Imanishi, K; Sakata, Y; Uchiyama, T			Exanthematous disease induced by toxic shock syndrome toxin 1 in the early neonatal period	LANCET			English	Article							HUMAN T-CELLS; STAPHYLOCOCCAL ENTEROTOXIN-B; CLASS-II MOLECULES; YERSINIA-PSEUDOTUBERCULOSIS; BACTERIAL SUPERANTIGEN; PATHOLOGIC FINDINGS; ACCESSORY CELLS; MICE; STIMULATION; ACTIVATION	Background We have seen a number of patients who developed systemic exanthema and thrombocytopenia in the first week of life. Although nearly 100% of the patients were cariers of meticillin-resistant Staphylococcus aureus (MRSA), no clear link between MRSA and this exanthematous disease has yet been made. Methods 20 neonates with exanthema and thrombocytopenia were selected for study. To see whether superantigenic exotoxins from MRSA are involved in the pathogensis of the exanthematous disease, we studied the production of these exotoxins by MRSA isolates from the neonates. We studied the expression of T-cell-receptor VP and CD45R0 in T cells taken from four of the neonates. We also analysed the DNA sequences of 16 cloned V beta 2-positive T-cell-receptor-chain genes taken from two of the neonates. Findings Although most of the patients recovered within 5 days of onset of the exanthematous disease without any active treatment, two preterm infants died in the recovery phase. All patients showed colonisation by MRSA. The MRSA produced toxic shock syndrome toxin-1 (TSST-1). The number of T cells positive for T-cell-receptor V beta 2, reactive to TSST-1, was increased in the four patients studied (p<0.0001), and these T cells expressed CD45R0 (p=0.0185). None of the V beta 2 clones had the same junctional sequences. Interpretation The polyclonal expansion of V beta 2-positive T cells in patients colonised by TSST-1-producing MRSA suggests that the pathogenic micro-organism of this neonatal exanthematous disease is S aureus, mainly MRSA, and that in its pathogenesis it activates T cells by TSST-1. Although the pathogenesis of both this exanthematous disease and toxic shock syndrome are fundamentally the same, a diagnosis of toxic shock syndrome cannot be made in this case, based on the clinical criteria for toxic shock syndrome. We propose neonatal toxic-shock-syndrome-like exanthematous disease (NTED) as the name for this disease.	Tokyo Womens Univ, Sch Med, Maternal & Perinatal Ctr, Shinjuku Ku, Tokyo 1628666, Japan; Tokyo Womens Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo 1628666, Japan		Takahashi, N (corresponding author), Tokyo Womens Univ, Sch Med, Maternal & Perinatal Ctr, Shinjuku Ku, 8-1 Kawadacho, Tokyo 1628666, Japan.							Abe J, 1997, J CLIN INVEST, V99, P1823, DOI 10.1172/JCI119349; ABE J, 1993, J IMMUNOL, V151, P4183; AKATSUKA H, 1994, CLIN EXP IMMUNOL, V96, P422; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; GUTTERMAN JU, 1980, ANN INTERN MED, V93, P399, DOI 10.7326/0003-4819-93-3-399; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KAWAMURA M, 1995, ACTA PAEDIATR, V84, P10, DOI 10.1111/j.1651-2227.1995.tb13475.x; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; Kuroda K, 1996, J IMMUNOL, V157, P1422; LARKIN SM, 1982, ANN INTERN MED, V96, P858, DOI 10.7326/0003-4819-96-6-858; LOTZE MT, 1985, J IMMUNOL, V135, P2865; MAKIMOTO A, 1996, J JPN PEDIAT SOC, V100, P609; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MATSUO Y, 1997, J JPN SOC PREMATURE, V9, P86; MIYOSHIAKIYAMA T, 1995, J IMMUNOL, V154, P5228; OKADA T, 1997, J JPN PEDIAT SOC, V101, P631; PARIS AL, 1982, ANN INTERN MED, V96, P852, DOI 10.7326/0003-4819-96-6-852; PARSONNET J, 1987, INFECT IMMUN, V55, P1070, DOI 10.1128/IAI.55.5.1070-1076.1987; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; SAKATA Y, 1997, JPN J OBSTET GYNECOL, V7, pS107; SCHATTNER A, 1981, LANCET, V2, P497; TAKAHASHI N, 1995, J IMMUNOL, V155, P5213; Takahashi N, 1997, ARCH DIS CHILD-FETAL, V77, pF79; Takahashi N., 1995, ACTA NEONAT JPN, V31, P371; TAUCHI M, 1993, J JPN PEDIAT SOC, V97, P1184; TODD J K, 1988, Clinical Microbiology Reviews, V1, P432; UCHIYAMA T, 1993, J IMMUNOL, V151, P4407; UCHIYAMA T, 1994, MICROBIOL IMMUNOL, V38, P245, DOI 10.1111/j.1348-0421.1994.tb01772.x; UCHIYAMA T, 1989, J IMMUNOL, V143, P3175; UCHIYAMA T, 1989, EUR J IMMUNOL, V19, P1803, DOI 10.1002/eji.1830191007; UCHIYAMA T, 1987, CLIN EXP IMMUNOL, V68, P638; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YAMANISHI K, 1988, LANCET, V1, P1065	35	80	82	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1614	1619		10.1016/S0140-6736(97)11125-4	http://dx.doi.org/10.1016/S0140-6736(97)11125-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620715				2022-12-28	WOS:000074026600008
J	Vainberg, IE; Lewis, SA; Rommelaere, H; Ampe, C; Vandekerckhove, J; Klein, HL; Cowan, NJ				Vainberg, IE; Lewis, SA; Rommelaere, H; Ampe, C; Vandekerckhove, J; Klein, HL; Cowan, NJ			Prefoldin, a chaperone that delivers unfolded proteins to cytosolic chaperonin	CELL			English	Article							MICROTUBULE-MEDIATED PROCESSES; T-COMPLEX POLYPEPTIDE-1; IN-VIVO; CYTOPLASMIC CHAPERONIN; MOLECULAR CHAPERONES; YEAST CYTOSKELETON; BINDING DOMAINS; RING COMPLEX; ATPASE CYCLE; ACTIN	We describe the discovery of a heterohexameric chaperone protein, prefoldin, based on its ability to capture unfolded actin. Prefoldin binds specifically to cytosolic chaperonin (c-cpn) and transfers target proteins to it. Deletion of the gene encoding a prefoldin subunit in S. cerevisiae results in a phenotype similar to those found when c-cpn is mutated, namely impaired functions of the actin and tubulin-based cytoskeleton. Consistent with prefoldin having a general role in chaperonin-mediated folding, we identify homologs in archaea, which have a class II chaperonin but contain neither actin nor tubulin. We show that by directing target proteins to chaperonin, prefoldin promotes folding in an environment in which there are many competing pathways for nonnative proteins.	NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA; Flanders Interuniv Inst Biotechnol, B-9000 Ghent, Belgium; State Univ Ghent, B-9000 Ghent, Belgium	New York University; Ghent University	Cowan, NJ (corresponding author), NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA.		Ampe, Christophe/B-5534-2012	Klein, Hannah/0000-0003-4228-8535				ARNBERG DC, 1996, YEAST, V11, P1275; Baumann P, 1996, P NATL ACAD SCI USA, V93, P6726, DOI 10.1073/pnas.93.13.6726; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Bukau B, 1996, TRENDS CELL BIOL, V6, P480, DOI 10.1016/0962-8924(96)84946-4; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; CHOWDHURY S, 1992, J CELL BIOL, V118, P561, DOI 10.1083/jcb.118.3.561; DOOLITTLE RF, 1995, PHILOS T R SOC B, V349, P235, DOI 10.1098/rstb.1995.0107; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; Fenton WA, 1997, PROTEIN SCI, V6, P743; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; Geiser JR, 1997, MOL BIOL CELL, V8, P1035, DOI 10.1091/mbc.8.6.1035; Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; HUFFAKER TC, 1987, ANNU REV GENET, V21, P259; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; Komar AA, 1997, J BIOL CHEM, V272, P10646; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; Lewis SA, 1997, TRENDS CELL BIOL, V7, P479, DOI 10.1016/S0962-8924(97)01168-9; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; Norcum MT, 1996, PROTEIN SCI, V5, P1366, DOI 10.1002/pro.5560050715; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; ROMMELAERE H, 1993, P NATL ACAD SCI USA, V90, P11975, DOI 10.1073/pnas.90.24.11975; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Sherman F., 1983, METHODS YEAST GENETI; STEARNS T, 1990, GENETICS, V124, P251; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TRENT JT, 1992, NATURE, V354, P490; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; URSIC D, 1994, MOL BIOL CELL, V5, P1065, DOI 10.1091/mbc.5.10.1065; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; XU Z, 1997, NATURE, V388, P735; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	51	411	426	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					863	873		10.1016/S0092-8674(00)81446-4	http://dx.doi.org/10.1016/S0092-8674(00)81446-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630229	hybrid			2022-12-28	WOS:000073956700021
J	Guttman, DS; Charlesworth, D				Guttman, DS; Charlesworth, D			An X-linked gene with a degenerate Y-linked homologue in a dioecious plant	NATURE			English	Article							DOSAGE COMPENSATION; SEX DETERMINATION; MELANDRIUM-ALBUM; FLOWERING PLANTS; EVOLUTION; CHROMOSOMES; EXPRESSION; OVERLAP; SILENE; MODEL	Most flowering plants are hermaphroditic, having flowers with both male and female parts. Less than 4% of plant species are dioecious (with individuals of separate sexes), and many of these species have chromosome-mediated sex determination. The taxonomic distribution of separate sexes and chromosomal sex-determination systems in the flowering planes indicates that plant sex chromosomes have evolved recently through replicated, independent events(1-4), contrasting with the ancient origins of mammalian and insect sex chromosomes. Plant sex chromosomes, therefore, offer opportunities to study the most interesting early stages of the evolution of sex chromosomes. Here we show that a gene encoding a male-specific protein is linked to the X chromosome in the dioecious plant Silene latifolia, and that it has a degenerate homologue in the non-pairing region of the Y chromosome. The Y-linked locus has degenerated as a result of nucleotide deletion and the accumulation of repetitive sequences. We have identified both the first X-linked gene and the first pair of homologous sex-linked loci to be found in plants. The homology between the active X-linked locus and the degenerate Y-linked locus supports a common ancestry for these two loci.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago	Guttman, DS (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 1103 E 57th St, Chicago, IL 60637 USA.		Guttman, David S/A-7839-2011; Charlesworth, Deborah/F-3071-2011	Guttman, David S/0000-0001-8479-3869; 				CHARLESWORTH B, 1978, AM NAT, V112, P975, DOI 10.1086/283342; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; CHARLESWORTH B, 1978, P NATL ACAD SCI USA, V75, P5618, DOI 10.1073/pnas.75.11.5618; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; Charlesworth D., 1985, EVOLUTION ESSAYS HON, P237; Darwin C, 1877, EFFECTS CROSS SELF F; Desfeux C, 1996, P ROY SOC B-BIOL SCI, V263, P409, DOI 10.1098/rspb.1996.0062; Donnison IS, 1996, GENETICS, V144, P1893; GRANT S, 1994, DEV GENET, V15, P214, DOI 10.1002/dvg.1020150304; GRAVES JAM, 1995, BIOESSAYS, V17, P311, DOI 10.1002/bies.950170407; Guttman DS, 1996, J CLIN MICROBIOL, V34, P652, DOI 10.1128/JCM.34.3.652-656.1996; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; JUKES T H, 1969, P21; Matsunaga S, 1996, PLANT J, V10, P679, DOI 10.1046/j.1365-313X.1996.10040679.x; MAYER SS, 1992, EVOLUTION, V46, P207, DOI 10.1111/j.1558-5646.1992.tb01995.x; NEI M, 1987, MOL EVOLUTIONARY GEN, P1, DOI DOI 10.7312/NEI-92038; PEDERSEN S, 1987, THEOR APPL GENET, V75, P200, DOI 10.1007/BF00249164; REJON CR, 1994, HEREDITY, V72, P209, DOI 10.1038/hdy.1994.28; STINSON JR, 1987, PLANT PHYSIOL, V83, P442, DOI 10.1104/pp.83.2.442; TANKSLEY SD, 1981, SCIENCE, V213, P453, DOI 10.1126/science.213.4506.453; VANNIGTE.G, 1966, GENETICA, V37, P281, DOI 10.1007/BF01547140; VANNIGTEVECHT G, 1966, GENETICA, V37, P307, DOI 10.1007/BF01547141; VYSKOT B, 1993, MOL GEN GENET, V239, P219, DOI 10.1007/BF00281621; WESTERGAARD M, 1958, ADV GENET, V9, P217, DOI 10.1016/S0065-2660(08)60163-7; ZUK J, 1969, CHROMOSOMES TODAY, V2, P183	25	110	118	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					263	266		10.1038/30492	http://dx.doi.org/10.1038/30492			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607762				2022-12-28	WOS:000073761000052
J	Mombaerts, I; Wilmink, JM; Goldschmeding, R; Koornneef, L				Mombaerts, I; Wilmink, JM; Goldschmeding, R; Koornneef, L			A man with a Hippocratic syndrome?	LANCET			English	Article							BEHCETS-DISEASE		Univ Amsterdam, Orbital Ctr, Dept Ophthalmol, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Dept Med, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Dept Pathol, Acad Med Ctr, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Mombaerts, I (corresponding author), Univ Amsterdam, Orbital Ctr, Dept Ophthalmol, POB 22700, NL-1100 DE Amsterdam, Netherlands.		Goldschmeding, Roel/I-1723-2014					FEIGENBAUM A, 1956, Br J Ophthalmol, V40, P355, DOI 10.1136/bjo.40.6.355; LIE JT, 1992, J RHEUMATOL, V19, P341; Mombaerts I, 1996, OPHTHALMOLOGY, V103, P1619, DOI 10.1016/S0161-6420(96)30454-5; ODUFFY JD, 1990, RHEUM DIS CLIN N AM, V16, P423; SILMAN AJ, 1990, LANCET, V335, P1078	5	2	2	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1486	1486		10.1016/S0140-6736(97)11311-3	http://dx.doi.org/10.1016/S0140-6736(97)11311-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605806				2022-12-28	WOS:000073707300012
J	Abdel-Razik, DA				Abdel-Razik, DA			A memorable experience - Why I became an anesthetist	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1998	316	7148					1914	1914						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632436				2022-12-28	WOS:000074686500082
J	Hjelm, NM; Tong, FFK				Hjelm, NM; Tong, FFK			Patients' records on the Internet: a boost for evidence-based medicine	LANCET			English	Editorial Material									Chinese Univ Hong Kong, Fac Med, Comm Telemed, Hong Kong, Hong Kong; Chinese Univ Hong Kong, Dept Informat Engn, Hong Kong, Hong Kong	Chinese University of Hong Kong; Chinese University of Hong Kong	Hjelm, NM (corresponding author), Chinese Univ Hong Kong, Fac Med, Comm Telemed, New Terr, Hong Kong, Hong Kong.							TSE JSY, 1997, P 4 HONG KONG AS PAC, P23	1	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1751	1752		10.1016/S0140-6736(05)78741-9	http://dx.doi.org/10.1016/S0140-6736(05)78741-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635944				2022-12-28	WOS:000074197600005
J	Ciosk, R; Zachariae, W; Michaelis, C; Shevchenko, A; Mann, M; Nasmyth, K				Ciosk, R; Zachariae, W; Michaelis, C; Shevchenko, A; Mann, M; Nasmyth, K			An ESP1/PDS1 complex regulates loss of sister chromatid cohesion at the metaphase to anaphase transition in yeast	CELL			English	Article							ELECTROSPRAY MASS-SPECTROMETRY; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; DNA-REPLICATION; FISSION YEAST; POLYACRYLAMIDE GELS; NUCLEAR DIVISION; S-PHASE; MITOSIS; CYCLIN	Cohesion between sister chromatids during G2 and M phases depends on the "cohesin" protein Scc1p (Mcd1p). Loss of cohesion at the metaphase to anaphase transition is accompanied by Scc1p's dissociation from chromatids, which depends on proteolysis of Pds1p mediated by a ubiquitin protein ligase called the anaphase promoting complex (APC). We show that destruction of Pds1p is the APC's sole role in triggering Scc1p's dissociation from chromatids and that Pds1p forms a stable complex with a 180 kDa protein called Esp1p, which is essential for the dissociation of Scc1p from sister chromatids and for their separation. We propose that the APC promotes sister separation not by destroying cohesins but instead by liberating the "sister-separating" Esp1 protein from its inhibitor Pds1p.	Res Inst Mol Pathol, A-1030 Vienna, Austria; European Mol Biol Lab, D-69012 Heidelberg, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); European Molecular Biology Laboratory (EMBL)	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Mann, Matthias/A-3454-2013; Ciosk, Rafal/L-7327-2013	Mann, Matthias/0000-0003-1292-4799; Nasmyth, Kim/0000-0001-7030-4403; Ciosk, Rafal/0000-0003-2234-6216				BAUM P, 1988, MOL CELL BIOL, V8, P5386, DOI 10.1128/MCB.8.12.5386; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Groigno L, 1998, CELL, V92, P193, DOI 10.1016/S0092-8674(00)80914-9; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; LIANG H, 1993, EXP CELL RES, V204, P110, DOI 10.1006/excr.1993.1015; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; MAY GS, 1992, J BIOL CHEM, V267, P15737; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; MICHAELIS C, 1997, CELL, V91, P32; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Rose M, 1990, LAB COURSE MANUAL ME; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WILM M, 1996, ANAL CHEM, V66, P1; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	42	505	520	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					1067	1076		10.1016/S0092-8674(00)81211-8	http://dx.doi.org/10.1016/S0092-8674(00)81211-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635435	Bronze			2022-12-28	WOS:000074205700017
J	Mullins, RJ; Mann, NC; Hedges, JR; Worrall, W; Helfand, M; Zechnich, AD; Jurkovich, GJ				Mullins, RJ; Mann, NC; Hedges, JR; Worrall, W; Helfand, M; Zechnich, AD; Jurkovich, GJ			Adequacy of hospital discharge status as a measure of outcome among injured patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY 18-22, 1997	WASHINGTON, D.C.	Soc Acad Emergency Med			TRAUMA SYSTEM; MAJOR TRAUMA; MORTALITY; DEATH; CARE; COMORBIDITIES; INSTITUTION; DATABASES; ACCURACY; BIAS	Context.-Crude mortality rates at the time of hospital discharge are commonly used to assess the quality of care provided to patients hospitalized following trauma. Objectives.-To evaluate the adequacy of hospital death rates as an outcome measure following trauma and to determine the influence of noninjury illness as a cause of hospital death and the frequency of postdischarge death. Design.-Retrospective cohort analyses using hospital discharge data for injured patients cross-linked to death certificate data that provided 1 year of followup for all patients discharged alive. Patients.-A total of 90 048 injured patients admitted to all acute care hospitals in the state of Washington from 1991 through 1993 and discharged with at least 1 diagnosis coded in the International Classification of Diseases, Ninth Revision, Clinical Modification to indicate trauma. Main Outcome Measures.-Death in the hospital and death within 30 days of hospital discharge. Results.-Among 1912 injured patients with in-hospital deaths, 825 death certificates (43%) listed a noninjury cause of death, The overall mortality rate at hospital discharge was 21.2 per 100 000 hospitalized injured patients, and was 12.1 per 100 000 for trauma deaths and 9.1 per 100 000 for those designated as nontrauma deaths. Patients with trauma-related death designations were younger (mean age, 51.5 years vs 77.9 years), had shorter lengths of stay (median stay, 2 days vs 5 days), and sustained more severe injures (P<.001). Including the 1273 deaths that occurred within 30 days of hospital discharge increased rates for trauma-designated deaths to 14.1 per 100 000 and increased rates for nontrauma-designated deaths to 21.3 per 100 000. Conclusions.-Hospital discharge death rates are incomplete measures of death frequency for injured patients. Designation of the cause of death, especially among older, hospitalized, injured patients often reflects preexisting medical conditions. Adequate assessment of mortality following trauma requires measurement of the frequency of death following hospital discharge.	Oregon Hlth & Sci Univ, Sch Med, Dept Surg, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Sch Med, Dept Emergency Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Sch Med, Div Hlth Informat & Outcomes Res, Portland, OR 97201 USA; Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; University of Washington; University of Washington Seattle	Mullins, RJ (corresponding author), Oregon Hlth & Sci Univ, Sch Med, Dept Surg, L223A,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	mullinsr@ohsu.edu	Hedges, Jerris/AAC-1847-2021		PHS HHS [R49/CCR-006283] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON RN, 1997, MON VITAL STAT REP, V45, P17; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; DEYO RA, 1994, SPINE, V19, pS2083; FINELLI FC, 1989, J TRAUMA, V29, P541, DOI 10.1097/00005373-198905000-00001; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; GARNICK DW, 1995, HEALTH SERV RES, V29, P679; Gubler KD, 1997, ARCH SURG-CHICAGO, V132, P1010; IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; JONES DR, 1982, INT J EPIDEMIOL, V11, P276, DOI 10.1093/ije/11.3.276; JONES JM, 1995, J TRAUMA, V38, P123, DOI 10.1097/00005373-199501000-00029; Kleinbaum DG, 1996, SURVIVAL ANAL SELF L; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Messite J, 1996, JAMA-J AM MED ASSOC, V275, P794, DOI 10.1001/jama.275.10.794; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; MULLINS RJ, 1994, JAMA-J AM MED ASSOC, V271, P1919, DOI 10.1001/jama.271.24.1919; MULLINS RJ, 1995, J TRAUMA, V39, P941, DOI 10.1097/00005373-199511000-00020; NORUSIS MJ, 1996, SPSS VERSION 6 01 WI; Osler T, 1996, J TRAUMA, V41, P380, DOI 10.1097/00005373-199609000-00002; POLLOCK DA, 1993, JAMA-J AM MED ASSOC, V269, P1525, DOI 10.1001/jama.269.12.1525; ROMANO PS, 1992, AM J EPIDEMIOL, V136, P863, DOI 10.1093/aje/136.7.863; SHACKFORD SR, 1986, J TRAUMA, V26, P812, DOI 10.1097/00005373-198609000-00006; Winer BJ., 1970, STAT PRINCIPLES EXPT, V2nd	25	101	101	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1727	1731		10.1001/jama.279.21.1727	http://dx.doi.org/10.1001/jama.279.21.1727			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZQ544	9624026	Bronze			2022-12-28	WOS:000073878700034
J	Fitzgerald, F; Murray, TJ				Fitzgerald, F; Murray, TJ			On the death of house officers	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Calif Davis, Sch Med, Dept Med, Sacramento, CA 95817 USA; Dalhousie Univ, Clin Res Ctr, Halifax, NS B3H 4H7, Canada	University of California System; University of California Davis; Dalhousie University	Fitzgerald, F (corresponding author), Univ Calif Davis, Sch Med, Dept Med, POB 179002, Sacramento, CA 95817 USA.								0	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					949	950		10.7326/0003-4819-128-11-199806010-00016	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634436				2022-12-28	WOS:000073808600012
J	Mason, AL; Xu, LZ; Guo, LS; Munoz, S; Jaspan, JB; Bryer-Ash, M; Cao, Y; Sander, DM; Shoenfeld, Y; Ahmed, A; Van de Water, J; Gershwin, ME; Garry, RF				Mason, AL; Xu, LZ; Guo, LS; Munoz, S; Jaspan, JB; Bryer-Ash, M; Cao, Y; Sander, DM; Shoenfeld, Y; Ahmed, A; Van de Water, J; Gershwin, ME; Garry, RF			Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders	LANCET			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; HEPATITIS-C VIRUS; LIVER-TRANSPLANTATION; SJOGRENS-SYNDROME; GRAVES-DISEASE; AUTOANTIBODIES; RECURRENCE; PROTEINS; PARTICLE	Background Retroviruses have been implicated in the aetiology of various autoimmune diseases. We used immunoblots as a surrogate test to find out whether retroviruses play a part in the development of primary biliary cirrhosis. Methods We did western blot tests for HIV-1 and the human intracisternal A-type particle (HIAP), on serum samples from 77 patients with primary biliary cirrhosis, 126 patients with chronic liver disease, 48 patients with systemic lupus erythematosus, and 25 healthy volunteers. Findings HIV-1 p24 gag seroreactivity was found in 27 (35%) of 77 patients with primary biliary cirrhosis, 14 (29%) of 48 patients with systemic lupus erythematosus, 14 (50%) of 28 patients with chronic viral hepatitis, and nine (39%) of 23 patients with either primary sclerosing cholangitis or biliary atresia, compared with only one (4%) of 24 patients with alcohol-related liver disease or alpha(1)-antitrypsin-deficiency liver disease, and only one (4%) of 25 healthy volunteers (p=0.003). Western blot reactivity to more than two HIAP proteins was found in 37 (51%) of patients with primary biliary cirrhosis, in 28 (58%) of patients with systemic lupus erythematosus, in 15 (20%) of patients with chronic viral hepatitis, and in four (17%) of those with other biliary diseases. None of the 23 patients with either alcohol-related liver disease or alpha(1)-antitrypsin deficiency, and only one of the healthy controls showed the same reactivity to HIAP proteins (p<0.0001). Our results showed a strong association between HIAP seroreactivity and the detection of autoantibodies to double-stranded DNA. HIAP seroreactivity was also strongly associated with the detection of mitochondrial, nuclear, and extractable nuclear antigens. Interpretation The HIV-1 and HIAP antibody reactivity found in patients with primary biliary cirrhosis and other biliary disorders may be attributable either to an autoimmune response to antigenically related cellular proteins or to an immune response to uncharacterised viral proteins that share antigenic determinants with these retroviruses.	Alton Ochsner Med Fdn & Ochsner Clin, Sect Gastroenterol & Hepatol, New Orleans, LA 70121 USA; Albert Einstein Med Ctr, Ctr Liver Dis, Philadelphia, PA 19141 USA; Tulane Univ, Med Ctr, Sch Med, Dept Med, New Orleans, LA USA; Tulane Univ, Med Ctr, Sch Med, Dept Microbiol & Immunol, New Orleans, LA USA; Univ Tennessee, Coll Med, Dept Med, Memphis, TN USA; Chaim Sheba Med Ctr, Dept Med B, Autoimmune Dis Res Unit, IL-52621 Tel Hashomer, Israel; Specialty Labs Inc, Santa Monica, CA USA; Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, Davis, CA USA	Ochsner Health System; Yeshiva University; Tulane University; Tulane University; University of Tennessee System; University of Tennessee Health Science Center; Chaim Sheba Medical Center; University of California System; University of California Davis	Mason, AL (corresponding author), Alton Ochsner Med Fdn & Ochsner Clin, Richard Freeman Res Inst, 1520 Jefferson Highway, New Orleans, LA 70121 USA.		Mason, Andrew/D-2938-2013	Mason, Andrew/0000-0002-0470-9522; Garry, Robert/0000-0002-5683-3250	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039588, R01DK039588] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE10862-03] Funding Source: Medline; NIDDK NIH HHS [DK39588] Funding Source: Medline; PHS HHS [A101467-01] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARKA N, 1995, CLIN DIAGN LAB IMMUN, V2, P469, DOI 10.1128/CDLI.2.4.469-472.1995; CELLO JP, 1989, AM J MED, V86, P539, DOI 10.1016/0002-9343(89)90381-1; CHA S, 1993, P NATL ACAD SCI USA, V90, P2527, DOI 10.1073/pnas.90.6.2527; Conrad B, 1997, CELL, V90, P303, DOI 10.1016/S0092-8674(00)80338-4; DORNER T, 1994, SCAND J GASTROENTERO, V29, P655, DOI 10.3109/00365529409092488; GARRY RF, 1990, SCIENCE, V250, P1127, DOI 10.1126/science.1701273; GARRY RF, 1995, RETROVIRUSES THEIR R; HADDAD J, 1992, LANCET, V339, P321, DOI 10.1016/0140-6736(92)91645-O; Jaspan JB, 1996, J CLIN ENDOCR METAB, V81, P2271, DOI 10.1210/jc.81.6.2271; JASPAN JB, 1995, AUTOIMMUNITY, V20, P135, DOI 10.3109/08916939509001938; KONIKOFF F, 1989, HEPATO-GASTROENTEROL, V36, P341; MUNOZ SJ, 1988, GASTROENTEROLOGY, V94, pA574; NEUBERGER J, 1982, NEW ENGL J MED, V306, P1, DOI 10.1056/NEJM198201073060101; Perron H, 1997, P NATL ACAD SCI USA, V94, P7583, DOI 10.1073/pnas.94.14.7583; PIRISI M, 1994, SCAND J GASTROENTERO, V29, P942; RODRIGUEZCUARTERO A, 1994, INFECTION, V22, P415, DOI 10.1007/BF01715500; Sherlock S, 1993, PRIMARY BILIARY CIRR; SWAAK T, 1985, ANN RHEUM DIS, V44, P245, DOI 10.1136/ard.44.4.245; TALAL N, 1990, J CLIN INVEST, V85, P1866, DOI 10.1172/JCI114647; TALAL N, 1990, ARTHRITIS RHEUM, V33, P741; VANDEWATER J, 1989, NEW ENGL J MED, V320, P1377, DOI 10.1056/NEJM198905253202104; VandeWater J, 1996, HEPATOLOGY, V24, P1079	22	125	129	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1620	1624		10.1016/S0140-6736(97)10290-2	http://dx.doi.org/10.1016/S0140-6736(97)10290-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620716				2022-12-28	WOS:000074026600009
J	Rosen, RC				Rosen, RC			Sildenafil: medical advance or media event?	LANCET			English	Editorial Material							IMPOTENCE		Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Rosen, RC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA.							ALTHOF SE, 1989, J SEX MARITAL THER, V15, P121; Boolell M, 1996, BRIT J UROL, V78, P257, DOI 10.1046/j.1464-410X.1996.10220.x; Burnett AL, 1998, GERIATRICS, V53, P34; DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; FuglMeyer AR, 1997, INT J IMPOT RES, V9, P141, DOI 10.1038/sj.ijir.3900269; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Laumann E. O., 1994, SOCIAL ORG SEXUALITY; LUE TF, 1990, WORLD J UROL, V8, P67, DOI 10.1007/BF01576350; Moreland RB, 1998, LIFE SCI, V62, pPL309, DOI 10.1016/S0024-3205(98)00158-1; Rosen RC, 1996, CLIN PSYCHOL REV, V16, P497, DOI 10.1016/0272-7358(96)00032-3; TAUB HC, 1993, UROLOGY, V42, P698, DOI 10.1016/0090-4295(93)90538-L	12	28	28	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	1998	351	9116					1599	1600		10.1016/S0140-6736(05)77682-0	http://dx.doi.org/10.1016/S0140-6736(05)77682-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620710				2022-12-28	WOS:000074026600003
J	Peet, DJ; Turley, SD; Ma, WZ; Janowski, BA; Lobaccaro, JMA; Hammer, RE; Mangelsdorf, DJ				Peet, DJ; Turley, SD; Ma, WZ; Janowski, BA; Lobaccaro, JMA; Hammer, RE; Mangelsdorf, DJ			Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha	CELL			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; 7-ALPHA-HYDROXYLASE GENE; HYPERCHOLESTEROLEMIA; BIOSYNTHESIS; PATHWAY; LIVER; FLUX; DIFFERENTIATION; SUPERFAMILY; ACTIVATION	We demonstrate that mice lacking the oxysterol receptor, LXR alpha, lose their ability to respond normally to dietary cholesterol and are unable to tolerate any amount of cholesterol in excess of that which they synthesize de novo. When fed diets containing cholesterol, LXR alpha (-/-) mice fair to induce transcription of the gene encoding cholesterol 7 alpha-hydroxylase (Cyp7a), the rate-limiting enzyme in bile acid synthesis. This defect is associated with a rapid accumulation of large amounts of cholesterol in the liver that eventually leads to impaired hepatic function. The regulation of several other crucial lipid metabolizing genes is also altered in LXR alpha (-/-) mice. These results demonstrate the existence of a physiologically significant feed-forward regulatory pathway for sterol metabolism and establish the role of LXR alpha as the major sensor of dietary cholesterol.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mangelsdorf, DJ (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia.		Lobaccaro, Jean-Marc/Q-3926-2019; Peet, Daniel/AAE-6698-2020; Lobaccaro, Jean-Marc A./U-1928-2019	Lobaccaro, Jean-Marc/0000-0001-9890-2392; Peet, Daniel/0000-0002-6085-8936; Mangelsdorf, David/0000-0002-4355-0796; Hammer, Robert E./0000-0001-5487-7551	NHLBI NIH HHS [HL09610] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL009610, R37HL009610] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYOSHI T, 1986, J LIPID RES, V27, P915; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; Breslow JL, 1996, SCIENCE, V272, P685, DOI 10.1126/science.272.5262.685; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BUCOLO G, 1973, CLIN CHEM, V19, P476; Carey Martin C., 1994, P719; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; COHEN BI, 1977, J LIPID RES, V18, P223; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; LAVY U, 1977, J LIPID RES, V18, P232; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LEHRMAN MA, 1987, J BIOL CHEM, V262, P3354; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MORI T, 1991, P NATL ACAD SCI USA, V88, P4338, DOI 10.1073/pnas.88.10.4338; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; RUDLING M, 1992, J LIPID RES, V33, P493; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; SHEFER S, 1991, J BIOL CHEM, V266, P2693; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; SHINAR DM, 1994, GENE, V147, P273, DOI 10.1016/0378-1119(94)90080-9; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; SPENCER TA, 1985, J BIOL CHEM, V260, P3391; SPENCER TA, 1994, ACCOUNTS CHEM RES, V27, P83, DOI 10.1021/ar00039a004; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Turley SD, 1997, HEPATOLOGY, V25, P797, DOI 10.1002/hep.510250403; TURLEY SD, 1988, LIVER BIOL PATHOBIOL, P617; UCHIDA K, 1980, J BIOCHEM, V87, P187, DOI 10.1093/oxfordjournals.jbchem.a132724; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; WILLY PJ, 1998, HORMONES SIGNALING, V1, P307; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	43	1197	1276	1	50	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					693	704		10.1016/S0092-8674(00)81432-4	http://dx.doi.org/10.1016/S0092-8674(00)81432-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630215	Bronze			2022-12-28	WOS:000073956700007
J	Rutila, JE; Suri, V; Le, M; So, WV; Rosbash, M; Hall, JC				Rutila, JE; Suri, V; Le, M; So, WV; Rosbash, M; Hall, JC			CYCLE is a second bHLH-PAS clock protein essential for circadian rhythmicity and transcription of Drosophila period and timeless	CELL			English	Article							MESSENGER-RNA LEVELS; GENOME PROJECT; GENE; MUTANTS; MELANOGASTER; BEHAVIOR; OSCILLATIONS; MUTAGENESIS; ELEMENTS; REVEALS	We report the identification, characterization, and cloning of another novel Drosophila clock gene, cycle (cyc). Homozygous cyc flies are completely arrhythmic. Heterozygous cyc/+ flies are rhythmic but have altered periods, indicating that the cyc locus has a dosage effect on period. The molecular circadian phenotype of homozygous cyc flies is like homozygous Clk flies presented in the accompanying paper: mutant flies have little or no transcription of the per and tim genes. Cloning of the gene indicates that it also encodes a bHLH-PAS transcription factor and is a Drosophila homolog of the human protein BMAL1. cyc is a nonsense mutation, consistent with its strong loss-of-function phenotype. We propose that the CYC:CLK heterodimer binds to per and tim E boxes and makes a major contribution to the circadian transcription of Drosophila clock genes.	Brandeis Univ, Dept Biol, NSF, Ctr Biol Timing, Waltham, MA 02254 USA; Brandeis Univ, Dept Biol, Howard Hughes Med Inst, Waltham, MA 02254 USA	Brandeis University; National Science Foundation (NSF); NSF - Center for Biological Timing; Brandeis University; Howard Hughes Medical Institute	Hall, JC (corresponding author), Brandeis Univ, Dept Biol, NSF, Ctr Biol Timing, Waltham, MA 02254 USA.							AJIOKA JW, 1991, CHROMOSOMA, V100, P495, DOI 10.1007/BF00352200; Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CAI HN, 1994, GENETICS, V136, P1385; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; HAMBLEN M, 1986, J NEUROGENET, V3, P249, DOI 10.3109/01677068609106855; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HARDIN PE, 1994, MOL CELL BIOL, V14, P7211, DOI 10.1128/MCB.14.11.7211; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; HUNTERENSOR M, 1996, CELL, V84, P577; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KONOPKA RJ, 1994, J BIOL RHYTHM, V9, P189, DOI 10.1177/074873049400900303; Marrus SB, 1996, EMBO J, V15, P6877, DOI 10.1002/j.1460-2075.1996.tb01080.x; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROSBASH M, 1996, IN PRESS COLD SPRING; Rouyer F, 1997, EMBO J, V16, P3944, DOI 10.1093/emboj/16.13.3944; Rutila JE, 1996, NEURON, V17, P921, DOI 10.1016/S0896-6273(00)80223-8; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SMITH RF, 1982, MOL GEN GENET, V185, P30, DOI 10.1007/BF00333786; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; SONNENFELD M, 1998, IN PRESS DEVELOPMENT; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Stanewsky R, 1996, GENETICS, V143, P259; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; ZERR DM, 1990, J NEUROSCI, V10, P2749	47	501	522	4	58	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					805	814		10.1016/S0092-8674(00)81441-5	http://dx.doi.org/10.1016/S0092-8674(00)81441-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630224	Bronze			2022-12-28	WOS:000073956700016
J	Delbanco, TL; Daley, J; Hartman, EE				Delbanco, TL; Daley, J; Hartman, EE			A 37-year-old man with multiple somatic complaints, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Barsky AJ, 1997, JAMA-J AM MED ASSOC, V278, P673, DOI 10.1001/jama.278.8.673	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1998	279	20					1658	1658		10.1001/jama.279.20.1658	http://dx.doi.org/10.1001/jama.279.20.1658			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP489	9613917				2022-12-28	WOS:000073758600037
J	McQuillan, P; Pilkington, S; Allan, A; Taylor, B; Short, A; Morgan, G; Nielsen, M; Barrett, D; Smith, G				McQuillan, P; Pilkington, S; Allan, A; Taylor, B; Short, A; Morgan, G; Nielsen, M; Barrett, D; Smith, G			Confidential inquiry into quality of care before admission to intensive care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL CARDIOPULMONARY ARREST; AVOIDABLE FACTORS; CARDIAC-ARREST; HEAD-INJURY; DOCTORS; CONSULTANTS; DEATHS; MANAGEMENT; PHYSICIANS; RESPONSES	Objective: To examine the prevalence, nature, causes, and consequences of suboptimal care before admission to intensive care units, and to suggest possible solutions. Design: Prospective confidential inquiry on the basis of structured interviews and questionnaires. Setting: A large district general hospital and a teaching hospital. Subjects: A cohort of 100 consecutive adult emergency admissions, 50 in each centre. Main outcome measures: Opinions of two external assessors on quality of care especially recognition, investigation, monitoring, and management of abnormalities of airway, breathing, and circulation, and oxygen therapy and monitoring. Results: Assessors agreed that 20 patients were well managed (group 1) and 54 patients received suboptimal care (group 2), Assessors disagreed on quality of management of 26 patients (group 3). The casemix and severity of illness, defined by the acute physiology and chronic health evaluation (APACHE II) score, were similar between centres and the three groups. In groups 1, 2, and 3 intensive care mortalities were 5 (25%), 26 (48%), and 6 (23%) respectively (P = 0.04) (group 1 versus group 2, P = 0.07). Hospital mortalities were 7 (35%), 30 (56%), and 8 (31%) (P = 0.07) and standardised hospital mortality ratios (95% confidence intervals) were 1.23 (0.49 to 2.54), 1.4 (0.94 to 2.0), and 1.26 (0.54 to 2.48) respectively. Admission to intensive care was considered late in 37 (69%) patients in group 2. Overall, a minimum of 4.5% and a maximum of 41% of admissions were considered potentially avoidable. Suboptimal care contributed to morbidity or mortality in most instances. The main causes of suboptimal care were failure of organisation, lack of knowledge, failure to appreciate clinical urgency, lack of supervision, and failure to seek advice. Conclusions: The management of airway breathing, and circulation, and oxygen therapy and monitoring in severely ill patients before admission to intensive care units may frequently be suboptimal. Major consequences may include increased morbidity and mortality and requirement for intensive care. Possible solutions include improved teaching, establishment of medical emergency teams, and widespread debate on the structure and process of acute care.	Queen Alexandra Hosp, Dept Intens Care Med, Portsmouth PO6 3LY, Hants, England; Southampton Gen Hosp, Intens Care Unit, Southampton SO16 6YD, Hants, England; Broomfield Hosp, Chelmsford CM1 7ET, Essex, England; Royal Cornwall Hosp, Truro TR1 3L, Cornwall, England; Univ Portsmouth, Sch Math Studies, Portsmouth PO1 2EG, Hants, England	Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; University of Southampton; Mid Essex Hospital Services NHS Trust; Broomfield Hospital; Royal Cornwall Hospital; University of Portsmouth	McQuillan, P (corresponding author), Queen Alexandra Hosp, Dept Intens Care Med, Portsmouth PO6 3LY, Hants, England.							ALLAN A, 1994, CLIN INTENSIVE CARE, V5, P152; Altman D.G., 1991, PRACTICAL STAT MED R; BEDELL SE, 1991, JAMA-J AM MED ASSOC, V265, P2815, DOI 10.1001/jama.265.21.2815; BOYD O, 1993, LANCET, V341, P1573, DOI 10.1016/0140-6736(93)90706-M; Capewell S, 1996, BRIT MED J, V312, P991; Daffurn K, 1994, Intensive Crit Care Nurs, V10, P115, DOI 10.1016/0964-3397(94)90007-8; DAVIES HTO, 1995, BRIT MED J, V311, P766, DOI 10.1136/bmj.311.7008.766; DELAMOTHE T, 1993, BRIT MED J, V307, P218, DOI 10.1136/bmj.307.6898.218; *DEPT HLTH UK, 1992, HLTH NAT; DILLNER L, 1995, BRIT MED J, V310, P757, DOI 10.1136/bmj.310.6982.757; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; FRANKLIN C, 1994, CRIT CARE MED, V22, P244, DOI 10.1097/00003246-199402000-00014; GEORGE AL, 1989, AM J MED, V87, P28; Goldhill DR, 1996, ANAESTHESIA, V51, P719, DOI 10.1111/j.1365-2044.1996.tb07882.x; GOULD TH, 1994, ANAESTHESIA, V49, P807; Hourihan F., 1995, CLIN INTENSIVE CARE, V6, P269, DOI [10.3109/tcic.6.6.269.272, DOI 10.3109/TCIC.6.6.269.272]; JEFFREYS RV, 1981, LANCET, V2, P459; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEE A, 1995, ANAESTH INTENS CARE, V23, P183, DOI 10.1177/0310057X9502300210; MATHER HM, 1995, BRIT MED J, V311, P1060, DOI 10.1136/bmj.311.7012.1060; MCGLOIN H, 1997, CLIN INTENSIVE CARE, V8, P104; MONTGOMERY H, 1994, BRIT MED J, V309, P1551, DOI 10.1136/bmj.309.6968.1551; MOSS F, 1995, BRIT MED J, V310, P925, DOI 10.1136/bmj.310.6984.925; *NAT CONF ENQ PER, 1993, NAT CONF ENQ PER DEA; PALAZZO M, 1993, LANCET, V342, P307; PAPPACHAN VJ, 1997, CLIN INTENSIVE CARE, V8, P97; PAYNE JN, 1993, BRIT MED J, V307, P1027, DOI 10.1136/bmj.307.6911.1027; POPE A, 1960, PENGUIN DICT QUOTATI; ROLFE S, 1995, BRIT MED J, V310, P1173, DOI 10.1136/bmj.310.6988.1173; *ROYAL COLL PHYS L, 1996, FUT PATT CAR GEN SPE; *ROYAL COLL SURG E, 1985, REP WORK PART MAN PA; SAX FL, 1987, CRIT CARE MED, V15, P510, DOI 10.1097/00003246-198705000-00012; SCHEIN RMH, 1990, CHEST, V98, P1388, DOI 10.1378/chest.98.6.1388; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; SIEGAL S, 1988, STAT BEHAV SCI; SMITH J, 1995, BRIT MED J, V310, P953, DOI 10.1136/bmj.310.6985.953; STONEHAM MD, 1994, LANCET, V344, P1339, DOI 10.1016/S0140-6736(94)90697-1; THAM KY, 1994, BRIT MED J, V309, P1408, DOI 10.1136/bmj.309.6966.1408a; THWAITES BC, 1992, J ROY COLL PHYS LOND, V26, P265; TUNNELL RD, 1996, CLIN INTENSIVE CARE, V7, P55; 1994, REP CONF ENQ MAT DEA	42	602	622	3	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 20	1998	316	7148					1853	1858						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632403				2022-12-28	WOS:000074686500015
J	Clemmer, TP; Spuhler, VJ; Berwick, DM; Nolan, TW				Clemmer, TP; Spuhler, VJ; Berwick, DM; Nolan, TW			Cooperation: The foundation of improvement	ANNALS OF INTERNAL MEDICINE			English	Article								Cooperation-working together to produce mutual benefit or attain a common purpose-is almost inseparable from the quest for improvement. Although the case for cooperation can be made on ethical grounds, neither the motivation for nor the effects of cooperation need to be interpreted solely in terms of altruism. Cooperation can be a shrewd and pragmatic strategy for accomplishing personal goals in an interdependent system. Earlier papers in this series have explored the conceptual roots of modern approaches to improvement, which lie in systems theory. To improve systems, we must usually attend first and foremost to interactions. Among hu mans, "better interaction" is almost synonymous with "better cooperation." Physicians have ample opportunities and, indeed, an obligation to cooperate with other physicians in the same or different specialties, with nurses and other clinical workers, with administrators, and with patients and families. Many intellectual disciplines have made cooperation an object of study. These include anthropology; social psychology; genetics; biology; mathematics; game theory; linguistics; operations research; economics; and, of course, moral and rational philosophy. Scientifically grounded methods to enhance cooperation include developing a shared purpose; creating an open, safe environment; including all who share a common purpose and encouraging diverse viewpoints; negotiating agreement; and insisting on fairness and equity in the application of rules. These methods apply at the organizational level and at the level of the individual physician. This paper describes the application of these methods at the organizational level and focuses on one especially successful example of system-level cooperation in a care delivery site where interactions matter a great deal: the modern intensive care unit.	Latter Day St Hosp, Salt Lake City, UT 84143 USA; Univ Utah, Sch Med, Salt Lake City, UT USA; Inst Hlth Care Improvement, Boston, MA USA	Utah System of Higher Education; University of Utah	Clemmer, TP (corresponding author), Latter Day St Hosp, 8th Ave & C St, Salt Lake City, UT 84143 USA.	tclemme@ihc.com						[Anonymous], 1965, LOGIC COLLECTIVE ACT; Argyris C., 1994, ORG LEARNING; Axelrod R., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; Clemmer TP, 1998, NEW HORIZ-SCI PRACT, V6, P12; CLEMMER TP, 1997, CRIT CARE MED S1, V25, pA43; COASE RH, 1960, J LAW ECON, V3, P1, DOI 10.1086/466560; Covey S., 1990, 7 HABITS HIGHLY EFFE; Dawkins Richard, 1976, SELFISH GENE; Deming WE, 1994, NEW EC; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; Fisher R., 1991, GETTING YES NEGOTIAT; FOUSHEE HC, 1988, HUMAN FACTORS AVIATI; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; HELMREICH RL, 1994, HUMAN ERROR MED; HIATT HH, 1975, NEW ENGL J MED, V293, P235, DOI 10.1056/NEJM197507312930506; Nolan TW, 1998, ANN INTERN MED, V128, P293, DOI 10.7326/0003-4819-128-4-199802150-00009; Oniki T A, 1995, Proc Annu Symp Comput Appl Med Care, P586; Raiffa H., 1997, DECIS ANAL; Reinertsen JL, 1998, ANN INTERN MED, V128, P833, DOI 10.7326/0003-4819-128-10-199805150-00007; SEAGAL S, 1997, HUMAN DYNAMICS NEW F; WEINER EL, 1993, COCKPIT RESOURCE MAN; Wilson E.O., 1975, P1	22	108	107	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				1004	1009		10.7326/0003-4819-128-12_Part_1-199806150-00008	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625663				2022-12-28	WOS:000074201300007
J	Dale, DC; Liles, C				Dale, DC; Liles, C			How many neutrophils are enough?	LANCET			English	Editorial Material							FC-GAMMA-RIII; SITES		Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Dale, DC (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.							CROSBY WH, 1969, ARCH INTERN MED, V123, P722, DOI 10.1001/archinte.123.6.722; FLEIT HB, 1992, BLOOD, V79, P2721; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; HOMBURG CHE, 1995, BLOOD, V85, P532; HUZINGA TWJ, 1990, J CLIN INVEST, V86, P416; HUZINGA TWJ, 1994, BRIT J HAEMATOL, V87, P459; INDIK ZK, 1995, BLOOD, V85, P532; Koene HR, 1998, BLOOD, V91, P1; KYLE RA, 1968, NEW ENGL J MED, V279, P1015, DOI 10.1056/NEJM196811072791902; McKenzie S E, 1998, Curr Opin Hematol, V5, P16, DOI 10.1097/00062752-199801000-00003	10	8	8	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1752	1753		10.1016/S0140-6736(05)78742-0	http://dx.doi.org/10.1016/S0140-6736(05)78742-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635945				2022-12-28	WOS:000074197600006
J	Kampfl, A; Schmutzhard, E; Franz, G; Pfausler, B; Haring, HP; Ulmer, H; Felber, S; Golaszewski, S; Alchner, F				Kampfl, A; Schmutzhard, E; Franz, G; Pfausler, B; Haring, HP; Ulmer, H; Felber, S; Golaszewski, S; Alchner, F			Prediction of recovery from post-traumatic vegetative state with cerebral magnetic-resonance imaging	LANCET			English	Article							CLOSED-HEAD INJURY; MR; FEATURES; COMA	Background The early post-traumatic vegetative state (VS) is compatible with recovery. Various clinical and laboratory tests have failed to predict recovery so we assessed the value of cerebral magnetic-resonance imaging (MRI) in prediction of recovery. Methods 80 adult patients in post-traumatic VS had cerebral MRI between 6 weeks and 8 weeks after injury. MRIs were reviewed by three neuroradiologists for the number, sizes, and location of brain lesions. Three neurologists assessed the patients at the time of MRI and at 2 months, 3 months, 6 months, 9 months, and 12 months after injury using the Glasgow Outcome Scale. Findings At 12 months, 38 patients had recovered while 42 patients remained in the VS. The demographic characteristics and causes and severity of injury were similar in patients in persistent VS (PVS) and those who recovered (NPVS). An average of 6.1 different brain areas were injured in patients in PVS compared with 4.6 areas in patients who had NPVS. Patients in PVS revealed a significantly higher frequency of corpus callosum, corona radiata, and dorsolateral brainstem injuries than did patients who recovered. Logistic regression analysis showed that corpus callosum and dorsolateral brainstem injuries were predictive of non-recovery. The adjusted odds ratios for non-recovery of patients with a corpus callosum lesion and dorsolateral brainstem injury were 213.8 (95% CI 14.2-3213.3), and 6.9 (1.1-42.9), respectively. In contrast, clinical characteristics, such as initial score on the Glasgow Coma Scale, age, and pupillary abnormalities failed to predict recovery. Interpretation Cerebral MRI findings in the subacute stage after head injury can predict the outcome of the posttraumatic VS. Corpus callosum and dorsolateral brainstem lesions are highly significant in predicting non-recovery.	Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria; Univ Innsbruck Hosp, Dept Biostat, A-6020 Innsbruck, Austria; Univ Innsbruck Hosp, Dept Magnet Resonance & Spect, A-6020 Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck	Kampfl, A (corresponding author), Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria.		Ulmer, Hanno/S-6615-2019	Ulmer, Hanno/0000-0001-5911-1002; Schmutzhard, Erich/0000-0003-3295-7491				ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; AGARDH CD, 1983, ANN NEUROL, V14, P482, DOI 10.1002/ana.410140414; AHMED I, 1988, CLIN ELECTROENCEPHAL, V19, P78, DOI 10.1177/155005948801900209; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; FRENCH JD, 1952, AMA ARCH NEUROL PSY, V68, P727, DOI 10.1001/archneurpsyc.1952.02320240002001; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1994, RADIOLOGY, V191, P1; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; HANSOTIA PL, 1985, ARCH NEUROL-CHICAGO, V42, P1048, DOI 10.1001/archneur.1985.04060100030015; JELLINGER K, 1977, APALLIC SYNDROME, P89; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; ODER W, 1991, INTENS CARE MED, V17, P49; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Payne K, 1996, ANN INTERN MED, V125, P104, DOI 10.7326/0003-4819-125-2-199607150-00004; RAMADAN NM, 1989, STROKE, V20, P1279, DOI 10.1161/01.STR.20.9.1279; WUILLEMUIER P, 1995, NEUROCHIRURGIE, V41, P98; Zeman A, 1997, LANCET, V350, P795, DOI 10.1016/S0140-6736(97)06447-7; 1996, J R COLL PHYSICIANS, V30, P19; [No title captured]	30	164	175	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1763	1767		10.1016/S0140-6736(97)10301-4	http://dx.doi.org/10.1016/S0140-6736(97)10301-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635948				2022-12-28	WOS:000074197600009
J	del Pozo, JC; Timpte, C; Tan, S; Callis, J; Estelle, M				del Pozo, JC; Timpte, C; Tan, S; Callis, J; Estelle, M			The ubiquitin-related protein RUB1 and auxin response in Arabidopsis	SCIENCE			English	Article							THALIANA; GENES	The AXR1 (auxin-resistant) protein, which has features of the ubiquitin-activating enzyme E1, is required for normal response to the plant hormone auxin in Arabidopsis thaliana. ECR1 functions together with AXR1 to activate members of the RUB/NEDD8 family of ubiquitin-related proteins. Extracts from mutant seedlings lacking AXR1 did not promote formation of the RUB-ECR1 thiolester, indicating that AXR1 is the major activity in this tissue. AXR1 was localized primarily to the nucleus of dividing and elongating cells, suggesting that the targets of RUB modification are nuclear. These results indicate that auxin response depends on RUB modification of one or more nuclear proteins.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	Indiana University System; Indiana University Bloomington; University of California System; University of California Davis	Estelle, M (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.		del Pozo, Juan C/K-7978-2014	del Pozo, Juan C/0000-0002-4113-457X; Callis, Judy/0000-0002-0622-078X	NIGMS NIH HHS [GM43644] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CALLIS J, 1995, GENETICS, V139, P921; Cernac A, 1997, DEVELOPMENT, V124, P1583; Chow NW, 1996, J BIOL CHEM, V271, P11339, DOI 10.1074/jbc.271.19.11339; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; EVANS ML, 1984, ENCY PLANT PHYSL, V10, P23; GRAY WM, IN PRESS CURR OPIN B; HAAS AL, 1997, FASEB J, V11, P125; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; HANDELI S, COMMUNICATION; HOBBIE L, 1994, PLANT CELL ENVIRON, V17, P525, DOI 10.1111/j.1365-3040.1994.tb00147.x; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; KLEE H, 1990, ANN REV PLANT PHYSL, V42, P1529; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; MAHAJAN R, 1997, CELL, V88, P197; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; PERKY SE, 1996, PLANT CELL, V8, P1977; Ruegger M, 1998, GENE DEV, V12, P198, DOI 10.1101/gad.12.2.198; Shayeghi M, 1997, NUCLEIC ACIDS RES, V25, P1162, DOI 10.1093/nar/25.6.1162; Tan S., UNPUB; TIMPTE C, 1995, PLANT J, V8, P561, DOI 10.1046/j.1365-313X.1995.8040561.x	25	179	189	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1760	1763		10.1126/science.280.5370.1760	http://dx.doi.org/10.1126/science.280.5370.1760			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624055				2022-12-28	WOS:000074197800044
J	Kume, T; Deng, KY; Winfrey, V; Gould, DB; Walter, MA; Hogan, BLM				Kume, T; Deng, KY; Winfrey, V; Gould, DB; Walter, MA; Hogan, BLM			The forkhead/winged helix gene Mf1 is disrupted in the pleiotropic mouse mutation congenital hydrocephalus	CELL			English	Article							AUTOSOMAL-DOMINANT IRIDOGONIODYSGENESIS; TGF-BETA-SUPERFAMILY; FORK HEAD; RIEGER SYNDROME; PROTEINS; MEMBER; EMBRYO; MAINTENANCE; HNF-3-BETA; MESENCHYME	Mf1 encodes a forkhead/winged helix transcription factor expressed in many embryonic tissues, including prechondrogenic mesenchyme, periocular mesenchyme, meninges, endothelial cells, and kidney. Homozygous null Mf1(lacZ) mice die at birth with hydrocephalus, eye defects, and multiple skeletal abnormalities identical to those of the classical mutant, congenital hydrocephalus. We show that congenital hydrocephalos involves a point mutation in Mf1, generating a truncated protein lacking the DNA-binding domain. Mesenchyme cells from Mf1(lacZ) embryos differentiate poorly into cartilage in micromass culture and do not respond to added BMP2 and TGF beta 1. The differentiation of arachnoid cells in the mutant meninges is also abnormal. The human Mf1 homolog FREAC3 is a candidate gene for ocular dysgenesis and glaucoma mapping to chromosome 6p25-pter, and deletions of this region are associated with multiple developmental disorders, including hydrocephaly and eye defects.	Vanderbilt Univ, Med Ctr, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Univ Alberta, Dept Opthalmol & Med Genet, Edmonton, AB T6G 2S2, Canada	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; University of Alberta	Hogan, BLM (corresponding author), Vanderbilt Univ, Med Ctr, Howard Hughes Med Inst, Nashville, TN 37232 USA.				NCI NIH HHS [CA68485] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALASHARI M, 1995, PEDIATR PATHOL LAB M, V15, P941, DOI 10.3109/15513819509027030; ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; CHEN JM, 1952, J ANAT, V86, P373; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; CHITAYAT D, 1987, American Journal of Medical Genetics, V26, P145, DOI 10.1002/ajmg.1320260122; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Dou CL, 1997, NEURON, V18, P539, DOI 10.1016/S0896-6273(00)80296-2; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Furuta Y, 1997, DEVELOPMENT, V124, P2203; Gould DB, 1997, AM J HUM GENET, V61, P765; GREEN MC, 1970, DEV BIOL, V23, P585, DOI 10.1016/0012-1606(70)90142-9; GRUNEBER.H, 1971, J EMBRYOL EXP MORPH, V25, P247; GRUNEBERG H, 1953, J GENET, V51, P327, DOI 10.1007/BF03023301; Gruneberg H, 1943, J GENET, V45, P1, DOI 10.1007/BF02982770; GRUNEBERG H, 1974, J EMBRYOL EXP MORPH, V31, P207; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; Hall BK, 1995, INT J DEV BIOL, V39, P881; Hatini V, 1996, GENE DEV, V10, P1467, DOI 10.1101/gad.10.12.1467; Hoffmann A, 1996, DEV DYNAM, V207, P332, DOI 10.1002/(SICI)1097-0177(199611)207:3<332::AID-AJA10>3.0.CO;2-6; Hogan B, 1994, MANIPULATING MOUSE E; Hong H.-K., 1995, American Journal of Human Genetics, V57, pA134; Huang RJ, 1997, ANAT EMBRYOL, V195, P435, DOI 10.1007/s004290050063; Iida K, 1997, DEVELOPMENT, V124, P4627; Jordan T, 1997, AM J HUM GENET, V61, P882, DOI 10.1086/514874; Kaestner KH, 1996, DEVELOPMENT, V122, P1751; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; KELLY PC, 1989, CLIN GENET, V36, P204; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Labosky PA, 1996, GENOMICS, V34, P241, DOI 10.1006/geno.1996.0275; Labosky PA, 1997, DEVELOPMENT, V124, P1263; Larsson C, 1995, GENOMICS, V30, P464, DOI 10.1006/geno.1995.1266; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MCLONE DG, 1975, AM J ANAT, V142, P273, DOI 10.1002/aja.1001420302; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Mears AJ, 1996, AM J HUM GENET, V59, P1321; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; NODEN DM, 1988, DEVELOPMENT, V103, P121; ODA Y, 1984, J COMP NEUROL, V225, P448, DOI 10.1002/cne.902250310; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ohe Y, 1996, J NEUROCHEM, V67, P964; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; SASAKI H, 1993, DEVELOPMENT, V118, P47; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; SOLLOWAY MJ, 1998, IN PRESS DEV GENET; Steinbach OC, 1997, NATURE, V389, P395, DOI 10.1038/38755; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; Storm EE, 1996, DEVELOPMENT, V122, P3969; Tanaka T, 1997, J BIOL CHEM, V272, P15789, DOI 10.1074/jbc.272.25.15789; TEPPERBERG JH, 1994, AM J HUM GENET SA119, V55; TOLMIE JLT, 1997, EMERY FRIMOINS PRINC, P2145; Walter MA, 1996, OPHTHALMOLOGY, V103, P1907, DOI 10.1016/S0161-6420(96)30408-9; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Winnier GE, 1997, GENE DEV, V11, P926, DOI 10.1101/gad.11.7.926; Wu SCY, 1998, MECH DEVELOP, V70, P3, DOI 10.1016/S0925-4773(97)00157-3; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; ZURCHER VL, 1990, AM J MED GENET, V35, P261, DOI 10.1002/ajmg.1320350223	62	291	297	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					985	996		10.1016/S0092-8674(00)81204-0	http://dx.doi.org/10.1016/S0092-8674(00)81204-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635428	Bronze			2022-12-28	WOS:000074205700010
J	Righter, K; Hauri, EH				Righter, K; Hauri, EH			Compatibility of rhenium in garnet during mantle melting and magma genesis	SCIENCE			English	Article							OS ISOTOPE SYSTEMATICS; OCEANIC ISLAND BASALTS; KOLAR SCHIST BELT; RE-OS; TRACE-ELEMENTS; ULTRAMAFIC COMPLEX; MUNRO-TOWNSHIP; SM-ND; RB-SR; CONSTRAINTS	Measurements of the partitioning of rhenium (Re) between garnet and silicate liquid from 1.5 to 2.0 gigapascals and 1250 degrees to 1350 degrees C show that Re is compatible in garnet. Oceanic island basalts (OIBs) have lower Re contents than mid-ocean ridge basalt, because garnet-bearing residues of deeper OIB melting will retain Re. Deep-mantle garnetite or eclogite may harbor the missing Re identified in crust-mantle mass balance calculations. Oceanic crust recycled into the upper mantle at subduction zones will retain high Re/Os (osmium) ratios and become enriched in radiogenic Os-187. Recycled eclogite in a mantle source should be easily traced using Re abundances and Os isotopes.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA	University of Arizona; Carnegie Institution for Science	Righter, K (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.	righter@lpl.arizona.edu		Righter, Kevin/0000-0002-6075-7908				ALLEGRE CJ, 1980, EARTH PLANET SC LETT, V48, P148, DOI 10.1016/0012-821X(80)90177-6; ARTH JG, 1977, GEOLOGY, V5, P590, DOI 10.1130/0091-7613(1977)5<590:GOAKFM>2.0.CO;2; BILCHERTTOFT J, 1997, EARTH PLANET SC LETT, V148, P243; BIRCK JL, 1994, EARTH PLANET SC LETT, V124, P139, DOI 10.1016/0012-821X(94)00086-7; Brandon AD, 1998, SCIENCE, V280, P1570, DOI 10.1126/science.280.5369.1570; BRUECKNER HK, 1995, J GEOPHYS RES-SOL EA, V100, P22283, DOI 10.1029/95JB02247; CARMICHAEL ISE, 1991, CONTRIB MINERAL PETR, V106, P129, DOI 10.1007/BF00306429; CHSE CG, 1986, EARTH PLANET SC LETT, V91, P66; COX KG, 1984, SPEC PUBL GEOL SOC S, V13, P149; Eiler JM, 1996, EARTH PLANET SC LETT, V144, P453, DOI 10.1016/S0012-821X(96)00170-7; ELLAM RM, 1992, NATURE, V359, P718, DOI 10.1038/359718a0; Esperanca S, 1997, GEOLOGY, V25, P651, DOI 10.1130/0091-7613(1997)025<0651:DCMSRO>2.3.CO;2; FRYER BJ, 1992, CAN J EARTH SCI, V29, P2329, DOI 10.1139/e92-181; GREEN TH, 1995, CHEM GEOL, V117, P1; HANSKI E, 1995, LITHOS, V34, P40; Hauri EH, 1997, CHEM GEOL, V139, P185, DOI 10.1016/S0009-2541(97)00035-1; HAURI EH, 1993, EARTH PLANET SC LETT, V114, P353, DOI 10.1016/0012-821X(93)90036-9; HAURI EH, 1994, CHEM GEOL, V117, P149, DOI 10.1016/0009-2541(94)90126-0; HAURI EH, 1996, J GEOPHYS RES, V101, P11701; HERTOGEN J, 1980, GEOCHIM COSMOCHIM AC, V44, P2125, DOI 10.1016/0016-7037(80)90209-4; Horan MF, 1995, GEOCHIM COSMOCHIM AC, V59, P5159, DOI 10.1016/0016-7037(96)89674-8; JONES JH, 1986, NATURE, V322, P221, DOI 10.1038/322221a0; KEAYS RR, 1995, LITHOS, V34, P1; Kinzler RJ, 1997, J GEOPHYS RES-SOL EA, V102, P853, DOI 10.1029/96JB00988; Kumar N, 1996, GEOCHIM COSMOCHIM AC, V60, P1429, DOI 10.1016/0016-7037(95)00443-2; MARCANTONIO F, 1995, EARTH PLANET SC LETT, V133, P397, DOI 10.1016/0012-821X(95)00092-Q; MARTIN CE, 1991, AUST J EARTH SCI, V38, P569, DOI 10.1080/08120099108727992; MARTIN CE, 1994, EARTH PLANET SC LETT, V128, P287, DOI 10.1016/0012-821X(94)90151-1; MCDONOUGH WF, 1991, PHILOS T ROY SOC A, V335, P407, DOI 10.1098/rsta.1991.0055; Meisel T, 1996, GEOCHIM COSMOCHIM AC, V60, P2583, DOI 10.1016/0016-7037(96)00107-X; MELSEI T, 1996, NATURE, V383, P517; MORGAN JW, 1981, TECTONOPHYSICS, V75, P47, DOI 10.1016/0040-1951(81)90209-2; MORGAN JW, 1967, EARTH PLANET SC LETT, V3, P219, DOI 10.1016/0012-821X(67)90041-6; MYERS J, 1983, CONTRIB MINERAL PETR, V82, P75, DOI 10.1007/BF00371177; NICHOLLS IA, 1980, GEOCHIM COSMOCHIM AC, V44, P287, DOI 10.1016/0016-7037(80)90138-6; OHARA MJ, 1966, AM MINERAL, V51, P336; PEARSON DG, 1995, NATURE, V374, P711, DOI 10.1038/374711a0; POUCHOU JL, 1991, ELECTRON PROBE QUANTITATION, P31; RAJAMANI V, 1985, J PETROL, V26, P92, DOI 10.1093/petrology/26.1.92; REISBERG L, 1993, EARTH PLANET SC LETT, V120, P149, DOI 10.1016/0012-821X(93)90236-3; REISBERG L, 1995, NATURE, V376, P159, DOI 10.1038/376159a0; REISBERG LC, 1991, EARTH PLANET SC LETT, V105, P196, DOI 10.1016/0012-821X(91)90131-Z; Righter K, 1997, PHYS EARTH PLANET IN, V100, P115, DOI 10.1016/S0031-9201(96)03235-9; RIGHTER K, 1995, EOS T AM GEOPHYS UN, V76, pF698; RIGHTER K, 1998, LUNAR PLANET SCI, V29, P1546; RINGWOOD AE, 1991, GEOCHIM COSMOCHIM AC, V55, P2083, DOI 10.1016/0016-7037(91)90090-R; Roy-Barman M, 1998, EARTH PLANET SC LETT, V154, P331, DOI 10.1016/S0012-821X(97)00180-5; RoyBarman M, 1996, CHEM GEOL, V130, P55, DOI 10.1016/0009-2541(96)00002-2; ROYBARMAN M, 1995, EARTH PLANET SC LETT, V129, P145, DOI 10.1016/0012-821X(94)00238-T; ROYBARMAN M, 1994, GEOCHIM COSMOCHIM AC, V53, P1583; Schiano P, 1997, EARTH PLANET SC LETT, V150, P363, DOI 10.1016/S0012-821X(97)00098-8; SHIMIZU N, 1975, GEOPHYS RES LETT, V2, P413, DOI 10.1029/GL002i010p00413; TAYLOR JR, 1992, AM MINERAL, V77, P284; Walker RJ, 1997, GEOCHIM COSMOCHIM AC, V61, P3145, DOI 10.1016/S0016-7037(97)00088-4; WALKER RJ, 1988, EARTH PLANET SC LETT, V87, P1, DOI 10.1016/0012-821X(88)90060-X; WALKER RJ, 1991, CONTRIB MINERAL PETR, V107, P150, DOI 10.1007/BF00310704; WALKER RJ, 1989, GEOCHIM COSMOCHIM AC, V53, P3005, DOI 10.1016/0016-7037(89)90176-2; WATSON EB, 1987, CHEM GEOL, V62, P191, DOI 10.1016/0009-2541(87)90085-4; Widom E, 1996, EARTH PLANET SC LETT, V142, P451, DOI 10.1016/0012-821X(96)00111-2; 1981, BASALTIC VOLCANISM S	60	104	106	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1737	1741		10.1126/science.280.5370.1737	http://dx.doi.org/10.1126/science.280.5370.1737			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624048				2022-12-28	WOS:000074197800037
J	Phillip, M; Arbelle, JE; Segev, Y; Parvari, R				Phillip, M; Arbelle, JE; Segev, Y; Parvari, R			Male hypogonadism due to a mutation in the gene for the beta-subunit of follicle-stimulating hormone	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LUTEINIZING-HORMONE; RECEPTOR GENE; LEYDIG-CELL; PARACRINE; TESTOSTERONE; HYPOPLASIA		Ben Gurion Univ Negev, Pediat Diagnost & Therapeut Ctr, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Endocrine Clin, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Genet Inst, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Soroka Med Ctr, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University; Ben Gurion University; Ben Gurion University; Soroka Medical Center; Ben Gurion University	Phillip, M (corresponding author), Schneider Childrens Med Ctr Israel, 14 Kaplan St, IL-49202 Petah Tiqwa, Israel.							AITTOMAKI K, 1995, CELL, V82, P959, DOI 10.1016/0092-8674(95)90275-9; ALANSARI AAK, 1984, FERTIL STERIL, V42, P618; Anawalt BD, 1996, J CLIN ENDOCR METAB, V81, P3341, DOI 10.1210/jc.81.9.3341; Carreau S, 1996, FOLIA HISTOCHEM CYTO, V34, P111; HARDELIN JP, 1993, HUM MOL GENET, V2, P373, DOI 10.1093/hmg/2.4.373; HIKIM APS, 1993, INT J ANDROL, V16, P324, DOI 10.1111/j.1365-2605.1993.tb01199.x; JAMESON JL, 1988, MOL ENDOCRINOL, V2, P806, DOI 10.1210/mend-2-9-806; Jameson JL, 1996, MOL CELL ENDOCRINOL, V125, P143; KJESSLER B, 1974, FERTIL STERIL, V25, P1007; KREMER H, 1995, NAT GENET, V9, P160, DOI 10.1038/ng0295-160; Latronico AC, 1996, NEW ENGL J MED, V334, P507, DOI 10.1056/NEJM199602223340805; LAUE L, 1995, HUM MOL GENET, V4, P1429, DOI 10.1093/hmg/4.8.1429; Layman LC, 1997, NEW ENGL J MED, V337, P607, DOI 10.1056/NEJM199708283370905; LECERF L, 1993, ENDOCRINOLOGY, V133, P2313, DOI 10.1210/en.133.5.2313; MANNI A, 1985, J CLIN ENDOCR METAB, V61, P705, DOI 10.1210/jcem-61-4-705; MATTHEWS CH, 1993, NAT GENET, V5, P83, DOI 10.1038/ng0993-83; MOZAFFARIAN GA, 1983, J ANDROL, V4, P393; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; Parvari R, 1997, EUR J HUM GENET, V5, P266, DOI 10.1159/000484776; RABINOWITZ D, 1975, AM J MED, V59, P584, DOI 10.1016/0002-9343(75)90266-1; RIVAROLA MA, 1995, J STEROID BIOCHEM, V53, P119, DOI 10.1016/0960-0760(95)00042-X; Somjen D, 1997, CLIN ENDOCRINOL, V46, P555, DOI 10.1046/j.1365-2265.1997.1720986.x; Tapanainen JS, 1997, NAT GENET, V15, P205, DOI 10.1038/ng0297-205; WEISS J, 1992, NEW ENGL J MED, V326, P179, DOI 10.1056/NEJM199201163260306; WU NX, 1994, MOL CELL ENDOCRINOL, V106, P99, DOI 10.1016/0303-7207(94)90191-0	25	180	185	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1998	338	24					1729	1732		10.1056/NEJM199806113382404	http://dx.doi.org/10.1056/NEJM199806113382404			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT654	9624193				2022-12-28	WOS:000074109800004
J	Adolphs, R; Tranel, D; Damasio, AR				Adolphs, R; Tranel, D; Damasio, AR			The human amygdala in social judgment	NATURE			English	Article							FACIAL EXPRESSIONS; DAMAGE; RECOGNITION; LESIONS; EMOTION; FEAR	Studies in animals have implicated the amygdala in emotional(1-3) and social(4-6) behaviours, especially those related to fear and aggression. Although lesion(7-10) and functional imaging(11-13) studies in humans have demonstrated the amygdala's participation in recognizing emotional facial expressions, its role in human social behaviour has remained unclear. We report here our investigation into the hypothesis that the human amygdala is required for accurate social judgments of other individuals on the basis of their facial appearance. We asked three subjects with complete bilateral amygdala damage to judge faces of unfamiliar people with respect to two attributes important in real-life social encounters: approachability and trustworthiness. All three subjects judged unfamiliar individuals to be more approachable and more trustworthy than did control subjects. The impairment was most striking for faces to which normal subjects assign the most negative ratings: unapproachable and untrustworthy looking individuals. Additional investigations revealed that the impairment does not extend to judging verbal descriptions of people. The amygdala appears to be an important component of the neural systems that help retrieve socially relevant knowledge on the basis of facial appearance.	Univ Iowa, Coll Med, Dept Neurol, Div Cognit Neurosci, Iowa City, IA 52242 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA	University of Iowa; Salk Institute	Adolphs, R (corresponding author), Univ Iowa, Coll Med, Dept Neurol, Div Cognit Neurosci, 200 Hawkins Dr, Iowa City, IA 52242 USA.	ralph-adolphs@uiowa.edu	Damasio, Antonio/AAD-1342-2019; Tudusciuc, Oana/C-1339-2011	Tranel, Daniel/0000-0002-1338-1389				ADOLPHS R, 1995, J NEUROSCI, V15, P5879; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; ANDERSON NH, 1968, J PERS SOC PSYCHOL, V9, P272, DOI 10.1037/h0025907; BLANCHARD DC, 1972, J COMP PHYSIOL PSYCH, V81, P281, DOI 10.1037/h0033521; Breiter HC, 1996, NEURON, V17, P875, DOI 10.1016/S0896-6273(00)80219-6; Broks P, 1998, NEUROPSYCHOLOGIA, V36, P59, DOI 10.1016/S0028-3932(97)00105-X; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; DDAMASIO AR, 1995, NEUROSCIENTIST, V1, P19; Ekman P., 1976, PICTURES FACIAL AFFE; Frank RJ, 1997, NEUROIMAGE, V5, P13, DOI 10.1006/nimg.1996.0250; KLING A, 1979, EXP NEUROL, V66, P88, DOI 10.1016/0014-4886(79)90065-7; KLING A S, 1992, P353; LeDoux J. E., 1996, EMOTIONAL BRAIN; LEWICKI P, 1992, AM PSYCHOL, V47, P796, DOI 10.1037/0003-066X.47.6.796; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; Morris JS, 1998, BRAIN, V121, P47, DOI 10.1093/brain/121.1.47; NAHM FKD, 1993, NEUROPSYCHOLOGIA, V31, P727, DOI 10.1016/0028-3932(93)90125-J; ROSVOLD HE, 1954, J COMP PHYSIOL PSYCH, V47, P173, DOI 10.1037/h0058870; Saarni C., 1998, P237; TRANEL D, 1990, ARCH NEUROL-CHICAGO, V47, P349, DOI 10.1001/archneur.1990.00530030131029; TRANEL D, 1996, NEUROPSYCHOLOGICAL A, P81; WEISKRANTZ L, 1956, J COMP PHYSIOL PSYCH, V49, P381, DOI 10.1037/h0088009; YOUNG AW, 1995, BRAIN, V118, P15, DOI 10.1093/brain/118.1.15	24	861	875	3	112	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					470	474		10.1038/30982	http://dx.doi.org/10.1038/30982			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZR842	9624002				2022-12-28	WOS:000074020000045
J	Muhua, L; Adames, NR; Murphy, MD; Shields, CR; Cooper, JA				Muhua, L; Adames, NR; Murphy, MD; Shields, CR; Cooper, JA			A cytokinesis checkpoint requiring the yeast homologue of an APC binding protein	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; SPINDLE ORIENTATION; GENE; MICROTUBULES; DYNEIN; MUTANT	Checkpoint controls ensure that events of the cell-division cycle are completed with fidelity and in the correct order. In budding yeast with a mutation in the motor protein dynein, the mitotic spindle is often misaligned and therefore slow to enter the neck between mother cell and budding daughter cell. When this occurs, cytokinesis (division of the cytoplasm into two) is delayed until the spindle is properly positioned(1). Here we describe mutations that abolish this delay, indicating the existence of a new checkpoint mechanism. One mutation lies in the gene encoding the yeast homologue of EB1, a human protein that binds the adenomatous polyposis coli (APC) protein, a tumour suppressor. EB1 is located on microtubules of the mitotic spindle and is important in spindle assembly. EB1 may therefore, by associating with microtubules, contribute to the sensor mechanism that activates the checkpoint. Another mutation affects Stt4, a phosphatidylinositol-4-OH kinase. Cold temperature is an environmental stimulus that causes misalignment of the mitotic spindle in yeast and appears to activate this checkpoint mechanism.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Cooper, JA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.		Adames, Neil/S-1460-2017; Adames, Neil/C-8863-2012; Cooper, John/E-9389-2012; Cooper, John/D-4448-2014	Adames, Neil/0000-0003-4331-9348; Adames, Neil/0000-0003-4331-9348; Cooper, John/0000-0002-0933-4571	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047337] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM047337, R01 GM047337-07] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; MCMILLAN JN, 1994, J CELL BIOL, V125, P143, DOI 10.1083/jcb.125.1.143; MUHUA L, 1994, CELL, V78, P669, DOI 10.1016/0092-8674(94)90531-2; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SMITH KJ, 1994, CANCER RES, V54, P3672; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; SU LK, 1995, CANCER RES, V55, P2972; SULLIVAN DS, 1992, J CELL BIOL, V119, P379, DOI 10.1083/jcb.119.2.379; Waddle JA, 1996, J CELL BIOL, V132, P861, DOI 10.1083/jcb.132.5.861; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; YEH E, 1995, J CELL BIOL, V130, P687, DOI 10.1083/jcb.130.3.687; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	19	136	138	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					487	491		10.1038/31014	http://dx.doi.org/10.1038/31014			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624007	Green Accepted			2022-12-28	WOS:000074020000050
J	Mustard, CA; Kaufert, P; Kozyrskyj, A; Mayer, T				Mustard, CA; Kaufert, P; Kozyrskyj, A; Mayer, T			Sex differences in the use of health care services	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; ADMINISTRATIVE DATA; MEDICAL-SERVICES; HEART-DISEASE; LAST YEAR; MORTALITY; CANADA; LIFE; MORBIDITY; MANITOBA	Background Sex differences in the use of health care services can be substantial at several stages of life. However, the extent to which differences in reproductive biology and mortality affect the use of health care services is unclear. Methods We studied age- and sex-specific per capita use of health care resources for a one-year period during 1994 and 1995 in the Canadian province of Manitoba, where there is universal insurance for a comprehensive range of health care services. Using information obtained from administrative records of physicians' services and acute hospital care, we tabulated the use of health care resources by male and female subjects in three categories: care for conditions specific to sex, care provided to persons who died during the study year, and care provided for all other conditions. Results The crude annual per capita use of health care resources tin Canadian dollars) was greater for female subjects ($1,164) than for male subjects ($918). Approximately 22 percent of health care expenditures for female subjects was associated with conditions specific to sex, including pregnancy and childbirth, as compared with 3 percent of expenditures for male subjects. An estimated 14 percent of health care expenditures for male subjects was consumed by persons who died during the study period, as compared with 10 percent of expenditures for female subjects. After adjustment for the use of health care associated with sex-specific conditions and differences in mortality, the female:male ratio in health care expenditures was reduced from 1.3 to 1.0. Conclusions Expenditures for health care are similar for male and female subjects after differences in reproductive biology and higher age-specific mortality rates among men have been accounted for. (C) 1998, Massachusetts Medical Society.	Univ Manitoba, Fac Med, Manitoba Ctr Hlth Policy & Evaluat, Winnipeg, MB, Canada; Univ Manitoba, Fac Med, Dept Community Hlth Sci, Winnipeg, MB, Canada; Canadian Inst Adv Res, Populat Hlth Program, Toronto, ON, Canada	University of Manitoba; University of Manitoba; Canadian Institute for Advanced Research (CIFAR)	Mustard, CA (corresponding author), Inst Work & Hlth, 250 Bloor St E, Toronto, ON M4W 1E6, Canada.							ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; Arber S, 1997, SOC SCI MED, V44, P773, DOI 10.1016/S0277-9536(96)00185-2; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BEVAN G, 1996, J HLTH SERV RES POLI, V1, P253; *CAN I HLTH INF, 1997, NAT HLTH EXP TRENDS; CLEARY PD, 1982, J HEALTH SOC BEHAV, V23, P106, DOI 10.2307/2136508; DAVID J, 1995, APPL BEHAV SCI, V3, P36; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; GILES WH, 1995, ARCH INTERN MED, V155, P18; HIBBARD JH, 1983, SOC SCI MED, V17, P129, DOI 10.1016/0277-9536(83)90246-0; JAGLAL SB, 1995, CAN MED ASSOC J, V152, P873; Katz SJ, 1996, AM J PUBLIC HEALTH, V86, P520, DOI 10.2105/AJPH.86.4.520; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; MacIntyre S, 1996, SOC SCI MED, V42, P617, DOI 10.1016/0277-9536(95)00335-5; *MAN HLTH, 1995, ANN STAT 1994 1995; MCCALL N, 1984, MED CARE, V22, P329, DOI 10.1097/00005650-198404000-00004; McKinlay JB, 1996, J HEALTH SOC BEHAV, V37, P1, DOI 10.2307/2137228; MCKINLAY JB, 1996, J HEALTH SOC BEHAV, V37, pA120; Millar W., 1996, CANADIAN SOCIAL TREN, V40, P24; Muhajarine N, 1997, J CLIN EPIDEMIOL, V50, P711, DOI 10.1016/S0895-4356(97)00019-X; MUSTARD CA, 1994, AM J PUBLIC HEALTH, V84, P1450, DOI 10.2105/AJPH.84.9.1450; MUSTARD CA, 1998, HLTH HLTH CARE HLTH, P159; Randhawa J, 1995, Health Rep, V7, P41; ROOS LL, 1987, J CHRON DIS, V40, P41, DOI 10.1016/0021-9681(87)90095-6; ROOS LL, 1990, JAMA-J AM MED ASSOC, V263, P2453, DOI 10.1001/jama.263.18.2453; ROOS LL, 1993, MED CARE, V31, P201, DOI 10.1097/00005650-199303000-00002; ROOS NP, 1987, MILBANK Q, V65, P231, DOI 10.2307/3350021; ROOS NP, 1988, MED CARE, V26, P221, DOI 10.1097/00005650-198803000-00001; SCHAPPERT SM, 1993, ADV DATA VITAL HLTH, V230; SCITOVSKY AA, 1994, MILBANK Q, V72, P561, DOI 10.2307/3350356; SHANAHAN M, 1994, HOSP CASE MIX COSTIN; STIRLING SL, 1995, J PUBLIC HEALTH MED, V17, P51; VANWIJK CMTG, 1991, WOMEN HEALTH, V17, P91; VANWIJK CMTG, 1992, SOC SCI MED, V35, P665, DOI 10.1016/0277-9536(92)90005-B; VERBRUGGE LM, 1995, AM J PUBLIC HEALTH, V85, P173, DOI 10.2105/AJPH.85.2.173; VERBRUGGE LM, 1987, WOMEN HEALTH, V12, P103, DOI 10.1300/J013v12n02_07; VERBRUGGE LM, 1986, SOC SCI MED, V22, P1195, DOI 10.1016/0277-9536(86)90187-5; WALDRON I, 1983, SOC SCI MED, V17, P1107, DOI 10.1016/0277-9536(83)90004-7; Welch WP, 1996, JAMA-J AM MED ASSOC, V275, P1410, DOI 10.1001/jama.275.18.1410; [No title captured]	41	137	138	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1998	338	23					1678	1683		10.1056/NEJM199806043382307	http://dx.doi.org/10.1056/NEJM199806043382307			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZR451	9614260				2022-12-28	WOS:000073978000007
J	Fossel, M				Fossel, M			Telomerase and the aging cell - Implications for human health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN FIBROBLASTS; REPLICATIVE SENESCENCE; HORMONE REPLACEMENT; LIFE-SPAN; CANCER; LENGTH; EXPRESSION; ACTIVATION; ELONGATION; CARCINOMA	Recent research has shown that inserting a gene for the protein component of telomerase into senescent human cells reextends their telomeres to lengths typical of young cells, and the cells then display all the other identifiable characteristics of young, healthy cells. This advance not only suggests that telomeres are the central timing mechanism for cellular aging, but also demonstrates that such a mechanism can be reset, extending the replicative life span of such cells and resulting in markers of gene expression typical of "younger" (ie, early passage) cells without the hallmarks of malignant transformation. It is now possible to explore the fundamental cellular mechanisms underlying human aging, clarifying the role played by replicative senescence. By implication, we may soon be able to determine the extent to which the major causes of death and disability in aging populations in developed countries-cancer, atherosclerosis, osteoarthritis, macular degeneration, and Alzheimer dementia-are attributable to such fundamental mechanisms. If they are amenable to prevention or treatment by alteration of cellular senescence, the clinical implications have few historic precedents.	Michigan State Univ, Coll Human Med, Dept Med, E Lansing, MI 48824 USA; Grand Valley State Univ, Coll Hlth Sci, Allendale, MI 49401 USA	Michigan State University; Michigan State University College of Human Medicine; Grand Valley State University	Fossel, M (corresponding author), 9464 Conservat Ave, Ada, MI 49301 USA.	Mfossel@aol.com						ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Banks DA, 1997, JAMA-J AM MED ASSOC, V278, P1345, DOI 10.1001/jama.278.16.1345; Berr C, 1996, P NATL ACAD SCI USA, V93, P13410, DOI 10.1073/pnas.93.23.13410; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Brash DE, 1996, NATURE, V379, P301, DOI 10.1038/379301a0; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Campisi J, 1997, J AM GERIATR SOC, V45, P482, DOI 10.1111/j.1532-5415.1997.tb05175.x; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; COOPER LT, 1994, J GERONTOL, V49, P191; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; Decary S, 1996, HUM GENE THER, V7, P1347, DOI 10.1089/hum.1996.7.11-1347; *DHEA, 1996, MED LETT DRUGS THER, V38, P91; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Engelhardt M, 1997, BLOOD, V90, P182; Faragher RGA, 1997, DRUG DISCOV TODAY, V2, P64, DOI 10.1016/S1359-6446(97)83293-X; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fossel M, 1996, REVERSING HUMAN AGIN; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Hammond CB, 1996, OBSTET GYNECOL, V87, pS2, DOI 10.1016/0029-7844(95)00429-7; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Harley CB, 1997, CANCER SURV, V29, P263; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1998, 89 ANN M AM ASS CANC; Harper JW, 1997, CANCER SURV, V29, P91; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1980, SCI AM, V242, P58, DOI 10.1038/scientificamerican0180-58; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HELZLSOUER KJ, 1995, CANCER-AM CANCER SOC, V76, P2059, DOI 10.1002/1097-0142(19951115)76:10+<2059::AID-CNCR2820761325>3.0.CO;2-1; Hemminki E, 1997, BRIT MED J, V315, P149, DOI 10.1136/bmj.315.7101.149; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1996, MOL CELL BIOL, V16, P2932; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPKING D, 1997, EUR J CANCER, V33, P792; Labrie F, 1997, J CLIN ENDOCR METAB, V82, P2396, DOI 10.1210/jc.82.8.2396; LAMBERTS SWJ, 1997, SCIENCE, V278, P410; Lane MA, 1997, J CLIN ENDOCR METAB, V82, P2093, DOI 10.1210/jc.82.7.2093; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LINSKENS MHK, 1995, NUCLEIC ACIDS RES, V23, P3244, DOI 10.1093/nar/23.16.3244; Lundblad V, 1996, CELL, V87, P369, DOI 10.1016/S0092-8674(00)81358-6; MARTIN GM, 1970, LAB INVEST, V23, P86; Moore MAS, 1997, STEM CELLS, V15, P239, DOI 10.1002/stem.5530150832; Morin GB, 1997, EXP GERONTOL, V32, P375, DOI 10.1016/S0531-5565(96)00164-7; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; Papadakis MA, 1996, ANN INTERN MED, V124, P708, DOI 10.7326/0003-4819-124-8-199604150-00002; Pierpaoli W, 1995, MELATONIN MIRACLE; Ramirez RD, 1997, J INVEST DERMATOL, V108, P113, DOI 10.1111/1523-1747.ep12285654; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1998, LANCET, V351, P153, DOI 10.1016/S0140-6736(05)78218-0; Shay JW, 1997, J CLIN PATHOL, V50, P106, DOI 10.1136/jcp.50.2.106; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; Speroff L, 1996, OBSTET GYNECOL, V87, pS44, DOI 10.1016/0029-7844(95)00428-9; THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Villeponteau B, 1997, EXP GERONTOL, V32, P383, DOI 10.1016/S0531-5565(96)00155-6; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wenger NK, 1997, BMJ-BRIT MED J, V315, P1085, DOI 10.1136/bmj.315.7115.1085; Wolf OT, 1997, J CLIN ENDOCR METAB, V82, P2363, DOI 10.1210/jc.82.7.2363; WOLFE J, 1998, J ANTI-AGING MED, V1, P9; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wright WE, 1996, DEV GENET, V18, P173; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; WynfordThomas D, 1997, NATURE, V389, P551, DOI 10.1038/39207; Wynn RF, 1998, LANCET, V351, P178, DOI 10.1016/S0140-6736(97)08256-1; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688	81	54	57	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1732	1735		10.1001/jama.279.21.1732	http://dx.doi.org/10.1001/jama.279.21.1732			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624027				2022-12-28	WOS:000073878700035
J	McNamee, D				McNamee, D			Cancer hopes and setbacks	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1450	1450		10.1016/S0140-6736(05)78868-1	http://dx.doi.org/10.1016/S0140-6736(05)78868-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605800				2022-12-28	WOS:000073707300006
J	Craven, SE; Bredt, DS				Craven, SE; Bredt, DS			PDZ proteins organize synaptic signaling pathways	CELL			English	Review							RECEPTOR		Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Craven, SE (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.							APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CHEN HJ, 1998, IN PRESS NEURON; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; Naisbitt S, 1997, J NEUROSCI, V17, P5687; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Rao A, 1997, NEURON, V19, P801, DOI 10.1016/S0896-6273(00)80962-9; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Thomas U, 1997, NEURON, V19, P787, DOI 10.1016/S0896-6273(00)80961-7; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	19	429	441	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					495	498		10.1016/S0092-8674(00)81179-4	http://dx.doi.org/10.1016/S0092-8674(00)81179-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604925	Bronze			2022-12-28	WOS:000073722200003
J	Holian, BL; Lomdahl, PS				Holian, BL; Lomdahl, PS			Plasticity induced by shock waves in nonequilibrium molecular-dynamics simulations	SCIENCE			English	Article							DEFORMATION; STRESS	Nonequilibrium molecular-dynamics simulations of shock waves in three-dimensional 10-million atom face-centered cubic crystals with cross-sectional dimensions of 100 by 100 unit cells show that the system slips along all of the available {111} slip planes, in different places along the nonplanar shock front. Comparison of these simulations with earlier ones on a smaller scale not only eliminates the possibility that the observed slippage is an artifact of transverse periodic boundary conditions, but also reveals the richness of the nanostructure left behind. By introducing a piston face that is no longer perfectly flat, mimicking a line or surface inhomogeneity in the unshocked material, it is shown that for weaker shock waves (below the perfect-crystal yield strength), stacking faults can be nucleated by preexisting extended defects.	Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	Holian, BL (corresponding author), Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA.	blh@lanl.gov						BEAZLEY DM, 1994, PARALLEL COMPUT, V20, P173, DOI 10.1016/0167-8191(94)90080-9; Beazley DM, 1997, COMPUT PHYS, V11, P230; Belonoshko AB, 1997, SCIENCE, V275, P955, DOI 10.1126/science.275.5302.955; BLUMBERG RL, COMMUNICATION; BRENNER DW, 1993, PHYS REV LETT, V70, P2174, DOI 10.1103/PhysRevLett.70.2174; HOLIAN BL, 1995, SHOCK WAVES, V5, P149, DOI 10.1007/BF01435522; HOLIAN BL, 1991, PHYS REV A, V43, P2655, DOI 10.1103/PhysRevA.43.2655; HOLIAN BL, 1995, PHYS REV B, V51, P11275, DOI 10.1103/PhysRevB.51.11275; HOLIAN BL, 1979, PHYS REV LETT, V43, P1598, DOI 10.1103/PhysRevLett.43.1598; HOLIAN BL, 1988, PHYS REV A, V37, P2562, DOI 10.1103/PhysRevA.37.2562; HOLIAN BL, 1980, PHYS REV A, V22, P2498; HOOVER WG, 1979, PHYS REV LETT, V42, P1531, DOI 10.1103/PhysRevLett.42.1531; JOHNSON JN, 1969, J APPL PHYS, V40, P4321, DOI 10.1063/1.1657194; Klimenko V. Y., 1978, DETONATION CRITICAL, P79; LIPKIN J, 1985, J APPL PHYS, V48, P692; Lomdahl P. S., 1993, Proceedings SUPERCOMPUTING '93, P520, DOI 10.1145/169627.169794; MEYERS MA, 1978, SCRIPTA METALL MATER, V12, P21, DOI 10.1016/0036-9748(78)90219-3; MOGILEVSKY MA, 1981, SHOCK WAVES HIGH STR, P531; SMITH CS, 1958, T AM I MIN MET ENG, V212, P574; STRAUB GK, 1980, B AM PHYS SOC, V25, P549; SWEGLE JW, 1985, J APPL PHYS, V58, P692, DOI 10.1063/1.336184; TONKS D, 1987, SHOCK WAVES CONDENSE, P231; WHITE CT, 1992, NATO ADV SCI I B-PHY, V292, P111; ZARETSKY E, 1995, ACTA METALL MATER, V43, P193, DOI 10.1016/0956-7151(95)90274-0; ZARETSKY EB, 1991, HIGH TEMP PHYS, V29, P1002; Zhou SJ, 1997, PHYS REV LETT, V78, P479, DOI 10.1103/PhysRevLett.78.479; ZHOU SJ, 1997, 9 INT C FRACT, P3085	27	402	413	3	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2085	2088		10.1126/science.280.5372.2085	http://dx.doi.org/10.1126/science.280.5372.2085			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641906				2022-12-28	WOS:000074435900034
J	Drife, JO				Drife, JO			Soundings - Dead hospitals	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1837	1837		10.1136/bmj.316.7147.1837	http://dx.doi.org/10.1136/bmj.316.7147.1837			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624097	Green Published			2022-12-28	WOS:000074286300079
J	Geiger, H; Sick, S; Bonifer, C; Muller, AM				Geiger, H; Sick, S; Bonifer, C; Muller, AM			Globin gene expression is reprogrammed in chimeras generated by injecting adult hematopoietic stem cells into mouse blastocysts	CELL			English	Article							YOLK-SAC; DEVELOPMENTAL REGULATION; EMBRYO; MICE; FETUSES; REGION; LOCUS; SPLANCHNOPLEURA; DIFFERENTIATION; CULTURE	To elucidate whether the differentiation capacity of hematopoietic stem cells (HSCs) is influenced by specific microenvironments, adult mouse bone marrow-derived HSCs were injected into mouse blastocysts. Embryos developing from injected blastocysts contained donor-derived cells at various developmental stages, and progeny of the stem cells were detected in hematopoietic tissues. Thus, HSCs derived from an adult animal survive after injection into blastocysts and are able to participate in hematopoietic development. We further find that the erythroid progeny of transplanted adult HSCs express embryonic/fetal-type globin genes and, conversely, that embryonic and fetal progenitor cells transplanted into adult recipients transcribe the adult-type globin gene. Thus, the developmental potential of adult HSCs is evidently more plastic than previously thought, and the developmental stage of the hematopoietic microenvironment controls the developmental fate of transplanted progenitor cells.	Max Planck Inst Immunobiol, D-79108 Freiburg, Germany; Univ Freiburg, Inst Biol 3, D-79104 Freiburg, Germany	Max Planck Society; University of Freiburg	Muller, AM (corresponding author), Max Planck Inst Immunobiol, D-79108 Freiburg, Germany.		Bonifer, Constanze/B-3000-2009	Bonifer, Constanze/0000-0002-4267-0825				BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; BLANCHET JP, 1982, DEV GENET, V3, P197, DOI 10.1002/dvg.1020030303; Bonifer C, 1998, IMMUNOL TODAY, V19, P236, DOI 10.1016/S0167-5699(98)01259-6; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Faust N, 1997, EXP HEMATOL, V25, P432; FLEISCHMAN RA, 1982, CELL, V30, P351, DOI 10.1016/0092-8674(82)90233-1; FLEISCHMAN RA, 1984, J EXP MED, V159, P731, DOI 10.1084/jem.159.3.731; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GARDNER RL, 1985, J EMBRYOL EXP MORPH, V88, P349; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; Herzenberg L. A., 1992, ANN N Y ACAD SCI, V651, P1, DOI 10.1111/j.1749-6632.1992.tb24588.x; HOPKINSONWOOLLEY J, 1994, J CELL SCI, V107, P1159; HUANG H, 1993, P NATL ACAD SCI USA, V90, P10110, DOI 10.1073/pnas.90.21.10110; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; LANSDORP PM, 1994, BLOOD CELLS, V20, P376; MAGLI MC, 1982, NATURE, V295, P527, DOI 10.1038/295527a0; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; METCALF D, 1971, HAEMOPOIETIC CELLS, P172; MORRIS L, 1991, DEVELOPMENT, V112, P517; MOUCHIROUD G, 1981, BLOOD, V57, P586; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; OKADA S, 1992, BLOOD, V80, P3044; PALACIOS R, 1993, P NATL ACAD SCI USA, V90, P6581, DOI 10.1073/pnas.90.14.6581; Rebel VI, 1996, BLOOD, V87, P3500, DOI 10.1182/blood.V87.8.3500.bloodjournal8783500; Ronchi A, 1996, EMBO J, V15, P143, DOI 10.1002/j.1460-2075.1996.tb00342.x; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; Tanosaki R, 1997, BRIT J HAEMATOL, V98, P1017, DOI 10.1046/j.1365-2141.1997.2983115.x; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TOLES JF, 1989, P NATL ACAD SCI USA, V86, P7456, DOI 10.1073/pnas.86.19.7456; VanZant G, 1997, EXP HEMATOL, V25, P187; WEISSMAN IL, 1976, COLD SPRING HARB SYM, V41, P9, DOI 10.1101/SQB.1977.041.01.005; Yoder MC, 1997, P NATL ACAD SCI USA, V94, P6776, DOI 10.1073/pnas.94.13.6776; ZANJANI ED, 1982, NATURE, V295, P244, DOI 10.1038/295244a0	45	105	112	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1998	93	6					1055	1065		10.1016/S0092-8674(00)81210-6	http://dx.doi.org/10.1016/S0092-8674(00)81210-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635434	Bronze			2022-12-28	WOS:000074205700016
J	Nowak, MA; Sigmund, K				Nowak, MA; Sigmund, K			Evolution of indirect reciprocity by image scoring	NATURE			English	Article							TIT-FOR-TAT; PRISONERS-DILEMMA; COOPERATION	Darwinian evolution has to provide an explanation for cooperative behaviour. Theories of cooperation are based on kin selection (dependent on genetic relatedness)(1,2), group selection(3-5) and reciprocal altruism(6-9). The idea of reciprocal altruism usually involves direct reciprocity: repeated encounters between the same individuals allow for the return of an altruistic act by the recipient(10-16). Here we present a new theoretical framework, which is based on indirect reciprocity(17) and does not require the same two individuals ever to meet again, individual selection can nevertheless favour cooperative strategies directed towards recipients that have helped others in the past. Cooperation pays because it confers the image of a valuable community member to the cooperating individual. We present computer simulations and analytic models that specify the conditions required for evolutionary stability(18) of indirect reciprocity. We show that the probability of knowing the 'image' of the recipient must exceed the cost-to-benefit ratio of the altruistic act. We propose that the emergence of indirect reciprocity was a decisive step for the evolution of human societies.	Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Univ Vienna, Inst Math, A-1090 Vienna, Austria	University of Oxford; University of Vienna	Nowak, MA (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	martin.nowak@zoo.ox.ac.uk	Nowak, Martin A/A-6977-2008					Alexander R., 1987, BIOL MORAL SYSTEMS; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Axelrod R., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; Binmore K., 1992, FUN GAMES TEXT GAME; BOYD R, 1989, SOC NETWORKS, V11, P213, DOI 10.1016/0378-8733(89)90003-8; Buss LW, 1987, EVOLUTION INDIVIDUAL, DOI DOI 10.1515/9781400858712; DUGATKIN LA, 1992, TRENDS ECOL EVOL, V7, P202, DOI 10.1016/0169-5347(92)90074-L; ESHEL I, 1972, THEOR POPUL BIOL, V3, P258, DOI 10.1016/0040-5809(72)90003-2; FRANK SA, 1995, J THEOR BIOL, V176, P403, DOI 10.1006/jtbi.1995.0208; HAMILTON WD, 1963, AM NAT, V97, P354, DOI 10.1086/497114; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Hofbauer J, 1998, EVOLUTIONARY GAMES P; Krebs J.R., 1987, BEHAV ECOL, Vsecond; Marler P, 1996, IBIS, V138, P26; MAY RM, 1987, NATURE, V327, P15, DOI 10.1038/327015a0; Maynard Smith J., 1982, pi; Michod R.E., 1985, P95; MILINSKI M, 1987, NATURE, V325, P433, DOI 10.1038/325433a0; NOWAK M, 1993, NATURE, V364, P56, DOI 10.1038/364056a0; NOWAK MA, 1992, NATURE, V355, P250, DOI 10.1038/355250a0; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; NOWAK MA, UNPUB J THEOR BIOL; PECK JR, 1986, AM NAT, V127, P209, DOI 10.1086/284479; POLLOCK G, 1992, J THEOR BIOL, V159, P25, DOI 10.1016/S0022-5193(05)80765-9; Sudgen R, 1986, EC RIGHTS COOPERATIO; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; Williams G.C., 1971, GROUP SELECTION; WILSON DS, 1994, BEHAV BRAIN SCI, V17, P585, DOI 10.1017/S0140525X00036104; Wilson E.O., 1975, P1; Zahavi A, 1997, HANDICAP PRINCIPLE M	30	1520	1560	8	289	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					573	577		10.1038/31225	http://dx.doi.org/10.1038/31225			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634232				2022-12-28	WOS:000074150100051
J	Wagner, A				Wagner, A			On being eighty	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1766	1766		10.1001/jama.279.22.1766-a	http://dx.doi.org/10.1001/jama.279.22.1766-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR635	9628693				2022-12-28	WOS:000073998500001
J	Smith, L				Smith, L			Problems in retrieving national data on births: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									Kings Fund Inst, London W1M 0AN, England		Smith, L (corresponding author), Kings Fund Inst, London W1M 0AN, England.							*DEP HLTH, 1996, ANN REP CONF ENQ STI; DOBSON P, 1995, BR J MIDWIFERY, V3, P487; MACFARLANE A, 1995, COUNTING CHANGES CHI; MIDDLE C, 1995, LABOUR DELIVERY NORM; *NHS EX, 1996, D4039 NHS EX HOSP IN	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1710	1711		10.1136/bmj.316.7146.1710	http://dx.doi.org/10.1136/bmj.316.7146.1710			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614019	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000074129500021
J	Nightingale, SL				Nightingale, SL			Viagra approval information on the Internet	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	10	11	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1684	1684		10.1001/jama.279.21.1684	http://dx.doi.org/10.1001/jama.279.21.1684			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624011				2022-12-28	WOS:000073878700004
J	Ye, WL; Shimamura, K; Rubenstein, JLR; Hynes, MA; Rosenthal, A				Ye, WL; Shimamura, K; Rubenstein, JLR; Hynes, MA; Rosenthal, A			FGF and Shh signals control dopaminergic and serotonergic cell fate in the anterior neural plate	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; EXPRESSION DOMAINS; SONIC HEDGEHOG; FLOOR PLATE; TYROSINE-HYDROXYLASE; MOUSE EMBRYO; RAT-BRAIN; MIDBRAIN; INDUCTION; DIFFERENTIATION	During development, distinct classes of neurons are specified in precise locations along the dorso-ventral and anterior-posterior axes of the neural tube. We provide evidence that intersections of Shh, which is expressed along the ventral neural tube, and FGF8, which is locally produced at the mid/hindbrain boundary and in the rostral forebrain, create induction sites for dopaminergic neurons in the midbrain and forebrain. The same intersection, when preceded by a third signal, FGF4, which is expressed in the primitive streak, defines an inductive center for hindbrain 5-HT neurons. These findings illustrate that cell patterning in the neural plate is a multistep process in which early inducers, which initially divide the neural plate into crude compartments, are replaced by multiple local organizing centers, which specify distinct neuronal cell types within these compartments.	Genentech Inc, Dept Neurosci, S San Francisco, CA 94080 USA; Univ Calif San Francisco, Dept Psychiat, Nina Ireland Lab Dev Neurobiol, San Francisco, CA 94143 USA	Roche Holding; Genentech; University of California System; University of California San Francisco	Rosenthal, A (corresponding author), Genentech Inc, Dept Neurosci, S San Francisco, CA 94080 USA.			Hynes, Mary/0000-0001-6623-6727; Ye, Weilan/0000-0002-6219-3982	NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH001046] Funding Source: NIH RePORTER; NIMH NIH HHS [K02 MH01046-01.18.] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ALVARADOMALLART RM, 1990, DEV BIOL, V139, P75, DOI 10.1016/0012-1606(90)90280-V; BALLYCUIF L, 1992, DEVELOPMENT, V115, P999; BALLYCUIF L, 1995, CURR OPIN GENET DEV, V5, P450, DOI 10.1016/0959-437X(95)90048-L; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cox WG, 1995, DEVELOPMENT, V121, P4349; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Dale JK, 1997, CELL, V90, P257, DOI 10.1016/S0092-8674(00)80334-7; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; Foley AC, 1997, DEVELOPMENT, V124, P2983; GARDNER CA, 1991, DEVELOPMENT, V113, P1037; GrapinBotton A, 1997, DEVELOPMENT, V124, P849; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; HORGER BA, 1995, J NEUROCHEM, V65, P770; Houart C, 1998, NATURE, V391, P788, DOI 10.1038/35853; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; Itasaki N, 1996, NEURON, V16, P487, DOI 10.1016/S0896-6273(00)80069-0; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; KENGAKU M, 1995, DEVELOPMENT, V121, P3121; LAMB TM, 1995, DEVELOPMENT, V121, P3627; LAUDER JM, 1974, J COMP NEUROL, V155, P469, DOI 10.1002/cne.901550407; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LAWSON KA, 1992, CIBA F SYMP, V165, P3; Lee SMK, 1997, DEVELOPMENT, V124, P959; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MARIN F, 1994, DEV BIOL, V163, P19, DOI 10.1006/dbio.1994.1120; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Muhr J, 1997, NEURON, V19, P487, DOI 10.1016/S0896-6273(00)80366-9; NISWANDER L, 1992, DEVELOPMENT, V114, P755; PLACZEK M, 1993, DEVELOPMENT, V117, P205; Pownall ME, 1996, DEVELOPMENT, V122, P3881; RESIBOIS A, 1992, NEUROSCIENCE, V46, P101, DOI 10.1016/0306-4522(92)90012-Q; ROGERS JH, 1992, BRAIN RES, V587, P203, DOI 10.1016/0006-8993(92)90998-O; ROWITCH DH, 1995, MECH DEVELOP, V52, P3, DOI 10.1016/0925-4773(95)00380-J; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; SASAKI H, 1993, DEVELOPMENT, V118, P47; Shimamura K, 1997, DEVELOPMENT, V124, P2709; Shimamura K, 1995, DEVELOPMENT, V121, P3923; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; SIMON H, 1995, CURR BIOL, V5, P205, DOI 10.1016/S0960-9822(95)00041-8; Smidt MP, 1997, P NATL ACAD SCI USA, V94, P13305, DOI 10.1073/pnas.94.24.13305; SPECHT LA, 1981, J COMP NEUROL, V199, P255, DOI 10.1002/cne.901990208; Storey KG, 1998, DEVELOPMENT, V125, P473; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; WANG MZ, 1995, NAT MED, V1, P1184, DOI 10.1038/nm1195-1184; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	57	703	737	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					755	766		10.1016/S0092-8674(00)81437-3	http://dx.doi.org/10.1016/S0092-8674(00)81437-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630220	Bronze			2022-12-28	WOS:000073956700012
J	Morino, J; Yamashita, T; Hasegawa, T; Nakano, T				Morino, J; Yamashita, T; Hasegawa, T; Nakano, T			Reflected infrared spectrum of a massive protostar in Orion	NATURE			English	Article							FU ORIONIS; SIO MASER; REGION; STARS; KL; NEBULA; RESOLUTION; EMISSION; DISK	The infrared source IRc2 (ref. 1) in the star-forming region Orion-KL, is generally believed to contain a massive and very young star(2). Its nature and evolutionary status, however, are difficult to determine because it is hidden from direct view by a dense disklike envelope of gas and dust. Here we report observations of infrared radiation (at a wavelength of about 2 mu m) that has escaped the surrounding dust in the polar direction, perpendicular to the plane of the disk, and then been reflected towards us by dust farther away from the star. The reflected spectrum contains absorption lines of neutral metallic atoms and carbon monoxide, which we interpret as indicating a source temperature of about 4,500 K, But, given the luminosity of the source, its radius must be at least 300 solar radii - too large to be attained with the modest gas-accretion rates in existing theories of massive-star formation. Whether the infrared radiation is coming from the protostar itself or the self-luminous accretion disk around it; the accretion rate must be around (5-15) x 10(-3) solar masses per year, at least two orders of magnitude greater than is commonly assumed in models of star formation.	Univ Tokyo, Inst Astron, Tokyo 1818588, Japan; Natl Astron Observ, Tokyo 1818588, Japan; Natl Astron Observ, Nobeyama Radio Observ, Minamisa Ku, Nagano 3841305, Japan	University of Tokyo; National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ)	Morino, J (corresponding author), Univ Tokyo, Inst Astron, Tokyo 1818588, Japan.			Hasegawa, Tetsuo/0000-0003-1853-0184				ALI B, 1995, ASTRON J, V110, P2415, DOI 10.1086/117701; BECKWITH S, 1978, ASTROPHYS J, V223, P464, DOI 10.1086/156281; CALVET N, 1991, ASTROPHYS J, V383, P752, DOI 10.1086/170832; DOUGADOS C, 1993, ASTROPHYS J, V406, P112, DOI 10.1086/172424; DRAINE BT, 1984, ASTROPHYS J, V285, P89, DOI 10.1086/162480; Elitzur M., 1992, ASTRONOMICAL MASERS; ERICKSON NR, 1982, ASTROPHYS J, V261, pL103, DOI 10.1086/183897; GENZEL R, 1989, ANNU REV ASTRON ASTR, V27, P41, DOI 10.1146/annurev.aa.27.090189.000353; GEZARI DY, 1992, ASTROPHYS J, V396, pL43, DOI 10.1086/186513; Greene TP, 1996, ASTRON J, V112, P2184, DOI 10.1086/118173; Hartmann L, 1996, ANNU REV ASTRON ASTR, V34, P207, DOI 10.1146/annurev.astro.34.1.207; HASEGAWA T, 1984, ASTROPHYS J, V283, P117, DOI 10.1086/162280; Hasegawa T., 1986, MASERS MOL MASS OUTF, P275; KLEINMANN SG, 1986, ASTROPHYS J SUPPL S, V62, P501, DOI 10.1086/191149; MATHIS JS, 1990, ANNU REV ASTRON ASTR, V28, P37, DOI 10.1146/annurev.aa.28.090190.000345; MENTEN KM, 1995, ASTROPHYS J, V445, pL157, DOI 10.1086/187913; MINCHIN NR, 1991, MON NOT R ASTRON SOC, V248, P715, DOI 10.1093/mnras/248.4.715; MORITA KI, 1992, PUBL ASTRON SOC JPN, V44, P373; PALLA F, 1993, ASTROPHYS J, V418, P414, DOI 10.1086/173402; PLAMBECK RL, 1990, ASTROPHYS J, V348, pL65, DOI 10.1086/185632; RIEKE GH, 1973, ASTROPHYS J, V186, pL7, DOI 10.1086/181346; SHU F, 1994, ASTROPHYS J, V429, P781, DOI 10.1086/174363; SNELL RL, 1984, ASTROPHYS J, V284, P176, DOI 10.1086/162397; SNYDER LE, 1974, ASTROPHYS J, V189, pL31, DOI 10.1086/181457; Wright MCH, 1996, ASTROPHYS J, V469, P216, DOI 10.1086/177773; WRIGHT MCH, 1983, ASTROPHYS J, V267, pL41, DOI 10.1086/183999; WYNNWILLIAMS CG, 1984, ASTROPHYS J, V281, P172, DOI 10.1086/162086	27	21	21	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1998	393	6683					340	342		10.1038/30678	http://dx.doi.org/10.1038/30678			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620798				2022-12-28	WOS:000073883600045
J	Tybjaerg-Hansen, A; Steffensen, R; Meinertz, H; Schnohr, P; Nordestgaard, BG				Tybjaerg-Hansen, A; Steffensen, R; Meinertz, H; Schnohr, P; Nordestgaard, BG			Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL DEFECTIVE APOLIPOPROTEIN-B-100; RECEPTOR-BINDING; CHOLESTEROL; B-100; PRAVASTATIN; PREVENTION	Background Familial hypercholesterolemia leads to premature ischemic heart disease and is often caused by mutations in the gene for the low-density lipoprotein receptor. Mutations in the apolipoprotein B gene, which encodes a ligand for this receptor, may also result in this phenotype, Methods We studied the genotypes of 9255 women and men from the general population, 948 patients with ischemic heart disease, and 36 patients with familial hypercholesterolemia, all from Denmark, for three mutations in the apolipoprotein B gene: Arg3500Gln, Arg3531Cys, and Arg3500Trp. Results The prevalence of heterozygotes in the general population was 0.08 percent (95 percent confidence interval, 0.03 to 0.16 percent) for both the Arg3500Gln and the Arg3531Cys mutations, and 0.00 percent (95 percent confidence interval, 0.00 to 0.18 percent) for the Arg3500Trp mutation. Among carriers of the Arg3500Gln mutation, cholesterol levels were significantly higher than among noncarriers in the general population - by 100 mg per deciliter (2.6 mmol per liter) among carriers in the general population, 154 mg per deciliter (4.0 mmol per liter) among patients with ischemic heart disease, and 172 mg per deciliter (4.5 mmol per liter) among patients with familial hypercholesterolemia. Heterozygous carriers of the Arg3500Gln mutation were significantly more common among patients with ischemic heart disease (odds ratio, 7.0; 95 percent confidence interval, 2.2 to 22; P=0.003) and patients with familial hypercholesterolemia (odds ratio, 78; 95 percent confidence interval, 16 to 388; P=0.001) than in the general population. Heterozygous carriers of the Arg3531Cys mutation in the general population did not have higher-than-normal plasma cholesterol levels or an increased risk of ischemic heart disease (odds ratio; 1.4; 95 percent confidence interval, 0.2 to 11; P=0.54), Conclusions The Arg3500Gln mutation in the apolipoprotein B gene, which is responsible for familial defective apolipoprotein B-100 and is present in approximately 1 in 1000 persons in Denmark, causes severe hypercholesterolemia and increases the risk of ischemic heart disease. (C) 1998, Massachusetts Medical Society.	Univ Copenhagen, Herlev Univ Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark; Univ Copenhagen, Rigshosp, Natl Univ Hosp, Dept Med B,Div Cardiol, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Rigshosp, Natl Univ Hosp, Copenhagen City Heart Study, DK-2100 Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Tybjaerg-Hansen, A (corresponding author), Herlev Univ Hosp, Dept Clin Biochem 54M1, Herlev Ringvej 75, DK-2730 Herlev, Denmark.		Nordestgaard, Borge Gronne/ABF-1310-2020					AgerholmLarsen B, 1997, CIRCULATION, V95, P2358, DOI 10.1161/01.CIR.95.10.2358; ANDERSEN GE, 1979, ACTA PAEDIATR SCAND, V68, P541, DOI 10.1111/j.1651-2227.1979.tb05052.x; ARMITAGE P, 1987, STAT METHODS MED RES, P67; CARLETON RA, 1991, CIRCULATION, V83, P2154, DOI 10.1161/01.CIR.83.6.2154; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GAFFNEY D, 1995, ARTERIOSCL THROM VAS, V15, P1025, DOI 10.1161/01.ATV.15.8.1025; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; *GRAPHP SOFTW, 1995, STATM VERS 1 0; HANSEN PS, 1994, CLIN CHIM ACTA, V230, P101, DOI 10.1016/0009-8981(94)90093-0; HANSEN PS, 1991, J LIPID RES, V32, P1229; INNERARITY TL, 1990, J LIPID RES, V31, P1337; INNERARITY TL, 1987, P NATL ACAD SCI USA, V84, P6919, DOI 10.1073/pnas.84.19.6919; Julian DG, 1997, EUR HEART J, V18, P394; Ludwig EH, 1997, J LIPID RES, V38, P1361; MYANT NB, 1993, ATHEROSCLEROSIS, V104, P1, DOI 10.1016/0021-9150(93)90171-P; Nordestgaard BG, 1997, CIRCULATION, V96, P1737, DOI 10.1161/01.CIR.96.6.1737; PEDERSEN TR, 1994, LANCET, V344, P1383; PULLINGER CR, 1995, J CLIN INVEST, V95, P1225, DOI 10.1172/JCI117772; PYORALA K, 1994, EUR HEART J, V15, P1300; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SORIA LF, 1989, P NATL ACAD SCI USA, V86, P587, DOI 10.1073/pnas.86.2.587; SPSS, 1996, SPSS BAS 7 0 WIND US; Talmud PJ, 1996, ATHEROSCLEROSIS, V125, P135, DOI 10.1016/0021-9150(96)05838-8; TybjaergHansen A, 1997, J CLIN INVEST, V99, P3034, DOI 10.1172/JCI119499; TYBJAERGHANSEN A, 1995, SCAND J CLIN LAB INV, V55, P57; TYBJAERGHANSEN A, 1992, ATHEROSCLEROSIS, V96, P91, DOI 10.1016/0021-9150(92)90056-M; Wenham PR, 1997, ATHEROSCLEROSIS, V129, P185, DOI 10.1016/S0021-9150(96)06029-7; Wittrup HH, 1997, J CLIN INVEST, V99, P1606, DOI 10.1172/JCI119323	30	150	154	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1998	338	22					1577	1584		10.1056/NEJM199805283382203	http://dx.doi.org/10.1056/NEJM199805283382203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ350	9603795	Bronze			2022-12-28	WOS:000073852400003
J	Liu, JP; Zhu, JK				Liu, JP; Zhu, JK			A calcium sensor homolog required for plant salt tolerance	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; CALCINEURIN; YEAST; ARABIDOPSIS; ACTIVATION; ADAPTATION; RECOVERIN; CELLS	Excessive sodium (Na+) in salinized soils inhibits plant growth and development. A mutation in the SOS3 gene renders Arabidopsis thaliana plants hypersensitive to Na+-induced growth inhibition. SOS3 encodes a protein that shares significant sequence similarity with the calcineurin B subunit from yeast and neuronal calcium sensors from animals. The results suggest that intracellular calcium signaling through a calcineurin-like pathway mediates the beneficial effect of calcium on plant salt tolerance.	Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA	University of Arizona	Zhu, JK (corresponding author), Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA.		Zhu, Jian-Kang/F-7658-2011	Zhu, Jian-Kang/0000-0001-5134-731X; LIU, JIPING/0000-0002-7558-0025				[Anonymous], 1972, MINERAL NUTR PLANTS; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; CHOI S, 1995, WEEDS WORLD, V2, P17; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; EPSTEIN E, 1980, SCIENCE, V210, P399, DOI 10.1126/science.210.4468.399; GREENWAY H, 1980, ANNU REV PLANT PHYS, V31, P149, DOI 10.1146/annurev.pp.31.060180.001053; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Knight H, 1997, PLANT J, V12, P1067, DOI 10.1046/j.1365-313X.1997.12051067.x; LAHAYE PA, 1969, SCIENCE, V166, P395, DOI 10.1126/science.166.3903.395; Lauchli A, 1990, AM SOC PLANT PHYSL S; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Liu JP, 1997, P NATL ACAD SCI USA, V94, P14960, DOI 10.1073/pnas.94.26.14960; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; LYNCH J, 1989, PLANT PHYSIOL, V90, P1271, DOI 10.1104/pp.90.4.1271; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MURGUIA JR, 1995, SCIENCE, V267, P232; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; NIU XM, 1995, PLANT PHYSIOL, V109, P735, DOI 10.1104/pp.109.3.735; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; Schaad NC, 1996, P NATL ACAD SCI USA, V93, P9253, DOI 10.1073/pnas.93.17.9253; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; Wu SJ, 1996, PLANT CELL, V8, P617, DOI 10.1105/tpc.8.4.617	29	594	707	16	138	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1943	1945		10.1126/science.280.5371.1943	http://dx.doi.org/10.1126/science.280.5371.1943			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632394				2022-12-28	WOS:000074323800066
J	Feng, WJ; Ribeiro, RCJ; Wagner, RL; Nguyen, H; Apriletti, JW; Fletterick, RJ; Baxter, JD; Kushner, PJ; West, BL				Feng, WJ; Ribeiro, RCJ; Wagner, RL; Nguyen, H; Apriletti, JW; Fletterick, RJ; Baxter, JD; Kushner, PJ; West, BL			Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVATION; CRYSTAL-STRUCTURE; CONSERVED REGION; DOMAIN; PROTEIN; COMPLEX	The ligand-binding domain of nuclear receptors contains a transcriptional activation function (AF-2) that mediates hormone-dependent binding of coactivator proteins. Scanning surface mutagenesis on the human thyroid hormone receptor was performed to define the site that binds the coactivators, glucocorticoid receptor-interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1), The residues involved encircle a small surface that contains a hydrophobic cleft. Ligand activation of transcription involves formation of this surface by folding the carboxyl-terminal cr helix against a scaffold of three other helices. These features may represent general ones for nuclear receptors.	Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Brasilia, Dept Pharmaceut Sci, BR-70910900 Brasilia, DF, Brazil; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Universidade de Brasilia; University of California System; University of California San Francisco	West, BL (corresponding author), Univ Calif San Francisco, Metab Res Unit, Box 0540, San Francisco, CA 94143 USA.	kushner@itsa.ucsf.edu; west@socrates.ucsf.edu		West, Brian/0000-0002-5320-3691	NCRR NIH HHS [P41-RR01081] Funding Source: Medline; NIDDK NIH HHS [DK51281, DK09516] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051281, F32DK009516] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APRILETTI JW, 1995, PROTEIN EXPRES PURIF, V6, P363, DOI 10.1006/prep.1995.1048; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEE JW, 1992, MOL ENDOCRINOL, V6, P1867, DOI 10.1210/me.6.11.1867; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; ONATE SA, 1995, SCIENCE, V270, P1354; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Saatcioglu F, 1997, MOL CELL BIOL, V17, P4687, DOI 10.1128/MCB.17.8.4687; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WHITFIELD GK, 1995, MOL ENDOCRINOL, V9, P1166, DOI 10.1210/me.9.9.1166; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	36	477	496	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1747	1749		10.1126/science.280.5370.1747	http://dx.doi.org/10.1126/science.280.5370.1747			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624051				2022-12-28	WOS:000074197800040
J	Reddington, E; Sapienza, A; Gurau, B; Viswanathan, R; Sarangapani, S; Smotkin, ES; Mallouk, TE				Reddington, E; Sapienza, A; Gurau, B; Viswanathan, R; Sarangapani, S; Smotkin, ES; Mallouk, TE			Combinatorial electrochemistry: A highly parallel, optical screening method for discovery of better electrocatalysts	SCIENCE			English	Article							SOLID-PHASE SYNTHESIS; LIBRARIES; ELECTROOXIDATION; MOLECULES; OXIDATION; METHANOL; BINDING	Combinatorial screening of electrochemical catalysts by current-voltage methods can be unwieldy for large sample sizes. By converting the ions generated in an electrochemical half-cell reaction to a fluorescence signal, the most active compositions in a large electrode array have been identified. A fluorescent acid-base indicator was used to image high concentrations of hydrogen ions, which were generated in the electrooxidation of methanol. A 645-member electrode array containing five elements (platinum, ruthenium, osmium, iridium, and rhodium), 80 binary, 280 ternary, and 280 quaternary combinations was screened to identify the most active regions of phase space. Subsequent "zoom" screens pinpointed several very active compositions, some in ternary and quaternary regions that were bounded by rather inactive binaries. The best catalyst, platinum(44)/ruthenium(41)/osmium(10)/iridium(5) (numbers in parentheses are atomic percent), was significantly more active than platinum(50)/ruthenium(50) in a direct methanol fuel cell operating at 60 degrees C, even though the latter catalyst had about twice the surface area of the former.	IIT, Dept Environm Chem & Engn, Chicago, IL 60616 USA; Penn State Univ, Dept Chem, University Pk, PA 16802 USA; ICET Inc, Norwood, MA 02062 USA	Illinois Institute of Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Smotkin, ES (corresponding author), IIT, Dept Environm Chem & Engn, Chicago, IL 60616 USA.		Mallouk, Thomas E/K-7391-2012	Mallouk, Thomas E/0000-0003-4599-4208; Sapienza, Anthony/0000-0003-2850-4123				BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BRICENO G, 1995, SCIENCE, V270, P273, DOI 10.1126/science.270.5234.273; BUNIN BA, 1992, J AM CHEM SOC, V114, P10997, DOI 10.1021/ja00053a067; CAMPBELL DA, 1995, J AM CHEM SOC, V117, P5381, DOI 10.1021/ja00124a030; CHO CY, 1993, SCIENCE, V261, P1303, DOI 10.1126/science.7689747; Danielson E, 1998, SCIENCE, V279, P837, DOI 10.1126/science.279.5352.837; DEWITT SH, 1993, P NATL ACAD SCI USA, V90, P6909, DOI 10.1073/pnas.90.15.6909; Dickinson TA, 1997, ANAL CHEM, V69, P3413, DOI 10.1021/ac970501b; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; FRELINK T, 1995, ELECTROCHIM ACTA, V40, P1537, DOI 10.1016/0013-4686(95)00034-C; FULLER TF, 1997, ELECTROCHEMICAL  FAL, P26; HANAK JJ, 1970, J MATER SCI, V5, P964, DOI 10.1007/BF00558177; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEMMO AV, 1997, BIOSENS BIOELECTRONI, V69, P543; Ley KL, 1997, J ELECTROCHEM SOC, V144, P1543, DOI 10.1149/1.1837638; MCKEE DW, 1969, J CATAL, V14, P355, DOI 10.1016/0021-9517(69)90326-1; Moates FC, 1996, IND ENG CHEM RES, V35, P4801, DOI 10.1021/ie960476k; MORI H, 1993, CHEM PHARM BULL, V41, P1944; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; PARSONS R, 1988, J ELECTROANAL CHEM, V257, P9, DOI 10.1016/0022-0728(88)87028-1; Taylor SJ, 1998, SCIENCE, V280, P267, DOI 10.1126/science.280.5361.267; TORNEIRO M, 1995, J AM CHEM SOC, V117, P5887, DOI 10.1021/ja00126a043; van Dover RB, 1998, NATURE, V392, P162, DOI 10.1038/32381; VIRGILIO AA, 1994, J AM CHEM SOC, V116, P11580, DOI 10.1021/ja00104a053; WATANABE M, 1987, J ELECTROANAL CHEM, V229, P395, DOI 10.1016/0022-0728(87)85156-2; XIANG XD, 1995, SCIENCE, V268, P1738, DOI 10.1126/science.268.5218.1738	27	854	901	4	250	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1735	1737		10.1126/science.280.5370.1735	http://dx.doi.org/10.1126/science.280.5370.1735			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624047				2022-12-28	WOS:000074197800036
J	Warrick, JM; Paulson, HL; Gray-Board, GL; Bui, QT; Fischbeck, KH; Pittman, RN; Bonini, NM				Warrick, JM; Paulson, HL; Gray-Board, GL; Bui, QT; Fischbeck, KH; Pittman, RN; Bonini, NM			Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila	CELL			English	Article							MACHADO-JOSEPH DISEASE; PROGRAMMED CELL-DEATH; SPINOCEREBELLAR ATAXIA; CAG EXPANSIONS; GENE; EXPRESSION; RETINA; EYE; DIFFERENTIATION; MELANOGASTER	Spinocerebellar ataxia type 3 (SCA3/MJD) is one of at least eight human neurodegenerative diseases caused by glutamine-repeat expansion. We have recreated glutamine-repeat disease in Drosophila using a segment of the SCA3/MJD protein. Targeted expression of the protein with an expanded polyglutamine repeat led to nuclear inclusion (NI) formation and late-onset cell degeneration. Differential sensitivity to the mutant transgene was observed among different cell types, with neurons being particularly susceptible; NI formation alone was not sufficient for degeneration. The viral antiapoptotic gene P35 mitigated polyglutamine-induced degeneration in vivo. Our results demonstrate that cellular mechanisms of human glutamine-repeat disease are conserved in invertebrates. This fly model will aid in identifying additional factors that modulate neurodegeneration.	Univ Penn, Dept Biol, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurol, Sch Med, Philadelphia, PA 19104 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Iowa	Bonini, NM (corresponding author), Univ Penn, Dept Biol, Sch Med, Philadelphia, PA 19104 USA.			Bonini, Nancy/0000-0003-0226-5291				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Andrew SE, 1997, HUM MOL GENET, V6, P2005, DOI 10.1093/hmg/6.12.2005; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BRAND AH, 1993, DEVELOPMENT, V118, P401; BURKE JR, 1994, NAT GENET, V7, P521, DOI 10.1038/ng0894-521; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Durr A, 1996, ANN NEUROL, V39, P490, DOI 10.1002/ana.410390411; ELLIS MC, 1993, DEVELOPMENT, V119, P855; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAY BA, 1994, DEVELOPMENT, V120, P2121; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Ordway JM, 1997, CELL, V91, P753, DOI 10.1016/S0092-8674(00)80464-X; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; RANUM LPW, 1995, AM J HUM GENET, V57, P603; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SCHOLS L, 1995, HUM MOL GENET, V4, P1001, DOI 10.1093/hmg/4.6.1001; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wolff Tanya, 1993, P1277; Yin JCP, 1996, CURR OPIN NEUROBIOL, V6, P264, DOI 10.1016/S0959-4388(96)80082-1; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	40	507	524	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					939	949		10.1016/S0092-8674(00)81200-3	http://dx.doi.org/10.1016/S0092-8674(00)81200-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635424	hybrid			2022-12-28	WOS:000074205700006
J	Poloniecki, J; Valencia, O; Littlejohns, P				Poloniecki, J; Valencia, O; Littlejohns, P			Cumulative risk adjusted mortality chart for detecting changes in death rate: observational study of heart surgery	BRITISH MEDICAL JOURNAL			English	Article							STRATIFICATION; OUTCOMES	Objective: To detect changes in mortality after surgery with allowance being made for variations in case mix. Design: Observational study of postoperative mortality from January 1992 to August 1995. Setting: Regional cardiothoracic unit. Subjects: 3983 patients aged 16 and over who had open heart operations. Main outcome measures: Preoperative risk factors and postoperative mortality in hospital within 30 days were recorded for all surgical heart operations. Mortality was adjusted for case mix using a preoperative estimate of risk based on additive Parsonnet factors. The number of operations required for statistical power to detect a doubling of mortality was examined, and control limits at a nominal significance level of P = 0.01 for detection of an adverse trend were determined. Results: Total mortality of 7.0% was 26% below the Parsonnet predictor (P < 0.0001). There was a highly significant variation in annual case mix (Parsonnet scores 8.7-10.6, P < 0.0001). There was no significant variation in mortality after adjustment for case mix (odds ratio 1-1.5, P = 0.18) with monitoring by calendar year. With continuous monitoring, however, nominal 99% control limits based on 16 expected deaths were crossed on two occasions. Conclusions: Hospital league tables for mortality from heart surgery will be of limited value because year to year differences in death rate can be large (odds ratio 1.5) even when the underlying risk or case mix does not change. Statistical quality control of a single series with adjustment for case mix is the only way to take into account recent performance when informing a patient of the risk of surgery at a particular hospital. If there is an increase in the number of deaths the chances of the next patient surviving surgery can be calculated from the last 16 deaths.	St George Hosp, Sch Med, London SW17 0RE, England; St George Hosp, Reg Cardiothorac Unit, London SW17 0RE, England	St Georges University London; St Georges University London	Poloniecki, J (corresponding author), St George Hosp, Sch Med, Cranmer Terrace, London SW17 0RE, England.							Capewell S, 1996, HEART, V76, P70, DOI 10.1136/hrt.76.1.70; COPELAND GP, 1995, BRIT J SURG, V82, P408, DOI 10.1002/bjs.1800820344; DELEVAL MR, 1994, J THORAC CARDIOV SUR, V107, P914; deLeval MR, 1997, LANCET, V349, P723, DOI 10.1016/S0140-6736(96)11327-1; DYER C, 1997, GUARDIAN        0502, P10; DZIUBAN SW, 1994, ANN THORAC SURG, V58, P1871, DOI 10.1016/0003-4975(94)91730-2; ELLIS SG, 1997, CIRCULATION, V96, P2479; Irvine D, 1997, BRIT MED J, V314, P1613, DOI 10.1136/bmj.314.7094.1613; LOVEGOVE J, 1997, HEART, V77, P18; Lovegrove J, 1997, LANCET, V350, P1128, DOI 10.1016/S0140-6736(97)06507-0; NASHEF SAM, 1992, BRIT MED J, V305, P1066, DOI 10.1136/bmj.305.6861.1066; PARSONNET V, 1989, CIRCULATION, V79, P3; REESMOGG W, 1996, TIMES           0401, P16; ROCKALL TA, 1995, LANCET, V346, P346, DOI 10.1016/S0140-6736(95)92227-X; TAYLOR K, 1991, BRIT J HEALTHCA 0530, P30; TODD CJ, 1995, BRIT MED J, V310, P904, DOI 10.1136/bmj.310.6984.904	16	136	136	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1697	1700		10.1136/bmj.316.7146.1697	http://dx.doi.org/10.1136/bmj.316.7146.1697			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614015	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000074129500014
J	Sibbald, B; Roberts, C				Sibbald, B; Roberts, C			Understanding controlled trials - Crossover trials	BRITISH MEDICAL JOURNAL			English	Article									Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of Manchester	Sibbald, B (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.							Chisholm A, 1996, BRIT MED J, V312, P931, DOI 10.1136/bmj.312.7036.931; FREEMAN PR, 1989, STAT MED, V8, P1421, DOI 10.1002/sim.4780081202; SENN S, 1993, CROSS OVER TRIALS CL	3	93	96	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1719	1719		10.1136/bmj.316.7146.1719	http://dx.doi.org/10.1136/bmj.316.7146.1719			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614025	Green Published			2022-12-28	WOS:000074129500025
J	Geraghty, RJ; Krummenacher, C; Cohen, GH; Eisenberg, RJ; Spear, PG				Geraghty, RJ; Krummenacher, C; Cohen, GH; Eisenberg, RJ; Spear, PG			Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS; CELL-SURFACE RECEPTORS; PSEUDORABIES VIRUS; GLYCOPROTEIN-D; HEPARAN-SULFATE; PENETRATION; EXPRESSION; MEMBER; FORMS; BIND	A human member of the immunoglobulin superfamily was shown to mediate entry of several alphaherpesviruses, including herpes simplex viruses (HSV) 1 and 2, porcine pseudorabies virus (PRV), and bovine Herpesvirus 1 (BHV-1). This membrane glycoprotein is poliovirus receptor-related protein 1 (Prr1), designated here as HveC, Incubation of HSV-1 with a secreted form of HveC inhibited subsequent infection of a variety of cell lines, suggesting that HveC interacts directly with the virus. Poliovirus receptor (Pvr) itself mediated entry of PRV and BHV-1 but not of the HSV strains tested. HveC was expressed in human cells of epithelial and neuronal origin; it is the prime candidate for the coreceptor that allows both HSV-1 and HSV-2 to infect epithelial cells on mucosal surfaces and spread to cells of the nervous system.	Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Univ Penn, Sch Dent Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Oral Hlth Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA	Northwestern University; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Spear, PG (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.	p-spear@nwu.edu		Krummenacher, Claude/0000-0002-3492-4987; Geraghty, Robert/0000-0002-0560-6509	NIAID NIH HHS [R01 AI 36293] Funding Source: Medline; NINDS NIH HHS [NS-30606, NS-36731] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030606, R01NS036731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Babic N, 1996, J GEN VIROL, V77, P2277, DOI 10.1099/0022-1317-77-9-2277; CAMPADELLIFIUME G, 1988, J VIROL, V62, P159, DOI 10.1128/JVI.62.1.159-167.1988; CHASE CCL, 1993, VIROLOGY, V194, P365, DOI 10.1006/viro.1993.1269; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; EJERCITO PM, 1968, J GEN VIROL, V2, P357, DOI 10.1099/0022-1317-2-3-357; FRANCKE U, 1981, SOMAT CELL GENET, V7, P171; GERAGHTY RJ, UNPUB; HOGGAN MD, 1959, AM J HYG, V70, P208, DOI 10.1093/oxfordjournals.aje.a120071; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; JOHNSON DC, 1988, J VIROL, V62, P4605, DOI 10.1128/JVI.62.12.4605-4612.1988; JOHNSON DC, 1990, J VIROL, V64, P2569, DOI 10.1128/JVI.64.6.2569-2576.1990; KARGER A, 1993, VIROLOGY, V194, P654, DOI 10.1006/viro.1993.1305; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; KRUMMENACHER C, UNPUB; KRUMMENACHER C, IN PRESS J VIROL; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; LEE WC, 1993, J VIROL, V67, P5088, DOI 10.1128/JVI.67.9.5088-5097.1993; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Mettenleiter Thomas C., 1995, P367, DOI 10.1016/B978-012397570-6/50022-8; MILLER JM, 1995, AM J VET RES, V56, P870; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Nicola AV, 1998, J VIROL, V72, P3595, DOI 10.1128/JVI.72.5.3595-3601.1998; PETROVSKIS EA, 1988, J VIROL, V62, P2196, DOI 10.1128/JVI.62.6.2196-2199.1988; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SPEAR PG, 1993, SEMIN VIROL, V4, P167, DOI 10.1006/smvy.1993.1012; TERRYALLISON T, IN PRESS J VIROL; Thomas JT, 1998, J VIROL, V72, P1131, DOI 10.1128/JVI.72.2.1131-1137.1998; WARNER MW, IN PRESS VIROLOGY; Whitbeck JC, 1997, J VIROL, V71, P6083, DOI 10.1128/JVI.71.8.6083-6093.1997; Willey JC, 1996, AM J RESP CELL MOL, V14, P262, DOI 10.1165/ajrcmb.14.3.8845177	33	742	765	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1618	1620		10.1126/science.280.5369.1618	http://dx.doi.org/10.1126/science.280.5369.1618			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616127				2022-12-28	WOS:000074061200045
J	Jacks, T; Weinberg, RA				Jacks, T; Weinberg, RA			The expanding role of cell cycle regulators	SCIENCE			English	Article							CDK-ACTIVATING KINASE; TRANSCRIPTION FACTOR TFIIH; DNA-REPLICATION; DIFFERENTIATION		MIT, Dept Biol, Cambridge, MA 02142 USA; MIT, Ctr Canc Res, Cambridge, MA 02142 USA; MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute	Jacks, T (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02142 USA.							Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DORER R, 1995, J CELL BIOL, V131, P845, DOI 10.1083/jcb.131.4.845; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FLORESROZAS, 1994, P NATL ACAD SCI US, V91, P8655; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	16	87	91	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1035	1036		10.1126/science.280.5366.1035	http://dx.doi.org/10.1126/science.280.5366.1035			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9616080				2022-12-28	WOS:000073663600034
J	Celentano, DD; Dilorio, C; Hartwell, T; Kelly, J; Magana, R; Maibach, E; O'Leary, A; Pequegnat, W; Rotheram-Borus, MJ; Schilling, R				Celentano, DD; Dilorio, C; Hartwell, T; Kelly, J; Magana, R; Maibach, E; O'Leary, A; Pequegnat, W; Rotheram-Borus, MJ; Schilling, R		NIMH Multisite HIV Prevention Trial Grp	The NIMH multisite HIV prevention trial: Reducing HIV sexual risk behavior	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMISSION; AIDS; MEN	The efficacy of a behavioral intervention to reduce human immunodeficiency virus (HIV) risk behaviors was tested in a randomized, controlled trial with three high-risk populations at 37 clinics from seven sites across the United States. Compared with the 1855 individuals in the control condition, the 1851 participants assigned to a small-group, seven-session HIV risk reduction program reported fewer unprotected sexual acts, had higher levels of condom use, and were more likely to use condoms consistently over a 12-month follow-up period. On the basis of clinical record review, no difference in overall sexually transmitted disease (STD) reinfection rate was found between intervention and control condition participants. However, among men recruited from STD clinics, those assigned to the intervention condition had a gonorrhea incidence rate one-half that of those; in the control condition. Intervention condition participants also reported fewer STD symptoms over the 12-month follow-up period. Study outcomes suggest that behavioral interventions can reduce HIV-related sexual risk behavior among low-income women and men served in public health settings. Studies that test strategies for reducing sexual risk behavior over longer periods of time are needed, especially with populations that remain most vulnerable to HIV infection.	NIMH, NIH, Rockville, MD 20857 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Celentano, DD (corresponding author), NIMH, NIH, Parklawn Bldg,Room 18-101,5600 Fishers Lane, Rockville, MD 20857 USA.		Potter, Jennifer Sharpe/C-6720-2008; Maibach, Edward/A-7102-2009	Potter, Jennifer Sharpe/0000-0002-7250-4422; Hansen, Nellie/0000-0003-4794-9646; Maibach, Edward/0000-0003-3409-9187				*AIDS, AIDS CHANG RUL; *CDC, 1993, MMWR-MORBID MORTAL W, V42, P66; Celentano DD, 1996, JAMA-J AM MED ASSOC, V275, P122, DOI 10.1001/jama.275.2.122; COATES RA, 1988, AM J EPIDEMIOL, V128, P719, DOI 10.1093/oxfordjournals.aje.a115025; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; Diggle PJ, 1994, ANAL LONGITUDINAL DA; ENG TR, 1997, HIDDEN EPIDEMIC CONF; FISHBEIN M, 1997, AIDS S2, V11; GAYLE HD, 1997, INTERVENTIONS PREVEN, P23; HOLTGRAVE DR, 1995, PUBLIC HLTH REP, V110, P133; HOOK EW, 1990, SEXUALLY TRANSMITTED, P149; LYNN WR, 1995, AM J PUBLIC HEALTH, V85, P183; MILLER HG, 1990, AIDS 2 DECADE, P359; MURPHY DA, IN PRESS AIDS BEHAV; *NIH, 1997, CONS DEV PAN REP HIV; PADIAN NS, 1993, J ACQ IMMUN DEF SYND, V6, P1043; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001	17	228	231	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1889	1894		10.1126/science.280.5371.1889	http://dx.doi.org/10.1126/science.280.5371.1889			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632382	Green Submitted			2022-12-28	WOS:000074323800047
J	Essell, JH; Schroeder, MT; Harman, GS; Halvorson, R; Lew, V; Callander, N; Snyder, M; Lewis, SK; Allerton, JP; Thompson, JM				Essell, JH; Schroeder, MT; Harman, GS; Halvorson, R; Lew, V; Callander, N; Snyder, M; Lewis, SK; Allerton, JP; Thompson, JM			Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						ursodeoxycholic acid; bone marrow transplantation; transplantation, homologous; hepatic veno-occlusive disease	PRIMARY BILIARY-CIRRHOSIS; VENO-OCCLUSIVE DISEASE; VERSUS-HOST DISEASE; VENOOCCLUSIVE DISEASE; URSODEOXYCHOLIC ACID; CONTINUOUS INFUSION; BUSULFAN; LIVER; PREVENTION; CYCLOPHOSPHAMIDE	Background: Hepatic complications are a major cause of illness and death after bone marrow transplantation. Objective: To confirm the results of a pilot study that indicated that ursodiol prophylaxis could reduce the incidence of veno-occlusive disease of the liver. Design: Randomized, double-blind, placebo-controlled study. Setting: Tertiary care teaching hospital. Patients: 67 consecutive patients undergoing transplantation with allogeneic bone marrow (donated by a relative) in whom busulfan plus cyclophosphamide was used as the preparative regimen and cyclosporine plus methotrexate was used to prevent graft-versus-host disease. Intervention: Before the preparative regimen was started, patients were randomly assigned to receive ursodiol, 300 mg twice daily (or 300 mg in the morning and 600 mg in the evening if body weight was > 90 kg), or placebo. Measurements: Patients were prospectively evaluated for the clinical diagnosis of veno-occlusive disease, the occurrence of acute graft-versus-host disease, and survival. Results: The incidence of veno-occlusive disease was 40% (13 of 32 patients) in placebo recipients and 15% (5 of 34 patients) in ursodiol recipients (P = 0.03). Assignment to placebo was the only pretransplantation characteristic that predicted the development of veno-occlusive disease. The most significant predictor of 100-day mortality was the diagnosis of veno-occlusive disease. The difference in actuarial risk for hematologic relapse in patients with chronic myelogenous leukemia and nonhepatic toxicities between the two groups was not statistically significant (13% in the ursodiol group and 20% in the placebo group; P > 0.2). Conclusion: Ursodiol prophylaxis seemed to decrease the incidence of hepatic complications after allogeneic bone marrow transplantation in patients who received a preparative regimen with busulfan plus cyclophosphamide.	Oncol Hematol Care Inc, Cincinnati, OH 45219 USA; Wilford Hall USAF Med Ctr, Lackland AFB, TX 78236 USA	United States Department of Defense; United States Air Force	Essell, JH (corresponding author), Oncol Hematol Care Inc, 199 William H Taft Rd, Cincinnati, OH 45219 USA.			Snyder, Michael/0000-0003-0784-7987				ATKINSON K, 1987, BONE MARROW TRANSPL, V2, P385; ATTAL M, 1992, BLOOD, V79, P2834; BACHRACH WH, 1982, DIGEST DIS SCI, V27, P737, DOI 10.1007/BF01393771; BATTA AK, 1989, HEPATOLOGY, V10, P414, DOI 10.1002/hep.1840100404; BEARMAN SI, 1995, BLOOD, V85, P3005, DOI 10.1182/blood.V85.11.3005.bloodjournal85113005; BEARMAN SI, 1988, J CLIN ONCOL, V6, P1562, DOI 10.1200/JCO.1988.6.10.1562; BEARMAN SI, 1993, BRIT J HAEMATOL, V84, P724, DOI 10.1111/j.1365-2141.1993.tb03152.x; BEARMAN SI, 1990, BONE MARROW TRANSPL, V5, P407; Bellentani S, 1996, BIOCHEM BIOPH RES CO, V220, P479, DOI 10.1006/bbrc.1996.0430; CARRERAS E, 1993, ANN HEMATOL, V66, P77, DOI 10.1007/BF01695888; CHRETIEN Y, 1989, GUT, V30, P1110, DOI 10.1136/gut.30.8.1110; CLIFT RA, 1994, BLOOD, V84, P2036, DOI 10.1182/blood.V84.6.2036.2036; COMBES B, 1995, HEPATOLOGY, V22, P759, DOI 10.1016/0270-9139(95)90294-5; DEEG HJ, 1991, BONE MARROW TRANSPL, V7, P193; ESSELL JH, 1992, BONE MARROW TRANSPL, V10, P367; ESSELL JH, 1992, BLOOD, V79, P2784; GLUCKMAN E, 1990, BRIT J HAEMATOL, V74, P277, DOI 10.1111/j.1365-2141.1990.tb02583.x; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; GROCHOW LB, 1989, CANCER CHEMOTH PHARM, V25, P55, DOI 10.1007/BF00694339; GULDUTUNA S, 1993, GASTROENTEROLOGY, V104, P1736; Lindor KD, 1996, GASTROENTEROLOGY, V110, P1515, DOI 10.1053/gast.1996.v110.pm8613058; MATTHEWS DE, 1988, USING UNDERSTANDING; MCDONALD GB, 1984, HEPATOLOGY, V4, P116, DOI 10.1002/hep.1840040121; MEHTA J, 1995, BONE MARROW TRANSPL, V15, P853; PARQUET M, 1985, EUR J CLIN INVEST, V15, P171, DOI 10.1111/j.1365-2362.1985.tb00164.x; PODDA M, 1988, J CLIN GASTROENTEROL, V10, pS25; PODDA M, 1990, GASTROENTEROLOGY, V98, P1044, DOI 10.1016/0016-5085(90)90032-V; PODDA M, 1989, DIGEST DIS SCI, V34, pS59, DOI 10.1007/BF01536665; POUPON RE, 1991, NEW ENGL J MED, V324, P1548, DOI 10.1056/NEJM199105303242204; Raybon K., 1995, Blood, V86, p961A; ROLLINS BJ, 1986, AM J MED, V81, P297, DOI 10.1016/0002-9343(86)90266-4; Rozman C, 1996, BONE MARROW TRANSPL, V17, P75; Schroeder M., 1996, Blood, V88, p259B; SCHROEDER M, 1993, BLOOD, V82, pA425; TUTSCHKA PJ, 1987, BLOOD, V70, P1382; WARD A, 1984, DRUGS, V27, P95, DOI 10.2165/00003495-198427020-00001; 1997, RED BOOK	37	121	125	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				975	+		10.7326/0003-4819-128-12_Part_1-199806150-00002	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625683				2022-12-28	WOS:000074201300002
J	Egger, M; Low, N; Smith, GD; Lindblom, B; Herrmann, B				Egger, M; Low, N; Smith, GD; Lindblom, B; Herrmann, B			Screening for chlamydial infections and the risk of ectopic pregnancy in a county in Sweden: ecological analysis	BRITISH MEDICAL JOURNAL			English	Article							PELVIC INFLAMMATORY DISEASE; SEXUALLY-TRANSMITTED DISEASES; TRACHOMATIS INFECTION; PREVENTION; EPIDEMIOLOGY; PREVALENCE; WISCONSIN; PROGRAM	Objectives: To analyse trends in rates of genital chlamydial infection and ectopic pregnancy between 1985 and 1995 in a county in Sweden. Setting: Uppsala county where screening for chlamydial infection, treatment, and contact tracing has been widespread and where ectopic pregnancies are recorded. Methods: Rates of chlamydial infections and ectopic pregnancy between 1985 and 1995 were calculated for women aged 20-39 years. Poisson and linear regression were used to examine the association between the risk of ectopic pregnancy and the current rates of chlamydial infection and rates of chlamydial infection from up to 5 years earlier. Main outcome measures: Rates of chlamydial infection per 100 examinations, rates of ectopic pregnancy per 1000 pregnancies, rate ratios and 95% confidence intervals for an increase in chlamydial infections of 5 new cases per 100 examinations. Results: 103 870 cervical samples from women aged 15-39 years were analysed; 5648 (5.4%) were positive for chlamydia. 51 630 pregnancies were analysed; 930 (1.8%) were ectopic. Both rates declined over time. For women aged 20-24 years there was a strong correlation between the rate of ectopic pregnancy and the rate of chlamydial infection in the same year (r=0.93, P < 0.001); among older women correlations were stronger with rates of chlamydial infection occurring 1 or 2 years earlier. In Poisson regression ectopic pregnancy was most strongly associated with the current rate of chlamydial infection among women aged 20-24 (rate ratio 1.85, 95% confidence interval 1.44 to 2.38), with the rate of infection 1 year earlier among 25-29 year olds (rate ratio 1.72, 1.33 to 2.22) and 30-34 year olds (rate ratio 2.27, 1.53 to 3.37); and with the rate 2 years earlier among 35 to 39 year olds (rate ratio 2.58, 1.45 to 4.60). Conclusions: Declining rates of genital chlamydial infections have probably led to a fall in the rate of ectopic pregnancies. The timing of the decline in the rate of ectopic pregnancies varies with age. Among young women falling rates of chlamydial infection have been accompanied by an immediate reduction in the rate of ectopic pregnancy.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ London Kings Coll, Sch Med & Dent, Dept Genitourinary Med, London SE5 9RS, England; Univ Uppsala Hosp, Dept Obstet & Gynaecol, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Infect Dis & Clin Microbiol, S-75185 Uppsala, Sweden	University of Bristol; University of London; King's College London; Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital	Egger, M (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	m.egger@bristol.ac.uk	Low, Nicola/H-4718-2019; Davey Smith, George/A-7407-2013	Low, Nicola/0000-0003-4817-8986; Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132				ADDISS DG, 1993, SEX TRANSM DIS, V20, P28, DOI 10.1097/00007435-199301000-00006; CATES W, 1990, EPIDEMIOL REV, V12, P199, DOI 10.1093/oxfordjournals.epirev.a036054; CATES W, 1991, AM J OBSTET GYNECOL, V164, P1771, DOI 10.1016/0002-9378(91)90559-A; CHOW JM, 1990, JAMA-J AM MED ASSOC, V263, P3164, DOI 10.1001/jama.263.23.3164; CHOW WH, 1987, EPIDEMIOL REV, V9, P70, DOI 10.1093/oxfordjournals.epirev.a036309; COSTE J, 1994, FERTIL STERIL, V62, P289; FRANKS AL, 1990, AM J OBSTET GYNECOL, V163, P1120, DOI 10.1016/0002-9378(90)90668-W; HERRMANN B, 1995, SEX TRANSM DIS, V22, P253, DOI 10.1097/00007435-199507000-00009; HILLIS SD, 1995, FAM PLANN PERSPECT, V27, P108, DOI 10.2307/2136107; Johnson AM, 1994, SEXUAL ATTITUDES LIF; Kamwendo F, 1996, SEX TRANSM DIS, V23, P384, DOI 10.1097/00007435-199609000-00007; MARDH PA, 1977, NEW ENGL J MED, V296, P1377, DOI 10.1056/NEJM197706162962403; *NAT BOARD HLTH WE, 1990, AN CHLAM INF PREV ME; Padian Nancy S., 1994, Annals of Epidemiology, V4, P128, DOI 10.1016/1047-2797(94)90058-2; PIANTADOSI S, 1988, AM J EPIDEMIOL, V127, P893, DOI 10.1093/oxfordjournals.aje.a114892; RIPA KT, 1977, J CLIN MICROBIOL, V6, P328; Robinson AJ, 1996, BRIT J OBSTET GYNAEC, V103, P859, DOI 10.1111/j.1471-0528.1996.tb09901.x; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; Skjeldestad FE, 1997, ACTA OBSTET GYN SCAN, V76, P159, DOI 10.3109/00016349709050073; SUSSER M, 1994, AM J PUBLIC HEALTH, V84, P825, DOI 10.2105/AJPH.84.5.825; TAYLORROBINSON D, 1994, BMJ-BRIT MED J, V308, P150, DOI 10.1136/bmj.308.6922.150; WESTROM L, 1980, AM J OBSTET GYNECOL, V138, P880, DOI 10.1016/0002-9378(80)91077-7; XIONG X, 1995, CONTRACEPTION, V52, P23, DOI 10.1016/0010-7824(95)00120-Y	23	147	157	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1776	1780		10.1136/bmj.316.7147.1776	http://dx.doi.org/10.1136/bmj.316.7147.1776			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624063	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000074286300023
J	Harrington, C; Pollock, AM				Harrington, C; Pollock, AM			Decentralisation and privatisation of long-term care in UK and USA	LANCET			English	Editorial Material							STATE		Univ Calif San Francisco, Dept Social & Behav Sci, San Francisco, CA 94143 USA; St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England	University of California System; University of California San Francisco; St Georges University London	Pollock, AM (corresponding author), Univ Calif San Francisco, Dept Social & Behav Sci, San Francisco, CA 94143 USA.			pollock, allyson/0000-0002-7388-3110				*AARP PUBL POL I, 1992, ACC FED PUBL BEN PRO; *AM HOSP ASS, 1996, HOSP STAT ANN STAT 1; Audit Commission, 1986, MAK REAL COMM CAR; BEDNEY B, 1996, 1995 STAT DAT BOOK L; *CA ADV NURS HOM R, 1995, IS YOU THINK YOU NEE; CROWN W, 1994, ANAL ASSET TESTING N; *DEP HLTH, 1995, LOC AUTH PERS SOC SE; *DEP HLTH, 1996, STAT B DEP HLTH; *DEP HLTH, 1996, LOC AUTH PERS SOC SE; *DEP HLTH COMM CAR, 1996, STAT B DEP HLTH COMM; HARRINGTON C, 1986, GERONTOLOGIST, V26, P437, DOI 10.1093/geront/26.4.437; Harrington C, 1996, J APPL GERONTOL, V15, P414, DOI 10.1177/073346489601500402; HARRINGTON C, 1996, NURSING FACILITIES S; HARRINGTON C, 1997, J APPL GERONTOL, V16, P53; HARRIS J, 1987, J MED ETHICS, V13, P117, DOI 10.1136/jme.13.3.117; *HCIA, 1995, 1995 GUID NURS HOM I; HENWOOD M, 1994, FITE CHANGE SNAPSHOT; *HLTH COMM HOUS CO, 1996, LONG TERM CAR FUT PR, V1; HOLAHAN J, 1987, MILBANK Q, V65, P112, DOI 10.2307/3350015; Leicester MC, 1996, PUBLIC HEALTH, V110, P109, DOI 10.1016/S0033-3506(96)80056-4; Levit KR, 1996, HEALTH CARE FINANC R, V18, P175; MANGAN T, 1994, RESIDENTIAL SERVICES; MECHANIC D, 1992, HEALTH AFFAIR, V11, P128, DOI 10.1377/hlthaff.11.1.128; *U CA, 1994, REP HLTH CAR FIN ADM; *US DEP COMM, 1996, STAT ABSTR US 1995; WALSH M, 1995, FORBES, V55, P180; WEINER JM, 1996, SPENDING DOWN MEDICA; 1996, LAINGS REV PRIVATE H; 1988, COMMUNITY CARE AGEND; 1989, CARING PEOPLE WHITE	30	17	17	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1805	1808		10.1016/S0140-6736(97)09039-9	http://dx.doi.org/10.1016/S0140-6736(97)09039-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZU444	9635970				2022-12-28	WOS:000074197600046
J	Kaplan, N				Kaplan, N			J-curve not burned off by HOT study	LANCET			English	Editorial Material							BLOOD-PRESSURE; MYOCARDIAL-INFARCTION		Univ Texas, SW Med Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kaplan, N (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; FLACK JM, 1995, CIRCULATION, V92, P2437, DOI 10.1161/01.CIR.92.9.2437; FLETCHER AE, 1992, NEW ENGL J MED, V326, P251; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; Wiklund Ingela, 1997, Blood Pressure, V6, P357, DOI 10.3109/08037059709062095	7	48	48	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1748	1749		10.1016/S0140-6736(98)22024-1	http://dx.doi.org/10.1016/S0140-6736(98)22024-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635941				2022-12-28	WOS:000074197600002
J	Smith, C				Smith, C			Medical academic staffs conference	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1834	1835						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624096				2022-12-28	WOS:000074286300075
J	Ludwig, A; Zong, XG; Jeglitsch, M; Hofmann, F; Biel, M				Ludwig, A; Zong, XG; Jeglitsch, M; Hofmann, F; Biel, M			A family of hyperpolarization-activated mammalian cation channels	NATURE			English	Article							THALAMIC RELAY NEURONS; VOLTAGE-CLAMP ANALYSIS; CYCLIC-AMP; SINOATRIAL NODE; PROTEIN-KINASE; MODULATION; I(F); SEQUENCE; SUBUNIT; HEART	Pacemaker activity of spontaneously active neurons(1-3) and heart cells(4-6) is controlled by a depolarizing, mixed Na+/K+ current, named I-h (or I-f in the sinoatrial node of the heart)(1,4). This current is activated on hyperpolarization of the plasma membrane. In addition to depolarizing pacemaker cells, I-h is involved in determining the resting membrane potential of neurons(1,2) and provides a mechanism to limit hyperpolarizing currents in these cells(7-9). Hormones and neurotransmitters that induce a rise in cyclic AMP levels increase I-h by a mechanism that is independent of protein phosphorylation, and which involves direct binding of the cyclic nucleotide to the channel that mediates I-h(10-13). Here we report the molecular cloning and functional expression of the gene encoding a hyperpolarization-activated cation channel (HAC1) that is present in brain and heart. This channel exhibits the general properties of I-h channels. We have also identified full-length sequences of two related channels, HAC2 and HAC3, that are specifically expressed in the brain, indicating the existence of a family of hyperpolarization-activated cation channels.	Tech Univ Munchen, Inst Pharmakol & Toxikol, D-80802 Munchen, Germany	Technical University of Munich	Biel, M (corresponding author), Tech Univ Munchen, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munchen, Germany.		Biel, Martin/G-1175-2014	Biel, Martin/0000-0002-9974-3052				Baker K, 1997, P NATL ACAD SCI USA, V94, P4554, DOI 10.1073/pnas.94.9.4554; BAYLISS DA, 1994, J NEUROPHYSIOL, V71, P119, DOI 10.1152/jn.1994.71.1.119; Biel M, 1996, J BIOL CHEM, V271, P6349, DOI 10.1074/jbc.271.11.6349; BIEL M, 1994, P NATL ACAD SCI USA, V91, P3505, DOI 10.1073/pnas.91.9.3505; BROWN HF, 1979, NATURE, V280, P235, DOI 10.1038/280235a0; DIFRANCESCO D, 1994, J PHYSIOL-LONDON, V474, P473, DOI 10.1113/jphysiol.1994.sp020038; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DIFRANCESCO D, 1981, J PHYSIOL-LONDON, V314, P359, DOI 10.1113/jphysiol.1981.sp013713; HALLIWELL JV, 1982, BRAIN RES, V250, P71, DOI 10.1016/0006-8993(82)90954-4; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Hille B., 1992, IONIC CHANNELS EXCIT; HO WK, 1994, PFLUG ARCH EUR J PHY, V426, P68, DOI 10.1007/BF00374672; Ludwig A, 1997, J NEUROSCI, V17, P1339; MAYER ML, 1983, J PHYSIOL-LONDON, V340, P19, DOI 10.1113/jphysiol.1983.sp014747; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P319, DOI 10.1113/jphysiol.1990.sp018332; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; PAPE HC, 1989, NATURE, V340, P715, DOI 10.1038/340715a0; PAPE HC, 1992, NEURON, V9, P441, DOI 10.1016/0896-6273(92)90182-D; PEDARZANI P, 1995, P NATL ACAD SCI USA, V92, P11716, DOI 10.1073/pnas.92.25.11716; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; SOLOMON JS, 1993, J PHYSIOL-LONDON, V462, P393, DOI 10.1113/jphysiol.1993.sp019561; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; YU HG, 1995, J PHYSIOL-LONDON, V485, P469, DOI 10.1113/jphysiol.1995.sp020743; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	28	750	792	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1998	393	6685					587	591		10.1038/31255	http://dx.doi.org/10.1038/31255			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634236				2022-12-28	WOS:000074150100055
J	Poloniecki, J				Poloniecki, J			Half of all doctors are below average	BRITISH MEDICAL JOURNAL			English	Article									Univ London St Georges Hosp, Sch Med, London SW17 0RE, England	St Georges University London	Poloniecki, J (corresponding author), Univ London St Georges Hosp, Sch Med, London SW17 0RE, England.							*BRIST HEALTHC TRU, 1997, IND REV AD CARD SURG, P1; DOBSON R, 1997, INDEPENDENT SUN 1116, P12; Dyer C, 1998, BRIT MED J, V316, P646; Dyer C, 1997, BRIT MED J, V315, P1177; Neoptolemos JP, 1997, BRIT J SURG, V84, P1370; PARSONNET V, 1989, CIRCULATION, V79, P3; Poloniecki J, 1998, BRIT MED J, V316, P1697, DOI 10.1136/bmj.316.7146.1697; TODD CJ, 1995, BRIT MED J, V310, P904, DOI 10.1136/bmj.310.6984.904	8	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1734	1736		10.1136/bmj.316.7146.1734	http://dx.doi.org/10.1136/bmj.316.7146.1734			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614030	Green Published			2022-12-28	WOS:000074129500035
J	Rennie, D				Rennie, D			Dealing with research misconduct in the United Kingdom - An American perspective on research integrity	BRITISH MEDICAL JOURNAL			English	Article									Inst Hlth Policy Studies, San Francisco, CA 94109 USA		Rennie, D (corresponding author), Inst Hlth Policy Studies, San Francisco, CA 94109 USA.							Broad W., 1982, BETRAYERS TRUTH; *COMM RES INT, 1995, INT MISC RES REP COM; Gunsalus CK, 1998, SCI ENG ETHICS, V4, P75, DOI 10.1007/s11948-998-0010-5; *NAT AC SCI, 1993, RESP SCI ENS INT RES, V2; Parrish DM, 1997, JAMA-J AM MED ASSOC, V277, P1315; RELMAN AS, 1983, NEW ENGL J MED, V308, P1415, DOI 10.1056/NEJM198306093082311; RENNIE D, 1993, JAMA-J AM MED ASSOC, V269, P915, DOI 10.1001/jama.269.7.915; RENNIE D, 1993, JAMA-J AM MED ASSOC, V270, P495; Youngner JS, 1998, JAMA-J AM MED ASSOC, V279, P62, DOI 10.1001/jama.279.1.62	9	23	23	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1726	1728		10.1136/bmj.316.7146.1726	http://dx.doi.org/10.1136/bmj.316.7146.1726			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614029	Green Published			2022-12-28	WOS:000074129500029
J	Darlington, TK; Wager-Smith, K; Ceriani, MF; Staknis, D; Gekakis, N; Steeves, TDL; Weitz, CJ; Takahashi, JS; Kay, SA				Darlington, TK; Wager-Smith, K; Ceriani, MF; Staknis, D; Gekakis, N; Steeves, TDL; Weitz, CJ; Takahashi, JS; Kay, SA			Closing the circadian loop: CLOCK-induced transcription of its own inhibitors per and tim	SCIENCE			English	Article							DROSOPHILA PERIOD PROTEIN; NUCLEAR ENTRY; IDENTIFICATION; COMPONENT; RECEPTOR; TIMELESS; SYSTEM; ARNT; DNA	The circadian oscillator generates a rhythmic output with a period of about 24 hours. Despite extensive studies in several model systems, the biochemical mode of action has not yet been demonstrated for any of its components. Here, the Drosophila CLOCK protein was shown to induce transcription of the circadian rhythm genes period and timeless. dCLOCK functioned as a heterodimer with a Drosophila homolog of BMAL1. These proteins acted through an E-box sequence in the period promoter. The timeless promoter contains an 18-base pair element encompassing an E-box, which was sufficient to confer dCLOCK responsiveness to a reporter gene. PERIOD and TIMELESS proteins blocked dCLOCK's ability to transactivate their promoters via the E-box. Thus, dCLOCK drives expression of period and timeless, which in turn inhibit dCLOCK's activity and close the circadian loop.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92093 USA; Scripps Res Inst, NSF, Ctr Biol Timing, La Jolla, CA 92093 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Northwestern Univ, NSF,Ctr Biol Timing, Howard Hughes Med Inst, Dept Neurobiol & Physiol, Evanston, IL 60208 USA	Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Scripps Research Institute; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University	Kay, SA (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92093 USA.		Takahashi, Joseph S/E-8482-2012; Kay, Steve A/F-6025-2011; Jansen, Heiko T./A-5770-2008; Takahashi, Joseph S./Y-2781-2019	Takahashi, Joseph S/0000-0003-0384-8878; Kay, Steve A/0000-0002-0402-2878; Jansen, Heiko T./0000-0003-0178-396X; Takahashi, Joseph S./0000-0003-0384-8878; Ceriani, Maria/0000-0001-8945-3070	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051573] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-51573] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ASHBURNER M, 1989, DROSOPHILA LAB HDB, P33; Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; DARLINGTON T, UNPUB; Dembinska ME, 1997, J BIOL RHYTHM, V12, P157, DOI 10.1177/074873049701200207; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; King DP, 1997, GENETICS, V146, P1049; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Park J.C., UNPUB; PELLEQUER JL, IN PRESS P NATL ACAD; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Rosato E, 1997, BIOESSAYS, V19, P1075, DOI 10.1002/bies.950191206; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; SIKORSKI RS, 1989, GENETICS, V122, P19; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; Stanewsky R, 1997, EMBO J, V16, P5006, DOI 10.1093/emboj/16.16.5006; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713	32	669	689	1	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1599	1603		10.1126/science.280.5369.1599	http://dx.doi.org/10.1126/science.280.5369.1599			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616122				2022-12-28	WOS:000074061200040
J	Nan, XS; Ng, HH; Johnson, CA; Laherty, CD; Turner, BM; Eisenman, RN; Bird, A				Nan, XS; Ng, HH; Johnson, CA; Laherty, CD; Turner, BM; Eisenman, RN; Bird, A			Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex	NATURE			English	Article							CHROMATIN STRUCTURE; DNA METHYLATION; CHROMOSOMAL PROTEIN; ACETYLATION; CELLS; MOUSE	Cytosine residues in the sequence 5'CpG (cytosine-guanine) are often postsynthetically methylated in animal genomes. CpG methylation is involved in long-term silencing of certain genes during mammalian development(1,2) and in repression of viral genomes(3,4). The methyl-CpG-binding proteins MeCP1 (ref. 5) and MeCP2 (ref. 6) interact specifically with methylated DNA and mediate transcriptional repression(7-9). Here we study the mechanism of repression by MeCP2, an abundant nuclear protein that is essential for mouse embryogenesis(10). MeCP2 binds tightly to chromosomes in a methylation-dependent manner(11,12). It contains a transcriptional-repression domain (TRD) that can GRAPHICS function at a distance in vitro and in vivo(9). We show that a region of MeCP2 that localizes with the TRD associates with a corepressor complex containing the transcriptional repressor mSin3A and histone deacetylases(13-19). Transcriptional repression in vivo is relieved by the deacetylase inhibitor trichostatin A(20), indicating that deacetylation of histones (and/or of other proteins) is an essential component of this repression mechanism. The data suggest that two global mechanisms of gene regulation, DNA methylation and histone deacetylation, can be linked by MeCP2.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Birmingham, Sch Med, Dept Anat, Birmingham B15 2TT, W Midlands, England; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA	University of Edinburgh; University of Birmingham; Fred Hutchinson Cancer Center	Bird, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.	A.Bird@ed.ac.uk	Ng, Huck Hui/A-1135-2009	Nan, Xinsheng/0000-0002-0865-7934; Bird, Adrian/0000-0002-8600-0372; Johnson, Colin/0000-0002-2979-8234	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; Chen ZJ, 1997, GENE DEV, V11, P2124, DOI 10.1101/gad.11.16.2124; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GROUDINE M, 1981, NATURE, V292, P311, DOI 10.1038/292311a0; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; LAHERTY CD, 1997, CELL, V89, P849; LEWIS J, 1991, FEBS LETT, V285, P155, DOI 10.1016/0014-5793(91)80795-5; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Li W, 1996, BIOCHEM J, V314, P631, DOI 10.1042/bj3140631; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1996, MOL CELL BIOL, V16, P414; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Tate P, 1996, NAT GENET, V12, P205, DOI 10.1038/ng0296-205; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	30	2606	2713	5	184	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1998	393	6683					386	389		10.1038/30764	http://dx.doi.org/10.1038/30764			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620804				2022-12-28	WOS:000073883600059
J	Ropper, AH; Gorson, KC				Ropper, AH; Gorson, KC			Current concepts - Neuropathies associated with paraproteinemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MYELIN-ASSOCIATED GLYCOPROTEIN; PLASMA-CELL DYSCRASIA; IGM MONOCLONAL GAMMOPATHY; CHONDROITIN SULFATE-C; PERIPHERAL NEUROPATHY; UNDETERMINED SIGNIFICANCE; POEMS-SYNDROME; ANTI-MAG; AXONAL POLYNEUROPATHY; AL AMYLOIDOSIS		St Elizabeth Hosp, Div Neurol, Neurol Serv, Boston, MA 02135 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Tufts University	Gorson, KC (corresponding author), St Elizabeth Hosp, Div Neurol, Neurol Serv, 736 Cambridge St, Boston, MA 02135 USA.		Gorson, Kenneth/K-7778-2019					BARDWICK PA, 1980, MEDICINE, V59, P311, DOI 10.1097/00005792-198007000-00006; Bataille R, 1997, NEW ENGL J MED, V336, P1657, DOI 10.1056/NEJM199706053362307; BLUME G, 1995, NEUROLOGY, V45, P1577, DOI 10.1212/WNL.45.8.1577; Comenzo RL, 1996, BLOOD, V88, P2801, DOI 10.1182/blood.V88.7.2801.bloodjournal8872801; DALAKAS MC, 1983, NEUROLOGY, V33, P1406, DOI 10.1212/WNL.33.11.1406; Dalakas MC, 1996, ANN NEUROL, V40, P792, DOI 10.1002/ana.410400516; DUSTON MA, 1989, ARCH INTERN MED, V149, P358, DOI 10.1001/archinte.149.2.358; DYCK PJ, 1991, NEW ENGL J MED, V325, P1482, DOI 10.1056/NEJM199111213252105; Ellie E, 1996, J NEUROL, V243, P34; Falk RH, 1997, NEW ENGL J MED, V337, P898, DOI 10.1056/NEJM199709253371306; GARCIABRAGADO F, 1988, ARCH NEUROL-CHICAGO, V45, P1210, DOI 10.1001/archneur.1988.00520350048015; GARCIN R, 1960, Sang, V31, P441; Gherardi RK, 1996, BLOOD, V87, P1458, DOI 10.1182/blood.V87.4.1458.bloodjournal8741458; Gordon PH, 1997, NEUROLOGY, V48, P1671, DOI 10.1212/WNL.48.6.1671; Gorson KC, 1997, NEUROLOGY, V48, P321, DOI 10.1212/WNL.48.2.321; Gorson KC, 1997, J NEUROL NEUROSUR PS, V63, P163, DOI 10.1136/jnnp.63.2.163; GOSSELIN S, 1991, ANN NEUROL, V30, P54, DOI 10.1002/ana.410300111; Hartung HP, 1996, SPRINGER SEMIN IMMUN, V18, P97, DOI 10.1007/BF00792612; HAYS AP, 1987, NEUROLOGY, V37, P242, DOI 10.1212/WNL.37.2.242; JACOBS JM, 1993, ATLAS CLIN NEUROLOGY; KELLY JJ, 1979, ANN NEUROL, V6, P1, DOI 10.1002/ana.410060102; KELLY JJ, 1981, NEUROLOGY, V31, P24, DOI 10.1212/WNL.31.1.24; KELLY JJ, 1983, NEUROLOGY, V33, P202, DOI 10.1212/WNL.33.2.202; KELLY JJ, 1981, NEUROLOGY, V31, P1480, DOI 10.1212/WNL.31.11.1480; KHELLA SL, 1995, NEUROLOGY, V45, P407, DOI 10.1212/WNL.45.3.407; Kissel JT, 1996, NEUROMUSCULAR DISORD, V6, P3, DOI 10.1016/0960-8966(95)00021-6; Kyle RA, 1997, NEW ENGL J MED, V336, P1202, DOI 10.1056/NEJM199704243361702; Kyle RA, 1993, PERIPHERAL NEUROPATH, P1275; LATOV N, 1988, CRIT REV NEUROBIOL, V3, P301; LAVENSTEIN B, 1979, NEUROLOGY, V29, P611; Mariette X, 1997, J NEUROL NEUROSUR PS, V63, P28, DOI 10.1136/jnnp.63.1.28; MCLEOD JG, 1984, PERIPHERAL NEUROPATH, V2, P1847; MENDELL JR, 1985, ANN NEUROL, V17, P243, DOI 10.1002/ana.410170305; MIRALLES GD, 1992, NEW ENGL J MED, V327, P1919, DOI 10.1056/NEJM199212313272705; NEMNI R, 1993, J NEUROIMMUNOL, V43, P79, DOI 10.1016/0165-5728(93)90077-C; NOBILEORAZIO E, 1994, ANN NEUROL, V36, P416, DOI 10.1002/ana.410360313; NOTERMANS NC, 1994, BRAIN, V117, P1385, DOI 10.1093/brain/117.6.1385; Notermans NC, 1996, NEUROLOGY, V47, P1227, DOI 10.1212/WNL.47.5.1227; Notermans NC, 1996, BRAIN, V119, P421, DOI 10.1093/brain/119.2.421; OKSENHENDLER E, 1995, J NEUROL NEUROSUR PS, V59, P243, DOI 10.1136/jnnp.59.3.243; PESTRONK A, 1988, ANN NEUROL, V24, P73, DOI 10.1002/ana.410240113; SADIQ SA, 1990, NEUROLOGY, V40, P1067, DOI 10.1212/WNL.40.7.1067; SHERMAN WH, 1984, J NEUROL NEUROSUR PS, V47, P813, DOI 10.1136/jnnp.47.8.813; SHERMAN WH, 1983, NEUROLOGY, V33, P192, DOI 10.1212/WNL.33.2.192; SIMMONS Z, 1993, NEUROLOGY, V43, P2202, DOI 10.1212/WNL.43.11.2202; Simovic D, 1998, ACTA NEUROL SCAND, V97, P194; SOUBRIER MJ, 1994, AM J MED, V97, P543, DOI 10.1016/0002-9343(94)90350-6; SUAREZ GA, 1993, NEUROLOGY, V43, P1304, DOI 10.1212/WNL.43.7.1304; TATUM AH, 1993, ANN NEUROL, V33, P502, DOI 10.1002/ana.410330514; Vallat JM, 1996, J NEUROL SCI, V137, P124, DOI 10.1016/0022-510X(95)00343-Z; vandenBerg LH, 1996, MUSCLE NERVE, V19, P637, DOI 10.1002/(SICI)1097-4598(199605)19:5<637::AID-MUS12>3.0.CO;2-K; VICTOR M, 1958, J NEUROL NEUROSUR PS, V21, P73, DOI 10.1136/jnnp.21.2.73; VRETHEM M, 1993, J NEUROL SCI, V114, P193, DOI 10.1016/0022-510X(93)90297-C; Weinstein R, 1993, J Clin Apher, V8, P72, DOI 10.1002/jca.2920080204; YEUNG KB, 1991, J NEUROL, V238, P383, DOI 10.1007/BF00319857; YOUNGER DS, 1990, NEUROLOGY, V40, P595, DOI 10.1212/WNL.40.4.595	56	173	181	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1998	338	22					1601	1607		10.1056/NEJM199805283382207	http://dx.doi.org/10.1056/NEJM199805283382207			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ350	9603799				2022-12-28	WOS:000073852400007
J	Conradt, B; Horvitz, HR				Conradt, B; Horvitz, HR			The C-elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; APOPTOSIS; SEQUENCE; BAX; SURVIVAL; GENETICS; ENCODES; DOMAIN; ACTIVATION; INHIBITION	Gain-of-function mutations in the Caenorhabditis elegans gene egl-1 cause the HSN neurons to undergo programmed cell death. By contrast, a loss-of-function egl-1 mutation prevents most if not all somatic programmed cell deaths. The egl-1 gene negatively regulates the ced-9 gene, which protects against cell death and is a member of the bcl-2 family. The EGL-1 protein contains a nine amino acid region similar to the Bcl-2 homology region 3 (BH3) domain but does not contain a BH1, BH2, or BH4 domain, suggesting that EGL-1 may be a member of a family of cell death activators that includes the mammalian proteins Bik, Bid, Harakiri, and Bad. The EGL-1 and CED-9 proteins interact physically. We propose that EGL-1 activates programmed cell death by binding to and directly inhibiting the activity of CED-9, perhaps by releasing the cell death activator CED-4 from a CED-9/CED-4-containing protein complex.	MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Horvitz, HR (corresponding author), MIT, Dept Biol, Howard Hughes Med Inst, 68-425,77 Massachusetts Ave, Cambridge, MA 02139 USA.		Conradt, Barbara/K-2665-2014	Conradt, Barbara/0000-0002-3731-4308				Anderson P, 1995, METHOD CELL BIOL, V48, P31; Bai C, 1996, METHOD ENZYMOL, V273, P331; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; BOYD JM, 1995, ONCOGENE, V11, P1921; BRENNER S, 1974, GENETICS, V77, P71; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; DELONG L, 1993, GENETICS, V133, P875; DESAI C, 1989, GENETICS, V121, P703; Diaz JL, 1997, J BIOL CHEM, V272, P11350; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, DEVELOPMENT, V112, P591; ELLIS RE, 1991, GENETICS, V129, P79; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Jacobson MD, 1997, TRENDS CELL BIOL, V7, P467, DOI 10.1016/S0962-8924(97)01182-3; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Mello C, 1995, METHOD CELL BIOL, V48, P451; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Ottilie S, 1997, CELL DEATH DIFFER, V4, P526, DOI 10.1038/sj.cdd.4400288; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Riddle DL, 1997, C ELEGANS; Rinkenberger JL, 1997, CURR OPIN GENET DEV, V7, P589, DOI 10.1016/S0959-437X(97)80004-4; Rose MD., 1990, METHODS YEAST GENETI; RUVKUN G, 1989, GENETICS, V121, P501; Sambrook J., 2002, MOL CLONING LAB MANU; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TRENT C, 1983, GENETICS, V104, P619; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS BD, 1992, GENETICS, V131, P609; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; ZHOU H, 1997, CELL, V90, P405; Zhu JW, 1997, GENE DEV, V11, P2883, DOI 10.1101/gad.11.21.2883	63	481	500	0	35	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					519	529		10.1016/S0092-8674(00)81182-4	http://dx.doi.org/10.1016/S0092-8674(00)81182-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604928	Bronze			2022-12-28	WOS:000073722200006
J	Mactier, H; Galea, P; McWilliam, R				Mactier, H; Galea, P; McWilliam, R			Lesson of the week - Acute obstructive hydrocephalus complicating bacterial meningitis in childhood	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRESSURE		Royal Hosp Sick Children, Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland; Royal Hosp Sick Children, Fraser Allander Unit, Glasgow G3 8SJ, Lanark, Scotland	University of Glasgow; University of Glasgow	Mactier, H (corresponding author), Royal Hosp Sick Children, Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland.							ADAMS R D, 1948, Arch Pediatr, V65, P408; CAMPBELL AGM, 1992, FORFAR ARNEILS TXB P, P1345; GEISELER PJ, 1982, SOUTHERN MED J, V75, P448, DOI 10.1097/00007611-198204000-00018; GOITEIN KJ, 1983, J PEDIATR-US, V103, P40, DOI 10.1016/S0022-3476(83)80772-0; HEYDERMAN RS, 1992, DEV MED CHILD NEUROL, V34, P870; HORWITZ SJ, 1980, ANN NEUROL, V7, P524, DOI 10.1002/ana.410070605; MCWILLIAM R, 1985, LANCET, V2, P341; ODIO CM, 1991, NEW ENGL J MED, V324, P1525, DOI 10.1056/NEJM199105303242201; POLPE IK, 1995, PEDIATR NEUROSURG, V23, P64; Roos Karen L., 1997, P335; SAEZLLORENS X, 1990, J PEDIATR-US, V116, P671, DOI 10.1016/S0022-3476(05)82647-2; Smith AL, 1982, HAEMOPHILUS INFLUENZ, P89; SNYDER RD, 1984, NEUROPEDIATRICS, V15, P136, DOI 10.1055/s-2008-1052356; STEPHENSON JBP, 1985, BRIT MED J, V291, P1123, DOI 10.1136/bmj.291.6502.1123-b; WALTON JN, 1977, BRAINS DIS NERVOUS S, P121	15	26	27	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 20	1998	316	7148					1887	1889						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632412	Green Published			2022-12-28	WOS:000074686500029
J	Katoh-Fukui, Y; Tsuchiya, R; Shiroishi, T; Nakahara, Y; Hashimoto, N; Noguchi, K; Higashinakagawa, T				Katoh-Fukui, Y; Tsuchiya, R; Shiroishi, T; Nakahara, Y; Hashimoto, N; Noguchi, K; Higashinakagawa, T			Male-to-female sex reversal in M33 mutant mice	NATURE			English	Article							SRY-RELATED GENE; Y-CHROMOSOME; CAMPOMELIC DYSPLASIA; POLYCOMB PROTEIN; DROSOPHILA; MOUSE; EXPRESSION; DIFFERENTIATION; MUTATIONS; EMBRYOS	Polycomb genes in Drosophila maintain the repressed state of homeotic and other developmentally regulated genes(1-4) by mediating changes in higher-order chromatin structure(5-7). M33, a mouse homologue of Polycomb, was isolated by means of the structural similarity of its chromodomain(8). The fifth exon of M33 contains a region of homology shared by Drosophila and Xenopus(8,9). In Drosophila, its deletion results in the loss of Polycomb function(10). Here we have disrupted M33 in mice by inserting a poly(A) capture-type neo(r) targeting vector into its fifth exon. More than half of the resultant M33(cterm)/M33(cterm) mutant mice died before weaning, and survivors showed male-to-female sex reversal. Formation of genital ridges was retarded in both XX and XY M33(cterm)/M33(cterm) embryos. Gonadal growth defects appeared near the time of expression of the Y-chromosome-specific Sry gene(11), suggesting that M33 deficiency may cause sex reversal by interfering with steps upstream of Sry. M33(cterm)\M33(cterm) mice may be a valuable model in which to test opposing views regarding sex determination.	Mitsubishi Kasei Inst Life Sci, Tokyo 1948511, Japan; Natl Inst Genet, Mammalian Genet Lab, Shizuoka 4118540, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Katoh-Fukui, Y (corresponding author), Mitsubishi Kasei Inst Life Sci, Tokyo 1948511, Japan.	kan@libra.ls.m-kagaku.co.jp	Katoh-Fukui, Yuko/Y-5383-2019	Katoh-Fukui, Yuko/0000-0001-6858-3693				Akasaka T, 1996, DEVELOPMENT, V122, P1513; BEACHY PA, 1985, NATURE, V313, P545, DOI 10.1038/313545a0; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; Burgoyne P.S., 1991, Seminars in Developmental Biology, V2, P277; CATTANACH BM, 1987, ANN NY ACAD SCI, V513, P27, DOI 10.1111/j.1749-6632.1987.tb24996.x; Core N, 1997, DEVELOPMENT, V124, P721; EICHER EM, 1983, J EXP ZOOL, V228, P297, DOI 10.1002/jez.1402280213; EICHER EM, 1982, SCIENCE, V217, P535, DOI 10.1126/science.7089579; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HACKER A, 1995, DEVELOPMENT, V121, P1603; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KUZIORA MA, 1988, EMBO J, V7, P3233, DOI 10.1002/j.1460-2075.1988.tb03190.x; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MITTWOCH U, 1989, J THEOR BIOL, V137, P445, DOI 10.1016/S0022-5193(89)80039-6; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; NAGAMINE CM, 1992, MAMM GENOME, V3, P84, DOI 10.1007/BF00431251; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PEARCE JJH, 1992, DEVELOPMENT, V114, P921; REIJNEN MJ, 1995, MECH DEVELOP, V53, P35, DOI 10.1016/0925-4773(95)00422-X; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Takihara Y, 1997, DEVELOPMENT, V124, P3673; Uchida K, 1996, MAMM GENOME, V7, P481, DOI 10.1007/s003359900147; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WEDEEN C, 1986, CELL, V44, P739, DOI 10.1016/0092-8674(86)90840-8; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0	30	233	241	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1998	393	6686					688	692		10.1038/31482	http://dx.doi.org/10.1038/31482			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641679				2022-12-28	WOS:000074289600054
J	Froelicher, VF; Lehmann, KG; Thomas, R; Goldman, S; Morrison, D; Edson, R; Lavori, P; Myers, J; Dennis, C; Shabetai, R; Do, D; Froning, J				Froelicher, VF; Lehmann, KG; Thomas, R; Goldman, S; Morrison, D; Edson, R; Lavori, P; Myers, J; Dennis, C; Shabetai, R; Do, D; Froning, J		Vet Affairs Cooperative Study Hlth Services 01	The electrocardiographic exercise test in a population with reduced workup bias: Diagnostic performance, computerized interpretation, and multivariable prediction	ANNALS OF INTERNAL MEDICINE			English	Article						exercise test; coronary angiography; sensitivity and specificity; coronary disease; image processing, computer assisted	CORONARY-ARTERY DISEASE; ST-SEGMENT DEPRESSION; PREVIOUS MYOCARDIAL-INFARCTION; AMERICAN-HEART-ASSOCIATION; TREADMILL SCORE; RATE ADJUSTMENT; RATE INDEX; ACCURACY; MEN; STANDARDS	Background: Empirical scores, computerized ST-segment measurements, and equations have been proposed as tools for improving the diagnostic performance of the exercise test. Objective: To compare the diagnostic utility of these scores, measurements, and equations with that of visual ST-segment measurements in patients with reduced workup bias. Design: Prospective analysis. Setting: 12 university-affiliated Veterans Affairs Medical Centers. Patients: 814 consecutive patients who presented with angina pectoris and agreed to undergo both exercise testing and coronary angiography. Measurements: Digital electrocardiographic recorders and angiographic calipers were used for testing at each site, and test results were sent to core laboratories. Results: Although 25% of patients had previously had testing, workup bias was reduced, as shown by comparison with a pilot study group. This reduction resulted in a sensitivity of 45% and a specificity of 85% for visual analysis. Computerized measurements and visual analysis had similar diagnostic power. Equations incorporating nonelectrocardiographic variables and either visual or computerized ST-segment measurement had similar discrimination and were superior to single ST-segment measurements. These equations correctly classified 5 more patients of every 100 tested (areas under the receiver-operating characteristic curve, 0.80 for equations and 0.68 for visual analysis; P < 0.001) in this population with a 50% prevalence of disease. Conclusions: Standard exercise tests had lower sensitivity but higher specificity in this population with reduced work-up bias than in previous studies. Computerized ST-segment measurements were similar to visual ST-segment measurements made by cardiologists. Considering more than ST-segment measurements can enhance the diagnostic power of the exercise test.	Palo Alto Vet Affairs Hlth Care Syst, Cardiol Div 111C, Palo Alto, CA 94304 USA		Froelicher, VF (corresponding author), Palo Alto Vet Affairs Hlth Care Syst, Cardiol Div 111C, 3801 Miranda Ave, Palo Alto, CA 94304 USA.			Froelicher, Victor/0000-0001-8831-4853				ASCOOP CA, 1977, BRIT HEART J, V39, P212; BERMAN JA, 1983, AM HEART J, V105, P60, DOI 10.1016/0002-8703(83)90279-X; BOBBIO M, 1991, CIRCULATION, V84, P1410, DOI 10.1161/01.CIR.84.3.1410; DECKERS JW, 1989, BRIT HEART J, V62, P438; DelCampo J, 1996, ANN NONINVAS ELECTRO, V1, P430; DETRANO R, 1987, J AM COLL CARDIOL, V10, P794, DOI 10.1016/S0735-1097(87)80272-3; DETRANO R, 1986, J AM COLL CARDIOL, V8, P836, DOI 10.1016/S0735-1097(86)80425-9; DETRY JMR, 1985, EUR HEART J, V6, P227, DOI 10.1093/oxfordjournals.eurheartj.a061846; Do D, 1997, CHEST, V111, P1742, DOI 10.1378/chest.111.6.1742; FLETCHER GF, 1995, CIRCULATION, V91, P580, DOI 10.1161/01.CIR.91.2.580; FLETCHER GF, 1990, CIRCULATION, V82, P2286, DOI 10.1161/01.CIR.82.6.2286; FROELICHER VF, 1993, EXERCISE HEART, P48; FRONING JN, 1988, J ELECTROCARDIOL, V21, pS141, DOI 10.1016/0022-0736(88)90082-9; GIANROSSI R, 1989, CIRCULATION, V80, P87, DOI 10.1161/01.CIR.80.1.87; Gibbons RJ, 1997, J AM COLL CARDIOL, V30, P260; HERBERT WG, 1991, AM HEART J, V122, P993, DOI 10.1016/0002-8703(91)90463-R; HOLLENBERG M, 1980, CIRCULATION, V61, P276, DOI 10.1161/01.CIR.61.2.276; LACHTERMAN B, 1990, CIRCULATION, V82, P44, DOI 10.1161/01.CIR.82.1.44; LACHTERMAN B, 1990, ANN INTERN MED, V112, P11, DOI 10.7326/0003-4819-112-1-11; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; MIRANDA CP, 1992, AM J CARDIOL, V69, P303, DOI 10.1016/0002-9149(92)90224-M; MORISE AP, 1995, AM HEART J, V130, P741, DOI 10.1016/0002-8703(95)90072-1; MORISE AP, 1992, AM J CARDIOL, V69, P603, DOI 10.1016/0002-9149(92)90149-S; MORRIS CK, 1993, J AM COLL CARDIOL, V22, P175, DOI 10.1016/0735-1097(93)90832-L; MYERS J, 1994, AM J CARDIOL, V73, P591, DOI 10.1016/0002-9149(94)90340-9; OKIN PM, 1995, J AM COLL CARDIOL, V25, P1726, DOI 10.1016/0735-1097(95)00085-I; PHILBRICK JT, 1989, AM J CARDIOL, V64, P1117; PRUVOST P, 1987, EUR HEART J, V8, P1287, DOI 10.1093/oxfordjournals.eurheartj.a062215; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; RIBISL PM, 1993, AM J CARDIOL, V71, P546, DOI 10.1016/0002-9149(93)90509-B; RODRIGUEZ M, 1993, AM HEART J, V126, P752, DOI 10.1016/0002-8703(93)90443-D; SHEFFIELD LT, 1969, CIRCULATION, V40, P935, DOI 10.1161/01.CIR.40.6.935; SIMOONS ML, 1977, CIRCULATION, V56, P552, DOI 10.1161/01.CIR.56.4.552; SIMOONS ML, 1977, COMPUT BIOMED RES, V10, P483, DOI 10.1016/0010-4809(77)90023-4; WILLEMS JL, 1991, NEW ENGL J MED, V325, P1767, DOI 10.1056/NEJM199112193252503; Yamada H, 1997, PROG CARDIOVASC DIS, V39, P457, DOI 10.1016/S0033-0620(97)80040-0	36	146	151	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				965	+		10.7326/0003-4819-128-12_Part_1-199806150-00001	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00001			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625682				2022-12-28	WOS:000074201300001
J	Johnson, JN				Johnson, JN			Cover picture meant that BMJ had descended to level of tabloid newspapers	BMJ-BRITISH MEDICAL JOURNAL			English	Letter									BMA, London WC1H 9JP, England		Johnson, JN (corresponding author), BMA, London WC1H 9JP, England.							Treasure T, 1998, BMJ-BRIT MED J, V316, P1685, DOI 10.1136/bmj.316.7146.1685	1	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	1998	316	7147					1831	1831		10.1136/bmj.316.7147.1831	http://dx.doi.org/10.1136/bmj.316.7147.1831			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624094				2022-12-28	WOS:000074286300059
J	Pak, CYC				Pak, CYC			Kidney stones	LANCET			English	Article							CALCIUM-OXALATE NEPHROLITHIASIS; VITAMIN-D-RECEPTOR; RENAL STONE; ABSORPTIVE HYPERCALCIURIA; IDIOPATHIC HYPERCALCIURIA; POTASSIUM CITRATE; URIC-ACID; UROLITHIASIS; PREVENTION; DIET		Univ Texas, SW Med Ctr, Ctr Mineral Metab & Clin Res, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Pak, CYC (corresponding author), Univ Texas, SW Med Ctr, Ctr Mineral Metab & Clin Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							BAGGIO B, 1986, NEW ENGL J MED, V314, P599, DOI 10.1056/NEJM198603063141002; BAGGIO B, 1993, MINER ELECTROL METAB, V19, P17; BARCELO P, 1993, J UROLOGY, V150, P1761, DOI 10.1016/S0022-5347(17)35888-3; BATAILLE P, 1991, KIDNEY INT, V39, P1193, DOI 10.1038/ki.1991.151; BIANCHI G, 1988, NEW ENGL J MED, V319, P897, DOI 10.1056/NEJM198810063191402; Borghi L, 1996, J UROLOGY, V155, P839, DOI 10.1016/S0022-5347(01)66321-3; BRESLAU NA, 1995, J BONE MINER RES, V10, P394; BRESLAU NA, 1992, J CLIN ENDOCR METAB, V75, P1446, DOI 10.1210/jc.75.6.1446; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; COE FL, 1982, AM J MED, V72, P25, DOI 10.1016/0002-9343(82)90567-8; COE FL, 1978, KIDNEY INT, V13, P418, DOI 10.1038/ki.1978.60; COWLEY DM, 1987, CLIN CHEM, V33, P243; CURHAN GC, 1993, NEW ENGL J MED, V328, P833, DOI 10.1056/NEJM199303253281203; DANPURE CJ, 1995, METABOLIC MOL BASES, P2385; DAUDON M, 1995, UROL RES, V23, P319, DOI 10.1007/BF00300021; ETTINGER B, 1986, NEW ENGL J MED, V315, P1386, DOI 10.1056/NEJM198611273152204; Ettinger B, 1997, J UROLOGY, V158, P2069, DOI 10.1016/S0022-5347(01)68155-2; ETTINGER B, 1998, J UROLOGY, V139, P679; FEGAN J, 1992, J UROLOGY, V147, P1212, DOI 10.1016/S0022-5347(17)37520-1; FINE JK, 1995, J UROLOGY, V153, P27, DOI 10.1097/00005392-199501000-00010; GRIFFITH DP, 1978, KIDNEY INT, V13, P372, DOI 10.1038/ki.1978.55; HESS B, 1995, J CLIN ENDOCR METAB, V80, P1916, DOI 10.1210/jc.80.6.1916; HOSKING DH, 1983, J UROLOGY, V130, P1003; JAEGER P, 1985, AM J NEPHROL, V5, P40, DOI 10.1159/000166901; JOHNSON CM, 1979, KIDNEY INT, V16, P624, DOI 10.1038/ki.1979.173; KHATCHADOURIAN J, 1995, J UROLOGY, V154, P1665, DOI 10.1016/S0022-5347(01)66743-0; LAERUM E, 1984, ACTA MED SCAND, V215, P383; LEVY FL, 1995, AM J MED, V98, P50, DOI 10.1016/S0002-9343(99)80080-1; LI XQ, 1993, J CLIN INVEST, V91, P661, DOI 10.1172/JCI116246; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; MANDEL NS, 1989, J UROLOGY, V142, P1516, DOI 10.1016/S0022-5347(17)39145-0; Melnick JZ, 1996, J CLIN INVEST, V98, P2381, DOI 10.1172/JCI119051; PAK CYC, 1994, MINER ELECTROL METAB, V20, P371; PAK CYC, 1989, J UROLOGY, V141, P798, DOI 10.1016/S0022-5347(17)41013-5; Pak CYC, 1997, AM J MED SCI, V313, P215, DOI 10.1097/00000441-199704000-00004; PAK CYC, 1985, J UROLOGY, V134, P867, DOI 10.1016/S0022-5347(17)47496-9; PAK CYC, 1986, KIDNEY INT, V30, P422, DOI 10.1038/ki.1986.201; Pak CYC, 1997, UROLOGY, V50, P504, DOI 10.1016/S0090-4295(97)00307-5; PAK CYC, 1996, CURRENT PRACTICE MED, V4; PREMINGER GM, 1987, J UROLOGY, V137, P1104, DOI 10.1016/S0022-5347(17)44415-6; REMIEN A, 1975, European Urology, V1, P227; RESNICK MI, 1995, J UROLOGY, V153, P4, DOI 10.1097/00005392-199501000-00004; Robertson W.G., 1993, METABOLIC BONE STONE, P249; ROBERTSON WG, 1987, MINER ELECTROL METAB, V13, P228; SAKHAEE K, 1994, J UROLOGY, V152, P324, DOI 10.1016/S0022-5347(17)32730-1; SAKHAEE K, 1993, J UROLOGY, V150, P310, DOI 10.1016/S0022-5347(17)35468-X; SUTHERLAND JW, 1985, MINER ELECTROL METAB, V11, P267; TISELIUS HG, 1986, J UROLOGY, V136, P50, DOI 10.1016/S0022-5347(17)44721-5; TISELIUS HG, 1978, EUR UROL, V4, P241; URIBARRI J, 1989, ANN INTERN MED, V111, P1006, DOI 10.7326/0003-4819-111-12-1006; Weisinger JR, 1996, KIDNEY INT, V49, P244, DOI 10.1038/ki.1996.34; YENDT ER, 1978, KIDNEY INT, V13, P397, DOI 10.1038/ki.1978.58; ZAIDMAN JL, 1976, J UROLOGY, V115, P626, DOI 10.1016/S0022-5347(17)59313-1; ZERWEKH JE, 1995, J CLIN ENDOCR METAB, V80, P2960, DOI 10.1210/jc.80.10.2960	54	273	282	1	25	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 13	1998	351	9118					1797	1801		10.1016/S0140-6736(98)01295-1	http://dx.doi.org/10.1016/S0140-6736(98)01295-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635968				2022-12-28	WOS:000074197600044
J	Wu, YC; Horvitz, HR				Wu, YC; Horvitz, HR			The C-elegans cell corpse engulfment gene ced-7 encodes a protein similar to ABC transporters	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; VITRONECTIN RECEPTOR; ATP-BINDING; MACROPHAGE RECOGNITION; MULTIDRUG RESISTANCE; ADENYLATE KINASE; APOPTOTIC CELLS; P-GLYCOPROTEIN; BODY REGION; DEATH	The C. elegans gene ced-7 functions in the engulfment of cell corpses during programmed cell death. We report that the CED-7 protein has sequence similarity to ABC transporters, is broadly expressed during embryogenesis, and is localized to the plasma membrane. Mosaic analysis revealed that ced-7 functions in both dying cells and engulfing cells during the engulfment process. We propose that CED-7 functions to translocate molecules that mediate homotypic adhesion between the cell surfaces of the dying and engulfing cells. Like CED-7, the mammalian ABC transporter ABC1 has been implicated in the engulfment of cell corpses, suggesting that CED-7 and ABC1 may be functionally similar and that the molecular mechanism underlying cell corpse engulfment during programmed cell death may be conserved from nematodes to mammals.	MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Horvitz, HR (corresponding author), MIT, Dept Biol, Howard Hughes Med Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Wu, Yi-Chun/F-7934-2012	Wu, Yi-Chun/0000-0002-8621-4098				Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; BRENNER S, 1974, GENETICS, V77, P71; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; Connors TD, 1997, GENOMICS, V39, P231, DOI 10.1006/geno.1996.4500; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; CULOTTI JG, 1978, GENETICS, V90, P243; DUVALL E, 1985, IMMUNOLOGY, V56, P351; ELLIS RE, 1991, GENETICS, V129, P79; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FRY DC, 1988, BIOCHEMISTRY-US, V27, P3588, DOI 10.1021/bi00410a009; GREENWALD I, 1987, NUCLEIC ACIDS RES, V15, P2295, DOI 10.1093/nar/15.5.2295; Guenther C, 1996, DEVELOPMENT, V122, P3509; GUO XD, 1991, NATURE, V349, P707, DOI 10.1038/349707a0; Harlow E., 1988, ANTIBODIES LAB MANUA; Hart SP, 1996, EXPERIENTIA, V52, P950, DOI 10.1007/BF01920103; HEDGECOCK EM, 1995, GENETICS, V141, P989; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; Klugbauer N, 1996, FEBS LETT, V391, P61, DOI 10.1016/0014-5793(96)00700-4; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; RUVKUN G, 1989, GENETICS, V121, P501; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1991, CHEST, V99, pS6, DOI 10.1378/chest.99.3_Supplement.6S-a; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILLIAMS BD, 1992, GENETICS, V131, P609; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; [No title captured]	64	232	245	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1998	93	6					951	960		10.1016/S0092-8674(00)81201-5	http://dx.doi.org/10.1016/S0092-8674(00)81201-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635425	Green Submitted, Bronze			2022-12-28	WOS:000074205700007
J	Yoshikawa, S; Shinzawa-Itoh, K; Nakashima, R; Yaono, R; Yamashita, E; Inoue, N; Yao, M; Fei, MJ; Libeu, CP; Mizushima, T; Yamaguchi, H; Tomizaki, T; Tsukihara, T				Yoshikawa, S; Shinzawa-Itoh, K; Nakashima, R; Yaono, R; Yamashita, E; Inoue, N; Yao, M; Fei, MJ; Libeu, CP; Mizushima, T; Yamaguchi, H; Tomizaki, T; Tsukihara, T			Redox-coupled crystal structural changes in bovine heart cytochrome c oxidase	SCIENCE			English	Article							MACROMOLECULAR CRYSTALLOGRAPHY; PROTEIN STRUCTURES; RESOLUTION; BINDING; OXYGEN; REFINEMENT; DYNAMICS; SOLVENT	Crystal structures of bovine heart cytochrome c oxidase in the fully oxidized, fully reduced, azide-bound, and carbon monoxide-bound states were determined at 2.30, 2.35, 2.9, and 2.8 angstrom resolution, respectively. An aspartate residue apart from the O-2 reduction site exchanges its effective accessibility to the matrix aqueous phase for one to the cytosolic phase concomitantly with a significant decrease in the pK of its carboxyl group, on reduction of the metal sites. The movement indicates the aspartate as the proton pumping site. A tyrosine acidified by a covalently linked imidazole nitrogen is a possible proton donor for the O-2 reduction by the enzyme.	Himeji Inst Technol, Dept Life Sci, Himeji, Hyogo 6781297, Japan; Japan Sci & Technol Corp, CREST, Himeji, Hyogo 6781297, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Kwansei Gakuin Univ, Fac Sci, Nishinomiya, Hyogo 662, Japan	University of Hyogo; Japan Science & Technology Agency (JST); Osaka University; Kwansei Gakuin University	Yoshikawa, S (corresponding author), Himeji Inst Technol, Dept Life Sci, Kamigohri Akoh, Himeji, Hyogo 6781297, Japan.		Yamashita, Eiki/V-6758-2019; yao, min/F-5287-2011	Yamashita, Eiki/0000-0002-4278-0039; yao, min/0000-0003-1687-5904				ANTONINI E, 1977, P NATL ACAD SCI USA, V74, P3128, DOI 10.1073/pnas.74.8.3128; ARGOS P, 1975, ACTA CRYSTALLOGR B, V32, P2975; BAKER GM, 1987, J BIOL CHEM, V262, P595; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P817, DOI 10.1006/jmbi.1994.1191; BRUDVIG GW, 1981, BIOCHEMISTRY-US, V20, P3912, DOI 10.1021/bi00516a039; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUEHNER M, 1974, J MOL BIOL, V82, P563, DOI 10.1016/0022-2836(74)90249-6; Capitanio N, 1997, BBA-BIOENERGETICS, V1318, P255, DOI 10.1016/S0005-2728(96)00143-0; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; Cotton F.A., 1980, ADV INORG CHEM, V4th ed.; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; GIBSON QH, 1965, J BIOL CHEM, V240, P888; HAN S, 1990, P NATL ACAD SCI USA, V87, P8408, DOI 10.1073/pnas.87.21.8408; HOLMES MA, 1991, J MOL BIOL, V218, P583, DOI 10.1016/0022-2836(91)90703-9; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Kirichenko A, 1998, FEBS LETT, V423, P329, DOI 10.1016/S0014-5793(98)00117-3; Kitagawa T, 1997, PROG INORG CHEM, V45, P431; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; Mattevi A, 1991, J Mol Recognit, V4, P1, DOI 10.1002/jmr.300040102; MESSERSCHMIDT A, 1993, J MOL BIOL, V230, P997, DOI 10.1006/jmbi.1993.1215; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Puustinen A, 1997, BIOCHEMISTRY-US, V36, P13195, DOI 10.1021/bi971091o; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; Riistama S, 1997, FEBS LETT, V414, P275, DOI 10.1016/S0014-5793(97)01003-X; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; STEFFENS GCM, 1993, EUR J BIOCHEM, V213, P1149, DOI 10.1111/j.1432-1033.1993.tb17865.x; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VANGELDE.BF, 1969, BIOCHIM BIOPHYS ACTA, V189, P1, DOI 10.1016/0005-2728(69)90219-9; VERKHOVSKY MI, 1994, BIOCHEMISTRY-US, V33, P3079, DOI 10.1021/bi00176a042; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WIKSTROM M, 1996, BIOCHIM BIOPHYS ACTA, V118, P106; WILLIAMS RJP, 1995, NATURE, V376, P643, DOI 10.1038/376643a0; WILSON MT, 1981, P NATL ACAD SCI-BIOL, V78, P7115, DOI 10.1073/pnas.78.11.7115; YOSHIKAWA S, 1982, J BIOL CHEM, V257, P412; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	39	952	966	2	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1723	1729		10.1126/science.280.5370.1723	http://dx.doi.org/10.1126/science.280.5370.1723			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624044				2022-12-28	WOS:000074197800033
J	Djerassi, C				Djerassi, C			Ethical discourse by science-in-fiction	NATURE			English	Editorial Material									Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University	Djerassi, C (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.								0	8	8	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1998	393	6685					511	511		10.1038/31088	http://dx.doi.org/10.1038/31088			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634224	Bronze			2022-12-28	WOS:000074150100020
J	Verity, CM; Greenwood, R; Golding, J				Verity, CM; Greenwood, R; Golding, J			Long-term intellectual and behavioral outcomes of children with febrile convulsions	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATIONAL COHORT; SEIZURES; EPILEPSY; RECURRENCE; CHILDHOOD; LIFE	Background Hospital-based studies have reported that children with febrile convulsions have subsequent mental retardation and behavior problems. In contrast, population-based studies have reported a better outcome. Methods We identified 398 children with febrile convulsions among 14,676 children enrolled in the Child Health and Education Study, a national population-based study in the United Kingdom of children born in one week in April 1970. The children were comprehensively assessed at the age of 10. After excluding 16 children who had neurodevelopmental problems before their first febrile convulsion and 1 child whose case was atypical, we studied 381 children, 287 with simple febrile convulsions and 94 with complex febrile convulsions. We compared them with the rest of the cohort using measures of academic progress, intelligence, and behavior that included questionnaires, standardized tests, and formal tests. Results At the 10-year assessment, only 4 of 102 measures of academic progress, intelligence, and behavior differed significantly between the entire group of children with febrile convulsions and the group without febrile convulsions - no more than would be expected by chance. Similar results were found when children with simple febrile convulsions and those with complex febrile convulsions were analyzed separately. The children with recurrent episodes of febrile convulsions had outcomes similar to those of the children with only one episode each. Special schooling was required for more children who had febrile convulsions in the first year of life than for those who had had them later in life (5 of 67, or 7.5 percent, vs. 4 of 265, or 1.5 percent; P = 0.02), but these numbers were small. Conclusions Children who had febrile convulsions performed as well as other children in terms of their academic progress, intellect, and behavior at 10 years of age. (C) 1998, Massachusetts Medical Society.	Addenbrookes Hosp, Child Dev Ctr, Dept Paediat, Cambridge CB2 2QQ, England; Univ Bristol, Inst Child Hlth, Unit Paediat & Perinatal Epidemiol, Bristol, Avon, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Bristol	Verity, CM (corresponding author), Addenbrookes Hosp, Child Dev Ctr, Dept Paediat, Box 107, Cambridge CB2 2QQ, England.			Golding, Jean/0000-0003-2826-3307				AICARDI J, 1994, EPILEPSY CHILDREN, P253; AICARDI J, 1976, INT BRAIN RES ORG MO, V2, P247; ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; BAUMER JH, 1981, DEV MED CHILD NEUROL, V23, P462; CAMFIELD P, 1993, NEW ENGL J MED, V329, P2034; CHAMBERLAIN R, 1975, BRIT BIRTHS 1970, V1; CONNERS CK, 1969, AM J PSYCHIAT, V126, P884, DOI 10.1176/ajp.126.6.884; ELLENBERG JH, 1978, ARCH NEUROL-CHICAGO, V35, P17, DOI 10.1001/archneur.1978.00500250021004; Elliott C., 1983, BRIT ABILITY SCALES; Fisher R.A., 1963, STAT TABLES BIOL AGR, V6th; LENNOX MA, 1949, J PEDIATR-US, V35, P427, DOI 10.1016/S0022-3476(49)80054-0; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; Millichap JG, 1968, FEBRILE CONVULSIONS; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; *NIH, 1980, BMJ-BRIT MED J, V281, P277; OSBORNE AF, 1987, EFFECTS EARLY ED; ROSS EM, 1980, BRIT MED J, V280, P207, DOI 10.1136/bmj.280.6209.207; Rutter M., 1970, ED HLTH BEHAV; SCHIOTTZ.E, 1973, DEV MED CHILD NEUROL, V15, P565; SMITH JA, 1982, ARCH DIS CHILD, V57, P104, DOI 10.1136/adc.57.2.104; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; VERITY CM, 1993, BMJ-BRIT MED J, V307, P225, DOI 10.1136/bmj.307.6898.225; VERITY CM, 1991, BMJ-BRIT MED J, V303, P1373, DOI 10.1136/bmj.303.6814.1373; VERITY CM, 1992, BRIT MED J, V304, P147; VERITY CM, 1992, BMJ-BRIT MED J, V305, P857, DOI 10.1136/bmj.305.6858.857; VERITY CM, 1985, BRIT MED J, V290, P13121; WALLACE S, 1988, CHILD FEBRILE SEIZUR; WALLACE SJ, 1979, DEV MED CHILD NEUROL, V21, P28; WALLACE SJ, 1976, INT BRAIN RES ORG MO, V2, P259; WOLF SM, 1978, PEDIATRICS, V61, P728	30	163	167	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1998	338	24					1723	1728		10.1056/NEJM199806113382403	http://dx.doi.org/10.1056/NEJM199806113382403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT654	9624192				2022-12-28	WOS:000074109800003
J	Raleigh, VS				Raleigh, VS			Abortion rates in England in 1995: comparative study of data from district health authorities	BRITISH MEDICAL JOURNAL			English	Article							FERTILITY		Univ Surrey, Natl Inst Epidemiol, Guildford GU2 5YD, Surrey, England	University of Surrey	Raleigh, VS (corresponding author), Univ Surrey, Natl Inst Epidemiol, Surrey Res Pk, Guildford GU2 5YD, Surrey, England.							Botting Beverley, 1991, Popul Trends, V64, P19; CLARKE M, 1988, BRIT MED J, V297, P832, DOI 10.1136/bmj.297.6652.832; Johnson AM, 1994, SEXUAL ATTITUDES LIF; Kulczycki A, 1996, LANCET, V347, P1663, DOI 10.1016/S0140-6736(96)91491-9; *OFF NAT STAT, 1996, SER AB, V21	5	8	8	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1711	1712		10.1136/bmj.316.7146.1711	http://dx.doi.org/10.1136/bmj.316.7146.1711			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614020	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000074129500022
J	McMichael, A				McMichael, A			T cell responses and viral escape	CELL			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-RESPONSE; HIV; LYMPHOCYTES; INFECTION; USAGE		John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England	University of Oxford	McMichael, A (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England.							Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Finzi D, 1998, CELL, V93, P665, DOI 10.1016/S0092-8674(00)81427-0; Goulder P, 1997, IMMUNOL REV, V159, P17, DOI 10.1111/j.1600-065X.1997.tb01004.x; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261; KLENERMAN P, 1995, EUR J IMMUNOL, V25, P1927, DOI 10.1002/eji.1830250720; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; MCMICHAEL AJ, 1998, J VIROL, V72, P1403; MOSKOPHIDIS D, 1993, EUR J IMMUNOL, V23, P3306, DOI 10.1002/eji.1830231237; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; Phillips AN, 1996, SCIENCE, V271, P497, DOI 10.1126/science.271.5248.497; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rowland-Jones S, 1997, ADV IMMUNOL, V65, P277, DOI 10.1016/S0065-2776(08)60745-2; Wiertz EJHJ, 1997, MOL MED TODAY, V3, P116, DOI 10.1016/S1357-4310(96)10059-9; Xu XN, 1997, J EXP MED, V186, P7, DOI 10.1084/jem.186.1.7; Yang OO, 1997, J VIROL, V71, P3120, DOI 10.1128/JVI.71.4.3120-3128.1997	22	113	114	1	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1998	93	5					673	676		10.1016/S0092-8674(00)81428-2	http://dx.doi.org/10.1016/S0092-8674(00)81428-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630211	Bronze			2022-12-28	WOS:000073956700003
J	Blum, LN; Bresolin, LB; Williams, MA				Blum, LN; Bresolin, LB; Williams, MA			Heat-related illness during extreme weather emergencies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									AMA, Council Sci Affairs, Chicago, IL 60611 USA	American Medical Association	Blum, LN (corresponding author), AMA, Council Sci Affairs, Chicago, IL 60611 USA.		Williams, Michael A./O-4075-2019	Williams, Michael A./0000-0002-7284-8014					0	35	36	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1514	1514		10.1001/jama.279.19.1514	http://dx.doi.org/10.1001/jama.279.19.1514			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN087	9605881				2022-12-28	WOS:000073608100008
J	Meier, CR; Jick, SS; Derby, LE; Vasilakis, C; Jick, H				Meier, CR; Jick, SS; Derby, LE; Vasilakis, C; Jick, H			Acute respiratory-tract infections and risk of first-time acute myocardial infarction	LANCET			English	Article							PHYSICAL EXERTION; CASE-CROSSOVER; ATHEROSCLEROSIS; INFLAMMATION; DISEASE; DEATH; ONSET	Background. There is growing interest in the role of infections in the aetiology of acute myocardial infarction (AMI). We undertook a large, population-based study to explore the association between risk of AMI and recent acute respiratory-tract infection Methods We used data from general practices in the UK (General Practice Research Database). Potential cases were people aged 75 years or younger, with no history of clinical risk factors, who had a first-time diagnosis of AMI between Jan 1, 1994, and Oct 31, 1996. Four controls were matched to each case on age, sex, and the practice attended. The date of the AMI in the case was defined as the index date. For both cases and controls the date of the last respiratory-tract infection before the index date was identified. We also did a case-crossover analysis of cases who had an acute respiratory-tract infection either before the index date or before an arbitrarily chosen date (1 year before AMI). Findings. In the case-control analysis of 1922 cases and 7649 matched controls, significantly more cases than controls had an acute respiratory-tract infection in the 10 days before the index date (54 [2.8%] vs 72 [0.9%]). The odds ratios, adjusted for smoking and body-mass index, for first-time AMI in association with an acute respiratory-tract infection 1-5, 6-10, 11-15, or 16-30 days before the index date (compared with participants who had no such infection during the preceding year) were 3.6 (95% CI 2.2-5.7), 2.3 (1.3-4.2), 1.8 (1.0-3.3), and 1.0 (0.7-1.6); (test for trend p < 0.01). The case-crossover analysis showed a relative risk of 2.7 (1.6-4.7) for AMI in relation to an acute respiratory-tract infection in the 10 days before the index date. Interpretation. Our findings suggest that in people without a history of clinical risk factors for AMI, acute respiratory-tract infections are associated with an increased risk of AMI for a period of about 2 weeks. We cannot, however, completely exclude the possibility of misdiagnosis bias, if prodromal symptoms of AMI were mistaken for respiratory-tract infection.	Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, Lexington, MA 02173 USA	Boston University	Meier, CR (corresponding author), Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, 11 Muzzey St, Lexington, MA 02173 USA.			Jick, Hershel/0000-0003-4270-5992; Jick, Susan/0000-0002-2215-1067				Buja LM, 1996, CIRCULATION, V94, P872, DOI 10.1161/01.CIR.94.5.872; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Gullette ECD, 1997, JAMA-J AM MED ASSOC, V277, P1521, DOI 10.1001/jama.277.19.1521; Gupta S, 1997, CIRCULATION, V96, P404; Gurfinkel E, 1997, LANCET, V350, P404, DOI 10.1016/S0140-6736(97)07201-2; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H, 1996, PHARMACOTHERAPY, V16, P321; Jick H, 1997, EPIDEMIOLOGY, V8, P446, DOI 10.1097/00001648-199707000-00017; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; MATTILA KJ, 1989, J INTERN MED, V225, P293, DOI 10.1111/j.1365-2796.1989.tb00084.x; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; MITTLEMAN MA, 1995, AM J EPIDEMIOL, V142, P91, DOI 10.1093/oxfordjournals.aje.a117550; Mittleman MA, 1997, JAMA-J AM MED ASSOC, V277, P1558; NIEMINEN MS, 1993, EUR HEART J, V14, P12; PESONEN E, 1981, AM HEART J, V101, P512, DOI 10.1016/0002-8703(81)90150-2; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Rothman K, 1986, MODERN EPIDEMIOLOGY; SPODICK DH, 1985, ANN INTERN MED, V102, P699, DOI 10.7326/0003-4819-102-5-699; SPODICK DH, 1984, AM J CARDIOL, V53, P481, DOI 10.1016/0002-9149(84)90016-X; SYRJANEN J, 1988, BRIT MED J, V296, P1156, DOI 10.1136/bmj.296.6630.1156; TILLETT HE, 1983, INT J EPIDEMIOL, V12, P344, DOI 10.1093/ije/12.3.344; Vallance P, 1997, LANCET, V349, P1391, DOI 10.1016/S0140-6736(96)09424-X; VALTONEN VV, 1991, ANN MED, V23, P539, DOI 10.3109/07853899109150515; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; WILLICH SN, 1993, NEW ENGL J MED, V329, P1684, DOI 10.1056/NEJM199312023292302; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	28	300	313	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1467	1471		10.1016/S0140-6736(97)11084-4	http://dx.doi.org/10.1016/S0140-6736(97)11084-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605802	hybrid			2022-12-28	WOS:000073707300008
J	Dyson, S; Gurdon, JB				Dyson, S; Gurdon, JB			The interpretation of position in a morphogen gradient as revealed by occupancy of activin receptors	CELL			English	Article							GROWTH-FACTOR-BETA; XENOPUS EMBRYOS; SPEMANNS ORGANIZER; MAD PROTEINS; DROSOPHILA; HEDGEHOG; MESODERM; CELLS; THRESHOLDS; OOCYTES	Xenopus blastula cells activate different mesodermal genes as a concentration-dependent response to activin, which behaves like a morphogen. To understand how cells recognize morphogen concentration, we have bound naturally labeled activin to cells and related this to choice of gene activation. We find that the increasing occupancy of a single receptor type can cause cells to switch gene expression. Cells sense ligand concentration by the absolute number of occupied receptors per cell (100 and 300 molecules of bound activin induce Xbra and Xgsc, respectively, i.e., 2% and 6% of the total receptors) and not by a ratio of occupied to unoccupied receptors. The long duration of occupancy explains a previously described ratchet effect. Our results suggest a new concept of morphogen gradient formation and interpretation that is particularly well suited to the needs of early development.	Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	University of Cambridge	Gurdon, JB (corresponding author), Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			GURDON, JOHN/0000-0002-5621-3799	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Armes NA, 1997, DEVELOPMENT, V124, P3797; Chang CB, 1997, DEVELOPMENT, V124, P827; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COLMAN A, 1979, CELL, V17, P517, DOI 10.1016/0092-8674(79)90260-5; DAWID IB, 1965, J MOL BIOL, V12, P581, DOI 10.1016/S0022-2836(65)80313-8; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; Furriols M, 1996, DEVELOPMENT, V122, P2313; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GURDON JB, 1971, NATURE, V233, P177, DOI 10.1038/233177a0; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; GURDON JB, 1995, NATURE, V376, P520, DOI 10.1038/376520a0; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HOPPLER S, 1995, EMBO J, V14, P5016, DOI 10.1002/j.1460-2075.1995.tb00184.x; HUSKENHINDI P, 1994, J BIOL CHEM, V269, P19380; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; Koenig JA, 1996, MOL PHARMACOL, V49, P351; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MASSAGUE J, 1986, J CELL PHYSIOL, V128, P216, DOI 10.1002/jcp.1041280212; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; McDowell N, 1997, CURR BIOL, V7, P671, DOI 10.1016/S0960-9822(06)00294-6; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Natsume T, 1997, J BIOL CHEM, V272, P11535; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NISHIMATSU SI, 1992, FEBS LETT, V303, P81, DOI 10.1016/0014-5793(92)80482-V; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Rothenberg EV, 1996, SCIENCE, V273, P78, DOI 10.1126/science.273.5271.78; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; ZernickaGoetz M, 1996, DEVELOPMENT, V122, P3719; Zorn AM, 1997, GENE DEV, V11, P2176, DOI 10.1101/gad.11.17.2176	50	184	192	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					557	568		10.1016/S0092-8674(00)81185-X	http://dx.doi.org/10.1016/S0092-8674(00)81185-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604931	Bronze			2022-12-28	WOS:000073722200009
J	Roberts, C; Sibbald, B				Roberts, C; Sibbald, B			Understanding controlled trials - Randomising groups of patients	BRITISH MEDICAL JOURNAL			English	Article									Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of Manchester	Roberts, C (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.							DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; KENDRICK T, 1995, BRIT MED J, V311, P93, DOI 10.1136/bmj.311.6997.93; Rice N, 1996, J Health Serv Res Policy, V1, P154	3	9	9	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1998	316	7148					1898	1898						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632417				2022-12-28	WOS:000074686500037
J	Toop, L				Toop, L			Primary care: core values - Patient centred primary care	BRITISH MEDICAL JOURNAL			English	Article									Christchurch Sch Med, Dept Publ Hlth & Gen Practice, Christchurch, New Zealand	University of Otago	Toop, L (corresponding author), Christchurch Sch Med, Dept Publ Hlth & Gen Practice, Christchurch, New Zealand.							DONALDSON M, 1994, DEFINING PRIMARY CAR, P20; FRANK E, 1995, J CLIN PSYCHIAT, V56, P11; HJORTDAHL P, 1992, BRIT MED J, V304, P1287, DOI 10.1136/bmj.304.6837.1287; HOWIE J, 1993, STRESS MANAGEMENT GE; LAWRENCE SL, 1994, J R SOC MED, V22, P11; Leopold N, 1996, J FAM PRACTICE, V42, P129; McQuoid-Mason D, 1996, Med Law, V15, P499; McWhinney IR, 1998, BRIT MED J, V316, P1807, DOI 10.1136/bmj.316.7147.1807; Parkhouse J, 1997, BRIT MED J, V314, P1810, DOI 10.1136/bmj.314.7097.1810; PROBERT CSJ, 1990, LANCET, V335, P1446; Royal College of General Practitioners, 1996, NAT GEN MED PRACT; Stewart M., 1995, PATIENT CTR MED PATIENT CTR MED; SZASZ TS, 1976, ARCH INTERN MED, V97, P585; Taylor DH, 1997, BRIT MED J, V314, P1806, DOI 10.1136/bmj.314.7097.1806; TOOP LJ, 1996, NZ FAM PHYS, V23, P51	15	39	39	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1998	316	7148					1882	1883						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632410				2022-12-28	WOS:000074686500027
J	Hutton, M; Lendon, CL; Rizzu, P; Baker, M; Froelich, S; Houlden, H; Pickering-Brown, S; Chakraverty, S; Isaacs, A; Grover, A; Hackett, J; Adamson, J; Lincoln, S; Dickson, D; Davies, P; Petersen, RC; Stevens, M; de Graaff, E; Wauters, E; van Baren, J; Hillebrand, M; Joosse, M; Kwon, JM; Nowotny, P; Che, LK; Norton, J; Morris, JC; Reed, LA; Trojanowski, J; Basun, H; Lannfelt, L; Neystat, M; Fahn, S; Dark, F; Tannenberg, T; Dodd, PR; Hayward, N; Kwok, JBJ; Schofield, PR; Andreadis, A; Snowden, J; Craufurd, D; Neary, D; Owen, F; Oostra, BA; Hardy, J; Goate, A; van Swieten, J; Mann, D; Lynch, T; Heutink, P				Hutton, M; Lendon, CL; Rizzu, P; Baker, M; Froelich, S; Houlden, H; Pickering-Brown, S; Chakraverty, S; Isaacs, A; Grover, A; Hackett, J; Adamson, J; Lincoln, S; Dickson, D; Davies, P; Petersen, RC; Stevens, M; de Graaff, E; Wauters, E; van Baren, J; Hillebrand, M; Joosse, M; Kwon, JM; Nowotny, P; Che, LK; Norton, J; Morris, JC; Reed, LA; Trojanowski, J; Basun, H; Lannfelt, L; Neystat, M; Fahn, S; Dark, F; Tannenberg, T; Dodd, PR; Hayward, N; Kwok, JBJ; Schofield, PR; Andreadis, A; Snowden, J; Craufurd, D; Neary, D; Owen, F; Oostra, BA; Hardy, J; Goate, A; van Swieten, J; Mann, D; Lynch, T; Heutink, P			Association of missense and 5 '-splice-site mutations in tau with the inherited dementia FTDP-17	NATURE			English	Article							PROTEIN-TAU; ALZHEIMERS-DISEASE; LOCALIZATION; PARKINSONISM; COMPLEX; GENE; RNA	Thirteen families have been described with an autosomal dominantly inherited dementia named frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)(1-9), historically termed Pick's disease(10). Most FTDP-17 cases show neuronal and/or glial inclusions that stain positively with antibodies raised against the microtubule-associated protein Tau, although the Tau pathology varies considerably in both its quantity (or severity) and characteristics(1-8,12). Previous studies have mapped the FTDP-17 locus to a 2-centimorgan region on chromosome 17q21.11; the tau gene also lies within this region. We have now sequenced tau in FTDP-17 families and identified three missense mutations (G272V, P301L and R406W) and three mutations in the 5' splice site of exon in. The splice-site mutations all destabilize a potential stem-loop structure which is probably involved in regulating the alternative splicing of exon10 (ref. 13). This causes more frequent usage of the 5' splice site and an increased proportion of tan transcripts that include exon 10. The increase in exon 10(+) messenger RNA will increase the proportion of Tau containing four microtubule-binding repeats, which is consistent with the neuropathology described in several families with FTDP-17 (refs 12, 14).	Mayo Clin Jacksonville, Jacksonville, FL 32224 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Erasmus Univ, Dept Clin Genet, Rotterdam, Netherlands; Erasmus Univ, Dept Neurol, Rotterdam, Netherlands; Karolinska Inst, Inst Clin Neurophysiol & Family Med, Geriatr Med Sect, S-14186 Huddinge, Sweden; Univ Manchester, Sch Biol Sci, Div Neurosci, Manchester M13 9PT, Lancs, England; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Mayo Clin, Rochester, MN 56007 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Columbia Univ, Dept Neurol, New York, NY 10032 USA; Princess Alexandra Hosp, Dept Psychiat, Woolloongabba, Qld 4102, Australia; Mater Misericordiae Hosp, Dept Anat Pathol, Brisbane, Qld 4101, Australia; Univ Queensland, Dept Biochem, Brisbane, Qld 4072, Australia; Queensland Inst Med Res, Human Genet Lab, Herston, Qld 4029, Australia; Garvan Inst Med Res, Sydney, NSW 2010, Australia; Eunice Kennedy Shriver Ctr Mental Retardat Inc, Dept Biomed Sci, Waltham, MA 02154 USA; Manchester Royal Infirm, Dept Neurol, Manchester M13 9WL, Lancs, England; St Marys Hosp, Dept Clin Genet, Manchester M13 0GH, Lancs, England; Univ Manchester, Dept Pathol Sci, Manchester M13 9PT, Lancs, England	Mayo Clinic; Washington University (WUSTL); Erasmus University Rotterdam; Erasmus University Rotterdam; Karolinska Institutet; University of Manchester; Yeshiva University; Albert Einstein College of Medicine; Mayo Clinic; Washington University (WUSTL); University of Pennsylvania; Columbia University; University of Queensland; QIMR Berghofer Medical Research Institute; Garvan Institute of Medical Research; University of Manchester; University of Manchester; University of Manchester	Hutton, M (corresponding author), Mayo Clin Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	hutton.michael@mayo.edu; heutink@kgen.fgg.eut.nl	Craufurd, David/G-5277-2013; Pickering-Brown, Stuart/D-4008-2009; Houlden, Henry J/C-1532-2008; hayward, nick/AAV-8802-2020; Morris, John C/A-1686-2012; hayward, nicholas k/C-1367-2015; Lynch, Timothy/M-1316-2019; Hardy, John/C-2451-2009; de Graaff, Esther/D-3287-2011; Dodd, Peter Ronald/A-4865-2010; Schofield, Peter/C-9669-2011	Pickering-Brown, Stuart/0000-0003-1561-6054; Houlden, Henry J/0000-0002-2866-7777; hayward, nicholas k/0000-0003-4760-1033; Hardy, John/0000-0002-3122-0423; Dodd, Peter Ronald/0000-0001-5970-0181; van Swieten, John/0000-0001-6278-6844; Schofield, Peter/0000-0003-2967-9662; Goate, Alison/0000-0002-0576-2472; Heutink, Peter/0000-0001-5218-1737; Kwok, John/0000-0001-9574-6195; Snowden, Julie/0000-0002-3976-4310; Dickson, Dennis W/0000-0001-7189-7917				ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Baker M, 1997, ANN NEUROL, V42, P794, DOI 10.1002/ana.410420516; BRUN A, 1994, J NEUROL NEUROSUR PS, V57, P416; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Conrad C, 1997, ANN NEUROL, V41, P277, DOI 10.1002/ana.410410222; CONSTANT.J, 1974, EUR NEUROL, V11, P208, DOI 10.1159/000114320; Dark F, 1997, AUST NZ J PSYCHIAT, V31, P139, DOI 10.3109/00048679709073812; Dickson DW, 1997, ANN NEUROL, V42, P541, DOI 10.1002/ana.410420403; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; Foster NL, 1997, ANN NEUROL, V41, P706, DOI 10.1002/ana.410410606; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; Froelich S, 1997, AM J MED GENET, V74, P380, DOI 10.1002/(SICI)1096-8628(19970725)74:4<380::AID-AJMG8>3.0.CO;2-T; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Heutink P, 1997, ANN NEUROL, V41, P150, DOI 10.1002/ana.410410205; Higgins JJ, 1998, NEUROLOGY, V50, P270, DOI 10.1212/WNL.50.1.270; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; McGeer PL, 1997, NEUROLOGY, V49, P400, DOI 10.1212/WNL.49.2.400; Murrell JR, 1997, AM J HUM GENET, V61, P1131, DOI 10.1086/301594; Reed LA, 1997, ANN NEUROL, V42, P564, DOI 10.1002/ana.410420406; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Spillantini MG, 1997, P NATL ACAD SCI USA, V94, P4113, DOI 10.1073/pnas.94.8.4113; Wijker M, 1996, HUM MOL GENET, V5, P151, DOI 10.1093/hmg/5.1.151; WILHELMSEN KC, 1994, AM J HUM GENET, V55, P1159; Yamaoka LH, 1996, AM J HUM GENET, V59, P1306	28	2719	2812	4	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1998	393	6686					702	705		10.1038/31508	http://dx.doi.org/10.1038/31508			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641683				2022-12-28	WOS:000074289600058
J	Oupadia, P; Ramaswamy, K				Oupadia, P; Ramaswamy, K			"R-on-T" phenomenon	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									St Elizabeths Med Ctr, Boston, MA 02135 USA	St. Elizabeth's Medical Center	Oupadia, P (corresponding author), St Elizabeths Med Ctr, Boston, MA 02135 USA.								0	18	18	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1998	338	25					1812	1812		10.1056/NEJM199806183382505	http://dx.doi.org/10.1056/NEJM199806183382505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU443	9632448				2022-12-28	WOS:000074197500005
J	Wang, JL; Liu, R; Hawkins, M; Barzilai, N; Rossetti, L				Wang, JL; Liu, R; Hawkins, M; Barzilai, N; Rossetti, L			A nutrient-sensing pathway regulates leptin gene expression in muscle and fat	NATURE			English	Article							INSULIN-RESISTANCE; OBESE GENE; IN-VIVO; HEXOSAMINE BIOSYNTHESIS; GLUCOSE-TRANSPORT; HUMANS; ADIPOSITY; PRODUCT; PROTEIN; MICE	Leptin, the protein encoded by the obese (ob) gene, is synthesized and released in response to increased energy storage in adipose tissue(1-4). However, it is still not known how incoming energy is sensed and transduced into increased expression of the ob gene. The hexosamine biosynthetic pathway is a cellular 'sensor' of energy availability(5-8) and mediates the effects of glucose on the expression of several gene products(9-12). Here we provide evidence for rapid activation of ob gene expression in skeletal muscle by glucosamine. Increased tissue concentrations of the end product of the hexosamine biosynthetic pathway, UDP-N-acetylglucosamine (UDP-GlcNAc), result in rapid and marked increases in leptin messenger RNA and protein levels (although these levels were much lower than those in fat). Plasma leptin levels and leptin mRNA and protein levels in adipose tissue also increase. Most important, stimulation of leptin synthesis is reproduced by either hyperglycaemia or hyperlipidaemia, which also increase tissue levels of UDP-N-acetylglucosamine in conscious rodents(7). Finally, incubation of 3T3-L1 pre-adipocytes and L6 myocytes with glucosamine rapidly induces ob gene expression. Our findings are the first evidence of inducible leptin expression in skeletal muscle and unveil an important biochemical Link between increased availability of nutrients and leptin expression.	Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Liu, R (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rossetti@aecom.yu.edu						Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; DANIELS MC, 1993, MOL ENDOCRINOL, V7, P1041, DOI 10.1210/me.7.8.1041; Flier JS, 1997, P NATL ACAD SCI USA, V94, P4242, DOI 10.1073/pnas.94.9.4242; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hawkins M, 1997, J BIOL CHEM, V272, P4889, DOI 10.1074/jbc.272.8.4889; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kolaczynski JW, 1996, DIABETES, V45, P1511, DOI 10.2337/diabetes.45.11.1511; Kolaczynski JW, 1996, DIABETES, V45, P699, DOI 10.2337/diabetes.45.5.699; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Segal KR, 1996, DIABETES, V45, P988, DOI 10.2337/diabetes.45.7.988; Wang JL, 1997, DIABETES, V46, P325; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	637	663	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1998	393	6686					684	688		10.1038/31474	http://dx.doi.org/10.1038/31474			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641678				2022-12-28	WOS:000074289600053
J	Wyatt, R; Kwong, PD; Desjardins, E; Sweet, RW; Robinson, J; Hendrickson, WA; Sodroski, JG				Wyatt, R; Kwong, PD; Desjardins, E; Sweet, RW; Robinson, J; Hendrickson, WA; Sodroski, JG			The antigenic structure of the HIV gp120 envelope glycoprotein	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY; NEUTRALIZING ANTIBODIES; CD4 BINDING; RECEPTOR; EPITOPE; CELLS; RETROVIRUS; EXPOSURE; REGION	The human immunodeficiency virus HIV-1 establishes persistent infections in humans which lead to acquired immunodeficiency syndrome (AIDS). The HIV-1 envelope glycoproteins, gp120 and gp41, are assembled into a trimeric complex that mediates virus entry into target cells(1). HIV-1 entry depends on the sequential interaction of the gp120 exterior envelope glycoprotein with the receptors on the cell, CD4 and members of the chemokine receptor family(2-4). The gp120 glycoprotein, which can be shed from the envelope complex, elicits both virus-neutralizing and non-neutralizing antibodies during natural infection. Antibodies that lack neutralizing activity are often directed against the gp120 regions that are occluded on the assembled trimer and which are exposed only upon shedding(5,6). Neutralizing antibodies, by contrast, must access the functional envelope glycoprotein complex(7) and typically recognize conserved or variable epitopes near the receptor-binding regions(8-11). Here we describe the spatial organization of conserved neutralization epitopes on gp120, using epitope maps in conjunction with the X-ray crystal structure of a ternary complex that includes a gp120 core, CD4 and a neutralizing antibody(12). A large fraction of the predicted accessible surface of gp120 in the trimer is composed of variable, heavily glycosylated core and loop structures that surround the receptor-binding regions. Understanding the structural basis for the ability of HIV-1 to evade the humoral immune response should assist in the design of a vaccine.	Harvard Univ, Sch Med, Charles A Dana Res Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA; SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA; Tulane Univ, Med Ctr, Dept Pediat, New Orleans, LA 70112 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Columbia University; Howard Hughes Medical Institute; GlaxoSmithKline; Tulane University	Sodroski, JG (corresponding author), Harvard Univ, Sch Med, Charles A Dana Res Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.							ALLEN J, 1983, SCIENCE, V228, P1091; BINLEY J, 1997, AIDS RES HUM RETROV, V14, P191; Cao J, 1997, J VIROL, V71, P9808, DOI 10.1128/JVI.71.12.9808-9812.1997; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FUNG MSC, 1992, J VIROL, V66, P848, DOI 10.1128/JVI.66.2.848-856.1992; HO DD, 1991, J VIROL, V65, P489, DOI 10.1128/JVI.65.1.489-493.1991; Karlsson GB, 1997, J VIROL, V71, P4218, DOI 10.1128/JVI.71.6.4218-4225.1997; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; MOORE JP, 1994, J VIROL, V68, P8350, DOI 10.1128/JVI.68.12.8350-8364.1994; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; MYERS G, 1996, HUMAN RETROVIRUSES A; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; POSNER MR, 1991, J IMMUNOL, V146, P4325; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SATTENTAU QJ, 1995, J EXP MED, V182, P185, DOI 10.1084/jem.182.1.185; THALI M, 1992, J VIROL, V66, P5635, DOI 10.1128/JVI.66.9.5635-5641.1992; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; WATKINS BA, 1993, J VIROL, V67, P7493, DOI 10.1128/JVI.67.12.7493-7500.1993; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1997, J VIROL, V71, P9722, DOI 10.1128/JVI.71.12.9722-9731.1997; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995	30	1042	1116	2	98	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1998	393	6686					705	711		10.1038/31514	http://dx.doi.org/10.1038/31514			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641684	Bronze			2022-12-28	WOS:000074289600059
J	Friedman, E				Friedman, E			What price survival? The future of Blue Cross and Blue Shield	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Friedman, E (corresponding author), 851 W Gunnison,Unit G, Chicago, IL 60640 USA.							*CAIN BROTH, 1997, BLUE CROSS BLUE SHIE; Cunningham Robert III, 1997, BLUES HIST BLUE CROS; Friedman E, 1996, JAMA-J AM MED ASSOC, V275, P957, DOI 10.1001/jama.275.12.957; *HOECHST MAR ROUSS, 1997, MAN CAR DIG SER 1997; WEEKS LE, 1985, SHAPERS AM HLTH POLI; 1998, REUTERS         0218	6	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1998	279	23					1863	1869		10.1001/jama.279.23.1863	http://dx.doi.org/10.1001/jama.279.23.1863			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT653	9634248				2022-12-28	WOS:000074109700014
J	Langford, CA; Klippel, JH; Balow, JE; James, SP; Sneller, MC				Langford, CA; Klippel, JH; Balow, JE; James, SP; Sneller, MC			Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease part 1: Rheumatologic and renal diseases	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Clinical Staff Conference	MAR 26, 1997	NIH, BETHESDA, MD	NIH	NIH		SYSTEMIC LUPUS-ERYTHEMATOSUS; INTERSTITIAL LUNG-DISEASE; TERM FOLLOW-UP; CHANGE NEPHROTIC SYNDROME; CONTROLLED TRIAL; INTRAVENOUS CYCLOPHOSPHAMIDE; PULSE CYCLOPHOSPHAMIDE; POLYMYOSITIS DERMATOMYOSITIS; MEMBRANOUS GLOMERULOPATHY; THERAPY	When cytotoxic agents were initially introduced, their ability to disrupt nucleic acid and protein synthesis led to their effective use for the treatment of neoplastic disease. During the course of this use, however, it became apparent that these agents also suppress the immune system. This usually unwelcome effect was subsequently studied and beneficially directed toward the treatment of non-neoplastic diseases in which autoimmune mechanisms were considered important to pathogenesis. As a result of these investigations, cytotoxic agents and, more recently, cyclosporine have emerged to become an important part of the therapeutic regimen for many autoimmune diseases. Nonetheless, these medications may sti II cause treatment-induced illness or even death. It is therefore particularly important to weigh the benefits and risks of cytotoxic therapy when treating a non-neoplastic disease. This two-part Clinical Staff Conference reviews data on the efficacy and toxicity of cytotoxic drugs and cyclosporine in selected autoimmune diseases. Part 1 examines the manner in which these agents have been used to treat rheumatologic and renal diseases.	NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Langford, CA (corresponding author), NIH, Bldg 10,Room 11B-13, Bethesda, MD 20892 USA.							Adu D, 1997, QJM-MON J ASSOC PHYS, V90, P401, DOI 10.1093/qjmed/90.6.401; AKESSON A, 1994, ARTHRITIS RHEUM, V37, P729, DOI 10.1002/art.1780370518; ALJANADI M, 1989, J RHEUMATOL, V16, P1592; Austin H. A., 1996, Journal of the American Society of Nephrology, V7, P1328; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; Balow James E., 1996, P109; BALOW JE, 1997, DIS KIDNEY, P1851; Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140-6736(97)01300-7; Bolton WK, 1996, KIDNEY INT, V50, P1753, DOI 10.1038/ki.1996.495; BOUMPAS DT, 1992, LANCET, V340, P741, DOI 10.1016/0140-6736(92)92292-N; BRUNS FJ, 1991, ANN INTERN MED, V114, P725, DOI 10.7326/0003-4819-114-9-725; BUNCH TW, 1981, ARTHRITIS RHEUM, V24, P45, DOI 10.1002/art.1780240107; Caccavo D, 1997, ARTHRITIS RHEUM, V40, P27, DOI 10.1002/art.1780400106; CASH JM, 1994, NEW ENGL J MED, V330, P1368; CATTRAN DC, 1995, KIDNEY INT, V47, P1130, DOI 10.1038/ki.1995.161; Cattran DC, 1997, KIDNEY INT, V51, P901, DOI 10.1038/ki.1997.127; CRONIN ME, 1989, J RHEUMATOL, V16, P1225; Cronstein BN, 1996, ARTHRITIS RHEUM-US, V39, P1951, DOI 10.1002/art.1780391203; Dalakas Marinos C., 1995, Annals of Neurology, V37, pS74; DENTON CP, 1994, BRIT J RHEUMATOL, V33, P90; DONADIO JV, 1978, NEW ENGL J MED, V299, P1151, DOI 10.1056/NEJM197811232992102; EISER AR, 1994, ARTHRITIS RHEUM, V37, P428, DOI 10.1002/art.1780370318; ELHENCE R, 1994, PEDIATR NEPHROL, V8, P1, DOI 10.1007/BF00868243; Falk RJ, 1997, J AM SOC NEPHROL, V8, P314; FALK RJ, 1992, ANN INTERN MED, V116, P438, DOI 10.7326/0003-4819-116-6-438; FUKUDA M, 1994, EUR J PEDIATR, V153, P167; FURST DE, 1989, ARTHRITIS RHEUM, V32, P584, DOI 10.1002/anr.1780320512; GISSLINGER H, 1991, CLIN EXP RHEUMATOL, V9, P383; Gourley MF, 1996, ANN INTERN MED, V125, P549, DOI 10.7326/0003-4819-125-7-199610010-00003; Haagsma CJ, 1997, BRIT J RHEUMATOL, V36, P1082; HOGAN SL, 1995, AM J KIDNEY DIS, V25, P862, DOI 10.1016/0272-6386(95)90568-5; JOHNSON JP, 1985, MEDICINE, V64, P219, DOI 10.1097/00005792-198507000-00003; JONES DW, 1987, ARTHRITIS RHEUM, V30, P959, DOI 10.1002/art.1780300825; Kasteler JS, 1997, J AM ACAD DERMATOL, V36, P67, DOI 10.1016/S0190-9622(97)70327-X; LEFF RL, 1993, MEDICINE, V72, P225, DOI 10.1097/00005792-199307000-00002; MACCIONI FJ, 1990, AUST NZ J MED, V20, P806, DOI 10.1111/j.1445-5994.1990.tb00428.x; Mak SK, 1996, NEPHROL DIAL TRANSPL, V11, P2192, DOI 10.1093/oxfordjournals.ndt.a027136; MartinezTaboada VM, 1996, LUPUS, V5, P74, DOI 10.1177/096120339600500114; MEENAN RF, 1991, ARTHRITIS RHEUM, V34, P761, DOI 10.1002/art.1780340618; Moreland LW, 1996, J RHEUMATOL, V23, P78; Moroni G, 1996, KIDNEY INT, V50, P2047, DOI 10.1038/ki.1996.528; NEUWELT CM, 1995, AM J MED, V98, P32, DOI 10.1016/S0002-9343(99)80078-3; NIAUDET P, 1994, J AM SOC NEPHROL, V5, P1049; NIELSEN EG, 1997, IMMUNOLOGIC RENAL DI; NOLASCO F, 1986, KIDNEY INT, V29, P1215, DOI 10.1038/ki.1986.130; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; ODell JR, 1997, RHEUM DIS CLIN N AM, V23, P779, DOI 10.1016/S0889-857X(05)70360-4; ORDONEZ JD, 1993, KIDNEY INT, V44, P638, DOI 10.1038/ki.1993.292; PONTICELLI C, 1993, NEPHROL DIAL TRANSPL, V8, P1326; PONTICELLI C, 1995, KIDNEY INT, V48, P1600, DOI 10.1038/ki.1995.453; Ponticelli C, 1997, TREATMENT PRIMARY GL; Ramos PC, 1996, CLIN EXP RHEUMATOL, V14, P295; Reiff A, 1997, J RHEUMATOL, V24, P2436; SILVER RM, 1993, J RHEUMATOL, V20, P838; STEEN VD, 1994, ARTHRITIS RHEUM-US, V37, P1290, DOI 10.1002/art.1780370904; Stein CM, 1997, ARTHRITIS RHEUM, V40, P1843, DOI 10.1002/art.1780401018; STEINBERG AD, 1972, ANN INTERN MED, V76, P619, DOI 10.7326/0003-4819-76-4-619; Tarshish P, 1997, J AM SOC NEPHROL, V8, P769; TORRES MA, 1990, RHEUM DIS CLIN N AM, V16, P217; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; Tune BM, 1997, J AM SOC NEPHROL, V8, P824; VandenHoogen FHJ, 1996, BRIT J RHEUMATOL, V35, P364; VANDERHEIJDE DMFM, 1992, ARTHRITIS RHEUM-US, V35, P26; vanZeben D, 1996, J RHEUMATOL, V23, P31; Villalba Lourdes, 1996, Current Opinion in Rheumatology, V8, P544, DOI 10.1097/00002281-199611000-00008; VILLALBA ML, 1995, ARTHRITIS RHEUM, V38, P5307; Wallace CA, 1997, ARTHRITIS RHEUM, V40, P1852, DOI 10.1002/art.1780401019; Wasserstein AG, 1997, J AM SOC NEPHROL, V8, P664; Wise CM, 1996, J RHEUMATOL, V23, P1005; Zeller V, 1996, J RHEUMATOL, V23, P1424	70	37	39	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				1021	1028		10.7326/0003-4819-128-12_Part_1-199806150-00012	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00012			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZU474	9625665				2022-12-28	WOS:000074201300009
J	Brayne, H; Sargeant, L; Brayne, C				Brayne, H; Sargeant, L; Brayne, C			Could boxing be banned? A legal and epidemiological perspective	BRITISH MEDICAL JOURNAL			English	Article									Univ Sunderland, Sunderland Business Sch, Sunderland SR60DD, England; Univ Cambridge, Dept Community Med, Cambridge CB2 2SR, England	University of Sunderland; University of Cambridge	Brayne, H (corresponding author), Univ Sunderland, Sunderland Business Sch, Sunderland SR60DD, England.		Brayne, Carol/AAA-4285-2020	Brayne, Carol/0000-0001-5307-663X				DILLNER L, 1993, BRIT MED J, V306, P1561; Grayson Edward, 1994, SPORT LAW; Gunn M. J., 1995, LEGAL STUDIES, V15, P181; *LAW COMM, 1995, 139 LAW COMM; Law Commission, 1994, 134 LAW COMM; 1997, TIMES           0220	6	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1813	1815		10.1136/bmj.316.7147.1813	http://dx.doi.org/10.1136/bmj.316.7147.1813			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624077	Green Published			2022-12-28	WOS:000074286300034
J	Brewster, R; Lee, J; Altaba, ARI				Brewster, R; Lee, J; Altaba, ARI			Gli/Zic factors pattern the neural plate by defining domains of cell differentiation	NATURE			English	Article							NEUROGENESIS; XENOPUS; INDUCTION; ECTODERM; EMBRYOS; PROTEIN; CREST; TUBE	Three cell types differentiate in the early frog neural plate: neural crest at the lateral edges, floorplate at the midline and primary neurons in three bilateral stripes. Floorplate cells and ventral neurons are induced by Sonic hedgehog(1,2) (Shh) and neural crest and dorsal. neurons are induced by epidermal factors such as bone morphogenetic proteins (BMPs)(3). Neurogenesis in a subset of cells within the stripes involves lateral inhibition(4). However, the process by which pools of precursors are defined in stereotypic domains in response to inductive signals is unknown. Here we show that frog Zic2 encodes a zinc-finger transcription factor of the Gli superfamily which is expressed in stripes that alternate with those in which primary neurons differentiate and overlap the domains of floorplate and neural crest progenitors. Zic2 inhibits neurogenesis and induces neural crest differentiation. Conversely, Gli proteins are widely expressed, induce neurogenesis and inhibit neural crest differentiation. Zic2 is therefore a vertebrate pre-pattern gene, encoding anti-neurogenic and crest-inducing functions that counteract the neurogenic but not the floorplate-inducing activity of Gli proteins. We propose that the combined function of Gli/Zic genes responds to inductive signals and induces patterned neural cell differentiation.	NYU, Med Ctr, Dept Cell Biol, Skirball Inst,Dev Genet Program, New York, NY 10016 USA	New York University	Altaba, ARI (corresponding author), NYU, Med Ctr, Dept Cell Biol, Skirball Inst,Dev Genet Program, 540 1st Ave, New York, NY 10016 USA.	ria@saturn.med.nyu.edu		Ruiz i Altaba, Ariel/0000-0003-2292-3933				Altaba AR, 1996, MECH DEVELOP, V60, P207, DOI 10.1016/S0925-4773(96)00618-1; ALTABA ARI, 1992, DEVELOPMENT, V116, P67; ALTABA ARI, 1995, MOL CELL NEUROSCI, V6, P106, DOI 10.1006/mcne.1995.1011; Altaba ARI, 1997, CELL, V90, P193, DOI 10.1016/S0092-8674(00)80325-6; ARUGA J, 1994, J NEUROCHEM, V63, P1880; Aruga J, 1996, J BIOL CHEM, V271, P1043, DOI 10.1074/jbc.271.2.1043; Baker NE, 1997, CURR BIOL, V7, P122, DOI 10.1016/S0960-9822(06)00056-X; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; ESSEX LJ, 1993, DEV DYNAM, V198, P108, DOI 10.1002/aja.1001980205; FERREIRO B, 1994, DEVELOPMENT, V120, P3649; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Lee J, 1997, DEVELOPMENT, V124, P2537; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Marine JC, 1997, MECH DEVELOP, V63, P211, DOI 10.1016/S0925-4773(97)00050-6; MAYOR R, 1995, DEVELOPMENT, V121, P767; Mizuseki K, 1998, DEVELOPMENT, V125, P579; Nagai T, 1997, DEV BIOL, V182, P299, DOI 10.1006/dbio.1996.8449; Nakata K, 1997, P NATL ACAD SCI USA, V94, P11980, DOI 10.1073/pnas.94.22.11980; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2	23	196	200	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					579	583		10.1038/31242	http://dx.doi.org/10.1038/31242			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634234				2022-12-28	WOS:000074150100053
J	Cruickshanks, KJ; Klein, R; Klein, BEK; Wiley, TL; Nondahl, DM; Tweed, TS				Cruickshanks, KJ; Klein, R; Klein, BEK; Wiley, TL; Nondahl, DM; Tweed, TS			Cigarette smoking and hearing loss - The epidemiology of hearing loss study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BEAVER-DAM EYE; RECEPTORS	Context.-Clinical studies have suggested that cigarette smoking may be associated with hearing loss, a common condition affecting older adults. Objective.-To evaluate the association between smoking and hearing loss. Design.-Population-based, cross-sectional study. Setting.-Community of Beaver Dam, Wis. Participants.-Adults aged 48 to 92 years. Of 4541 eligible subjects, 3753 (83%) participated in the hearing study. Main Outcome Measures.-The examination included otoscopy, screening tympanometry, and pure-tone air-conduction and bone-conduction audiometry, Smoking history was ascertained by self-report. Hearing loss was defined as a pure-tone average (0.5, 1, 2, and 4 kHz) greater than 25-dB hearing level in the worse ear. Results.-After adjusting for other factors, current smokers were 1.69 times as likely to have a hearing loss as nonsmokers (95% confidence interval, 1.31-2.17), This relationship remained for those without a history of occupational noise exposure and in analyses excluding those with non-age-related hearing loss. There was weak evidence of a dose-response effect. Nonsmoking participants who lived with a smoker were more likely to have a hearing loss than those who were not exposed to a household member who smoked (odds ratio, 1.94; 95% confidence interval, 1.01-3.74). Conclusions.-These data suggest that environmental exposures may play a role in age-related hearing loss. If longitudinal studies confirm these findings, modification of smoking habits may prevent or delay age-related declines in hearing sensitivity.	Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53705 USA; Univ Wisconsin, Dept Communicat Disorders, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Cruickshanks, KJ (corresponding author), Univ Wisconsin, Dept Ophthalmol & Visual Sci, 610 N Walnut St,460 WARF, Madison, WI 53705 USA.	cruickshanks@epi.ophth.wisc.edu	Legarth, Jonas/A-9156-2012		NEI NIH HHS [EY0694] Funding Source: Medline; NIA NIH HHS [AG11099] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011099] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM NAT STAND I, 1989, ANSI PUBL; *AM NAT STAND I, 1991, ANSI PUBL; [Anonymous], 1978, ASHA, V20, P297; Blanchet C, 1996, J NEUROSCI, V16, P2574; Brant L J, 1996, J Am Acad Audiol, V7, P152; CAMPBELL JA, 1988, P SURV RES METH SECT, P549; CRUICKSHANKS KJ, IN PRESS AM J EPIDEM; GATES GA, 1993, ARCH OTOLARYNGOL, V119, P156; Guth PS, 1996, HEARING RES, V98, P1, DOI 10.1016/0378-5955(96)00031-7; HOSMER DW, 1989, APPL LOGISTIC REGRES; Jarvis J F, 1967, J Laryngol Otol, V81, P63, DOI 10.1017/S0022215100066779; Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5; LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049; LYONS JA, 1992, J TRAUMA STRESS, V5, P111, DOI 10.1007/BF00976816; MAFFEL G, 1962, ARCHIV OTOLARYNGOL, V75, P386; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MCCARTNEY JS, 1994, NEUROTOXICOL TERATOL, V16, P269, DOI 10.1016/0892-0362(94)90048-5; *NAT CTR HLTH STAT, 1967, VITAL HLTH STAT 10, V34, P11; *NAT STRAT RES PLA, 1996, HEAR HEAR IMP, P33; Nondahl D M, 1996, J Am Acad Audiol, V7, P251; ROSEN S, 1962, ANN OTO RHINOL LARYN, V71, P727, DOI 10.1177/000348946207100313; SHAPIRO SL, 1965, EYE EAR NOSE THROAT, V44, P94; SIEGELAUB AB, 1974, ARCH ENVIRON HEALTH, V29, P107, DOI 10.1080/00039896.1974.10666542; Weiss W, 1970, Med Times, V98, P84; WESTON T E, 1964, J Laryngol Otol, V78, P273, DOI 10.1017/S0022215100062071; Wiley T L, 1996, J Am Acad Audiol, V7, P260; ZELMAN S, 1973, JAMA-J AM MED ASSOC, V223, P920, DOI 10.1001/jama.1973.03220080050016	27	264	278	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1715	1719		10.1001/jama.279.21.1715	http://dx.doi.org/10.1001/jama.279.21.1715			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624024	Bronze			2022-12-28	WOS:000073878700032
J	Nightingale, SL				Nightingale, SL			Web site for "year 2000" information on biomedical equipment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	10	11	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1684	1684		10.1001/jama.279.21.1684	http://dx.doi.org/10.1001/jama.279.21.1684			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624011				2022-12-28	WOS:000073878700006
J	Penninx, BWJH; Guralnik, JM; Ferrucci, L; Simonsick, EM; Deeg, DJH; Wallace, RB				Penninx, BWJH; Guralnik, JM; Ferrucci, L; Simonsick, EM; Deeg, DJH; Wallace, RB			Depressive symptoms and physical decline in community-dwelling older persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; IMMUNE-SYSTEM; DISABILITY; PERFORMANCE; ANXIETY; FALLS; CARE	Context.-Significant symptoms of depression are common in the older community-dwelling population. Although depressive symptoms and disability may commonly occur in the same person, whether depressive symptoms contribute to subsequent functional decline has not been elucidated, Objective.-To determine whether depressive symptoms in older persons increase the risk of subsequent decline in physical function as measured by objective performance-based tests. Design.-A 4-year prospective cohort study. Setting.-The communities of Iowa and Washington counties, Iowa. Participants.-A total of 1286 persons aged 71 years and older who completed a short battery of physical performance tests in 1988 and again 4 years later. Main Outcome Measures.-Baseline depressive symptoms were assessed by the Center for Epidemiological Studies Depression Scale. Physical performance tests included an assessment of standing balance, a timed 2.4-m (8-ft) walk, and a timed test of 5 repetitions of rising from a chair and sitting down. Results.-After adjustment far baseline performance score, health status, and sociodemographic factors, increasing levels of depressive symptoms were predictive of greater decline in physical performance over 4 years (odds ratio for decline in those with depressed mood vs those without, 1.55; 95% confidence interval [CI], 1.02-2.34), Even among those at the high end of the functional spectrum, who reported no disability, the severity of depressive symptoms predicted subsequent decline in physical performance (odds ratio for decline, 1.03; 95% CI, 1.00-1.08). Conclusions.-This study provides evidence that older persons who report depressive symptoms are at higher risk of subsequent physical decline, These results suggest that prevention or reduction of depressed mood could play a role in reducing functional decline in older persons.	NIA, Epidemiol Demogr & Biometry Program, Bethesda, MD 20892 USA; INRCA Florence, Dept Geriatr, Florence, Italy; Vrije Univ Amsterdam, Inst Res Extramural Med, Amsterdam, Netherlands; Vrije Univ Amsterdam, Dept Psychiat, Amsterdam, Netherlands; Univ Iowa, Dept Prevent Med & Environm Hlth, Iowa City, IA 52242 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); IRCCS INRCA; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Iowa	Guralnik, JM (corresponding author), NIA, Epidemiol Demogr & Biometry Program, Gateway Bldg,Suite 3C-309,7201 Wisconsin Ave, Bethesda, MD 20892 USA.	jg48s@nih.gov	Simonsick, Eleanor/W-6864-2019; Penninx, Brenda WJH/S-7627-2017	Penninx, Brenda WJH/0000-0001-7779-9672	NATIONAL INSTITUTE ON AGING [Z01AG000215, N01AG002106, N01AG002107] Funding Source: NIH RePORTER; NIA NIH HHS [N01-AG-02107, N01-AG-02106, N01-AG-0215] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barefoot JC, 1996, CIRCULATION, V93, P1976, DOI 10.1161/01.CIR.93.11.1976; BARSKY AJ, 1988, PSYCHOSOM MED, V50, P510, DOI 10.1097/00006842-198809000-00007; Beekman ATF, 1995, J AFFECT DISORDERS, V36, P65, DOI 10.1016/0165-0327(95)00061-5; Beekman ATF, 1997, PSYCHOL MED, V27, P231, DOI 10.1017/S0033291796003510; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; BRUCE ML, 1994, AM J PUBLIC HEALTH, V84, P1796, DOI 10.2105/AJPH.84.11.1796; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; CRESS ME, 1995, J AM GERIATR SOC, V43, P93, DOI 10.1111/j.1532-5415.1995.tb06372.x; CRONBACH LJ, 1970, PSYCHOL BULL, V74, P68, DOI 10.1037/h0029382; Gallo JJ, 1997, J AM GERIATR SOC, V45, P570, DOI 10.1111/j.1532-5415.1997.tb03089.x; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1989, J GERONTOL, V44, pM141, DOI 10.1093/geronj/44.5.M141; GURALNIK JM, 1994, AGING-CLIN EXP RES, V6, P303, DOI 10.1007/BF03324256; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; HUISIANI BA, 1980, J COMMUNITY PSYCHOL, V8, P20; *HYP DET FOLL UP P, 1977, JAMA-J AM MED ASSOC, V237, P2385; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kempen GIJM, 1996, J GERONTOL B-PSYCHOL, V51, pP254, DOI 10.1093/geronb/51B.5.P254; Kohout FJ, 1993, J AGING HEALTH, V5, P79; KRONFOL Z, 1984, LANCET, V1, P1026; Lyness JM, 1997, ARCH INTERN MED, V157, P449, DOI 10.1001/archinte.157.4.449; MILLER AH, 1993, ANN MED, V25, P481, DOI 10.3109/07853899309147316; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; ORMEL J, 1991, ARCH GEN PSYCHIAT, V48, P700; ORMEL J, 1993, AM J PUBLIC HEALTH, V83, P385, DOI 10.2105/AJPH.83.3.385; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; ROSOW I, 1966, J GERONTOL, V39, P686; SEEMAN TE, 1994, J GERONTOL, V49, pM97, DOI 10.1093/geronj/49.3.M97; SEEMAN TE, 1995, J GERONTOL A-BIOL, V50, pM177, DOI 10.1093/gerona/50A.4.M177; *SPSS INC, 1993, SPSS ADV STAT REF GU; STEIN M, 1991, ARCH GEN PSYCHIAT, V48, P171; STURM R, 1995, JAMA-J AM MED ASSOC, V273, P51; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1988, JAMA-J AM MED ASSOC, V259, P1190, DOI 10.1001/jama.259.8.1190; TURNER RJ, 1988, J HEALTH SOC BEHAV, V29, P23, DOI 10.2307/2137178; Unutzer J, 1997, JAMA-J AM MED ASSOC, V277, P1618, DOI 10.1001/jama.277.20.1618; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WHO (World Health Organization), 1977, MAN INT STAT CLASS D; WINOGRAD CH, 1994, J AM GERIATR SOC, V42, P743, DOI 10.1111/j.1532-5415.1994.tb06535.x	42	580	589	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1720	1726		10.1001/jama.279.21.1720	http://dx.doi.org/10.1001/jama.279.21.1720			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZQ544	9624025				2022-12-28	WOS:000073878700033
J	Chiang, CW; Lo, SK; Ko, YS; Cheng, NJ; Lin, PJ; Chang, CH				Chiang, CW; Lo, SK; Ko, YS; Cheng, NJ; Lin, PJ; Chang, CH			Predictors of systemic embolism in patients with mitral stenosis - A prospective study	ANNALS OF INTERNAL MEDICINE			English	Article						embolism; mitral valve stenosis; anticoagulants; atrial fibrillation; balloon dilation	PRESSURE HALF-TIME; TWO-DIMENSIONAL ECHOCARDIOGRAPHY; SPONTANEOUS ECHO CONTRAST; ATRIAL-FIBRILLATION; VALVE DISEASE; COMMISSUROTOMY; COMPLICATIONS; PREVENTION; ACCURACY; CATHETER	Background: Most studies of the predictors of systemic embolism in patients with mitral stenosis have been retrospective. Objective: To prospectively study factors associated with systemic embolism in mitral stenosis. Design: Prospective cohort study. Setting: University-affiliated medical institution with 3000 beds. Patients: 534 consecutive patients with a mitral valve area of 2.0 cm(2) or less; 132 patients were in sinus rhythm, and 402 were in atrial fibrillation. Measurements: Nine clinical and 10 echocardiographic variables were assessed for prediction of systemic embolism over a mean (+/- SD) follow-up of 36.9 +/- 22.5 months. Diagnosis of systemic embolism was based on symptoms and signs (sudden onset of peripheral arterial ischemic or neurologic manifestations without prodromes) and on findings on computed tomography, angiography, and surgery. Results: For patients in sinus rhythm, age (relative risk [RR], 1.12 [95% CI, 1.04 to 1.21]), the presence of a left atrial thrombus (RR, 37.1 [CI, 2.82 to 487.8]), mitral valve area (RR, 16.9 [CI, 1.53 to 187.0]), and the presence of significant aortic regurgitation (RR, 22.4 [CI, 2.72 to 184.8]) were positively associated with embolism. For patients in atrial fibrillation, previous embolism (RR, 3.11 [CI, 1.66 to 5.85]) was positively associated with embolism; percutaneous balloon mitral commissurotomy (RR, 0.37 [CI, 0.18 to 0.79]) was a negative predictor. Conclusions: It may be prudent to give anticoagulants not only to patients in atrial fibrillation and patients with previous systemic embolism but also to those showing a left atrial thrombus or significant aortic regurgitation on echocardiography. Early percutaneous balloon mitral commissurotomy may also help prevent systemic embolism in patients with mitral stenosis.	Chang Gung Univ, Chang Gung Mem Hosp, Cardiovasc Div 1, Taipei 105, Taiwan; Deaking Univ, Burwood, Vic, Australia	Chang Gung Memorial Hospital; Chang Gung University; Deakin University	Chiang, CW (corresponding author), Chang Gung Univ, Chang Gung Mem Hosp, Cardiovasc Div 1, 199 Tung Hwa N Rd, Taipei 105, Taiwan.			LO, Sing Kai/0000-0001-8401-1759				[Anonymous], 1986, Arch Neurol, V43, P71; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; BLACK IW, 1991, J AM COLL CARDIOL, V18, P398, DOI 10.1016/0735-1097(91)90592-W; CASELLA L, 1964, ARCH INTERN MED, V114, P773, DOI 10.1001/archinte.1964.03860120085008; Chiang C W, 1992, Changgeng Yi Xue Za Zhi, V15, P72; CHIANG CW, 1994, CHEST, V106, P396, DOI 10.1378/chest.106.2.396; CHIANG CW, 1988, AM HEART J, V115, P908, DOI 10.1016/0002-8703(88)90899-X; CHIANG CW, 1987, J ULTRAS MED, V6, P525; Chiang CW, 1998, AM J CARDIOL, V81, P515, DOI 10.1016/S0002-9149(97)00943-0; Cooper J W, 1989, J Am Soc Echocardiogr, V2, P56; COULSHED N, 1970, BRIT HEART J, V32, P26; DANIEL WG, 1988, J AM COLL CARDIOL, V11, P1204, DOI 10.1016/0735-1097(88)90283-5; Dixon WJ, 1990, BMDP STAT SOFTWARE M; EASTON JD, 1980, STROKE, V11, P433, DOI 10.1161/01.STR.11.5.433; HATLE L, 1979, CIRCULATION, V60, P1096, DOI 10.1161/01.CIR.60.5.1096; HORSTKOTTE D, 1991, EUR HEART J, V12, P55, DOI 10.1093/eurheartj/12.suppl_B.55; HUNG JS, 1991, AM J CARDIOL, V67, P854, DOI 10.1016/0002-9149(91)90619-V; HWANG JJ, 1992, AM J CARDIOL, V70, P769, DOI 10.1016/0002-9149(92)90557-F; ILICETO S, 1985, AM J CARDIOL, V55, P603, DOI 10.1016/0002-9149(85)90267-X; INOUE K, 1984, J THORAC CARDIOV SUR, V87, P394; Loyd D, 1988, J Am Soc Echocardiogr, V1, P313; PETERSEN P, 1986, STROKE, V17, P622, DOI 10.1161/01.STR.17.4.622; PETERSEN P, 1989, LANCET, V1, P175; PEVERILL RE, 1995, CIRCULATION, V92, P96; RICHARDS KL, 1986, CIRCULATION, V73, P964, DOI 10.1161/01.CIR.73.5.964; ROY D, 1986, AM HEART J, V112, P1039, DOI 10.1016/0002-8703(86)90318-2; RUIZ CE, 1990, AM J CARDIOL, V65, P473, DOI 10.1016/0002-9149(90)90813-G; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SELVIN S, 1995, PRACTICAL BIOSTATIST, P124; SIGEL B, 1981, INVEST RADIOL, V16, P71, DOI 10.1097/00004424-198101000-00013; SMITH MD, 1986, CIRCULATION, V73, P100, DOI 10.1161/01.CIR.73.1.100; THOMAS JD, 1987, J AM COLL CARDIOL, V10, P923, DOI 10.1016/S0735-1097(87)80290-5; VAHANIAN A, 1989, AM J CARDIOL, V63, P847, DOI 10.1016/0002-9149(89)90055-6	33	101	105	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					885	+		10.7326/0003-4819-128-11-199806010-00001	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634425				2022-12-28	WOS:000073808600001
J	Chan, DC; Kim, PS				Chan, DC; Kim, PS			HIV entry and its inhibition	CELL			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; GLYCOPROTEIN; ANTIBODIES; VACCINES; DOMAIN		MIT, Howard Hughes Med Inst, Dept Biol, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	Chan, DC (corresponding author), MIT, Howard Hughes Med Inst, Dept Biol, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.		Chan, Doris/O-1227-2014	Chan, Doris/0000-0002-4990-986X				Bolognesi DP, 1998, NATURE, V391, P638, DOI 10.1038/35504; Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Connor RI, 1998, J VIROL, V72, P1552, DOI 10.1128/JVI.72.2.1552-1576.1998; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Haynes BF, 1996, LANCET, V348, P933, DOI 10.1016/S0140-6736(96)09339-7; Hughson FM, 1997, CURR BIOL, V7, pR565, DOI 10.1016/S0960-9822(06)00283-1; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; Judice JK, 1997, P NATL ACAD SCI USA, V94, P13426, DOI 10.1073/pnas.94.25.13426; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Luciw PA, 1996, FIELD VIROLOGY, P1881; Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; VANCOTT TC, 1995, J IMMUNOL, V155, P4100; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770	22	1075	1150	0	146	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					681	684		10.1016/S0092-8674(00)81430-0	http://dx.doi.org/10.1016/S0092-8674(00)81430-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630213	Bronze			2022-12-28	WOS:000073956700005
J	Zhu, JY; Shibasaki, F; Price, R; Guillemot, JC; Yano, T; Dotsch, V; Wagner, G; Ferrara, P; McKeon, F				Zhu, JY; Shibasaki, F; Price, R; Guillemot, JC; Yano, T; Dotsch, V; Wagner, G; Ferrara, P; McKeon, F			Intramolecular masking of nuclear import signal on NF-AT4 by casein kinase I and MEKK1	CELL			English	Article							NF-KAPPA-B; SUBSTRATE DETERMINANTS; MOLECULAR-CLONING; PROTEIN-KINASE; GENE FAMILY; CALCINEURIN; PHOSPHORYLATION; LOCALIZATION; EXPRESSION; ACTIVATION	T cell activation requires the import of NF-AT transcription factors to the nucleus, a process promoted by calcineurin-dependent dephosphorylation and inhibited by poorly understood protein kinases. Here, we report the identification of two protein kinases that oppose NF-AT4 nuclear import. Casein kinase I alpha directly binds and phosphorylates NF-AT4, resulting in the inhibiton of NF-AT4 nuclear translocation. MEKK1 indirectly suppresses NF-AT4 nuclear import by stabilizing the interaction between NF-AT4 and CKI alpha. CKI alpha thus acts to establish an intramolecular masking of the nuclear location signal on NF-AT4, while MEKK1 augments this mechanism, and may further provide a link to signal transduction pathways regulating NF-AT4.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Sanofi Biorech, F-31676 Labege, France	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Sanofi-Aventis; Sanofi France	McKeon, F (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Doetsch, Volker/D-5697-2011	Dotsch, Volker/0000-0001-5720-212X				Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; HO U, 1997, P NATL ACAD SCI USA, V94, P581; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Kusuda J, 1996, GENOMICS, V32, P140, DOI 10.1006/geno.1996.0091; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; YAN MH, 1994, NATURE, V372, P798; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717	34	261	266	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					851	861		10.1016/S0092-8674(00)81445-2	http://dx.doi.org/10.1016/S0092-8674(00)81445-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630228	Bronze			2022-12-28	WOS:000073956700020
J	Stenzl, A; Ninkovic, M; Kolle, D; Napp, R; Anderl, H; Bartsch, G				Stenzl, A; Ninkovic, M; Kolle, D; Napp, R; Anderl, H; Bartsch, G			Restoration of voluntary emptying of the bladder by transplantation of innervated free skeletal muscle	LANCET			English	Article							NEUROGENIC BLADDER; DETRUSOR-MYOPLASTY	Background. On the basis of studies with animals and experience with functioning muscle transfer in plastic surgery, we have developed a surgical technique to restore detrusor function for patients with bladder acontractility in whom there is no treatment alternative. Methods. Three patients (aged 26 years, 28 years, and 68 years) with bladder acontractility as a result of spinal-cord injury (two patients) and chronic overdistension (one patient), who required catheterisation for bladder emptying for 5 years, 2 years, and 2 years, respectively, took part in our study. The patients were treated with microneurovascular free transfer of autologous latissimus dorsi muscle to the bladder to restore detrusor function. Follow-up included clinical and urodynamic evaluation, colour doppler sonography, intravenous urography, and flow-mode computerised tomography. Findings. The three patients voluntarily emptied their bladders at 16 weeks, 16 weeks, and 30 weeks after surgery, respectively. There was no need for further catheterisation throughout the follow-up period. On urodynamic assessment at 12 months after the operation bladder capacity was found to be 600 mt, 600 mt, and 650 mL, residual urinary volume 0 mL, 50 mL, 90 mL, and maximum flow rate 26 mL/s, 25 mL/s, and 18 mL/s, respectively. Activity at the transplanted latissimus dorsi was confirmed by ultrasonography and flow-mode computerised tomography. Interpretation. Microneurovascular free transfer of latissimus dorsi muscle to functionally restore a deficient detrusor muscle has proved to be successful for the three patients in our study. This technique may also be an option to restore the function of other smooth-muscle organs.	Univ Innsbruck, Med Ctr, Dept Urol, A-6020 Innsbruck, Austria; Univ Innsbruck, Med Ctr, Dept Plast Surg, A-6020 Innsbruck, Austria; Univ Innsbruck, Med Ctr, Dept Gynaecol, A-6020 Innsbruck, Austria; Univ Innsbruck, Med Ctr, Dept Radiodiagnost 2, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck; University of Innsbruck; University of Innsbruck	Stenzl, A (corresponding author), Univ Innsbruck, Med Ctr, Dept Urol, Anichstr 35, A-6020 Innsbruck, Austria.	arnulf.stenzl@uibk.ac.at						BAETEN CGMI, 1991, LANCET, V338, P1163, DOI 10.1016/0140-6736(91)92030-6; BRINDLEY GS, 1990, PARAPLEGIA, V28, P469, DOI 10.1038/sc.1990.63; CARPENTIER A, 1985, LANCET, V1, P1267; CHANCELLOR MB, 1994, LANCET, V343, P669, DOI 10.1016/S0140-6736(94)92661-1; CHANCELLOR MB, 1994, NEUROUROL URODYNAM, V13, P547, DOI 10.1002/nau.1930130509; MANKTELOW R, 1985, RECENT ADV PLASTIC S, P123; MANKTELOW RT, 1989, ANN PLAS SURG, V22, P275, DOI 10.1097/00000637-198904000-00001; MESSING EM, 1985, J UROLOGY, V134, P1202, DOI 10.1016/S0022-5347(17)47687-7; Ninkovic M, 1997, PLAST RECONSTR SURG, V100, P402, DOI 10.1097/00006534-199708000-00020; NINKOVIC M, 1994, BRIT J PLAST SURG, V47, P185, DOI 10.1016/0007-1226(94)90052-3; Ninkovic M, 1998, PLAST RECONSTR SURG, V101, P971, DOI 10.1097/00006534-199804040-00013; RUSSELL RC, 1986, PLAST RECONSTR SURG, V78, P336, DOI 10.1097/00006534-198609000-00009; Stenzl A, 1997, J UROLOGY, V157, P1103, DOI 10.1016/S0022-5347(01)65150-4; TANAGHO EA, 1988, J UROLOGY, V140, P1331, DOI 10.1016/S0022-5347(17)42038-6; Wechselberger G, 1997, J RECONSTR MICROSURG, V13, P125, DOI 10.1055/s-2007-1000228; ZHANG YH, 1990, J UROLOGY, V144, P1194	16	35	38	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1483	1485		10.1016/S0140-6736(97)10005-8	http://dx.doi.org/10.1016/S0140-6736(97)10005-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605805				2022-12-28	WOS:000073707300011
J	Aukerman, MJ; Amasino, RM				Aukerman, MJ; Amasino, RM			Floral induction and florigen	CELL			English	Review							PHYTOCHROME-A; ARABIDOPSIS; SHOOTS; PLANT; GENE		Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Aukerman, MJ (corresponding author), Univ Wisconsin, Dept Biochem, 420 Henry Mall, Madison, WI 53706 USA.							BERNIER G, 1993, PLANT CELL, V5, P1147, DOI 10.1105/tpc.5.10.1147; Chailakhyan MK., 1936, C R ACAD SCI URSS, V13, P79; Colasanti J, 1998, CELL, V93, P593, DOI 10.1016/S0092-8674(00)81188-5; Furner IJ, 1996, DEVELOPMENT, V122, P1041; Garner WW., 1920, J AGR RES, VXVII, P553; HEMPEL FD, 1995, PLANT J, V8, P725, DOI 10.1046/j.1365-313X.1995.08050725.x; Irish E, 1997, PLANT J, V11, P63, DOI 10.1046/j.1365-313X.1997.11010063.x; JOHNSON E, 1994, PLANT PHYSIOL, V105, P141, DOI 10.1104/pp.105.1.141; LANG A, 1977, P NATL ACAD SCI USA, V74, P2412, DOI 10.1073/pnas.74.6.2412; LEE I, 1994, PLANT CELL, V6, P75, DOI 10.1105/tpc.6.1.75; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; McDaniel CN, 1996, PLANT J, V9, P55, DOI 10.1046/j.1365-313X.1996.09010055.x; Okamuro JK, 1996, P NATL ACAD SCI USA, V93, P13831, DOI 10.1073/pnas.93.24.13831; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; RuizGarcia L, 1997, PLANT CELL, V9, P1921, DOI 10.1105/tpc.9.11.1921; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; Weller JL, 1997, PLANT PHYSIOL, V114, P1225, DOI 10.1104/pp.114.4.1225; Weller JL, 1997, TRENDS PLANT SCI, V2, P412, DOI 10.1016/S1360-1385(97)85580-X; ZEEVAART JAD, 1984, LIGHT FLOWERING PROC, P137	20	22	23	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					491	494		10.1016/S0092-8674(00)81178-2	http://dx.doi.org/10.1016/S0092-8674(00)81178-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604924	Bronze			2022-12-28	WOS:000073722200002
J	Stell, IM; Gransden, WR				Stell, IM; Gransden, WR			Simple tests for septic bursitis: comparative study	BRITISH MEDICAL JOURNAL			English	Article									Guys Hosp, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust	Stell, IM (corresponding author), Univ London Kings Coll Hosp, Kings Healthcare NHS Trust, Dept Accid & Emergency, London SE5 9RS, England.							FREEMONT AJ, 1991, ANN RHEUM DIS, V50, P101, DOI 10.1136/ard.50.2.101; HO G, 1979, ARCH INTERN MED, V139, P1269, DOI 10.1001/archinte.139.11.1269; RADDATZ DA, 1987, J RHEUMATOL, V14, P1160; VONESSEN R, 1986, ANN RHEUM DIS, V45, P454, DOI 10.1136/ard.45.6.454; ZIMMERMANN B, 1995, SEMIN ARTHRITIS RHEU, V24, P391, DOI 10.1016/S0049-0172(95)80008-5	5	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1998	316	7148					1877	1877						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632407	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000074686500024
J	Letvin, NL				Letvin, NL			Progress in the development of an HIV-1 vaccine	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC LYMPHOCYTES-T; RHESUS-MONKEYS; NEUTRALIZING ANTIBODIES; PERSISTENT INFECTION; POLIOVIRUS REPLICONS; CEREBROSPINAL-FLUID; IMMUNE-RESPONSES; SIV VACCINE; TYPE-1	Containment of the acquired immunodeficiency syndrome (AIDS) epidemic will require an effective human immunodeficiency virus type 1 (HIV-1) vaccine. Accumulating evidence suggests that such a vaccine must efficiently elicit an HIV-1-specific cytotoxic T lymphocyte (CTL) response. Nonhuman primate models will continue to provide an important tool for assessing the extent of protective immunity induced by various immunization strategies. Although replication-competent AIDS viruses attenuated for pathogenicity by selective gene deletions have provided protective immunity in nonhuman primate models, the long-term safety of-such vaccines in human populations is suspect. Inactivated virus and subunit vaccines have elicited neither CTLs nor antibodies capable of neutralizing a wide array of patient HIV-1 isolates. Considerable effort is now being focused on evaluating live vector-based vaccine and plasmid DNA vaccine approaches for preventing HIV-1 infection both in animal model and human studies. Our growing understanding of the biology of HIV-1 and immune responses to this virus will continue to suggest improved vaccination approaches for exploration.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Letvin, NL (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.	nletvin@bidmc.harvard.edu						BERMAN PW, 1988, P NATL ACAD SCI USA, V85, P5200, DOI 10.1073/pnas.85.14.5200; BOUHABIB DC, 1994, J VIROL, V68, P6006, DOI 10.1128/JVI.68.9.6006-6013.1994; Boyer JD, 1997, NAT MED, V3, P526, DOI 10.1038/nm0597-526; Burton DR, 1997, AIDS, V11, pS87; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHEN ZW, 1995, J EXP MED, V182, P21, DOI 10.1084/jem.182.1.21; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Cranage MP, 1997, VIROLOGY, V229, P143, DOI 10.1006/viro.1996.8419; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Davis NL, 1996, J VIROL, V70, P3781, DOI 10.1128/JVI.70.6.3781-3787.1996; DESROSIERS R, COMMUNICATION; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FUITZ P, COMMUNICATION; GIRARD M, 1995, J VIROL, V69, P6239, DOI 10.1128/JVI.69.10.6239-6248.1995; HADIDA F, 1992, J CLIN INVEST, V89, P53, DOI 10.1172/JCI115585; HART MK, 1990, J IMMUNOL, V145, P2677; HIRSCH VM, 1994, VIRUS RES, V32, P183, DOI 10.1016/0168-1702(94)90041-8; Hirsch VM, 1996, J VIROL, V70, P3741, DOI 10.1128/JVI.70.6.3741-3752.1996; HU SL, 1987, NATURE, V328, P721, DOI 10.1038/328721a0; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; IGARASHI T, 1994, AIDS RES HUM RETROV, V10, P1021, DOI 10.1089/aid.1994.10.1021; JASSOY C, 1992, J IMMUNOL, V149, P3113; Johnson RP, 1997, J VIROL, V71, P7711, DOI 10.1128/JVI.71.10.7711-7718.1997; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LETVIN NL, 1990, J ACQ IMMUN DEF SYND, V3, P1023; Letvin NL, 1997, P NATL ACAD SCI USA, V94, P9378, DOI 10.1073/pnas.94.17.9378; LI J, 1992, J ACQ IMMUN DEF SYND, V5, P639; LI JT, 1995, J VIROL, V69, P7061, DOI 10.1128/JVI.69.11.7061-7067.1995; LOHMAN BL, 1995, J IMMUNOL, V155, P5855; LUCIW PA, 1995, P NATL ACAD SCI USA, V92, P7490, DOI 10.1073/pnas.92.16.7490; Luo LZ, 1998, VIROLOGY, V240, P316, DOI 10.1006/viro.1997.8922; Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340; MEYER H, 1991, J GEN VIROL, V72, P1031, DOI 10.1099/0022-1317-72-5-1031; Meyers G, 1993, HUMAN RETROVIRUSES A; MOLDOVEANU Z, 1995, VACCINE, V13, P1013, DOI 10.1016/0264-410X(95)00018-V; Montefiori DC, 1996, J INFECT DIS, V173, P60, DOI 10.1093/infdis/173.1.60; MORRIS L, IN PRESS J EXP MED; MORROW CD, 1994, AIDS RES HUM RETROV, V10, pS61; MOSSMAN SP, 1995, P NATL ACAD SCI USA, V92, P1953; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; Novembre FJ, 1997, J VIROL, V71, P4086, DOI 10.1128/JVI.71.5.4086-4091.1997; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Pellegrin I, 1996, J ACQ IMMUN DEF SYND, V11, P438, DOI 10.1097/00042560-199604150-00003; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Pilgrim AK, 1997, J INFECT DIS, V176, P924, DOI 10.1086/516508; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; REDFIELD RR, 1998, NEW ENGL J MED, V316, P673; Reimann KA, 1996, J VIROL, V70, P6922, DOI 10.1128/JVI.70.10.6922-6928.1996; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; SETHI KK, 1988, NATURE, V335, P178, DOI 10.1038/335178a0; SHEN L, 1991, SCIENCE, V252, P440, DOI 10.1126/science.1708168; Shibata R, 1997, J VIROL, V71, P8141, DOI 10.1128/JVI.71.11.8141-8148.1997; STAMATATOS L, 1995, J VIROL, V69, P6191, DOI 10.1128/JVI.69.10.6191-6198.1995; Tobin GJ, 1997, VIROLOGY, V236, P307, DOI 10.1006/viro.1997.8745; TRAUGER RJ, 1994, J INFECT DIS, V169, P1256, DOI 10.1093/infdis/169.6.1256; VAHEY M, 1994, AIDS RES HUM RETROV, V10, P649, DOI 10.1089/aid.1994.10.649; VANCOTT TC, 1995, AIDS RES HUM RETROV, V11, P1379, DOI 10.1089/aid.1995.11.1379; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; Wang YJ, 1997, J VIROL, V71, P3677, DOI 10.1128/JVI.71.5.3677-3683.1997; WEINHOLD K, COMMUNICATION; WEINHOLD KJ, 1997, RETROVIRUSES HUMAN A; WHATMORE AM, 1995, J VIROL, V69, P5117, DOI 10.1128/JVI.69.8.5117-5123.1995; *WHO, 1995, AIDS, V9; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; YAMAMOTO H, 1992, J IMMUNOL, V149, P728; YASUTOMI Y, 1993, J IMMUNOL, V150, P3101	70	217	265	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1998	280	5371					1875	1880		10.1126/science.280.5371.1875	http://dx.doi.org/10.1126/science.280.5371.1875			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632379				2022-12-28	WOS:000074323800044
J	Ravid, M; Brosh, D; Levi, Z; Bar-Dayan, Y; Ravid, D; Rachmani, R				Ravid, M; Brosh, D; Levi, Z; Bar-Dayan, Y; Ravid, D; Rachmani, R			Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						enalapril; diabetes mellitus, non-insulin-dependent; albuminuria; diabetic nephropathies; angiotensin-converting enzyme inhibitors	CONVERTING ENZYME-INHIBITION; BLOOD-PRESSURE; NEPHROPATHY; MICROALBUMINURIA; PREDICTOR; HYPERTENSION; PROGRESSION; PROTEINURIA; RETINOPATHY; PREVENTION	Background: Angiotensin-converting enzyme (ACE) inhibitors attenuate the decline in renal function in diabetic patients with microalbuminuria. However, no data are available on the use of ACE inhibitors to prevent the decrease in renal function in normotensive, normoalbuminuric patients with type 2 diabetes. Objective: To evaluate the effect of prolonged ACE inhibition on renal function and albuminuria in patients with type 2 diabetes. Design: Randomized, double-blind, placebo-controlled trial with 6-year follow-up. Setting: Eight outpatient clinics coordinated by a department of medicine in a university hospital. Patients: 156 patients in whom type 2 diabetes was diagnosed after 40 years of age who had a baseline mean blood pressure less than 107 mm Hg and albuminuria (albumin excretion less than or equal to 30 mg/24 h). Intervention: Enalapril, 10 mg/d, or placebo. Measurements: Degree of albuminuria at 24 hours, creatinine clearance, blood pressure, and hemoglobin A(1c) values. Results: Enalapril therapy decreased albumin excretion from a mean +/- SD of 11.6 +/- 7 mg/24 h to 9.7 +/- 6 mg/24 h at 2 years. This was followed by a gradual increase to 15.8 +/- 8 mg/24 h at 6 years, In the placebo group, albumin excretion increased from 10.8 +/- 8 mg/24 h to 26.5 +/- 10 mg/24 h at 6 years (P = 0.001 far enalapril compared with placebo). Transition to microalbuminuria occurred in 15 of 79 (19%) placebo recipients and 5 of 77 (6.5%) enalapril recipients. Enalapril treatment resulted in an absolute risk reduction of 12.5% (95% CI, 2% to 23%; P = 0.042) for development of microalbuminuria. After 6 years, creatinine clearance decreased from 1.78 +/- 0.13 mL/s to 1.63 +/- 0.12 mL/s (mean decrease, 0.025 mL/s per year) in enalapril recipients and from 1.81 +/- 0.15 mL/s to 1.57 +/- 0.17 mL/s (mean decrease, 0.04 mL/s per year) in placebo recipients (P = 0.040). Hemoglobin A(1c) values decreased modestly in both groups. Mean blood pressure remained normal (<107 mm Hg) in all patients. Conclusions: Enalapril attenuated the decline in renal function and reduced the extent of albuminuria in normotensive, normoalbuminuric patients with type 2 diabetes, Further research is needed to determine whether this treatment forestalls the development of overt nephropathy.	Meir Hosp, IL-44281 Kefar Sava, Israel	Tel Aviv University; Sackler Faculty of Medicine	Ravid, M (corresponding author), Meir Hosp, IL-44281 Kefar Sava, Israel.	mravid@netvision.net.il		Levi, Zohar/0000-0003-2456-8891				BAKRIS GL, 1992, KIDNEY INT, V41, P912, DOI 10.1038/ki.1992.139; BARTELS H, 1972, CLIN CHIM ACTA, V37, P193, DOI 10.1016/0009-8981(72)90432-9; BJORCK S, 1992, BMJ-BRIT MED J, V304, P339, DOI 10.1136/bmj.304.6823.339; Chaturvedi N, 1997, LANCET, V349, P1787, DOI 10.1016/S0140-6736(96)10244-0; DERBY L, 1989, DIABETES METAB, V15, P320; Dinneen SF, 1997, ARCH INTERN MED, V157, P1413, DOI 10.1001/archinte.157.13.1413; JANKA HU, 1989, DIABETES, V38, P460, DOI 10.2337/diabetes.38.4.460; KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009; KLEIN R, 1989, ARCH INTERN MED, V149, P2427, DOI 10.1001/archinte.149.11.2427; KONEN J, 1993, AM J KIDNEY DIS, V22, P791, DOI 10.1016/S0272-6386(12)70336-0; Koren W, 1997, DIABETOLOGIA, V40, P302, DOI 10.1007/s001250050678; LEBOVITZ HE, 1994, KIDNEY INT, V45, pS150; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MATHIESEN ER, 1991, BMJ-BRIT MED J, V303, P81, DOI 10.1136/bmj.303.6794.81; MATTOCK MB, 1992, DIABETES, V41, P736, DOI 10.2337/diabetes.41.6.736; MILES DW, 1970, SCAND J CLIN LAB INV, V26, P5, DOI 10.3109/00365517009049206; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MOGENSEN CE, 1992, CLIN NEPHROL, V38, pS28; MOTULSKY H, 1995, INTUITIVE BIOSTATIST, P198; NATHAN DM, 1993, NEW ENGL J MED, V328, P1676, DOI 10.1056/NEJM199306103282306; NEIL A, 1993, DIABETES CARE, V16, P996, DOI 10.2337/diacare.16.7.996; PARVING HH, 1995, AM J KIDNEY DIS, V26, P99, DOI 10.1016/0272-6386(95)90162-0; Ravid M, 1996, ARCH INTERN MED, V156, P286, DOI 10.1001/archinte.156.3.286; Ravid M, 1997, CONTRIB NEPHROL, V120, P39; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; ROSSING P, 1994, DIABETOLOGIA, V37, P511, DOI 10.1007/s001250050140; SATHIANATHAN P, 1986, CLIN CHEM, V32, P202; SCHMITZ A, 1988, DIABETIC MED, V5, P126, DOI 10.1111/j.1464-5491.1988.tb00958.x; SHOTT S, 1990, STAT HLTH PROFESSION, P57; VIBERTI GC, 1982, LANCET, V1, P1430; World Health Organization, 1980, TECHN REP SER, V646; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521	33	299	310	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				982	+		10.7326/0003-4819-128-12_Part_1-199806150-00004	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625684				2022-12-28	WOS:000074201300003
J	van't Hof, AW; Suryapranata, H; de Boer, MJ; Hoorntje, JCA; Zijlstra, F				van't Hof, AW; Suryapranata, H; de Boer, MJ; Hoorntje, JCA; Zijlstra, F			Costs of stenting for acute myocardial infarction	LANCET			English	Letter									De Weezenlanden Hosp, Dept Cardiol, NL-8011 JW Zwolle, Netherlands		Zijlstra, F (corresponding author), De Weezenlanden Hosp, Dept Cardiol, NL-8011 JW Zwolle, Netherlands.		Suryapranata, H./H-8095-2014					Lieu TA, 1997, J AM COLL CARDIOL, V30, P1741, DOI 10.1016/S0735-1097(97)00391-4; Steinhubl SR, 1997, LANCET, V350, P532, DOI 10.1016/S0140-6736(05)63135-2; SURYAPRANATA H, IN PRESS CIRCULATION; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093; Zijlstra F, 1996, EUR HEART J, V17, P382	5	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1817	1817		10.1016/S0140-6736(05)78785-7	http://dx.doi.org/10.1016/S0140-6736(05)78785-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635984	Bronze			2022-12-28	WOS:000074197600063
J	Galmiche, JP; Letessier, E; Scarpignato, C				Galmiche, JP; Letessier, E; Scarpignato, C			Fortnightly review - Treatment of gastro-oesophageal reflux disease in adults	BRITISH MEDICAL JOURNAL			English	Review							GASTROESOPHAGEAL REFLUX; H-2-RECEPTOR ANTAGONISTS; NISSEN FUNDOPLICATION; ESOPHAGITIS; THERAPY; OMEPRAZOLE; MANAGEMENT; RANITIDINE; STRICTURE; RELAPSE		Hotel Dieu Univ Hosp, Dept Gastroenterol & Hepatol, F-44035 Nantes 01, France; Univ Nantes, Coll Med, Gastrosurg Unit, F-44035 Nantes, France; Univ Parma, Sch Med & Dent, Inst Pharmacol, I-43100 Parma, Italy	Nantes Universite; CHU de Nantes; Nantes Universite; University of Parma	Galmiche, JP (corresponding author), Hotel Dieu Univ Hosp, Dept Gastroenterol & Hepatol, F-44035 Nantes 01, France.	Galmiche@easynet.fr	Scarpignato, Carmelo/ABC-1745-2021	Scarpignato, Carmelo/0000-0001-5645-857X				ANVARI M, 1995, BRIT J SURG, V82, P938, DOI 10.1002/bjs.1800820728; BARDHAN KD, 1997, GASTROENTEROLOGY, V112, pA165; Bate CM, 1996, ALIMENT PHARM THERAP, V10, P547, DOI 10.1046/j.1365-2036.1996.44186000.x; BERENSON MM, 1993, GASTROENTEROLOGY, V104, P1686, DOI 10.1016/0016-5085(93)90646-T; BLUM AL, 1993, DIGEST DIS SCI, V38, P551, DOI 10.1007/BF01316514; Carlsson R, 1997, ALIMENT PHARM THER, V11, P473, DOI 10.1046/j.1365-2036.1997.00167.x; Chiba N, 1997, GASTROENTEROLOGY, V112, P1798, DOI 10.1053/gast.1997.v112.pm9178669; COLINJONES DG, 1995, ALIMENT PHARM THERAP, V9, P9; COLLET D, 1995, AM J SURG, V169, P622, DOI 10.1016/S0002-9610(99)80234-7; DEBOER WA, 1994, ALIMENT PHARM THER, V8, P147; FENNERTY MB, 1993, ALIMENT PHARM THER, V7, P339; Galmiche JP, 1997, ALIMENT PHARM THER, V11, P765, DOI 10.1046/j.1365-2036.1997.00185.x; GALMICHE JP, 1994, SCAND J GASTROENTERO, V29, P62, DOI 10.3109/00365529409105366; GRAHAM DY, 1983, AM J GASTROENTEROL, V78, P257; HARVEY RF, 1987, LANCET, V2, P1200; HEADING RC, 1995, SCAND J GASTROENTERO, V30, P25; Heudebert GR, 1997, GASTROENTEROLOGY, V112, P1078, DOI 10.1016/S0016-5085(97)70118-5; HILLMAN AL, 1994, SCAND J GASTROENTERO, V29, P98, DOI 10.3109/00365529409105374; HOLT S, 1994, DRUGS, V47, P1, DOI 10.2165/00003495-199447010-00001; Hunter JG, 1996, ANN SURG, V224, P51, DOI 10.1097/00000658-199607000-00008; Kahrilas PJ, 1996, JAMA-J AM MED ASSOC, V276, P983, DOI 10.1001/jama.276.12.983; KITCHIN LI, 1991, ARCH INTERN MED, V151, P448, DOI 10.1001/archinte.151.3.448; Kuipers EJ, 1996, NEW ENGL J MED, V334, P1018, DOI 10.1056/NEJM199604183341603; LUOSTARINEN M, 1993, GUT, V34, P1015, DOI 10.1136/gut.34.8.1015; MARKS RD, 1994, GASTROENTEROLOGY, V106, P907, DOI 10.1016/0016-5085(94)90749-8; ORR WC, 1988, ALIMENT PHARM THERAP, V2, P229; POYNARD T, 1993, ALIMENT PHARM THERAP, V7, P385; SCARPIGNATO C, 1992, FRONT GASTROINTEST R, V20, P153; SCARPIGNATO C, INPRESS GUIDELINES M; SCHINDLBECK NE, 1995, ARCH INTERN MED, V155, P1808, DOI 10.1001/archinte.155.16.1808; SCHWARTZ JI, 1995, J CLIN PHARMACOL, V35, P362, DOI 10.1002/j.1552-4604.1995.tb04074.x; SMITH PM, 1994, GASTROENTEROLOGY, V107, P1312, DOI 10.1016/0016-5085(94)90532-0; SONTAG SJ, 1990, GASTROENTEROLOGY, V99, P613, DOI 10.1016/0016-5085(90)90945-W; SPECHLER SJ, 1992, NEW ENGL J MED, V326, P786, DOI 10.1056/NEJM199203193261202; SPECHLER SJ, 1992, DIGESTION, V51, P24, DOI 10.1159/000200911; Tytgat GNJ, 1996, EUR J GASTROEN HEPAT, V8, P603, DOI 10.1097/00042737-199606000-00020; VIGNERI S, 1995, NEW ENGL J MED, V333, P1106, DOI 10.1056/NEJM199510263331703; Watson DI, 1996, BRIT J SURG, V83, P1284, DOI 10.1002/bjs.1800830933; WATSON DI, 1994, GUT, V35, pS15; Watson RGP, 1996, ALIMENT PHARM THERAP, V10, P913, DOI 10.1046/j.1365-2036.1996.69240000.x; Weinberg DS, 1996, MED CLIN N AM, V80, P411, DOI 10.1016/S0025-7125(05)70446-6; WILDERSMITH CH, 1992, SCAND J GASTROENTERO, V27, P14, DOI 10.3109/00365529209096000	42	55	57	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1720	1723		10.1136/bmj.316.7146.1720	http://dx.doi.org/10.1136/bmj.316.7146.1720			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614026	Green Published			2022-12-28	WOS:000074129500026
J	Bennett, SRM; Carbone, FR; Karamalis, F; Flavell, RA; Miller, JFAP; Heath, WR				Bennett, SRM; Carbone, FR; Karamalis, F; Flavell, RA; Miller, JFAP; Heath, WR			Help for cytotoxic-T-cell responses is mediated by CD40 signalling	NATURE			English	Article							CD40-CD40 LIGAND INTERACTION; ANTIBODY-RESPONSES; HUMAN MONOCYTES; CD8(+) CTL; MICE; ACTIVATION; INDUCTION; INVIVO; LYMPHOCYTES; REQUIREMENT	Cytotoxic T lymphocytes (CTLs) which carry the CD8 antigen recognize antigens that are presented on target cells by the class I major histocompatibility complex. CTLs are responsible for the killing of antigen-bearing target cells, such as virus-infected cells. Although CTL effecters can act alone when killing target cells, their differentiation from naive CD8-positive T cells is often dependent on 'help' from CD4-positive helper T (T-H) cells(1-4).Furthermore, for effective CTL priming, this help must be provided in a cognate manner, such that both the T-H cell and the CTL recognize antigen on the same antigen-presenting cell(2,4). One explanation for this requirement is that T-H cells are needed to convert the antigen-presenting cell into a cell that is fully competent to prime CTL5. Here we show that signalling through CD40 on the antigen-presenting cells can replace the requirement for T-H cells, indicating that T-cell 'help', at least for generation of CTLs by cross-priming, is mediated by signalling through CD40 on the antigen-presenting cell.	PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia; PO Royal Brisbane Hosp, Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Herston, Qld 4029, Australia; Monash Med Sch, Prahran, Vic 3181, Australia; Yale Univ, Immunol Sect, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Monash University; Yale University; Howard Hughes Medical Institute; Yale University	Carbone, FR (corresponding author), PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia.		Carbone, Francis/ABF-2141-2020	Heath, William/0000-0001-9670-259X				AHMED R, 1988, J VIROL, V62, P2102, DOI 10.1128/JVI.62.6.2102-2106.1988; ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ARMITAGE RJ, 1993, EUR J IMMUNOL, V23, P2326, DOI 10.1002/eji.1830230941; Bennett SRM, 1997, J EXP MED, V186, P65, DOI 10.1084/jem.186.1.65; Borrow P, 1996, J EXP MED, V183, P2129, DOI 10.1084/jem.183.5.2129; BUTLER RM, 1987, NATURE, V328, P77; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; Cardin RD, 1996, J EXP MED, V184, P863, DOI 10.1084/jem.184.3.863; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; Grewal IS, 1996, SCIENCE, V273, P1864, DOI 10.1126/science.273.5283.1864; Grewal IS, 1996, IMMUNOL TODAY, V17, P410, DOI 10.1016/0167-5699(96)10030-X; GUERDER S, 1992, J EXP MED, V176, P553, DOI 10.1084/jem.176.2.553; Guo Y, 1996, J EXP MED, V184, P955, DOI 10.1084/jem.184.3.955; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Ke Y, 1996, J IMMUNOL, V156, P916; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; KIENER PA, 1995, J IMMUNOL, V155, P4917; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; ROY M, 1993, J IMMUNOL, V151, P2497; Sad S, 1997, EUR J IMMUNOL, V27, P914, DOI 10.1002/eji.1830270417; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Shinde S, 1996, J IMMUNOL, V157, P2764; SHU U, 1995, EUR J IMMUNOL, V25, P1125, DOI 10.1002/eji.1830250442; Stout RD, 1996, IMMUNOL TODAY, V17, P487, DOI 10.1016/0167-5699(96)10060-I; vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996; WAGNER DH, 1994, EUR J IMMUNOL, V24, P3148, DOI 10.1002/eji.1830241235; Whitmire JK, 1996, J VIROL, V70, P8375, DOI 10.1128/JVI.70.12.8375-8381.1996; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; Yang YP, 1996, J VIROL, V70, P6370, DOI 10.1128/JVI.70.9.6370-6377.1996; Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862	30	1701	1783	0	51	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					478	480		10.1038/30996	http://dx.doi.org/10.1038/30996			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624004				2022-12-28	WOS:000074020000047
J	Ahsan, H; Neugut, AI; Garbowski, GC; Jacobson, JS; Forde, KA; Treat, MR; Waye, JD				Ahsan, H; Neugut, AI; Garbowski, GC; Jacobson, JS; Forde, KA; Treat, MR; Waye, JD			Family history of colorectal adenomatous polyps and increased risk for colorectal cancer	ANNALS OF INTERNAL MEDICINE			English	Article						colorectal neoplasms; adenomatous polyposis coli; age factors; colonoscopy; risk factors	NONPOLYPOSIS COLON-CANCER; FIRST-DEGREE RELATIVES; LARGE BOWEL; TUMORS; SUSCEPTIBILITY; INHERITANCE; DISEASE; HABITS; AGE	Background: The risk for colorectal cancer among family members of patients with colorectal cancer is well established, but the risk among family members of patients with colorectal adenomas is less well established. Objective: To examine the risk for colorectal cancer among first-degree relatives of patients with adenoma compared with that among first-degree relatives of controls without adenoma. Design: Reconstructed cohort study. Setting: Three university-based colonoscopy practices in New York City. Patients: 1554 first-degree relatives of 244 patients with newly diagnosed adenomas and 2173 first-degree relatives of 362 endoscopically normal controls. Measurements: Structured interviews were used to obtain family history. Adjusted relative risks (RR) were estimated from Cox proportional hazards regression models. Results: The risk for colorectal cancer was elevated (RR, 1.74 [95% CI, 1.24 to 2.45]) among first-degree relatives of patients with newly diagnosed adenomas compared with the risk among first-degree relatives of controls. This increased risk was the same for parents (RR, 1.58 [CI, 1.07 to 2.34]) and siblings (RR, 1.58 [CI, 0.81 to 3.08]). First-degree relatives of patients with adenomas did not have elevated risk for other cancers. The risk for colorectal cancer among family members increased with decreasing age at diagnosis of adenoma in probands. Among first-degree relatives of patients who were 50 years of age or younger when the adenoma was diagnosed, the risk was more than four times greater (RR, 4.36 [CI, 2.24 to 8.51]) than that among first-degree relatives of patients who were older than 60 years of age when the adenoma was diagnosed. Conclusions: First-degree relatives of patients with newly diagnosed adenomas, particularly of patients who are 50 years of age or younger at diagnosis, are at increased risk for colorectal cancer and should undergo screening similar to that recommended for relatives of patients with colorectal cancer.	Columbia Presbyterian Med Ctr, Div Oncol, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, Dept Surg, New York, NY 10032 USA; Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA; Columbia Univ, Sch Publ Hlth, New York, NY 10027 USA; Mt Sinai Sch Med, New York, NY USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai	Neugut, AI (corresponding author), Columbia Presbyterian Med Ctr, Div Oncol, 630 W 168th St, New York, NY 10032 USA.	ain1@columbia.edu			NATIONAL CANCER INSTITUTE [T32CA009529, R01CA037196] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA37196, 5T32-CA09529-11A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN J, 1995, AM J EPIDEMIOL, V141, P863, DOI 10.1093/oxfordjournals.aje.a117522; BAZZOLI F, 1995, GASTROENTEROLOGY, V109, P783, DOI 10.1016/0016-5085(95)90385-2; BONELLI L, 1988, INT J CANCER, V41, P513; BOUTRON MC, 1995, GUT, V37, P830, DOI 10.1136/gut.37.6.830; BURT RW, 1985, NEW ENGL J MED, V312, P1540, DOI 10.1056/NEJM198506133122403; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; DELEON MP, 1987, CANCER, V60, P2848, DOI 10.1002/1097-0142(19871201)60:11<2848::AID-CNCR2820601141>3.0.CO;2-F; FISHER G, 1989, MED J AUSTRALIA, V150, P22, DOI 10.5694/j.1326-5377.1989.tb136314.x; FUCHS CS, 1994, NEW ENGL J MED, V331, P1669, DOI 10.1056/NEJM199412223312501; GROSSMAN S, 1988, GASTROENTEROLOGY, V94, P395, DOI 10.1016/0016-5085(88)90427-1; GUILLEM JG, 1988, AM J GASTROENTEROL, V83, P271; GUILLEM JG, 1992, DIS COLON RECTUM, V35, P523, DOI 10.1007/BF02050530; HALL NR, 1994, BRIT J SURG, V81, P1485, DOI 10.1002/bjs.1800811029; JACOBY RF, 1995, GASTROENTEROLOGY, V109, P73, DOI 10.1016/0016-5085(95)90270-8; KATO I, 1990, JPN J CANCER RES, V81, P115, DOI 10.1111/j.1349-7006.1990.tb02536.x; KATO I, 1990, JPN J CANCER RES, V81, P1101, DOI 10.1111/j.1349-7006.1990.tb02520.x; KHOURY MJ, 1995, EPIDEMIOLOGY, V6, P511, DOI 10.1097/00001648-199509000-00009; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; KUNE GA, 1991, NUTR CANCER, V16, P25, DOI 10.1080/01635589109514137; KUNE GA, 1989, WORLD J SURG, V13, P124, DOI 10.1007/BF01671173; LeMarchand L, 1996, AM J EPIDEMIOL, V144, P1122, DOI 10.1093/oxfordjournals.aje.a008890; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LOVETT E, 1976, BRIT J SURG, V63, P13, DOI 10.1002/bjs.1800630103; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; Marder K, 1996, NEUROLOGY, V47, P155, DOI 10.1212/WNL.47.1.155; NEUGUT AI, 1993, AM J GASTROENTEROL, V88, P1179; NEUGUT AI, 1993, CANCER EPIDEM BIOMAR, V2, P159; NEUGUT AI, 1993, ANN INTERN MED, V118, P91, DOI 10.7326/0003-4819-118-2-199301150-00002; NEUGUT AI, 1988, AM J GASTROENTEROL, V83, P295; STJOHN DJB, 1993, ANN INTERN MED, V118, P785, DOI 10.7326/0003-4819-118-10-199305150-00005; SUSSER E, 1989, AM J EPIDEMIOL, V129, P23, DOI 10.1093/oxfordjournals.aje.a115119; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; Winawer SJ, 1996, NEW ENGL J MED, V334, P82, DOI 10.1056/NEJM199601113340204	34	108	109	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					900	+		10.7326/0003-4819-128-11-199806010-00006	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634428				2022-12-28	WOS:000073808600004
J	Kester, KE; Turiansky, GW; McEvoy, PL				Kester, KE; Turiansky, GW; McEvoy, PL			Nodular cutaneous microsporidiosis in a patient with AIDS and successful treatment with long-term oral clindamycin therapy	ANNALS OF INTERNAL MEDICINE			English	Article							ENCEPHALITOZOON-HELLEM	Background: In AIDS, nodular skin disease can result from various causes. Objective: To report a new manifestation of microsporidial infection presenting as nodular skin disease with underlying osteomyelitis. Design: Case report. Setting: Tertiary-care military medical center in Washington, D.C. Patient: A 36-year-old woman with late-stage AIDS who presented with disseminated, nodular cutaneous lesions and underlying osteomyelitis. Measurements: Disseminated microsporidial infection with an Encephalitozoon-like species was diagnosed by electron microscopic examination of material obtained from the skin lesions. Intervention: The patient received long-term oral clindamycin therapy, which cured her disseminated infection, Conclusions: Microsporidia can cause disseminated cutaneous infections in AIDS patients. The response of this patient to long-term clindamycin therapy merits further evaluation.	Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Dept Immunol, Washington, DC 20307 USA; Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Serv Dermatol, Washington, DC 20307 USA; Armed Forces Inst Pathol, Dept Infect & Parasit Dis Pathol, Washington, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; United States Department of Defense	Kester, KE (corresponding author), Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Dept Immunol, Washington, DC 20307 USA.	kesterk@wrsmtp-ccmail.army.mil	Kester, Kent/AAF-8235-2020; Kester, Kent/A-2114-2011	Kester, Kent/0000-0002-5056-0802; Kester, Kent/0000-0002-5056-0802				DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; DEGROOTE MA, 1995, J INFECT DIS, V171, P1375, DOI 10.1093/infdis/171.5.1375; DOULTREE JC, 1995, J CLIN MICROBIOL, V33, P463, DOI 10.1128/JCM.33.2.463-470.1995; Field AS, 1996, J CLIN MICROBIOL, V34, P2803, DOI 10.1128/JCM.34.11.2803-2811.1996; GUNNARSSON G, 1995, CLIN INFECT DIS, V21, P37, DOI 10.1093/clinids/21.1.37; RAY MC, 1994, INFECT DIS CLIN N AM, V8, P583; Saubolle MA, 1996, CLIN MICROBIOL REV, V9, P435, DOI 10.1128/CMR.9.4.435; SCHWARTZ DA, 1992, ARCH PATHOL LAB MED, V116, P660; SHADDUCK JA, 1989, REV INFECT DIS, V11, P203; WEBER R, 1994, CLIN MICROBIOL REV, V7, P426, DOI 10.1128/CMR.7.4.426-461.1994; WEBER R, 1993, CLIN INFECT DIS, V17, P415, DOI 10.1093/clinids/17.3.415	11	21	22	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					911	914		10.7326/0003-4819-128-11-199806010-00009	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634430				2022-12-28	WOS:000073808600006
J	Koff, RS				Koff, RS			Hepatitis A	LANCET			English	Article							INTENSIVE-CARE UNIT; A VIRUS-INFECTION; IMMUNE-RESPONSE; INACTIVATED VIROSOME; CONTROLLED TRIAL; RISK-FACTORS; B VACCINE; IMMUNOGENICITY; OUTBREAK; CHILDREN		Metrow Med Ctr, Dept Med, Framingham, MA 01702 USA		Koff, RS (corresponding author), Metrow Med Ctr, Dept Med, Framingham Union Campus,115 Lincoln St, Framingham, MA 01702 USA.							Alter MJ, 1997, NEW ENGL J MED, V336, P741, DOI 10.1056/NEJM199703133361101; AMBROSCH F, 1994, J MED VIROL, V44, P452, DOI 10.1002/jmv.1890440426; AMBROSCH F, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P98; Ambrosch F, 1997, VACCINE, V15, P1209, DOI 10.1016/S0264-410X(97)00015-7; ANDRE FE, 1992, VACCINE, V10, pS160, DOI 10.1016/0264-410X(92)90576-6; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; ASHER LVS, 1995, J MED VIROL, V47, P260, DOI 10.1002/jmv.1890470312; Barrett PN, 1997, TRANSFUSION, V37, P215, DOI 10.1046/j.1537-2995.1997.37297203527.x; BEHRENS RH, 1995, BRIT MED J, V311, P193, DOI 10.1136/bmj.311.6998.193a; Bodsworth NJ, 1997, AIDS, V11, P747, DOI 10.1097/00002030-199706000-00007; BRYAN JP, 1994, ARCH INTERN MED, V154, P663, DOI 10.1001/archinte.154.6.663; Carlsson U, 1996, SCAND J INFECT DIS, V28, P435, DOI 10.3109/00365549609037934; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P637; Chen XQ, 1997, J HEPATOL, V26, P260, DOI 10.1016/S0168-8278(97)80039-6; Dalton CB, 1996, ARCH INTERN MED, V156, P1013, DOI 10.1001/archinte.156.9.1013; Debray D, 1997, HEPATOLOGY, V26, P1018, DOI 10.1053/jhep.1997.v26.pm0009328329; Demicheli V, 1996, J INFECTION, V33, P87, DOI 10.1016/S0163-4453(96)92948-5; DeSerres G, 1997, OCCUP ENVIRON MED, V54, P60, DOI 10.1136/oem.54.1.60; Emerson SU, 1996, J INFECT DIS, V173, P592, DOI 10.1093/infdis/173.3.592; EMERSON SU, 1994, ARCH VIROL, P205; Flehmig B, 1997, J INFECTION, V35, P37, DOI 10.1016/S0163-4453(97)90929-4; FRANCKI RIB, 1991, ARCH VIROL         S, V2, P320; Fujiwara K, 1997, HEPATOLOGY, V26, P1634, DOI 10.1002/hep.510260636; FUJIWARA K, 1997, HEPATOLOGY, V26, P432; Fujiyama S, 1997, J GASTROEN HEPATOL, V12, P172, DOI 10.1111/j.1440-1746.1997.tb00402.x; GarciaFulgueiras A, 1997, EUR J EPIDEMIOL, V13, P481, DOI 10.1023/A:1007397906494; Gay NJ, 1996, INT J EPIDEMIOL, V25, P854, DOI 10.1093/ije/25.4.854; GOILAV C, 1995, J MED VIROL, V46, P287, DOI 10.1002/jmv.1890460321; Graff J, 1997, J GEN VIROL, V78, P1841, DOI 10.1099/0022-1317-78-8-1841; GREEN MS, 1993, J INFECT DIS, V168, P740, DOI 10.1093/infdis/168.3.740; Grinde B, 1997, J MED VIROL, V53, P69, DOI 10.1002/(SICI)1096-9071(199709)53:1&lt;69::AID-JMV12&gt;3.0.CO;2-S; HALLIDAY ML, 1991, J INFECT DIS, V164, P852, DOI 10.1093/infdis/164.5.852; Halsey NA, 1996, PEDIATRICS, V98, P1207; HENNING KJ, 1995, AM J MED, V99, P132, DOI 10.1016/S0002-9343(99)80132-6; HESS G, 1995, J MED VIROL, V46, P40, DOI 10.1002/jmv.1890460109; Holzer BR, 1996, VACCINE, V14, P982, DOI 10.1016/0264-410X(96)00042-4; INNIS BL, 1994, JAMA-J AM MED ASSOC, V271, P1328, DOI 10.1001/jama.271.17.1328; Inoue K, 1996, J MED VIROL, V50, P322, DOI 10.1002/(SICI)1096-9071(199612)50:4&lt;322::AID-JMV7&gt;3.0.CO;2-A; Kaplan G, 1996, EMBO J, V15, P4282, DOI 10.1002/j.1460-2075.1996.tb00803.x; Kusov YY, 1997, RNA, V3, P291; Lawlor E, 1996, VOX SANG, V71, P126, DOI 10.1046/j.1423-0410.1996.7120126.x; LEE SD, 1993, GASTROENTEROLOGY, V104, P1129, DOI 10.1016/0016-5085(93)90283-I; Lee SD, 1997, J MED VIROL, V52, P215, DOI 10.1002/(SICI)1096-9071(199706)52:2&lt;215::AID-JMV16&gt;3.0.CO;2-J; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; LEENTVAARKUIJPERS A, 1992, VACCINE, V10, pS138, DOI 10.1016/0264-410X(92)90569-6; Leino T, 1997, SCAND J INFECT DIS, V29, P213, DOI 10.3109/00365549709019029; LEMON SM, 1992, VACCINE, V10, pS40, DOI 10.1016/0264-410X(92)90540-Z; Lemon SM, 1997, NEW ENGL J MED, V336, P196, DOI 10.1056/NEJM199701163360307; LEMON SM, 1994, J MED VIROL, V43, P44, DOI 10.1002/jmv.1890430109; LerouxRoels G, 1996, SCAND J GASTROENTERO, V31, P1027, DOI 10.3109/00365529609003124; LOUTAN L, 1994, LANCET, V343, P322, DOI 10.1016/S0140-6736(94)91162-2; MANNUCCI PM, 1994, ANN INTERN MED, V120, P1, DOI 10.7326/0003-4819-120-1-199401010-00001; Mao JS, 1997, VACCINE, V15, P944, DOI 10.1016/S0264-410X(96)00304-0; Mausezahl D, 1996, INT J EPIDEMIOL, V25, P1271, DOI 10.1093/ije/25.6.1271; MCMAHON BJ, 1995, J INFECT DIS, V171, P676, DOI 10.1093/infdis/171.3.676; McMahon BJ, 1996, ARCH PEDIAT ADOL MED, V150, P733, DOI 10.1001/archpedi.1996.02170320079014; Nachbaur K, 1996, CLIN NEPHROL, V45, P398; Ochnio JJ, 1997, J CLIN MICROBIOL, V35, P98, DOI 10.1128/JCM.35.1.98-101.1997; POOVORAWAN Y, 1995, VACCINE, V13, P891, DOI 10.1016/0264-410X(95)00007-N; Poovorawan Y, 1997, ANN TROP MED PARASIT, V91, P119, DOI 10.1080/00034983.1997.11813120; Press J, 1997, J RHEUMATOL, V24, P965; Redlinger T, 1997, AM J PUBLIC HEALTH, V87, P1715, DOI 10.2105/AJPH.87.10.1715; Richtmann R, 1996, J MED VIROL, V48, P147, DOI 10.1002/(SICI)1096-9071(199602)48:2&lt;147::AID-JMV5&gt;3.0.CO;2-9; RIEDEMANN S, 1992, VACCINE, V10, pS152, DOI 10.1016/0264-410X(92)90573-3; ROBERTSON BH, 1992, J GEN VIROL, V73, P1365, DOI 10.1099/0022-1317-73-6-1365; ROBERTSON BH, 1994, J MED VIROL, V43, P249, DOI 10.1002/jmv.1890430310; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBLUM LS, 1991, J INFECT DIS, V164, P476, DOI 10.1093/infdis/164.3.476; Safadi R, 1996, LIVER, V16, P288; Severo CA, 1997, EUR J EPIDEMIOL, V13, P139, DOI 10.1023/A:1007336609638; Shouval D, 1997, HEPATOLOGY, V26, P1213; Smith PF, 1997, EPIDEMIOL INFECT, V118, P243, DOI 10.1017/S0950268897007462; STAPLETON JT, 1985, GASTROENTEROLOGY, V89, P637, DOI 10.1016/0016-5085(85)90462-7; STEFFEN R, 1994, JAMA-J AM MED ASSOC, V272, P885, DOI 10.1001/jama.272.11.885; TORMANS G, 1992, VACCINE, V10, pS88, DOI 10.1016/0264-410X(92)90554-W; Totos G, 1997, VACCINE, V15, P1252, DOI 10.1016/S0264-410X(97)00022-4; Troisi CL, 1997, VACCINE, V15, P1613, DOI 10.1016/S0264-410X(97)00199-0; Tsai JF, 1996, CLIN IMMUNOL IMMUNOP, V78, P291, DOI 10.1006/clin.1996.0041; VANDAMME P, 1994, J MED VIROL, V44, P446, DOI 10.1002/jmv.1890440425; VANDAMME P, 1994, J MED VIROL, V44, P435, DOI 10.1002/jmv.1890440422; Vento S, 1998, NEW ENGL J MED, V338, P286, DOI 10.1056/NEJM199801293380503; Vidor E, 1996, INFECTION, V24, P447, DOI 10.1007/BF01713047; Villano SA, 1997, CLIN INFECT DIS, V25, P726, DOI 10.1086/513757; WAGNER G, 1993, VACCINE, V11, P1027, DOI 10.1016/0264-410X(93)90128-K; Wang CH, 1996, J CLIN MICROBIOL, V34, P707, DOI 10.1128/JCM.34.3.707-713.1996; WATSON JC, 1993, J INFECT DIS, V167, P567, DOI 10.1093/infdis/167.3.567; Weltman AC, 1996, EPIDEMIOL INFECT, V117, P333, DOI 10.1017/S0950268800001515; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; Wiedermann G, 1997, VACCINE, V15, P612, DOI 10.1016/S0264-410X(96)00242-3; Wiens BL, 1996, J MED VIROL, V49, P235, DOI 10.1002/(SICI)1096-9071(199607)49:3&lt;235::AID-JMV13&gt;3.0.CO;2-B; Willner IR, 1998, ANN INTERN MED, V128, P111, DOI 10.7326/0003-4819-128-2-199801150-00006; WINOKUR PL, 1992, CLIN INFECT DIS, V14, P580, DOI 10.1093/clinids/14.2.580; Yotsuyanagi H, 1996, HEPATOLOGY, V24, P10, DOI 10.1053/jhep.1996.v24.pm0008707246; YU MYW, 1994, TRANSFUSION, V34, P596, DOI 10.1046/j.1537-2995.1994.34794330014.x; ZAAIJER HL, 1993, J MED VIROL, V40, P22, DOI 10.1002/jmv.1890400106; Zanetti A, 1997, J HEPATOL, V26, P25, DOI 10.1016/S0168-8278(97)80005-0	96	200	208	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	1998	351	9116					1643	1649		10.1016/S0140-6736(98)01304-X	http://dx.doi.org/10.1016/S0140-6736(98)01304-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620732				2022-12-28	WOS:000074026600036
J	Tsujii, M; Kawano, S; Tsuji, S; Sawaoka, H; Hori, M; DuBois, RN				Tsujii, M; Kawano, S; Tsuji, S; Sawaoka, H; Hori, M; DuBois, RN			Cyclooxygenase regulates angiogenesis induced by colon cancer cells	CELL			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1; MICROVASCULAR ENDOTHELIAL-CELLS; GROWTH-FACTOR; EXPRESSION; DIFFERENTIATION; MODULATION; MIGRATION; MATRIX; MODEL	To explore the role of cyclooxygenase (COX) in endothelial cell migration and angiogenesis, we have used two in vitro model systems involving coculture of endothelial cells with colon carcinoma cells. COX-2-overexpressing cells produce prostaglandins, proangiogenic factors, and stimulate both endothelial migration and tube formation, while control cells have little activity. The effect is inhibited by antibodies to combinations of angiogenic factors, by NS-398 (a selective COX-2 inhibitor), and by aspirin. NS-398 does not inhibit production of angiogenic factors or angiogenesis induced by COX-2-negative cells. Treatment of endothelial cells with aspirin or a COX-1 antisense oligonucleotide inhibits COX-1 activity/expression and suppresses tube formation. Cyclooxygenase regulates colon carcinoma-induced angiogenesis by two mechanisms: COX-2 can modulate production of angiogenic factors by colon cancer cells, while COX-1 regulates angiogenesis in endothelial cells.	Vanderbilt Univ, Med Ctr, Dept Med, VA Med Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Osaka Univ, Sch Med, Dept Med 1, Osaka 5650871, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Osaka University	Tsujii, M (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, VA Med Ctr, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047297, R37DK047297] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47297] Funding Source: Medline; NCEH CDC HHS [NIEHS-00267] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCEH CDC HHS		ABE T, 1993, J CLIN INVEST, V92, P54, DOI 10.1172/JCI116599; BRANNON TS, 1994, J CLIN INVEST, V93, P2230, DOI 10.1172/JCI117220; Breyer MD, 1996, J AM SOC NEPHROL, V7, P8; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; DuBois RN, 1996, CANCER RES, V56, P733; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; GIARDIELLO FM, 1995, EUR J CANCER, V31A, P1071, DOI 10.1016/0959-8049(95)00137-8; HOFF T, 1993, FEBS LETT, V320, P38, DOI 10.1016/0014-5793(93)81653-H; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Kawamori T, 1998, CANCER RES, V58, P409; Koolwijk P, 1996, J CELL BIOL, V132, P1177, DOI 10.1083/jcb.132.6.1177; MASUDA E, 1992, AM J PHYSIOL, V262, pG785, DOI 10.1152/ajpgi.1992.262.5.G785; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; Narko K, 1997, J BIOL CHEM, V272, P21455, DOI 10.1074/jbc.272.34.21455; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Papapetropoulos A, 1997, AM J PATHOL, V150, P1835; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; Seed MP, 1997, CANCER RES, V57, P1625; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Shiff SJ, 1997, GASTROENTEROLOGY, V113, P1992, DOI 10.1016/S0016-5085(97)99999-6; SKOBE M, 1997, NAT MED, V3, P122; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006/bbrc.1993.1483; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Ueda N, 1997, BBA-LIPID LIPID MET, V1344, P103, DOI 10.1016/S0005-2760(96)00131-2; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WILLIAMS CS, 1997, J CLIN INVEST, V100, P1; Yamazaki K, 1996, IN VIVO, V10, P459; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731	35	2030	2226	0	91	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					705	716		10.1016/S0092-8674(00)81433-6	http://dx.doi.org/10.1016/S0092-8674(00)81433-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630216	Bronze			2022-12-28	WOS:000073956700008
J	Peterson, HB; Delbanco, TL; Parker				Peterson, HB; Delbanco, TL; Parker			A 40-year-old woman considering contraception	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DOSE ORAL-CONTRACEPTIVES; UNITED-STATES MEN; PROSTATE-CANCER; TUBAL-STERILIZATION; VENOUS THROMBOEMBOLISM; INTRAUTERINE-DEVICES; OVARIAN-CANCER; RISK-FACTORS; VASECTOMY; USERS		Ctr Dis Control & Prevent, Womens Hlth & Fertil Branch, Div Reprod Hlth, Atlanta, GA 30333 USA; Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA 30322 USA; Univ N Carolina, Sch Med, Dept Obstet & Gynecol, Chapel Hill, NC 27599 USA	Centers for Disease Control & Prevention - USA; Emory University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Peterson, HB (corresponding author), Care of Hartman EE, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Carr BR, 1997, CONTRACEPTION, V55, P267, DOI 10.1016/S0010-7824(97)00029-2; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P4; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P820; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P589; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P597; COULSON AH, 1993, J CLIN EPIDEMIOL, V46, P857, DOI 10.1016/0895-4356(93)90192-4; Creinin MD, 1996, FERTIL STERIL, V66, P101, DOI 10.1016/S0015-0282(16)58394-0; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; ESCOBEDO LG, 1989, AM J OBSTET GYNECOL, V160, P147, DOI 10.1016/0002-9378(89)90108-7; FARLEY TMM, 1992, LANCET, V339, P785, DOI 10.1016/0140-6736(92)91904-M; Farley TMM, 1998, CONTRACEPTION, V57, P211, DOI 10.1016/S0010-7824(98)00019-5; Forrest J D, 1996, Obstet Gynecol Surv, V51, pS30, DOI 10.1097/00006254-199612000-00012; GAMBACCIANI M, 1994, OBSTET GYNECOL, V83, P392; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P873, DOI 10.1001/jama.269.7.873; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P878, DOI 10.1001/jama.269.7.878; Glasier A, 1997, NEW ENGL J MED, V337, P1058, DOI 10.1056/NEJM199710093371507; HANKINSON SE, 1993, JAMA-J AM MED ASSOC, V270, P2813, DOI 10.1001/jama.270.23.2813; HARLAP S, 1991, PREVENTING PREGNANCY; HAYES RB, 1995, J NATL CANCER I, V87, P629, DOI 10.1093/jnci/87.9.629; Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P24, DOI 10.2307/2991522; Hillis SD, 1998, OBSTET GYNECOL, V91, P241, DOI 10.1016/S0029-7844(97)00648-0; HOWARDS SS, 1993, JAMA-J AM MED ASSOC, V269, P913, DOI 10.1001/jama.269.7.913; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; JICK SS, 1993, OBSTET GYNECOL, V82, P931; JOHN EM, 1995, J NATL CANCER I, V87, P662, DOI 10.1093/jnci/87.9.662; LANES SF, 1992, AM J OBSTET GYNECOL, V166, P956, DOI 10.1016/0002-9378(92)91371-G; LISKIN L, 1983, POPUL REP SERIES D; MATTSON RH, 1993, AM J OBSTET GYNECOL, V168, P2027, DOI 10.1016/S0002-9378(12)90945-X; MENKEN J, 1986, SCIENCE, V233, P1389, DOI 10.1126/science.3755843; PARDTHAISONG T, 1980, LANCET, V1, P509; Pasquale S, 1996, Obstet Gynecol Surv, V51, pS25, DOI 10.1097/00006254-199612000-00011; PETERSON HB, 1990, OBSTET GYNECOL, V76, P568; Peterson HB, 1996, AM J OBSTET GYNECOL, V174, P1161, DOI 10.1016/S0002-9378(96)70658-0; Peterson HB, 1997, NEW ENGL J MED, V336, P762, DOI 10.1056/NEJM199703133361104; Peterson Herbert B., 1997, P529; Peterson LS, 1998, FAM PLANN PERSPECT, V30, P19, DOI 10.2307/2991521; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; Piccinino LJ, 1998, FAM PLANN PERSPECT, V30, P4, DOI 10.2307/2991517; REUBINOFF BE, 1995, FERTIL STERIL, V63, P516, DOI 10.1016/S0015-0282(16)57419-6; Rosenberg L, 1997, AM J OBSTET GYNECOL, V177, P707, DOI 10.1016/S0002-9378(97)70168-6; ROSENBERG L, 1994, AM J EPIDEMIOL, V139, P654, DOI 10.1093/oxfordjournals.aje.a117055; ROSENFIELD A, 1997, MMWR-MORBID MORTAL W, V46, P971; Sidney S, 1996, OBSTET GYNECOL, V88, P939, DOI 10.1016/S0029-7844(96)00351-1; Speroff L., 1996, CLIN GUIDE CONTRACEP; TRUSSELL J, 1995, AM J PUBLIC HEALTH, V85, P494, DOI 10.2105/AJPH.85.4.494; Trussell J, 1997, AM J PUBLIC HEALTH, V87, P932, DOI 10.2105/AJPH.87.6.932; Trussell J, 1996, FAM PLANN PERSPECT, V28, P58, DOI 10.2307/2136125; TRUSSELL J, 1996, FAMILY PLANNING PERS, V28, P87; TRUSSELL J, IN PRESS CONTRACEPTI; URSIN G, 1994, LANCET, V344, P1390, DOI 10.1016/S0140-6736(94)90567-3; US Department of Health and Human Services. Food and Drug Administration, 1997, FED REGISTER, V62, P8610; *WHO SCI GROUP OR, 1992, WHO TECHN REP SER, V817; WILCOX LS, 1991, FERTIL STERIL, V55, P927; WILCOX LS, 1992, AM J EPIDEMIOL, V135, P1368, DOI 10.1093/oxfordjournals.aje.a116248; Zhu KM, 1996, AM J EPIDEMIOL, V144, P717, DOI 10.1093/oxfordjournals.aje.a008994	56	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1998	279	20					1651	1658		10.1001/jama.279.20.1651	http://dx.doi.org/10.1001/jama.279.20.1651			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP489	9613916				2022-12-28	WOS:000073758600036
J	Kemp, M				Kemp, M			Hyde's horrors	NATURE			English	Editorial Material									Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.							Darwin Charles, 1998, EXPRESS EMOT MAN, V3rd, DOI [10.1037/h0076058, DOI 10.1037/10001-000]; Stevenson R.L., 1886, STRANGE CASE DR JEKY	2	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					219	219		10.1038/30370	http://dx.doi.org/10.1038/30370			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607757	Bronze			2022-12-28	WOS:000073761000032
J	Kurlemann, G; Schuierer, G				Kurlemann, G; Schuierer, G			Ash-leaf spots in tuberous sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Munster, D-48129 Munster, Germany	University of Munster	Kurlemann, G (corresponding author), Univ Munster, D-48129 Munster, Germany.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1998	338	26					1887	1887		10.1056/NEJM199806253382606	http://dx.doi.org/10.1056/NEJM199806253382606			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV898	9637809				2022-12-28	WOS:000074352800006
J	Nestler, JE; Jakubowicz, DJ; Evans, WS; Pasquali, R				Nestler, JE; Jakubowicz, DJ; Evans, WS; Pasquali, R			Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN THECAL CELLS; INSULIN-RESISTANCE; ANDROGEN PRODUCTION; OBESE WOMEN; HYPERANDROGENISM; TESTOSTERONE; HYPERINSULINEMIA; REDUCTION; FEATURES; THERAPY	Background Obese women with the polycystic ovary syndrome are relatively unresponsive to the induction of ovulation by clomiphene. We hypothesized that reducing insulin secretion by administering metformin would increase the ovulatory response to clomiphene. Methods We performed oral glucose-tolerance tests before and after the administration of 500 mg of metformin or placebo three times daily for 35 days in 61 obese women with the polycystic ovary syndrome. Women who did not ovulate spontaneously were then given 50 mg of clomiphene daily for five days while continuing to take metformin or placebo. Serum progesterone was measured on days 14, 28, 35, 44, and 53, and ovulation was presumed to have occurred if the concentration exceeded 8 ng per milliliter (26 nmol per liter) on any of these days. Results Twenty-one women in the metformin group and 25 women in the placebo group were given clomiphene because they did not ovulate spontaneously during the first phase of the study. Among the 21 women given metformin plus clomiphene, the mean (+/-SE) area under the serum insulin curve after oral glucose administration decreased from 6745+/-2021 to 3479+/-455 mu U per milliliter per minute (40.5+/-12.1 to 20.9+/-2.7 nmol per liter per minute, P=0.03), but it did not change significantly in the 25 women given placebo plus clomiphene. Nineteen of the 21 women (90 percent) who received metformin plus clomiphene ovulated (mean peak serum progesterone concentration, 23.8+/-3.4 ng per milliliter [7.6+/-10.9 nmol per liter]). Two of the 25 women (8 percent) who received placebo plus clomiphene ovulated (P<0.001). Overall, 31 of the 35 women (89 percent) treated with metformin ovulated spontaneously or in response to clomiphene, as compared with 3 of the 26 women (12 percent) treated with placebo. Conclusions The ovulatory response to clomiphene can be increased in obese women with the polycystic ovary syndrome by decreasing insulin secretion with metformin. (N Engl J Med 1998;338:1876-80.) (C) 1998, Massachusetts Medical Society.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA; Hosp Clin Caracas, Dept Med, Caracas, Venezuela; Univ Virginia, Dept Med, Charlottesville, VA 22903 USA; Univ Bologna, Dept Med, I-40126 Bologna, Italy	Virginia Commonwealth University; University of Virginia; University of Bologna	Nestler, JE (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, POB 980111, Richmond, VA 23298 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035629] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA064500] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000847] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA64500] Funding Source: Medline; NCRR NIH HHS [M01RR00847] Funding Source: Medline; NICHD NIH HHS [R01HD35629] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADASHI EY, 1981, ENDOCRINOLOGY, V108, P1441, DOI 10.1210/endo-108-4-1441; APTER D, 1995, J CLIN ENDOCR METAB, V80, P2966, DOI 10.1210/jc.80.10.2966; BARBIERI RL, 1986, J CLIN ENDOCR METAB, V62, P904, DOI 10.1210/jcem-62-5-904; BERGH C, 1993, FERTIL STERIL, V59, P323; CARMINA E, 1992, AM J OBSTET GYNECOL, V167, P1807, DOI 10.1016/0002-9378(92)91779-A; COETZEE EJ, 1979, DIABETOLOGIA, V16, P241, DOI 10.1007/BF01221950; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DUNAIF A, 1989, DIABETES, V38, P1165, DOI 10.2337/diabetes.38.9.1165; Dunaif A, 1996, J CLIN ENDOCR METAB, V81, P3299, DOI 10.1210/jc.81.9.3299; Ehrmann DA, 1997, J CLIN ENDOCR METAB, V82, P2108, DOI 10.1210/jc.82.7.2108; EHRMANN DA, 1995, J CLIN INVEST, V96, P520, DOI 10.1172/JCI118064; FRANKS S, 1995, NEW ENGL J MED, V333, P1435; LOBO RA, 1982, FERTIL STERIL, V37, P168; NAHUM R, 1995, HUM REPROD, V10, P75, DOI 10.1093/humrep/10.1.75; Nestler JE, 1996, NEW ENGL J MED, V335, P617, DOI 10.1056/NEJM199608293350902; NESTLER JE, 1989, J CLIN ENDOCR METAB, V68, P1027, DOI 10.1210/jcem-68-6-1027; NESTLER JE, 1991, J CLIN ENDOCR METAB, V72, P83, DOI 10.1210/jcem-72-1-83; Nestler JE, 1997, J CLIN ENDOCR METAB, V82, P4075, DOI 10.1210/jc.82.12.4075; NESTLER JE, 1994, J CLIN ENDOCR METAB, V78, P549, DOI 10.1210/jc.78.3.549; OHERLIHY C, 1981, OBSTET GYNECOL, V58, P535; PRELEVIC GM, 1990, GYNECOL ENDOCRINOL, V4, P1, DOI 10.3109/09513599009030686; SHEPARD MK, 1979, FERTIL STERIL, V32, P641; SODERGARD R, 1982, J STEROID BIOCHEM, V16, P801, DOI 10.1016/0022-4731(82)90038-3; Velazquez E, 1997, OBSTET GYNECOL, V90, P392; Velazquez EM, 1997, METABOLISM, V46, P454, DOI 10.1016/S0026-0495(97)90066-4; VELAZQUEZ EM, 1994, METABOLISM, V43, P647, DOI 10.1016/0026-0495(94)90209-7; YEH HC, 1987, RADIOLOGY, V163, P111, DOI 10.1148/radiology.163.1.3547491; YEN SSC, 1993, ANN NY ACAD SCI, V687, P98	28	566	592	0	43	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1998	338	26					1876	1880		10.1056/NEJM199806253382603	http://dx.doi.org/10.1056/NEJM199806253382603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV898	9637806	Green Published			2022-12-28	WOS:000074352800003
J	Blitzer, RD; Conner, JH; Brown, GP; Wong, T; Shenolikar, S; Iyengar, R; Landau, EM				Blitzer, RD; Conner, JH; Brown, GP; Wong, T; Shenolikar, S; Iyengar, R; Landau, EM			Gating of CaMKII by cAMP-regulated protein phosphatase activity during LTP	SCIENCE			English	Article							LONG-TERM POTENTIATION; DEPENDENT KINASE-II; PHOSPHORYLATION; INHIBITOR-1; MEMORY; TRANSMISSION; LOCALIZATION; HIPPOCAMPUS; ACTIVATION; NEURONS	Long-term potentiation (LTP) at the Schaffer collateral-CA1 synapse involves interacting signaling components, including calcium (Ca2+)/calmodulin-dependent protein kinase II (CaMKII) and cyclic adenosine monophosphate (cAMP) pathways. Postsynaptic injection of thiophosphorylated inhibitor-1 protein, a specific inhibitor of protein phosphatase-1 (PP1), substituted for cAMP pathway activation in LTP. Stimulation that induced LTP triggered cAMP-dependent phosphorylation of endogenous inhibitor-1 and a decrease in PP1 activity. This stimulation also increased phosphorylation of CaMKII at Thr(286) and Ca2+-independent CaMKII activity in a cAMP-dependent man ner. The blockade of LTP by a CaMKII inhibitor was not overcome by thiophosphorylated inhibitor-1. Thus, the cAMP pathway uses PP1 to gate CaMKII signaling in LTP.	Bronx VA Med Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27712 USA; CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Duke University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Blitzer, RD (corresponding author), Bronx VA Med Ctr, New York, NY 10029 USA.			Connor, John/0000-0002-8867-7256	NIDDK NIH HHS [DK52054] Funding Source: Medline; NIGMS NIH HHS [GM54508] Funding Source: Medline; NINDS NIH HHS [NS33646] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033646] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLITCH JG, 1995, AI EXCHANGE, V9, P15; BRAUN AP, 1995, J PHYSIOL-LONDON, V488, P37, DOI 10.1113/jphysiol.1995.sp020944; CAHILL L, 1994, NATURE, V371, P702, DOI 10.1038/371702a0; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Huang Y Y, 1994, Learn Mem, V1, P74; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; PATTON BL, 1993, MOL BIOL CELL, V4, P159, DOI 10.1091/mbc.4.2.159; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; SAKAGAMI H, 1994, MOL BRAIN RES, V25, P7, DOI 10.1016/0169-328X(94)90273-9; SHARP GWG, 1973, ANNU REV MED, V24, P19, DOI 10.1146/annurev.me.24.020173.000315; SHIELDS SM, 1985, J NEUROSCI, V5, P3414; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8	27	336	343	2	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1940	1943		10.1126/science.280.5371.1940	http://dx.doi.org/10.1126/science.280.5371.1940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632393				2022-12-28	WOS:000074323800065
J	Luecke, H; Richter, HT; Lanyi, JK				Luecke, H; Richter, HT; Lanyi, JK			Proton transfer pathways in bacteriorhodopsin at 2.3 Angstrom resolution	SCIENCE			English	Article							RELEASE; RESIDUES; CYCLE; PUMP	Photoisomerization of the retinal of bacteriorhodopsin initiates a cyclic reaction in which a proton is translocated across the membrane. Studies of this protein promise a better understanding of how ion pumps function. Together with a large amount of spectroscopic and mutational data, the atomic structure of bacteriorhodopsin, determined in the last decade at increasing resolutions, has suggested plausible but often contradictory mechanisms. X-ray diffraction of bacteriorhodopsin crystals grown in cubic lipid phase revealed unexpected two-fold symmetries that indicate merohedral twinning along the crystallographic c axis. The structure, refined to 2.3 angstroms taking this twinning into account, is different from earlier models, including that most recently reported. One of the carboxyl oxygen atoms of the proton acceptor Asp(85) is connected to the proton donor, the retinal Schiff base, through a hydrogen-bonded water and forms a second hydrogen bond with another water. The other carboxyl oxygen atom of Asp(85) accepts a hydrogen bond from Thr(89). This structure forms the active site. The nearby Arg(82) is the center of a network of numerous hydrogen-bonded residues and an ordered water molecule. This network defines the pathway of the proton from the buried Schiff base to the extracellular surface.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Luecke, H (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.		Luecke, Hartmut/F-4712-2012; Lanyi, Janos/C-3808-2011	Luecke, Hartmut/0000-0002-4938-0775; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029498, R01GM056445] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM56445, R01-GM29498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balashov SP, 1996, BIOPHYS J, V70, P473, DOI 10.1016/S0006-3495(96)79591-7; BALASHOV SP, 1993, BIOCHEMISTRY-US, V32, P10331, DOI 10.1021/bi00090a008; Balashov SP, 1997, BIOCHEMISTRY-US, V36, P8671, DOI 10.1021/bi970744y; BROWN LO, UNPUB; BROWN LS, 1994, J MOL BIOL, V239, P401, DOI 10.1006/jmbi.1994.1381; BROWN LS, 1995, J BIOL CHEM, V270, P27122, DOI 10.1074/jbc.270.45.27122; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; DEGROOT HJM, 1989, BIOCHEMISTRY-US, V28, P3346, DOI 10.1021/bi00434a033; Dioumaev AK, 1998, BIOCHEMISTRY-US, V37, P2496, DOI 10.1021/bi971842m; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; Kimura Y, 1997, PHOTOCHEM PHOTOBIOL, V66, P764, DOI 10.1111/j.1751-1097.1997.tb03221.x; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; MARTI T, 1991, J BIOL CHEM, V266, P6919; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; REDINBO MR, 1993, ACTA CRYSTALLOGR D, V49, P375, DOI 10.1107/S090744499300294X; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SZARAZ S, 1994, BIOPHYS J, V67, P1706, DOI 10.1016/S0006-3495(94)80644-7; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; YAMAZAKI Y, 1995, BIOCHEMISTRY-US, V34, P577; ZHOU F, 1993, BIOCHEMISTRY-US, V32, P2291, DOI 10.1021/bi00060a022	25	529	537	0	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1934	1937		10.1126/science.280.5371.1934	http://dx.doi.org/10.1126/science.280.5371.1934			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632391				2022-12-28	WOS:000074323800063
J	Duhaime, AC; Christian, CW; Rorke, LB; Zimmerman, RA				Duhaime, AC; Christian, CW; Rorke, LB; Zimmerman, RA			Nonaccidental head injury in infants - The "shaken-baby syndrome"	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DIFFUSE AXONAL INJURY; PERMANENT BRAIN-DAMAGE; CHILD-ABUSE; OSTEOGENESIS IMPERFECTA; SUBDURAL-HEMATOMA; INTRACRANIAL HEMORRHAGE; CEREBRAL CONCUSSION; RETINAL HEMORRHAGES; COMPUTED-TOMOGRAPHY; MENTAL-RETARDATION		Childrens Hosp Philadelphia, Div Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Neuropathol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Neuroradiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Duhaime, AC (corresponding author), Childrens Hosp Philadelphia, Div Neurosurg, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.							ADAMS JH, 1986, ARCH PATHOL LAB MED, V110, P485; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1986, ARCH PATHOL LAB MED, V110, P1075; ADAMS JH, 1984, RECENT ADV HISTOPATH, P241; ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; ASTLEY R, 1979, BRIT J RADIOL, V52, P441, DOI 10.1259/0007-1285-52-618-441; BAUM JD, 1970, ARCH DIS CHILD, V45, P344, DOI 10.1136/adc.45.241.344; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; BIRD CR, 1987, RADIOLOGY, V163, P373, DOI 10.1148/radiology.163.2.3562816; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; BUDENZ DL, 1994, OPHTHALMOLOGY, V101, P559; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CHEN MH, 1991, J NEUROSURG, V74, P944, DOI 10.3171/jns.1991.74.6.0944; CHIAVIELLO CT, 1994, PEDIATRICS, V94, P679; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; COHEN RA, 1986, AM J ROENTGENOL, V146, P97, DOI 10.2214/ajr.146.1.97; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Duhaime AC, 1996, PEDIATR NEUROSURG, V25, P116, DOI 10.1159/000121108; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; DUHAIME AC, 1996, PRACTICE NEUROSURGER, V2, P1553; Duhaime AC., 1993, J NEUROTRAUM, V10, pS59; DUHAIME AC, 1996, NEUROLOGICAL SURG CO, V3, P1777; Feldman KW, 1997, CHILD ABUSE NEGLECT, V21, P199, DOI 10.1016/S0145-2134(96)00145-7; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; Gennarelli T.A., 1985, NEUROSURGERY, P1531; Gilliland MGF, 1996, J FORENSIC SCI, V41, P114; GILLILAND MGF, 1993, AM J FOREN MED PATH, V14, P187, DOI 10.1097/00000433-199309000-00003; GOETTING MG, 1990, PEDIATRICS, V85, P585; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; GREENWALD MJ, 1986, OPHTHALMOLOGY, V93, P618; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HAHN YS, 1983, CHILD BRAIN, V10, P229; HAN BK, 1989, AM J NEURORADIOL, V10, P1191; HANIGAN WC, 1987, PEDIATRICS, V80, P618; HARCOURT B, 1971, BMJ-BRIT MED J, V3, P398, DOI 10.1136/bmj.3.5771.398; HAWORTH JC, 1991, J PEDIATR-US, V118, P52, DOI 10.1016/S0022-3476(05)81843-8; HELFER RE, 1977, PEDIATRICS, V60, P533; HIRSCH CS, 1990, HDB FORENSIC PATHOLO, P182; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; INGLIS FM, 1990, ACT NEUR S, V51, P277; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; KLEIN M, 1971, AM J DIS CHILD, V122, P15, DOI 10.1001/archpedi.1971.02110010051005; KLEINMAN PK, 1990, AM J ROENTGENOL, V155, P703, DOI 10.2214/ajr.155.4.2119097; Lazoritz S, 1997, CHILD ABUSE NEGLECT, V21, P1009, DOI 10.1016/S0145-2134(97)00061-6; Levy HL, 1996, J PEDIATR-US, V129, P922, DOI 10.1016/S0022-3476(96)70041-0; LINDENBERG R, 1969, ARCH PATHOL, V87, P298; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; LUERSSEN TG, 1991, CONC PED N, V11, P87; LUERSSEN TG, 1993, PEDIATR NEUROSURG, V19, P170, DOI 10.1159/000120726; MASSICOTTE SJ, 1991, OPHTHALMOLOGY, V98, P1124; MCLELLAN NJ, 1986, ARCH DIS CHILD, V61, P1130, DOI 10.1136/adc.61.11.1130; MERTEN DF, 1984, PEDIATR RADIOL, V14, P272, DOI 10.1007/BF01601874; MESERVY CJ, 1987, AM J ROENTGENOL, V149, P173, DOI 10.2214/ajr.149.1.173; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PARENT AD, 1992, PEDIATR NEUROSURG, V18, P266, DOI 10.1159/000120674; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; REIBER GD, 1993, AM J FOREN MED PATH, V14, P201, DOI 10.1097/00000433-199309000-00005; RIFFENBURGH RS, 1991, OPHTHALMOLOGY, V98, P1519; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; RORKE LB, 1992, CHILD ABUSE MED REFE, P403; RYAN CA, 1992, PEDIATR EMERG CARE, V8, P143, DOI 10.1097/00006565-199206000-00008; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; Shaver EG, 1996, PEDIATR NEUROSURG, V25, P123, DOI 10.1159/000121109; Shugerman RP, 1996, PEDIATRICS, V97, P664; SILLS JA, 1977, DEV MED CHILD NEUROL, V19, P26; SKALINA MEL, 1983, J PEDIATR-US, V103, P781, DOI 10.1016/S0022-3476(83)80485-5; SMITH FW, 1980, PEDIATR RADIOL, V10, P103, DOI 10.1007/BF01001749; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; STARLING SP, 1995, PEDIATRICS, V95, P259; Steiner RD, 1996, J PEDIATR-US, V128, P542, DOI 10.1016/S0022-3476(96)70367-0; TOKORO K, 1988, NEUROSURGERY, V22, P595, DOI 10.1227/00006123-198803000-00029; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; WENSTRUP RJ, 1990, AM J HUM GENET, V46, P975; WETZEL RC, 1995, PEDIATRICS, V95, P771; Willman KY, 1997, CHILD ABUSE NEGLECT, V21, P929, DOI 10.1016/S0145-2134(97)00054-9; YOFFE G, 1988, J PEDIATR-US, V113, P333, DOI 10.1016/S0022-3476(88)80277-4; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687	87	410	425	0	32	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1998	338	25					1822	1829		10.1056/NEJM199806183382507	http://dx.doi.org/10.1056/NEJM199806183382507			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU443	9632450				2022-12-28	WOS:000074197500007
J	Shingyoji, C; Higuchi, H; Yoshimura, M; Katayama, E; Yanagida, T				Shingyoji, C; Higuchi, H; Yoshimura, M; Katayama, E; Yanagida, T			Dynein arms are oscillating force generators	NATURE			English	Article							SEA-URCHIN SPERM; IONTOPHORETIC APPLICATION; MICROTUBULES INVITRO; FLAGELLAR AXONEMES; TETRAHYMENA CILIA; SUBUNIT; ACTOMYOSIN; DIRECTION; ATP	Eukaryotic flagella beat rhythmically(1). Dynein is a protein that powers flagellar motion, and oscillation may be inherent to this protein(2-5). Here we determine whether oscillation is a property of dynein arms themselves or whether oscillation requires an intact axoneme(6), which is the central core of the flagellum and consists of a regular array of microtubules. Using optical trapping nanometry(7,8), we measured the force generated by a few dynein arms on an isolated doublet microtubule, When the dynein arms on the doublet microtubule contact a singlet microtubule and are activated by photolysis of caged ATP(8), they generate a peak force of similar to 6 pN and move the singlet microtubule over the doublet microtubule in a processive manner. The force and displacement oscillate with a peak-to-peak force and amplitude of similar to 2 pN and similar to 30 nm, respectively. The geometry of the interaction indicates that very few (possibly one) dynein arms are needed to generate the oscillation. The maximum frequency of the oscillation at 0.75 mM ATP is similar to 70 Hz; this frequency decreases as the ATP concentration decreases. A similar oscillatory force is also generated by inner dynein arms alone on doublet microtubules that are depleted of outer dynein arms. The oscillation of the dynein arm may be a basic mechanism underlying flagellar beating.	Univ Tokyo, Grad Sch Sci, Dept Sci Biol, Tokyo 1130033, Japan; JRDC, ERATO, Yanagida Biotron Project, Osaka 5620035, Japan; Univ Tokyo, Inst Med Sci, Dept Fine Morphol, Minato Ku, Tokyo 1080071, Japan; Osaka Univ, Sch Med, Dept Physiol, Osaka 5650871, Japan	University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; Osaka University	Shingyoji, C (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Sci Biol, Tokyo 1130033, Japan.	chikako@biol.s.u-tokyo.ac.jp	Yanagida, Toshio/D-1919-2009					Brokaw C.J., 1989, CELL MOVEMENT, V1, P267; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FOX LA, 1987, J CELL BIOL, V105, P1781, DOI 10.1083/jcb.105.4.1781; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GIBBONS BH, 1973, J CELL SCI, V13, P337; GIBBONS IR, 1988, J BIOL CHEM, V263, P15837; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; Higuchi H, 1997, P NATL ACAD SCI USA, V94, P4395, DOI 10.1073/pnas.94.9.4395; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; JOHNSON KA, 1985, ANNU REV BIOPHYS BIO, V14, P161, DOI 10.1146/annurev.bb.14.060185.001113; KAMIMURA S, 1989, NATURE, V340, P476, DOI 10.1038/340476a0; KATAYAMA E, 1989, J BIOCHEM-TOKYO, V106, P751, DOI 10.1093/oxfordjournals.jbchem.a122928; MOSS AG, 1992, J CELL BIOL, V118, P1189, DOI 10.1083/jcb.118.5.1189; MOSS AG, 1992, J CELL BIOL, V118, P1177, DOI 10.1083/jcb.118.5.1177; OMOTO CK, 1989, J THEOR BIOL, V137, P163, DOI 10.1016/S0022-5193(89)80203-6; SALE WS, 1977, P NATL ACAD SCI USA, V74, P2045, DOI 10.1073/pnas.74.5.2045; SALE WS, 1988, J CELL BIOL, V107, P1793, DOI 10.1083/jcb.107.5.1793; SALE WS, 1985, J CELL BIOL, V101, P1400, DOI 10.1083/jcb.101.4.1400; SHIMIZU T, 1989, BIOCHEMISTRY-US, V28, P7016, DOI 10.1021/bi00443a035; SHINGYOJI C, 1995, J CELL SCI, V108, P1359; SHINGYOJI C, 1977, NATURE, V265, P269, DOI 10.1038/265269a0; SMITH EF, 1992, SCIENCE, V257, P1557, DOI 10.1126/science.1387971; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; TAKAHASHI K, 1982, SYM SOC EXP BIOL, P159; Thomas N, 1998, J PHYS D APPL PHYS, V31, P253, DOI 10.1088/0022-3727/31/3/002; Thomas N, 1996, J PHYSIOL-LONDON, V491P, pP124; VALE RD, 1988, CELL, V52, P459, DOI 10.1016/S0092-8674(88)80038-2; Wang ZH, 1995, BIOPHYS J, V69, P2011, DOI 10.1016/S0006-3495(95)80071-8; YOKOTA E, 1994, J CELL SCI, V107, P353	30	197	202	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1998	393	6686					711	714		10.1038/31520	http://dx.doi.org/10.1038/31520			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641685				2022-12-28	WOS:000074289600060
J	Hippisley-Cox, J; Fielding, K; Pringle, M				Hippisley-Cox, J; Fielding, K; Pringle, M			Depression as a risk factor for ischaemic heart disease in men: population based case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SERUM-CHOLESTEROL CONCENTRATION; ACUTE MYOCARDIAL-INFARCTION; GENERAL-PRACTICE; MORTALITY; SYMPTOMS; EVENTS; TRIALS	Objective: To determine the relation between depression, anxiety, and use of antidepressants and the onset of ischaemic heart disease. Design: Population based case-control study. Setting: All 5623 patients registered with one general practice. Subjects: 188 male cases with ischaemic heart disease matched by age to 485 male controls without ischaemic heart disease; 139 female cases with ischaemic heart disease matched by age to 412 female controls. Main outcome measure: Adjusted odds ratios calculated by conditional logistic regression. Results: The risk of ischaemic heart disease was three times higher among men with a recorded diagnosis of depression than among controls of the sane age (odds ratio 3.09; 95% confidence interval 1.33 to 7.21; P = 0.009). This association persisted when smoking status, diabetes, hypertension, and underprivileged area (UPA(8)) score were included in a multivariate model (adjusted 2.75; 1.13 to 6.69; P = 0.03). Men with depression within the preceding 10 years were three times more likely to develop ischaemic heart disease than were the controls (3.13; 1.27 to 7.70; P = 0.01). Men with ischaemic heart disease had a higher risk of subsequent ischaemic heart disease than men without ischaemic heart disease (adjusted 2.34; 1.34 to 4.10; P = 0.003). Depression was not a risk factor for ischaemic heart disease in women on multivariate analysis (adjusted 1.34; 0.70 to 2.56; P = 0.38). Anxiety and subsequent ischaemic heart disease were not significantly associated in men or women. Conclusion: Depression may be an independent risk factor for ischaemic heart disease in men, but not in women.	Queens Med Ctr, Sch Med, Dept Gen Practice, Nottingham NG7 2UH, England; Queens Med Ctr, Sch Med, Trent Inst Hlth Serv Res, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Hippisley-Cox, J (corresponding author), Queens Med Ctr, Sch Med, Dept Gen Practice, Nottingham NG7 2UH, England.	julia.h-cox@nottingham.ac.uk	Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283				APPELS A, 1990, BRIT J PSYCHIAT, V156, P465, DOI 10.1192/bjp.156.4.465; BROWN SL, 1994, BRIT MED J, V308, P1328, DOI 10.1136/bmj.308.6940.1328; CARNEY RM, 1990, PSYCHOSOM MED, V52, P603, DOI 10.1097/00006842-199011000-00001; CARNEY RM, 1988, PSYCHOSOM MED, V50, P627, DOI 10.1097/00006842-198811000-00009; FIELDING R, 1991, SOC SCI MED, V32, P1017, DOI 10.1016/0277-9536(91)90159-A; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; KEECH A, 1994, EUR HEART J, V15, P255, DOI 10.1093/oxfordjournals.eurheartj.a060485; LADWIG KH, 1994, LANCET, V343, P20, DOI 10.1016/S0140-6736(94)90877-X; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; Lesperance F, 1996, PSYCHOSOM MED, V58, P99, DOI 10.1097/00006842-199603000-00001; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; MORGAN RE, 1993, LANCET, V341, P75, DOI 10.1016/0140-6736(93)92556-9; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; OCONNOR NJ, 1995, CIRCULATION, V92, P1458, DOI 10.1161/01.CIR.92.6.1458; PRINGLE M, 1995, BRIT J GEN PRACT, V45, P537; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; SIEGLER IC, 1992, AM J EPIDEMIOL, V136, P146, DOI 10.1093/oxfordjournals.aje.a116481; SIRELING LI, 1985, BRIT J PSYCHIAT, V147, P113, DOI 10.1192/bjp.147.2.113; SIRELING LI, 1985, BRIT J PSYCHIAT, V147, P119, DOI 10.1192/bjp.147.2.119; THOMAS C, 1992, J GERONTOL, V47, pS80, DOI 10.1093/geronj/47.2.S80; TILYARD MW, 1995, NEW ZEAL MED J, V108, P118; Wardle J, 1996, BRIT MED J, V313, P75, DOI 10.1136/bmj.313.7049.75; WassertheilSmoller S, 1996, ARCH INTERN MED, V156, P553, DOI 10.1001/archinte.156.5.553; WYSOWSKI DK, 1990, ARCH INTERN MED, V150, P2169, DOI 10.1001/archinte.150.10.2169; Zureik M, 1996, BMJ-BRIT MED J, V313, P649, DOI 10.1136/bmj.313.7058.649	26	136	140	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 6	1998	316	7146					1714	1719		10.1136/bmj.316.7146.1714	http://dx.doi.org/10.1136/bmj.316.7146.1714			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZT806	9614024	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000074129500024
J	[Anonymous]				[Anonymous]			Whistleblowing or professional assassination	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 6	1998	316	7146					1756	1757						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614051				2022-12-28	WOS:000074129500089
J	Farquhar, J; Thiemens, MH; Jackson, T				Farquhar, J; Thiemens, MH; Jackson, T			Atmosphere-surface interactions on Mars: Delta O-17 measurements of carbonate from ALH 84001	SCIENCE			English	Article							SNC METEORITES; MARTIAN ATMOSPHERE; ISOTOPIC COMPOSITION; OXYGEN-ISOTOPE; VOLATILE EVOLUTION; CHAOTIC OBLIQUITY; STRATOSPHERIC CO2; WATER; ORIGIN; FRACTIONATION	Oxygen isotope measurements of carbonate from martian meteorite ALH 84001 (delta(18)O = 18.3 +/- 0.4 per mil, delta(17)O = 10.3 +/- 0.2 per mil, and Delta(17)O = 0.8 +/- 0.05 per mil) are fractionated with respect to those of silicate minerals. These measurements support the existence of two oxygen isotope reservoirs (the atmosphere and the silicate planet) on Mars at the time of carbonate growth. The cause of the atmospheric oxygen isotope anomaly may be exchange between CO2 and O(D-1) produced by the photodecomposition of ozone. Atmospheric oxygen isotope compositions may be transferred to carbonate minerals by CO2-H2O exchange and mineral growth. A sink of O-17-depleted oxygen, as required by mass balance, may exist in the planetary regolith.	Univ Calif San Diego, Dept Chem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Farquhar, J (corresponding author), Univ Calif San Diego, Dept Chem, La Jolla, CA 92093 USA.	jfarquha@ucsd.edu; mht@ucsd.edu; tjackson@ucsd.edu						BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; BARTH CA, 1986, PHOTOCHEMISTRY ATMOS, P337; BECKER RH, 1984, EARTH PLANET SC LETT, V69, P225, DOI 10.1016/0012-821X(84)90183-3; BHATTACHARYA SK, 1989, Z NATURFORSCH A, V44, P435; BJORAAKER GL, 1989, B AM ASTRON SOC, V29, P991; BOGARD DD, 1983, SCIENCE, V221, P651, DOI 10.1126/science.221.4611.651; CARR MH, 1986, ICARUS, V68, P187, DOI 10.1016/0019-1035(86)90019-9; CARR MH, 1990, ICARUS, V87, P210, DOI 10.1016/0019-1035(90)90031-4; CARR RH, 1985, NATURE, V314, P248, DOI 10.1038/314248a0; Clayton RN, 1996, GEOCHIM COSMOCHIM AC, V60, P1999, DOI 10.1016/0016-7037(96)00074-9; CLAYTON RN, 1963, GEOCHIM COSMOCHIM AC, V27, P43, DOI 10.1016/0016-7037(63)90071-1; CLAYTON RN, 1983, EARTH PLANET SC LETT, V62, P1, DOI 10.1016/0012-821X(83)90066-3; Cliff SS, 1997, SCIENCE, V278, P1774, DOI 10.1126/science.278.5344.1774; COPLEN TB, 1983, NATURE, V302, P236, DOI 10.1038/302236a0; CRISS RE, 1986, REV MINERAL, V16, P373; DONAHUE TM, 1995, NATURE, V374, P432, DOI 10.1038/374432a0; FANALE FP, 1971, NATURE, V230, P502, DOI 10.1038/230502a0; FANALE FP, 1974, J GEOPHYS RES, V79, P3397, DOI 10.1029/JC079i024p03397; Farmer C. B., 1977, Journal of Geophysical Research, V82, P4225, DOI 10.1029/JS082i028p04225; Forget F, 1997, SCIENCE, V278, P1273, DOI 10.1126/science.278.5341.1273; FORSYTHE RD, 1998, LUNAR PLANET SCI C, V29, P1410; GEISSLER PE, 1993, ICARUS, V106, P380, DOI 10.1006/icar.1993.1179; Gregory R. T., 1991, GEOCHEM SOC SPEC PUB, V3, P65; Gulick VC, 1997, ICARUS, V130, P68, DOI 10.1006/icar.1997.5802; GULICK VC, 1990, J GEOPHYS RES-SOLID, V95, P14325, DOI 10.1029/JB095iB09p14325; HABERLE RM, 1994, ICARUS, V109, P102, DOI 10.1006/icar.1994.1079; Harvey RP, 1996, NATURE, V382, P49, DOI 10.1038/382049a0; Holland HD., 1984, CHEM EVOLUTION ATMOS; Hutchins KS, 1996, J GEOPHYS RES-PLANET, V101, P14933, DOI 10.1029/96JE00860; JAKOSKY BM, 1993, ICARUS, V102, P286, DOI 10.1006/icar.1993.1049; Jakosky BM, 1997, REV GEOPHYS, V35, P1, DOI 10.1029/96RG02903; Jakosky BM, 1997, ICARUS, V130, P87, DOI 10.1006/icar.1997.5799; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; JAKOSKY BM, 1993, GEOPHYS RES LETT, V20, P1591, DOI 10.1029/93GL01598; JAKOSKY BM, 1991, ICARUS, V94, P14, DOI 10.1016/0019-1035(91)90138-J; JAKOSKY BM, 1994, NATURE, V370, P328, DOI 10.1038/370328a0; JAKOSKY BM, 1982, J GEOPHYS RES, V87, P2999, DOI 10.1029/JB087iB04p02999; JAKOSKY BM, 1990, J GEOPHYS RES-SOLID, V95, P1475, DOI 10.1029/JB095iB02p01475; JAKOSKY BM, 1995, J GEOPHYS RES-PLANET, V100, P1579, DOI 10.1029/94JE02801; Johnston JC, 1997, J GEOPHYS RES-ATMOS, V102, P25395, DOI 10.1029/97JD02075; JULL AJT, 1995, METEORITICS, V30, P311, DOI 10.1111/j.1945-5100.1995.tb01129.x; KARRISON HR, 1992, SCIENCE, V255, P1409; KASS DM, 1995, SCIENCE, V268, P697, DOI 10.1126/science.7732377; KERRIDGE JF, 1988, LUNAR PLANET SCI, V19, P599; KRASNOPOLSKY VA, 1996, ICARUS, V553, P124; LASKAR J, 1993, NATURE, V361, P608, DOI 10.1038/361608a0; Leshin LA, 1996, GEOCHIM COSMOCHIM AC, V60, P2635, DOI 10.1016/0016-7037(96)00122-6; LESHIN LA, 1997, LUNAR PLANET SCI, V28, P805; LESHIN LA, 1998, LUNAR PLANET SCI C, V29, P1468; MARTI K, 1995, SCIENCE, V267, P1981, DOI 10.1126/science.7701319; MAUERSBERGER K, 1987, GEOPHYS RES LETT, V14, P80, DOI 10.1029/GL014i001p00080; MCCREA JM, 1950, J CHEM PHYS, V18, P849, DOI 10.1063/1.1747785; MCELROY MB, 1976, SCIENCE, V194, P70, DOI 10.1126/science.194.4260.70; MCSWEEN HY, 1984, GEOLOGY, V12, P3, DOI 10.1130/0091-7613(1984)12<3:SMATMR>2.0.CO;2; MELLON MT, 1995, J GEOPHYS RES-PLANET, V100, P11781, DOI 10.1029/95JE01027; MUEHLENBACHS K, 1976, J GEOPHYS RES, V81, P4365, DOI 10.1029/JB081i023p04365; NAIR H, 1994, ICARUS, V111, P124, DOI 10.1006/icar.1994.1137; Nier A. O., 1977, Journal of Geophysical Research, V82, P4341, DOI 10.1126/science.194.4271.1298; NIER AO, 1976, SCIENCE, V194, P68, DOI 10.1126/science.194.4260.68; OWEN T, 1988, SCIENCE, V240, P1767, DOI 10.1126/science.240.4860.1767; PEPIN RO, 1994, ICARUS, V111, P289, DOI 10.1006/icar.1994.1146; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; ROSENBAUM J, 1986, GEOCHIM COSMOCHIM AC, V50, P1147, DOI 10.1016/0016-7037(86)90396-0; Sagan C, 1997, SCIENCE, V276, P1217, DOI 10.1126/science.276.5316.1217; SCAMBOS TA, 1990, J GEOPHYS RES-SOLID, V95, P14779, DOI 10.1029/JB095iB09p14779; THIEMENS MH, 1991, GEOPHYS RES LETT, V18, P669, DOI 10.1029/91GL00121; THIEMENS MH, 1995, SCIENCE, V270, P969, DOI 10.1126/science.270.5238.969; THIEMENS MH, 1995, GEOPHYS RES LETT, V22, P255, DOI 10.1029/94GL02996; TOUMA J, 1993, SCIENCE, V259, P1294, DOI 10.1126/science.259.5099.1294; Valley JW, 1997, SCIENCE, V275, P1633, DOI 10.1126/science.275.5306.1633; WALLIS MK, 1978, PLANET SPACE SCI, V26, P949, DOI 10.1016/0032-0633(78)90077-6; WALLIS MK, 1989, EARTH PLANET SC LETT, V93, P321, DOI 10.1016/0012-821X(89)90031-9; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; WIENS RC, 1986, EARTH PLANET SC LETT, V77, P149, DOI 10.1016/0012-821X(86)90156-1; Wood C.A., 1981, P LUNAR PLANET SCI C, V12B, P1359; WRIGHT IP, 1990, J GEOPHYS RES-SOLID, V95, P14789, DOI 10.1029/JB095iB09p14789; YUNG YL, 1988, ICARUS, V76, P146, DOI 10.1016/0019-1035(88)90147-9; [No title captured]	79	108	113	5	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1580	1582		10.1126/science.280.5369.1580	http://dx.doi.org/10.1126/science.280.5369.1580			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616116				2022-12-28	WOS:000074061200034
J	Nachman, JB; Sather, HN; Sensel, MG; Trigg, ME; Cherlow, JM; Lukens, JN; Wolff, L; Uckun, FM; Gaynon, PS				Nachman, JB; Sather, HN; Sensel, MG; Trigg, ME; Cherlow, JM; Lukens, JN; Wolff, L; Uckun, FM; Gaynon, PS			Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEDIATRIC-ONCOLOGY-GROUP; CANCER STUDY-GROUP; PRESENTING FEATURES; PROGNOSTIC FACTORS; POOR-PROGNOSIS; MARROW RESPONSE; CHILDHOOD; METHOTREXATE; ADOLESCENTS; TRIAL	Background Children with high-risk acute lymphoblastic leukemia (ALL) who have a slow response to initial chemotherapy (more than 25 percent blasts in the bone marrow on day 7) have a poor outcome despite intensive therapy. We conducted a randomized trial in which such patients were treated with either an augmented intensive regimen of post-induction chemotherapy or a standard regimen of intensive post-induction chemotherapy. Methods Between January 1991 and June 1995, 311 children with newly diagnosed ALL who were either 1 to 9 years of age with white-cell counts of at least 50,000 per cubic millimeter or 10 years of age or older, had a slow response to initial therapy, and entered remission at the end of induction chemotherapy were randomly assigned to receive standard therapy (156 children) or augmented therapy (155). Those with lymphomatous features were excluded. Event-free survival and overall survival were assessed from the end of induction treatment. Results The outcome at five years was significantly better in the augmented-therapy group than in the standard-therapy group (Kaplan-Meier estimate of event-free survival [+/-SD]: 75.0+/-3.8 vs. 55.0+/-4.5 percent, P<0.001; overall survival: 78.4+/-3.7 vs. 66.7+/-4.2 percent, P=0.02). The difference between treatments was most pronounced among patients one to nine years of age, all of whom had white-cell counts of at least 50,000 per cubic millimeter (P<0.001). Risk factors for an adverse event in the entire cohort included a white-cell count of 200,000 per cubic millimeter or higher (P=0.004), race other than black or white (P<0.001), and the presence of a t(9;22) translocation (P=0.007). The toxic effects of augmented therapy were considerable but manageable. Conclusions Augmented post-induction chemotherapy results in an excellent outcome for most patients with high-risk ALL and a slow response to initial therapy. (C) 1998, Massachusetts Medical Society.	Childrens Canc Grp, Grp Operat Ctr, Arcadia, CA 91066 USA; Univ Chicago, Sect Pediat Hematol Oncol, Chicago, IL 60637 USA; Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ Iowa Hosp & Clin, Div Pediat Bone Marrow Transplantat, Iowa City, IA 52242 USA; Long Beach Mem Med Ctr, Dept Radiat Oncol, Long Beach, CA USA; Vanderbilt Univ, Dept Pediat Hematol Oncol, Nashville, TN USA; Oregon Hlth & Sci Univ, Dept Pediat Hematol Oncol, Portland, OR 97201 USA; Doernbecher Childrens Hosp, Portland, OR 97201 USA; Wayne Hughes Inst, St Paul, MN USA; Childrens Canc Grp, Acute Lymphoblast Leukemia Biol Reference Lab, St Paul, MN USA; Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA	University of Chicago; University of Southern California; University of Iowa; Vanderbilt University; Oregon Health & Science University; University of Wisconsin System; University of Wisconsin Madison	Nachman, JB (corresponding author), Childrens Canc Grp, Grp Operat Ctr, POB 60012, Arcadia, CA 91066 USA.			Uckun, Fatih M./0000-0001-9334-183X	NATIONAL CANCER INSTITUTE [U10CA017829, U10CA002971, U10CA013539] Funding Source: NIH RePORTER; NCI NIH HHS [CA 17829, CA 13539, CA 02971] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arico M., 1997, Blood, V90, p560A; BLOOMFIELD CD, 1986, BLOOD, V67, P415; Breslow N., 1984, CANCER CLIN TRIALS, P381; BRESLOW NE, 1975, INT STAT REV, V43, P45, DOI 10.2307/1402659; CAMITTA B, 1994, J CLIN ONCOL, V12, P1383, DOI 10.1200/JCO.1994.12.7.1383; Childhood A, 1996, LANCET, V347, P1783, DOI DOI 10.1016/S0140-6736(96)91615-3; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; CRIST W, 1986, MED PEDIATR ONCOL, V14, P135, DOI 10.1002/mpo.2950140306; CRIST W, 1992, LEUKEMIA, V6, P162; CRIST WM, 1990, BLOOD, V76, P117; FLEMING T, 1958, CONTEMP CLIN TRIALS, V53, P457; GAJJAR A, 1995, BLOOD, V86, P1292, DOI 10.1182/blood.V86.4.1292.bloodjournal8641292; Garand R, 1993, Recent Results Cancer Res, V131, P283; GAYNON PS, 1988, AM J PEDIAT HEMATOL, V10, P42; GAYNON PS, 1990, MED PEDIATR ONCOL, V18, P273, DOI 10.1002/mpo.2950180403; HAMMOND D, 1986, MED PEDIATR ONCOL, V14, P124, DOI 10.1002/mpo.2950140305; HENZE G, 1981, KLIN PADIATR, V193, P145, DOI 10.1055/s-2008-1034450; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAND VJ, 1994, J CLIN ONCOL, V12, P1939, DOI 10.1200/JCO.1994.12.9.1939; Lange B., 1997, Blood, V90, p559A; LILLEYMAN JS, 1986, MED PEDIATR ONCOL, V14, P182, DOI 10.1002/mpo.2950140314; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MILLER DR, 1983, CANCER, V51, P1041, DOI 10.1002/1097-0142(19830315)51:6<1041::AID-CNCR2820510612>3.0.CO;2-G; Nachman J, 1997, J CLIN ONCOL, V15, P2222, DOI 10.1200/JCO.1997.15.6.2222; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PINKERTON CR, 1986, MED PEDIATR ONCOL, V14, P69, DOI 10.1002/mpo.2950140202; PUI CH, 1994, J CLIN ONCOL, V12, P2601, DOI 10.1200/JCO.1994.12.12.2601; PUI CH, 1992, LEUKEMIA LYMPHOMA, V7, P173, DOI 10.3109/10428199209053620; PUI CH, 1991, BLOOD, V77, P440; PULLEN DJ, 1982, BLOOD, V60, P1159; RAIMONDI SC, 1993, BLOOD, V81, P2237; REITER A, 1994, BLOOD, V84, P3122, DOI 10.1182/blood.V84.9.3122.3122; RIEHM H, 1987, KLIN PADIATR, V199, P151, DOI 10.1055/s-2008-1026781; RIVERA GK, 1993, NEW ENGL J MED, V329, P1289, DOI 10.1056/NEJM199310283291801; SANTANA VM, 1990, LEUKEMIA, V4, P87; Schrappe M, 1996, J CLIN ONCOL, V14, P2403, DOI 10.1200/JCO.1996.14.8.2403; SCHRAPPE M, 1994, KLIN PADIATR, V206, P208, DOI 10.1055/s-2008-1046607; SHIKANO T, 1986, CANCER, V58, P2239, DOI 10.1002/1097-0142(19861115)58:10<2239::AID-CNCR2820581013>3.0.CO;2-I; Steinherz PG, 1996, J CLIN ONCOL, V14, P389, DOI 10.1200/JCO.1996.14.2.389; STEINHERZ PG, 1991, CANCER-AM CANCER SOC, V68, P751, DOI 10.1002/1097-0142(19910815)68:4<751::AID-CNCR2820680416>3.0.CO;2-T; STEINHERZ PG, 1986, J CLIN ONCOL, V4, P744, DOI 10.1200/JCO.1986.4.5.744; TUBERGEN DG, 1993, J CLIN ONCOL, V11, P527, DOI 10.1200/JCO.1993.11.3.527; TUBERGEN DG, 1993, J CLIN ONCOL, V11, P520, DOI 10.1200/JCO.1993.11.3.520; Uckun FM, 1996, LEUKEMIA LYMPHOMA, V24, P57, DOI 10.3109/10428199609045714	44	330	340	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1998	338	23					1663	1671		10.1056/NEJM199806043382304	http://dx.doi.org/10.1056/NEJM199806043382304			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR451	9614257				2022-12-28	WOS:000073978000004
J	Nierenberg, DW; Nordgren, RE; Chang, MB; Siegler, RW; Blayney, MB; Hochberg, F; Toribara, TY; Cernichiari, E; Clarkson, T				Nierenberg, DW; Nordgren, RE; Chang, MB; Siegler, RW; Blayney, MB; Hochberg, F; Toribara, TY; Cernichiari, E; Clarkson, T			Delayed cerebellar disease and death after accidental exposure to dimethylmercury	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METHYLMERCURY; MERCURY; IRAQ; ACID		Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med,Sect Clin Pharmacol, Hanover, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pharmacol Toxicol,Sect Clin Pharmacol, Hanover, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pathol, Hanover, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med,Sect Neurol, Hanover, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pediat,Sect Neurol, Hanover, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Off Environ Hlth & Safety, Hanover, NH 03756 USA; Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY USA; Massachusetts Gen Hosp, Neurol Serv, Boston, MA 02114 USA	Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College; University of Rochester; Harvard University; Massachusetts General Hospital	Nierenberg, DW (corresponding author), Dartmouth Hitchcock Med Ctr, Hinman Box 7506, Lebanon, NH 03756 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 01247] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AASETH J, 1995, ANALYST, V120, P853, DOI 10.1039/an9952000853; AASETH J, 1978, ACTA PHARMACOL TOX, V42, P248; *AM C GOV IND HYG, 1997, THRESH LIM VAL BIOL; *AT TOX SUBST DIS, 1993, PUBL AG TOX SUBST DI, P166; BAKIR F, 1973, SCIENCE, V181, P230, DOI 10.1126/science.181.4096.230; Blayney MB, 1997, CHEM ENG NEWS, V75, P7; Cernichiari E, 1995, NEUROTOXICOLOGY, V16, P613; Clarkson TW, 1997, CRIT REV CL LAB SCI, V34, P369, DOI 10.3109/10408369708998098; CLARKSON TW, 1981, J PHARMACOL EXP THER, V218, P74; DAVIS LE, 1994, ANN NEUROL, V35, P680, DOI 10.1002/ana.410350608; DEWHURST F, 1989, CHEM BRIT, V25, P702; GOLDBERG C, 1997, NY TIMES        0203, pA10; Gosselin RE, 1984, CLIN TOXICOLOGY COMM; IPCS, 1990, ENV HLTH CRIT 101 ME; JUNGHANS RP, 1983, ENVIRON RES, V31, P1, DOI 10.1016/0013-9351(83)90059-2; KOLP P, 1993, AM J IND MED, V23, P135, DOI 10.1002/ajim.4700230119; KOSNETT MJ, 1992, J TOXICOL-CLIN TOXIC, V30, P529, DOI 10.3109/15563659209017939; Lapham LW, 1995, NEUROTOXICOLOGY, V16, P689; Lipfert FW, 1997, WATER AIR SOIL POLL, V97, P119; ONEILL H, 1997, VALLEY NEWS     0914, pA7; ONEILL H, 1997, VALLEY NEWS     0914, pA1; OSTLAND K, 1969, ACTA PHARM TOXICO S1, V27; PAZDEROVA J, 1974, INT ARCH ARBEITSMED, V33, P323, DOI 10.1007/BF00538936; Rice DC, 1996, NEUROTOXICOLOGY, V17, P583; *SIGM CHEM, 1997, 328081 SIGM CHEM; TORIBARA TY, 1982, ANAL CHEM, V54, P1844, DOI 10.1021/ac00248a043; Toribara TY, 1997, CHEM ENG NEWS, V75, P6; Weiss B, 1995, NEUROTOXICOLOGY, V16, P577; *WHO, 1989, ENV HLTH CRIT, V86; ZACKS R, 1997, SCI AM, V227, P20	30	137	142	2	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1998	338	23					1672	1676		10.1056/NEJM199806043382305	http://dx.doi.org/10.1056/NEJM199806043382305			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR451	9614258	Bronze			2022-12-28	WOS:000073978000005
J	Smith, L				Smith, L			Death in springtime	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Mt Sinai Sch Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Smith, L (corresponding author), Mt Sinai Hosp, 1 Gustave L Levy Pl,Box 118, New York, NY 10029 USA.								0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					955	955		10.7326/0003-4819-128-11-199806010-00019	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00019			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634438				2022-12-28	WOS:000073808600014
J	Kennedy, I; Sells, RA; Daar, AS; Guttmann, RD; Hoffenberg, R; Lock, M; Radcliffe-Richards, J; Tilney, N				Kennedy, I; Sells, RA; Daar, AS; Guttmann, RD; Hoffenberg, R; Lock, M; Radcliffe-Richards, J; Tilney, N		Int Forum Transplant Ethics	The case for "presumed consent" in organ donation	LANCET			English	Article									Univ Liverpool, Royal Liverpool Hosp, Renal Transplant Unit, Int Forum Transplant Eth, Liverpool L7 8XP, Merseyside, England; Univ London, Univ Coll, Sch Publ Policy, London WC1E 7HN, England; Sultan Qaboos Univ, Coll Med, Dept Surg, Muscat, Oman; Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; Dept Social Studies Med, Montreal, PQ, Canada; Brigham & Womens Hosp, Boston, MA 02115 USA	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of London; University College London; Sultan Qaboos University; McGill University; Royal Victoria Hospital; Harvard University; Brigham & Women's Hospital	Sells, RA (corresponding author), Univ Liverpool, Royal Liverpool Hosp, Renal Transplant Unit, Int Forum Transplant Eth, Liverpool L7 8XP, Merseyside, England.							BIRKELAND SA, 1997, LANCET, V349, P35; HAUPTMAN JP, 1997, NEW ENGL J MED, V336, P422; MATESANZ R, 1995, TRANSP CL IMMUN SFMM, V26, P167; Michielsen P, 1996, J ROY SOC MED, V89, P663, DOI 10.1177/014107689608901203; MICHIELSEN P, 1995, TRANSP CL IMMUN SFMM, V26, P33; MUHLBACHER F, 1992, SYSTEMS DONOR RECRUI, P65; NEW W, 1994, 18 KINGS FUND I, P25; SELLS RA, IN PRESS IMPACT EURO; STEVENS P, 1992, SYSTEMS DONOR RECRUI, P105; *WHO, 1994, LEG RESP ORG TRANSPL, P276; *WHO, 1991, HUM ORG TRANSPL REP, P7	11	78	79	1	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1650	1652		10.1016/S0140-6736(97)08212-3	http://dx.doi.org/10.1016/S0140-6736(97)08212-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620733				2022-12-28	WOS:000074026600037
J	Wannamethee, SG; Shaper, AG; Walker, M				Wannamethee, SG; Shaper, AG; Walker, M			Changes in physical activity, mortality, and incidence of coronary heart disease in older men	LANCET			English	Article							AGED BRITISH MEN; LEISURE-TIME; RISK-FACTORS; ACTIVITY LEVEL; FOLLOW-UP; DEATH; EXERCISE; ATTACK; RATES	Background We studied the relations between physical activity and changes in physical activity, all-cause mortality, and incidence of major coronary-heart-disease events in older men. Methods In 1978-80 (Q1), 7735 men aged 40-59 were selected from general practices in 24 British towns, and enrolled in a prospective study of cardiovascular disease, which included physical activity data. In 1992 (Q92), 12-14 years later, 5934 of the men (91% of available survivors, mean age 63 years) gave further information on physical activity and,were then followed up for a further 4 years. The main endpoints were all-cause mortality during 4 years of follow-up from Q92, and major fatal and non-fatal coronary-heart-disease events during 3 years of follow-up from Q92. Findings Among 4311 men with no history of coronary heart disease, stroke, or "other heart trouble" by Q92 and who did not report "poor health", there were 219 deaths. In the inactive/occasionally active, light, moderate, and moderately vigorous/vigorous activity groups there were 101 (18.5/1000 person-years) 48 (11.4), 23 (7.3), and 47 (9.1) deaths, respectively (adjusted risk ratios 1.00, 0.61 [95% CI 0.48-0.86], 0.50 [0.31-0.79], 0.65 [0.45-0.94]). Men who were sedentary at Q1 and who began at least light activity by Q92 had significantly lower all-cause mortality than those who remained sedentary, even after adjustment for potential confounders (risk ratio=0.55 [0.36-0.84]). Physical activity improved both cardiovascular mortality (0.66 [0.35-1.23]) and noncardiovascular mortality (0.48 [0.27-0.85]). The relation between physical activity at Q92, changes in physical activity, and mortality were similar for men with pre-existing cardiovascular disease. Interpretation Maintaining or taking up light or moderate physical activity reduces mortality and heart attacks in older men with and without diagnosed cardiovascular disease. Our results support public-health recommendations for older sedentary people to increase physical activity, and for active middle-aged people to continue their activity into old age.	Royal Free Hosp, Sch Med, Dept Publ Hlth & Primary Care, London NW3 2PF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Wannamethee, SG (corresponding author), Royal Free Hosp, Sch Med, Dept Publ Hlth & Primary Care, London NW3 2PF, England.		Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351				[Anonymous], 1996, JAMA, V276, P241; ASTRAND PO, 1986, ACTA MED SCAND, P241; Bennett N, 1995, HLTH SURVEY ENGLAND; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; CHAVE SPW, 1978, J EPIDEMIOL COMMUN H, V32, P239, DOI 10.1136/jech.32.4.239; *DEP HLTH PHYS ACT, 1995, MOR PEOPL MOR ACT MO; EDWARDS KE, 1992, CLIN GERIATR MED, V1, P35; HAGBERG JM, 1994, PHYSICAL ACTIVITY FI, P993; Hakim AA, 1998, NEW ENGL J MED, V338, P94, DOI 10.1056/NEJM199801083380204; Hein H. O., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P57; *HLTH ED AUTH, 1995, HLTH UPD PHYS ACT; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; Kujala UM, 1998, JAMA-J AM MED ASSOC, V279, P440, DOI 10.1001/jama.279.6.440; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; Lissner L, 1996, AM J EPIDEMIOL, V143, P54; MORRIS JN, 1990, BRIT HEART J, V63, P325; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHAPER AG, 1994, J HUM HYPERTENS, V8, P3; SHERMAN SE, 1994, AM HEART J, V128, P965, DOI 10.1016/0002-8703(94)90596-7; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365; WANNAMETHEE G, 1992, BRIT MED J, V304, P597, DOI 10.1136/bmj.304.6827.597; WANNAMETHEE G, 1991, INT J EPIDEMIOL, V20, P239, DOI 10.1093/ije/20.1.239; WANNAMETHEE G, 1993, AM J EPIDEMIOL, V137, P735, DOI 10.1093/oxfordjournals.aje.a116734; WILSON PWF, 1986, AM HEART J, V111, P1177, DOI 10.1016/0002-8703(86)90022-0	30	350	358	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	1998	351	9116					1603	1608		10.1016/S0140-6736(97)12355-8	http://dx.doi.org/10.1016/S0140-6736(97)12355-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620713				2022-12-28	WOS:000074026600006
J	Hardt, WD; Chen, LM; Schuebel, KE; Bustelo, XR; Galan, JE				Hardt, WD; Chen, LM; Schuebel, KE; Bustelo, XR; Galan, JE			S-typhimurium encodes an activator of Rho GTPases that induces membrane ruffling and nuclear responses in host cells	CELL			English	Article							CULTURED EPITHELIAL-CELLS; SALMONELLA-TYPHIMURIUM; PROTEIN SECRETION; INVASION GENES; FAMILY; ENTRY; IDENTIFICATION; GROWTH; RAS; CYTOSKELETAL	S. typhimurium stimulates signaling pathways leading to membrane ruffling, actin cytoskeleton rearrangements, and nuclear responses. The stimulation requires a protein secretion system (type III) that translocates bacterial proteins into the host cell. We show that SopE, a substrate of this secretion system, stimulates cytoskeletal reorganization and JNK activation in a CDC42- and Rac-1-dependent manner. A lambda gt11 cDNA library screen for proteins that interact with SopE identified Rac-1 and CDC42. Furthermore, purified SopE was shown to stimulate GDP/GTP nucleotide exchange in several Rho GTPases in vitro, including Rac-1 and CDC42. These findings establish a paradigm for microbial stimulation of cellular responses in which the pathogen induces signaling events by directly engaging the signaling machinery within the host cell.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Med, Dept Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Galan, JE (corresponding author), SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.		Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Hardt, Wolf-Dietrich/0000-0002-9892-6420	NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030492, R29AI030492, R37AI030492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052543] Funding Source: NIH RePORTER; NCI NIH HHS [CA7373501] Funding Source: Medline; NIAID NIH HHS [AI30492] Funding Source: Medline; NIGMS NIH HHS [GM52543] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD JW, 1993, MICROB PATHOGENESIS, V14, P217, DOI 10.1006/mpat.1993.1021; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; COLLAZO CM, 1995, MOL MICROBIOL, V15, P25, DOI 10.1111/j.1365-2958.1995.tb02218.x; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FINLAY BB, 1990, J INFECT DIS, V162, P1096, DOI 10.1093/infdis/162.5.1096; FINLAY BB, 1991, J CELL SCI, V99, P283; Fu YX, 1998, MOL MICROBIOL, V27, P359, DOI 10.1046/j.1365-2958.1998.00684.x; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GALAN JE, 1992, J BACTERIOL, V174, P4338; GALAN JE, 1996, ANNU REV CELL DEV BI, V12, P219; GARCIADELPORTILLO F, 1994, INFECT IMMUN, V62, P4641, DOI 10.1128/IAI.62.10.4641-4645.1994; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hardt WD, 1997, P NATL ACAD SCI USA, V94, P9887, DOI 10.1073/pnas.94.18.9887; Hardt WD, 1998, P NATL ACAD SCI USA, V95, P2574, DOI 10.1073/pnas.95.5.2574; Hobbie S, 1997, J IMMUNOL, V159, P5550; Hotchin NA, 1996, CANCER SURV, V27, P311; JONES BD, 1993, P NATL ACAD SCI USA, V90, P10390, DOI 10.1073/pnas.90.21.10390; KANIGA K, 1995, J BACTERIOL, V177, P3965, DOI 10.1128/jb.177.14.3965-3971.1995; KANIGA K, 1994, MOL MICROBIOL, V13, P555, DOI 10.1111/j.1365-2958.1994.tb00450.x; Kaniga K, 1996, MOL MICROBIOL, V21, P633, DOI 10.1111/j.1365-2958.1996.tb02571.x; KANIGA K, 1995, J BACTERIOL, V177, P7078, DOI 10.1128/jb.177.24.7078-7085.1995; LI J, 1995, P NATL ACAD SCI USA, V92, P7252, DOI 10.1073/pnas.92.16.7252; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PEGUES DA, 1995, MOL MICROBIOL, V17, P169, DOI 10.1111/j.1365-2958.1995.mmi_17010169.x; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; Wood MW, 1996, MOL MICROBIOL, V22, P327, DOI 10.1046/j.1365-2958.1996.00116.x; XU X, 1997, BIOCHEMISTRY-US, V36, P826	40	640	658	2	33	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					815	826		10.1016/S0092-8674(00)81442-7	http://dx.doi.org/10.1016/S0092-8674(00)81442-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630225	Bronze			2022-12-28	WOS:000073956700017
J	Kaufer, D; Friedman, A; Seidman, S; Soreq, H				Kaufer, D; Friedman, A; Seidman, S; Soreq, H			Acute stress facilitates long-lasting changes in cholinergic gene expression	NATURE			English	Article							HUMAN ACETYLCHOLINESTERASE; ALZHEIMERS-DISEASE; GULF-WAR; PROMOTER; BRAIN; PYRIDOSTIGMINE; NEURONS; CALCIUM; TACRINE; CELLS	Acute traumatic stress may lead to post-traumatic stress disorder (PTSD)(1), which is characterized by delayed neuropsychiatric symptoms including depression, irritability, and impaired cognitive performance(2). Curiously, inhibitors of the acetylcholine-hydrolysing enzyme acetylcholinesterase may induce psychopathologies that are reminiscent of PTSD3,4. It is unknown how a single stressful event mediates long-term neuronal plasticity. Moreover, no mechanism has been proposed to explain the convergent neuropsychological outcomes of stress and of acetylcholinesterase inhibition. However, acute stress elicits a transient increase in the amounts released of the neurotransmitter acetylcholine and a phase of enhanced neuronal excitability(5). Inhibitors of acetylcholinesterase also promote enhanced electrical brain activity(6), presumably by increasing the survival of acetylcholine at the synapse. Here we report that there is similar bidirectional modulation of genes that regulate acetylcholine availability after stress and blockade of acetylcholinesterase. These calcium-dependent changes in gene expression coincide with phases of rapid enhancement and delayed depression of neuronal excitability, Both of these phases are mediated by muscarinic acetylcholine receptors, Our results suggest a model in which robust cholinergic stimulation triggers rapid induction of the gene encoding the transcription factor c-Fos. This protein then mediates selective regulatory effects on the long-lasting activities of genes involved in acetylcholine metabolism.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Dept Neurosurg, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel	Hebrew University of Jerusalem; Ben Gurion University; Ben Gurion University; Ben Gurion University	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	soreq@shum.huji.ac.il		Soreq, Hermona/0000-0002-0955-526X				Andres C, 1997, P NATL ACAD SCI USA, V94, P8173, DOI 10.1073/pnas.94.15.8173; BAUSERO P, 1993, NEUROREPORT, V4, P287, DOI 10.1097/00001756-199303000-00015; Beeri R, 1997, J NEUROCHEM, V69, P2441; BEERI R, 1995, CURR BIOL, V5, P1063, DOI 10.1016/S0960-9822(95)00211-9; BENAZIZALOYA R, 1993, P NATL ACAD SCI USA, V90, P2471, DOI 10.1073/pnas.90.6.2471; CERVINI R, 1995, J BIOL CHEM, V270, P24654, DOI 10.1074/jbc.270.42.24654; COLE AE, 1983, SCIENCE, V221, P1299, DOI 10.1126/science.6612345; ENNIS M, 1992, EXP NEUROL, V118, P164, DOI 10.1016/0014-4886(92)90033-M; Friedman A, 1996, NAT MED, V2, P1382, DOI 10.1038/nm1296-1382; FRIEDMAN A, 1989, EUR J NEUROSCI, V1, P374, DOI 10.1111/j.1460-9568.1989.tb00802.x; GHOSH A, 1994, J NEUROBIOL, V25, P294, DOI 10.1002/neu.480250309; GURVITS TV, 1993, J NEUROPSYCH CLIN N, V5, P183; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; IMPERATO A, 1991, BRAIN RES, V538, P111, DOI 10.1016/0006-8993(91)90384-8; KARPEL R, 1994, EXP CELL RES, V210, P268, DOI 10.1006/excr.1994.1039; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; Koenigsberger C, 1997, J NEUROCHEM, V69, P1389; LAYER PG, 1995, PROG HISTOCHEM CYTOC, V29, P1; LI Y, 1993, J BIOL CHEM, V268, P3563; MILNER IB, 1994, JAMA-J AM MED ASSOC, V271, P661, DOI 10.1001/jama.1994.03510330039024; ROSENSTOCK L, 1991, LANCET, V338, P223, DOI 10.1016/0140-6736(91)90356-T; Sapolsky RM, 1996, SCIENCE, V273, P749, DOI 10.1126/science.273.5276.749; SEIDMAN S, 1995, MOL CELL BIOL, V15, P2993; SHARABI Y, 1991, ISRAEL J MED SCI, V27, P656; Sternfeld M, 1998, J NEUROSCI, V18, P1240; Wickelgren I, 1997, SCIENCE, V278, P1404; WINKER MA, 1994, JAMA-J AM MED ASSOC, V271, P1023, DOI 10.1001/jama.271.13.1023	27	510	528	1	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 28	1998	393	6683					373	377		10.1038/30741	http://dx.doi.org/10.1038/30741			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620801				2022-12-28	WOS:000073883600056
J	Kemp, M				Kemp, M			Max's modelling	NATURE			English	Editorial Material									Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.								0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1998	393	6683					315	315		10.1038/30625	http://dx.doi.org/10.1038/30625			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620795	Bronze			2022-12-28	WOS:000073883600031
J	Williams, SP; Sigler, PB				Williams, SP; Sigler, PB			Atomic structure of progesterone complexed with its receptor	NATURE			English	Article							THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; CRYSTAL-STRUCTURE; RETINOIC ACID; C-TERMINUS; ACTIVATION; DIMERIZATION; RU486; MECHANISM; DNA	The physiological effects of progestins are mediated by the progesterone receptor, a member of the steroid/nuclear receptor superfamily(1). As progesterone is required for maintenance of pregnancy, its receptor has been a target for pharmaceuticals(2). Here we report the 1.8 Angstrom crystal structure of a progesterone-bound ligand-binding domain of the human progesterone receptor. The nature of this structure explains the receptor's selective affinity for progestins and establishes a common mode of recognition of 3-oxy steroids by the cognate receptors. Although the overall fold of the progesterone receptor is similar to that found in related receptors(3-6), the progesterone receptor has a quite different mode of dimerization(3,6). A hormone-induced stabilization of the carboxy-terminal secondary structure of the ligand-binding domain of the progesterone receptor accounts for the stereo-chemistry of this distinctive dimer, explains the receptor's characteristic pattern of ligand-dependent protease resistance and its loss of repression(7,8), and indicates how the anti-progestin RU486 might work in birth control. The structure also indicates that the analogous 3-keto-steroid receptors may have a similar mechanism of action.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06510 USA	Yale University; Howard Hughes Medical Institute; Yale University	Sigler, PB (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 160 Whitney Ave, New Haven, CT 06510 USA.			Williams, Shawn/0000-0001-8311-2638				ALLAN GF, 1992, J BIOL CHEM, V267, P19513; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BENHAMOU B, 1992, SCIENCE, V255, P206, DOI 10.1126/science.1372753; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; DEMARZO AM, 1992, BIOCHEMISTRY-US, V31, P10491, DOI 10.1021/bi00158a012; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EDWARDS DP, 1995, J STEROID BIOCHEM, V53, P449, DOI 10.1016/0960-0760(95)00091-D; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Jeyakumar M, 1997, MOL ENDOCRINOL, V11, P755, DOI 10.1210/me.11.6.755; Klotzbucher M, 1997, MOL ENDOCRINOL, V11, P768, DOI 10.1210/me.11.6.768; LANZ R, 1996, ENDOCRINOLOGY, V135, P2183; LeDouarin B, 1996, PHILOS T R SOC B, V351, P569, DOI 10.1098/rstb.1996.0056; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RODRIGUEZ R, 1990, MOL ENDOCRINOL, V4, P1782, DOI 10.1210/mend-4-12-1782; SKAFAR DF, 1993, J STEROID BIOCHEM, V44, P39, DOI 10.1016/0960-0760(93)90149-Q; SKAFAR DF, 1991, BIOCHEMISTRY-US, V30, P6148, DOI 10.1021/bi00239a010; TETAL MJ, 1997, MOL ENDOCRINOL, V11, P1114; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WISHART DS, 1994, COMPUT APPL BIOSCI, V10, P687; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang SM, 1996, MOL ENDOCRINOL, V10, P24, DOI 10.1210/me.10.1.24	28	542	564	3	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1998	393	6683					392	396		10.1038/30775	http://dx.doi.org/10.1038/30775			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620806				2022-12-28	WOS:000073883600061
J	Catalona, WJ; Partin, AW; Slawin, KM; Brawer, MK; Flanigan, RC; Patel, A; Richie, JP; deKernion, JB; Walsh, PC; Scardino, PT; Lange, PH; Subong, ENP; Parson, RE; Gasior, GH; Loveland, KG; Southwick, PC				Catalona, WJ; Partin, AW; Slawin, KM; Brawer, MK; Flanigan, RC; Patel, A; Richie, JP; deKernion, JB; Walsh, PC; Scardino, PT; Lange, PH; Subong, ENP; Parson, RE; Gasior, GH; Loveland, KG; Southwick, PC			Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease - A prospective multicenter clinical trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SERUM; ALPHA-1-ANTICHYMOTRYPSIN; MEN; PERFORMANCE; PROPORTIONS; COMPLEX	Context.-The percentage of free prostate-specific antigen (PSA) in serum has been shown to enhance the specificity of PSA testing for prostate cancer detection, but earlier studies provided only preliminary cutoffs for clinical use. Objective.-To develop risk assessment guidelines and a cutoff value for defining abnormal percentage of free PSA in a population of men to whom the test would be applied. Design.-Prospective blinded study using the Tandem PSA and free PSA assays (Hybritech Inc, San Diego, Calif). Setting.-Seven nationwide university medical centers. Participants.-A total of 773 men (379 with prostate cancer, 394 with benign prostatic disease) 50 to 75 years of age with a palpably benign prostate gland, PSA level of 4.0 to 10.0 ng/mL, and histologically confirmed diagnosis. Main Outcome Measures.-A percentage of free PSA cutoff that maintained 95% sensitivity for prostate cancer detection, and probability of cancer for individual patients. Results.-The percentage of free PSA may be used in 2 ways: as a single cutoff tie, perform a biopsy for all patients at or below a cutoff of 25% free PSA) or as an individual patient risk assessment tie, base biopsy decisions on each patient's risk of cancer). The 25% free PSA cutoff detected 95% of cancers while avoiding 20% of unnecessary biopsies. The cancers associated with greater than 25% free PSA were more prevalent in older patients, and generally were less threatening in terms of tumor grade and volume. For individual patients, a lower percentage of free PSA was associated with a higher risk of cancer (range, 8%-56%), In the multivariate model used, the percentage of free PSA was an independent predictor of prostate cancer (odds ratio [OR], 3.2; 95% confidence interval [CI], 2.5-4.1; P<.001) and contributed significantly more than age (OR, 1.2; 95% CI, 0.92-1.55) or total PSA level (OR, 1.0; 95% CI, 0.92-1.11) in this cohort of subjects with total PSA values between 4.0 and 10.0 ng/mL. Conclusions.-Use of the percentage of free PSA can reduce unnecessary biopsies in patients undergoing evaluation for prostate cancer, with a minimal loss in sensitivity in detecting cancer. A cutoff of 25% or less free PSA is recommended for patients with PSA values between 4.0 and 10.0 ng/mL and a palpably benign gland, regardless of patient age or prostate size. To our knowledge, this study is the largest series to date evaluating the percentage of free PSA in a population representative of patients in whom the test would be used in clinical practice.	Washington Univ, Sch Med, Dept Surg, Div Urol Surg, St Louis, MO 63110 USA; Johns Hopkins Univ Hosp, Dept Urol, Baltimore, MD 21287 USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Washington, Seattle, WA 98195 USA; Loyola Univ, Med Ctr, Maywood, IL 60153 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA; Harvard Univ, Brigham & Womens Hosp, Program Urol, Boston, MA 02115 USA; Hybritech Inc, Dept Res & Dev, San Diego, CA USA	Washington University (WUSTL); Johns Hopkins University; Johns Hopkins Medicine; Baylor College of Medicine; University of Washington; University of Washington Seattle; Loyola University Chicago; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Brigham & Women's Hospital	Catalona, WJ (corresponding author), Washington Univ, Sch Med, Dept Surg, Div Urol Surg, 4960 Childrens Pl, St Louis, MO 63110 USA.	catalonaw@msnotes.wustl.edu		Southwick, Paula/0000-0003-2923-9173				[Anonymous], 1982, JACKKNIFE BOOTSTRAP; ARCANGELI CG, IN PRESS UROLOGY; ARCANGELI CG, 1996, J UROLOGY, V155, P415; Bangma CH, 1997, J UROLOGY, V157, P544, DOI 10.1016/S0022-5347(01)65197-8; CANCANGH PJ, 1996, UROLOGY S, V48, P67; Carter HB, 1997, UROLOGY, V49, P379; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; Catalona WJ, 1997, JAMA-J AM MED ASSOC, V277, P1452, DOI 10.1001/jama.277.18.1452; CATALONA WJ, 1995, JAMA-J AM MED ASSOC, V274, P1214; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; Chan Daniel W., 1997, Journal of Urology, V157, P112; Chen YT, 1996, UROLOGY, V47, P518, DOI 10.1016/S0090-4295(99)80487-7; CHRISTENSSON A, 1993, J UROLOGY, V150, P100, DOI 10.1016/S0022-5347(17)35408-3; CHRISTENSSON A, 1990, EUR J BIOCHEM, V194, P755, DOI 10.1111/j.1432-1033.1990.tb19466.x; EFRON B, 1993, J AM STAT ASSOC, V82, P171; Elgamal AAA, 1996, J UROLOGY, V156, P1042, DOI 10.1016/S0022-5347(01)65696-9; FORTUNATO A, 1996, CLIN CHEM S, V42, P268; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; HOSMER DW, 1989, APPL LOGISTIC REGRES; Jung K, 1996, CLIN CHEM, V42, P1026; KEETCH DW, 1994, J UROLOGY, V151, P1571, DOI 10.1016/S0022-5347(17)35304-1; Lerner SE, 1996, UROLOGY, V48, P240, DOI 10.1016/S0090-4295(96)00159-8; LILJA H, 1991, CLIN CHEM, V37, P1618; LITTRUP PJ, 1995, CANCER, V75, P1987, DOI 10.1002/1097-0142(19950401)75:7+<1987::AID-CNCR2820751639>3.0.CO;2-0; LUDERER AA, 1995, UROLOGY, V46, P187, DOI 10.1016/S0090-4295(99)80192-7; OESTERLING JE, 1995, J UROLOGY, V154, P1090, DOI 10.1016/S0022-5347(01)66984-2; Pannek J, 1998, J UROLOGY, V159, P1238, DOI 10.1016/S0022-5347(01)63571-7; Partin AW, 1996, UROLOGY, V48, P55, DOI 10.1016/S0090-4295(96)00611-5; Pearson JD, 1996, J UROL S, V155, P606; Smith DS, 1996, JAMA-J AM MED ASSOC, V276, P1309, DOI 10.1001/jama.276.16.1309; STENMAN UH, 1991, CANCER RES, V51, P222; VanCangh PJ, 1996, PROSTATE, P30; Vashi AR, 1997, UROLOGY, V49, P19, DOI 10.1016/S0090-4295(96)00511-0; Woodrum D, 1996, UROLOGY, V48, P33, DOI 10.1016/S0090-4295(96)00607-3; Woodrum DL, 1997, CLIN CHEM, V43, P1203; Woodrum DL, 1998, J UROLOGY, V159, P5, DOI 10.1016/S0022-5347(01)63996-X	36	831	874	2	33	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1542	1547		10.1001/jama.279.19.1542	http://dx.doi.org/10.1001/jama.279.19.1542			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN087	9605898				2022-12-28	WOS:000073608100032
J	Salama, AD; Pusey, CD				Salama, AD; Pusey, CD			Tuberous sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Hammersmith Hosp, London W12 0NN, England	Imperial College London	Salama, AD (corresponding author), Hammersmith Hosp, London W12 0NN, England.		Salama, Alan/B-5183-2010						0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1998	338	26					1886	1886		10.1056/NEJM199806253382605	http://dx.doi.org/10.1056/NEJM199806253382605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV898	9637808				2022-12-28	WOS:000074352800005
J	Adrain, JM; Fortey, RA; Westrop, SR				Adrain, JM; Fortey, RA; Westrop, SR			Post-Cambrian trilobite diversity and evolutionary faunas	SCIENCE			English	Article							ORDOVICIAN TRILOBITES; MASS EXTINCTION; SURVIVORSHIP; PATTERNS	A cluster analysis of the stratigraphic distribution of all Ordovician trilobite families, based on a comprehensive taxonomic database, identified two major faunas with disjunct temporal diversity trends. The Ibex Fauna behaved as a cohort, declining through the Ordovician and disappearing at the end-Ordovician mass extinction. In contrast, the Whiterock Fauna radiated rapidly during the Middle Ordovician and gave rise to all post-Ordovician trilobite diversity. Its pattern of diversification matches that of the Paleozoic Evolutionary Fauna; hence, trilobites were active participants in the great Ordovician radiations. Extinction patterns at the end of the Ordovician are related to clade size: Surviving trilobite families show higher genus diversity than extinguished families.	Nat Hist Museum, Dept Palaeontol, London SW7 5BD, England; Univ Oklahoma, Sch Geol & Geophys, Norman, OK 73019 USA; Univ Oklahoma, Oklahoma Museum Nat Hist, Norman, OK 73019 USA	Natural History Museum London; University of Oklahoma System; University of Oklahoma - Norman; University of Oklahoma System; University of Oklahoma - Norman	Adrain, JM (corresponding author), Nat Hist Museum, Dept Palaeontol, Cromwell Rd, London SW7 5BD, England.							ADRAIN JM, 1996, GEOL SOC AM ABSTR, V28, pA291; Anstey Robert L., 1995, P239; BRENCHLEY P, 1990, MASS EXTINCTGIONS PR, P104; CHATTERTON BDE, 1989, PALEOBIOLOGY, V15, P118, DOI 10.1017/S0094837300009313; Cope JCW, 1997, PALAEONTOLOGY, V40, P713; Cope JCW, 1996, PALAEONTOLOGY, V39, P979; CULVER SJ, 1987, PALEOBIOLOGY, V13, P169; Droser M. L., 1995, ORDOVICIAN ODYSSEY, P405; Droser ML, 1996, AM SCI, V84, P122; Edgecombe Gregory D., 1992, P144; ERWIN DH, 1990, PALEOBIOLOGY, V16, P187, DOI 10.1017/S0094837300009878; FOOTE M, 1988, PALEOBIOLOGY, V14, P258, DOI 10.1017/S0094837300011994; Fortey RA, 1997, BIOESSAYS, V19, P429, DOI 10.1002/bies.950190510; FORTEY RA, 1986, PALAEONTOLOGY, V29, P631; FORTEY RA, 1989, PHILOS T ROY SOC B, V325, P327, DOI 10.1098/rstb.1989.0092; FORTEY RA, 1983, SPEC PAP PALAEONTOL, V30, P179; FORTEY RA, 1990, SYSTEMATICS ASS SPEC, V42, P139; Fortey Richard A., 1996, Journal of Paleontology, V70, P73; JABLONSKI D, 1986, SCIENCE, V231, P129, DOI 10.1126/science.231.4734.129; McKerrow W.S., 1990, GEOL SOC LONDON MEM, V12; Patzkowsky Mark E., 1995, P413; Pojeta J., 1977, B BUREAU MINERAL RES, V174, P1; Robison R.A., 1987, P221; Sepkoski J.J. Jr, 1985, P153; Sepkoski J. John Jr, 1995, P393; SEPKOSKI JJ, 1981, PALEOBIOLOGY, V7, P36, DOI 10.1017/S0094837300003778; Sepkoski JJ, 1983, BIOTIC INTERACTIONS, P673; Sepkoski Jr J.J., 1992, MILWAUKEE PUBLIC MUS, V83, P1; SEPKOSKI JR. J.J., 1981, 2 INT S CAMBR SYST, V81-743, P203; SPRINKLE J, 1992, ORIGIN EARLY EVOLUTI, P375; THOMAS AT, 1985, ATLAS INVERTEBRATE M, P199; WESTROP SR, 1989, PALEOBIOLOGY, V15, P46, DOI 10.1017/S0094837300009179; WESTROP SR, 1995, PALAIOS, V10, P75, DOI 10.2307/3515008; Westrop SR, 1998, PALEOBIOLOGY, V24, P1; WHITTINGTON H. B., 1963, BULL MUS COMP ZOOL HARVARD UNIV, V129, P1; WHITTINGTON HB, 1981, GEOL MAG, V118, P591, DOI 10.1017/S0016756800033823	36	85	94	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1922	1925		10.1126/science.280.5371.1922	http://dx.doi.org/10.1126/science.280.5371.1922			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632387	Green Submitted			2022-12-28	WOS:000074323800059
J	Emerman, M; Malim, MH				Emerman, M; Malim, MH			HIV-1 regulatory/accessory genes: Keys to unraveling viral and host cell biology	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROVIRAL DNA-SYNTHESIS; REVERSE TRANSCRIPTION; RNA-POLYMERASE; NUCLEAR IMPORT; TYPE-1; PROTEIN; CYCLE; VIF; INFECTION	Human immunodeficiency virus type-1 (HIV-1) manipulates fundamental host cell processes in sophisticated ways to achieve optimum replicative efficiency. Recent studies have provided new details on the molecular interactions of HIV-1 with its host cell. For example, HIV-1 encodes a protein that regulates transcriptional elongation by interacting with a cellular cyclin-dependent kinase, another that activates the specific nuclear export of viral RNA, and several others that affect the intracellular trafficking of viral and host cell proteins. Detailed analysis of the interplay between these viral proteins and normal cellular activities has provided new insights into central questions of virology and host cell biology.	Fred Hutchinson Canc Res Ctr, Div Mol Med, Seattle, WA 98109 USA; Univ Penn, Howard Hughes Med Inst, Dept Microbiol, Philadelphia, PA 19104 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; University of Pennsylvania	Emerman, M (corresponding author), Fred Hutchinson Canc Res Ctr, Div Mol Med, 1100 Fairview Ave N-Mailstop C2-023, Seattle, WA 98109 USA.	memerman@fhcrc.org; malim@hhmi.upenn.edu		Malim, Michael/0000-0002-7699-2064				Aiken C, 1997, J VIROL, V71, P5871, DOI 10.1128/JVI.71.8.5871-5877.1997; AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; Best S, 1996, NATURE, V382, P826, DOI 10.1038/382826a0; Bevec D, 1996, SCIENCE, V271, P1858, DOI 10.1126/science.271.5257.1858; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; Braaten D, 1996, J VIROL, V70, P3551, DOI 10.1128/JVI.70.6.3551-3560.1996; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; Cartier C, 1997, J VIROL, V71, P4832, DOI 10.1128/JVI.71.6.4832-4837.1997; Chackerian B, 1997, J VIROL, V71, P3932, DOI 10.1128/JVI.71.5.3932-3939.1997; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Coffin JM, 1996, NATURE, V382, P762, DOI 10.1038/382762a0; Coffin JM, 1996, FIELDS VIROLOGY, P1767; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; EMERMAN M, UNPUB; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37; FOUCHIER RAM, IN PRESS J VIROL; FOUCHIER RAM, IN PRESS SEM VIROL; FRANKEL AD, IN PRESS ANN REV BIO, V67; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; GarciaMartinez LF, 1997, EMBO J, V16, P2836, DOI 10.1093/emboj/16.10.2836; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Goncalves J, 1996, J VIROL, V70, P8701, DOI 10.1128/JVI.70.12.8701-8709.1996; Greenberg ME, 1997, EMBO J, V16, P6964, DOI 10.1093/emboj/16.23.6964; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Jacque JM, 1998, EMBO J, V17, P2607, DOI 10.1093/emboj/17.9.2607; JIN MJ, 1994, EMBO J, V13, P2935, DOI 10.1002/j.1460-2075.1994.tb06588.x; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Kerkau T, 1997, J EXP MED, V185, P1295, DOI 10.1084/jem.185.7.1295; LEGALL, 1998, IMMUNITY, V8, P1; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Luban J, 1996, CELL, V87, P1157, DOI 10.1016/S0092-8674(00)81811-5; Luo TC, 1998, VIROLOGY, V241, P224, DOI 10.1006/viro.1997.8966; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; MORI K, 1993, J VIROL, V67, P2807, DOI 10.1128/JVI.67.5.2807-2814.1993; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NISHI K, 1994, J BIOL CHEM, V269, P6320; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Piguet V, 1998, EMBO J, V17, P2472, DOI 10.1093/emboj/17.9.2472; Planelles V, 1996, J VIROL, V70, P2516, DOI 10.1128/JVI.70.4.2516-2524.1996; POLLARD VW, IN PRESS ANN REV MIC; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Schubert U, 1998, J VIROL, V72, P2280, DOI 10.1128/JVI.72.3.2280-2288.1998; Schwartz O, 1998, J VIROL, V72, P3845, DOI 10.1128/JVI.72.5.3845-3850.1998; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Sharp P.M., 1994, AIDS S1, V8, pS27; Simon JHM, 1997, J VIROL, V71, P5259, DOI 10.1128/JVI.71.7.5259-5267.1997; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; Simon JHM, 1998, EMBO J, V17, P1259, DOI 10.1093/emboj/17.5.1259; SOVA P, 1993, J VIROL, V67, P6322, DOI 10.1128/JVI.67.10.6322-6326.1993; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stevenson M, 1996, TRENDS CELL BIOL, V6, P9, DOI 10.1016/0962-8924(96)81032-4; Stivahtis GL, 1997, J VIROL, V71, P4331, DOI 10.1128/JVI.71.6.4331-4338.1997; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; Sune C, 1997, MOL CELL BIOL, V17, P6029, DOI 10.1128/MCB.17.10.6029; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WILLEY RL, 1992, J VIROL, V66, P226, DOI 10.1128/JVI.66.1.226-234.1992; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	77	297	311	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1998	280	5371					1880	1884		10.1126/science.280.5371.1880	http://dx.doi.org/10.1126/science.280.5371.1880			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632380				2022-12-28	WOS:000074323800045
J	Shepperd, S; Harwood, D; Gray, A; Vessey, M; Morgan, P				Shepperd, S; Harwood, D; Gray, A; Vessey, M; Morgan, P			Randomised controlled trial comparing hospital at home care with inpatient hospital care. II: cost minimisation analysis	BRITISH MEDICAL JOURNAL			English	Article							EARLY DISCHARGE	Objectives: To examine the cost of providing hospital at home in place of some for ms of inpatient hospital care, Design: Cost minimisation study within a randomised controlled trial. Setting: District general hospital and catchment area of neighbouring community trust. Subjects: Patients recovering from hip replacement (n = 86), knee replacement (n = 86), and hysterectomy (n = 238); elderly medical patients (n = 96); and patients with chronic obstructive airways disease (n = 32), Interventions: Hospital at home or inpatient hospital care. Main outcome measures: Cost of hospital at home scheme to health sen ice, to general practitioners, and to patients and their families compared with hospital care. Results: No difference was detected in total healthcare costs between hospital at home and hospital care for patients recovering from a hip or knee replacement or elderly medical patients. Hospital at home significantly increased healthcare costs for patients recovering from a hysterectomy (ratio of geometrical means 1.15, 95% confidence interval 1.04 to 1.29, P = 0.009) and for those with chronic obstructive airways disease (Mann-Whitney U test, P = 0.01). Hospital at home significantly increased general practitioners' costs for elderly medical patients (Mann-Whitney U test P < 0.01) and for those with chronic obstructive airways disease (P = 0.02), Patient and carer expenditure made up a small proportion of total costs. Conclusion: Hospital at home care did not reduce total healthcare costs for the conditions studied in this trial, and costs were significantly increased for patients recovering fi-om a hysterectomy and those with chronic obstructive airways disease, There was some evidence that costs were shifted to primary care for elderly medical patients and those with chronic obstructive airways disease.	Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Hlth Econ Res Ctr, Oxford OX3 7LF, England; Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Hlth Serv Res Unit, Oxford OX3 7LF, England; NOrthamptonshire Hlth Author, Northampton NN1 5DN, England	University of Oxford; University of Oxford	Shepperd, S (corresponding author), Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Hlth Serv Res Unit, Oxford OX3 7LF, England.			Shepperd, Sasha/0000-0001-6384-8322				ADLER MW, 1978, J EPIDEMIOL COMMUN H, V32, P136, DOI 10.1136/jech.32.2.136; DONALD IP, 1995, AGE AGEING, V24, P434, DOI 10.1093/ageing/24.5.434; Drummond MF, 2015, METHODS EC EVALUATIO; Gilbert DN, 1997, NEW ENGL J MED, V337, P829, DOI 10.1056/NEJM199709183371207; Hensher M, 1996, J ROY SOC MED, V89, P548, DOI 10.1177/014107689608901003; HOLLINGWORTH W, 1993, BRIT MED J, V307, P903, DOI 10.1136/bmj.307.6909.903; HUGHES SL, 1992, HEALTH SERV RES, V26, P801; JONSSON B, 1980, SOC SCI MED-MED ECON, V14, P27, DOI 10.1016/0160-7995(80)90005-2; MARTIN F, 1994, AGE AGEING, V23, P228, DOI 10.1093/ageing/23.3.228; NETTEN A, 1996, UNIT COSTS HLTH SOCI; RUCKLEY CV, 1978, BRIT J SURG, V65, P456, DOI 10.1002/bjs.1800650704; Shepperd S, 1998, BRIT MED J, V316, P1786, DOI 10.1136/bmj.316.7147.1786; SHEPPERD S, 1998, COCHRANE LIB	13	113	114	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1791	1796		10.1136/bmj.316.7147.1791	http://dx.doi.org/10.1136/bmj.316.7147.1791			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624069	Green Published			2022-12-28	WOS:000074286300028
J	Cooley, L				Cooley, L			Drosophila ring canal growth requires Src and Tec kinases	CELL			English	Review									Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA	Yale University	Cooley, L (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06520 USA.							Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; DODSON GS, 1998, DEVELOPMENT; Guarnieri DJ, 1998, MOL CELL, V1, P831, DOI 10.1016/S1097-2765(00)80082-9; Hime GR, 1996, J CELL SCI, V109, P2779; Robinson DN, 1996, TRENDS CELL BIOL, V6, P474, DOI 10.1016/0962-8924(96)84945-2; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; Robinson DN, 1997, GENETICS, V145, P1063; Roulier EM, 1998, MOL CELL, V1, P819, DOI 10.1016/S1097-2765(00)80081-7; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tilney LG, 1996, J CELL BIOL, V133, P61, DOI 10.1083/jcb.133.1.61	11	34	34	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					913	915		10.1016/S0092-8674(00)81196-4	http://dx.doi.org/10.1016/S0092-8674(00)81196-4			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635420	hybrid			2022-12-28	WOS:000074205700002
J	Lannin, DR; Mathews, HF; Mitchell, J; Swanson, MS; Swanson, FH; Edwards, MS				Lannin, DR; Mathews, HF; Mitchell, J; Swanson, MS; Swanson, FH; Edwards, MS			Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AFRICAN-AMERICAN WOMEN; CARE-SEEKING BEHAVIOR; CERVICAL-CANCER; UNITED-STATES; MAMMOGRAPHY UTILIZATION; WHITE WOMEN; SURVIVAL; RACE; BLACK; DIAGNOSIS	Context.-Breast cancer mortality is higher among African American women than among white women in the United States, but the reasons for the racial difference are not known. Objective.-To evaluate the influence of socioeconomic and cultural factors on the racial difference in breast cancer stage at diagnosis. Design.-Case-control study of patients diagnosed as having breast cancer at the University Medical Center of Eastern Carolina from 1985 through 1992. Setting.-The major health care facility for 2 rural counties in eastern North Carolina. Subjects.-Five hundred forty of 743 patients with newly diagnosed breast cancer and 414 control women from the community matched by age, race, and area of residence. Main Outcome Measures.-Breast cancer stage at diagnosis. Results.-Of the 540 patients, 94 (17.4%) presented with TNM stage III or IV disease. The following demographic and socioeconomic factors were significant predictors of advanced stage: being African American (odds ratio [OR], 3.0; 95% confidence interval [CI], 1.9-4.7); having low income (OR, 3.7; 95% CI, 2.1-6.5); never having been married (OR, 2.9; 95% CI, 1.4-5.9); having no private health insurance (OR, 2.5; 95% CI, 1.6-4.0);delaying seeing a physician because of money (OR, 1.6, 95% CI, 1.1-2.5); or lacking transportation (OR, 2.0; 95% CI, 1.2-3.6). Univariate analysis also revealed a large number of cultural beliefs to be significant predictors. Examples include the following beliefs: air causes a cancer to spread (OR, 2.8; 95% CI, 1.8-4.3); the devil can cause a person to get cancer (OR, 2.1, 95% CI, 1.2-3.5);women who have breast surgery are no longer attractive to men (OR, 1.9, 95% CI, 1.1-3.5); and chiropractic is an effective treatment for breast cancer (OR, 2.4; 95% CI, 1.4-4.4). When the demographic and socioeconomic variables were included in a multivariate logistic regression model, the OR for late stage among Af rican Americans decreased to 1.8 (95% CI, 1.1-3.2) compared with 3.0 (95% CI, 1.9-4.7) for race alone. However, when the belief measures were included with the demographic and socioeconomic variables, the OR for late stage among African Americans decreased further to 1.2 (95% CI, 0.6-2.5). Conclusions.-Socioeconomic factors alone were not sufficient to explain the dramatic effect of race on breast cancer stage; however, socioeconomic variables in conjunction with cultural beliefs and attitudes could largely account for the observed effect.	E Carolina Univ, Sch Med, Dept Surg, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Dept Family Med, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Dept Sociol, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Dept Anthropol, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Leo W Jenkins Canc Ctr, Greenville, NC 27858 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	Lannin, DR (corresponding author), E Carolina Univ, Sch Med, Dept Surg, PCMH 304, Greenville, NC 27858 USA.							AZTELL LM, 1978, J NATL CANCER I, V60, P1209; BAILEY EJ, 1987, J NATL MED ASSOC, V79, P389; BAIN RP, 1986, J CHRON DIS, V39, P631, DOI 10.1016/0021-9681(86)90188-8; BAQUET CR, 1986, PUBL NIH; BERG JW, 1977, CANCER, V39, P467, DOI 10.1002/1097-0142(197702)39:2<467::AID-CNCR2820390215>3.0.CO;2-B; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BUESCHER PA, 1994, CHES STUDIES SPECIAL, V82, P1; CAPLAN LS, 1992, J GERONTOL, V47, P101; CELLA DF, 1991, J CLIN ONCOL, V9, P1500, DOI 10.1200/JCO.1991.9.8.1500; CHAVEZ LR, 1995, MED ANTHROPOL Q, V9, P40, DOI 10.1525/maq.1995.9.1.02a00030; CHEN VW, 1994, CANCER EPIDEM BIOMAR, V3, P127; Chevarley F, 1997, AM J PUBLIC HEALTH, V87, P775, DOI 10.2105/AJPH.87.5.775; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; DRESSLER WW, 1993, MED ANTHROPOL Q, V7, P325, DOI 10.1525/maq.1993.7.4.02a00030; ELEY JW, 1994, JAMA-J AM MED ASSOC, V272, P947, DOI 10.1001/jama.272.12.947; FARLEY TA, 1989, AM J PUBLIC HEALTH, V79, P1508, DOI 10.2105/AJPH.79.11.1508; FISHER ER, 1993, CANCER, V71, P2507, DOI 10.1002/1097-0142(19930415)71:8<2507::AID-CNCR2820710813>3.0.CO;2-0; FLETCHER SW, 1993, JNCI-J NATL CANCER I, V85, P112, DOI 10.1093/jnci/85.2.112; FREEMAN HP, 1989, CANCER, V63, P2562, DOI 10.1002/1097-0142(19890615)63:12<2562::AID-CNCR2820631234>3.0.CO;2-0; FREEMAN HP, 1989, CA, V39, P267; GORDON NH, 1992, AM J EPIDEMIOL, V135, P609, DOI 10.1093/oxfordjournals.aje.a116340; GREGG J, 1994, SOC SCI MED, V39, P519, DOI 10.1016/0277-9536(94)90094-9; Hsu JL, 1997, J NATL CANCER I, V89, P1311, DOI 10.1093/jnci/89.17.1311; HUNTER CP, 1993, J NATL CANCER I, V85, P1129, DOI 10.1093/jnci/85.14.1129; JEPSON C, 1991, AM J PUBLIC HEALTH, V81, P501, DOI 10.2105/AJPH.81.4.501; JONES BA, 1995, CANCER, V75, P2103, DOI 10.1002/1097-0142(19950415)75:8<2103::AID-CNCR2820750813>3.0.CO;2-2; KATZ SJ, 1994, JAMA-J AM MED ASSOC, V272, P530, DOI 10.1001/jama.272.7.530; Kleinbaum DG, 1994, LOGISTIC REGRESSION; LAUVER D, 1992, NURS RES, V41, P236; LAUVER D, 1994, RES NURS HEALTH, V17, P421, DOI 10.1002/nur.4770170605; LOEHRER PJ, 1991, CANCER, V68, P1665, DOI 10.1002/1097-0142(19911001)68:7<1665::AID-CNCR2820680734>3.0.CO;2-3; MANDELBLATT J, 1991, AM J PUBLIC HEALTH, V81, P646, DOI 10.2105/AJPH.81.5.646; MATHEWS HF, 1994, SOC SCI MED, V38, P789, DOI 10.1016/0277-9536(94)90151-1; MICHIELUTTE R, 1982, SOC SCI MED, V16, P245, DOI 10.1016/0277-9536(82)90335-5; Mitchell J, 1997, RES AGING, V19, P199, DOI 10.1177/0164027597192003; NATARAJAN N, 1985, CANCER-AM CANCER SOC, V56, P1704, DOI 10.1002/1097-0142(19851001)56:7<1704::AID-CNCR2820560740>3.0.CO;2-L; OMalley MS, 1997, AM J PUBLIC HEALTH, V87, P782, DOI 10.2105/AJPH.87.5.782; OVERBY MM, 1997, ANTHR NEWSLETT, V38, P1; PACHTER LM, 1994, JAMA-J AM MED ASSOC, V271, P690, DOI 10.1001/jama.271.9.690; PEREZSTABLE EJ, 1992, JAMA-J AM MED ASSOC, V268, P3219, DOI 10.1001/jama.268.22.3219; REYNOLDS P, 1994, CANCER EPIDEM BIOMAR, V3, P253; RICHARDSON JL, 1992, BRIT J CANCER, V65, P922, DOI 10.1038/bjc.1992.193; ROACH M, 1995, J NATL MED ASSOC, V87, P214; SWANSON GM, 1990, CANCER-AM CANCER SOC, V66, P1297, DOI 10.1002/1097-0142(19900915)66:6<1297::AID-CNCR2820660633>3.0.CO;2-M; SWANSON GM, 1993, CANCER, V72, P788, DOI 10.1002/1097-0142(19930801)72:3<788::AID-CNCR2820720326>3.0.CO;2-C; TROCK B, 1993, CANCER EPIDEM BIOMAR, V2, P151; VERNON SW, 1985, CANCER-AM CANCER SOC, V55, P1563, DOI 10.1002/1097-0142(19850401)55:7<1563::AID-CNCR2820550726>3.0.CO;2-1; WELLS BL, 1992, AM J PUBLIC HEALTH, V82, P1383, DOI 10.2105/AJPH.82.10.1383; Wilson-Ford V, 1992, Health Soc Work, V17, P28; YOUNG JL, 1984, J NATL CANCER I, V73, P341, DOI 10.1093/jnci/73.2.341; [No title captured]	51	469	474	0	40	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1801	1807		10.1001/jama.279.22.1801	http://dx.doi.org/10.1001/jama.279.22.1801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZR635	9628711	Bronze			2022-12-28	WOS:000073998500032
J	Anderson, JD; Schubert, G; Jacobson, RA; Lau, EL; Moore, WB; Sjogren, WL				Anderson, JD; Schubert, G; Jacobson, RA; Lau, EL; Moore, WB; Sjogren, WL			Distribution of rock, metals, and ices in Callisto	SCIENCE			English	Article							GALILEAN SATELLITES; TIDAL DISSIPATION; ICY SATELLITES; INTERNAL STRUCTURES; GANYMEDE; MODELS; IO; EVOLUTION; MIXTURES	Radio Doppler data from a single encounter (C3) of the Galileo spacecraft with Callisto, the outermost Galilean moon of Jupiter, indicated that Callisto was probably undifferentiated. Now, similar data from a second encounter (C9) corroborate this conclusion, but more accurate data from a third encounter (C10) indicate that the rock and ice within Callisto have partially, but not completely, separated. Callisto may be differentiated into a rock-metal core less than 25 percent of Callisto's radius, an outer layer of clean ice less than 350 km thick, and a middle layer of mixed rock and ice. Models in which ice and rock are mixed all the way to the center of Callisto are also consistent with the data.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Dept Earth & Space Sci, Los Angeles, CA 90095 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of California System; University of California Los Angeles	Anderson, JD (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.							Anderson JD, 1996, NATURE, V384, P541, DOI 10.1038/384541a0; Anderson JD, 1997, NATURE, V387, P264, DOI 10.1038/387264a0; ANDERSON JD, 1974, EXPT GRAVITATION, P163; COHEN ER, 1996, PHYS TODAY, V49, pBG9; Collins GC, 1998, GEOPHYS RES LETT, V25, P233, DOI 10.1029/97GL03772; Davies ME, 1992, CELEST MECH DYN ASTR, V53, P377, DOI 10.1007/BF00051818; DERMOTT SF, 1979, ICARUS, V37, P310, DOI 10.1016/0019-1035(79)90137-4; FRIEDSON AJ, 1983, ICARUS, V56, P1, DOI 10.1016/0019-1035(83)90124-0; HOBBS PV, 1974, ICE PHYSICS; HUBBARD WB, 1978, ICARUS, V33, P336, DOI 10.1016/0019-1035(78)90153-7; Kaula W.M., 1966, THEORY SATELLITE GEO; KESZTHELYI L, IN PRESS ICARUS; Khurana KK, 1997, NATURE, V387, P262, DOI 10.1038/387262a0; KLEMASZEWSKI J, COMMUNICATION; LELIWAKOPYSTYNSKI J, 1994, PLANET SPACE SCI, V42, P545, DOI 10.1016/0032-0633(94)90076-0; LIESKE JH, 1980, ASTRON ASTROPHYS, V82, P340; LUPO MJ, 1982, ICARUS, V52, P40, DOI 10.1016/0019-1035(82)90167-1; MALHOTRA R, 1991, ICARUS, V94, P399, DOI 10.1016/0019-1035(91)90237-N; MCEWEN AB, UNPUB; McKinnon WB, 1997, ICARUS, V130, P540, DOI 10.1006/icar.1997.5826; Moyer T., 1971, JPLTR321527 CALTECH; MUELLER S, 1988, ICARUS, V76, P437, DOI 10.1016/0019-1035(88)90014-0; PAPPALARDO RR, UNPUB; PEALE SJ, 1979, SCIENCE, V203, P892, DOI 10.1126/science.203.4383.892; PROCKTER LM, UNPUB; ROSS MN, 1985, ICARUS, V64, P391, DOI 10.1016/0019-1035(85)90063-6; SCHENK PM, 1995, J GEOPHYS RES-PLANET, V100, P19023, DOI 10.1029/95JE01855; Schubert G, 1996, NATURE, V384, P544, DOI 10.1038/384544a0; SCHUBERT G, 1994, ICARUS, V111, P433, DOI 10.1006/icar.1994.1154; SCHUBERT G, 1981, ICARUS, V47, P46, DOI 10.1016/0019-1035(81)90090-7; SCHUBERT G, 1986, SATELLITES, P629; SEGATZ M, 1988, ICARUS, V75, P187, DOI 10.1016/0019-1035(88)90001-2; Showman AP, 1997, ICARUS, V127, P93, DOI 10.1006/icar.1996.5669; SHOWMAN DJ, 1997, ICARUS, V129, P367; Squyres S. W., 1986, SATELLITES, P293; TAPLEY BD, 1973, RECENT ADV DYNAMICAL, P396; WOO R, 1979, J GEOPHYS RES-SPACE, V84, P7288, DOI 10.1029/JA084iA12p07288; ZHARKOV VN, 1985, ICARUS, V61, P92, DOI 10.1016/0019-1035(85)90157-5; [No title captured]	39	67	71	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1573	1576		10.1126/science.280.5369.1573	http://dx.doi.org/10.1126/science.280.5369.1573			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616114				2022-12-28	WOS:000074061200032
J	Griffiths, I; Klugmann, M; Anderson, T; Yool, D; Thomson, C; Schwab, MH; Schneider, A; Zimmermann, F; McCulloch, M; Nadon, N; Nave, KA				Griffiths, I; Klugmann, M; Anderson, T; Yool, D; Thomson, C; Schwab, MH; Schneider, A; Zimmermann, F; McCulloch, M; Nadon, N; Nave, KA			Axonal swellings and degeneration in mice lacking the major proteolipid of myelin	SCIENCE			English	Article							PELIZAEUS-MERZBACHER DISEASE; PROTEIN GENE; TRANSPORTED ORGANELLES; JIMPY MOUSE; EXPRESSION; MUTATION; FAMILY; HYPOMYELINATION; ACCUMULATION; DISRUPTION	Glial cells produce myelin and contribute to axonal morphology in the nervous system. Two myelin membrane proteolipids, PLP and DM20, were shown to be essential for the integrity of myelinated axons. In the absence of PLP-DM20, mice assembled compact myelin sheaths but subsequently developed widespread axonal swellings and degeneration, associated predominantly with small-caliber nerve fibers. Similar swellings were absent in dysmyelinated shiverer mice, which lack myelin basic protein (MBP), but recurred in (MBPPLP)-P-star double mutants. Thus, fiber degeneration, which was probably secondary to impaired axonal transport, could indicate that myelinated axons require local oligodendroglial support.	Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; Univ Glasgow, Dept Vet Clin Sci, Appl Neurobiol Grp, Glasgow G61 1QH, Lanark, Scotland	Ruprecht Karls University Heidelberg; Oklahoma Medical Research Foundation; University of Glasgow	Nave, KA (corresponding author), Univ Heidelberg, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	nave@sun0.urz.uni-heldelberg.de	Nave, Klaus-Armin/C-8883-2011	Yool, Donald/0000-0002-3562-9111	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anzini P, 1997, J NEUROSCI, V17, P4545; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BOISON D, 1994, P NATL ACAD SCI USA, V91, P11709, DOI 10.1073/pnas.91.24.11709; BUCHHEIT TE, 1992, J NEUROBIOL, V23, P217, DOI 10.1002/neu.480230303; DENTINGER P, 1982, J NEUROCYTOL, V11, P671; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; Duncan A, 1996, GLIA, V17, P349, DOI 10.1002/(SICI)1098-1136(199608)17:4<349::AID-GLIA10>3.3.CO;2-V; DUNCAN ID, 1987, P NATL ACAD SCI USA, V84, P6287, DOI 10.1073/pnas.84.17.6287; DUNCAN ID, 1989, GLIA, V2, P148, DOI 10.1002/glia.440020303; FRIEDE RL, 1970, BRAIN RES, V19, P165, DOI 10.1016/0006-8993(70)90432-4; FRIEDE RL, 1972, ANAT RECORD, V172, P1, DOI 10.1002/ar.1091720101; Garbern JY, 1997, NEURON, V19, P205, DOI 10.1016/S0896-6273(00)80360-8; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; Gow A, 1996, NAT GENET, V13, P422, DOI 10.1038/ng0896-422; Griffiths I. M., UNPUB; GRIFFITHS IR, 1981, J NEUROL SCI, V50, P423, DOI 10.1016/0022-510X(81)90154-4; Griffiths IR, 1996, BIOESSAYS, V18, P789, DOI 10.1002/bies.950181005; HELYNCK G, 1983, EUR J BIOCHEM, V133, P689, DOI 10.1111/j.1432-1033.1983.tb07518.x; Jung M, 1996, J NEUROSCI, V16, P7920; KITAGAWA K, 1993, NEURON, V11, P433, DOI 10.1016/0896-6273(93)90148-K; Klugmann M, 1997, NEURON, V18, P59, DOI 10.1016/S0896-6273(01)80046-5; MCDONALD WI, 1994, J NEUROPATH EXP NEUR, V53, P338, DOI 10.1097/00005072-199407000-00003; NADON NL, 1994, J NEUROCHEM, V63, P822; OLDFIELD BJ, 1982, J NEUROCYTOL, V11, P627, DOI 10.1007/BF01262428; RASKIND WH, 1991, AM J HUM GENET, V49, P1355; READHEAD C, 1994, NEURON, V12, P583, DOI 10.1016/0896-6273(94)90214-3; ROACH A, 1985, CELL, V42, P149, DOI 10.1016/S0092-8674(85)80110-0; Sanchez I, 1996, J NEUROSCI, V16, P5095; SAUGIERVEBER P, 1994, NAT GENET, V6, P257, DOI 10.1038/ng0394-257; SCHNEIDER A, 1995, P NATL ACAD SCI USA, V92, P4447, DOI 10.1073/pnas.92.10.4447; SCHNEIDER A, 1992, NATURE, V358, P758, DOI 10.1038/358758a0; Seitelberger F, 1996, NEURODYSTROPHIES NEU, P559; Sistermans EA, 1996, HUM GENET, V97, P337, DOI 10.1007/s004390050046; SKOFF R, 1981, BRAIN RES, V212, P175, DOI 10.1016/0006-8993(81)90047-0; SMITH RS, 1980, J NEUROCYTOL, V9, P39, DOI 10.1007/BF01205226; SNIPES GJ, 1995, BRAIN PATHOL, V5, P233, DOI 10.1111/j.1750-3639.1995.tb00600.x; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; TSUKITA S, 1980, J CELL BIOL, V84, P513, DOI 10.1083/jcb.84.3.513; TYTELL M, 1986, BRAIN RES, V363, P161, DOI 10.1016/0006-8993(86)90671-2; WILLIAMS MA, 1977, PRACTICAL METHODS EL, V6, P5	40	637	642	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1610	1613		10.1126/science.280.5369.1610	http://dx.doi.org/10.1126/science.280.5369.1610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616125				2022-12-28	WOS:000074061200043
J	Lan, N; Howrey, RP; Lee, SW; Smith, CA; Sullenger, BA				Lan, N; Howrey, RP; Lee, SW; Smith, CA; Sullenger, BA			Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors	SCIENCE			English	Article							MESSENGER-RNA; TETRAHYMENA; HEMOGLOBIN; SEQUENCE; GENE; MORBIDITY; GELATION	Sickle cell anemia is the most common heritable hematological disease, yet no curative treatment exists for this disorder. Moreover, the intricacies of globin gene expression have made the development of treatments for hemoglobinopathies based on gene therapy difficult. An alternative genetic approach to sickle cell therapy is based on RNA repair. A trans-splicing group I ribozyme was used to alter mutant beta-globin transcripts in erythrocyte precursors derived from peripheral blood from individuals with sickle cell disease. Sickle beta-globin transcripts were converted into messenger RNAs encoding the anti-sickling protein gamma-globin. These results suggest that RNA repair may become a useful approach in the treatment of genetic disorders.	Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Genet, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Pediat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Med, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Sullenger, BA (corresponding author), Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Surg, Durham, NC 27710 USA.	sulle001@mc.duke.edu		Lee, Seong-Wook/0000-0003-1718-7601	NHLBI NIH HHS [HL57606] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057606] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRIN C, 1994, BIOCHEM CELL BIOL, V72, P377, DOI 10.1139/o94-050; ASHCROFT MT, 1976, LANCET, V2, P784; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEHE MJ, 1979, J MOL BIOL, V133, P137, DOI 10.1016/0022-2836(79)90254-7; Bertrand E, 1997, RNA, V3, P75; CAMPBELL TB, 1995, RNA, V1, P598; CAVALLESCO C, 1980, GENE, V12, P215, DOI 10.1016/0378-1119(80)90103-1; CECH T, 1995, BIO-TECHNOL, V13, P323, DOI 10.1038/nbt0495-323; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; GRASSO JA, 1977, J CELL BIOL, V73, P206, DOI 10.1083/jcb.73.1.206; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; Jones JT, 1997, NAT BIOTECHNOL, V15, P902, DOI 10.1038/nbt0997-902; Jones JT, 1996, NAT MED, V2, P643, DOI 10.1038/nm0696-643; KRAMER MS, 1978, NEW ENGL J MED, V299, P686, DOI 10.1056/NEJM197809282991303; LAN N, UNPUB; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PLATT OS, 1993, HEMATOLOGY INFANCY C, P732; POWARS DR, 1984, BLOOD, V63, P921, DOI 10.1182/blood.V63.4.921.921; RAMIREZ F, 1975, J BIOL CHEM, V250, P6054; RUCKNAGEL DL, 1987, DEV CONTROL GLOBIN G, P487; SADELAIN M, 1995, P NATL ACAD SCI USA, V92, P6728, DOI 10.1073/pnas.92.15.6728; SEARS DA, 1978, AM J MED, V64, P1021, DOI 10.1016/0002-9343(78)90458-8; SULLENGER BA, 1995, CHEM BIOL, V2, P249, DOI 10.1016/1074-5521(95)90043-8; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; SUNSHINE HR, 1978, NATURE, V275, P238, DOI 10.1038/275238a0; TELEN MJ, 1987, VOX SANG, V52, P236, DOI 10.1111/j.1423-0410.1987.tb03035.x; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	29	179	192	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	1998	280	5369					1593	1596		10.1126/science.280.5369.1593	http://dx.doi.org/10.1126/science.280.5369.1593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616120				2022-12-28	WOS:000074061200038
J	Yin, MJ; Christerson, LB; Yamamoto, Y; Kwak, YT; Xu, SC; Mercurio, F; Barbosa, M; Cobb, MH; Gaynor, RB				Yin, MJ; Christerson, LB; Yamamoto, Y; Kwak, YT; Xu, SC; Mercurio, F; Barbosa, M; Cobb, MH; Gaynor, RB			HTLV-I tax protein binds to MEKK1 to stimulate I kappa B kinase activity and NF-kappa B activation	CELL			English	Article							CELL LEUKEMIA-VIRUS; SITE-SPECIFIC PHOSPHORYLATION; ALPHA; GENE; IDENTIFICATION; TRANSFORMATION; PATHWAYS; CASCADE; REGION; CREB	NF-kappa B, a key regulator of the cellular inflammatory and immune response, is activated by the HTLV-I transforming and transactivating protein Tax. We show that Tax binds to the amino terminus of the protein kinase MEKK1, a component of an I kappa B kinase complex, and stimulates MEKK1 kinase activity. Tax expression increases the activity of I kappa B kinase 8 (IKK beta) to enhance phosphorylation of serine residues in I kappa B alpha that lead to its degradation. Dominant negative mutants of both IKK beta and MEKK1 prevent Tax activation of the NF-kappa B pathway. Furthermore, recombinant MEKK1 stimulates IKK beta phosphorylation of I kappa B alpha. Thus, Tax-mediated increases in NF-kappa B nuclear translocation result from direct interactions of Tax and MEKK1 leading to enhanced IKK beta phosphorylation of I kappa B alpha.	Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Harold Simmons Canc Ctr,Div Hematol Oncol, Dallas, TX 75235 USA; Signal Pharmaceut Inc, San Diego, CA 92121 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gaynor, RB (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, Dallas, TX 75235 USA.			Cobb, Melanie/0000-0003-0833-5473				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHOI KY, 1994, CELL, V78, P499; DEAK JC, 1997, J BIOCH, V322, P185; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FELBER BK, 1985, SCIENCE, V229, P54; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; KOEFFLER HP, 1984, BLOOD, V64, P482; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; OHTANI K, 1989, NUCLEIC ACIDS RES, V17, P1589, DOI 10.1093/nar/17.4.1589; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; POLESZ BJ, 1980, P NATL ACAD SCI USA, V77, P7415; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YAN MH, 1994, NATURE, V372, P798; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	43	229	234	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					875	884		10.1016/S0092-8674(00)81447-6	http://dx.doi.org/10.1016/S0092-8674(00)81447-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630230	Bronze			2022-12-28	WOS:000073956700022
J	Rosenson, RS; Tangney, CC				Rosenson, RS; Tangney, CC			Antiatherothrombotic properties of statins - Implications for cardiovascular event reduction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY-ARTERY DISEASE; SMOOTH-MUSCLE CELLS; FACTOR PATHWAY INHIBITOR; KUOPIO ATHEROSCLEROSIS PREVENTION; DENSITY-LIPOPROTEIN PARTICLES; CHOLESTEROL-LOWERING THERAPY; MONOCYTE-DERIVED MACROPHAGES; COLLAGEN GENE-EXPRESSION; PLASMA-FIBRINOGEN LEVEL; ISCHEMIC-HEART-DISEASE	Clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or statin therapy have demonstrated that baseline or treated low-density lipoprotein (LDL) cholesterol levels are only weakly associated with net coronary angiographic change or cardiovascular events. The beneficial effects of statins on clinical events may involve nonlipid mechanisms that modify endothelial function, inflammatory responses, plaque stability, and thrombus formation. Experimental animal models suggest that statins may foster stability through a reduction in macrophages and cholesterol ester content and an increase in volume of collagen and smooth muscle cells. The thrombotic sequelae caused by plaque disruption is mitigated by statins through inhibition of platelet aggregation and maintenance of a favorable balance between prothrombotic and fibrinolytic mechanisms. These nonlipid properties of statins may help to explain the early and significant cardiovascular event reduction reported in several clinical trials of statin therapy.	Rush Presbyterian St Lukes Med Ctr, Dept Med, Prevent Cardiol Ctr, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Clin Nutr, Chicago, IL 60612 USA	Rush University; Rush University	Rosenson, RS (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Med, Prevent Cardiol Ctr, 1725 W Harrison St,Suite 1159, Chicago, IL 60612 USA.							Aengevaeren WRM, 1997, CIRCULATION, V96, P429; AMENTO EP, 1991, ARTERIOSCLER THROMB, V11, P1223, DOI 10.1161/01.ATV.11.5.1223; ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; ANDERSON TJ, 1995, AM J CARDIOL, V75, pB71, DOI 10.1016/0002-9149(95)80017-M; Andrews TC, 1997, CIRCULATION, V95, P324; [Anonymous], 1993, Am J Cardiol, V72, P1031; Aoki I, 1997, J AM COLL CARDIOL, V30, P91, DOI 10.1016/S0735-1097(97)00129-0; ARMSTRONG ML, 1970, CIRC RES, V27, P59, DOI 10.1161/01.RES.27.1.59; AVELLONE G, 1994, CURR THER RES CLIN E, V55, P1335, DOI 10.1016/S0011-393X(05)80318-2; AVIRAM M, 1992, METABOLISM, V41, P229, DOI 10.1016/0026-0495(92)90263-A; BALLEISEN L, 1985, THROMB HAEMOSTASIS, V54, P721; Behague I, 1996, CIRCULATION, V93, P440, DOI 10.1161/01.CIR.93.3.440; BEIGEL Y, 1991, J CLIN PHARMACOL, V31, P512, DOI 10.1002/j.1552-4604.1991.tb03729.x; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BERNINI F, 1993, ATHEROSCLEROSIS, V104, P19, DOI 10.1016/0021-9150(93)90172-Q; Bevilacqua M, 1997, AM J CARDIOL, V79, P84, DOI 10.1016/S0002-9149(96)00684-4; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BO M, 1991, ANGIOLOGY, V42, P106, DOI 10.1177/000331979104200204; BRANCHI A, 1993, THROMB HAEMOSTASIS, V70, P241; Brosche T, 1996, ARCH GERONTOL GERIAT, V22, P207, DOI 10.1016/0167-4943(95)00694-X; BROZE GJ, 1992, SEMIN HEMATOL, V29, P159; BYINGTON RP, 1995, CIRCULATION, V92, P2419, DOI 10.1161/01.CIR.92.9.2419; Campeau L, 1997, NEW ENGL J MED, V336, P153; *CAN CONS C CHOL, 1988, CAN MED ASSOC J, V26, P369; CARVALHO AC, 1974, NEW ENGL J MED, V290, P434, DOI 10.1056/NEJM197402212900805; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; Chen LY, 1996, CIRCULATION, V93, P1740, DOI 10.1161/01.CIR.93.9.1740; CHENG GC, 1993, CIRCULATION, V87, P1179, DOI 10.1161/01.CIR.87.4.1179; Cheng GC, 1996, CIRCULATION, V93, P99, DOI 10.1161/01.CIR.93.1.99; CLARKSON TB, 1981, EXP MOL PATHOL, V34, P345, DOI 10.1016/0014-4800(81)90052-6; Colli S, 1997, ARTERIOSCL THROM VAS, V17, P265, DOI 10.1161/01.ATV.17.2.265; Corsini A, 1996, LANCET, V348, P1584, DOI 10.1016/S0140-6736(05)66196-X; CORSINI A, 1991, PHARMACOL RES, V23, P173, DOI 10.1016/S1043-6618(05)80119-7; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; DAVI G, 1989, ATHEROSCLEROSIS, V79, P79, DOI 10.1016/0021-9150(89)90036-1; Davidson M, 1997, AM J CARDIOL, V79, P1475, DOI 10.1016/S0002-9149(97)00174-4; Davies MJ, 1996, CIRCULATION, V94, P2013, DOI 10.1161/01.CIR.94.8.2013; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; DENTAN C, 1994, ARTERIOSCLER THROMB, V14, P353, DOI 10.1161/01.ATV.14.3.353; Dimmeler S, 1997, CIRCULATION, V95, P1760; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; EGASHIRA K, 1994, CIRCULATION, V89, P2519, DOI 10.1161/01.CIR.89.6.2519; EICHSTADT HW, 1995, AM J CARDIOL, V76, pA122, DOI 10.1016/S0002-9149(05)80033-5; *EXP PAN DET EV TR, 1986, ARCH INTERN MED, V148, P36; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; Farb A, 1996, CIRCULATION, V93, P1354, DOI 10.1161/01.CIR.93.7.1354; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562, DOI 10.1016/0735-1097(94)90657-2; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; Gardner CD, 1996, JAMA-J AM MED ASSOC, V276, P875, DOI 10.1001/jama.276.11.875; GHIRLANDA G, 1993, J CLIN PHARMACOL, V33, P226, DOI 10.1002/j.1552-4604.1993.tb03948.x; GIROUX LM, 1993, BIOCHIM BIOPHYS ACTA, V1165, P335, DOI 10.1016/0005-2760(93)90145-Y; Green F, 1989, Baillieres Clin Haematol, V2, P945, DOI 10.1016/S0950-3536(89)80053-8; GROVER SA, 1992, JAMA-J AM MED ASSOC, V267, P816; GROVER SA, 1995, JAMA-J AM MED ASSOC, V274, P801, DOI 10.1001/jama.274.10.801; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HACKETT D, 1988, EUR HEART J, V9, P1317, DOI 10.1093/oxfordjournals.eurheartj.a062449; HAFFNER S, 1995, CLIN CARDIOL, V18, P261, DOI 10.1002/clc.4960180507; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HANSEN JB, 1994, ARTERIOSCLER THROMB, V14, P223, DOI 10.1161/01.ATV.14.2.223; HANSSON GK, 1989, AM J PATHOL, V135, P169; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HASSALL DG, 1983, BIOCHEM J, V216, P43, DOI 10.1042/bj2160043; HAYOZ D, 1995, HYPERTENSION, V26, P497, DOI 10.1161/01.HYP.26.3.497; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; HOFFMAN R, 1992, ATHEROSCLEROSIS, V93, P105, DOI 10.1016/0021-9150(92)90204-T; HUNNINGHAKE DB, 1993, J CLIN PHARMACOL, V33, P574, DOI 10.1002/j.1552-4604.1993.tb04706.x; Igarashi M, 1997, BRIT J PHARMACOL, V120, P1172, DOI 10.1038/sj.bjp.0701018; ISAACSOHN JL, 1994, AM J CARDIOL, V74, P735, DOI 10.1016/0002-9149(94)90322-0; JAY RH, 1993, AM J CARDIOL, V72, P1031; JuhanVague I, 1996, CIRCULATION, V94, P2057, DOI 10.1161/01.CIR.94.9.2057; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; KEMPEN HJM, 1991, ARTERIOSCLER THROMB, V11, P146, DOI 10.1161/01.ATV.11.1.146; Kimura M, 1997, ARTERIOSCL THROM VAS, V17, P1521, DOI 10.1161/01.ATV.17.8.1521; Kinlay S, 1996, CURR OPIN LIPIDOL, V7, P389, DOI 10.1097/00041433-199612000-00009; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; KOENIG W, 1992, J CLIN PHARMACOL, V32, P539, DOI 10.1177/009127009203200609; KOPPENSTEINER R, 1990, ATHEROSCLEROSIS, V83, P53, DOI 10.1016/0021-9150(90)90130-B; KOSTNER GM, 1989, CIRCULATION, V80, P1313, DOI 10.1161/01.CIR.80.5.1313; Laaksonen R, 1996, AM J CARDIOL, V77, P851, DOI 10.1016/S0002-9149(97)89180-1; LACOSTE L, 1995, CIRCULATION, V92, P3172, DOI 10.1161/01.CIR.92.11.3172; Lacoste Lucie, 1996, Journal of the American College of Cardiology, V27, p413A; LEREN TP, 1988, ATHEROSCLEROSIS, V73, P135, DOI 10.1016/0021-9150(88)90034-2; LESNIK P, 1993, ARTERIOSCLER THROMB, V13, P1066, DOI 10.1161/01.ATV.13.7.1066; LEUNG WH, 1993, LANCET, V341, P1496, DOI 10.1016/0140-6736(93)90634-S; LEWIS B, 1988, EUR HEART J, V9, P571; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; Marais AD, 1997, ARTERIOSCL THROM VAS, V17, P1527, DOI 10.1161/01.ATV.17.8.1527; MARINARI UM, 1995, ITAL J BIOCHEM, V44, P1; MAYER J, 1992, ANN HEMATOL, V64, P196, DOI 10.1007/BF01696223; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; Miller BD, 1996, CIRCULATION, V94, P2146, DOI 10.1161/01.CIR.94.9.2146; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Mitropoulos KA, 1997, EUR HEART J, V18, P235; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; NegreAminou P, 1997, BBA-LIPID LIPID MET, V1345, P259, DOI 10.1016/S0005-2760(96)00184-1; NEMERSON Y, 1988, BLOOD, V71, P1; Neumann FJ, 1997, CIRCULATION, V95, P2387, DOI 10.1161/01.CIR.95.10.2387; Nickenig G, 1997, CIRCULATION, V95, P473; Nofer JR, 1997, CIRCULATION, V95, P1370; NOTARBARTOLO A, 1995, ARTERIOSCL THROM VAS, V15, P247, DOI 10.1161/01.ATV.15.2.247; ODriscoll G, 1997, CIRCULATION, V95, P1126, DOI 10.1161/01.cir.95.5.1126; OLIVER MF, 1994, LANCET, V344, P633; Packard CJ, 1998, CIRCULATION, V97, P1440; PADGETT RC, 1992, CIRC RES, V70, P423, DOI 10.1161/01.RES.70.2.423; PEDERSEN TR, 1995, LANCET, V345, P1274; PEDERSEN TR, 1994, LANCET, V344, P1383; PEDRENO J, 1992, ARTERIOSCLER THROMB, V12, P1353, DOI 10.1161/01.ATV.12.11.1353; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; PEKKANEN J, 1993, CARDIOLOGY, V82, P181, DOI 10.1159/000175867; PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0; REKHTER MD, 1993, AM J PATHOL, V143, P1634; RICHARDSON PD, 1989, LANCET, V2, P941; ROSENSON RS, 1994, ARTERIOSCLER THROMB, V14, P1928, DOI 10.1161/01.ATV.14.12.1928; Rosenson RS, 1996, LANCET, V348, P1583, DOI 10.1016/S0140-6736(05)66194-6; ROSENSON RS, IN PRESS ATHEROSCLER; ROSENSON RS, 1993, J VASC MED BIOL, V4, P206; SACKS FM, 1995, AM J CARDIOL, V76, pC78, DOI 10.1016/S0002-9149(99)80475-5; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SALONEN R, 1995, AM J CARDIOL, V76, pC34, DOI 10.1016/S0002-9149(99)80468-8; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; SANDERS NL, 1985, BLOOD, V66, P204; SANDSET PM, 1991, ARTERIOSCLER THROMB, V11, P138, DOI 10.1161/01.ATV.11.1.138; SANG KHLQ, 1995, ARTERIOSCL THROM VAS, V15, P759, DOI 10.1161/01.ATV.15.6.759; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SHIOMI M, 1995, ARTERIOSCL THROM VAS, V15, P1938, DOI 10.1161/01.ATV.15.11.1938; SLUNGA L, 1992, EUR J CLIN PHARMACOL, V43, P369, DOI 10.1007/BF02220611; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; SOMA MR, 1993, ARTERIOSCLER THROMB, V13, P571, DOI 10.1161/01.ATV.13.4.571; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; Stein JH, 1997, ARCH INTERN MED, V157, P1170, DOI 10.1001/archinte.157.11.1170; STRAZNICKY NE, 1995, AM J CARDIOL, V75, P582, DOI 10.1016/S0002-9149(99)80621-3; STROES ESG, 1995, LANCET, V346, P467, DOI 10.1016/S0140-6736(95)91322-X; Sweetnam PM, 1996, EUR HEART J, V17, P1814; Thompson GR, 1995, CURR OPIN LIPIDOL, V6, P386, DOI 10.1097/00041433-199512000-00010; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; TONKIN A, 1997, 70 SCI SESS AM HEART; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; Tsuda Y, 1996, ATHEROSCLEROSIS, V122, P225, DOI 10.1016/0021-9150(95)05757-9; Vallance P, 1997, LANCET, V349, P1391, DOI 10.1016/S0140-6736(96)09424-X; vanBoven AJ, 1996, CIRCULATION, V94, P1503, DOI 10.1161/01.CIR.94.7.1503; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36; VANWILLIGEN G, 1994, ARTERIOSCLER THROMB, V14, P41, DOI 10.1161/01.ATV.14.1.41; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2; Vogel RA, 1996, AM J CARDIOL, V77, P37, DOI 10.1016/S0002-9149(97)89131-X; WADA H, 1992, CLIN THER, V14, P829; WARNER SJC, 1989, J CLIN INVEST, V83, P1174, DOI 10.1172/JCI113998; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; WATTS GF, 1993, J CLIN PATHOL, V46, P1055, DOI 10.1136/jcp.46.11.1055; Weber C, 1997, J AM COLL CARDIOL, V30, P1212, DOI 10.1016/S0735-1097(97)00324-0; Weissberg PL, 1996, LANCET, V347, P305, DOI 10.1016/S0140-6736(96)90472-9; Wierzbicki AS, 1998, LANCET, V351, P569, DOI 10.1016/S0140-6736(05)78556-1; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; Williams JK, 1998, J AM COLL CARDIOL, V31, P684, DOI 10.1016/S0735-1097(97)00537-8; WILLIS RA, 1990, P NATL ACAD SCI USA, V87, P8928, DOI 10.1073/pnas.87.22.8928; WINNIFORD M, 1996, 66 C EUR ATH SOC JUL; Woodward M, 1997, BRIT J HAEMATOL, V97, P785, DOI 10.1046/j.1365-2141.1997.1232935.x; Zitoun D, 1996, ARTERIOSCL THROM VAS, V16, P77, DOI 10.1161/01.ATV.16.1.77	160	787	843	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1998	279	20					1643	1650		10.1001/jama.279.20.1643	http://dx.doi.org/10.1001/jama.279.20.1643			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP489	9613915	Bronze			2022-12-28	WOS:000073758600035
J	Kargel, JS				Kargel, JS			The salt of Europa	SCIENCE			English	Article							ICY		US Geol Survey, Flagstaff, AZ 86001 USA	United States Department of the Interior; United States Geological Survey	Kargel, JS (corresponding author), US Geol Survey, Flagstaff, AZ 86001 USA.							Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CONSOLMAGNO GJ, 1978, ICARUS, V34, P280, DOI 10.1016/0019-1035(78)90168-9; FANALE FP, 1974, SCIENCE, V186, P922, DOI 10.1126/science.186.4167.922; FANALE FP, 1977, PLANETARY SATELLITES, P379; KARGEL JS, 1991, ICARUS, V94, P368, DOI 10.1016/0019-1035(91)90235-L; KARGEL JS, 1996, LUNAR PLANET SCI C, V27, P643; Kerr RA, 1998, SCIENCE, V279, P30, DOI 10.1126/science.279.5347.30; Kivelson MG, 1997, SCIENCE, V276, P1239, DOI 10.1126/science.276.5316.1239; LEWIS JS, 1971, ICARUS, V15, P175; McCord TB, 1998, SCIENCE, V280, P1242, DOI 10.1126/science.280.5367.1242; REYNOLDS RT, 1983, ICARUS, V56, P246, DOI 10.1016/0019-1035(83)90037-4	12	22	22	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 22	1998	280	5367					1211	1212		10.1126/science.280.5367.1211	http://dx.doi.org/10.1126/science.280.5367.1211			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9634401				2022-12-28	WOS:000073852500030
J	Zimmerli, W; Widmer, AF; Blatter, M; Frei, R; Ochsner, PE				Zimmerli, W; Widmer, AF; Blatter, M; Frei, R; Ochsner, PE		Foreign-Body Infection (FBI) Study Grp	Role of rifampin for treatment of orthopedic implant-related staphylococcal infections - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	26th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 15-18, 1996	NEW ORLEANS, LA	Amer Soc Microbiol			ANTIMICROBIAL AGENTS; ANTIBIOTIC-TREATMENT; DRUG-USERS; ENDOCARDITIS; THERAPY; AUREUS	Context.-Rifampin-containing regimens are able to cure staphylococcal implant-related infections based on in vitro and in vivo observations. However, this evidence has not been proven by a controlled clinical trial. Objective.-To evaluate the clinical efficacy of a rifampin combination in staphylococcal infections associated with stable orthopedic devices. Design.-A randomized, placebo-controlled, double-blind trial conducted from 1992 through 1997. Setting.-Two infectious disease services in tertiary care centers in collaboration with 5 orthopedic surgeons in Switzerland. Patients.-A total of 33 patients with culture-proven staphylococcal infection associated with stable orthopedic implants and with a short duration of symptoms of infection (exclusion limit <1 year; actual experience 0-21 days). Intervention.-Initial debridement and 2-week intravenous course of flucloxacillin or vancomycin with rifampin or placebo, followed by either ciprofloxacin-rifampin or ciprofloxacin-placebo long-term therapy. Main Outcome Measures.-Cure was defined as (1) lack of clinical signs and symptoms of infection, (2) C-reactive protein level less than 5 mg/L, and (3) absence of radiological signs of loosening or infection at the final follow-up visit at 24 months. Failure was defined as (1) persisting clinical and/or laboratory signs of infection or (2) persisting or new isolation of the initial microorganism. Results.-A total of 18 patients were allocated to ciprofloxacin-rifampin and 15 patients to the ciprofloxacin-placebo combination. Twenty-four patients fully completed the trial with a follow-up of 35 and 33 months. The cure rate was 12 (100%) of 12 in the ciprofloxacin-rifampin group compared with 7 (58%) of 12 in the ciprofloxacin-placebo group (P=.02), Nine of 33 patients dropped out due to adverse events (n=6), noncompliance (n=1), or protocol violation (n=2), Seven of the 9 patients who dropped out were subsequently treated with rifampin combinations, and 5 of them were cured without removal of the device. Conclusion.-Among patients with stable implants, short duration of infection, and initial debridement, patients able to tolerate long-term (3-6 months) therapy with rifampin-ciprofloxacin experienced cure of the infection without removal of the implant.	Univ Basel Hosp, Div Infect Dis, Dept Internal Med, CH-4031 Basel, Switzerland; Univ Basel Hosp, Div Clin Epidemiol, CH-4031 Basel, Switzerland; Univ Basel Hosp, Bacteriol Lab, CH-4031 Basel, Switzerland; Kantonsspital, Clin Orthoped Surg, Liestal, Switzerland	University of Basel; University of Basel; University of Basel; Kantonsspital Aarau AG (KSA); Kantonsspital Baselland	Zimmerli, W (corresponding author), Univ Basel Hosp, Div Infect Dis, Dept Internal Med, Petersgraben 4, CH-4031 Basel, Switzerland.	zimmerliw@ubaclu.unibas.ch						BLASER J, 1995, ANTIMICROB AGENTS CH, V39, P1134, DOI 10.1128/AAC.39.5.1134; Brandt CM, 1997, CLIN INFECT DIS, V24, P914, DOI 10.1093/clinids/24.5.914; BURGER RR, 1991, CLIN ORTHOP RELAT R, P105; Cox D.R., 1990, ANAL SURVIVAL DATA; DELLAMONICA P, 1990, J ANTIMICROB CHEMOTH, V26, P199, DOI 10.1093/jac/26.suppl_B.199; DRANCOURT M, 1993, ANTIMICROB AGENTS CH, V37, P1214, DOI 10.1128/AAC.37.6.1214; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; DWORKIN RJ, 1989, LANCET, V2, P1071; GARVIN KL, 1995, J BONE JOINT SURG AM, V77, P1576, DOI 10.2106/00004623-199510000-00015; GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258; Gristina Anthony G., 1994, Clinical Microbiology Newsletter, V16, P171, DOI 10.1016/0196-4399(94)90037-X; GUSTILO RB, 1990, J BONE JOINT SURG AM, V72A, P299, DOI 10.2106/00004623-199072020-00023; HARTMAN MB, 1991, CLIN ORTHOP RELAT R, P113; Heldman AW, 1996, AM J MED, V101, P68, DOI 10.1016/S0002-9343(96)00070-8; HOOPER DC, 1991, NEW ENGL J MED, V324, P384, DOI 10.1056/NEJM199102073240606; Lew DP, 1997, NEW ENGL J MED, V336, P999, DOI 10.1056/NEJM199704033361406; MCGRAW JM, 1988, J BONE JOINT SURG AM, V70A, P900, DOI 10.2106/00004623-198870060-00015; Morscher E., 1995, ORTHOP INT, V3, P343; MURRAY DG, 1995, JAMA-J AM MED ASSOC, V273, P1950, DOI 10.1001/jama.1995.03520480070043; Murray P.R., 1995, MANUAL CLIN MICROBIO; OCHSNER PE, 1994, ORTHOPEDICS, V17, P433; PFALLER MA, 1992, CLIN MICROBIOLOGY PR, V1, P1; Rasul Jr A. T., 1991, CLIN ORTHOP RELAT R, V273, P98; Salvati E, 1984, INFECTIONS ASS PROST, P181; SCHOIFET SD, 1990, J BONE JOINT SURG AM, V72A, P1383, DOI 10.2106/00004623-199072090-00018; SCHUTZER SF, 1988, J BONE JOINT SURG AM, V70A, P724, DOI 10.2106/00004623-198870050-00013; Steckelberg James M., 1994, P259; TSHEFU K, 1983, REV INFECT DIS, V5, pS474; Tsukayama DT, 1996, J BONE JOINT SURG AM, V78A, P512, DOI 10.2106/00004623-199604000-00005; TSUKAYAMA DT, 1991, ORTHOPEDICS, V14, P841; WIDMER AF, 1990, J INFECT DIS, V162, P96, DOI 10.1093/infdis/162.1.96; WIDMER AF, 1992, CLIN INFECT DIS, V14, P1251, DOI 10.1093/clinids/14.6.1251; WILSON MG, 1990, J BONE JOINT SURG AM, V72A, P878, DOI 10.2106/00004623-199072060-00013; WOLFE SW, 1990, J BONE JOINT SURG AM, V72A, P198, DOI 10.2106/00004623-199072020-00007; ZIMMERLI W, 1984, J CLIN INVEST, V73, P1191, DOI 10.1172/JCI111305; ZIMMERLI W, 1994, J ANTIMICROB CHEMOTH, V33, P959; ZYCH GA, 1995, CLIN ORTHOP RELAT R, P153	37	712	738	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1537	1541		10.1001/jama.279.19.1537	http://dx.doi.org/10.1001/jama.279.19.1537			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZN087	9605897	Bronze			2022-12-28	WOS:000073608100031
J	Gillam, S; Pencheon, D				Gillam, S; Pencheon, D			Managing demand - Managing demand in general practice	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE; COSTS		Kings Fund, Primary Care Programme, London W1M 0AN, England; Univ Forvie Site, Inst Publ Hlth, Cambridge CB2 2SR, England	University of Cambridge	Gillam, S (corresponding author), Kings Fund, Primary Care Programme, London W1M 0AN, England.	cnsgil@kehf.org.uk						Bell W H, 1996, Health Care Strateg Manage, V14, P6; *BMA HLTH POL EC R, 1997, OPT FUND HLTH CAR; BRITTEN N, 1995, BRIT MED J, V310, P1084, DOI 10.1136/bmj.310.6987.1084; Buchan I., 1996, BJHC&IM-British Journal of Healthcare Computing & Information Management, V13, P20; Campbell H, 1998, BMJ-BRIT MED J, V316, P133; Campbell SM, 1996, FAM PRACT, V13, P75, DOI 10.1093/fampra/13.1.75; Christensen MB, 1998, BMJ-BRIT MED J, V316, P1502, DOI 10.1136/bmj.316.7143.1502; DALE J, 1996, RINGING CHANGE REPOR; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; GILLAM SJ, 1995, BRIT J GEN PRACT, V45, P649; Hallam L, 1997, BMJ-BRIT MED J, V314, P157, DOI 10.1136/bmj.314.7075.157; Harrison R, 1996, BRIT MED J, V313, P1377, DOI 10.1136/bmj.313.7069.1377; HOBBS FDR, 1997, HLTH TECHNOL ASSES, V1; Little P, 1997, BRIT MED J, V315, P350; Lynch W D, 1993, Am J Health Promot, V8, P87; PIETRONI P, 1993, BRIT J GEN PRACT, V43, P341; VICKERY DM, 1983, JAMA-J AM MED ASSOC, V250, P2952, DOI 10.1001/jama.250.21.2952; WENNBERG JE, 1990, NEW ENGL J MED, V323, P1202, DOI 10.1056/NEJM199010253231710; WENNBERG JE, 1982, SOC SCI MED, V16, P811, DOI 10.1016/0277-9536(82)90234-9	19	19	19	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 20	1998	316	7148					1895	1898						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632416				2022-12-28	WOS:000074686500036
J	Schwan, TG; Hinnebusch, BJ				Schwan, TG; Hinnebusch, BJ			Bloodstream- versus tick-associated variants of a relapsing fever bacterium	SCIENCE			English	Article							VARIABLE MAJOR PROTEINS; OUTER SURFACE PROTEIN; BORRELIA-HERMSII; ANTIGENIC VARIATION; BURGDORFERI; GENES; OSPC; CULTIVATION; SEQUENCE; EPITOPE	The relapsing fever spirochete, Borrelia hermsii, alternates infections between a mammal and a tick vector. Whether the spirochete changes;phenotypically in the different hosts was examined by allowing the tick vector Ornithodoros hermsi to feed on mice infected with serotype 7 or serotype 8 of B. hermsii. Upon infection of ticks, the spirochetal serotype-specific variable major proteins (Vmps) 7 and 8 became undetectable and were replaced by Vmp33. This switch from a bloodstream- to tick-associated phenotype could be induced in culture by a decrease in temperature. After tick-bite transmission back to mice, the process was reversed and the spirochetes resumed expression of the same Vmp present in the previous infectious blood meal.	NIAID, Microbial Struct & Funct Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Schwan, TG (corresponding author), NIAID, Microbial Struct & Funct Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.	tom_schwan@nih.gov						Barbour A G, 1987, Contrib Microbiol Immunol, V8, P125; Barbour A.G., 1985, GENOME REARRANGEMENT, P123; BARBOUR AG, 1982, J EXP MED, V156, P1312, DOI 10.1084/jem.156.5.1312; BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; BARBOUR AG, 1986, MICROBIOL REV, V50, P381, DOI 10.1128/MMBR.50.4.381-400.1986; BARBOUR AG, 1986, INFECT IMMUN, V52, P549, DOI 10.1128/IAI.52.2.549-554.1986; BARBOUR AG, UNPUB; BARSTAD PA, 1985, J EXP MED, V161, P1302, DOI 10.1084/jem.161.6.1302; Cadavid D, 1997, INFECT IMMUN, V65, P3352, DOI 10.1128/IAI.65.8.3352-3360.1997; CARTER CJ, 1994, INFECT IMMUN, V62, P2792, DOI 10.1128/IAI.62.7.2792-2799.1994; Dworkin MS, 1998, CLIN INFECT DIS, V26, P122, DOI 10.1086/516273; Felsenfeld O., 1971, BORRELIA STRAINS VEC; HAJDUK SL, 1981, PARASITOLOGY, V83, P609, DOI 10.1017/S0031182000080574; Hinnebusch BJ, 1998, INFECT IMMUN, V66, P432, DOI 10.1128/IAI.66.2.432-440.1998; HINNEBUSCH BJ, UNPUB; KELLY R, 1971, SCIENCE, V173, P443, DOI 10.1126/science.173.3995.443; KITTEN T, 1990, P NATL ACAD SCI USA, V87, P6077, DOI 10.1073/pnas.87.16.6077; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE RS, 1991, ANNU REV ENTOMOL, V36, P587, DOI 10.1146/annurev.en.36.010191.003103; MARCONI RT, 1993, J CLIN MICROBIOL, V31, P2577, DOI 10.1128/JCM.31.10.2577-2583.1993; MARGOLIS N, 1994, GENE, V143, P105, DOI 10.1016/0378-1119(94)90613-0; MEIER JT, 1985, CELL, V41, P403, DOI 10.1016/S0092-8674(85)80013-1; PIESMAN J, 1987, J CLIN MICROBIOL, V25, P557, DOI 10.1128/JCM.25.3.557-558.1987; PLASTERK RHA, 1985, NATURE, V318, P257, DOI 10.1038/318257a0; PORCELLA SF, UNPUB; RESTREPO BI, 1994, MOL MICROBIOL, V13, P287, DOI 10.1111/j.1365-2958.1994.tb00423.x; RESTREPO BI, 1994, CELL, V78, P867, DOI 10.1016/S0092-8674(94)90642-4; SCHWAN TG, 1995, P NATL ACAD SCI USA, V92, P2909, DOI 10.1073/pnas.92.7.2909; SCHWAN TG, 1989, INFECT IMMUN, V57, P3445, DOI 10.1128/IAI.57.11.3445-3451.1989; Schwan Tom G., 1995, P626; SOUTHERN PM, 1969, MEDICINE, V48, P129, DOI 10.1097/00005792-196903000-00002; STOENNER HG, 1982, J EXP MED, V156, P1297, DOI 10.1084/jem.156.5.1297; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILSKE B, 1993, INFECT IMMUN, V61, P2182, DOI 10.1128/IAI.61.5.2182-2191.1993	34	124	127	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1938	1940		10.1126/science.280.5371.1938	http://dx.doi.org/10.1126/science.280.5371.1938			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632392				2022-12-28	WOS:000074323800064
J	Lyznicki, JM; Doege, TC; Davis, RM; Williams, MA				Lyznicki, JM; Doege, TC; Davis, RM; Williams, MA		Am Med Assoc	Sleepiness, driving, and motor vehicle crashes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							AUTOMOBILE ACCIDENTS; OPERATIONAL SETTINGS; DRIVER SLEEPINESS; MANAGING FATIGUE; SHIFT WORK; APNEA; NARCOLEPSY; DISORDERS; VIGILANCE; INSOMNIA	Objective.-To assess the contribution of driver sleepiness to highway crashes and review recent recommendations to change federal hours-of-service regulations for commercial motor vehicle drivers. Data Sources.-Information was derived from a search of the MEDLINE, Transportation Research information Service (TRIS), and Bibliographic Electronic Databases of Sleep (BEDS) databases from 1975 through 1997 and from manual review of the reference lists in relevant journal articles, government publications, conference proceedings, and textbooks. Data Synthesis.-Driver sleepiness is a causative factor in 1% to 3% of all US motor vehicle crashes. Surveys of the prevalence of sleepy behavior in drivers suggest that sleepiness may be a more common cause of highway crashes than is reflected in these estimates. About 96% of sleep-related crashes involve passenger vehicle drivers and 3% involve drivers of large trucks. Risk factors include youth, shift work, alcohol and other drug use, over-the-counter and prescription medications, and sleep disorders. Conclusions.-Increased awareness of the relationship between sleepiness and motor vehicle crashes will promote the health and safely of drivers and highway users. Physicians can contribute by encouraging good sleep habits, recognizing and treating sleep-related problems, and counseling patients about the risks of driving while sleepy. To protect public health and safety, the American Medical Association recommends continued research on devices and technologies to detect the signs of sleepiness and prevent the deterioration of driver alertness and performance. Educational programs about the risks of falling asleep while driving are needed for physicians, the public, and commercial truck drivers.	Amer Med Assoc, Council Sci Affairs, Chicago, IL 60610 USA	American Medical Association	Lyznicki, JM (corresponding author), Amer Med Assoc, Council Sci Affairs, 515 N State St, Chicago, IL 60610 USA.		Williams, Michael A./O-4075-2019	Williams, Michael A./0000-0002-7284-8014				*AA FDN TRAFF SAF, 1985, REP DET EV ROL FAT H; AKERSTEDT T, 1994, J SLEEP RES, V3, P152, DOI 10.1111/j.1365-2869.1994.tb00122.x; Akerstedt T, 1995, J SLEEP RES, V4, P15, DOI 10.1111/j.1365-2869.1995.tb00221.x; AKERSTEDT T, 1988, SLEEP, V11, P17, DOI 10.1093/sleep/11.1.17; ALDRICH MS, 1989, SLEEP, V12, P487, DOI 10.1093/sleep/12.6.487; ALDRICH MS, 1990, NEW ENGL J MED, V323, P389; American Psychiatric Association, 1994, DIAGN CRIT DSM 4; American Sleep Disorders Association International Classification of Sleep Disorders, 1997, INT CLASS SLEEP DIS; [Anonymous], 1995, FACT AFF FAT HEAV TR, V1-2; BALLIN JC, 1986, JAMA-J AM MED ASSOC, V255, P522; BEILOCK R, 1995, ACCIDENT ANAL PREV, V27, P33, DOI 10.1016/0001-4575(94)00042-K; Braver Elisa R., 1992, Journal of Public Health Policy, V13, P341, DOI 10.2307/3342733; BROWN ID, 1994, HUM FACTORS, V36, P298, DOI 10.1177/001872089403600210; Brown ID, 1997, ACCIDENT ANAL PREV, V29, P525, DOI 10.1016/S0001-4575(97)00032-8; BROWN ID, 1993, ALCOHOL DRUGS DRIVIN, V9, P239; *CAN MED ASS, 1991, PHYS GUID DRIV EX; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P869; Chaska B, 1996, AM FAM PHYSICIAN, V53, P247; CORFITSEN MT, 1994, ACCIDENT ANAL PREV, V26, P617, DOI 10.1016/0001-4575(94)90023-X; Culebras A, 1996, CLIN HDB SLEEP DISOR; DEMENT WC, 1993, JAMA-J AM MED ASSOC, V269, P1548, DOI 10.1001/jama.269.12.1548; Dement WC, 1997, NEW ENGL J MED, V337, P783, DOI 10.1056/NEJM199709113371111; Dinges DF, 1995, J SLEEP RES, V4, P4, DOI 10.1111/j.1365-2869.1995.tb00220.x; Dinges DF, 1997, SLEEP, V20, P267; DOEGE TC, 1986, MED CONDITIONS AFFEC; Evans L., 1991, TRAFFIC SAFETY DRIVE; *EXP PAN DRIV FAT, 1997, DROWS DRIV AUT CRASH; *FED HIGHW ADM, 1995, 1995 TRUCK BUS SAF S; FINDLEY L, 1995, CHEST, V108, P619, DOI 10.1378/chest.108.3.619; FINDLEY LJ, 1989, NEW ENGL J MED, V320, P868; FINDLEY LJ, 1988, AM REV RESPIR DIS, V138, P337, DOI 10.1164/ajrccm/138.2.337; GENGO FM, 1990, J ALLERGY CLIN IMMUN, V86, P1034, DOI 10.1016/S0091-6749(05)80250-7; George CFP, 1996, SLEEP, V19, P711, DOI 10.1093/sleep/19.9.711; GILLIN JC, 1990, NEW ENGL J MED, V322, P239; GOLD DR, 1992, AM J PUBLIC HEALTH, V82, P1011, DOI 10.2105/AJPH.82.7.1011; HARTENBAUM NP, 1997, DOT MED EXAMINATION; Hemmelgarn B, 1997, JAMA-J AM MED ASSOC, V278, P27, DOI 10.1001/jama.278.1.27; HERTZ RP, 1988, ACCIDENT ANAL PREV, V20, P431, DOI 10.1016/0001-4575(88)90041-3; Horne JA, 1996, PSYCHOPHYSIOLOGY, V33, P306, DOI 10.1111/j.1469-8986.1996.tb00428.x; Horne JA, 1995, J SLEEP RES, V4, P23, DOI 10.1111/j.1365-2869.1995.tb00222.x; HUBLIN C, 1994, SLEEP, V17, pS7, DOI 10.1093/sleep/17.suppl_8.S7; Itoi A, 1993, CAN DRIVERS AVOID FA; KANEKO T, 1992, ACCIDENT ANAL PREV, V24, P437, DOI 10.1016/0001-4575(92)90055-N; KNIPLING RR, 1996, 15 INT TECHN C ENH S; KNIPLING RR, 1994, INT VEH HIGHW SOC AM; Knipling RR., 1994, CRASHES FATALITIES R; KNIPLING RR, 1995, ANN M ASS ADV AUT ME; KOELEGA HS, 1995, PSYCHOPHARMACOLOGY, V118, P233, DOI 10.1007/BF02245951; Kryger M, 1994, PRINCIPLES PRACTICE; Kupfer DJ, 1997, NEW ENGL J MED, V336, P341, DOI 10.1056/NEJM199701303360506; LAUBER JK, 1988, SLEEP, V11, P503; LEVEILLE SG, 1994, EPIDEMIOLOGY, V5, P591, DOI 10.1097/00001648-199411000-00006; Maycock G, 1997, ACCIDENT ANAL PREV, V29, P453, DOI 10.1016/S0001-4575(97)00024-9; McCartt AT, 1996, ACCIDENT ANAL PREV, V28, P511, DOI 10.1016/0001-4575(96)00021-8; McCartt AT, 1997, ASS ADV AUT MED 41 A; Mitler MM, 1997, NEW ENGL J MED, V337, P755, DOI 10.1056/NEJM199709113371106; MITLER MM, 1988, SLEEP, V11, P100, DOI 10.1093/sleep/11.1.100; *NAT COM SLEEP DIS, 1993, WAK AM NAT SLEEP AL; *NAT SAF COUNC, 1909, ACC FACTS; *NAT SAF COUNC TRA, 1991, NCHRP SYNTH, V191; *NAT SLEEP FDN, 1997, US CONT SHOULD RUMBL; *NAT TRANSP SAF BO, 1990, NTSBSS9001 NAT TRANS, V1; Neutel C. Ineke, 1995, Annals of Epidemiology, V5, P239; OGILVIE RD, 1989, SLEEP, V12, P458, DOI 10.1093/sleep/12.5.458; OHANLON JF, 1986, DRUGS DRIVING; OHANLON JF, 1995, 75 ANN M TRANSP RES; Pack AI, 1995, ACCIDENT ANAL PREV, V27, P769, DOI 10.1016/0001-4575(95)00034-8; Pack AM, 1995, J SLEEP RES, V24, P452; PAKOLA SJ, 1995, SLEEP, V18, P787, DOI 10.1093/sleep/18.9.787; PARTINEN M, 1994, PRINCIPLES PRACTICE; Pary R, 1996, POSTGRAD MED, V100, P195, DOI 10.3810/pgm.1996.11.117; RAY WA, 1992, AM J EPIDEMIOL, V136, P873, DOI 10.1093/aje/136.7.873; Reyner LA, 1998, SLEEP, V21, P46; ROEHRS T, 1994, ALCOHOL CLIN EXP RES, V18, P154, DOI 10.1111/j.1530-0277.1994.tb00896.x; Rosa RR, 1997, PLAIN LANGUAGE SHIFT, P97; Rosekind MR, 1996, BEHAV MED, V21, P157, DOI 10.1080/08964289.1996.9933753; Rosekind MR, 1996, BEHAV MED, V21, P166, DOI 10.1080/08964289.1996.9933754; ROSEN RC, 1993, SLEEP, V16, P249, DOI 10.1093/sleep/16.3.249; STOOHS RA, 1995, CHEST, V107, P1275, DOI 10.1378/chest.107.5.1275; STOOHS RA, 1994, SLEEP, V17, P619; STROHL KP, 1994, AM J RESP CRIT CARE, V150, P1463; Strollo PJ, 1996, NEW ENGL J MED, V334, P99, DOI 10.1056/NEJM199601113340207; *US C, 1991, PUBL US C; WANG JS, 1993, ASS ADV AUT MED 40 A; WANG JS, 1994, DOT PUBLICATION; WEBB WB, 1995, SLEEP, V18, P276, DOI 10.1093/sleep/18.4.276; Williamson AM, 1996, ACCIDENT ANAL PREV, V28, P709, DOI 10.1016/S0001-4575(96)00044-9; WYLIE CD, 1996, FHWA PUBLICATION; Young T, 1997, SLEEP, V20, P608, DOI 10.1093/sleep/20.8.608; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; 1996, FED REG, V61, P57251	91	289	313	1	40	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1998	279	23					1908	1913		10.1001/jama.279.23.1908	http://dx.doi.org/10.1001/jama.279.23.1908			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZT653	9634264				2022-12-28	WOS:000074109700040
J	Andes, GM				Andes, GM			Mark Twain's cat	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Andes, GM (corresponding author), 51 Hunthurst Circle, Worcester, MA 01602 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				1043	1044		10.7326/0003-4819-128-12_Part_1-199806150-00019	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00019			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625670				2022-12-28	WOS:000074201300014
J	Morrison, RS; Chassin, MR; Siu, AL				Morrison, RS; Chassin, MR; Siu, AL			The medical consultant's role in caring for patients with hip fracture	ANNALS OF INTERNAL MEDICINE			English	Review							PROXIMAL FEMORAL FRACTURE; ACUTE CONFUSIONAL STATES; RANDOMIZED CLINICAL-TRIAL; LOW-DOSE HEPARIN; ELDERLY PATIENTS; VENOUS THROMBOEMBOLISM; ANTIBIOTIC-PROPHYLAXIS; INTERNAL-FIXATION; NECK FRACTURES; FUNCTIONAL RECOVERY	Background: Hip fractures are an important cause of death and functional dependence in the United States. Purpose: To review the evidence for clinical decisions that medical consultants make for patients with hip fracture and to develop recommendations for care. Data Sources: Published reports of clinical studies were found by searching MEDLINE and selected bibliographies. Study Selection: Studies were included if data were presented on clinical interventions to improve care of conditions typically encountered by medical consultants in the care of patients with hip fracture. Such conditions include timing of surgery, infection prophylaxis, thromboembolic prophylaxis, postoperative nutritional management, urinary tract management, prevention and management of delirium, application and timing of rehabilitation services, and prevention of subsequent falls. Meta-analyses; randomized, controlled trials; or other controlled studies were included if possible. If no such trials were identified, the best evidence from studies with other designs was included. Data Extraction: Interventions were selected on the basis of their efficacy or potential efficacy in improving functional outcome. Trials with positive and negative results were compared for differences in intervention and strength of study methods. Data Synthesis: Strong evidence supports medical recommendations for decisions about timing and duration of prophylactic antibiotics, selection of thromboembolic prophylaxis, urinary tract and nutritional management, and rehabilitative services. Many case series support early surgical repair, although patients who would benefit from delay and further medical work-up have not been well identified. Evidence for decisions about assessment of subsequent risk for fall and risk for and management of delirium is based largely on data from patients without hip fracture but is probably applicable. Future research should target optimal duration of thromboembolic prophylaxis, cost-effectiveness of low-molecular-weight heparin compared with that of other thromboembolic prophylactic regimens, management of delirium, rehabilitative services, and efficacy of assessment of risk for later falls. Conclusions: The data suggest that evidence-based medical care can improve hip fracture outcomes. The medical consultant has a key role in providing this care and managing the preoperative conditions and postoperative complications that may affect optimal functional recovery.	CUNY Mt Sinai Sch Med, Dept Geriatr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Morrison, RS (corresponding author), CUNY Mt Sinai Sch Med, Dept Geriatr, Box 1070,1 Gustave L Levy Pl, New York, NY 10029 USA.	smorriso@smtplink.mssm.edu			AHRQ HHS [U18HS09459-0] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		APPLEGATE WB, 1990, NEW ENGL J MED, V322, P1572, DOI 10.1056/NEJM199005313222205; ARNOLD WD, 1984, J BONE JOINT SURG AM, V66A, P847, DOI 10.2106/00004623-198466060-00004; BARRETTCONNOR E, 1995, AM J MED, V98, pS3, DOI 10.1016/S0002-9343(05)80037-3; BASTOW MD, 1983, BRIT MED J, V287, P1589, DOI 10.1136/bmj.287.6405.1589; BASTOW MD, 1983, LANCET, V1, P143; BERGQVIST D, 1991, SURGERY, V109, P617; BERGQVIST D, 1979, ACTA CHIR SCAND, V145, P213; BODOKY A, 1993, J BONE JOINT SURG AM, V75A, P61, DOI 10.2106/00004623-199301000-00009; BOYD RJ, 1973, J BONE JOINT SURG AM, VA 55, P1251, DOI 10.2106/00004623-197355060-00012; BREDAHL C, 1992, INJURY, V23, P83, DOI 10.1016/0020-1383(92)90037-S; BUCKLEY R, 1990, CAN J SURG, V33, P122; CAMERON ID, 1994, J CLIN EPIDEMIOL, V47, P1307, DOI 10.1016/0895-4356(94)90136-8; CEDER L, 1987, CLIN ORTHOP RELAT R, P53; CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501; COLE MG, 1993, CAN MED ASSOC J, V149, P41; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, CLIN ORTHOP RELAT R, P163; DALEN N, 1988, J TRAUMA, V28, P405; DAVIS FM, 1987, BRIT J ANAESTH, V59, P1080, DOI 10.1093/bja/59.9.1080; DELMI M, 1990, LANCET, V335, P1013, DOI 10.1016/0140-6736(90)91073-J; DOLK T, 1990, INJURY, V21, P369, DOI 10.1016/0020-1383(90)90121-A; ELMERSON S, 1988, ACTA ORTHOP SCAND, V59, P372, DOI 10.3109/17453678809149384; ERICSON C, 1973, J BONE JOINT SURG AM, VA 55, P808, DOI 10.2106/00004623-197355040-00015; Feldman D S, 1993, J Orthop Trauma, V7, P1, DOI 10.1097/00005131-199302000-00001; FINSEN V, 1986, ACTA ORTHOP SCAND, V57, P431, DOI 10.3109/17453678609014764; FISHER CG, 1995, J ORTHOP TRAUMA, V9, P1, DOI 10.1097/00005131-199502000-00001; FOREMAN MD, 1989, RES NURS HEALTH, V12, P21, DOI 10.1002/nur.4770120105; FRANCIS J, 1992, J AM GERIATR SOC, V40, P829, DOI 10.1111/j.1532-5415.1992.tb01859.x; FRANCIS J, 1992, J AM GERIATR SOC, V40, P601, DOI 10.1111/j.1532-5415.1992.tb02111.x; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; GARCIA S, 1991, J BONE JOINT SURG AM, V73A, P1044, DOI 10.2106/00004623-199173070-00013; GATELL JM, 1987, J BONE JOINT SURG AM, V69A, P1189, DOI 10.2106/00004623-198769080-00012; Gent M, 1996, CIRCULATION, V93, P80, DOI 10.1161/01.CIR.93.1.80; GERHART TN, 1991, J BONE JOINT SURG AM, V73A, P494, DOI 10.2106/00004623-199173040-00003; GILCHRIST WJ, 1988, BRIT MED J, V297, P1116, DOI 10.1136/bmj.297.6656.1116; Guccione AA, 1996, PHYS THER, V76, P818, DOI 10.1093/ptj/76.8.818; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P525, DOI 10.1111/j.1532-5415.1988.tb04023.x; GUSTAFSON Y, 1991, J AM GERIATR SOC, V39, P655, DOI 10.1111/j.1532-5415.1991.tb03618.x; HEDSTROM SA, 1987, ACTA ORTHOP SCAND, V58, P361, DOI 10.3109/17453678709146355; HJORTRUP A, 1990, ACTA ORTHOP SCAND, V61, P152, DOI 10.3109/17453679009006509; HOLMBERG S, 1987, CLIN ORTHOP RELAT R, P42; HORNBROOK MC, 1994, GERONTOLOGIST, V34, P16, DOI 10.1093/geront/34.1.16; IMPERIALE TF, 1994, JAMA-J AM MED ASSOC, V271, P1780, DOI 10.1001/jama.271.22.1780; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; Jarnlo G B, 1991, Scand J Rehabil Med Suppl, V24, P1; JETTE AM, 1987, ARCH PHYS MED REHAB, V68, P735; JITAPUNKUL S, 1992, Q J MED, V83, P307; KARACHALIOS T, 1990, CHEMOTHERAPY, V36, P448, DOI 10.1159/000238803; KARUMO I, 1977, ANN CHIR GYNAECOL, V66, P278; KENNIE DC, 1988, BRIT MED J, V297, P1083, DOI 10.1136/bmj.297.6656.1083; KENZORA JE, 1984, CLIN ORTHOP RELAT R, P45; LASSEN MR, 1991, SEMIN THROMB HEMOST, V17, P284; LEVKOFF SE, 1992, ARCH INTERN MED, V152, P334, DOI 10.1001/archinte.152.2.334; LUYAO GL, 1994, AM J PUBLIC HEALTH, V84, P1287, DOI 10.2105/AJPH.84.8.1287; MAGAZINER J, 1990, J GERONTOL, V45, pM101, DOI 10.1093/geronj/45.3.M101; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; March L, 1996, PREVENTION TREATMENT; MCQUEEN MM, 1990, INJURY, V21, P104, DOI 10.1016/0020-1383(90)90065-3; MICHELSON JD, 1988, NEW ENGL J MED, V319, P321; MORRIS GK, 1977, BRIT MED J, V1, P535, DOI 10.1136/bmj.1.6060.535; MOSES H, 1986, AM J MED, V81, P955, DOI 10.1016/0002-9343(86)90386-4; MULROW CD, 1994, JAMA-J AM MED ASSOC, V271, P519, DOI 10.1001/jama.271.7.519; MURRAY AM, 1993, J GERONTOL, V48, pM181, DOI 10.1093/geronj/48.5.M181; Nungu S, 1991, J Orthop Trauma, V5, P452, DOI 10.1097/00005131-199112000-00011; OERTLI D, 1992, WORLD J SURG, V16, P980, DOI 10.1007/BF02067011; OLERUD C, 1991, J BONE JOINT SURG BR, V73, P16, DOI 10.1302/0301-620X.73B1.1991755; PARKER MJ, 1992, J BONE JOINT SURG BR, V74, P203, DOI 10.1302/0301-620X.74B2.1544952; PATTERSON BM, 1992, J BONE JOINT SURG AM, V74A, P251, DOI 10.2106/00004623-199274020-00011; PEREZ JV, 1995, INJURY, V26, P237, DOI 10.1016/0020-1383(95)90008-L; PINI M, 1985, J BONE JOINT SURG BR, V67, P305, DOI 10.1302/0301-620X.67B2.2579953; POMPEI P, 1994, J AM GERIATR SOC, V42, P809, DOI 10.1111/j.1532-5415.1994.tb06551.x; POWERS PJ, 1989, ARCH INTERN MED, V149, P771, DOI 10.1001/archinte.149.4.771; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; PURDLE FR, 1981, ANN EMERG MED, V10, P455, DOI 10.1016/S0196-0644(81)80276-4; REINSCH S, 1992, GERONTOLOGIST, V32, P450, DOI 10.1093/geront/32.4.450; ROCKWOOD K, 1990, J CLIN EPIDEMIOL, V43, P971, DOI 10.1016/0895-4356(90)90080-9; ROGERS FB, 1995, J TRAUMA, V39, P261, DOI 10.1097/00005373-199508000-00012; ROGERS MP, 1989, INT J PSYCHIAT MED, V19, P109; RUBENSTEIN LZ, 1990, ANN INTERN MED, V113, P308, DOI 10.7326/0003-4819-113-4-308; RUMMANS TA, 1995, MAYO CLIN PROC, V70, P989, DOI 10.4065/70.10.989; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; SKELLY JM, 1992, CAN MED ASSOC J, V146, P1185; SKINNER P, 1989, INJURY, V20, P291, DOI 10.1016/0020-1383(89)90171-X; Smith NKG, 1996, AGE AGEING, V25, P150, DOI 10.1093/ageing/25.2.150; SORENSEN JL, 1992, ACTA ORTHOP SCAND, V63, P288, DOI 10.3109/17453679209154784; STABLEFORTH PG, 1986, BRIT J SURG, V73, P651, DOI 10.1002/bjs.1800730826; STROMQVIST B, 1987, CLIN ORTHOP RELAT R, P58; TENGVE B, 1978, J BONE JOINT SURG AM, V60, P97, DOI 10.2106/00004623-197860010-00014; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TKATCH L, 1992, J AM COLL NUTR, V11, P519; TODD CJ, 1995, BRIT MED J, V310, P904, DOI 10.1136/bmj.310.6984.904; U.S. Preventive Service Task Force, 1989, GUID CLIN PREV SERV; VETTER NJ, 1992, BMJ-BRIT MED J, V304, P888, DOI 10.1136/bmj.304.6831.888; VILLAR RN, 1986, BRIT MED J, V293, P1203, DOI 10.1136/bmj.293.6556.1203; VIR SC, 1980, GERONTOLOGY, V26, P1, DOI 10.1159/000212387; WAGNER EH, 1994, AM J PUBLIC HEALTH, V84, P1800, DOI 10.2105/AJPH.84.11.1800; WILLIAMS MA, 1985, RES NURS HEALTH, V8, P31, DOI 10.1002/nur.4770080107; WILLIAMS MA, 1985, RES NURS HEALTH, V8, P329, DOI 10.1002/nur.4770080405; WILLIAMSRUSSO P, 1992, J AM GERIATR SOC, V40, P759, DOI 10.1111/j.1532-5415.1992.tb01846.x; Zuckerman JD, 1996, NEW ENGL J MED, V334, P1519, DOI 10.1056/NEJM199606063342307; ZUCKERMAN JD, 1995, J BONE JOINT SURG AM, V77, P1551, DOI 10.2106/00004623-199510000-00010; ZUCKERMAN JD, 1992, CLIN ORTHOP RELAT R, P213; 1994, ANTIPLATELET TRIALIS, V308, P235	105	106	109	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				1010	1020		10.7326/0003-4819-128-12_Part_1-199806150-00010	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00010			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625664				2022-12-28	WOS:000074201300008
J	Ridker, PM; Miletich, JP; Buring, JE; Ariyo, AA; Price, DT; Manson, JE; Hill, JA				Ridker, PM; Miletich, JP; Buring, JE; Ariyo, AA; Price, DT; Manson, JE; Hill, JA			Factor V Leiden mutation as a risk factor for recurrent pregnancy loss	ANNALS OF INTERNAL MEDICINE			English	Article							ACTIVATED PROTEIN-C; POOR ANTICOAGULANT RESPONSE; COAGULATION-FACTOR-V; VENOUS THROMBOSIS; RESISTANCE; THROMBOPHILIA; THROMBOEMBOLISM	Background: Recurrent pregnancy loss may result from hypercoagulability. Objective: To determine whether women with factor V Leiden mutation, a common inherited defect of coagulation, are at increased risk for recurrent pregnancy loss. Design: Case-control study. Setting: University hospital. Patients: 113 consecutive women referred for evaluation of recurrent spontaneous abortion (case-patients) and 437 postmenopausal women with at least one successful pregnancy and no history of pregnancy loss (controls). An additional survey of 387 postmenopausal women with at least one pregnancy loss was also conducted. Measurements: Prevalence of factor V Leiden mutation determined by a second-generation screening test for resistance to activated protein C with genetic confirmation of all borderline and low-value results. Results: Prevalence of the factor V Leiden mutation was greater among case-patients (8.0%) than among controls (3.7%) (odds ratio, 2.3 [95% CI, 1.0 to 5.2]; P = 0.050). In the subgroup of case-patients with three or more pregnancy losses and no successful pregnancies, prevalence of the mutation was 9.0% (odds ratio, 2.6 [CI, 1.0 to 6.7]; P = 0.048). Among the additional women surveyed, the prevalence of the mutation in those with three or more pregnancy losses (7.5%) was almost identical to that in case-patients. Thus, in all evaluated women with several pregnancy losses, the prevalence of factor V Leiden was increased 2.2-fold (P = 0.026). Conclusion: These data are compatible with the hypothesis that factor V Leiden mutation may play a role in some cases of unexplained recurrent pregnancy loss.	Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Washington Univ, Med Ctr, St Louis, MO USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Washington University (WUSTL)	Ridker, PM (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.							BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Brenner B, 1997, BRIT J HAEMATOL, V97, P551, DOI 10.1046/j.1365-2141.1997.882901.x; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; CUMMING AM, 1995, BRIT J HAEMATOL, V90, P725, DOI 10.1111/j.1365-2141.1995.tb05610.x; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DizonTownson DS, 1997, AM J OBSTET GYNECOL, V176, P883, DOI 10.1016/S0002-9378(97)70615-X; Grandone E, 1997, THROMB HAEMOSTASIS, V77, P822; Grisaru D, 1996, AM J OBSTET GYNECOL, V174, P801, DOI 10.1016/S0002-9378(96)70478-7; HELLGREN M, 1995, AM J OBSTET GYNECOL, V173, P210, DOI 10.1016/0002-9378(95)90192-2; HILL JA, 1994, CURRENT PROBLEMS OBS, V4, P116; Hirsch DR, 1996, AM HEART J, V131, P1145, DOI 10.1016/S0002-8703(96)90089-7; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; Preston FE, 1996, LANCET, V348, P913, DOI 10.1016/S0140-6736(96)04125-6; Price DT, 1997, ANN INTERN MED, V127, P895, DOI 10.7326/0003-4819-127-10-199711150-00007; Rai R, 1996, BRIT J HAEMATOL, V92, P489, DOI 10.1046/j.1365-2141.0000.d01-1465.x; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; Ridker PM, 1997, ANN INTERN MED, V126, P528, DOI 10.7326/0003-4819-126-7-199704010-00005; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; Ridker PM, 1997, JAMA-J AM MED ASSOC, V277, P1305, DOI 10.1001/jama.277.16.1305; Ridker PM, 1997, CIRCULATION, V95, P1777; SVENSSON PJ, 1998, NEW ENGL J MED, V330, P517; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8	23	165	167	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				1000	1003		10.7326/0003-4819-128-12_Part_1-199806150-00007	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625662				2022-12-28	WOS:000074201300006
J	Stock, JL; Waud, CE; Coderre, JA; Overdorf, JH; Janikas, JS; Heiniluoma, KM; Morris, MA				Stock, JL; Waud, CE; Coderre, JA; Overdorf, JH; Janikas, JS; Heiniluoma, KM; Morris, MA			Clinical reporting to primary care physicians leads to increased use and understanding of bone densitometry and affects the management of osteoporosis - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	19th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research	SEP 10-14, 1997	CINCINNATI, OH	Amer Soc Bone & Mineral Res			HIP FRACTURE; RISK-FACTORS; WOMEN; DENSITY; MASS	Background: A major barrier to wider use of bone densitometry has been a lack of reports that are comprehensible to primary care physicians. Objective: To compare the effect of short technical reports and longer clinical reports on use, understanding, and acceptance of bone densitometry by primary care physicians and on management of osteoporosis. Design: Randomized trial. Setting: Osteoporosis center of a community teaching hospital. Subjects: 57 primary care physicians ordering bone mineral density tests with dual x-ray absorptiometry. Intervention: Physicians were randomly assigned to receive short technical reports or long clinical reports written by endocrinologists with access to clinical information. Measurements: Physicians were interviewed by telephone after receiving at least two reports. Results: Before being interviewed, physicians receiving short reports ordered a mean +/- SD of 0.72 +/- 0.71 tests per month; those receiving long reports ordered 1.30 +/- 1.21 tests per month (P = 0.002). At the first interview, 30% of physicians receiving short reports and 86% of those receiving long reports understood the bone mineral density definition of osteoporosis (P < 0.001). Receiving long reports led to more modifications in the pharmacologic treatment of osteoporosis by gynecologists (19% of patients whose reports were short and 61% of patients whose reports were long; P = 0.021) and less confusion about reports by all physicians (36% of physicians receiving short reports and 1% of those receiving long reports; P = 0.003). Conclusions: Clinical reporting of bone densitometry to primary care physicians increased use and understanding of bone densitometry, changed management of osteoporosis, and was well accepted. It may help achieve appropriate use of bone densitometry and may allow convenient dissemination of information on osteoporosis.	UMass Mem Hlth Care, Osteoporosis Res & Treatment Ctr, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Stock, JL (corresponding author), UMass Mem Hlth Care, Osteoporosis Res & Treatment Ctr, 119 Belmont St, Worcester, MA 01605 USA.							[Anonymous], 1994, World Health Organ Tech Rep Ser, V843, P1; CHEN Z, 1997, PROGR ABSTR M GUID 3, P48; Chesnut CH, 1997, AM J MED, V102, P29, DOI 10.1016/S0002-9343(96)00387-7; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; Hans D, 1996, LANCET, V348, P511, DOI 10.1016/S0140-6736(95)11456-4; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; MELTON LJ, 1995, J BONE MINER RES, V10, P175; Miller PD, 1996, CALCIFIED TISSUE INT, V58, P207; Ross PD, 1996, ARCH INTERN MED, V156, P1399, DOI 10.1001/archinte.156.13.1399; ROSS PD, 1993, OSTEOPOROSIS INT, V3, P120, DOI 10.1007/BF01623272	11	46	47	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				996	999		10.7326/0003-4819-128-12_Part_1-199806150-00006	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZU474	9625686				2022-12-28	WOS:000074201300005
J	Kunkele, KP; Heins, S; Dembowski, M; Nargang, FE; Benz, R; Thieffry, M; Walz, J; Lill, R; Nussberger, S; Neupert, W				Kunkele, KP; Heins, S; Dembowski, M; Nargang, FE; Benz, R; Thieffry, M; Walz, J; Lill, R; Nussberger, S; Neupert, W			The preprotein translocation channel of the outer membrane of mitochondria	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; PROTEIN IMPORT RECEPTOR; GENERAL INSERTION PORE; PRECURSOR PROTEINS; ESCHERICHIA-COLI; NEUROSPORA-CRASSA; SECRETORY PROTEINS; CATIONIC CHANNEL; CELL VIABILITY; COMPLEX	The preprotein translocase of the outer membrane of mitochondria (TOM complex) facilitates the recognition, insertion, and translocation of nuclear-encoded mitochondrial preproteins. We have purified the TOM complex from Neurospora crassa and analyzed its composition and functional properties. The TOM complex contains a cation-selective high-conductance channel. Upon reconstitution into liposomes, it mediates integration of proteins into and translocation across the lipid bilayer. TOM complex particles have a diameter of about 138 Angstrom, as revealed by electron microscopy and image analysis; they contain two or three centers of stain-filled openings, which we interpret as pores with an apparent diameter of about 20 Angstrom. We conclude that the structure reported here represents the protein-conducting channel of the mitochondrial outer membrane.	Univ Munich, Inst Physiol Chem Phys Biochem & Zellbiol, D-80336 Munich, Germany; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; CNRS, Neurobiol Cellulaire & Mol Lab, F-91198 Gif Sur Yvette, France; Univ Wurzburg, Theodor Boveri Inst, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany; Max Planck Inst Biochem, Abt Mol Strukturbiol, D-82152 Martinsried, Germany; Philipps Univ Marburg, Inst Zytobiol, D-35033 Marburg, Germany	University of Munich; University of Alberta; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Wurzburg; Max Planck Society; Philipps University Marburg	Kunkele, KP (corresponding author), Univ Munich, Inst Physiol Chem Phys Biochem & Zellbiol, Goethestr 33, D-80336 Munich, Germany.		Nargang, Frank/A-2669-2014	Nargang, Frank/0000-0002-1383-4720; Nussberger, Stephan/0000-0003-3619-4452; Benz, Roland/0000-0002-9510-9265; Lill, Roland/0000-0002-8345-6518				AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CAO W, 1995, J BIOL CHEM, V270, P5674, DOI 10.1074/jbc.270.10.5674; COURT DA, 1995, CAN J BOT, V73, pS193; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Dekker PJT, 1996, BIOL CHEM, V377, P535; deKroon AIPM, 1997, BBA-BIOMEMBRANES, V1325, P108, DOI 10.1016/S0005-2736(96)00240-4; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; FEVRE F, 1994, BIOPHYS J, V66, P1887, DOI 10.1016/S0006-3495(94)80982-8; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; FRANK J, 1982, J MOL BIOL, V161, P134, DOI 10.1016/0022-2836(82)90282-0; FREITAG H, 1983, METHOD ENZYMOL, V97, P286; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GOPING IS, 1995, FEBS LETT, V373, P45; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HALLERMAYER G, 1974, H-S Z PHYSIOL CHEM, V355, P279, DOI 10.1515/bchm2.1974.355.1.279; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; Haucke V, 1997, TRENDS CELL BIOL, V7, P103, DOI 10.1016/S0962-8924(96)10052-0; Hegerl R, 1996, J STRUCT BIOL, V116, P30, DOI 10.1006/jsbi.1996.0006; Hille B, 1992, IONIC CHANNELS EXCIT, P291; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; IWAHASHI J, 1994, J BIOCHEM-TOKYO, V116, P156, DOI 10.1093/oxfordjournals.jbchem.a124488; Iwahashi J, 1997, J BIOL CHEM, V272, P18467, DOI 10.1074/jbc.272.29.18467; Juin P, 1997, J BIOL CHEM, V272, P6044, DOI 10.1074/jbc.272.9.6044; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; MANNELLA CA, 1992, TRENDS BIOCHEM SCI, V17, P315, DOI 10.1016/0968-0004(92)90444-E; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; MUELLER P, 1963, J PHYS CHEM-US, V67, P534, DOI 10.1021/j100796a529; NAKAI M, 1995, FEBS LETT, V357, P202; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1989, J BIOL CHEM, V264, P34; Pfanner N, 1997, CURR BIOL, V7, pR100, DOI 10.1016/S0960-9822(06)00048-0; PFANNER N, 1987, EUR J BIOCHEM, V169, P289, DOI 10.1111/j.1432-1033.1987.tb13610.x; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; Schlossmann J, 1996, J BIOL CHEM, V271, P17890, DOI 10.1074/jbc.271.30.17890; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; Sebald W, 1979, Methods Enzymol, V55, P144; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; THIEFFRY M, 1988, EMBO J, V7, P1449, DOI 10.1002/j.1460-2075.1988.tb02962.x; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0	75	311	315	1	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1998	93	6					1009	1019		10.1016/S0092-8674(00)81206-4	http://dx.doi.org/10.1016/S0092-8674(00)81206-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635430	Bronze			2022-12-28	WOS:000074205700012
J	Liu, QA; Hengartner, MO				Liu, QA; Hengartner, MO			Candidate adaptor protein CED-6 promotes the engulfment of apoptotic cells in C-elegans	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; PHOSPHOTYROSINE INTERACTION DOMAIN; RECEPTOR-MEDIATED PHAGOCYTOSIS; VITRONECTIN RECEPTOR; MACROPHAGE RECOGNITION; SIGNAL-TRANSDUCTION; GENETIC MOSAICS; SH3 DOMAINS; PTB DOMAIN; DEATH	The rapid engulfment (phagocytosis) of cells undergoing programmed cell death (apoptosis) is a fundamental biological process that is not well understood. Here we report the cloning and functional characterization of ced-6, a gene specifically required for the engulfment of apoptotic cells in the nematode C. elegans. The CED-6 protein contains a phosphotyrosine binding domain at its N terminus and a proline/serine-rich region in its C-terminal half. Genetic mosaic analysis demonstrates that ced-6 acts within engulfing cells. We also show that ced-6 can promote the engulfment of cells at both early and late stages of apoptosis. Our data suggest that CED-6 is an adaptor molecule acting in a signal transduction pathway that specifically mediates the recognition and engulfment of apoptotic cells.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hengartner, MO (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.		Hengartner, Michael O/A-7058-2008; Hengartner, Michael O/E-6235-2011	Liu, Alison/0000-0002-4636-0920; Hengartner, Michael/0000-0002-7584-596X; Liu (liu qiong), Alison/0000-0003-0171-6441	NIGMS NIH HHS [GM-52540] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052540] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BIANCO C, 1975, J EXP MED, V141, P1278, DOI 10.1084/jem.141.6.1278; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLUMENTHAL T, 1997, C ELEGANS, V2, P117; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BRENNER S, 1974, GENETICS, V77, P71; DUVALL E, 1985, IMMUNOLOGY, V56, P351; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; ELLIS RE, 1991, GENETICS, V129, P79; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Franc NC, 1996, IMMUNITY, V4, P431, DOI 10.1016/S1074-7613(00)80410-0; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GREENBERG S, 1995, TRENDS CELL BIOL, V5, P93, DOI 10.1016/S0962-8924(00)88957-6; GRIGG JM, 1991, LANCET, V338, P720, DOI 10.1016/0140-6736(91)91443-X; HEDGECOCK EM, 1995, GENETICS, V141, P989; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HERMAN RK, 1984, GENETICS, V108, P165; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; Hodgkin J, 1997, C ELEGANS, P881; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KLASS M, 1976, DEV BIOL, V52, P1, DOI 10.1016/0012-1606(76)90002-6; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Lockshin R. A, 1981, CELL DEATH BIOL PATH, P79; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; Mello C, 1995, METHOD CELL BIOL, P452; Metchnikoff E, 1983, LECT COMP PATHOLOGY; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; ROBERTSON AMG, 1982, J EMBRYOL EXP MORPH, V67, P89; ROSENBLUTH RE, 1985, GENETICS, V109, P493; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Sun AY, 1997, GENETICS, V147, P1077; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; [No title captured]	64	164	176	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1998	93	6					961	972		10.1016/S0092-8674(00)81202-7	http://dx.doi.org/10.1016/S0092-8674(00)81202-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635426	Bronze, Green Accepted			2022-12-28	WOS:000074205700008
J	Moore, MS; DeZazzo, J; Luk, AY; Tully, T; Singh, CM; Heberlein, U				Moore, MS; DeZazzo, J; Luk, AY; Tully, T; Singh, CM; Heberlein, U			Ethanol intoxication in Drosophila: Genetic and pharmacological evidence for regulation by the cAMP signaling pathway	CELL			English	Article							CYCLIC-AMP PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; MUTANT MICE LACKING; MUSHROOM BODIES; PREFERENTIAL EXPRESSION; A RECEPTORS; ALCOHOL; MEMORY; DUNCE; MELANOGASTER	Upon exposure to ethanol, Drosophila display behaviors that are similar to ethanol intoxication in rodents and humans. Using an inebriometer to measure ethanol-induced loss of postural control, we identified cheapdate, a mutant with enhanced sensitivity to ethanol. Genetic and molecular analyses revealed that cheapdate is an allele of the memory mutant amnesiac. amnesiac has been postulated to encode a neuropeptide that activates the cAMP pathway. Consistent with this, we find that enhanced ethanol sensitivity of cheapdate can be reversed by treatment with agents that increase cAMP levels or PKA activity. Conversely, genetic or pharmacological reduction in PKA activity results in increased sensitivity to ethanol. Taken together, our results provide functional evidence for the involvement of the cAMP signal transduction pathway in the behavioral response to intoxicating levels of ethanol.	Univ Calif San Francisco, Gallo Ctr, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94110 USA; Univ Calif San Francisco, Program Dev Biol, San Francisco, CA 94110 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cold Spring Harbor Laboratory	Moore, MS (corresponding author), Univ Calif San Francisco, Gallo Ctr, San Francisco, CA 94110 USA.				NIAAA NIH HHS [AA10035, F32 AA05482] Funding Source: Medline; NINDS NIH HHS [T32 NS07067] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [F32AA005482, R01AA010035] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Buck KJ, 1996, BEHAV GENET, V26, P313, DOI 10.1007/BF02359387; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; COHAN FM, 1986, GENETICS, V114, P145; Crabbe JC, 1996, NAT GENET, V14, P98, DOI 10.1038/ng0996-98; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; Crews FT, 1996, INT REV NEUROBIOL, V39, P283, DOI 10.1016/S0074-7742(08)60670-4; DAVIS RL, 1981, J CELL BIOL, V90, P101, DOI 10.1083/jcb.90.1.101; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; DIAMOND I, 1987, P NATL ACAD SCI USA, V84, P1413, DOI 10.1073/pnas.84.5.1413; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; FEANY MB, 1995, SCIENCE, V268, P869, DOI 10.1126/science.7754370; FERVEUR JF, 1995, SCIENCE, V267, P902, DOI 10.1126/science.7846534; GORDON AS, 1992, G PROTEINS, V8, P191; GRANT KA, 1995, CLIN NEUROSCI, V3, P155; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HARRIS RA, 1995, P NATL ACAD SCI USA, V92, P3658, DOI 10.1073/pnas.92.9.3658; Iourgenko V, 1997, FEBS LETT, V413, P104, DOI 10.1016/S0014-5793(97)00891-0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; MOHLER JD, 1977, GENETICS, V85, P259; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; QUI Y, 1991, J MOL BIOL, V222, P553; QUINN WG, 1979, NATURE, V277, P212, DOI 10.1038/277212a0; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; SCHUCKIT MA, 1988, ARCH GEN PSYCHIAT, V45, P211; SCHUCKIT MA, 1994, AM J PSYCHIAT, V151, P184; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; TABAKOFF B, 1988, NEW ENGL J MED, V318, P134, DOI 10.1056/NEJM198801213180302; Tabakoff B, 1996, NEURON, V16, P909, DOI 10.1016/S0896-6273(00)80113-0; TULLY T, 1986, J NEUROGENET, V3, P33, DOI 10.3109/01677068609106893; WAFFORD KA, 1990, SCIENCE, V249, P291, DOI 10.1126/science.1695761; WEBER KE, 1988, INEBRIOMETER, V67, P91; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301	39	365	371	0	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					997	1007		10.1016/S0092-8674(00)81205-2	http://dx.doi.org/10.1016/S0092-8674(00)81205-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635429	Bronze, Green Submitted			2022-12-28	WOS:000074205700011
J	Fishman, JA; Rubin, RH				Fishman, JA; Rubin, RH			Infection in organ-transplant recipients	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CYTOMEGALO-VIRUS INFECTION; ORTHOTOPIC LIVER-TRANSPLANTATION; DEVELOPING CHRONIC REJECTION; RENAL-TRANSPLANTATION; ALLOGRAFT RECIPIENTS; FUNGAL-INFECTIONS; CMV INFECTION; HEART-TRANSPLANTATION; GANCICLOVIR THERAPY; SEROPOSITIVE DONORS		Massachusetts Gen Hosp, Program Transplantat Infect Dis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Med, Div Hlth Sci & Technol, Ctr Expt Pharmacol & Therapeut, Cambridge, MA 02138 USA; MIT, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT)	Rubin, RH (corresponding author), Massachusetts Gen Hosp, Program Transplantat Infect Dis, 55 Fruit St, Boston, MA 02114 USA.							AGARWAL SK, 1994, AM J KIDNEY DIS, V24, P78, DOI 10.1016/S0272-6386(12)80163-6; Aguado JM, 1997, TRANSPLANTATION, V63, P1278, DOI 10.1097/00007890-199705150-00015; AMACHER DE, 1991, ANTIMICROB AGENTS CH, V35, P1186, DOI 10.1128/AAC.35.6.1186; BALDWIN WM, 1982, CLIN EXP IMMUNOL, V50, P515; BASGOZ N, 1995, INFECT DIS CLIN N AM, V9, P901; BECK S, 1988, NATURE, V331, P209; Bocchi EA, 1996, ANN THORAC SURG, V61, P1727, DOI 10.1016/0003-4975(96)00141-5; BRONSTHER O, 1995, TRANSPLANT P, V27, P1206; CHOU S, 1990, REV INFECT DIS, V12, P727; COHEN IM, 1982, ARCH INTERN MED, V142, P489, DOI 10.1001/archinte.142.3.489; COLLINS LA, 1994, J INFECT DIS, V170, P644, DOI 10.1093/infdis/170.3.644; COUVREUR J, 1992, PRESSE MED, V21, P1569; deCarvalho VB, 1996, CIRCULATION, V94, P1815, DOI 10.1161/01.CIR.94.8.1815; ERICE A, 1992, J CLIN MICROBIOL, V30, P2822, DOI 10.1128/JCM.30.11.2822-2825.1992; ETTINGER NA, 1991, AM REV RESPIR DIS, V143, P1386, DOI 10.1164/ajrccm/143.6.1386; Falagas ME, 1996, CLIN INFECT DIS, V23, P468, DOI 10.1093/clinids/23.3.468; Falagas ME, 1996, CLIN INFECT DIS, V23, P292, DOI 10.1093/clinids/23.2.292; FIETZE E, 1994, TRANSPLANTATION, V58, P675; Fishman JA, 1996, TRANSPLANTATION, V62, P147, DOI 10.1097/00007890-199607270-00001; FISHMAN JA, 1995, INFECT DIS CLIN N AM, V9, P1005; FOX JC, 1992, J GEN VIROL, V73, P2405, DOI 10.1099/0022-1317-73-9-2405; FUJINAMI RS, 1988, J VIROL, V62, P100, DOI 10.1128/JVI.62.1.100-105.1988; Gilbert MJ, 1996, NATURE, V383, P720, DOI 10.1038/383720a0; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; GREFTE A, 1993, J INFECT DIS, V167, P270, DOI 10.1093/infdis/167.2.270; Grossi P, 1996, TRANSPLANTATION, V61, P1659, DOI 10.1097/00007890-199606150-00022; HADLEY S, 1995, TRANSPLANTATION, V59, P851; HADLEY S, 1995, INFECT DIS CLIN N AM, V9, P1045; HIBBERD PL, 1995, ANN INTERN MED, V123, P18, DOI 10.7326/0003-4819-123-1-199507010-00002; HO M, 1985, J INFECT DIS, V152, P876, DOI 10.1093/infdis/152.5.876; HOOPER DC, 1982, MEDICINE, V61, P166, DOI 10.1097/00005792-198205000-00004; HOPKINS CC, 1989, J HOSP INFECT, V13, P19, DOI 10.1016/0195-6701(89)90091-1; HORNEF MW, 1995, TRANSPLANTATION, V60, P474, DOI 10.1097/00007890-199509000-00013; HUMBERT M, 1993, TRANSPLANTATION, V56, P623, DOI 10.1097/00007890-199309000-00024; JOHNSON RP, 1991, RESP DIS IMMUNOSUPPR, P567; Kanj SS, 1996, CLIN INFECT DIS, V22, P537, DOI 10.1093/clinids/22.3.537; KEENAN RJ, 1991, TRANSPLANTATION, V51, P433, DOI 10.1097/00007890-199102000-00032; Kowdley KV, 1996, TRANSPLANT INT, V9, P161, DOI 10.1111/j.1432-2277.1996.tb00872.x; LABALETTE M, 1994, CLIN EXP IMMUNOL, V95, P465; LABALETTE M, 1995, TRANSPLANTATION, V59, P1714, DOI 10.1097/00007890-199506270-00013; LAKE KD, 1995, HDB CARDIAC TRANSPLA, P173; LAMMERMEIER DE, 1990, ANN THORAC SURG, V50, P222, DOI 10.1016/0003-4975(90)90738-R; LAUTENSCHLAGER I, 1995, TRANSPLANT INT, V8, P446; LEBRANCHU Y, 1995, TRANSPLANT P, V27, P960; LLOVERAS J, 1982, ARCH INTERN MED, V142, P888, DOI 10.1001/archinte.142.5.888; LUFT BJ, 1983, ANN INTERN MED, V99, P27, DOI 10.7326/0003-4819-99-1-27; Manez R, 1996, J INFECT DIS, V173, P1072, DOI 10.1093/infdis/173.5.1072; Manion D J, 1996, Antivir Ther, V1, P237; NELSON PW, 1984, TRANSPLANTATION, V37, P313, DOI 10.1097/00007890-198403000-00020; Niubo J, 1996, DIAGN MICR INFEC DIS, V24, P19, DOI 10.1016/0732-8893(95)00248-0; OGRADY JG, 1988, LANCET, V2, P302; ORR KE, 1994, J INFECTION, V29, P249, DOI 10.1016/S0163-4453(94)91082-0; Patel R, 1996, TRANSPLANTATION, V62, P926, DOI 10.1097/00007890-199610150-00010; PAYA CV, 1993, CLIN INFECT DIS, V16, P677, DOI 10.1093/clind/16.5.677; Peddi VR, 1996, CLIN TRANSPLANT, V10, P160; Poterucha JJ, 1997, ANN INTERN MED, V126, P805, DOI 10.7326/0003-4819-126-10-199705150-00012; REINKE P, 1994, LANCET, V344, P1737, DOI 10.1016/S0140-6736(94)92887-8; RICHARDSON WP, 1981, NEW ENGL J MED, V305, P57, DOI 10.1056/NEJM198107093050201; RUBIN RH, 1991, NEW ENGL J MED, V324, P1057, DOI 10.1056/NEJM199104113241509; RUBIN RH, 1993, KIDNEY INT, V44, P221, DOI 10.1038/ki.1993.234; RUBIN RH, 1993, ANTIMICROB AGENTS CH, V37, P619, DOI 10.1128/AAC.37.4.619; RUBIN RH, 1981, AM J MED, V70, P405, DOI 10.1016/0002-9343(81)90780-4; RUBIN RH, 1990, REV INFECT DIS    S7, V12, P754; Rubin Robert H., 1994, P121; Rubin Robert H., 1994, P629; SERODY JS, 1993, CLIN INFECT DIS, V16, P54, DOI 10.1093/clinids/16.1.54; Sharma RK, 1996, AM J NEPHROL, V16, P358, DOI 10.1159/000169024; SIMMONS RL, 1970, TRANSPL P, V2, P419; SINZGER C, 1993, J INFECT DIS, V167, P1427, DOI 10.1093/infdis/167.6.1427; SNYDMAN DR, 1993, ANN INTERN MED, V119, P984, DOI 10.7326/0003-4819-119-10-199311150-00004; TERRAULT NA, 1995, INFECT DIS CLIN N AM, V9, P943; Touraine F, 1991, Eur Cytokine Netw, V2, P47; VANDENBERG AP, 1995, TRANSPLANT P, V27, P936; vandenBerg AP, 1996, CLIN TRANSPLANT, V10, P224; VANSON WJ, 1989, CLIN IMMUNOL IMMUNOP, V50, P109, DOI 10.1016/0090-1229(89)90226-2; VENKATARAMANAN R, 1989, CLIN PHARMACOKINET, V16, P134, DOI 10.2165/00003088-198916030-00002; VONWILLEBRAND E, 1986, TRANSPLANTATION, V42, P364, DOI 10.1097/00007890-198610000-00006; WHITING PH, 1983, TRANSPLANT P, V15, P2702; WINSTON DJ, 1995, CLIN INFECT DIS, V21, P1077, DOI 10.1093/clinids/21.5.1077; WREGHITT TG, 1989, J CLIN PATHOL, V42, P194, DOI 10.1136/jcp.42.2.194	80	1090	1128	0	70	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1998	338	24					1741	1751		10.1056/NEJM199806113382407	http://dx.doi.org/10.1056/NEJM199806113382407			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT654	9624195				2022-12-28	WOS:000074109800007
J	Krasnopolsky, VA; Mumma, MJ; Gladstone, GR				Krasnopolsky, VA; Mumma, MJ; Gladstone, GR			Detection of atomic deuterium in the upper atmosphere of Mars	SCIENCE			English	Article							INNER SOLAR-SYSTEM; MARTIAN ATMOSPHERE; LYMAN-ALPHA; TERRESTRIAL PLANETS; CHARGE-TRANSFER; WATER; D/H; EVOLUTION; IONS; ABUNDANCE	High-resolution spectroscopy of Mars' atmosphere with the Hubble Space Telescope revealed the deuterium Lyman alpha line at an intensity of 23 +/- 6 rayleighs. This measured intensity corresponds to HD/H-2 = 1.5 +/- 0.6 x 10(-4), which is smaller by a factor of 11 than HDO/H2O. This indicates that fractionation of HD/H-2 relative to that of HDO/H2O is not kinetically controlled by the rates of formation and destruction of H-2 and HD but is thermodynamically controlled by the isotope exchange HD + H2O <-> HDO + H-2. Molecular hydrogen is strongly depleted in deuterium relative to water on Mars because of the very long lifetime of H-2 (1200 years). The derived isotope fractionation corresponds to an estimate of a planetwide reservoir of water ice about 5 meters thick that is exchangeable with the atmosphere.	NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Catholic Univ Amer, Dept Phys, Washington, DC 20064 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Catholic University of America	Krasnopolsky, VA (corresponding author), NASA, Goddard Space Flight Ctr, Code 6902, Greenbelt, MD 20771 USA.		mumma, michael j/I-2764-2013; Krasnopolsky, Vladimir/L-5085-2013	mumma, michael j/0000-0003-4627-750X; 				Acuna MH, 1998, SCIENCE, V279, P1676, DOI 10.1126/science.279.5357.1676; AJELLO JM, 1987, ASTROPHYS J, V317, P964, DOI 10.1086/165345; ANDERSON DE, 1974, J GEOPHYS RES, V79, P1513, DOI 10.1029/JA079i010p01513; ANICICH VG, 1993, J PHYS CHEM REF DATA, V22, P1469, DOI 10.1063/1.555940; Atreya S. K., 1986, ATMOSPHERES IONOSPHE; Bertaux J. L., 1992, SCI HUBBLE SPACE TEL, P459; Bjoraker G. L., 1989, B AM ASTRON SOC, V21, P991; CARR MH, 1990, ICARUS, V87, P210, DOI 10.1016/0019-1035(90)90031-4; CLARKE JT, 1995, ASTROPHYS J, V448, P893, DOI 10.1086/176018; DEMORE WB, 1994, JPL PUBL, V9426; DONAHUE TM, 1995, NATURE, V374, P432, DOI 10.1038/374432a0; EBERHARDT P, 1995, ASTRON ASTROPHYS, V302, P301; Gurvich L.V., 1989, THERMODYNAMIC PROPER; HAGEMANN R, 1970, TELLUS, V22, P712, DOI 10.1111/j.2153-3490.1970.tb00540.x; Hanson W. B., 1977, Journal of Geophysical Research, V82, P4351, DOI 10.1029/JS082i028p04351; HUNTEN DM, 1993, SCIENCE, V259, P915, DOI 10.1126/science.259.5097.915; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; JAKOSKY BM, 1994, NATURE, V370, P328, DOI 10.1038/370328a0; JAKOSKY BM, 1990, J GEOPHYS RES-SOLID, V95, P1475, DOI 10.1029/JB095iB02p01475; Kieffer L. J., 1969, Atomic Data, V1, P19, DOI 10.1016/S0092-640X(69)80020-3; Krasnopolsky V. A., 1986, PHOTOCHEMISTRY ATMOS; KRASNOPOLSKY VA, 1995, J GEOPHYS RES-PLANET, V100, P3263, DOI 10.1029/94JE03283; Krasnopolsky VA, 1997, J GEOPHYS RES-PLANET, V102, P6525, DOI 10.1029/96JE03766; KRASNOPOLSKY VA, 1993, ICARUS, V101, P313, DOI 10.1006/icar.1993.1027; KRASNOPOLSKY VA, 1994, ICARUS, V109, P337, DOI 10.1006/icar.1994.1098; KRASNOPOLSKY VA, 1993, ICARUS, V101, P33, DOI 10.1006/icar.1993.1003; Krasnopolsky VA, 1996, J GEOPHYS RES-SPACE, V101, P15765, DOI 10.1029/96JA01080; LECLUSE C, 1994, GEOCHIM COSMOCHIM AC, V58, P2927, DOI 10.1016/0016-7037(94)90126-0; LEMAIRE P, 1978, ASTROPHYS J, V223, pL55, DOI 10.1086/182727; LUHMANN JG, 1992, GEOPHYS RES LETT, V19, P2151, DOI 10.1029/92GL02485; MELOSH HJ, 1989, NATURE, V338, P487, DOI 10.1038/338487a0; MERLIVAT L, 1967, TELLUS, V19, P122, DOI 10.1111/j.2153-3490.1967.tb01465.x; NAIR H, 1994, ICARUS, V111, P124, DOI 10.1006/icar.1994.1137; NAKAI Y, 1987, ATOM DATA NUCL DATA, V37, P69, DOI 10.1016/0092-640X(87)90005-2; NEWMAN JH, 1982, PHYS REV A, V25, P2976, DOI 10.1103/PhysRevA.25.2976; Nier A. O., 1977, Journal of Geophysical Research, V82, P4341, DOI 10.1126/science.194.4271.1298; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; OWEN T, 1988, SCIENCE, V240, P1767, DOI 10.1126/science.240.4860.1767; RICHARDS PG, 1994, J GEOPHYS RES-SPACE, V99, P8981, DOI 10.1029/94JA00518; STUMPNER W, 1998, ANN GEOPHYS S111, V16, pC1002; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; WU FM, 1980, ASTROPHYS J, V239, P389, DOI 10.1086/158119; YUNG YL, 1988, ICARUS, V76, P146, DOI 10.1016/0019-1035(88)90147-9; Yung YL, 1998, SCIENCE, V280, P1545, DOI 10.1126/science.280.5369.1545; ZHANG MHG, 1993, J GEOPHYS RES-PLANET, V98, P3311, DOI 10.1029/92JE02229	45	95	94	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1576	1580		10.1126/science.280.5369.1576	http://dx.doi.org/10.1126/science.280.5369.1576			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616115				2022-12-28	WOS:000074061200033
J	Zimetbaum, PJ; Kim, KY; Josephson, ME; Goldberger, AL; Cohen, DJ				Zimetbaum, PJ; Kim, KY; Josephson, ME; Goldberger, AL; Cohen, DJ			Diagnostic yield and optimal duration of continuous-loop event monitoring for the diagnosis of palpitations - A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article						cost-benefit analysis; electrocardiography, ambulatory; time factors; arrhythmia; palpitations		Background: Continuous-loop event recorders are widely used for the evaluation of palpitations, but the optimal duration of monitoring is unknown. Objective: To determine the yield, timing, and incremental cost-effectiveness of each week of event monitoring for palpitations. Design: Prospective cohort study. Patients: 105 consecutive outpatients referred for the placement of a continuous-loop event recorder for the evaluation of palpitations. Measurements: Diagnostic yield, incremental cost, and cost-effectiveness for each week of monitoring. Results: The diagnostic yield of continuous-loop event recorders was 1.04 diagnoses per patient in week 1, 0.15 diagnoses per patient in week 2, and 0.01 diagnoses per patient in week 3 and beyond. Over time, the cost effectiveness ratio increased from $98 per new diagnosis in week 1 to $576 per new diagnosis in week 2 and $5832 per new diagnosis in week 3. Conclusions: In patients referred for evaluation of palpitations, the diagnostic yield of continuous-loop event recording decreases rapidly after 2 weeks of monitoring. A 2-week monitoring period is reasonably cost-effective for most patients and should be the standard period for continuous-loop event recording for the evaluation of palpitations.	Bath Israel Deaconess Med Ctr, Cardiovasc Div GZ435, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Cohen, DJ (corresponding author), Bath Israel Deaconess Med Ctr, Cardiovasc Div GZ435, 330 Brookline Ave, Boston, MA 02115 USA.							DIMARCO JP, 1990, ANN INTERN MED, V113, P53, DOI 10.7326/0003-4819-113-1-53; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; Fogel RI, 1997, AM J CARDIOL, V79, P207, DOI 10.1016/S0002-9149(96)00717-5; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kinlay S, 1996, ANN INTERN MED, V124, P16, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00003; KRAHN AD, 1995, CIRCULATION, V92, P1819, DOI 10.1161/01.CIR.92.7.1819; REIFFEL JA, 1991, J ELECTROCARDIOL, V24, P165, DOI 10.1016/0022-0736(91)90007-9	7	87	91	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					890	+		10.7326/0003-4819-128-11-199806010-00002	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634426				2022-12-28	WOS:000073808600002
J	Littman, DR				Littman, DR			Chemokine receptors: Keys to AIDS pathogenesis?	CELL			English	Review							INFECTION; ENTRY; HIV		NYU, Med Ctr, Dept Microbiol, Howard Hughes Med Inst,Skirball Inst Biomol Med, New York, NY 10016 USA	Howard Hughes Medical Institute; New York University	Littman, DR (corresponding author), NYU, Med Ctr, Dept Microbiol, Howard Hughes Med Inst,Skirball Inst Biomol Med, New York, NY 10016 USA.							Bieniasz P. D., 1998, FRONT BIOSCI, V3, P44; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CLAPHAM P, 1993, PHILOS T ROY SOC B, V342, P67, DOI 10.1098/rstb.1993.0137; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Dumonceaux J, 1998, J VIROL, V72, P512, DOI 10.1128/JVI.72.1.512-519.1998; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P14742, DOI 10.1073/pnas.94.26.14742; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1; MORI K, 1993, J VIROL, V67, P2807, DOI 10.1128/JVI.67.5.2807-2814.1993; Murakami T, 1997, J EXP MED, V186, P1389, DOI 10.1084/jem.186.8.1389; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Stewart G, 1998, NAT MED, V4, P275, DOI 10.1038/nm0398-275; Weiss RA, 1996, NATURE, V381, P647, DOI 10.1038/381647a0; Weissman D, 1997, NATURE, V389, P981, DOI 10.1038/40173	21	268	276	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					677	680		10.1016/S0092-8674(00)81429-4	http://dx.doi.org/10.1016/S0092-8674(00)81429-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630212	hybrid			2022-12-28	WOS:000073956700004
J	Villa, A; Santagata, S; Bozzi, F; Giliani, S; Frattini, A; Imberti, L; Gatta, LB; Ochs, HD; Schwarz, K; Notarangelo, LD; Vezzoni, P; Spanopoulou, E				Villa, A; Santagata, S; Bozzi, F; Giliani, S; Frattini, A; Imberti, L; Gatta, LB; Ochs, HD; Schwarz, K; Notarangelo, LD; Vezzoni, P; Spanopoulou, E			Partial V(D)J recombination activity leads to Omenn syndrome	CELL			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; IMMUNOGLOBULIN-E PRODUCTION; COMBINED IMMUNE-DEFICIENCY; T-CELLS; LYMPHOCYTES-T; SCID MICE; DNA; RAG-1; SEQUENCE; GENES	Genomic rearrangement of the antigen receptor loci is initiated by the two lymphoid-specific proteins Rag-1 and Rag-2. Null mutations in either of the two proteins abrogate initiation of V(D)J recombination and cause severe combined immunodeficiency with complete absence of mature B and T rymphocytes. We report here that patients with Omenn syndrome, a severe immunodeficiency characterized by the presence of activated, anergic, oligoclonal T cells, hypereosinophilia, and high IgE levels, bear missense mutations in either the Rag-1 or Rag-2 genes that result in partial activity of the two proteins. Two of the amino acid substitutions map within the Rag-1 homeodomain and decrease DNA binding activity, while three others lower the efficiency of Rag-1/Rag-2 interaction. These findings provide evidence to indicate that the immunodeficiency manifested in patients with Omenn syndrome arises from mutations that decrease the efficiency of V(D)J recombination.	CNR, Ist Tecnol Biomed Avanzate, Dept Human Genome & Multifactorial Dis, I-20090 Segrate, Milano, Italy; Mt Sinai Sch Med, Ruttenberg Canc Ctr, Howard Hughes Med Inst, New York, NY 10029 USA; Spedali Civili, Dept Paediat, I-25123 Brescia, Italy; Univ Brescia, I-25123 Brescia, Italy; Spedali Civili, Terzo Lab Anal, I-25123 Brescia, Italy; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Univ Ulm, Dept Transfus Med, D-89070 Ulm, Germany	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Howard Hughes Medical Institute; Icahn School of Medicine at Mount Sinai; Hospital Spedali Civili Brescia; University of Brescia; Hospital Spedali Civili Brescia; University of Washington; University of Washington Seattle; Ulm University	Vezzoni, P (corresponding author), CNR, Ist Tecnol Biomed Avanzate, Dept Human Genome & Multifactorial Dis, Via Fratelli Cervi 93, I-20090 Segrate, Milano, Italy.		Vezzoni, Paolo/K-3197-2018; Frattini, Annalisa/B-7684-2015; Santagata, Sandro/A-7714-2009; Vezzoni, Paolo/R-3416-2019; Bozzi, Fabio Luigi/H-6091-2017; Giliani, Silvia/AAX-8843-2020; Notarangelo, Luigi D/F-9718-2016	Frattini, Annalisa/0000-0002-1166-3091; Bozzi, Fabio Luigi/0000-0003-0729-1288; Giliani, Silvia/0000-0001-8137-4642; Notarangelo, Luigi D/0000-0002-8335-0262; Santagata, Sandro/0000-0002-7528-9668; Villa, Anna/0000-0003-4428-9013; Vezzoni, Paolo/0000-0002-6382-3923; Imberti, Luisa/0000-0002-2075-8391	NIAID NIH HHS [AI40191] Funding Source: Medline; NICHD NIH HHS [HD17427] Funding Source: Medline; Telethon [E.0495, E.0668] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017427, R37HD017427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040191] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Telethon(Fondazione Telethon); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Arden Bernhard, 1995, Immunogenetics, V42, P455; Bendelac A, 1996, J EXP MED, V184, P1285, DOI 10.1084/jem.184.4.1285; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Bernstein RM, 1996, P NATL ACAD SCI USA, V93, P9454, DOI 10.1073/pnas.93.18.9454; BETTINARDI A, 1992, J IMMUNOL METHODS, V146, P71, DOI 10.1016/0022-1759(92)90050-4; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; Bogue MA, 1997, IMMUNITY, V7, P37, DOI 10.1016/S1074-7613(00)80508-7; Brugnoni D, 1997, EUR J IMMUNOL, V27, P2765, DOI 10.1002/eji.1830271104; CAVAZZANACALVO M, 1993, J CLIN INVEST, V91, P1214, DOI 10.1172/JCI116282; Chilosi M, 1996, EUR J IMMUNOL, V26, P329, DOI 10.1002/eji.1830260209; Cortes P, 1996, P NATL ACAD SCI USA, V93, P14008, DOI 10.1073/pnas.93.24.14008; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DESAINTBASILE G, 1991, J CLIN INVEST, V87, P1352, DOI 10.1172/JCI115139; Difilippantonio MJ, 1996, CELL, V87, P253, DOI 10.1016/S0092-8674(00)81343-4; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; GOMEZ L, 1995, J PEDIATR-US, V127, P76, DOI 10.1016/S0022-3476(95)70260-1; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; GU Y, 1997, IMMUNITY, V7, P853; GUIDOS CJ, 1995, J EXP MED, V181, P1187, DOI 10.1084/jem.181.3.1187; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Harville TO, 1997, J CLIN IMMUNOL, V17, P322, DOI 10.1023/A:1027330800085; Hiom K, 1997, CELL, V88, P65, DOI 10.1016/S0092-8674(00)81859-0; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Imberti L, 1997, BLOOD, V89, P2822, DOI 10.1182/blood.V89.8.2822; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Leu TMJ, 1997, IMMUNITY, V7, P303, DOI 10.1016/S1074-7613(00)80532-4; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; Livak F, 1996, J EXP MED, V184, P419, DOI 10.1084/jem.184.2.419; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MACHE CJ, 1994, ANN HEMATOL, V69, P85, DOI 10.1007/BF01698488; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McMahan CJ, 1997, J IMMUNOL, V158, P2202; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Nagawa F, 1998, MOL CELL BIOL, V18, P655, DOI 10.1128/MCB.18.1.655; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OMENN GS, 1965, NEW ENGL J MED, V273, P427, DOI 10.1056/NEJM196508192730806; RAMSDEN DA, 1994, NUCLEIC ACIDS RES, V22, P1785, DOI 10.1093/nar/22.10.1785; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; ROLDAN EQ, 1995, IMMUNOGENETICS, V41, P91; Roman CAJ, 1996, P NATL ACAD SCI USA, V93, P2333, DOI 10.1073/pnas.93.6.2333; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; SANTAGATA S, 1998, IN PRESS J BIOL CHEM; SCHANDENE L, 1993, EUR J IMMUNOL, V23, P56, DOI 10.1002/eji.1830230110; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; SILVER DP, 1994, THESIS MIT CAMBRIDGE; Sottini A, 1996, HUM IMMUNOL, V48, P12, DOI 10.1016/0198-8859(96)00087-0; Spanopoulou E, 1995, IMMUNITY, V3, P715, DOI 10.1016/1074-7613(95)90061-6; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; WeisGarcia F, 1997, MOL CELL BIOL, V17, P6379, DOI 10.1128/MCB.17.11.6379; WEN L, 1994, NATURE, V369, P654, DOI 10.1038/369654a0; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	67	325	338	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					885	896		10.1016/S0092-8674(00)81448-8	http://dx.doi.org/10.1016/S0092-8674(00)81448-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630231	Bronze			2022-12-28	WOS:000073956700023
J	van den Bosch, HCM; Vos, LD				van den Bosch, HCM; Vos, LD			Achilles'-tendon xanthoma in familial hypercholesterolemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Catharina Hosp, NL-5623 EJ Eindhoven, Netherlands	Catharina Hospital	van den Bosch, HCM (corresponding author), Catharina Hosp, NL-5623 EJ Eindhoven, Netherlands.								0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1998	338	22					1591	1591		10.1056/NEJM199805283382205	http://dx.doi.org/10.1056/NEJM199805283382205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ350	9603797				2022-12-28	WOS:000073852400005
J	Hinuma, S; Habata, Y; Fujii, R; Kawamata, Y; Hosoya, N; Fukusumi, S; Kitada, C; Masuo, Y; Asano, T; Matsumoto, H; Sekiguchi, M; Kurokawa, T; Nishimura, O; Onda, H; Fujino, M				Hinuma, S; Habata, Y; Fujii, R; Kawamata, Y; Hosoya, N; Fukusumi, S; Kitada, C; Masuo, Y; Asano, T; Matsumoto, H; Sekiguchi, M; Kurokawa, T; Nishimura, O; Onda, H; Fujino, M			A prolactin-releasing peptide in the brain	NATURE			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; COUPLED RECEPTOR; PITUITARY-GLAND; GROWTH-HORMONE; CELL-LINE; RAT; SECRETION; CLONING; EXPRESSION; INVITRO	Hypothalamic peptide hormones regulate the secretion of most of the anterior pituitary hormones, that is, growth hormone, follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone and adrenocorticotropin(1,2). These peptides do not regulate the secretion of prolactin(1,2), at least in a specific manner, however. The peptides act through specific receptors, which are referred to as seven-transmembrane-domain receptors or G-protein-coupled receptors(3-7). Although prolactin is important in pregnancy and lactation in mammals, and is involved in the development of the mammary glands and the promotion of milk synthesis(8,9), a specific prolactin-releasing hormone has remained unknown. Here we identify a potent candidate for such a hormone. We first proposed that there may still be unknown peptide hormone factors that control pituitary function through seven-transmembrane-domain receptors. We isolated the complementary DNA encoding an 'orphan' receptor (that is, one for which the ligand is unknown). This receptor, hGR3, is specifically expressed in the human pituitary. We then searched for the hGR3 Ligand in the hypothalamus and identified a new peptide. which shares no sequence similarity with known peptides and proteins, as an endogenous ligand. We show that this ligand is a potent prolactin-releasing factor for rat anterior pituitary cells; we have therefore named this peptide prolactin-releasing peptide.	Takeda Chem Ind Ltd, Pharmaceut Discovery Res Div, Discovery Res Labs 1, Ibaraki, Osaka 3004293, Japan; Takeda Chem Ind Ltd, Div Pharmaceut Res, Ibaraki, Osaka 3004293, Japan; Takeda Chem Ind Ltd, Pharmaceut Dev Div, Ibaraki, Osaka 3004293, Japan	Takeda Chemical Industries; Takeda Chemical Industries; Takeda Chemical Industries	Hinuma, S (corresponding author), Takeda Chem Ind Ltd, Pharmaceut Discovery Res Div, Discovery Res Labs 1, 10 Wadai, Ibaraki, Osaka 3004293, Japan.	Hinuma_Shuji@takeda.co.jp		Kawamata, Yuji/0000-0001-5652-4899				CANONICO PL, 1983, NEUROENDOCRINOLOGY, V37, P212, DOI 10.1159/000123545; Chalmers DT, 1996, TRENDS PHARMACOL SCI, V17, P166, DOI 10.1016/0165-6147(96)81594-X; Cox KJA, 1997, J NEUROSCI, V17, P1197; DROUHAULT R, 1994, NEUROENDOCRINOLOGY, V60, P179, DOI 10.1159/000126749; Erfurth EM, 1996, HORM METAB RES, V28, P599, DOI 10.1055/s-2007-979861; FRANTZ AG, 1978, NEW ENGL J MED, V298, P201, DOI 10.1056/NEJM197801262980408; Hammond PJ, 1996, J NEUROENDOCRINOL, V8, P457, DOI 10.1046/j.1365-2826.1996.04747.x; HINUMA S, 1994, BBA-GENE STRUCT EXPR, V1219, P251, DOI 10.1016/0167-4781(94)90046-9; HURBAINKOSMATH I, 1990, IN VITRO CELL DEV B, V26, P431; HYDE JF, 1987, ENDOCRINOLOGY, V121, P1531, DOI 10.1210/endo-121-4-1531; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V189, P289, DOI 10.1016/0006-291X(92)91556-6; KOENIG JI, 1989, TOXICOL PATHOL, V17, P256, DOI 10.1177/019262338901700204; KOYAMA N, 1994, J BIOTECHNOL, V32, P273, DOI 10.1016/0168-1656(94)90213-5; LAMBERTS SWJ, 1990, PHYSIOL REV, V70, P279, DOI 10.1152/physrev.1990.70.2.279; MARCHESE A, 1995, GENOMICS, V29, P335, DOI 10.1006/geno.1995.9996; Mayo KE, 1996, ANN NY ACAD SCI, V805, P184, DOI 10.1111/j.1749-6632.1996.tb17483.x; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MIYAMOTO Y, 1994, BBA-GENE STRUCT EXPR, V1218, P297, DOI 10.1016/0167-4781(94)90181-3; NAKAGAWA S, 1994, J AM CHEM SOC, V116, P5513, DOI 10.1021/ja00091a083; PATEL YC, 1995, LIFE SCI, V57, P1249, DOI 10.1016/0024-3205(95)02082-T; REICHLIN S, 1989, TOXICOL PATHOL, V17, P250, DOI 10.1177/019262338901700203; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; RIVIER C, 1977, ENDOCRINOLOGY, V100, P751, DOI 10.1210/endo-100-3-751; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SAMSON WK, 1986, ENDOCRINOLOGY, V119, P554, DOI 10.1210/endo-119-2-554; SAMSON WK, 1980, PEPTIDES, V1, P325, DOI 10.1016/0196-9781(80)90010-8; SHIOTA K, 1984, ACTA ENDOCRINOL-COP, V106, P71, DOI 10.1530/acta.0.1060071; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WELCH SK, 1995, BIOCHEM BIOPH RES CO, V209, P606, DOI 10.1006/bbrc.1995.1543	29	482	525	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 21	1998	393	6682					272	276		10.1038/30515	http://dx.doi.org/10.1038/30515			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607765				2022-12-28	WOS:000073761000055
J	Wistuba, II; Behrens, C; Milchgrub, S; Virmani, AK; Jagirdar, J; Thomas, B; Ioachim, HL; Litzky, LA; Brambilla, EM; Minna, JD; Gazdar, AF				Wistuba, II; Behrens, C; Milchgrub, S; Virmani, AK; Jagirdar, J; Thomas, B; Ioachim, HL; Litzky, LA; Brambilla, EM; Minna, JD; Gazdar, AF			Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; IMMUNODEFICIENCY-VIRUS INFECTION; HUMAN PAPILLOMAVIRUS DNA; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; CHEST RADIOGRAPHS; CT SCANS; CARCINOMA; LESIONS; GENE	Context.-Human immunodeficiency virus (HIV) infection has been associated with an increasing incidence of malignancy, and HIV-infected persons have an increased incidence of primary lung carcinoma compared with the general population, Objective.-To investigate the molecular changes present in HIV-associated lung tumors and compare them with those present in lung carcinomas arising in HIV-indeterminate subjects ("sporadic tumors"). Design.-Convenience sample. Subjects.-Archival tissues from 11 HIV-positive persons and from 35 persons of indeterminate HIV status. Setting.-University-based medical centers and affiliated hospitals. Main Outcome Measures.-Analysis of frequency of loss of heterozygosity (LOH) and microsatellite alteration (MA) using polymerase chain reaction and 16 polymorphic microsatellite markers at 8 chromosomal regions frequently deleted in lung cancer. Presence of HIV and human papillomavirus (HPV) sequences. Results.-The overall frequency of LOH at all chromosomal regions tested and the frequencies at most of the individual regions were similar in the 2 groups, Frequency of MA present in the HIV-associated tumors (0.18) was 6-fold higher than in sporadic tumors (0.03) (P<.001). At least 1 MA was present in 10 (91%) of 11 HIV-associated tumors vs 17 (48%) of 35 sporadic tumors (P=.02). Molecular changes were independent of tumor stage and gender. HIV and HPV sequences were not detected in the HIV-associated lung carcinomas. Conclusions.-Microsatellite alterations, which reflect widespread genomic instability, occur at greatly increased frequency in HIV-associated lung carcinomas, Although the mechanism underlying the development of increased MAs is unknown, it may play a crucial role in the development of many HIV-associated tumors.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Pontificia Univ Catolica Chile, Dept Pathol, Santiago, Chile; Bellevue NYU, Med Ctr, New York, NY 10016 USA; Lenox Hill Hosp, New York, NY 10021 USA; Univ Penn, Med Ctr, Philadelphia, PA 19104 USA; Reg Hosp Ctr Michallon, Dept Cellular Pathol, Grenoble, France	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pontificia Universidad Catolica de Chile; Bellevue Hospital Center; Northwell Health; University of Pennsylvania	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, NB8-106,5323 Harry Hines Blvd, Dallas, TX 75235 USA.	gazdar@simmons.swmed.edu	Brambilla, Elisabeth MP/L-8796-2013		NATIONAL CANCER INSTITUTE [U01CA066531, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA70907, UO1-CA66531] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI J, 1995, GENE CHROMOSOME CANC, V14, P301, DOI 10.1002/gcc.2870140409; Baay MFD, 1996, J CLIN MICROBIOL, V34, P745, DOI 10.1128/JCM.34.3.745-747.1996; BEDI GC, 1995, NAT MED, V1, P65, DOI 10.1038/nm0195-65; Biggar RJ, 1996, HEMATOL ONCOL CLIN N, V10, P997, DOI 10.1016/S0889-8588(05)70380-4; Birch DE, 1996, NATURE, V381, P445, DOI 10.1038/381445a0; CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Dubrova YE, 1996, NATURE, V380, P683, DOI 10.1038/380683a0; FAN YJ, 1995, INT J RADIAT BIOL, V68, P177, DOI 10.1080/09553009514551081; FISHMAN JE, 1995, AM J ROENTGENOL, V164, P57, DOI 10.2214/ajr.164.1.7998569; FONG KM, 1995, CANCER RES, V55, P28; FRAIRE AE, 1992, CANCER-AM CANCER SOC, V70, P432, DOI 10.1002/1097-0142(19920715)70:2&lt;432::AID-CNCR2820700210&gt;3.0.CO;2-2; Gaidano G, 1997, HUM PATHOL, V28, P748, DOI 10.1016/S0046-8177(97)90187-8; Gaidano G, 1996, AIDS, V10, P941, DOI 10.1097/00002030-199610090-00003; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; Gleeson CM, 1996, CANCER RES, V56, P259; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Imai H, 1997, P NATL ACAD SCI USA, V94, P10817, DOI 10.1073/pnas.94.20.10817; IRWIN LE, 1984, ANN INTERN MED, V100, P158, DOI 10.7326/0003-4819-100-1-158_2; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KARP J, 1993, CHEST, V103, P410, DOI 10.1378/chest.103.2.410; KISHIMOTO Y, 1995, JNCI-J NATL CANCER I, V87, P1224, DOI 10.1093/jnci/87.16.1224; Knowles DM, 1996, HEMATOL ONCOL CLIN N, V10, P1081, DOI 10.1016/S0889-8588(05)70386-5; KNUDSON AG, 1989, BRIT J CANCER, V59, P661, DOI 10.1038/bjc.1989.137; KOSARY CL, 1995, NIH PUBLICATION; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LOEB LA, 1994, CANCER RES, V54, P5059; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MERLO A, 1994, CANCER RES, V54, P2098; MILES SA, 1996, HEMATOL ONCOL CLIN N, V10, P1013; Minna John D., 1997, P849; Miozzo M, 1996, CANCER RES, V56, P2285; ORLOW I, 1994, CANCER RES, V54, P2848; Parker MS, 1998, CHEST, V113, P154, DOI 10.1378/chest.113.1.154; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PARKIN DM, 1994, INT J CANCER, V59, P494, DOI 10.1002/ijc.2910590411; PETERSCHMITT AM, 1994, CLIN INFECT DIS, V19, P1178, DOI 10.1093/clinids/19.6.1178; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Remick SC, 1996, HEMATOL ONCOL CLIN N, V10, P1203, DOI 10.1016/S0889-8588(05)70394-4; Sekine I, 1997, JPN J CANCER RES, V88, P559, DOI 10.1111/j.1349-7006.1997.tb00419.x; SHIBATA D, 1997, AM J PATHOL, V151, P648; SRIDHAR KS, 1992, CHEST, V102, P1704, DOI 10.1378/chest.102.6.1704; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBERVILLE L, 1995, CANCER RES, V55, P5133; Thomas P, 1995, CELL MOL BIOL, V41, P1093; TOGUCHIDA J, 1993, GENOMICS, V17, P535, DOI 10.1006/geno.1993.1368; VACCHER E, 1993, ANN ONCOL, V4, P85, DOI 10.1093/oxfordjournals.annonc.a058371; Warren ST, 1996, SCIENCE, V271, P1374, DOI 10.1126/science.271.5254.1374; WEBER JL, 1989, AM J HUM GENET, V44, P388; WHITE CS, 1995, AM J ROENTGENOL, V164, P593, DOI 10.2214/ajr.164.3.7863877; Wistuba II, 1997, CANCER RES, V57, P3154; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366; Yamamoto Y, 1996, HUM PATHOL, V27, P1204, DOI 10.1016/S0046-8177(96)90316-0	55	107	111	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1554	1559		10.1001/jama.279.19.1554	http://dx.doi.org/10.1001/jama.279.19.1554			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN087	9605900	Bronze			2022-12-28	WOS:000073608100034
J	Kinzler, KW; Vogelstein, B				Kinzler, KW; Vogelstein, B			Landscaping the cancer terrain	SCIENCE			English	Article							COMPONENT		Johns Hopkins Oncol Ctr, Mol Genet Lab, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Kinzler, KW (corresponding author), Johns Hopkins Oncol Ctr, Mol Genet Lab, Baltimore, MD 21231 USA.		Califano, Andrea/F-7239-2012					Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; FLETCHER JA, 1992, GENE CHROMOSOME CANC, V5, P260, DOI 10.1002/gcc.2870050315; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Jacoby RF, 1997, GASTROENTEROLOGY, V112, P1398, DOI 10.1016/S0016-5085(97)70156-2; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Olschwang S, 1998, NAT GENET, V18, P12, DOI 10.1038/ng0198-12; SHIBATA D, 1993, J NATL CANCER I, V85, P1058, DOI 10.1093/jnci/85.13.1058; VANNI R, 1995, CANCER RES, V55, P31; Wang SI, 1997, CANCER RES, V57, P4183	12	362	378	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1036	1037		10.1126/science.280.5366.1036	http://dx.doi.org/10.1126/science.280.5366.1036			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9616081				2022-12-28	WOS:000073663600035
J	Reichardt, HM; Kaestner, KH; Tuckermann, J; Kretz, O; Wessely, O; Bock, R; Gass, P; Schmid, W; Herrlich, P; Angel, P; Schutz, G				Reichardt, HM; Kaestner, KH; Tuckermann, J; Kretz, O; Wessely, O; Bock, R; Gass, P; Schmid, W; Herrlich, P; Angel, P; Schutz, G			DNA binding of the glucocorticoid receptor is not essential for survival	CELL			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTORS; RESPONSE ELEMENT; FUNCTIONAL ANTAGONISM; THYMOCYTE APOPTOSIS; PROTEIN-INTERACTION; POSSIBLE MECHANISM; GENE-EXPRESSION; MESSENGER-RNA; C-JUN	Transcriptional regulation by the glucocorticoid receptor (GR) is essential for survival. Since the GR can influence transcription both through DNA-binding-dependent and -independent mechanisms, we attempted to assess their relative importance in vivo. In order to separate these modes of action, we introduced the point mutation A458T into the GR by gene targeting using the Cre/loxP system. This mutation impairs dimerization and therefore GRE-dependent transactivation while functions that require cross-talk with other transcription factors, such as transrepression of AP-1-driven genes, remain intact. In contrast to GR(-/-) mice, these mutants termed GR(dim) are viable, revealing the in vivo relevance of DNA-binding-independent activities of the GR.	German Canc Res Ctr, Div Mol Biol Cell 1, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany; Univ Saarland, Inst Anat, D-66421 Homburg, Germany; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Saarland University; Helmholtz Association; Karlsruhe Institute of Technology	Schutz, G (corresponding author), German Canc Res Ctr, Div Mol Biol Cell 1, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Reichardt, Holger/AAF-3048-2020; Piris, Miguel A/AAP-1445-2020	Reichardt, Holger/0000-0003-4647-057X; Piris, Miguel A/0000-0001-5839-3634; Kretz, Oliver/0000-0003-1152-5956				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BIRNBERG NC, 1983, P NATL ACAD SCI-BIOL, V80, P6982, DOI 10.1073/pnas.80.22.6982; BOCK R, 1991, ACTA HISTOCHEM, V91, P201, DOI 10.1016/S0065-1281(11)80277-1; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; GACK S, 1994, J BIOL CHEM, V269, P10363; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; IMAI E, 1993, J BIOL CHEM, V268, P5353; JIANG W, 1989, INT J DEV NEUROSCI, V7, P513, DOI 10.1016/0736-5748(89)90010-5; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Murphy EP, 1997, MOL ENDOCRINOL, V11, P39, DOI 10.1210/me.11.1.39; NAZARETH LV, 1991, J BIOL CHEM, V266, P12976; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NITSCH D, 1990, MOL CELL BIOL, V10, P3334, DOI 10.1128/MCB.10.7.3334; OEHLER T, 1992, MOL CELL BIOL, V12, P5508, DOI 10.1128/MCB.12.12.5508; Phillips A, 1997, MOL CELL BIOL, V17, P5952, DOI 10.1128/MCB.17.10.5952; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reichardt HM, 1996, MOL MED, V2, P735, DOI 10.1007/BF03401657; ROSS ME, 1990, J NEUROSCI, V10, P520; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEASHOLTZ AF, 1988, MOL ENDOCRINOL, V2, P1311, DOI 10.1210/mend-2-12-1311; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; Wilkinson DG, 1992, SITU HYBRIDIZATION P; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	48	871	920	1	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1998	93	4					531	541		10.1016/S0092-8674(00)81183-6	http://dx.doi.org/10.1016/S0092-8674(00)81183-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604929	hybrid			2022-12-28	WOS:000073722200007
J	Thomas, MJ; Platas, AA; Hawley, DK				Thomas, MJ; Platas, AA; Hawley, DK			Transcriptional fidelity and proofreading by RNA polymerase II	CELL			English	Article							DNA-REPLICATION FIDELITY; ELONGATION-FACTOR TFIIS; SACCHAROMYCES-CEREVISIAE; KINETIC MECHANISM; FACTOR-SII; CLEAVAGE; COMPLEXES; SITES; TERMINATION; EXONUCLEASE	We have addressed whether the intrinsic 3'-->15' nuclease activity of human RNA polymerase II (pol II) can proofread during transcription in vitro. In the presence of SII, a protein that stimulates the nuclease activity, pol II quantitatively removed misincorporated nucleotides from the nascent transcript during rapid chain extension. The basis of discrimination between the correct and incorrect base was the slow addition of the next nucleotide to the mismatched terminus. Incorporation of inosine monophosphate inhibited next nucleotide addition by a similar magnitude as a mismatched base. We used this finding to demonstrate that addition of SII to a transcription reaction dramatically altered the RNA base content, reflecting the stable incorporation of more "correct" (GMP) and fewer "incorrect" (IMP) nucleotides.	Univ Oregon, Inst Mol Biol, Dept Chem, Eugene, OR 97403 USA; Univ Oregon, Inst Mol Biol, Dept Biol, Eugene, OR 97403 USA	University of Oregon; University of Oregon	Hawley, DK (corresponding author), Univ Oregon, Inst Mol Biol, Dept Chem, Eugene, OR 97403 USA.							ABBOTTS J, 1988, J BIOL CHEM, V263, P15094; ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; CHAMBERLIN M, 1974, ENZYMES, P333; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; Jeon C, 1996, P NATL ACAD SCI USA, V93, P13677, DOI 10.1073/pnas.93.24.13677; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; KAHN JD, 1989, J MOL BIOL, V205, P291, DOI 10.1016/0022-2836(89)90342-2; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KIRKWOOD TBL, 1986, ACCURACY MOL PROCESS; KOHALMI SE, 1991, J MOL BIOL, V220, P933, DOI 10.1016/0022-2836(91)90364-C; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; LIBBY RT, 1991, MOL MICROBIOL, V5, P999, DOI 10.1111/j.1365-2958.1991.tb01872.x; LO KY, 1976, J BIOL CHEM, V251, P2480; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; NAKANISHI Y, 1981, FEBS LETT, V130, P69, DOI 10.1016/0014-5793(81)80667-9; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; Shilatifard A, 1997, CURR OPIN GENET DEV, V7, P199, DOI 10.1016/S0959-437X(97)80129-3; TAMURA H, 1980, J BIOCHEM-TOKYO, V88, P1475, DOI 10.1093/oxfordjournals.jbchem.a133117; Umehara T, 1997, J BIOCHEM-TOKYO, V121, P598, DOI 10.1093/oxfordjournals.jbchem.a021627; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WIEST DK, 1992, J BIOL CHEM, V267, P7733; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	45	199	202	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					627	637		10.1016/S0092-8674(00)81191-5	http://dx.doi.org/10.1016/S0092-8674(00)81191-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604937	Bronze			2022-12-28	WOS:000073722200015
J	Shekelle, PG; Kahan, JP; Bernstein, SJ; Leape, LL; Kamberg, CJ; Park, RE				Shekelle, PG; Kahan, JP; Bernstein, SJ; Leape, LL; Kamberg, CJ; Park, RE			The reproducibility of a method to identify the overuse and underuse of medical procedures	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEW-YORK-STATE; COST-EFFECTIVENESS; CORONARY-ANGIOGRAPHY; MYOCARDIAL-INFARCTION; APPROPRIATENESS; HYSTERECTOMY; VARIABILITY; TRIALS; CARE; AGREEMENT	Background To assess the overuse and underuse of medical procedures, various methods have been developed, but their reproducibility has not been evaluated. This study estimates the reproducibility of one commonly used method. Methods We performed a parallel, three-way replication of the RAND-University of California at Los Angeles appropriateness method as applied to two medical procedures, coronary revascularization and hysterectomy. Three nine-member multidisciplinary panels of experts were composed for each procedure by stratified random sampling from a list of experts nominated by the relevant specialty societies. Each panel independently rated the same set of clinical scenarios in terms of the appropriateness of the relevant procedure on a risk-benefit scale ranging from 1 to 9. Final ratings were used to classify the procedure in each scenario as necessary or not necessary (to evaluate underuse) and inappropriate or not inappropriate (to evaluate overuse). Reproducibility was measured by overall agreement and by the kappa statistic. The criteria for underuse and overuse derived from these ratings were then applied to real populations of patients who had undergone coronary revascularization or hysterectomy. Results The rates of agreement among the three coronary-revascularization panels were 95, 94, and 96 percent for inappropriate-use scenarios and 93, 92, and 92 percent for necessary-use scenarios. Agreement among the three hysterectomy panels was 88, 70, and 74 percent for inappropriate-use scenarios. Scenarios involving necessary use of hysterectomy were not assessed. The three-way kappa statistic to detect overuse was 0.52 for coronary revascularization and 0.51 for hysterectomy. The three-way kappa statistic to detect underuse of coronary revascularization was 0.83. Application of individual panels' criteria to real populations of patients resulted in a 100 percent variation in the proportion of cases classified as inappropriate and a 20 percent variation in the proportion of cases classified as necessary. Conclusions The appropriateness method is far from perfect. Appropriateness criteria may be useful in comparing levels of appropriate procedures among populations but should not by themselves be used to direct care for individual patients. (N Engl J Med 1998; 338:1888-95.) (C) 1998, Massachusetts Medical Society.	Rand Corp, Santa Monica, CA 90407 USA; W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA; Vet Affairs Med Ctr, Ann Arbor, MI USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Hlth Management & policy, Ann Arbor, MI 48109 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Harvard T.H. Chan School of Public Health	Shekelle, PG (corresponding author), Rand Corp, 1700 Main St,POB 2138, Santa Monica, CA 90407 USA.		Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213	AHRQ HHS [HSO7185-02] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ATWOOD JE, 1981, CIRCULATION, V64, P601, DOI 10.1161/01.CIR.64.3.601; BENGTSON A, 1994, JAMA-J AM MED ASSOC, V271, P1260, DOI 10.1001/jama.271.16.1260; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P2398, DOI 10.1001/jama.269.18.2398; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; BIRKMEYER JD, 1994, ANN THORAC SURG, V57, P161, DOI 10.1016/0003-4975(94)90386-7; BORZAK S, 1995, ANN INTERN MED, V123, P873, DOI 10.7326/0003-4819-123-11-199512010-00010; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; Cappelleri JC, 1996, JAMA-J AM MED ASSOC, V276, P1332, DOI 10.1001/jama.276.16.1332; CARLSON KJ, 1993, NEW ENGL J MED, V328, P856; CHALMERS TC, 1987, STAT MED, V6, P733, DOI 10.1002/sim.4780060704; COLICE GL, 1990, ARCH INTERN MED, V150, P2517, DOI 10.1001/archinte.150.12.2517; DEROUEN TA, 1977, CIRCULATION, V55, P324, DOI 10.1161/01.CIR.55.2.324; Dubinsky M, 1990, Int J Technol Assess Health Care, V6, P480; ELMORE JG, 1994, NEW ENGL J MED, V331, P1493, DOI 10.1056/NEJM199412013312206; ETCHASON J, 1995, NEW ENGL J MED, V332, P719, DOI 10.1056/NEJM199503163321106; FINK A, 1987, WESTERN J MED, V147, P609; GOODNOUGH LT, 1994, UROLOGY, V44, P226; GRAY D, 1990, LANCET, V335, P137; HAAS S, 1993, AM J OBSTET GYNECOL, V169, P150, DOI 10.1016/0002-9378(93)90152-9; HICKS NR, 1994, BRIT MED J, V309, P730, DOI 10.1136/bmj.309.6956.730; Institute of Medicine, 1985, ASS MED TECHN; ISMAIL SM, 1989, BRIT MED J, V298, P707, DOI 10.1136/bmj.298.6675.707; KAHAN JP, 1994, MED CARE, V32, P357, DOI 10.1097/00005650-199404000-00004; KATO I, 1995, J CLIN EPIDEMIOL, V48, P1167, DOI 10.1016/0895-4356(94)00242-I; KATTAN MW, 1995, MED DECIS MAKING, V15, P429; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; *NY STAT STAT DEP, 1988, HYST NEW YORK STAT S, P1; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; ROOS NP, 1984, AM J PUBLIC HEALTH, V74, P327, DOI 10.2105/AJPH.74.4.327; RUTKOW IM, 1979, ANN SURG, V190, P409, DOI 10.1097/00000658-197909000-00017; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; SONNENBERG FA, 1995, MED DECIS MAKING, V15, P428; WACKERS FJT, 1993, J AM COLL CARDIOL, V21, P1064, DOI 10.1016/0735-1097(93)90226-Q	36	296	300	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1998	338	26					1888	1895		10.1056/NEJM199806253382607	http://dx.doi.org/10.1056/NEJM199806253382607			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV898	9637810				2022-12-28	WOS:000074352800007
J	McWhinney, IR				McWhinney, IR			Primary care: core values - Core values in a changing world	BRITISH MEDICAL JOURNAL			English	Article							ORIENTED PRIMARY CARE; GENERAL-PRACTITIONERS; COMMUNITY		Univ Western Ontario, Ctr Studies Family Med, Dept Family Med, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	McWhinney, IR (corresponding author), Univ Western Ontario, Ctr Studies Family Med, Dept Family Med, London, ON N6A 5C1, Canada.							Brown JB, 1997, CAN FAM PHYSICIAN, V43, P901; Carmichael LP, 1997, AM FAM PHYSICIAN, V56, P713; Dostoevsky Fyodor, 1958, BROTHERS KARAMAZOV; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; HART JT, 1970, LANCET, V2, P223; HJORTDAHL P, 1992, FAM PRACT, V9, P3, DOI 10.1093/fampra/9.1.3; *I MED, 1978, IOM PUBL, V7302; MacIntyre A., 1981, AFTER VIRTUE; MAY WF, 1983, PHYSICIANS COVENANT; MCCORMICK J, 1994, LANCET, V344, P390; Nutting P A, 1986, Am J Prev Med, V2, P140; NUTTING PA, 1986, AM J PUBLIC HEALTH, V76, P279, DOI 10.2105/AJPH.76.3.279; SALTMAN DC, 1995, MED J AUSTRALIA, V162, P3, DOI 10.5694/j.1326-5377.1995.tb138397.x; SMITH LFP, 1994, J MED ETHICS, V20, P175, DOI 10.1136/jme.20.3.175; Stewart M., 1995, PATIENT CTR MED PATIENT CTR MED; VEALE BM, 1996, THESIS AUSTR NATL U; WHITE KL, 1987, INT CLASSIFICATION P; Wilber K., 1995, SEX ECOLOGY SPIRITUA; World Health Organisation, 1978, ALM 1978 PRIM HLTH C; WRIGHT RA, 1993, JAMA-J AM MED ASSOC, V269, P2544, DOI 10.1001/jama.269.19.2544	21	89	89	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1807	1809		10.1136/bmj.316.7147.1807	http://dx.doi.org/10.1136/bmj.316.7147.1807			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624075	Green Published			2022-12-28	WOS:000074286300032
J	Zou, YR; Kottmann, AH; Kuroda, M; Taniuchi, I; Littman, DR				Zou, YR; Kottmann, AH; Kuroda, M; Taniuchi, I; Littman, DR			Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development	NATURE			English	Article							NERVOUS-SYSTEM; BONE-MARROW; LYMPHOCYTE CHEMOATTRACTANT; HIV-1 ENTRY; CELL-LINE; SDF-1; LESTR/FUSIN; EXPRESSION; MIGRATION; LIGAND	Chemokines and their receptors are important in cell migration during inflammation(1), in the establishment of functional lymphoid microenvironments(2), and in organogenesis(3). The chemokine receptor CXCR4 is broadly expressed in cells of both the immune and the central nervous systems(4,5) and can mediate migration of resting leukocytes and haematopoietic progenitors in response to its ligand, SDF-1 (refs 6-9). CXCR4 is also a major receptor for strains of human immunodeficiency virus-1 (HIV-1) that arise during progression to immunodeficiency and AIDS dementia(10). Here we show that mice lacking CXCR4 exhibit haematopoietic and cardiac defects identical to those of SDF-1-deficient mice(3), indicating that CXCR4 may be the only receptor for SDF-1. Furthermore, fetal cerebellar development in mutant animals is markedly different from that in wild-type animals, with many proliferating granule cells invading the cerebellar anlage. This is, to our knowledge, the first demonstration df the involvement of a G-protein-coupled chemokine receptor in neuronal cell migration and patterning in the central nervous system. These results may be important for designing strategies to block HIV entry into cells and for understanding mechanisms of pathogenesis in AIDS dementia.	NYU, Med Ctr, Div Mol Pathogenesis, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst Biomol Med, Howard Hughes Med Inst, New York, NY 10016 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA	New York University; Howard Hughes Medical Institute; New York University; Columbia University	Zou, YR (corresponding author), NYU, Med Ctr, Div Mol Pathogenesis, New York, NY 10016 USA.	zou@saturn.med.nyu.edu	Taniuchi, Ichiro/N-6399-2015; Kottmann, Andreas/Y-1180-2019	Taniuchi, Ichiro/0000-0002-9853-9068; Kottmann, Andreas/0000-0002-5435-7502				Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Delassus S, 1996, IMMUNITY, V4, P97, DOI 10.1016/S1074-7613(00)80302-7; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Drescher U, 1997, CURR OPIN NEUROBIOL, V7, P75, DOI 10.1016/S0959-4388(97)80123-7; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hatten M E, 1993, Curr Opin Neurobiol, V3, P38, DOI 10.1016/0959-4388(93)90033-U; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; Jazin EE, 1997, J NEUROIMMUNOL, V79, P148, DOI 10.1016/S0165-5728(97)00117-3; LANDRETH KS, 1988, J IMMUNOL, V140, P845; Moepps B, 1997, EUR J IMMUNOL, V27, P2102, DOI 10.1002/eji.1830270839; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0	29	2010	2116	2	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					595	599		10.1038/31269	http://dx.doi.org/10.1038/31269			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634238				2022-12-28	WOS:000074150100057
J	Boardman, LA; Thibodeau, SN; Schaid, DJ; Lindor, NM; McDonnell, SK; Burgart, LJ; Ahlquist, DA; Podratz, KC; Pittelkow, M; Hartmann, LC				Boardman, LA; Thibodeau, SN; Schaid, DJ; Lindor, NM; McDonnell, SK; Burgart, LJ; Ahlquist, DA; Podratz, KC; Pittelkow, M; Hartmann, LC			Increased risk for cancer in patients with the Peutz-Jeghers syndrome	ANNALS OF INTERNAL MEDICINE			English	Article						Peutz-Jeghers syndrome; genital neoplasms, female; breast neoplasms; gastrointestinal neoplasms; risk	SEX CORD TUMOR; ANNULAR TUBULES; POLYPOSIS SYNDROMES; ADENOMA-MALIGNUM	Background: Some reports describe an increased risk for cancer in patients with the Peutz-Jeghers syndrome. Objective: To characterize occurrences of cancer in a large cohort of patients with the Peutz-Jeghers syndrome. Design: Retrospective cohort study. Setting: Tertiary care center. Patients: 34 patients with the Peutz-Jeghers syndrome identified from Mayo Clinic records from 1945 to 1996. Measurements: Cases of cancer documented by chart review and telephone follow-up. Results: 26 cases of noncutaneous cancer developed in 18 of the 34 patients: 10 cases of gastrointestinal cancer and 16 cases of extraintestinal cancer. With the use of SEER (Surveillance, Epidemiology, and End Results) data for comparison, the relative risk for cancer was 18.5 (95% CI, 8.5 to 35.2) in women with the Peutz-Jeghers syndrome and 6.2 (CI, 2.5 to 12.8) in men with the syndrome (P = 0.001). In women, the relative risk for breast and gynecologic cancer was 20.3 (CI, 7.4 to 44.2). Conclusions: The Peutz-Jeghers syndrome is associated with an increased risk for cancer. The relative risk for breast and gynecologic cancers is particularly high.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Mayo Clinic	Hartmann, LC (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.			McDonnell, Shannon/0000-0001-6201-369X				Amos CI, 1997, CANCER RES, V57, P3653; CANTU JM, 1980, CANCER, V46, P223, DOI 10.1002/1097-0142(19800701)46:1<223::AID-CNCR2820460137>3.0.CO;2-8; COBURN MC, 1995, ANN SURG ONCOL, V2, P386, DOI 10.1007/BF02306370; COHEN PR, 1991, AM J MED, V90, P606; DOZOIS RR, 1969, ARCH SURG-CHICAGO, V98, P509; DUBOIS RS, 1982, J PEDIATR-US, V101, P568, DOI 10.1016/S0022-3476(82)80705-1; FINAN MC, 1989, DERMATOL CLIN, V7, P419, DOI 10.1016/S0733-8635(18)30575-8; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Gilchrist DM, 1997, CAN J GASTROENTEROL, V11, P421, DOI 10.1155/1997/859106; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; LINOS DA, 1981, ARCH SURG-CHICAGO, V116, P1182; Lynch HT, 1996, CANCER, V78, P1149, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.3.CO;2-Q; NUSS DD, 1978, ARCH DERMATOL, V114, P743, DOI 10.1001/archderm.114.5.743; *SEER PROGR, 1993, NIH PUB; SPIGELMAN AD, 1989, GUT, V30, P1588, DOI 10.1136/gut.30.11.1588; SRIVATSA PJ, 1994, GYNECOL ONCOL, V53, P256, DOI 10.1006/gyno.1994.1127; YOUNG RH, 1982, CANCER, V50, P1384, DOI 10.1002/1097-0142(19821001)50:7<1384::AID-CNCR2820500726>3.0.CO;2-5	20	285	303	3	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					896	+		10.7326/0003-4819-128-11-199806010-00004	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634427				2022-12-28	WOS:000073808600003
J	Anderson, GB; Seidel, GE				Anderson, GB; Seidel, GE			Developmental biology - Cloning for profit	SCIENCE			English	Article							SHEEP EMBRYOS; NUCLEAR TRANSPLANTATION; INVIVO		Univ Calif Davis, Dept Anim Sci, Livermore, CA 95616 USA; Colorado State Univ, Anim Reprod & Biotechnol Lab, Ft Collins, CO 80523 USA	University of California System; University of California Davis; Colorado State University	Anderson, GB (corresponding author), Univ Calif Davis, Dept Anim Sci, Livermore, CA 95616 USA.		Seidel, George/AAE-2371-2019					Butler D, 1998, NATURE, V392, P113, DOI 10.1038/32238; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Seidel G. E. Jr., 1997, Theriogenology, V47, P236, DOI 10.1016/S0093-691X(97)82363-1; SMITH LC, 1989, BIOL REPROD, V40, P1027, DOI 10.1095/biolreprod40.5.1027; SZELL A, 1991, THERIOGENOLOGY, V36, P379, DOI 10.1016/0093-691X(91)90466-Q; Vignon X, 1998, THERIOGENOLOGY, V49, P392, DOI 10.1016/S0093-691X(98)90745-2; Wells DN, 1997, BIOL REPROD, V57, P385, DOI 10.1095/biolreprod57.2.385; WILLADSEN SM, 1986, NATURE, V320, P63, DOI 10.1038/320063a0; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	11	13	15	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 29	1998	280	5368					1400	1401		10.1126/science.280.5368.1400	http://dx.doi.org/10.1126/science.280.5368.1400			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9634416				2022-12-28	WOS:000073883400044
J	Chalmers, R; Guhathakurta, A; Benjamin, H; Kleckner, N				Chalmers, R; Guhathakurta, A; Benjamin, H; Kleckner, N			IHF modulation of Tn10 transposition: Sensory transduction of supercoiling status via a proposed protein/DNA molecular spring	CELL			English	Article							SITE-SPECIFIC RECOMBINATION; DNA; INVIVO; FAVOR	Architectural protein IHF modulates Tn10 transposition in vitro. IHF stimulates transposon excision. Also, separately, IHF forces transposon end/target DNA interactions into a constrained pathway, "channeling," that yields only unknotted intratransposon inversion circles. Negative supercoiling influences both effects, differently. We infer that IHF is an architectural catalyst: it promotes initial transpososome assembly and is then ejected from the transpososome. IHF then rebinds, altering transpososome conformation to promote channeling. We also infer that the developing transpososome is a molecular spring: DNA provides basic elasticity; a conformational change in transposase provides force; and IHF and/or supercoiling provide conformational inputs. In vivo, IHF is a sensory transducer of chromosomal supercoiling status: with supercoiling absent, IHF is "supercoiling relief factor"; with supercoiling present, stimulation and channeling comprise a homeostatic pair such that modest changes in chromosome condition strongly influence transpositional outcome.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Chalmers, R (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.			chalmers, ronald/0000-0002-1395-7173	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025326] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37-GM25326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; Benjamin KR, 1996, J MOL BIOL, V256, P50, DOI 10.1006/jmbi.1996.0067; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; Carmona M, 1997, P NATL ACAD SCI USA, V94, P9568, DOI 10.1073/pnas.94.18.9568; CASSLER MR, 1995, EMBO J, V14, P5833, DOI 10.1002/j.1460-2075.1995.tb00271.x; Chalmers RM, 1996, EMBO J, V15, P5112, DOI 10.1002/j.1460-2075.1996.tb00892.x; HUISMAN O, 1989, EMBO J, V8, P211; Johnson RC, 1991, CURR OPIN GENET DEV, V1, P404, DOI 10.1016/S0959-437X(05)80307-7; KLECKNER N, 1990, GENETICS, V124, P449; Kleckner N, 1996, CURR TOP MICROBIOL, V204, P49; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; LEE MS, 1997, P ANTL ACAD SCI US, V91, P9823; MIZUUCHI M, 1995, CELL, V83, P375, DOI 10.1016/0092-8674(95)90115-9; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; MOSKOWITZ IPG, 1991, GENE DEV, V5, P1635, DOI 10.1101/gad.5.9.1635; Nash Howard A., 1996, P149; PETTIJOHN DE, 1980, P NATL ACAD SCI-BIOL, V77, P1331, DOI 10.1073/pnas.77.3.1331; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; Sakai J, 1997, CELL, V89, P205, DOI 10.1016/S0092-8674(00)80200-7; SAKAI J, 1995, EMBO J, V14, P4374, DOI 10.1002/j.1460-2075.1995.tb00112.x; SAKAI J, 1996, THESIS HARVARD U CAM; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SIGNON L, 1995, GENE DEV, V9, P1123, DOI 10.1101/gad.9.9.1123; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; WANG ZG, 1994, P NATL ACAD SCI USA, V91, P699, DOI 10.1073/pnas.91.2.699; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x	28	94	94	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					897	908		10.1016/S0092-8674(00)81449-X	http://dx.doi.org/10.1016/S0092-8674(00)81449-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630232	Bronze			2022-12-28	WOS:000073956700024
J	Grindstaff, KK; Yeaman, C; Anandasabapathy, N; Hsu, SC; Rodriguez-Boulan, E; Scheller, RH; Nelson, WJ				Grindstaff, KK; Yeaman, C; Anandasabapathy, N; Hsu, SC; Rodriguez-Boulan, E; Scheller, RH; Nelson, WJ			Sec6/8 complex is recruited to cell-cell contacts and specifies transport vesicle delivery to the basal-lateral membrane in epithelial cells	CELL			English	Article							CANINE KIDNEY-CELLS; GTP-BINDING-PROTEIN; PLASMA-MEMBRANE; NONPOLARIZED CELLS; TIGHT JUNCTION; SEC15 PROTEIN; MDCK CELLS; POLARITY; YEAST; SURFACE	In budding yeast, the Sec6/8p complex is essential for generating cell polarity by specifying vesicle delivery to the bud tip. We show that Sec6/8 homologs are components of a cytosolic, similar to 17S complex in nonpolarized MDCK epithelial cells. Upon initiation of calcium-dependent cell-cell adhesion, similar to 70% of Sec6/8 is rapidly (t(1/2) = 3-6 hr) recruited to sites of cell-cell contact. In streptolysin-O-permeabilized MDCK cells, Sec8 antibodies inhibit delivery of LDL receptor to the basal-lateral membrane, but not p75(NTR) to the apical membrane. These results indicate that lateral membrane recruitment of the Sec6/8 complex is a consequence of cell-cell adhesion and is essential for the biogenesis of epithelial cell surface polarity.	Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Cornell Univ, Coll Med, Dyson Vis Res Inst, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Cell Biol & Anat, New York, NY 10021 USA	Stanford University; Howard Hughes Medical Institute; Stanford University; Cornell University; Dyson; Cornell University	Nelson, WJ (corresponding author), Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA.		Yeaman, Charles A/A-1624-2009	Yeaman, Charles/0000-0001-6149-628X; Anandasabapathy, Niroshana/0000-0002-0473-8358	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035527, R37GM035527, R01GM034107] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09368] Funding Source: Medline; NIGMS NIH HHS [GM34107, R01 GM034107, GM35527] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Finger FP, 1997, MOL BIOL CELL, V8, P647, DOI 10.1091/mbc.8.4.647; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; Grindstaff KK, 1998, MOL BIOL CELL, V9, P685, DOI 10.1091/mbc.9.3.685; Hazuka CD, 1997, GENE, V187, P67, DOI 10.1016/S0378-1119(96)00720-2; Herskowitz I, 1995, COLD SPRING HARB SYM, V60, P717, DOI 10.1101/SQB.1995.060.01.078; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LOUVARD D, 1980, P NATL ACAD SCI-BIOL, V77, P4132, DOI 10.1073/pnas.77.7.4132; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; PASDAR M, 1989, J CELL BIOL, V109, P163, DOI 10.1083/jcb.109.1.163; Pringle JR, 1995, COLD SPRING HARB SYM, V60, P729, DOI 10.1101/SQB.1995.060.01.079; SALMINEN A, 1989, J CELL BIOL, V109, P1023, DOI 10.1083/jcb.109.3.1023; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHELLER RH, 1995, NEURON, V14, P893; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; TING AE, 1995, P NATL ACAD SCI USA, V92, P9613, DOI 10.1073/pnas.92.21.9613; VEGASALAS DE, 1987, J CELL BIOL, V104, P905, DOI 10.1083/jcb.104.4.905; VESTWEBER D, 1984, EXP CELL RES, V152, P169, DOI 10.1016/0014-4827(84)90241-6; WANG AZ, 1990, J CELL SCI, V95, P137; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; WOLLNER DA, 1992, J CELL BIOL, V116, P889, DOI 10.1083/jcb.116.4.889; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101	39	424	430	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					731	740		10.1016/S0092-8674(00)81435-X	http://dx.doi.org/10.1016/S0092-8674(00)81435-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630218	hybrid			2022-12-28	WOS:000073956700010
J	Anthony, RG; Waldin, TR; Ray, JA; Bright, SWJ; Hussey, PJ				Anthony, RG; Waldin, TR; Ray, JA; Bright, SWJ; Hussey, PJ			Herbicide resistance caused by spontaneous mutation of the cytoskeletal protein tubulin	NATURE			English	Article							DINITROANILINE HERBICIDES; ELEUSINE-INDICA; GENE FAMILY; ZEA-MAYS; PLANTS; INVITRO; CELLS	The dinitroaniline herbicides (such as trifluralin and oryzalin) have been developed for the selective control of weeds in arable crops. However, prolonged use of these chemicals has resulted in the selection of resistant biotypes of goosegrass, a major weed. These herbicides bind to the plant tubulin protein but not to mammalian tubulin(1). Here we show that the major alpha-tubulin gene of the resistant biotype has three base changes within the coding sequence. These base changes swap cytosine and thymine, most likely as the result of the spontaneous deamination of methylated cytosine. One of these base changes causes an amino-acid change in the protein: normal threonine at position 239 is changed to isoleucine. This position is dose to the site of interaction between tubulin dimers in the microtubule protofilament. We show that the mutated gene is the cause of the herbicide resistance by using it to transform maize and confer resistance to dinitroaniline herbicides. Our results provide a molecular explanation for the resistance of goosegrass to dinitroanaline herbicides, a phenomenon that has arisen, and been selected for, as a result of repeated exposure to this class of herbicide.	Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England; Zeneca Agrochem, Jeolotts Hill Res Stn, Bracknell RG42 6ET, Berks, England	University of London; Royal Holloway University London	Hussey, PJ (corresponding author), Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham Hill, Egham TW20 0EX, Surrey, England.			Hussey, Patrick/0000-0002-7349-8722				AKASHI T, 1988, PLANT CELL PHYSIOL, V29, P1053; APPLEBY AP, 1989, WEED TECHNOL, V3, P198, DOI 10.1017/S0890037X00031626; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Burns Roy G., 1994, V13, P3; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRAME BR, 1994, PLANT J, V6, P941, DOI 10.1046/j.1365-313X.1994.6060941.x; HUSSEY PJ, 1990, PLANT MOL BIOL, V15, P957, DOI 10.1007/BF00039438; JIANG CJ, 1993, J CELL SCI, V105, P891; LAST DI, 1991, THEOR APPL GENET, V81, P581, DOI 10.1007/BF00226722; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; MOREJOHN LC, 1987, PLANTA, V172, P252, DOI 10.1007/BF00394595; MOREJOHN LC, 1991, PHARMACOL THERAPEUT, V51, P217, DOI 10.1016/0163-7258(91)90078-Z; MUDGE LC, 1984, WEED SCI, V32, P591, DOI 10.1017/S0043174500059610; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; PARKA SJ, 1977, WEED SCI, V25, P79, DOI 10.1017/S0043174500032975; THOMPSON C, 1995, EUPHYTICA, V85, P169, DOI 10.1007/BF00023945; VAUGHN KC, 1987, PLANT PHYSIOL, V83, P956, DOI 10.1104/pp.83.4.956; VILLEMUR R, 1992, J MOL BIOL, V227, P81, DOI 10.1016/0022-2836(92)90683-B; WALDIN TR, 1992, PLANTA, V188, P258, DOI 10.1007/BF00216822	19	113	117	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					260	263		10.1038/30484	http://dx.doi.org/10.1038/30484			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607761				2022-12-28	WOS:000073761000051
J	Kawasaki, H; Eckner, R; Yao, TP; Taira, K; Chiu, R; Livingston, DM; Yokoyama, KK				Kawasaki, H; Eckner, R; Yao, TP; Taira, K; Chiu, R; Livingston, DM; Yokoyama, KK			Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation	NATURE			English	Article							300 KDA PROTEIN; TRANSCRIPTIONAL ADAPTER; COACTIVATOR; CELLS; APOPTOSIS; ANTIGEN; TARGET; E1A	The related proteins p300 and CBP (cAMP-response-element-binding protein (CREB)-binding protein)) are transcriptional co-activators that act with other factors to regulate gene expression(1-5) and play roles in many cell-differentiation add signal transduction pathways(6-10). Both proteins have intrinsic histone-acetyltransferase activity(11,12) and may act directly on chromatin, of which histone is a component, to facilitate transcription. They are also involved in growth control pathways, as shown by their interaction with the tumour-suppressor p53 (refs 13-15) and the viral oncogenes E1A (refs 1, 2, 16) and SV40 T antigen(5). Here we report functional differences of p300 and CBP in vivo. We examined their roles during retinoic-acid-induced differentiation, cell-cycle exit and programmed cell death (apoptosis) of embryonal carcinoma F9 cells(17,20), using hammerhead ribozymes capable of cleaving either p300 or CBP messenger RNAs. F9 cells expressing a p300-specific ribozyme became resistant to retinoic-acid-induced differentiation, whereas cells expressing a CBP-specific ribozyme were unaffected. Similarly, retinoic-acid-induced transcriptional upregulation of the cell-cycle inhibitor p21(Cip1) required normal levels of p300, but not CBP, whereas the reverse was true for p27(Kip1). In contrast, both ribozymes blocked retinoic-acid-induced apoptosis, indicating that both co-activators are required for this process. Thus, despite their similarities, p300 and CBP have distinct functions during retinoic-acid-induced differentiation of F9 cells.	Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba Sci City 3050074, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba Sci City 3050006, Japan; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Calif Los Angeles, Sch Med, Dept Surg Oncol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA	RIKEN; University of Tsukuba; University of Zurich; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Yokoyama, KK (corresponding author), Inst Phys & Chem Res, Tsukuba Life Sci Ctr, 3-1-1 Koyadai, Tsukuba Sci City 3050074, Japan.							ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ATENCIA R, 1994, EXP CELL RES, V214, P663, DOI 10.1006/excr.1994.1304; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHAMBON P, 1996, FASEB J, V10, P1187; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1996, NUCLEIC ACIDS RES, V24, P3010, DOI 10.1093/nar/24.15.3010; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUND J, 1995, MG PESH INST LEIDEN, V8, P85; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; TANAKA Y, 1995, P NATL ACAD SCI USA, V94, P10125; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	28	292	302	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					284	289		10.1038/30538	http://dx.doi.org/10.1038/30538			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607768				2022-12-28	WOS:000073761000058
J	Koepp, MJ; Gunn, RN; Lawrence, AD; Cunningham, VJ; Dagher, A; Jones, T; Brooks, DJ; Bench, CJ; Grasby, PM				Koepp, MJ; Gunn, RN; Lawrence, AD; Cunningham, VJ; Dagher, A; Jones, T; Brooks, DJ; Bench, CJ; Grasby, PM			Evidence for striatal dopamine release during a video game	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; C-11 RACLOPRIDE; BASAL GANGLIA; MOTOR CONTROL; HUMAN BRAIN; PET; ACTIVATION; RESPONSES; NEURONS; BINDING	Dopaminergic neurotransmission may be involved in learning, reinforcement of behaviour, attention, and sensorimotor integration(1,2). Binding of the radioligand C-11-labelled raclopride to dopamine D-2 receptors is sensitive to levels of endogenous dopamine, which can be released by pharmacological challenge(3-8). Here we use C-11-labelled raclopride and positron emission tomography scans to provide evidence that endogenous dopamine is released in the human striatum during a goal-directed motor task, namely a video game. Binding of raclopride to dopamine receptors in the striatum was significantly reduced during the video game compared with baseline levels of binding, consistent with increased release and binding of dopamine to its receptors. The reduction in binding of raclopride in the striatum positively correlated with the performance level during the task and was greatest in the ventral striatum. These results show, to our knowledge for the first time, behavioural conditions under which dopamine is released in humans, and illustrate the ability of positron emission tomography to detect neurotransmitter fluxes in vivo during manipulations of behaviour.	Hammersmith Hosp, MRC, Cyclotron Unit, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Div Neurosci & Psychol Med, London W6 8RP, England	Imperial College London; Imperial College London	Grasby, PM (corresponding author), Hammersmith Hosp, MRC, Cyclotron Unit, DuCane Rd, London W12 0NN, England.	grasby@cu.rpms.ac.uk	Lawrence, Andrew/A-1673-2010; Gunn, Roger/H-1666-2012	Gunn, Roger/0000-0003-1181-5769; Law, Ian/0000-0001-9644-7496				ASHBURNER J, 1996, QUANTIFICATION BRAIN, P301; Breier A, 1997, P NATL ACAD SCI USA, V94, P2569, DOI 10.1073/pnas.94.6.2569; BROOKS DJ, 1995, J NEUROL SCI, V128, P1, DOI 10.1016/0022-510X(94)00206-4; DEWEY SL, 1993, P NATL ACAD SCI USA, V90, P11816, DOI 10.1073/pnas.90.24.11816; Endres CJ, 1997, J CEREBR BLOOD F MET, V17, P932, DOI 10.1097/00004647-199709000-00002; FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538; Fisher RE, 1995, HUM BRAIN MAPP, V3, P24, DOI 10.1002/hbm.460030104; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; HUME SP, 1992, SYNAPSE, V12, P47, DOI 10.1002/syn.890120106; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Laruelle M, 1997, SYNAPSE, V25, P1, DOI 10.1002/(SICI)1098-2396(199701)25:1<1::AID-SYN1>3.0.CO;2-H; LJUNGBERG T, 1992, J NEUROPHYSIOL, V67, P145, DOI 10.1152/jn.1992.67.1.145; LOGAN J, 1994, J CEREBR BLOOD F MET, V14, P995, DOI 10.1038/jcbfm.1994.132; Morris ED, 1995, HUM BRAIN MAPP, V3, P35, DOI 10.1002/hbm.460030105; Richardson NR, 1996, J NEUROSCI, V16, P8160; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; SALAMONE JD, 1994, PHARM BIOCH BEHAV, V49, P651; Schultz W, 1997, CURR OPIN NEUROBIOL, V7, P191, DOI 10.1016/S0959-4388(97)80007-4; SCHULTZ W, 1993, J NEUROSCI, V13, P900; THIERRY AM, 1976, NATURE, V263, P242, DOI 10.1038/263242a0; VOLKOW ND, 1993, J NUCL MED, V34, P609; VOLKOW ND, 1994, SYNAPSE, V16, P255, DOI 10.1002/syn.890160402; WISE R, 1980, TRENDS NEUROSCI, V3, P91, DOI 10.1016/0166-2236(80)90035-1; YAMAMURO Y, 1994, NEUROSCI LETT, V177, P83, DOI 10.1016/0304-3940(94)90050-7	26	796	815	4	111	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					266	268		10.1038/30498	http://dx.doi.org/10.1038/30498			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607763				2022-12-28	WOS:000073761000053
J	Paul, AV; van Boom, JH; Filippov, D; Wimmer, E				Paul, AV; van Boom, JH; Filippov, D; Wimmer, E			Protein-primed RNA synthesis by purified poliovirus RNA polymerase	NATURE			English	Article							GENOME-LINKED PROTEIN; DNA-REPLICATION; INITIATION; 3AB; TRANSLATION; SEQUENCE; VIRUSES; LINKAGE; POLY(A); ENTRY	A small protein, VPg, is covalently linked to the 5' end of the plus-stranded poliovirus genomic RNA(1-3). Poliovirus messenger RNA, identical in nucleotide sequence to genomic RNA,is not capped at its 5' end by the methylated structure that is common to most eukaryotic mRNAs, These discoveries presented two problems. First, as cap structures are usually required for transition of mRNA into protein, how does this uncapped viral RNA act as a template for translation? Second, what is the function of VPg? The identification of the internal ribosomal-entry site, which allows the entry of ribosomes into viral mRNA independently of the 5' mRNA end, has solved the first conundrum(4-6). Here we describe the resolution of the second problem. VPg is linked to the genomic RNA through the 5'-terminal uridylic acid of the RNA. We show that VPg can be uridylylated by the poliovirus RNA polymerase 3D(pol). Uridylylated VPg can then prime the transcription of polyadenylate RNA by 3D(pol) to produce VPg-linked poly(U). Initiation of transcription of the poliovirus genome from the polyadenylated 3' end therefore depends on VPg.	SUNY Stony Brook, Hlth Sci Ctr, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; Leiden Univ, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Leiden University; Leiden University - Excl LUMC	Paul, AV (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	apaul@asterix.bio.sunysb.edu	Filippov, Dmitri/J-7612-2017	Filippov, Dmitri/0000-0002-6978-7425				AMBROS V, 1978, J BIOL CHEM, V253, P5263; Barton DJ, 1996, VIROLOGY, V217, P459, DOI 10.1006/viro.1996.0140; CAO XM, 1995, VIROLOGY, V209, P315, DOI 10.1006/viro.1995.1263; DORSCHHASLER K, 1975, J VIROL, V16, P1512; DREEFTROMP CM, 1992, NUCLEIC ACIDS RES, V20, P2435, DOI 10.1093/nar/20.10.2435; ESTEBAN JA, 1992, BIOCHEMISTRY-US, V31, P350, DOI 10.1021/bi00117a006; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P961, DOI 10.1073/pnas.74.3.961; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P3677, DOI 10.1073/pnas.74.9.3677; HSIEH JC, 1990, P NATL ACAD SCI USA, V87, P8665, DOI 10.1073/pnas.87.21.8665; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; KUHN RJ, 1988, P NATL ACAD SCI USA, V85, P519, DOI 10.1073/pnas.85.2.519; LEE YF, 1977, P NATL ACAD SCI USA, V74, P59, DOI 10.1073/pnas.74.1.59; LEE YF, 1976, PROGR NUCL ACID RES, P89; MOLLA A, 1992, NATURE, V356, P255, DOI 10.1038/356255a0; NOMOTO A, 1977, NATURE, V268, P208, DOI 10.1038/268208a0; PATA JD, 1995, RNA, V1, P466; PAUL AV, 1994, J BIOL CHEM, V269, P29173; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; RICHARDS OC, 1990, CURR TOP MICROBIOL, V161, P89; RODRIGUEZ PL, 1992, J VIROL, V66, P1971, DOI 10.1128/JVI.66.4.1971-1976.1992; ROTHBERG PG, 1978, P NATL ACAD SCI USA, V75, P4868, DOI 10.1073/pnas.75.10.4868; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; TAKEDA N, 1986, J VIROL, V60, P43, DOI 10.1128/JVI.60.1.43-53.1986; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; TOYODA H, 1987, J VIROL, V61, P2816, DOI 10.1128/JVI.61.9.2816-2822.1987; WIMMER E, 1982, CELL, V28, P199, DOI 10.1016/0092-8674(82)90335-X; Xiang WK, 1995, RNA, V1, P892; YOGO Y, 1972, P NATL ACAD SCI USA, V69, P1877, DOI 10.1073/pnas.69.7.1877; YOGO Y, 1975, J MOL BIOL, V92, P467, DOI 10.1016/0022-2836(75)90292-2	30	286	296	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 21	1998	393	6682					280	284		10.1038/30529	http://dx.doi.org/10.1038/30529			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607767				2022-12-28	WOS:000073761000057
J	Winberg, ML; Mitchell, KJ; Goodman, GS				Winberg, ML; Mitchell, KJ; Goodman, GS			Genetic analysis of the mechanisms controlling target selection: Complementary and combinatorial functions of netrins, semaphorins, and IgCAMs	CELL			English	Article							GROWTH CONE GUIDANCE; C-ELEGANS; MOTOR AXON; NEUROMUSCULAR SPECIFICITY; COLORECTAL-CANCER; COMMISSURAL AXONS; SYNAPSE FORMATION; DROSOPHILA; UNC-6; MOTONEURON	The molecular mechanisms controlling the ability of motor axons to recognize their appropriate muscle targets were dissected using Drosophila genetics to add or subtract Netrin A, Netrin B, Semaphorin II, and Fasciclin II alone or in combination, Fas II and Sema II are expressed by all muscles where they promote (Fas II) or inhibit (Sema II) promiscuous synaptogenesis, NetB is expressed by a subset of muscles where it attracts some axons and repels others, However, growth cones in this system apparently do not rely solely on single molecular labels on individual targets, Rather, these growth cones assess the relative balance of attractive and repulsive forces and select their targets based on the combinatorial and simultaneous input of multiple cues.	Univ Calif Berkeley, Dept Mol & Cell Biol, Howard Hughes Med Inst, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Goodman, GS (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Howard Hughes Med Inst, 229 Stanley Hall, Berkeley, CA 94720 USA.			Mitchell, Kevin/0000-0002-3433-4530	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021294, R37HD021294] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21294] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BALL EE, 1985, J NEUROSCI, V5, P1808; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BRAND AH, 1993, DEVELOPMENT, V118, P401; CASH S, 1992, J NEUROSCI, V12, P2051; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHIANG C, 1994, DEVELOPMENT, V120, P3581; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; CHIBA A, 1993, J NEUROSCI, V13, P714; Davis GW, 1997, NEURON, V19, P561, DOI 10.1016/S0896-6273(00)80372-4; Fambrough D, 1996, CELL, V87, P1049, DOI 10.1016/S0092-8674(00)81799-7; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; GORCZYCA MG, 1994, DEVELOPMENT, V120, P2143; HALFON MS, 1995, DEV BIOL, V169, P151, DOI 10.1006/dbio.1995.1134; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KESHISHIAN H, 1993, J NEUROBIOL, V24, P757, DOI 10.1002/neu.480240606; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; Kose H, 1997, DEVELOPMENT, V124, P4143; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; Schuster CM, 1996, NEURON, V17, P641, DOI 10.1016/S0896-6273(00)80197-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Sink H., 1994, Society for Neuroscience Abstracts, V20, P1283; SINK H, 1991, DEVELOPMENT, V113, P701; Stewart B., 1973, DROS INFORM SERV, V50, P167; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Thor S, 1997, NEURON, V18, P397, DOI 10.1016/S0896-6273(00)81241-6; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	37	212	215	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					581	591		10.1016/S0092-8674(00)81187-3	http://dx.doi.org/10.1016/S0092-8674(00)81187-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604933	Green Published, Bronze			2022-12-28	WOS:000073722200011
J	Zhou, W; King, WM				Zhou, W; King, WM			Premotor commands encode monocular eye movements	NATURE			English	Article							PONTINE RETICULAR-FORMATION; ALERT MONKEYS; NEURONS; ABDUCENS	Binocular coordination of eye movements is essential for stereopsis (depth perception) and to prevent double vision. More than a century ago, Hering and Helmholtz debated the neural basis of binocular coordination. Helmholtz(1) believed that each eye is controlled independently and that binocular coordination is learned, Hering(2) believed that both eyes are innervated by common command signals that yoke the eye movements (Hering's law of equal innervation). Here we provide evidence that Hering's law is unlikely to be correct. We show that premotor neurons in the paramedian pontine reticular formation that were thought to encode conjugate(3-6) velocity commands for saccades (rapid eye movements) actually encode monocular commands for either right or left eye saccades, However, 66% of the abducens motor neurons, which innervate the ipsilateral lateral rectus muscle, fire as a result of movements of either eye. The distribution of sensitivity to ipsilateral and contralateral eye movements across the abducens motor neuron pool may provide a basis for learning binocular coordination in infancy and adapting it throughout life.	Univ Mississippi, Med Ctr, Dept Neurol, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Anat, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center	Zhou, W (corresponding author), Univ Mississippi, Med Ctr, Dept Neurol, 2500 N State St, Jackson, MS 39216 USA.			King, Michael/0000-0002-7848-6595				FUCHS AF, 1970, J NEUROPHYSIOL, V33, P382, DOI 10.1152/jn.1970.33.3.382; FUCHS AF, 1985, ANNU REV NEUROSCI, V8, P307, DOI 10.1146/annurev.ne.08.030185.001515; Helmholtz J. A., 1910, TREATISE PHYSL OPTIC; HENN V, 1976, BRAIN RES, V108, P307, DOI 10.1016/0006-8993(76)90188-8; Henn V, 1982, Hum Neurobiol, V1, P87; HENN V, 1973, J NEUROPHYSIOL, V36, P115, DOI 10.1152/jn.1973.36.1.115; Hering E., 1977, THEORY BINOCULAR VIS; KELLER EL, 1974, J NEUROPHYSIOL, V37, P316, DOI 10.1152/jn.1974.37.2.316; King W. M., 1997, Society for Neuroscience Abstracts, V23, P1559; LUSCHEI ES, 1972, J NEUROPHYSIOL, V35, P445, DOI 10.1152/jn.1972.35.4.445; MAYS LE, 1984, J NEUROPHYSIOL, V52, P743, DOI 10.1152/jn.1984.52.4.743	11	159	161	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1998	393	6686					692	695		10.1038/31489	http://dx.doi.org/10.1038/31489			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641680				2022-12-28	WOS:000074289600055
J	Messerli, FH; Grossman, E; Goldbourt, U				Messerli, FH; Grossman, E; Goldbourt, U			Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LEFT-VENTRICULAR HYPERTROPHY; CONVERTING-ENZYME-INHIBITOR; ANTIHYPERTENSIVE THERAPY; PROPRANOLOL THERAPY; RESISTANCE ARTERIES; MILD HYPERTENSION; STOP-HYPERTENSION; BLOOD-PRESSURE; RENAL-FUNCTION; DOUBLE-BLIND	Objective.-To assess antihypertensive efficacy of beta-blockers and their effects on cardiovascular morbidity and mortality and all-cause morbidity compared with diuretics in elderly patients with hypertension. Data Source.-A MEDLINE search of English-language articles published between January 1966 and January 1998 using the terms hypertension (drug therapy) and elderly or aged or geriatric, and cerebrovascular or cardiovascular diseases, and morbidity or mortality. References from identified articles were also reviewed. Data Selection.-Randomized trials lasting at least 1 year, which used as first-line agents diuretics and/or beta-blockers, and reported morbidity and mortality outcomes in elderly patients with hypertension. Data Synthesis and Results.-Ten trials involving a total of 16 164 elderly patients (greater than or equal to 60 years) were included. Two thirds of the patients assigned to diuretics were well controlled on monotherapy, whereas less than a third of the patients assigned to beta-blockers were well controlled on monotherapy. Diuretic therapy was superior to beta-blockade with regard to all end points and was effective in preventing cerebrovascular events (odds ratio [OR], 0.61; 95% confidence interval [CI], 0.51-0.72), fatal stroke (OR, 0.67; 95% CI, 0.49-0.90), coronary heart disease (OR, 0.74; 95% CI, 0.64-0.85), cardiovascular mortality (OR, 0.75; 95% CI, 0.64-0.87), and all-cause mortality (OR, 0.86; 95% CI, 0.77-0.96). In contrast, beta-blocker therapy only reduced the odds for cerebrovascular events (OR, 0.75; 95% CI, 0.57-0.98) but was ineffective in preventing coronary heart disease, cardiovascular mortality, and all-cause mortality (ORs, 1.01, 0.98, and 1.05, respectively). Conclusions.-In contrast to diuretics, which remain the standard first-line therapy, beta-blockers, until proven otherwise, should no longer be considered appropriate first-line therapy of uncomplicated hypertension in the elderly hypertensive patient.	Alton Ochsner Med Fdn & Ochsner Clin, Dept Internal Med, Hypertens Dis Sect, New Orleans, LA 70121 USA; Chaim Sheba Med Ctr, Neufeld Cardiac Inst, IL-52621 Tel Hashomer, Israel	Ochsner Health System; Chaim Sheba Medical Center	Messerli, FH (corresponding author), Alton Ochsner Med Fdn & Ochsner Clin, Dept Internal Med, Hypertens Dis Sect, 1514 Jefferson Hwy, New Orleans, LA 70121 USA.	Fmesserli@aol.com	Messerli, Franz/AAR-4783-2021	Grossman, Ehud/0000-0001-8353-0661				AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1985, J Hypertens, V3, P379; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1981, MED J AUSTRALIA, V2, P398; [Anonymous], 1972, CIRCULATION, V45, P991; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; BAUER JH, 1994, SOUTH MED J, V87, P1043, DOI 10.1097/00007611-199410000-00017; BAUER JH, 1979, AM J MED, V66, P405, DOI 10.1016/0002-9343(79)91059-3; BENGTSSON C, 1992, J INTERN MED, V231, P583, DOI 10.1111/j.1365-2796.1992.tb01243.x; BLACK HR, 1994, HYPERTENSION, V23, P275; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; CRUICKSHANK JM, 1992, J HUM HYPERTENS, V6, P85; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DELEEUW PW, 1995, HYPERTENSION PATHOPH, V2, P1857; EKBOM T, 1992, J HYPERTENS, V10, P1525, DOI 10.1097/00004872-199210120-00013; FELDMAN RD, 1984, NEW ENGL J MED, V310, P815, DOI 10.1056/NEJM198403293101303; FLEG JL, 1994, CIRCULATION, V90, P2333, DOI 10.1161/01.CIR.90.5.2333; FLEISS JL, 1991, STAT METHODS RATES P; FOLKOW B, 1982, PHYSIOL REV, V62, P347, DOI 10.1152/physrev.1982.62.2.347; FRISHMAN WH, 1984, NEW ENGL J MED, V310, P830; GAHLINGER PM, 1995, CASECONT PROGRAMS EP, P33; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; Gottdiener JS, 1997, CIRCULATION, V95, P2007, DOI 10.1161/01.CIR.95.8.2007; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; GRIMM RH, 1991, AM HEART J, V122, P910, DOI 10.1016/0002-8703(91)90811-U; GUARNIERI T, 1980, AM J PHYSIOL, V239, pH501, DOI 10.1152/ajpheart.1980.239.4.H501; HOES AW, 1995, ANN INTERN MED, V123, P481, DOI 10.7326/0003-4819-123-7-199510010-00001; HOLLENBERG NK, 1969, AM J MED, V47, P845, DOI 10.1016/0002-9343(69)90199-5; KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009; KASISKE BL, 1995, ANN INTERN MED, V122, P133, DOI 10.7326/0003-4819-122-2-199501150-00010; Kostis JB, 1995, AM J HYPERTENS, V8, P1147, DOI 10.1016/0895-7061(95)00363-0; KURAMOTO K, 1981, JPN HEART J, V22, P75; LAKATTA EG, 1975, CIRC RES, V36, P262, DOI 10.1161/01.RES.36.2.262; Lever AF, 1992, HIGH BLOOD PRESS, V1, P132; Lithell H, 1992, Blood Press, V1, P92, DOI 10.3109/08037059209077499; LONDON GM, 1984, HYPERTENSION, V6, P743, DOI 10.1161/01.HYP.6.5.743; Lund-Johansen P, 1995, HYPERTENSION PATHOPH, V1, P323; LUNDJOHANSEN P, 1979, J CARDIOVASC PHARM, V1, P487, DOI 10.1097/00005344-197909000-00001; MAKI DD, 1995, ARCH INTERN MED, V155, P1073, DOI 10.1001/archinte.155.10.1073; MAXWELL MH, 1985, J CARDIOVASC PHARM, V7, pS5, DOI 10.1097/00005344-198507002-00002; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MESSERLI FH, 1983, LANCET, V2, P983; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; POLLARE T, 1989, BRIT MED J, V298, P1152, DOI 10.1136/bmj.298.6681.1152; ROBERTS WC, 1989, AM HEART J, V117, P709, DOI 10.1016/0002-8703(89)90757-6; SCHIFFRIN EL, 1995, AM J HYPERTENS, V8, P229, DOI 10.1016/0895-7061(95)96211-2; SCHIFFRIN EL, 1994, HYPERTENSION, V23, P83, DOI 10.1161/01.HYP.23.1.83; Schmieder RE, 1996, JAMA-J AM MED ASSOC, V275, P1507, DOI 10.1001/jama.275.19.1507; SCHMIEDER RE, 1994, HYPERTENSION, V23, P351, DOI 10.1161/01.HYP.23.3.351; SCHULMAN SP, 1990, NEW ENGL J MED, V322, P1350, DOI 10.1056/NEJM199005103221904; SKARFORS ET, 1989, BRIT MED J, V298, P1147, DOI 10.1136/bmj.298.6681.1147; STAESSEN J, 1988, JAMA-J AM MED ASSOC, V260, P1713, DOI 10.1001/jama.1988.03410120059015; STRATTON JR, 1992, CIRCULATION, V86, P504, DOI 10.1161/01.CIR.86.2.504; VANBRUMMELEN P, 1981, CLIN SCI, V60, P571, DOI 10.1042/cs0600571; VELD AJM, 1988, AM J HYPERTENS, V1, P91, DOI 10.1093/ajh/1.1.91; VLACHAKIS ND, 1980, AM J CARDIOL, V45, P321, DOI 10.1016/0002-9149(80)90653-0; WEIDMANN P, 1988, DRUGS, V35, P118, DOI 10.2165/00003495-198800356-00017; WILHELMSEN L, 1987, J HYPERTENS, V5, P561, DOI 10.1097/00004872-198710000-00009	60	389	403	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1998	279	23					1903	1907		10.1001/jama.279.23.1903	http://dx.doi.org/10.1001/jama.279.23.1903			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT653	9634263				2022-12-28	WOS:000074109700039
J	Gennery, AR; Cant, AJ; Spickett, GP; Walshaw, D; Hunter, S; Hasan, A; Hamilton, JRL; Dark, J				Gennery, AR; Cant, AJ; Spickett, GP; Walshaw, D; Hunter, S; Hasan, A; Hamilton, JRL; Dark, J			Effect of immunosuppression after cardiac transplantation in early childhood on antibody response to polysaccharide antigen	LANCET			English	Article							INFLUENZAE TYPE-B; HEART-TRANSPLANTATION; CAPSULAR POLYSACCHARIDE; CYCLOSPORIN-A; IGG-SUBCLASS; DEFICIENCY; INFECTION	Background Three children who had cardiac transplantation before age 4 years later presented with recurrent sinopulmonary infection caused by organisms including Streptococcus pneumoniae, in which capsular polysaccharide plays an important part, one developed bronchiectasis. We therefore studied responses to polysaccharide antigen after immunosuppression started in early childhood. Methods Antibodies against pneumococcal and haemophilus polysaccharides, and total IgG, IgG1, IgG2, and IgA concentrations were measured in 33 cardiac-transplant recipients transplanted before the age 4 years (group 1) and after that age (group 2). Patients with low pneumococcal and haemophilus antibody concentrations were immunised with 23 polyvalent pneumococcal and tetanus-haemophilus conjugate vaccines and antibody responses were measured. Findings Five patients from group 1 and seven from group 2 were transplanted for congenital heart disease and ten patients in each group had heart transplants because of cardiomyopathy; none were asplenic. Group 1 (16 patients) were aged 2-10 years when investigated, group 2 (17 patients), were 6-16 years. Four of 16 patients in group 1 responded to pneumococcal polysaccharide vaccine compared with 14 of 17 in group 2 (p=0.0016). This difference remained when those in group 1, aged less than 4 years at investigation, were excluded (p=0.0060). Response to haemophilus-conjugate vaccine was similar in both groups (14 of 16 vs 14 of 17, p=1.0). Significantly more patients who failed to respond to pneumococcal vaccine had low IgG2 concentrations (p=0.0269). Interpretation Children who had a transplantation and immunosuppression in early childhood before they had developed antibody responses to pneumococcal polysaccharide, still failed to show a response when older-ie, when such responses are the norm. Ongoing immunosuppression prevents the maturation of antipolysaccharide responses leaving children susceptible to severe and recurrent damaging infection.	Freeman Rd Hosp, Dept Paediat Cardiol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Newcastle Gen Hosp, Dept Paediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England; Newcastle Gen Hosp, Reg Dept Immunol, Newcastle Upon Tyne, Tyne & Wear, England; Univ Newcastle Upon Tyne, Dept Stat, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle Freeman Hospital; Newcastle University - UK; Newcastle General Hospital; Newcastle General Hospital; Newcastle University - UK	Gennery, AR (corresponding author), Freeman Rd Hosp, Dept Paediat Cardiol, High Heaton, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.							BAILEY LL, 1993, J THORAC CARDIOV SUR, V105, P805; BORK J, 1993, J HEART LUNG TRANSPL, V12, pS199; BRUTON OC, 1952, PEDIATRICS, V9, P722; BUNJES D, 1981, EUR J IMMUNOL, V11, P657, DOI 10.1002/eji.1830110812; DIMITRIU A, 1978, J IMMUNOL, V121, P2335; DROOR Y, 1993, BLOOD, V8, P2021; FULEIHAN R, 1994, J CLIN INVEST, V93, P1315, DOI 10.1172/JCI117089; GALANAUD P, 1976, CELL IMMUNOL, V22, P83, DOI 10.1016/0008-8749(76)90009-5; GRIFFIOEN AW, 1992, IMMUNOL LETT, V32, P265, DOI 10.1016/0165-2478(92)90060-2; GRIFFITHS H, 1992, CLIN EXP IMMUNOL, V89, P374; HAZLEWOOD M, 1993, CLIN EXP IMMUNOL, V93, P157; HERRMANN DJ, 1992, J IMMUNOL METHODS, V148, P101, DOI 10.1016/0022-1759(92)90163-N; KLIPPEL JH, 1980, ARTHRITIS RHEUM, V23, P705; KNUTSEN AP, 1989, J ALLERGY CLIN IMMUN, V84, P640, DOI 10.1016/0091-6749(89)90203-0; KRIETT JM, 1991, J HEART LUNG TRANSPL, V10, P491; KUNKL A, 1980, J IMMUNOL, V125, P2526; LANE PJL, 1986, CLIN EXP IMMUNOL, V65, P427; MARXMILLER J, 1991, J HEART LUNG TRANSPL, V10, P846; MOSIER DE, 1982, IMMUNOL TODAY, V3, P217, DOI 10.1016/0167-5699(82)90095-0; OXELIUS VA, 1979, CLIN EXP IMMUNOL, V36, P112; ROTHBACH C, 1979, J PEDIATR-US, V94, P250, DOI 10.1016/S0022-3476(79)80836-7; SANDERS LAM, 1993, J ALLERGY CLIN IMMUN, V91, P110, DOI 10.1016/0091-6749(93)90303-W; SCHNEERSON R, 1980, J EXP MED, V152, P361, DOI 10.1084/jem.152.2.361; SCHUBERT MS, 1992, ANN ALLERGY, V69, P231; SLAUGHTER MS, 1994, J HEART LUNG TRANSPL, V13, P624	25	34	34	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1778	1781		10.1016/S0140-6736(97)08486-9	http://dx.doi.org/10.1016/S0140-6736(97)08486-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635951				2022-12-28	WOS:000074197600012
J	Casari, G; De Fusco, M; Ciarmatori, S; Zeviani, M; Mora, M; Fernandez, P; De Michele, G; Filla, A; Cocozza, S; Marconi, R; Durr, A; Fontaine, B; Ballabio, A				Casari, G; De Fusco, M; Ciarmatori, S; Zeviani, M; Mora, M; Fernandez, P; De Michele, G; Filla, A; Cocozza, S; Marconi, R; Durr, A; Fontaine, B; Ballabio, A			Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; INNER MEMBRANE; CELL-ADHESION; GENE; FAMILY; LOCUS; LINKAGE; COMPLEX; MEMBER; YEAST	Hereditary spastic paraplegia (HSP) is characterized by progressive weakness and spasticity of the lower limbs due to degeneration of corticospinal axons. We found that patients from a chromosome 16q24.3-linked HSP family are homozygous for a 9.5 kb deletion involving a gene encoding a novel protein, named Paraplegin. Two additional Paraplegin mutations, both resulting in a frameshift, were found in a complicated and in a pure form of HSP. Paraplegin is highly homologous to the yeast mitochondrial ATPases, AFG3, RCA1, and YME1, which have both proteolytic and chaperon-like activities at the inner mitochondrial membrane. Immunofluorescence analysis and import experiments showed that Paraplegin localizes to mitochondria. Analysis of muscle biopsies from two patients carrying Paraplegin mutations showed typical signs of mitochondrial OXPHOS defects, thus suggesting a mechanism for neurodegeneration in HSP-type disorders.	Telethon Inst Genet & Med, I-20132 Milan, Italy; Natl Neurol Inst C Besta, I-20132 Milan, Italy; Univ Naples Federico II, CNR, Dept Neurol, I-80136 Naples, Italy; Univ Naples Federico II, CNR, Dept Mol & Cellular Biol Pathol, I-80136 Naples, Italy; Univ Naples Federico II, CNR, CEOS, I-80136 Naples, Italy; Misericordia Hosp, Dept Neurol, I-58100 Grosseto, Italy; Hop La Pitie Salpetriere, Federat Neurol, F-75013 Paris, France; Hop La Pitie Salpetriere, INSERM, F-75013 Paris, France; Univ Vita Salute, I-20132 Milan, Italy; Childrens Hosp Bambino Gesu, I-00165 Rome, Italy	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); IRCCS Istituto Neurologico Besta; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Vita-Salute San Raffaele University; IRCCS Bambino Gesu	Ballabio, A (corresponding author), Telethon Inst Genet & Med, I-20132 Milan, Italy.		Casari, Giorgio/J-3070-2018; Zeviani, Massimo/K-2891-2014; Zeviani, Massimo/AAU-2632-2021; Silva, Patricio Fernandez/U-2256-2017; De Fusco, Maurizio/AAN-7358-2020; BALLABIO, Andrea/AAL-2672-2020; Cocozza, Sergio/F-6488-2010; Mora, Marina/J-2883-2018	Casari, Giorgio/0000-0002-0115-8980; Zeviani, Massimo/0000-0002-9067-5508; Silva, Patricio Fernandez/0000-0001-8971-7355; BALLABIO, Andrea/0000-0003-1381-4604; Mora, Marina/0000-0002-5765-2320	Telethon [TGM97000, 767, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREWS PW, 1984, LAB INVEST, V50, P147; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; BONNEAU D, 1993, J MED GENET, V30, P381, DOI 10.1136/jmg.30.5.381; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DEMICHELE G, 1998, IN PRESS AM J HUM GE; Dubowitz V., 1985, MUSCLE BIOPSY PRACTI; Durbin H, 1997, P NATL ACAD SCI USA, V94, P14578, DOI 10.1073/pnas.94.26.14578; DURBIN H, 1994, GENOMICS, V19, P181, DOI 10.1006/geno.1994.1038; DURR A, 1994, NEUROLOGY, V44, P1274, DOI 10.1212/WNL.44.7.1274; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FILLA A, 1992, J NEUROL, V239, P351, DOI 10.1007/BF00867594; Fink JK, 1997, CURR OPIN NEUROL, V10, P313, DOI 10.1097/00019052-199708000-00006; FINK JK, 1995, AM J HUM GENET, V56, P188; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIGLI GL, 1993, AM J MED GENET, V45, P711, DOI 10.1002/ajmg.1320450610; Gray JV, 1997, NAT GENET, V16, P323, DOI 10.1038/ng0897-323; GUELIN E, 1994, YEAST, V10, P1389, DOI 10.1002/yea.320101016; HARDING AE, 1981, J MED GENET, V18, P436, DOI 10.1136/jmg.18.6.436; HAZAN J, 1993, NAT GENET, V5, P163, DOI 10.1038/ng1093-163; HAZAN J, 1994, HUM MOL GENET, V3, P1569, DOI 10.1093/hmg/3.9.1569; HENTATI A, 1994, HUM MOL GENET, V3, P1263, DOI 10.1093/hmg/3.8.1263; IOANNOU PA, 1996, CURRENT PROTOCOLS HU, P1; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; KELMAN Z, 1993, ONCOGENE, V8, P37; KOYAMA K, 1993, GENOMICS, V16, P264, DOI 10.1006/geno.1993.1173; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; LizcanoGil LA, 1997, AM J MED GENET, V68, P1, DOI 10.1002/(SICI)1096-8628(19970110)68:1<1::AID-AJMG1>3.0.CO;2-V; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; PAUL MF, 1995, FEBS LETT, V373, P66, DOI 10.1016/0014-5793(95)00979-J; PELOSI L, 1991, J NEUROL NEUROSUR PS, V54, P1099, DOI 10.1136/jnnp.54.12.1099; POLO JM, 1993, J NEUROL NEUROSUR PS, V56, P175, DOI 10.1136/jnnp.56.2.175; PULLMAN WE, 1992, NATURE, V356, P529, DOI 10.1038/356529a0; Reid E, 1997, J MED GENET, V34, P499, DOI 10.1136/jmg.34.6.499; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; Rep M, 1996, CURR GENET, V30, P206, DOI 10.1007/s002940050122; RHEIN J, 1914, J NERV MENT DIS, V44, P115; ROBERTS L, 1991, SCIENCE, V254, P805, DOI 10.1126/science.1948063; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Sambrook J., 2002, MOL CLONING LAB MANU; SAUGIERVEBER P, 1994, NAT GENET, V6, P257, DOI 10.1038/ng0394-257; SCHADY W, 1991, J NEUROL NEUROSUR PS, V54, P1099; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SHOFFNER JM, 1995, METABOLIC MOL BASES, P1535; SUTHERLAND JM, 1975, HDB CLIN NEUROLOGY, V22, P420; TAUER R, 1994, FEBS LETT, V353, P197, DOI 10.1016/0014-5793(94)01045-5; TEDESCHI G, 1991, J NEUROL SCI, V103, P55, DOI 10.1016/0022-510X(91)90284-E; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; Tiranti V, 1997, HUM MOL GENET, V6, P615, DOI 10.1093/hmg/6.4.615; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Webb S, 1997, EPILEPSIA, V38, P495, DOI 10.1111/j.1528-1157.1997.tb01741.x; Zeviani M, 1997, CURR OPIN NEUROL, V10, P160, DOI 10.1097/00019052-199704000-00015	57	609	628	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					973	983		10.1016/S0092-8674(00)81203-9	http://dx.doi.org/10.1016/S0092-8674(00)81203-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635427	Bronze			2022-12-28	WOS:000074205700009
J	Frank, S; Poncharal, P; Wang, ZL; de Heer, WA				Frank, S; Poncharal, P; Wang, ZL; de Heer, WA			Carbon nanotube quantum resistors	SCIENCE			English	Article							ELECTRICAL-RESISTANCE; QUANTIZED CONDUCTANCE; TUBULES; CONTACT	The conductance of multiwalled carbon nanotubes (MWNTs) was found to be quantized. The experimental method involved measuring the conductance of nanotubes by replacing the tip of a scanning probe microscope with a nanotube fiber, which could be lowered into a liquid metal to establish a gentle electrical contact with a nanotube at the tip of the fiber. The conductance of are-produced MWNTs is one unit of the conductance quantum G(0) = 2e(2)/h = (12.9 kilohms)(-1). The nanotubes conduct current ballistically and do not dissipate heat. The nanotubes, which are typically 15 nanometers wide and 4 micrometers long, are several orders of magnitude greater in size and stability than other typical room-temperature quantum conductors. Extremely high stable current densities, J > 10(7) amperes per square centimeter, have been attained.	Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA; Georgia Inst Technol, Sch Mat Sci & Engn, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology	de Heer, WA (corresponding author), Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA.		Wang, Zhong Lin/E-2176-2011	Wang, Zhong Lin/0000-0002-5530-0380				Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; BRANDBYGE M, 1995, PHYS REV B, V52, P8499, DOI 10.1103/PhysRevB.52.8499; BRANDT NB, 1988, SEMIMETALS, V1, P74; Carroll DL, 1997, PHYS REV LETT, V78, P2811, DOI 10.1103/PhysRevLett.78.2811; Chauvet O, 1996, PHYS REV B, V53, P13996, DOI 10.1103/PhysRevB.53.13996; Chico L, 1996, PHYS REV LETT, V76, P971, DOI 10.1103/PhysRevLett.76.971; Chico L, 1996, PHYS REV B, V54, P2600, DOI 10.1103/PhysRevB.54.2600; Dai HJ, 1996, SCIENCE, V272, P523, DOI 10.1126/science.272.5261.523; Datta S., 1995, ELECT TRANSPORT PROP; De Heer WA, 1997, NATO ADV SCI I E-APP, V340, P227; DEHEER WA, 1995, SCIENCE, V270, P1179, DOI 10.1126/science.270.5239.1179; DEHEER WA, 1997, Z PHYS B, V104, P468; DRESSELHAUS MS, 1996, SCIENCE FULLERENES C; DUJARDIN E, 1994, SCIENCE, V265, P1850, DOI 10.1126/science.265.5180.1850; Ebbesen TW, 1996, NATURE, V382, P54, DOI 10.1038/382054a0; EBBESEN TW, 1992, NATURE, V358, P220, DOI 10.1038/358220a0; FRANK SJ, UNPUB; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; LANDAUER R, 1970, PHILOS MAG, V21, P863, DOI 10.1080/14786437008238472; LANDAUER R, 1989, J PHYS-CONDENS MAT, V1, P8099, DOI 10.1088/0953-8984/1/43/011; LANDMAN U, 1990, SCIENCE, V248, P454, DOI 10.1126/science.248.4954.454; LANGER L, 1994, J MATER RES, V9, P927, DOI 10.1557/JMR.1994.0927; LIN MF, 1995, PHYS REV B, V51, P7592, DOI 10.1103/PhysRevB.51.7592; MINTMIRE JW, 1992, PHYS REV LETT, V68, P631, DOI 10.1103/PhysRevLett.68.631; Odom TW, 1998, NATURE, V391, P62, DOI 10.1038/34145; PASCUAL JI, 1993, PHYS REV LETT, V71, P1852, DOI 10.1103/PhysRevLett.71.1852; PASCUAL JI, 1995, SCIENCE, V267, P1793, DOI 10.1126/science.267.5205.1793; SMITH DPE, 1995, SCIENCE, V269, P371, DOI 10.1126/science.269.5222.371; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; TIAN WD, 1994, PHYS REV B, V49, P5097, DOI 10.1103/PhysRevB.49.5097; Ugarte D, 1996, SCIENCE, V274, P1897, DOI 10.1126/science.274.5294.1897; VANWEES BJ, 1988, PHYS REV LETT, V60, P848, DOI 10.1103/PhysRevLett.60.848; Wildoer JWG, 1998, NATURE, V391, P59, DOI 10.1038/34139	33	1831	1896	10	372	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1744	1746		10.1126/science.280.5370.1744	http://dx.doi.org/10.1126/science.280.5370.1744			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624050	Green Submitted			2022-12-28	WOS:000074197800039
J	Brandon, AD; Walker, RJ; Morgan, JW; Norman, MD; Prichard, HM				Brandon, AD; Walker, RJ; Morgan, JW; Norman, MD; Prichard, HM			Coupled Os-186 and Os-187 evidence for core-mantle interaction	SCIENCE			English	Article							OS ISOTOPE SYSTEMATICS; OCEANIC ISLAND BASALTS; HIGH-PRESSURE; LIQUID-IRON; EARTHS CORE; OSMIUM; PLUME; RE; METEORITES; SILICATES	Osmium isotopic analyses of picritic lavas from Hawaii show enrichments in the osmium-186/osmium-188 ratio (Os-186/Os-188) of 0.008 to 0.018%, relative to a chondritic upper mantle, that are positively correlated with enrichments in Os-187/Os-188 Of 5.4 to 9.0%. The most viable mechanism to produce these coupled Os-186 and Os-187 enrichments is by addition of 0.5 to 1 weight percent of outer core metal to a portion of the D " layer and subsequent upwelling of the mixture. These data suggest that some plumes originate at the core-mantle boundary and that Os isotopes may be used to distinguish plumes derived from shallow versus deep mantle sources.	Univ Maryland, Dept Geol, Isotope Geochem Lab, College Pk, MD 20742 USA; Colorado State Univ, Dept Earth Resources, Ft Collins, CO 80523 USA; Macquarie Univ, Sch Earth Sci, GEMOC, N Ryde, NSW 2109, Australia; Univ Wales, Dept Earth Sci, Cardiff CF1 3YE, S Glam, Wales	University System of Maryland; University of Maryland College Park; Colorado State University; Macquarie University; Cardiff University	Brandon, AD (corresponding author), Univ Maryland, Dept Geol, Isotope Geochem Lab, College Pk, MD 20742 USA.	brandon@geol.umd.edu	Walker, Richard/K-6869-2016	Walker, Richard/0000-0003-0348-2407; Norman, Marc/0000-0002-1357-5415				ANDERSON DL, 1994, EARTH PLANET SC LETT, V128, P303, DOI 10.1016/0012-821X(94)90152-X; BARNES SJ, 1985, CHEM GEOL, V53, P303, DOI 10.1016/0009-2541(85)90076-2; Bennett VC, 1996, NATURE, V381, P221, DOI 10.1038/381221a0; Brandon AD, 1996, SCIENCE, V272, P861, DOI 10.1126/science.272.5263.861; BRUGMANN GE, 1993, GEOCHIM COSMOCHIM AC, V57, P2001, DOI 10.1016/0016-7037(93)90089-F; Cohen AS, 1996, ANAL CHIM ACTA, V332, P269, DOI 10.1016/0003-2670(96)00226-7; FRYER BJ, 1992, CAN J EARTH SCI, V29, P2329, DOI 10.1139/e92-181; GOARANT F, 1992, J GEOPHYS RES-SOL EA, V97, P4477, DOI 10.1029/92JB00018; HART SR, 1992, SCIENCE, V256, P517, DOI 10.1126/science.256.5056.517; Hauri EH, 1997, CHEM GEOL, V139, P185, DOI 10.1016/S0009-2541(97)00035-1; Hauri EH, 1996, NATURE, V382, P415, DOI 10.1038/382415a0; HAURI EH, 1993, EARTH PLANET SC LETT, V114, P353, DOI 10.1016/0012-821X(93)90036-9; Hauri EH, 1996, Journal Geophysics Reviews, V101, P11795; HERTOGEN J, 1980, GEOCHIM COSMOCHIM AC, V44, P2125, DOI 10.1016/0016-7037(80)90209-4; HUMAYUN M, 1997, T AM GEOPHYS UNION, V78, pF737; ITO E, 1995, J GEOPHYS RES-SOL EA, V100, P5901, DOI 10.1029/94JB02645; JEANLOZ R, 1990, ANNU REV EARTH PL SC, V18, P357; JONES JH, 1991, EARTH PLANET SC LETT, V105, P127, DOI 10.1016/0012-821X(91)90125-2; Kellogg LH, 1997, GEOPHYS RES LETT, V24, P2749, DOI 10.1029/97GL02952; KELLOGG LH, 1993, GEOPHYS RES LETT, V20, P379, DOI 10.1029/93GL00045; KNITTLE E, 1989, GEOPHYS RES LETT, V16, P609, DOI 10.1029/GL016i007p00609; LAUER HV, 1998, LUNAR PLANET SCI C, V29, P1796; Lay T, 1998, NATURE, V392, P461, DOI 10.1038/33083; LIU M, 1994, SCIENCE, V264, P1904, DOI 10.1126/science.264.5167.1904; LUCK JM, 1983, NATURE, V302, P130, DOI 10.1038/302130a0; Manga M, 1996, GEOPHYS RES LETT, V23, P3091, DOI 10.1029/96GL03021; MARCANTONIO F, 1995, EARTH PLANET SC LETT, V133, P397, DOI 10.1016/0012-821X(95)00092-Q; MARTIN CE, 1994, EARTH PLANET SC LETT, V128, P287, DOI 10.1016/0012-821X(94)90151-1; MARTIN CE, 1991, GEOCHIM COSMOCHIM AC, V55, P1421, DOI 10.1016/0016-7037(91)90318-Y; Meisel T, 1996, NATURE, V383, P517, DOI 10.1038/383517a0; MORGAN JW, 1986, J GEOPHYS RES-SOLID, V91, P2375, DOI 10.1029/JB091iB12p12375; NEWSOM HE, 1991, SCIENCE, V252, P926, DOI 10.1126/science.252.5008.926; NORMAND MD, UNPUB; PEGRAM WJ, 1992, EARTH PLANET SC LETT, V111, P59, DOI 10.1016/0012-821X(92)90169-V; PERNICKA E, 1987, GEOCHIM COSMOCHIM AC, V51, P1717, DOI 10.1016/0016-7037(87)90350-4; POIRIER JP, 1993, J GEOMAGN GEOELECTR, V45, P1221, DOI 10.5636/jgg.45.1221; Ravizza G, 1997, CHEM GEOL, V141, P251, DOI 10.1016/S0009-2541(97)00091-0; Rehkamper M, 1997, SCIENCE, V278, P1595, DOI 10.1126/science.278.5343.1595; REISBERG L, 1993, EARTH PLANET SC LETT, V120, P149, DOI 10.1016/0012-821X(93)90236-3; RODEN MF, 1994, GEOCHIM COSMOCHIM AC, V58, P1431, DOI 10.1016/0016-7037(94)90547-9; ROYBARMAN M, 1995, EARTH PLANET SC LETT, V129, P145, DOI 10.1016/0012-821X(94)00238-T; Schmidt G, 1997, GEOCHIM COSMOCHIM AC, V61, P2977, DOI 10.1016/S0016-7037(97)00129-4; Shirey SB, 1998, ANNU REV EARTH PL SC, V26, P423, DOI 10.1146/annurev.earth.26.1.423; SHIREY SB, 1995, ANAL CHEM, V67, P2136, DOI 10.1021/ac00109a036; SLEEP NH, 1990, J GEOPHYS RES-SOLID, V95, P6715, DOI 10.1029/JB095iB05p06715; Smoliar MI, 1996, SCIENCE, V271, P1099, DOI 10.1126/science.271.5252.1099; SNOW JE, 1995, EARTH PLANET SC LETT, V133, P411, DOI 10.1016/0012-821X(95)00099-X; SONG X, 1994, GEOPHYS RES LETT, V21, P153, DOI 10.1029/93GL03262; STACEY FD, 1992, PHYSICS EARTH; TSURU A, 1997, THESIS U MARYLAND CO; Walker RJ, 1997, GEOCHIM COSMOCHIM AC, V61, P4799, DOI 10.1016/S0016-7037(97)00270-6; WALKER RJ, 1991, CONTRIB MINERAL PETR, V107, P150, DOI 10.1007/BF00310704; WALKER RJ, 1995, SCIENCE, V269, P819, DOI 10.1126/science.269.5225.819; Widom E, 1996, EARTH PLANET SC LETT, V142, P451, DOI 10.1016/0012-821X(96)00111-2; Williams Q, 1996, SCIENCE, V273, P1528, DOI 10.1126/science.273.5281.1528	55	227	242	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1570	1573		10.1126/science.280.5369.1570	http://dx.doi.org/10.1126/science.280.5369.1570			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616113				2022-12-28	WOS:000074061200031
J	Kemp, M				Kemp, M			Vesalius's veracity	NATURE			English	Editorial Material									Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.								0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					421	421		10.1038/30867	http://dx.doi.org/10.1038/30867			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9623996	Bronze			2022-12-28	WOS:000074020000028
J	Epstein, AM				Epstein, AM			Rolling down the runway - The challenges ahead for quality report cards	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BYPASS GRAFT-SURGERY; NEW-YORK-STATE; PERFORMANCE REPORTS; MORTALITY; PHYSICIANS; OUTCOMES; PLANS	Today, steadily increasing numbers of hospitals and health plans are publicly releasing performance reports on the quality of care to permit comparisons across different providers. Our experience in recent years has provided important new evidence of what public quality reporting can accomplish and the difficulties it faces. Several years ago, the most important impediments to quality reporting may have been the availability of acceptable quality indicators and the feasibility of voluntary, standardized data collection by health plans, We have made strides in these areas. The Health Employer Data and Information Set (HEDIS) has expanded, and there have been new innovations in collecting data on quality from both patients and physicians. Hundreds of health plans have begun to report standardized quality data on a routine basis either voluntarily or in response to requirements from the Health Care Financing Administration, state Medicaid agencies, or private payers. Now, the more formidable barriers to the use of quality report cards may relate to the ways we report the data and use it. We need to find acceptable middle ground for those who believe information on individual physicians is critical and those who believe it is harmful. We need to reap the advantages in different modalities of data collection and different tools for quality management. Most of all, we need to find better ways to use quality reporting to empower purchasers and consumers and improve quality of care.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Med, Sect Hlth Serv & Policy Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Epstein, AM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.							BENTLEY JM, IN PRESS JT COMM J Q; Borowsky SJ, 1997, JAMA-J AM MED ASSOC, V278, P917, DOI 10.1001/jama.278.11.917; Borowsky SJ, 1996, ANN INTERN MED, V125, P239, DOI 10.7326/0003-4819-125-3-199608010-00014; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; *FDN ACC, 1996, ACCOUNTABILITY A FAL, V1; Ghali WA, 1997, JAMA-J AM MED ASSOC, V277, P379, DOI 10.1001/jama.277.5.379; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; Hannan EL, 1997, AM HEART J, V134, P55, DOI 10.1016/S0002-8703(97)70106-6; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; *KAIS FAM FDN AG H, 1996, AM CONS ROL HLTH CAR; Landon BE, 1998, JAMA-J AM MED ASSOC, V279, P211, DOI 10.1001/jama.279.3.211; NASH DB, 1997, HLTH POL NEWSLET SEP, P1; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; Omoigui NA, 1996, CIRCULATION, V93, P27, DOI 10.1161/01.CIR.93.1.27; PETERSON ED, 1994, ANN INTERN MED, V121, P919, DOI 10.7326/0003-4819-121-12-199412150-00003; Robinson S, 1997, JOINT COMM J QUAL IM, V23, P239, DOI 10.1016/S1070-3241(16)30313-3; Schneider EC, 1996, NEW ENGL J MED, V335, P251, DOI 10.1056/NEJM199607253350406; Schneider EC, 1998, JAMA-J AM MED ASSOC, V279, P1638, DOI 10.1001/jama.279.20.1638; TOPOL EJ, 1994, ANN INTERN MED, V120, P65, DOI 10.7326/0003-4819-120-1-199401010-00011; *US DEP HHS, 1987, PUBL US DEP HLTH HUM, V1002	21	130	131	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1691	1696		10.1001/jama.279.21.1691	http://dx.doi.org/10.1001/jama.279.21.1691			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624015				2022-12-28	WOS:000073878700011
J	Lantz, PM; House, JS; Lepkowski, JM; Williams, DR; Mero, RP; Chen, JM				Lantz, PM; House, JS; Lepkowski, JM; Williams, DR; Mero, RP; Chen, JM			Socioeconomic factors, health behaviors, and mortality - Results from a nationally representative prospective study of US adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; SOCIAL-CLASS; UNITED-STATES; RISK-FACTORS; RACIAL-DIFFERENCES; ALAMEDA-COUNTY; MEDICAL-CARE; SELF-REPORT; LIFE-STYLE; PATTERNS	Context.-A prominent hypothesis regarding social inequalities in mortality is that the elevated risk among the socioeconomically disadvantaged is largely due to the higher prevalence of health risk behaviors among those with lower levels of education and income. Objective.-To investigate the degree to which 4 behavioral risk factors (cigarette smoking, alcohol drinking, sedentary lifestyle, and relative body weight) explain the observed association between socioeconomic characteristics and all-cause mortality. Design.-Longitudinal survey study investigating the impact of education, income, and health behaviors on the risk of dying within the next 7.5 years. Participants.-A nationally representative sample of 3617 adult women and men participating in the Americans' Changing Lives survey. Main Outcome Measure.-All-cause mortality verified through the National Death Index and death certificate reviews. Results.-Educational differences in mortality were explained in full by the strong association between education and income. Controlling for age, sex, race, urbanicity, and education, the hazard rate ratio of mortality was 3.22 (95% confidence interval [CI], 2.01-5.16) for those in the lowest-income group and 2.34 (95% CI, 1.49-3.67) for those in the middle-income group. When health risk behaviors were considered, the risk of dying was still significantly elevated for the lowest-income group (hazard rate ratio, 2.77; 95% CI, 1.74-4.42) and the middle-income group (hazard rate ratio, 2.14; 95% CI, 1.38-3.25). Conclusion.-Although reducing the prevalence of health risk behaviors in low-income populations is an important public health goal, socioeconomic differences in mortality are due to a wider array of factors and, therefore, would persist even with improved health behaviors among the disadvantaged.	Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA; Univ Michigan, Survey Res Ctr, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Sociol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Lantz, PM (corresponding author), Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, 109 Observ, Ann Arbor, MI 48109 USA.	plantz@umich.edu			NIA NIH HHS [P01AG05561, R01AG09978-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG005561, R01AG009978] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ANTONOVSKY A, 1967, MILBANK FUND Q, V45, P31, DOI 10.2307/3348839; BARANOWSKI T, 1985, J SCHOOL HEALTH, V55, P179, DOI 10.1111/j.1746-1561.1985.tb04115.x; BERKMAN L, 1983, HLTH WAYS LIVING; BLANE D, 1995, AM J PUBLIC HEALTH, V85, P903, DOI 10.2105/AJPH.85.7.903; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; COHEN BB, 1995, ALCOHOL CLIN EXP RES, V19, P1156, DOI 10.1111/j.1530-0277.1995.tb01595.x; DUIJKERS TJ, 1989, INT J EPIDEMIOL, V18, P658, DOI 10.1093/ije/18.3.658; Durante R, 1996, MED SCI SPORT EXER, V28, P1282, DOI 10.1097/00005768-199610000-00012; DUTTON DB, 1978, AM SOCIOL REV, V43, P348, DOI 10.2307/2094495; Elo IT, 1996, SOC SCI MED, V42, P47, DOI 10.1016/0277-9536(95)00062-3; HAAN M, 1987, AM J EPIDEMIOL, V125, P989, DOI 10.1093/oxfordjournals.aje.a114637; HIRDES JP, 1992, J CLIN EPIDEMIOL, V45, P175, DOI 10.1016/0895-4356(92)90010-K; HOUSE JS, 1994, J HEALTH SOC BEHAV, V35, P213, DOI 10.2307/2137277; HOUSE JS, 1990, MILBANK Q, V68, P383, DOI 10.2307/3350111; HOUSE JS, 1995, C SOC STAT CARD HLTH, P119; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; Kaplan GA, 1996, BRIT MED J, V312, P999; KESSLER RC, 1986, J HEALTH SOC BEHAV, V27, P107, DOI 10.2307/2136310; KRIEGER N, 1993, AM J PREV MED, V9, P82, DOI 10.1016/S0749-3797(18)30666-4; Lantz PM, 1997, MED CARE, V35, P219, DOI 10.1097/00005650-199703000-00004; LIU K, 1982, CIRCULATION, V66, P1308, DOI 10.1161/01.CIR.66.6.1308; Lynch JW, 1996, AM J EPIDEMIOL, V144, P934, DOI 10.1093/oxfordjournals.aje.a008863; Lynch JW, 1997, SOC SCI MED, V44, P809, DOI 10.1016/S0277-9536(96)00191-8; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; MARMOT MG, 1984, LANCET, V1, P1003; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Mechanic D., 1989, PATHWAYS HLTH ROLE S, P9; MIROWSKY J, 1989, SOCIAL CAUSES DISTRE; MOORE DE, 1990, DEMOGRAPHY, V27, P31, DOI 10.2307/2061551; OSLER M, 1993, PUBLIC HEALTH, V107, P251, DOI 10.1016/S0033-3506(05)80504-9; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PATTERSON RE, 1994, PREV MED, V23, P453, DOI 10.1006/pmed.1994.1062; RIESSMAN CK, 1974, SOC POLICY, V5, P41; RODIN J, 1986, SCIENCE, V233, P1271, DOI 10.1126/science.3749877; ROSE G, 1981, BRIT HEART J, V45, P13, DOI 10.1136/hrt.45.1.13; SALONEN JT, 1982, J EPIDEMIOL COMMUN H, V36, P294, DOI 10.1136/jech.36.4.294; Satel S, 1996, WALL STREET J   1212; Shyrock H. S., 1976, METHODS MAT DEMOGRAP; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; SORLIE PD, 1995, AM J PUBLIC HEALTH, V85, P949, DOI 10.2105/AJPH.85.7.949; Stevenson THC, 1923, BIOMETRIKA, V15, P382; *US DEP HHS, 1990, HLTH PEOPL 2000 NAT; WAGENKNECHT LE, 1990, PREV MED, V19, P158, DOI 10.1016/0091-7435(90)90017-E; WILEY JA, 1980, PREV MED, V9, P1, DOI 10.1016/0091-7435(80)90056-0; WILLIAMS DR, 1990, SOC PSYCHOL QUART, V53, P81, DOI 10.2307/2786672; WILLIAMS DR, 1995, ANNU REV SOCIOL, V21, P349, DOI 10.1146/annurev.so.21.080195.002025; WILSON PS, 1994, AM J HYPERTENS, V7, P75; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; WOOLHANDLER S, 1985, INT J HEALTH SERV, V15, P1, DOI 10.2190/90P3-LEFF-WNU0-GLY6	50	1048	1058	1	106	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1703	1708		10.1001/jama.279.21.1703	http://dx.doi.org/10.1001/jama.279.21.1703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZQ544	9624022				2022-12-28	WOS:000073878700030
J	Turka, LA				Turka, LA			What's new in transplant immunology: Problems and prospects	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							INTRATHYMIC ISLET TRANSPLANTATION; LONG-TERM ACCEPTANCE; ALLOGRAFT-REJECTION; CARDIAC ALLOGRAFTS; CYCLOSPORINE; PREVENTION; CHIMERISM	In the past 40 years, transplantation has moved from an experimental form of therapy used almost exclusively for renal failure to an accepted treatment for end-stage kidney disease, heart disease, liver disease, lung disease, and diabetes mellitus. Tissue transplantation for conditions from thermal injury to Parkinson disease is being investigated. The primary barrier in transplantation medicine is the immunologic reaction of the recipient to donor organs and tissues. Currently available drugs permit excellent short-term graft survival but have not led to reliable longterm survival. Recent advances in the understanding of this immune response have suggested new approaches to induction of immunologic tolerance and reduction of late graft losses. Because of the excellent short-term success of current agents, integration of these new approaches into clinical trials is challenging and raises important questions about the design of such trials.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Turka, LA (corresponding author), Univ Penn, Dept Med, 901 Stellar Chance Lab,422 Curie Blvd, Philadelphia, PA 19104 USA.							BIERER BE, 1993, CURR OPIN HEMATOL, P149; Elwood ET, 1997, LANCET, V349, P1358, DOI 10.1016/S0140-6736(96)09105-2; GarciaMorales R, 1997, J CLIN INVEST, V99, P1118, DOI 10.1172/JCI119240; Gjertson DW, 1995, TRANSPLANTATION, V60, P1384, DOI 10.1097/00007890-199560120-00002; ILDSTAD ST, 1984, NATURE, V307, P168, DOI 10.1038/307168a0; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; LIN H, 1993, J EXP MED, V178, P1801, DOI 10.1084/jem.178.5.1801; Lui S L, 1996, Curr Opin Nephrol Hypertens, V5, P508, DOI 10.1097/00041552-199611000-00009; MORRIS PJ, 1994, KIDNEY TRANSPLANTATI, P524; Morris R.E., 1992, TRANSPLANT REV-ORLAN, P39; Paul Leendert C., 1996, P567; POSSELT AM, 1992, SCIENCE, V256, P1321, DOI 10.1126/science.1598576; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1993, IMMUNOL TODAY, V14, P326, DOI 10.1016/0167-5699(93)90054-O; Sykes M, 1990, Semin Immunol, V2, P401; TULLIUS SG, 1995, TRANSPLANTATION, V59, P313, DOI 10.1097/00007890-199502150-00001	22	6	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					946	948		10.7326/0003-4819-128-11-199806010-00015	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634435				2022-12-28	WOS:000073808600011
J	Reynolds, JD; Hardy, RJ; Kennedy, KA; Spencer, R; van Heuven, WAJ; Fielder, AR				Reynolds, JD; Hardy, RJ; Kennedy, KA; Spencer, R; van Heuven, WAJ; Fielder, AR		LIGHT-ROP Cooperat Grp	Lack of efficacy of light reduction in preventing retinopathy of prematurity	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Hospital-nursery lighting has been suggested as a factor in causing retinopathy of prematurity. Despite ongoing debate, a causal relation has not been established. Methods We conducted a prospective, randomized, multicenter study of the effects of light reduction on 409 premature infants with birth weights of less than 1251 g and gestational ages of less than 31 weeks. Two hundred five infants were exposed to reduced light, and 204 to typical nursery lighting. The amount of light reaching the infants' eyes was reduced within 24 hours after birth by placing goggles on the infants that reduced visible-light exposure by 97 percent and ultraviolet-light exposure by 100 percent. The babies wore the goggles until 31 weeks' postconceptional age or 4 weeks after birth, whichever was longer. Once the goggles were removed, ophthalmologists masked to the treatment assignments assessed the infants for retinopathy of prematurity at least biweekly for up to 13 weeks. Results There were 188 infants in the group that wore goggles and 173 in the control group who survived and were available for follow-up. The mean birth weights were 906 g in the goggles group and 914 g in the control group; the mean gestational ages were 27.4 weeks and 27.2 weeks, respectively. The mean ambient-light level adjacent to the infants' faces was 399 lux for the goggles group and 447 lux for the control group. Retinopathy of prematurity was diagnosed in 102 infants (54 percent) in the goggles group and 100 (58 percent) in the control group (relative risk, 0.9; 95 percent confidence interval, 0.8 to 1.1; P=0.50). Conclusions A reduction in ambient-light exposure does not alter the incidence of retinopathy of prematurity. (C) 1998, Massachusetts Medical Society.	SUNY Buffalo, Buffalo, NY 14260 USA; Univ Texas, Hlth Sci Ctr, Houston, TX USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Imperial Coll Sci Technol & Med, Sch Med, London, England	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Health San Antonio; Imperial College London	Reynolds, JD (corresponding author), Childrens Hosp, Dept Ophthalmol, 219 Bryant St, Buffalo, NY 14222 USA.				NATIONAL EYE INSTITUTE [U10EY009953] Funding Source: NIH RePORTER; NEI NIH HHS [UIO EY09953] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ACKERMAN B, 1989, PEDIATRICS, V83, P958; Aleff H. P., 1991, IATROGENICS, V2, P68; Bullough J., 1996, Lighting Research and Technology, V28, P189; GARNER A, 1984, ARCH OPHTHALMOL-CHIC, V102, P1130; GLASS P, 1985, NEW ENGL J MED, V313, P401, DOI 10.1056/NEJM198508153130701; HEPNER WR, 1949, PEDIATRICS, V3, P824; HOMMURA S, 1988, Nippon Ganka Gakkai Zasshi, V92, P456; KREMER I, 1992, INVEST OPHTH VIS SCI, V33, P1595; LOCKE JC, 1952, AMA ARCH OPHTHALMOL, V48, P44, DOI 10.1001/archopht.1952.00920010047006; *NY STAT DEP HLTH, 1990, REP TECHN ADV GROUP; PALMER EA, 1991, OPHTHALMOLOGY, V98, P1628; REDDY VM, 1994, AM J OPHTHALMOL, V117, P262, DOI 10.1016/S0002-9394(14)73089-2; ROBINSON J, 1992, EYE, V6, P166, DOI 10.1038/eye.1992.33; SEIBERTH V, 1994, AM J OPHTHALMOL, V118, P492, DOI 10.1016/S0002-9394(14)75801-5; Terry TL, 1943, ARCH OPHTHALMOL-CHIC, V29, P36, DOI 10.1001/archopht.1943.00880130054003; WESOLOWSKI E, 1994, INVEST OPHTH VIS SCI, V35, P112	16	139	145	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1998	338	22					1572	1576		10.1056/NEJM199805283382202	http://dx.doi.org/10.1056/NEJM199805283382202			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ350	9603794				2022-12-28	WOS:000073852400002
J	Klassen, TP; Craig, WR; Moher, D; Osmond, MH; Pasterkamp, H; Sutcliffe, T; Watters, LK; Rowe, PC				Klassen, TP; Craig, WR; Moher, D; Osmond, MH; Pasterkamp, H; Sutcliffe, T; Watters, LK; Rowe, PC			Nebulized budesonide and oral dexamethasone for treatment of group - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ACUTE LARYNGOTRACHEITIS; RACEMIC EPINEPHRINE; CLINICAL-TRIALS; CROUP; CHILDREN	Context.-The effectiveness of glucocorticoids for patients with croup is well established but it remains uncertain which glucocorticoid regimen is most effective. Objective.-To determine the effectiveness of 3 glucocorticoid regimens in patients with croup. Design.-Randomized controlled trial with parallel design. Setting.-Emergency departments of 2 Canadian pediatric tertiary care hospitals. Participants.-Children with a clinical syndrome consistent with croup, aged 3 months to 5 years, with a croup score of 2 or greater following at least 15 minutes of mist therapy. Interventions.-Oral dexamethasone, 0.6 mg/kg, and nebulized placebo; oral placebo and nebulized budesonide, 2 mg; or oral dexamethasone, 0.6 mg/kg, and nebulized budesonide, 2 mg. Main Outcome Measures.-Westley croup score (primary outcome), hospital admission rates, time spent in the emergency department, return visits to the emergency department, or ongoing symptoms at 1 week. Results.-The mean change in the croup score from baseline to the final study assessment was -2.3 (95% confidence interval [CI], -2.6 to -2.0) in the budesonide group (n = 65), -2.4 (95% CI, -2.6 to -2.2) in the dexamethasone group (n = 69), and -2.4 (95% CI, -2.7 to -2.1) in the budesonide and dexamethasone group (n = 64, P = .70). Conclusions.-Based on the similar outcomes in the 3 groups, oral dexamethasone is the preferred intervention because of its ease of administration, lower cost, and more widespread availability.	Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada; Univ Manitoba, Dept Child Hlth, Winnipeg, MB, Canada; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA	University of Ottawa; University of Ottawa; University of Manitoba; Johns Hopkins University	Klassen, TP (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.		Pasterkamp, Hans/M-8184-2019; Pasterkamp, Hans/AAL-4060-2021	Pasterkamp, Hans/0000-0001-8611-2895; Craig, William/0000-0002-4804-194X; Osmond, Martin/0000-0001-8275-8381; Moher, David/0000-0003-2434-4206				CRUZ MN, 1995, PEDIATRICS, V96, P220; DAY SJ, 1991, STAT MED, V10, P33, DOI 10.1002/sim.4780100109; DETSKY AS, 1985, ARCH INTERN MED, V145, P709, DOI 10.1001/archinte.145.4.709; Fleiss J., 1996, DESIGN ANAL CLIN EXP; Friedman LM, 1985, FUNDAMENTALS CLIN TR; GEELHOED CC, 1995, PEDIAT PULMONOL, V20, P362; Geelhoed GC, 1995, PEDIATR PULM, V20, P355, DOI 10.1002/ppul.1950200604; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; HENRICKSON KJ, 1994, CLIN INFECT DIS, V18, P770, DOI 10.1093/clinids/18.5.770; KAIRYS SW, 1989, PEDIATRICS, V83, P683; Klassen T, 1995, ARCH PEDIAT ADOLESC, V149, P60; Klassen Terry P., 1996, Current Opinion in Pediatrics, V8, P449, DOI 10.1097/00008480-199610000-00005; Klassen TP, 1996, PEDIATRICS, V97, P463; Klassen TP, 1997, PEDIATR CLIN N AM, V44, P249, DOI 10.1016/S0031-3955(05)70472-7; KLASSEN TP, 1994, NEW ENGL J MED, V331, P285, DOI 10.1056/NEJM199408043310501; KUUSELA AL, 1988, ACTA PAEDIATR SCAND, V77, P99, DOI 10.1111/j.1651-2227.1988.tb10606.x; SUPER DM, 1989, J PEDIATR-US, V115, P323, DOI 10.1016/S0022-3476(89)80095-2; TIBBALLS J, 1992, LANCET, V340, P745, DOI 10.1016/0140-6736(92)92293-O; WESTLEY CR, 1978, AM J DIS CHILD, V132, P484, DOI 10.1001/archpedi.1978.02120300044008	19	77	80	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1998	279	20					1629	1632		10.1001/jama.279.20.1629	http://dx.doi.org/10.1001/jama.279.20.1629			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP489	9613912	Bronze			2022-12-28	WOS:000073758600032
J	Kogan, MD; Martin, JA; Alexander, GR; Kotelchuck, M; Ventura, SJ; Frigoletto, FD				Kogan, MD; Martin, JA; Alexander, GR; Kotelchuck, M; Ventura, SJ; Frigoletto, FD			The changing pattern of prenatal care utilization in the United States, 1981-1995, using different prenatal care indices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BIRTH-WEIGHT; GESTATIONAL-AGE; PREGNANCY; MEDICAID; HEALTH; ADEQUACY; INDEXES; ULTRASOUND; LITIGATION; EXPANSION	Context.-Two measures traditionally used to examine adequacy of prenatal care indicate that prenatal care utilization remained unchanged through the 1980s and only began to rise slightly in the 1990s. In recent years, new measures have been developed that include a category for women who receive more than the recommended amount of care (intensive utilization). Objective.-To compare the older and newer indices in the monitoring of prenatal care trends in the United States from 1981 to 1995, for the overall population and for selected subpopulations. Second, to examine factors associated with receiving intensive utilization. Design.-Cross-sectional and trend analysis of national birth records. Setting.-The United States. Subjects.-All live births between 1981 and 1995 (N=54 million). Main Outcome Measures.-Trends in prenatal care utilization, according to 4 indices (the older indices: the Institute of Medicine Index and the trimester that care began, and the newer indices: the R-GINDEX and the Adequacy of Prenatal Care Utilization Index). Multiple logistic regression was used to assess the risk of intensive prenatal care use in 1981 and 1995. Results.-The newer indices showed a steadily increasing trend toward more prenatal care use throughout the study period (R-GINDEX, intensive or adequate use, 32.7% in 1981 to 47.1% in 1995; the Adequacy of Prenatal Care Utilization Index, intensive use, 18.4% in 1981 to 28.8% in 1995), especially for intensive utilization. Women having a multiple birth were much more likely to have had intensive utilization in 1995 compared with 1981 (R-GINDEX, 22.8% vs 8.5%). Teenagers were more likely to begin care later than adults, but similar proportions of teens and adults had intensive utilization. Intensive use among low-risk women also increased steadily each year. Factors associated with a greater likelihood of receiving intensive use in 1981 and 1995 were having a multiple birth, primiparity, being married, and maternal age of 35 years or older. Conclusions.-The proportion of women who began care early and received at least the recommended number of visits increased between 1981 and 1995. This change was undetected by more traditional prenatal care indices. These increases have cost and practice implications and suggest a paradox since previous studies have shown that rates of preterm delivery and low birth weight did not improve during this time.	Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; Univ Alabama, Dept Maternal & Child Hlth, Birmingham, AL USA; Univ N Carolina, Dept Maternal & Child Hlth, Chapel Hill, NC USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Obstet, Boston, MA USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); University of Alabama System; University of Alabama Birmingham; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Harvard Medical School; Massachusetts General Hospital	Kogan, MD (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 6525 Belcrest Rd,Room 820, Hyattsville, MD 20782 USA.							Alexander GR, 1996, PUBLIC HEALTH REP, V111, P408; ALEXANDER GR, 1987, AM J PREV MED, V3, P243; ALEXANDER GR, 1995, PUBLIC HEALTH REP, V110, P395; ALEXANDER GR, 1995, FUTURE CHILD, V5, P103, DOI 10.2307/1602510; Alexander GR, 1997, AM J PREV MED, V13, P290, DOI 10.1016/S0749-3797(18)30177-6; ALEXANDER GR, 1991, AM J PUBLIC HEALTH, V81, P1013, DOI 10.2105/AJPH.81.8.1013; *AM COLL OBST GYN, 1985, PROF LIAB INS ITS EF; *AM COLL OBST GYN, 1974, STAND OBST GYN SERV; [Anonymous], CAR OUR FUT CONT PRE; BALDWIN LM, 1995, JAMA-J AM MED ASSOC, V274, P1606, DOI 10.1001/jama.274.20.1606; BUESCHER PA, 1993, AM J PUBLIC HEALTH, V83, P1163, DOI 10.2105/AJPH.83.8.1163; DelgadoRodriguez M, 1996, EPIDEMIOLOGY, V7, P648, DOI 10.1097/00001648-199611000-00016; ENNIS M, 1991, LANCET, V338, P616, DOI 10.1016/0140-6736(91)90616-W; EWIGMAN B, 1993, BIRTH-ISS PERINAT C, V20, P212, DOI 10.1111/j.1523-536X.1993.tb00229.x; Farrow DC, 1997, MED CARE, V35, P297, DOI 10.1097/00005650-199703000-00010; FISCELLA K, 1995, OBSTET GYNECOL, V85, P468, DOI 10.1016/0029-7844(94)00408-6; Floyd L, 1981, J Med Assoc Ga, V70, P871; GORSKY RD, 1989, HLTH SERV RES, V24, P580; GORTMAKER SL, 1979, AM J PUBLIC HEALTH, V69, P653, DOI 10.2105/AJPH.69.7.653; GUYER B, 1990, JAMA-J AM MED ASSOC, V264, P2264, DOI 10.1001/jama.264.17.2264; HUNTINGTON J, 1994, NEW ENGL J MED, V331, P1303, DOI 10.1056/NEJM199411103311910; *I MED, 1993, ACC HLTH CAR AM; *I MED, 1985, PREV LOW BIRTH WEIGH; JEWELL SE, 1995, OBSTET GYNECOL, V85, P229, DOI 10.1016/0029-7844(94)00354-G; JOYCE T, 1988, MED CARE, V26, P348, DOI 10.1097/00005650-198804000-00004; KESSNER DM, 1973, CONTRASTS HLTH STATU, V1, P50; Kirby RS, 1997, PAEDIATR PERINAT EP, V11, P122, DOI 10.1046/j.1365-3016.1997.d01-6.x; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V271, P1340, DOI 10.1001/jama.271.17.1340; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1486, DOI 10.2105/AJPH.84.9.1486; Kotelchuck M, 1994, AM J PUBLIC HEALTH, V84, P1314; KRAMER MS, 1988, JAMA-J AM MED ASSOC, V260, P3306, DOI 10.1001/jama.260.22.3306; LEWIS CT, 1996, VITAL HLTH STAT, V21; McDermott J, 1997, PAEDIATR PERINAT EP, V11, P105, DOI 10.1046/j.1365-3016.1997.d01-4.x; MOR JM, 1995, AM J PREV MED, V11, P79, DOI 10.1016/S0749-3797(18)30481-1; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; MUSTARD CA, 1994, AM J PUBLIC HEALTH, V84, P1450, DOI 10.2105/AJPH.84.9.1450; *NAT CTR HLTH STAT, 1995, 1992 VIT STAT US, V1; *NAT CTR HLTH STAT, 1982, VIT HLTH STAT, V2; National Center for Health Statistics, 1987, HOSP PHYS HDB BIRTH; OREILLY MP, 1991, P 1991 PUBL HLTH C R, P57; Petersen D J, 1994, Minn Med, V77, P41; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; QUICK JD, 1981, AM J PUBLIC HEALTH, V71, P381, DOI 10.2105/AJPH.71.4.381; RICCIOTTI HA, 1995, FUTURE CHILD, V5, P71, DOI 10.2307/1602508; SAARIKEMPPAINEN A, 1995, ACTA OBSTET GYN SCAN, V74, P12, DOI 10.3109/00016349509009935; Schappert SM, 1997, VITAL HLTH STAT, V13; SCHRAMM WF, 1992, PUBLIC HEALTH REP, V107, P647; SHIONO PH, 1986, JAMA-J AM MED ASSOC, V255, P48, DOI 10.1001/jama.255.1.48; SHOWSTACK JA, 1984, AM J PUBLIC HEALTH, V74, P1003, DOI 10.2105/AJPH.74.9.1003; *US DEP HHS, 1991, HLTH PEOPL 2000 NAT; *US DEP HHS, 1996, TRENDS WELL BEING AM; *US GEN ACC OFF, 1993, PUBL GAO; VENTURA SJ, 1997, MON VITAL STAT RE S2, V11; WEISMAN CS, 1989, MED CARE, V27, P16, DOI 10.1097/00005650-198901000-00002; Wells S, 1991, J Fla Med Assoc, V78, P31; Wilcox LS, 1996, FERTIL STERIL, V65, P361, DOI 10.1016/S0015-0282(16)58100-X	56	154	157	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1998	279	20					1623	1628		10.1001/jama.279.20.1623	http://dx.doi.org/10.1001/jama.279.20.1623			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZP489	9613911	Bronze			2022-12-28	WOS:000073758600031
J	Tan, PB; Lackner, MR; Kim, SK				Tan, PB; Lackner, MR; Kim, SK			MAP kinase signaling specificity mediated by the LIN-1 Ets/LIN31 WH transcription factor complex during C-elegans vulval induction	CELL			English	Article							CAENORHABDITIS-ELEGANS; REGULATED KINASE; CELL LINEAGE; LET-60 RAS; PROTEIN; PATHWAY; GENES; ACTIVATION; DEFINES; FATES	The let-23 receptor/mpk-1 MAP kinase signaling pathway induces the vulva in C. elegans. We show that MPK-1 directly regulates both the LIN-31 winged-helix and the LIN-1 Ets transcription factors to specify the vulval cell fate, lin-31 and lin-1 act genetically downstream of mpk-1, and both proteins can be directly phosphorylated by MAP kinase. LIN-31 binds to LIN-1, and the LIN-1/LIN-31 complex inhibits vulval induction. Phosphorylation of LIN-31 by MPK-1 disrupts the LIN-1/LIN-31 complex, relieving vulval inhibition. Phosphorylated LIN-31 may also act as a transcriptional activator, promoting vulval cell fates. LIN-31 is a vulval-specific effector of MPK-1, while LIN-1 acts as a general effector. The partnership of tissue-specific and general effecters may confer specificity onto commonly used signaling pathways, creating distinct tissue-specific outcomes.	Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA	Stanford University	Kim, SK (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.		Lackner, Mark/G-4597-2012	Lackner, Mark/0000-0002-6375-2037				AROIAN RV, 1991, GENETICS, V128, P251; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; CHAMBERLIN HM, 1994, DEVELOPMENT, V120, P2713; CHURCH DL, 1995, DEVELOPMENT, V121, P2525; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Euling S, 1996, CELL, V84, P667, DOI 10.1016/S0092-8674(00)81045-4; FERGUSON EL, 1985, GENETICS, V110, P17; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Hajnal A, 1997, GENE DEV, V11, P2715, DOI 10.1101/gad.11.20.2715; HAN M, 1990, GENETICS, V126, P899; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KOGA M, 1995, DEVELOPMENT, V121, P2655; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Maloof JN, 1998, DEVELOPMENT, V125, P181; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; PTASHNE M, 1980, CELL, V19, P1, DOI 10.1016/0092-8674(80)90383-9; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Sundaram M, 1996, DEVELOPMENT, V122, P2823; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wood WB, 1988, NEMATODE CAENORHABDI; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147; Yochem J, 1997, MOL CELL BIOL, V17, P2716, DOI 10.1128/MCB.17.5.2716	33	161	173	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					569	580		10.1016/S0092-8674(00)81186-1	http://dx.doi.org/10.1016/S0092-8674(00)81186-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604932	Bronze			2022-12-28	WOS:000073722200010
J	Ayanian, JZ; Landrum, MB; Normand, SLT; Guadagnoli, E; McNeil, BJ				Ayanian, JZ; Landrum, MB; Normand, SLT; Guadagnoli, E; McNeil, BJ			Rating the appropriateness of coronary angiography - Do practicing physicians agree with an expert panel and with each other?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; NEW-YORK-STATE; PRACTICE GUIDELINES; PRIMARY ANGIOPLASTY; CARDIAC PROCEDURES; CLINICAL-PRACTICE; UNITED-STATES; MEDICAL-CARE; SPECIALTY; CARDIOLOGISTS	Background Evaluations of the appropriateness of medical care are important to monitor the quality of care and to contain costs and enhance safety by reducing inappropriate care. Experts' views are usually incorporated into evaluations of appropriateness. However, practicing physicians may not concur with these views, and physicians' clinical backgrounds may influence their beliefs. Methods We asked 1058 internists, family practitioners, and cardiologists in California, Florida, New York, Pennsylvania, and Texas to rate the appropriateness of coronary angiography after acute myocardial infarction for 20 common indications. Nine clinical experts also rated these indications using an established consensus method. Results For 17 of the 20 indications, median ratings of surveyed physicians and the expert panel agreed within 1 unit on a 9-unit scale. Patients' older age had a negative effect on ratings by the expert panel but not on ratings by surveyed physicians. In multivariable analyses of surveyed physicians, cardiologists rated angiography as significantly more appropriate than did primary care physicians for complicated indications, and for uncomplicated indications cardiologists who performed invasive procedures gave higher appropriateness ratings for angiography than did cardiologists who did not perform such procedures and primary care physicians. For uncomplicated indications, physicians from hospitals providing coronary angioplasty and bypass surgery rated angiography as more appropriate than physicians from other hospitals. Physicians from New York and those employed by health maintenance organizations rated angiography as less appropriate than other physicians. Conclusions Surveyed physicians agreed with clinical experts about the appropriateness of coronary angiography after myocardial infarction for most indications, indicating that well-designed expert panels can closely reflect the views of practicing physicians. Variations in beliefs among practicing physicians suggest that evaluations of medical practice should incorporate the views of a range of relevant types of physicians. (N Engl J Med 1998;338:1896-904.) (C) 1998, Massachusetts Medical Society.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Gen Med & Primary Care, Sect Hlth Serv & Policy Res, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Ayanian, JZ (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.			Normand, Sharon-Lise/0000-0001-7027-4769	AHRQ HHS [HS07081] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAY L, 1989, DESIGNING CONDUCTING; [Anonymous], CORONARY ANGIOGRAPHY; Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Ayanian JZ, 1997, ARCH INTERN MED, V157, P2570, DOI 10.1001/archinte.157.22.2570; Bates DW, 1997, ANN INTERN MED, V126, P539, DOI 10.7326/0003-4819-126-7-199704010-00007; BATTISTA RN, 1995, J CLIN EPIDEMIOL, V48, P875, DOI 10.1016/0895-4356(94)00199-Z; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BLUSTEIN J, 1993, JAMA-J AM MED ASSOC, V270, P344, DOI 10.1001/jama.270.3.344; BOROWSKY SJ, 1995, J AM COLL CARDIOL, V26, P1484, DOI 10.1016/0735-1097(95)00337-1; BROOK RH, 1988, LANCET, V1, P750; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2543, DOI 10.1001/jama.258.18.2543; DiSalvo TG, 1996, J AM COLL CARDIOL, V27, P262, DOI 10.1016/0735-1097(95)00488-2; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; Friedmann PD, 1996, ANN INTERN MED, V124, P414, DOI 10.7326/0003-4819-124-4-199602150-00005; GATSONIS CA, 1995, MED CARE, V33, P625, DOI 10.1097/00005650-199506000-00005; GILKS WR, 1994, STATISTICIAN, V43, P169, DOI 10.2307/2348941; GRILLI R, 1994, MED CARE, V32, P202, DOI 10.1097/00005650-199403000-00002; Grines CL, 1996, NEW ENGL J MED, V335, P1313; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; Kahan JP, 1996, MED CARE, V34, P512, DOI 10.1097/00005650-199606000-00002; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2538, DOI 10.1001/jama.258.18.2538; LANDRUM MB, IN PRESS STAT MED; Lange RA, 1996, NEW ENGL J MED, V335, P1311; Layde PM, 1996, J CLIN EPIDEMIOL, V49, P835, DOI 10.1016/0895-4356(96)00006-6; MCGLYNN EA, 1994, JAMA-J AM MED ASSOC, V272, P934, DOI 10.1001/jama.272.12.934; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; Peterson ED, 1997, ANN INTERN MED, V126, P561, DOI 10.7326/0003-4819-126-7-199704010-00012; Peterson ED, 1997, ANN INTERN MED, V126, P556, DOI 10.7326/0003-4819-126-7-199704010-00012; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; Pilote L, 1996, NEW ENGL J MED, V335, P1198, DOI 10.1056/NEJM199610173351606; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; PILOTE L, 1995, MED CARE, V33, P598, DOI 10.1097/00005650-199506000-00003; Poses RM, 1997, MED CARE, V35, P603, DOI 10.1097/00005650-199706000-00006; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; STONE GW, 1995, J AM COLL CARDIOL, V25, P370, DOI 10.1016/0735-1097(94)00367-Y; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; Wennberg DE, 1997, J GEN INTERN MED, V12, P172	41	134	134	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1998	338	26					1896	1904		10.1056/NEJM199806253382608	http://dx.doi.org/10.1056/NEJM199806253382608			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV898	9637811				2022-12-28	WOS:000074352800008
J	Berthold, HK; Sudhop, T; von Bergmann, K				Berthold, HK; Sudhop, T; von Bergmann, K			Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							METAANALYSIS; LIPIDS; BIOSYNTHESIS; HEPATOCYTES; EXCRETION; POWDER; PLASMA; HUMANS	Context.-Garlic-containing drugs have been used in the treatment of hypercholesterolemia even though their efficacy is not generally established. Little is known about the mechanisms of action of the possible effects on cholesterol in humans. Objective.-To estimate the hypocholesterolemic effect of garlic oil and to investigate the possible mechanism of action. Design-Double-blind, randomized, placebo-controlled trial. Setting.-Outpatient lipid clinic. Patients.-We investigated 25 patients (mean age, 58 years) with moderate hypercholesterolemia. Intervention.-Steam-distilled garlic oil preparation (5 mg twice a day) vs placebo each for 12 weeks with wash-out periods of 4 weeks. Main Outcome Measures.-Serum lipoprotein concentrations, cholesterol absorption, and cholesterol synthesis. Results.-Baseline lipoprotein profiles were (mean [SD]):total cholesterol, 7.53 (0.75) mmol/L (291 [29] mg/dL); low-density lipoprotein cholesterol (LDL-C), 5.35 (0.78) mmol/L (207 [30] mg/dL); high-density lipoprotein cholesterol (HDL-C), 1.50 (0.41) mmol/L (58 [16] mg/dL); and triglycerides, 1.45 (0.73) mmol/L (127 [64] mg/dL). Lipoprotein levels were virtually unchanged at the end of both treatment periods (mean difference [95% confidence interval]): total cholesterol, 0.085 (-0.201 to 0.372) mmol/L (3.3 [-7.8 to 14.4] mg/dL), P=.54; LDL-C, 0.001 (-0.242 to 0.245) mmol/L (0.04 [-9.4 to 9.5] mg/dL), P=.99; HDL-C, 0.050 (-0.028 to 0.128) mmol/L (1.9 [-1.1 to 4.9] mg/dL), P=.20; triclycerides, 0.047 (-0.229 to 0.135) mmol/L (4.2 [-20.3 to 12.0]) mg/dL, P=.60. Cholesterol absorption (37.5% [10.5%] vs 38.3% [10.7%], P=.58), cholesterol synthesis (12.7 [6.5] vs 13.4 [6.6] mg/kg of body weight per day, P=.64), mevalonic acid excretion (192 [66] vs 187 [66] mu g/d, P=.78), and changes in the ratio of lathosterol to cholesterol in serum (4.4% [24.3%] vs 10.6% [21.1%], P=.62) were not different in garlic and placebo treatment. Conclusions.-The commercial garlic oil preparation investigated had no influence on serum lipoproteins, cholesterol absorption, or cholesterol synthesis. Garlic therapy for treatment of hypercholesterolemia cannot be recommended on the basis of this study.	Univ Bonn, Dept Clin Pharmacol, D-53105 Bonn, Germany	University of Bonn	Berthold, HK (corresponding author), Univ Bonn, Dept Clin Pharmacol, Sigmund Freud St 25, D-53105 Bonn, Germany.		Berthold, Heiner K./E-6017-2011	Berthold, Heiner K./0000-0002-1457-2216				Adler AJ, 1997, AM J CLIN NUTR, V65, P445, DOI 10.1093/ajcn/65.2.445; BEAGLEHOLE R, 1996, LANCET, V348, P186; BJORKHEM I, 1987, J LIPID RES, V28, P1137; CZUBAYKO F, 1991, J LIPID RES, V32, P1861; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GEBHARDT R, 1994, BBA-LIPID LIPID MET, V1213, P57, DOI 10.1016/0005-2760(94)90222-4; GEBHARDT R, 1993, LIPIDS, V28, P613, DOI 10.1007/BF02536055; HARENBERG J, 1988, ATHEROSCLEROSIS, V74, P247, DOI 10.1016/0021-9150(88)90244-4; JAIN AK, 1993, AM J MED, V94, P632, DOI 10.1016/0002-9343(93)90216-C; Jones PJH, 1997, AM J CLIN NUTR, V66, P438, DOI 10.1093/ajcn/66.2.438; LELORIE J, 1997, NEW ENGL J MED, V337, P736; Lindenthal B, 1996, J LIPID RES, V37, P2193; LUTJOHANN D, 1993, J LIPID RES, V34, P1039; MADER FH, 1990, ARZNEIMITTEL-FORSCH, V40-2, P1111; Neil Andrew, 1994, Current Opinion in Lipidology, V5, P6, DOI 10.1097/00041433-199402000-00002; Neil HAW, 1996, J ROY COLL PHYS LOND, V30, P329; REUTER HD, 1991, Z PHYTOTHER, V12, P83; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P329; SILAGY CA, 1994, J ROY COLL PHYS LOND, V28, P39; SIMONS LA, 1995, ATHEROSCLEROSIS, V113, P219, DOI 10.1016/0021-9150(94)05449-S; Steiner M, 1996, AM J CLIN NUTR, V64, P866, DOI 10.1093/ajcn/64.6.866; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; WARSHAFSKY S, 1993, ANN INTERN MED, V119, P599, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00009; WINKLER G, 1992, DTSCH APOTH ZTG, V132, P2312	24	136	146	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1998	279	23					1900	1902		10.1001/jama.279.23.1900	http://dx.doi.org/10.1001/jama.279.23.1900			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT653	9634262				2022-12-28	WOS:000074109700038
J	Andrews, K				Andrews, K			Prediction of recovery from post-traumatic vegetative state	LANCET			English	Editorial Material									Royal Hosp Neurodisabil, London SW15 3SW, England		Andrews, K (corresponding author), Royal Hosp Neurodisabil, London SW15 3SW, England.								0	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1751	1751		10.1016/S0140-6736(05)78740-7	http://dx.doi.org/10.1016/S0140-6736(05)78740-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635943				2022-12-28	WOS:000074197600004
J	Rainer, G; Asaad, WF; Miller, EK				Rainer, G; Asaad, WF; Miller, EK			Selective representation of relevant information by neurons in the primate prefrontal cortex	NATURE			English	Article							NEURAL MECHANISMS; VISUAL-ATTENTION; MEMORY	The severe limitation of the capacity of working memory, the ability to store temporarily and manipulate information(1), necessitates mechanisms that restrict access to it. Here we report tests to discover whether the activity of neurons in the prefrontal (PF) cortex, the putative neural correlate of working memory(2-8), might reflect these mechanisms and preferentially represent behaviourally relevant information. Monkeys performed a 'delayed-matching-to-sample' task with an array of three objects. Only one of the objects in the array was relevant for task performance and the monkeys needed to find that object (the target) and remember its location. For many PF neurons, activity to physically identical arrays varied with the target location; the location of the non-target objects had little or no influence on activity. Information about the target location was present in activity as early as 140 ms after array onset. Also, information about which object was the target was reflected in the sustained activity of many PF neurons. These results suggest that the prefrontal cortex is involved in selecting and maintaining behaviourally relevant information.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; MIT, Ctr Learning & Memory, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Miller, EK (corresponding author), MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA.	ekm@ai.mit.edu	Rainer, Gregor/B-5876-2012; Miller, Earl K./AAE-8187-2019; Asaad, Wael/I-8485-2012	Miller, Earl K./0000-0002-0582-6958; Asaad, Wael/0000-0003-4406-9096; Rainer, Gregor/0000-0002-5805-2220				Baddeley A.D., 1986, WORKING MEMORY THOUG; CHELAZZI L, 1993, NATURE, V363, P345, DOI 10.1038/363345a0; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DIPELLEGRINO G, 1991, BRAIN, V114, P951; DUNCAN J, 1989, PSYCHOL REV, V96, P433, DOI 10.1037/0033-295X.96.3.433; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; Gottlieb JP, 1998, NATURE, V391, P481, DOI 10.1038/35135; Hasegawa R, 1998, J NEUROPHYSIOL, V79, P322, DOI 10.1152/jn.1998.79.1.322; HOFFMAN JE, 1995, PERCEPT PSYCHOPHYS, V57, P787, DOI 10.3758/BF03206794; Kahneman D., 1973, ATTENTION EFFORT; KUBOTA K, 1971, J NEUROPHYSIOL, V34, P337, DOI 10.1152/jn.1971.34.3.337; Luck SJ, 1997, NATURE, V390, P279, DOI 10.1038/36846; Luck SJ, 1997, J NEUROPHYSIOL, V77, P24, DOI 10.1152/jn.1997.77.1.24; Miller EK, 1996, J NEUROSCI, V16, P5154; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; Moody SL, 1998, J NEUROSCI, V18, P399; Rao SC, 1997, SCIENCE, V276, P821, DOI 10.1126/science.276.5313.821; SHEPARD M, 1997, Q J EXP PSYCHOL-A, V38, P475	19	428	436	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					577	579		10.1038/31235	http://dx.doi.org/10.1038/31235			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634233				2022-12-28	WOS:000074150100052
J	Sillanpaa, M; Jalava, M; Kaleva, O; Shinnar, S				Sillanpaa, M; Jalava, M; Kaleva, O; Shinnar, S			Long-term prognosis of seizures with onset in childhood	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUDDEN UNEXPLAINED DEATH; ANTIEPILEPTIC DRUGS; EPILEPSY; PREDICTORS; ADJUSTMENT; REMISSION; CHILDREN; THERAPY; COHORT	Background The long-term prognosis of seizures that begin in childhood is uncertain. Methods We prospectively studied 245 children from the catchment area of Turku University Hospital in Turku, Finland, who had active epilepsy diagnosed between 1961 and 1964. Sixty-eight patients (28 percent) had idiopathic seizures (presumed to have a genetic origin), 54 (22 percent) had cryptogenic seizures (occurring in otherwise normal persons with no clear cause), and 123 (50 percent) had remote symptomatic seizures (with no immediate cause but occurring in persons with a prior brain injury or a static encephalopathy). Results At the final follow-up in 1992, we had sufficient data on 220 patients (90 percent), 176 of whom were alive and 44 of whom had died; the remaining 25 had emigrated, could not be traced, or declined to participate. Thirty-nine patients who died were not free of seizures at the time of death, and 33 had remote symptomatic seizures. Among the surviving patients, 112 (64 percent) had been seizure-free for at least five years, including 83 (47 percent) who were not taking antiepileptic medications. The most important predictors of being seizure-free for at least five years were a rapid response to therapy (defined as a reduction in the frequency of seizures of 75 to 100 percent within three months of beginning treatment) and a diagnosis of idiopathic seizures. As compared with a matched control group, 99 patients with epilepsy but no other initial neurologic impairment were of similar socioeconomic status and had similar rates of passing an examination given after 12 years of school. Significantly more patients, however, had completed only six years of school (relative risk, 2.13), were unemployed (relative risk, 3.76), were not married (relative risk, 3.50), and did not have children (relative risk, 3.00). Conclusions Although the majority of patients with epilepsy in childhood are free of seizures by the time they become adults, they are at increased risk for social and educational problems. Patients whose epilepsy does not remit also have an increased risk of death. (C) 1998, Massachusetts Medical Society.	Univ Turku, Dept Pediat Neurol, Turku, Finland; Univ Turku, Dept Biostat, Turku, Finland; Montefiore Med Ctr, Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA; Montefiore Med Ctr, Albert Einstein Coll Med, Comprehens Epilepsy Management Ctr, Bronx, NY 10467 USA	University of Turku; University of Turku; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Sillanpaa, M (corresponding author), Turku Univ Hosp TYKS, Dept Child Neurol, FIN-20520 Turku, Finland.		Sillanpaa, Matti L/G-4708-2015	Sillanpaa, Matti L/0000-0003-4190-3698	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026151] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26151] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1993, EPILEPSIA, V34, P592; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BAX M C, 1964, Dev Med Child Neurol, V6, P295; BEGHI E, 1988, EPILEPSIA, V29, P236, DOI 10.1111/j.1528-1157.1988.tb03712.x; Berg A T, 1995, CHILDHOOD SEIZURES, P1; Berg AT, 1996, EPILEPSIA, V37, P24, DOI 10.1111/j.1528-1157.1996.tb00507.x; BERG AT, 1995, EPILEPSIA, V36, P3; BERG AT, 1995, CHILDHOOD SEIZURES, P93; BRORSON LO, 1987, EPILEPSIA, V28, P324, DOI 10.1111/j.1528-1157.1987.tb03651.x; CALLAGHAN N, 1992, IRISH MED J, V85, P17; CAMFIELD C, 1993, J PEDIATR-US, V122, P861, DOI 10.1016/S0022-3476(09)90008-7; CAMFIELD C, 1993, J PEDIATR-US, V122, P869, DOI 10.1016/S0022-3476(09)90009-9; Camfield CS, 1996, EPILEPSIA, V37, P19, DOI 10.1111/j.1528-1157.1996.tb00506.x; CARLTONFORD S, 1995, J HEALTH SOC BEHAV, V36, P285, DOI 10.2307/2137344; *CENTR STAT OFF, 1989, CLASS SOC GROUPS; COCKERELL OC, 1995, LANCET, V346, P140, DOI 10.1016/S0140-6736(95)91208-8; COX DR, 1972, J R STAT SOC B, V34, P187; Derby LE, 1996, EPILEPSIA, V37, P931, DOI 10.1111/j.1528-1157.1996.tb00529.x; Dichter MA, 1996, NEW ENGL J MED, V334, P1583, DOI 10.1056/NEJM199606133342407; Dixon W.J, 1990, BMDP STAT SOFTWARE; Elandt-Johnson RC, 1980, SURVIVAL MODELS DATA, P150; ELWES RDC, 1984, NEW ENGL J MED, V311, P944, DOI 10.1056/NEJM198410113111503; Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; Hauser W, 1990, EPILEPSY FREQUENCY C; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1980, EPILEPSIA, V21, P399, DOI 10.1111/j.1528-1157.1980.tb04088.x; HUTTENLOCHER PR, 1990, ANN NEUROL, V28, P699, DOI 10.1002/ana.410280516; Jacoby A, 1996, EPILEPSIA, V37, P148, DOI 10.1111/j.1528-1157.1996.tb00006.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELSEY JL, 1986, METHODS OBSERVATIONA; LATHERS CM, 1990, EPILEPSY SUDDEN DEAT; LEESTMA JE, 1989, ANN NEUROL, V26, P195, DOI 10.1002/ana.410260203; MITCHELL WG, 1991, J CHILD NEUROL, V6, P65, DOI 10.1177/088307389100600114; NASHEF L, 1995, EPILEPSIA, V36, P1187, DOI 10.1111/j.1528-1157.1995.tb01061.x; OLSSON I, 1993, EPILEPSIA, V34, P846, DOI 10.1111/j.1528-1157.1993.tb02101.x; OUNSTED C, 1987, 103 CLIN DEV MED; SCHUPF N, 1994, EPILEPSIA, V35, P750, DOI 10.1111/j.1528-1157.1994.tb02506.x; Shinnar S, 1996, EPILEPSIA, V37, P701, DOI 10.1111/j.1528-1157.1996.tb00639.x; Sillanpaa M., 1973, ACTA PAEDIATR SC   S, V237, P1; SOFIJANOV NG, 1982, EPILEPSIA, V23, P61, DOI 10.1111/j.1528-1157.1982.tb05053.x; TENNIS P, 1995, EPILEPSIA, V36, P29, DOI 10.1111/j.1528-1157.1995.tb01661.x; WESTBROOK LE, 1991, J EPILEPSY, V4, P87, DOI 10.1016/S0896-6974(05)80066-0; World Health Organization, 1980, INT CLASS IMP DIS HA	45	497	503	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1998	338	24					1715	1722		10.1056/NEJM199806113382402	http://dx.doi.org/10.1056/NEJM199806113382402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT654	9624191	Bronze			2022-12-28	WOS:000074109800002
J	Jenks, PJ; Stewart, B				Jenks, PJ; Stewart, B			Vertebral tuberculosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Inst Pasteur, F-75724 Paris, France; Royal London Hosp, London E1 7BE, England	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Barts Health NHS Trust; Royal London Hospital	Jenks, PJ (corresponding author), Inst Pasteur, F-75724 Paris, France.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1998	338	23					1677	1677		10.1056/NEJM199806043382306	http://dx.doi.org/10.1056/NEJM199806043382306			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR451	9614259				2022-12-28	WOS:000073978000006
J	Camus, M; Siemiatycki, J; Meek, B				Camus, M; Siemiatycki, J; Meek, B			Nonoccupational exposure to Chrysotile asbestos and the risk of lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MAN-MADE FIBERS; PLEURAL MESOTHELIOMA; PUBLIC-POLICY; DUST EXPOSURE; METSOVO LUNG; MORTALITY; TREMOLITE; WORKERS; COHORT; CARCINOGENICITY	Background Heavy industrial exposure to asbestos causes lung cancer and mesothelioma, but it remains unknown whether much lower environmental exposure to asbestos also causes these cancers. Nevertheless, regulatory agencies, including the Environmental Protection Agency (EPA), have assessed the risk of lung cancer by extrapolating known risks from past industrial exposure to asbestos to today's much lower environmental asbestos levels (roughly 100,000 times lower). We also tested the EPA's model for predicting the risk of asbestos-induced lung cancer in a population of women with relatively high levels of nonoccupational exposure to asbestos. Methods Mortality among women in 2 chrysotile-asbestos-mining areas of the province of Quebec was compared with mortality among women in 60 control areas, and age-standardized mortality ratios were derived. With the help of an expert panel, we estimated past exposure to asbestos among women in the mining areas and used these data with the EPA's model to predict the relative risk of lung cancer. We then compared this prediction with the ob served mortality ratios. Results On the basis of the estimated exposure in the asbestos-mining areas, a relative risk of death due to lung cancer of 2.1 was predicted by the EPA's model, amounting to about 75 excess deaths from lung cancer in this population. By contrast, we cal culated a standardized mortality ratio of 1.0 and a standardized proportionate mortality ratio of 1.1 (P>0.05), suggesting that there were between 0 and 6.5 excess deaths from lung cancer among the women en with nonoccupational exposure to asbestos. Seven deaths from pleural cancer were observed (relative risk, 7.63; P<0.05). Conclusions We found no measurable excess risk of death due to lung cancer among women in two chrysotile-asbestos-mining regions. The EPA's model overestimated the risk of asbestos-induced lung cancer by at least a factor of 10. (C) 1998, Massachusetts Medical Society.	Univ Quebec, Inst Armand Frappier, Unit Epidemiol & Biostat, Laval, PQ H7V 4Z3, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; Hlth Canada, Ctr Environm Hlth, Ottawa, ON K1A 0L2, Canada	University of Quebec; McGill University; Health Canada	Camus, M (corresponding author), Univ Quebec, Inst Armand Frappier, Unit Epidemiol & Biostat, 531 Boul Prairies, Laval, PQ H7V 4Z3, Canada.							ABELSON PH, 1990, SCIENCE, V247, P1017, DOI 10.1126/science.2309114; ACHESON AD, 1983, ASBESTOS CONTROL LIM; Anderson H., 1982, ASBESTOS HLTH SOC, P349; AXELSON O, 1978, SCAND J WORK ENV HEA, V4, P98, DOI 10.5271/sjweh.2720; BARIS I, 1987, INT J CANCER, V39, P10, DOI 10.1002/ijc.2910390104; BERRY J, 1990, SCIENCE, V248, P1595, DOI 10.1126/science.2363042; BOTHA JL, 1986, AM J EPIDEMIOL, V123, P30, DOI 10.1093/oxfordjournals.aje.a114221; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BRODY AR, 1990, SCIENCE, V248, P795; CAMUS M, 1997, THESIS MCGILL U MONT; CARTER RF, 1970, AEWRE02870; CASE BW, 1989, IARC SCI PUBL, V90, P207; Committee on Nonoccupational Health Risks of Asbestiform Fibers; Board on Toxicology and Environmental Health Hazards; Commission on Life Sciences; and National Research Council (NRC), 1984, ASB FIB NON HLTH RIS; *CONSAD, 1990, J9F80033 OSHA DEP LA; CONSTANTOPOULOS SH, 1985, ENVIRON RES, V38, P319, DOI 10.1016/0013-9351(85)90096-9; *DIR HLTH SCI, 1983, REP US CONS PROD SAF; DOLL R, 1985, ASBESTOS EFFECTS HLT, P1; EMOND A, 1988, SANTE CAVA RAPPORT E; GIBBS GW, 1972, ARCH ENVIRON HEALTH, V24, P189; GIBBS GW, 1980, 73 ANN M AIR POLL CO; GOLDBERG P, 1995, REV EPIDEMIOL SANTE, V43, P444; Hammond E C, 1979, Ann N Y Acad Sci, V330, P473, DOI 10.1111/j.1749-6632.1979.tb18749.x; HUNT R, 1982, DIFFERENCES REAEROSA; LANGER AM, 1987, LANCET, V1, P965; LANGER AM, 1990, SCIENCE, V249, P1485, DOI 10.1126/science.2218485; Lash TL, 1997, OCCUP ENVIRON MED, V54, P254, DOI 10.1136/oem.54.4.254; LOSLIER L, 1983, MED QUEBEC, V18, P97; LUCE D, 1994, LANCET, V344, P1777, DOI 10.1016/S0140-6736(94)92919-X; LUMLEY K P S, 1971, Annals of Occupational Hygiene, V14, P255; MAGNANI C, 1993, BRIT J IND MED, V50, P779; MCCLELLAN RO, 1994, ENVIRON HEALTH PERSP, V102, P277, DOI 10.2307/3432103; MCCLELLAN RO, 1992, REGUL TOXICOL PHARM, V16, P321, DOI 10.1016/0273-2300(92)90011-W; MCDONALD JC, 1993, BRIT J IND MED, V50, P1058; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; MOSSMAN BT, 1989, NEW ENGL J MED, V320, P1721, DOI 10.1056/NEJM198906293202604; NICHOLSON WJ, 1990, SCIENCE, V248, P796, DOI 10.1126/science.248.4957.796; Nicholson WJ, 1986, EPA600884003F OFF HL; NICHOLSON WJ, 1980, AIRC SCI PUBLICATION, V30, P823; *ONT MIN ATT GEN, 1984, REP ROYAL COMM MATT, V1; PAMPALON R, 1982, UNION MED CAN, V111, P475; RIBAK J, 1989, SCAND J WORK ENV HEA, V15, P106, DOI 10.5271/sjweh.1877; RIBAK J, 1991, J SOC OCCUP MED, V41, P137; ROHL AN, 1982, SCIENCE, V216, P518, DOI 10.1126/science.7071597; SAMUELS SW, 1990, SCIENCE, V248, P795, DOI 10.1126/science.248.4957.795-b; SARACCI R, 1977, INT J CANCER, V20, P323, DOI 10.1002/ijc.2910200302; SAWYER RN, 1977, ENVIRON RES, V13, P146, DOI 10.1016/0013-9351(77)90013-5; SEBASTIEN P, 1989, BRIT J IND MED, V46, P180; SEBASTIEN P, 1991, MINERAL FIBERS HLTH, P229; SEBASTIEN P, 1986, 5APRQ2 EPS ENV CAN; SELIKOFF IJ, 1992, AM J IND MED, V22, P481, DOI 10.1002/ajim.4700220403; SIEMIATYCKI J, 1982, P WORLD S ASB MONTR, P337; STONE R, 1991, SCIENCE, V254, P928, DOI 10.1126/science.1948074; Tonnel AB, 1997, EFFETS SANTE PRINCIP; Upton A, 1991, ASBESTOS PUBLIC COMM; WAGNER JC, 1974, BRIT J CANCER, V29, P252, DOI 10.1038/bjc.1974.65; WIGLE DT, 1977, ARCH ENVIRON HEALTH, V32, P185, DOI 10.1080/00039896.1977.10667278; 1989, WALL STREET J   0918, pA16	57	124	126	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1998	338	22					1565	1571		10.1056/NEJM199805283382201	http://dx.doi.org/10.1056/NEJM199805283382201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ350	9603793				2022-12-28	WOS:000073852400001
J	Hafen, E				Hafen, E			Kinases and phosphatases - A marriage is consummated	SCIENCE			English	Article							OF-FUNCTION MUTATION; SIGNALING PATHWAYS		Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland	University of Zurich	Hafen, E (corresponding author), Univ Zurich, Inst Zool, Winterthurerstr 190, CH-8057 Zurich, Switzerland.							BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Muda M, 1996, J BIOL CHEM, V271, P4319; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sundaram M, 1996, BIOESSAYS, V18, P473, DOI 10.1002/bies.950180609; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; WESTPHAL RS, COMMUNICATION	12	33	35	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 22	1998	280	5367					1212	1213		10.1126/science.280.5367.1212	http://dx.doi.org/10.1126/science.280.5367.1212			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9634402				2022-12-28	WOS:000073852500031
J	Agmon-Snir, H; Carr, CE; Rinzel, J				Agmon-Snir, H; Carr, CE; Rinzel, J			The role of dendrites in auditory coincidence detection	NATURE			English	Article							INTERAURAL TIME DIFFERENCES; MEDIAL SUPERIOR OLIVE; COCHLEAR NUCLEUS; BRAIN-STEM; NEURONS; CELLS; INFORMATION; MODEL; INTERNEURONS; INTEGRATION	Coincidence-detector neurons in the auditory brainstem of mammals and birds use interaural time differences to localize sounds(1,2). Each neuron receives many narrow-band inputs from both ears and compares the time of arrival of the inputs with an accuracy of 10-100 mu s (refs 3-6). Neurons that receive low-frequency auditory inputs (up to about 2 kHz) have bipolar dendrites, and each dendrite receives inputs from only one ear(7,8). Using a simple model that mimics the essence of the known electrophysiology and geometry of these cells, we show here that dendrites improve the coincidence-detection properties of the cells. The biophysical mechanism for this improvement is based on the nonlinear summation of excitatory inputs in each of the dendrites and the use of each dendrite as a current sink for inputs to the other dendrite. This is a rare casein which the contribution of dendrites to the known computation of a neuron may be understood. Our results show that, in these neurons, the cell morphology and the spatial distribution of the inputs enrich the computational power of these neurons beyond that expected from 'point neurons' (model neurons lacking dendrites).	Univ Maryland, Dept Zool, College Pk, MD 20742 USA; NIDDK, Math Res Branch, NIH, Bethesda, MD 20892 USA	University System of Maryland; University of Maryland College Park; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Carr, CE (corresponding author), Univ Maryland, Dept Zool, College Pk, MD 20742 USA.	carr@zool.umd.edu						Agmon-Snir H., 1996, Society for Neuroscience Abstracts, V22, P402; BORST A, 1994, TRENDS NEUROSCI, V17, P257, DOI 10.1016/0166-2236(94)90009-4; Borst A, 1996, ACTA PHYSIOL SCAND, V157, P403, DOI 10.1046/j.1365-201X.1996.30250000.x; Brughera AR, 1996, AUDIT NEUROSCI, V2, P219; CARR CE, 1993, ANNU REV NEUROSCI, V16, P223, DOI 10.1146/annurev.ne.16.030193.001255; CARR CE, 1990, J NEUROSCI, V10, P3227; COLBURN HS, 1990, HEARING RES, V49, P335, DOI 10.1016/0378-5955(90)90112-3; Gerstner W, 1996, NATURE, V383, P76, DOI 10.1038/383076a0; GOLDBERG JM, 1969, J NEUROPHYSIOL, V32, P613, DOI 10.1152/jn.1969.32.4.613; Haag J, 1996, NATURE, V379, P639, DOI 10.1038/379639a0; JEFFRESS LA, 1948, J COMP PHYSIOL PSYCH, V41, P35, DOI 10.1037/h0061495; Mainen ZF, 1996, NATURE, V382, P363, DOI 10.1038/382363a0; MANIS PB, 1991, J NEUROSCI, V11, P2865; MEL BW, 1994, NEURAL COMPUT, V6, P1031, DOI 10.1162/neco.1994.6.6.1031; MORRIS C, 1981, BIOPHYS J, V35, P193, DOI 10.1016/S0006-3495(81)84782-0; OVERHOLT EM, 1992, J NEUROSCI, V12, P1698; PARKS TN, 1978, J COMP NEUROL, V180, P439, DOI 10.1002/cne.901800303; Pinsky P F, 1994, J Comput Neurosci, V1, P39, DOI 10.1007/BF00962717; REYES AD, 1994, J NEUROSCI, V14, P5352; Reyes AD, 1996, J NEUROSCI, V16, P993; Rinzel J., 1989, METHODS NEURONAL MOD, P135; SEGEV I, 1995, HDB BRAIN THEORY NEU, P282; Shepherd G.M., 1995, THEORETICAL FDN DEND; SMITH DJ, 1979, J COMP NEUROL, V186, P213, DOI 10.1002/cne.901860207; SMITH PH, 1995, J NEUROPHYSIOL, V73, P1653, DOI 10.1152/jn.1995.73.4.1653; SOFTKY WR, 1993, J NEUROSCI, V13, P334; STOTLER WA, 1953, J COMP NEUROL, V98, P401, DOI 10.1002/cne.900980303; WARCHOL ME, 1990, J COMP PHYSIOL A, V166, P721; YIN TCT, 1990, J NEUROPHYSIOL, V64, P465, DOI 10.1152/jn.1990.64.2.465; ZHANG S, 1994, J NEUROPHYSIOL, V72, P705, DOI 10.1152/jn.1994.72.2.705	30	268	271	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					268	272		10.1038/30505	http://dx.doi.org/10.1038/30505			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607764				2022-12-28	WOS:000073761000054
J	Pellegrino, ED				Pellegrino, ED			Emerging ethical issues in palliative care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Georgetown Univ, Med Ctr, Ctr Clin Bioeth, Washington, DC 20007 USA	Georgetown University	Pellegrino, ED (corresponding author), Georgetown Univ, Med Ctr, Ctr Clin Bioeth, 4000 Reservior Rd NW,Room D-238, Washington, DC 20007 USA.							ASHLEY BM, 1989, HLTH CARE ETHICS, P184; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Canadian Palliative Care Association, 1995, PALL CAR CONS STAND; CLARK D, 1993, FUTURE PALLIATIVE CA; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FOLEY KM, 1993, OPIOIDS, V2, P697; Glick SM, 1997, NEW ENGL J MED, V336, P954, DOI 10.1056/NEJM199703273361312; GREGORY J, 1772, DUTIES OFFICES PHYSI; HIGGINSON I, 1993, J PUBLIC HEALTH MED, V15, P3, DOI 10.1093/oxfordjournals.pubmed.a042817; HIPPOCRATES, 1972, JOINTS 8, V2, P299; Hippocrates, 1923, ART HIPPOCRATES, V2, P193; Kaldjian LC, 1998, AIDS, V12, P103, DOI 10.1097/00002030-199801000-00012; Limbird, 1996, GOODMAN GILMANS PHAR, P557; Lynn J, 1997, New Horiz, V5, P56; Nash A, 1989, Prof Nurse, V4, P443; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; PELLEGRINO ED, 1981, PHILOS BASIS MED PRA, P223; PIUS XII, 1957, ALLOCUTIO ACTA APOST, V49, P129; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; RANDALL F, 1996, PALLIATIVE CARE ETHI; Sulmasy DP, 1996, CLIN PULM MED, V3, P86; SURBONE A, 1997, COMMUNICATION CANC P; WOODRUFF R, 1993, PALLIATIVE MED SYMPT	23	34	36	2	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1521	1522		10.1001/jama.279.19.1521	http://dx.doi.org/10.1001/jama.279.19.1521			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN087	9605885				2022-12-28	WOS:000073608100013
J	Dodwell, DJ				Dodwell, DJ			Adjuvant cytotoxic chemotherapy for early breast cancer: doubts and decisions	LANCET			English	Editorial Material							BENEFIT		Cookridge Hosp, York Ctr Clin Oncol, Leeds LS16 6QB, W Yorkshire, England; Leeds Gen Infirm, Breast Unit, Leeds, W Yorkshire, England	Cookridge Hospital; Leeds General Infirmary; University of Leeds	Dodwell, DJ (corresponding author), Cookridge Hosp, York Ctr Clin Oncol, Leeds LS16 6QB, W Yorkshire, England.							ABE O, 1992, LANCET, V339, P71; COATES AS, 1992, INTRO NEW TREATMENTS, P448; *EARL BREAST CANC, 1992, LANCET, V339, P1; FETTING JH, 1990, J CLIN ONCOL, V8, P1476, DOI 10.1200/JCO.1990.8.9.1476; Fisher B, 1997, JNCI-J NATL CANCER I, V89, P1673, DOI 10.1093/jnci/89.22.1673; Gelber RD, 1996, LANCET, V347, P1066, DOI 10.1016/S0140-6736(96)90277-9; Hurny C, 1996, LANCET, V347, P1279; LINDLEY CM, 1995, P AN M AM SOC CLIN, V14, P149; MACKILLOP WJ, 1988, BRIT J CANCER, V58, P355, DOI 10.1038/bjc.1988.218; McNeil C, 1997, J NATL CANCER I, V89, P838; RAJAGOPAL S, 1994, J CLIN ONCOL, V12, P1296, DOI 10.1200/JCO.1994.12.6.1296; RICHARDS MA, 1995, EUR J CANCER, V31A, P112, DOI 10.1016/0959-8049(94)00478-N; SAINSBURY R, 1995, BRIT J CANCER, V71, P1275, DOI 10.1038/bjc.1995.246; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458	14	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1506	1507		10.1016/S0140-6736(97)11247-8	http://dx.doi.org/10.1016/S0140-6736(97)11247-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605820				2022-12-28	WOS:000073707300043
J	Blennerhassett, M				Blennerhassett, M			Deadly charades	BRITISH MEDICAL JOURNAL			English	Article											Blennerhassett, M (corresponding author), Wyville Lodge, York YO62 4AQ, N Yorkshire, England.							Arnott SJ, 1996, LANCET, V348, P1049; KESEY K, 1973, ONE FLEW CUCKOOS NES	2	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1998	316	7148					1890	1891						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632414				2022-12-28	WOS:000074686500032
J	Bernabei, R; Gambassi, G; Lapane, K; Landi, F; Gatsonis, C; Dunlop, R; Lipsitz, L; Steel, K; Mor, V				Bernabei, R; Gambassi, G; Lapane, K; Landi, F; Gatsonis, C; Dunlop, R; Lipsitz, L; Steel, K; Mor, V		SAGE Study Grp	Management of pain in elderly patients with cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NURSING-HOME; GERIATRIC PAIN; PREVALENCE; RELIEF; ETHNICITY; RESIDENTS; PROGRAM; HOSPICE; SAMPLE; CARE	Context.-Cancer pain can be relieved with pharmacological agents as indicated by the World Health Organization (WHO). All too frequently pain management is reported to be poor. Objective.-To evaluate the adequacy of pain management in elderly and minority cancer patients admitted to nursing homes. Design.-Retrospective, cross-sectional study. Setting.-A total of 1492 Medicare-certified and/or Medicaid-certified nursing homes in 5 states participating in the Health Care Financing Administration's demonstration project, which evaluated the implementation of the Resident Assessment Instrument and its Minimum Data Set. Study Population.-A group of 13 625 cancer patients aged 65 years and older discharged from the hospital to any of the facilities from 1992 to 1995, Data were from the multilinked Systematic Assessment of Geriatric Drug Use via Epidemiology (SAGE) database. Main Outcome Measure.-Prevalence and predictors of daily pain and of analgesic treatment. Pain assessment was based on patients' report and was completed by a multidisciplinary team of nursing home personnel that observed, over a 7-day period, whether each resident complained or showed evidence of pain daily. Results.-A total of 4003 patients (24%, 29%, and 38% of those aged greater than or equal to 85 years, 75 to 84 years, and 65 to 74 years, respectively) reported daily pain. Age, gender, race, marital status, physical function, depression, and cognitive status were all independently associated with the presence of pain. Of patients with daily pain, 16% received a WHO level 1 drug, 32% a WHO level 2 drug, and only 26% received morphine. Patients aged 85 years and older were less likely to receive either weak opiates or morphine than those aged 65 to 74 years (13% vs 38%, respectively). More than a quarter of patients (26%) in daily pain did not receive any analgesic agent. Patients older than 85 years in daily pain were also more likely to receive no analgesia (odds ratio [OR], 1.40; 95% confidence interval [CI], 1.13-1.73), Other independent predictors of failing to receive any analgesic agent were minority race (OR, 1.63; 95% CI, 1.18-2.26 for African Americans), low cognitive performance (OR, 1.23; 95% CI, 1.05-1.44), and the number of other medications received (Oc, 0.65; 95% CI, 0.5-0.84 for 11 or more medications). Conclusions.-Daily pain is prevalent among nursing home residents with cancer and is often untreated, particularly among older and minority patients.	Brown Univ, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA; Brown Univ, Dept Community Hlth, Providence, RI 02912 USA; Brown Univ, Ctr Stat Sci, Providence, RI 02912 USA; Univ Cattolica Sacro Cuore, Ist Med Interna & Geriatria, Rome, Italy; St Christophers Hospice, London, England; Harvard Univ, Sch Med, Hebrew Rehabil Ctr Aged, Boston, MA USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Hackensack, NJ USA; Hackensack Univ Med Ctr, Homecare Inst, Hackensack, NJ USA	Brown University; Brown University; Brown University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Harvard University; Harvard Medical School; Rutgers State University New Brunswick; Rutgers State University Medical Center; Hackensack University Medical Center	Gambassi, G (corresponding author), Brown Univ, Ctr Gerontol & Hlth Care Res, Box G-B213, Providence, RI 02912 USA.	Giovanni_Gambassi@brown.edu	Bernabei, Roberto/AAB-2704-2019	Bernabei, Roberto/0000-0002-9197-004X	PHS HHS [17C90428] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ball JK, 1996, MED CARE, V34, P970, DOI 10.1097/00005650-199609000-00008; Bernabei R, 1998, J AM GERIATR SOC, V46, P251, DOI 10.1111/j.1532-5415.1998.tb02553.x; BERNABEI R, IN PRESS J GERONTOL; Bookbinder M, 1996, J PAIN SYMPTOM MANAG, V12, P334, DOI 10.1016/S0885-3924(96)00204-7; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; Cleeland CS, 1997, ANN INTERN MED, V127, P813, DOI 10.7326/0003-4819-127-9-199711010-00006; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Cleeland CS, 1996, PAIN, V67, P267, DOI 10.1016/0304-3959(96)03131-4; COHENMANSFIELD J, 1993, J GERONTOL, V48, pP96, DOI 10.1093/geronj/48.2.P96; CORRAN TM, 1994, PROG PAIN RES MANAG, V2, P895; DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; DONOVAN M, 1987, PAIN, V30, P69, DOI 10.1016/0304-3959(87)90084-4; Elliott TE, 1997, J PAIN SYMPTOM MANAG, V13, P191, DOI 10.1016/S0885-3924(96)00275-8; Ferrell BA, 1995, J PAIN SYMPTOM MANAG, V10, P591, DOI 10.1016/0885-3924(95)00121-2; Fisher-Morris M, 1997, AGE AGEING, V26, P497, DOI 10.1093/ageing/26.6.497; FOLEY KM, 1995, J CLIN ONCOL, V13, P2149, DOI 10.1200/JCO.1995.13.9.2149; Fries BE, 1997, J AM GERIATR SOC, V45, P994, DOI 10.1111/j.1532-5415.1997.tb02972.x; Gambassi G, 1998, MED CARE, V36, P167, DOI 10.1097/00005650-199802000-00006; GOLDBERG RJ, 1986, J CHRON DIS, V39, P37, DOI 10.1016/0021-9681(86)90105-0; GREENWALD HP, 1987, CANCER, V60, P2563, DOI 10.1002/1097-0142(19871115)60:10<2563::AID-CNCR2820601036>3.0.CO;2-L; HIGGINSON I, 1994, SOC SCI MED, V38, P553, DOI 10.1016/0277-9536(94)90251-8; *I MED, 1997, APPR DEATH IMPR CAR, P51; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KWENTUS JA, 1985, GERIATRICS, V40, P48; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; Lindesay J, 1997, INT J GERIATR PSYCH, V12, P344, DOI 10.1002/(SICI)1099-1166(199703)12:3<344::AID-GPS504>3.0.CO;2-I; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; MCDONALD DD, 1994, RES NURS HEALTH, V17, P45, DOI 10.1002/nur.4770170107; MELDING PS, 1991, PAIN, V46, P119, DOI 10.1016/0304-3959(91)90064-5; Mogil JS, 1997, PAIN, V70, P267, DOI 10.1016/S0304-3959(97)03333-2; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PARMELEE PA, 1993, J AM GERIATR SOC, V41, P517, DOI 10.1111/j.1532-5415.1993.tb01888.x; PARMELEE PA, 1989, J GERONTOL, V44, pM22, DOI 10.1093/geronj/44.1.M22; Phillips CD, 1997, J AM GERIATR SOC, V45, P986, DOI 10.1111/j.1532-5415.1997.tb02971.x; PORTENOY RK, 1994, CANCER-AM CANCER SOC, V74, P907, DOI 10.1002/1097-0142(19940801)74:3<907::AID-CNCR2820740318>3.0.CO;2-#; PORTENOY RK, 1989, CANCER, V63, P2298, DOI 10.1002/1097-0142(19890601)63:11<2298::AID-CNCR2820631140>3.0.CO;2-A; PORTENOY RK, 1992, ONCOLOGY, V2, P86; Porter FL, 1996, PAIN, V68, P413, DOI 10.1016/S0304-3959(96)03210-1; Repetto L, 1998, CANCER, V82, P760, DOI 10.1002/(SICI)1097-0142(19980215)82:4<760::AID-CNCR20>3.0.CO;2-V; Rischer JB, 1996, JOINT COMM J QUAL IM, V22, P683, DOI 10.1016/S1070-3241(16)30275-9; SAS, 2003, US GUID STAT; SCHECHTERN L, 1989, PEDIATR CLIN N AM, V36, P631; Scherder EJA, 1997, ALZ DIS ASSOC DIS, V11, P171, DOI 10.1097/00002093-199709000-00010; Schroll M, 1997, LANCET, V350, P604, DOI 10.1016/S0140-6736(05)63321-1; SENGSTAKEN EA, 1993, J AM GERIATR SOC, V41, P541, DOI 10.1111/j.1532-5415.1993.tb01892.x; SHAUGHNESSY PW, 1990, NEW ENGL J MED, V322, P21, DOI 10.1056/NEJM199001043220105; Sneeuw KCA, 1997, MED CARE, V35, P490, DOI 10.1097/00005650-199705000-00006; STEIN WM, 1993, J PAIN SYMPTOM MANAG, V8, P474, DOI 10.1016/0885-3924(93)90190-7; STJERNSWARD J, 1988, CANCER SURV, V7, P195; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; Vallerand A H, 1997, Semin Oncol Nurs, V13, P16, DOI 10.1016/S0749-2081(97)80045-9; Yeager K A, 1997, Cancer Pract, V5, P39; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M; 1991, MINIMUM DATA SET PLU	57	759	776	1	65	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1998	279	23					1877	1882		10.1001/jama.279.23.1877	http://dx.doi.org/10.1001/jama.279.23.1877			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZT653	9634258	Bronze			2022-12-28	WOS:000074109700034
J	Climo, MW; Israel, DS; Wong, ES; Williams, D; Coudron, P; Markowitz, SM				Climo, MW; Israel, DS; Wong, ES; Williams, D; Coudron, P; Markowitz, SM			Hospital-wide restriction of clindamycin: Effect on the incidence of Clostridium difficile-associated diarrhea and cost	ANNALS OF INTERNAL MEDICINE			English	Article						clindamycin; Clostridium difficile; diarrhea; drug resistance, microbial; cost savings	TOXIN-ASSOCIATED DIARRHEA; AMINOGLYCOSIDE USAGE; RISK-FACTORS; SURVEILLANCE; RESISTANCE; COLITIS	Background: Widespread antibiotic use has been associated with increases in both bacterial resistance and nosocomial infection. Objective: To characterize the impact of hospital-wide clindamycin restriction on the incidence of Clostridium difficile-associated diarrhea and on antimicrobial prescribing practices. Design: Prospective, observational cohort study. Setting: University-affiliated Veterans Affairs Medical Center. Patients: Hospitalized patients with symptomatic diarrhea. Measurements: Clinical data on individual patients and data on antibiotic use were obtained from hospital pharmacy records. Hospital-wide use of antimicrobial agents was monitored. Isolates of C. difficile underwent antimicrobial susceptibility testing and molecular typing. Results: An outbreak of C. difficile-associated diarrhea was ca used by a clonal isolate of clindamycin-resistant C. difficile and was associated with increased use of clindamycin. Hospital-wide requirement of approval by an infectious disease consultant of clindamycin use led to an overall reduction in clindamycin use, a sustained reduction in the mean number of cases of C. difficile-associated diarrhea (11.5 cases/month compared with 3.33 cases/month; P < 0.001), and an increase in clindamycin susceptibility among C. difficile isolates (9% compared with 61%, P < 0.001). A parallel increase was noted in the use of and costs associated with other antibiotics with antianaerobic activity, including cefotetan, ticarcillin-clavulanate, and imipenem-cilastin. The hospital realized overall cost savings as a result of the decreased incidence of C. difficile-associated diarrhea. Conclusions: Hospital formulary restriction of clindamycin is an effective way to decrease the number of infections due to C. difficile. It can also lead to a return in clindamycin susceptibility among isolates and can effect cost savings to the hospital.	Virginia Commonwealth Univ Med Coll Virginia, Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA 23249 USA	Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University	Climo, MW (corresponding author), Virginia Commonwealth Univ Med Coll Virginia, Hunter Holmes McGuire Vet Affairs Med Ctr, 1201 Broad Rock Blvd,Sect 111C, Richmond, VA 23249 USA.							BALLOW CH, 1992, DIAGN MICR INFEC DIS, V15, pS37; BAMBERGER DM, 1992, ARCH INTERN MED, V152, P554, DOI 10.1001/archinte.152.3.554; BARTLETT JG, 1990, REV INFECT DIS, V12, pS243, DOI 10.1093/clinids/12.Supplement_2.S243; BARTLETT JG, 1981, JOHNS HOPKINS MED J, V149, P6; BARTLETT JG, 1992, CLIN INFECT DIS, V15, P573, DOI 10.1093/clind/15.4.573; BETTS RF, 1984, ANN INTERN MED, V100, P219, DOI 10.7326/0003-4819-100-2-219; BROWN E, 1990, INFECT CONT HOSP EP, V11, P283; DONTA ST, 1980, J INFECT DIS, V141, P218, DOI 10.1093/infdis/141.2.218; FEKETY R, 1993, JAMA-J AM MED ASSOC, V1, P71; GEORGE WL, 1979, J CLIN MICROBIOL, V9, P214; GERDING DN, 1989, ANN INTERN MED, V110, P255, DOI 10.7326/0003-4819-110-4-255; GERDING DN, 1991, ANTIMICROB AGENTS CH, V35, P1284, DOI 10.1128/AAC.35.7.1284; JOHNSON S, 1990, AM J MED, V88, P137, DOI 10.1016/0002-9343(90)90462-M; JONES RN, 1992, DIAGN MICR INFEC DIS, V15, pS3; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; KING JW, 1992, CLIN INFECT DIS, V14, P908, DOI 10.1093/clinids/14.4.908; KOFSKY P, 1991, DIS COLON RECTUM, V34, P244, DOI 10.1007/BF02090164; Maslow Joel N., 1993, P563; MCFARLAND LV, 1990, J INFECT DIS, V162, P678, DOI 10.1093/infdis/162.3.678; MULLANY P, 1995, J ANTIMICROB CHEMOTH, V35, P305, DOI 10.1093/jac/35.2.305; OLSON MM, 1994, INFECT CONT HOSP EP, V15, P371; PEAR SM, 1994, ANN INTERN MED, V120, P272, DOI 10.7326/0003-4819-120-4-199402150-00003; REINKE CM, 1994, AM J HOSP PHARM, V51, P1771, DOI 10.1093/ajhp/51.14.1771; RILEY TV, 1995, LANCET, V345, P455, DOI 10.1016/S0140-6736(95)90439-5; STRATTON CW, 1993, CLIN THER, V15, P12; THIBAULT A, 1991, INFECT CONT HOSP EP, V12, P345, DOI 10.2307/30145209; YOUNG EJ, 1985, AM J MED SCI, V290, P223, DOI 10.1097/00000441-198512000-00001	27	185	189	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				989	+		10.7326/0003-4819-128-12_Part_1-199806150-00005	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625685				2022-12-28	WOS:000074201300004
J	Tachibana, K; Hirota, S; Iizasa, H; Yoshida, H; Kawabata, K; Kataoka, Y; Kitamura, Y; Matsushima, K; Yoshida, N; Nishikawa, S; Kishimoto, T; Nagasawa, T				Tachibana, K; Hirota, S; Iizasa, H; Yoshida, H; Kawabata, K; Kataoka, Y; Kitamura, Y; Matsushima, K; Yoshida, N; Nishikawa, S; Kishimoto, T; Nagasawa, T			The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract	NATURE			English	Article							BLOOD-VESSEL DEVELOPMENT; HIV-1 INFECTION; TYROSINE KINASE; ANGIOGENESIS; ENTRY; MICE; GENE; VASCULOGENESIS; LESTR/FUSIN; ENDOTHELIUM	Vascularization of organs generally occurs by remodelling of the preexisting vascular system during their differentiation and growth to enable them to perform their specific functions during development. The molecules required by early vascular systems, many of which are receptor tyrosine kinases and their ligands, have been defined by analysis of mutant mice(1-3). As most of these mice die during early gestation before many of their organs have developed, the molecules responsible for vascularization during organogenesis have not been identified. The cell-surface receptor CXCR4 (refs 4-6) is a seven-transmembrane-spanning, G-protein-coupled receptor for the CXC chemokine PBSF/SDF-1 (for pre-B-cell growth-stimulating factor/stromal-cell-derived factor), which is responsible for B-cell lymphopoiesis, bone-marrow myelopoiesis and cardiac ventricular septum formation(7). CXCR4 also functions as a co-receptor for T-cell-line tropic human immunodeficiency virus HIV-1 (ref. 8). Here we report that CXCR4 is expressed in developing vascular endothelial cells, and that mice lacking CXCR4 or PBSF/SDF-1 have defective formation of the large vessels supplying the gastrointestinal tract. In addition, mice lacking CXCR4 die in utero and are defective in vascular development, haematopoiesis and cardiogenesis, like mice lacking PBSF/SDF-1, indicating that CXCR4 is a primary physiological receptor for PBSF/SDF-1. We conclude that PBSF/SDF-1 and CXCR4 define a new signalling system for organ vascularization.	Osaka Med Ctr Maternal & Child Hlth, Res Inst, Dept Immunol, Osaka 59002, Japan; Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 565, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Prevent Med, Div Social Med,Bunkyo Ku, Tokyo 113, Japan; Kyoto Univ, Fac Med, Dept Mol Genet, Sakyo Ku, Kyoto 606, Japan; Osaka Univ, Sch Med, Dept Med 3, Suita, Osaka 565, Japan	Osaka University; University of Tokyo; Kyoto University; Osaka University	Nagasawa, T (corresponding author), Osaka Med Ctr Maternal & Child Hlth, Res Inst, Dept Immunol, 840 Murodo Cho, Osaka 59002, Japan.		Kishimoto, Tadamitsu/C-8470-2009; Iizasa, Hisashi/A-9821-2012	Nagasawa, Takashi/0000-0002-1085-0960; Yoshida, Hisahiro/0000-0001-6360-5988				Adachi S, 1997, INT IMMUNOL, V9, P507, DOI 10.1093/intimm/9.4.507; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cui JS, 1996, NATURE, V384, P66, DOI 10.1038/384066a0; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Nagasawa T, 1996, P NATL ACAD SCI USA, V93, P14726, DOI 10.1073/pnas.93.25.14726; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; VECCHI A, 1994, EUR J CELL BIOL, V63, P247	30	1255	1337	0	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1998	393	6685					591	594		10.1038/31261	http://dx.doi.org/10.1038/31261			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634237				2022-12-28	WOS:000074150100056
J	Shafer, RW; Winters, MA; Palmer, S; Merigan, TC				Shafer, RW; Winters, MA; Palmer, S; Merigan, TC			Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients	ANNALS OF INTERNAL MEDICINE			English	Article							ZIDOVUDINE; INFECTION	Background: Drug resistance of HIV-1 is an obstacle to the long-term efficacy of antiretroviral therapy. Objective: To characterize reverse transcriptase and protease genes of multidrug-resistant HIV-1 isolates. Design: Descriptive case series. Setting: Academic medical center. Patients: Four consecutive patients with HIV-1 infection were selected because they had previously received many antiretroviral drugs and had not achieved plasma HIV-1 RNA suppression despite treatment with several three-drug combinations. Measurements: Reverse transcriptase sequencing, protease sequencing, and drug susceptibility testing of HIV-1. Results: Isolates of HIV-1 from the four patients shared seven protease mutations and eight reverse transcriptase mutations. These mutations were present in biological clones and at three time points in three of the patients. Susceptibility testing showed high-level resistance (30-fold to >100-fold) to zidovudine, lamivudine, saquinavir, indinavir, and nelfinavir and lower-level resistance (3-fold to 5-fold) to didanosine, zalcitabine, and stavudine. Conclusions: Simultaneous resistance to almost all available antiretroviral drugs may occur in HIV-1. The concordance and persistence of mutations in drug-resistant HIV-1 isolates suggest that some combinations of reverse transcriptase and protease mutations give the virus a selective advantage in the presence of various drug combinations.	Stanford Univ, Med Ctr, Div Infect Dis, Stanford, CA 94305 USA	Stanford University	Shafer, RW (corresponding author), Stanford Univ, Med Ctr, Div Infect Dis, Room S-156, Stanford, CA 94305 USA.	rshafer@cmgm.stanford.edu	Merigan, Thomas/AGQ-7464-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027666] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27666] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benson DA, 1997, NUCLEIC ACIDS RES, V25, P1, DOI 10.1093/nar/25.1.1; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; HERTOGS K, 1998, P 5 C RETR OPP INF C; LARDER B, 1996, 5 INT WORKSH HIV DRU, P61; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; Learn GH, 1996, J VIROL, V70, P5720, DOI 10.1128/JVI.70.8.5720-5730.1996; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Myers GK, 1995, HUMAN RETROVIRUSES A; PALMER S, 1998, P 5 C RETR OPP INF C; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; SCHAPIRO JM, 1997, ANTIVIR THER S, P57; SCHINAZI RF, 1997, INT ANTIVIRAL NEWS, V5, P2; SHAFER RW, 1993, J VIROL METHODS, V41, P297, DOI 10.1016/0166-0934(93)90019-N; Shafer RW, 1997, J CLIN MICROBIOL, V35, P520, DOI 10.1128/JCM.35.2.520-522.1997; WINTERS MA, 1997, ANTIVIR THER S, P11; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	20	171	175	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					906	911		10.7326/0003-4819-128-11-199806010-00008	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634429				2022-12-28	WOS:000073808600005
J	Waites, R; Selvadurai, HRN; Oliver, IR; Hudson, A				Waites, R; Selvadurai, HRN; Oliver, IR; Hudson, A			The PHANTASTICA gene encodes a MYB transcription factor involved in growth and dorsoventrality of lateral organs in Antirrhinum	CELL			English	Article							HOMEOBOX GENE; FLOWER DEVELOPMENT; TRANSGENIC PLANTS; ARABIDOPSIS; MERISTEM; EXPRESSION; MAJUS; MORPHOLOGY; SHOOT; LEAF	The organs of a higher plant show two fundamental axes of asymmetry: proximodistal and dorsoventral. Dorsoventrality in leaves, bracts, and petal lobes of Antirrhinum majus requires activity of the PHANTASTICA (PHAN) gene. Conditional mutants revealed that PHAN is also required for earlier elaboration of the proximodistal axis. PHAN was isolated and shown to encode a MYB transcription factor homolog. PHAN mRNA is first detected in organ initials before primordium initiation. The structure and expression pattern of PHAN, together with its requirement in two key features of organ development, are consistent with a role in specifying lateral organ identity as distinct from that of the stem or meristem. PHAN also appears to maintain meristem activity in a non-cell-autonomous manner.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JH, Midlothian, Scotland	University of Edinburgh	Hudson, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Kings Bldg,Mayfield Rd, Edinburgh EH9 3JH, Midlothian, Scotland.		Waites, Richard/B-4877-2008	Waites, Richard/0000-0003-4783-0338				BAUR E, 1926, Z IND ABST VER, V41, P47; BIRD DM, 1994, MOL PLANT MICROBE IN, V7, P419, DOI 10.1094/MPMI-7-0419; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; Carpenter R, 1995, PLANT CELL, V7, P2001, DOI 10.1105/tpc.7.12.2001; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; Clark SE, 1996, DEVELOPMENT, V122, P1567; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; FROHMAN MA, 1989, TECHNIQUE, V1, P165; HANAWA J., 1961, Bot. Mag., V74, P303; Laux T, 1996, DEVELOPMENT, V122, P87; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; LUO D, 1991, PLANT J, V1, P59, DOI 10.1111/j.1365-313X.1991.00059.x; Martin C, 1997, TRENDS GENET, V13, P67, DOI 10.1016/S0168-9525(96)10049-4; MATSUOKA M, 1993, PLANT CELL, V5, P1039, DOI 10.1105/tpc.5.9.1039; MEDFORD JI, 1992, PLANT CELL, V4, P631, DOI 10.1105/tpc.4.6.631; OPPERMAN C, 1994, FUND APPL NEMATOL, V17, P211; Pickett FB, 1996, DEVELOPMENT, V122, P3799; POETHIG RS, 1985, PLANTA, V165, P158, DOI 10.1007/BF00395038; SMITH LG, 1992, DEVELOPMENT, V116, P21; SNOW M., 1959, NEW PHYTOL, V58, P188, DOI 10.1111/j.1469-8137.1959.tb05351.x; Snow M, 1933, PHILOS T R SOC LON B, V222, P353; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; Souer E, 1996, CELL, V85, P159, DOI 10.1016/S0092-8674(00)81093-4; STROME S, 1995, DEVELOPMENT, V121, P2961; STUBBE H, 1932, P 6 INT C GEN, V2, P290; SUSSEX I. M., 1955, PHYTOMORPHOLOGY [DELHI], V5, P286; TALBERT PB, 1995, DEVELOPMENT, V121, P2723; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; WAITES R, 1995, DEVELOPMENT, V121, P2143; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7	31	390	435	2	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					779	789		10.1016/S0092-8674(00)81439-7	http://dx.doi.org/10.1016/S0092-8674(00)81439-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630222	Bronze			2022-12-28	WOS:000073956700014
J	Chappert, C; Bernas, H; Ferre, J; Kottler, V; Jamet, JP; Chen, Y; Cambril, E; Devolder, T; Rousseaux, F; Mathet, V; Launois, H				Chappert, C; Bernas, H; Ferre, J; Kottler, V; Jamet, JP; Chen, Y; Cambril, E; Devolder, T; Rousseaux, F; Mathet, V; Launois, H			Planar patterned magnetic media obtained by ion irradiation	SCIENCE			English	Article							BEAM MIXED MULTILAYERS; OPTICAL-DATA STORAGE; LITHOGRAPHY; DENSITY	By ion irradiation through a lithographically made resist mask, the magnetic properties of cobalt-platinum simple sandwiches and multilayers were patterned without affecting their roughness and optical properties. This was demonstrated on arrays of 1-micrometer lines by near- and far-field magnetooptical microscopy, The coercive force and magnetic anisotropy of the irradiated regions can be accurately controlled by the irradiation fluence. If combined with high-resolution lithography, this technique holds promise for ultrahigh-density magnetic recording applications.	Univ Paris Sud, Inst Elect Fondamentale, CNRS, Unite Rech Associee 022, F-91405 Orsay, France; Univ Paris Sud, Ctr Spectrometrie Nucl & Spectrometrie Masse, CNRS, Unite Propre Rech 6412, F-91405 Orsay, France; Univ Paris Sud, Phys Solides Lab, CNRS, Unite Rech Associee 02, F-91405 Orsay, France; Microstruct & Microelect Lab, CNRS, Unite Propre Rech 020, F-92225 Bagneux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)	Chappert, C (corresponding author), Univ Paris Sud, Inst Elect Fondamentale, CNRS, Unite Rech Associee 022, F-91405 Orsay, France.		bernas, harry/O-7892-2019; Chen, Yong/A-1700-2009; Devolder, Thibaut/A-7027-2015	Chen, Yong/0000-0002-2903-8753; Devolder, Thibaut/0000-0001-7998-0993; CAMBRIL, Edmond/0000-0001-5954-5871; Bernas, Harry/0000-0002-9325-221X				Belliard L, 1997, J APPL PHYS, V81, P5315, DOI 10.1063/1.364531; BETZIG E, 1992, APPL PHYS LETT, V61, P142, DOI 10.1063/1.108198; Cai M, 1997, J APPL PHYS, V81, P5200, DOI 10.1063/1.364465; CHEN Y, 1994, J VAC SCI TECHNOL B, V12, P3959, DOI 10.1116/1.587410; CHOU SY, 1994, J APPL PHYS, V76, P6673, DOI 10.1063/1.358164; Chou SY, 1996, SCIENCE, V272, P85, DOI 10.1126/science.272.5258.85; DEVILLE JP, 1993, MATER RES SOC SYMP P, V313, P519, DOI 10.1557/PROC-313-519; Fernandez A, 1996, IEEE T MAGN, V32, P4472, DOI 10.1109/20.538901; Gadetsky S, 1996, J APPL PHYS, V79, P5687, DOI 10.1063/1.362218; GROCHOWSKI E, 1994, IEEE T MAGN, V30, P3797, DOI 10.1109/20.333908; Johnson M, 1997, APPL PHYS LETT, V71, P974, DOI 10.1063/1.119704; Kottler V, 1997, J MAGN MAGN MATER, V165, P398, DOI 10.1016/S0304-8853(96)00568-9; KOTTLER V, IN PRESS IEEE T MAGN; Lambeth DN, 1996, J APPL PHYS, V79, P4496, DOI 10.1063/1.361876; LEBOITE MG, 1988, J MATER RES, V3, P1089, DOI 10.1557/JMR.1988.1089; LEBOITE MG, 1988, MATER LETT, V6, P173, DOI 10.1016/0167-577X(88)90095-X; Lemerle S, 1997, NATO ADV SCI I E-APP, V338, P537; MANSURIPUR M, 1995, PHYSICAL PRINCIPLES; Martin Y, 1997, APPL PHYS LETT, V71, P1, DOI 10.1063/1.119458; Massalski T.B., 1996, BINARY ALLOY PHASE D, Vsecond; POMMIER J, 1990, PHYS REV LETT, V65, P2054, DOI 10.1103/PhysRevLett.65.2054; SILVA TJ, 1994, APPL PHYS LETT, V65, P658, DOI 10.1063/1.112261; SIMONDS JL, 1995, PHYS TODAY, V48, P26, DOI 10.1063/1.881482; Terris BD, 1996, APPL PHYS LETT, V68, P141, DOI 10.1063/1.116127; TERRIS BD, 1994, APPL PHYS LETT, V65, P388, DOI 10.1063/1.112341; TRAVERSE A, 1989, EUROPHYS LETT, V8, P633, DOI 10.1209/0295-5075/8/7/009; Xia YN, 1996, MICROELECTRON ENG, V32, P255, DOI 10.1016/0167-9317(95)00174-3; Ziegler JF., 1985, TREATISE HEAVY ION S	28	699	719	1	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1919	1922		10.1126/science.280.5371.1919	http://dx.doi.org/10.1126/science.280.5371.1919			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632386				2022-12-28	WOS:000074323800058
J	Henry, JA; Fallon, JK; Kicman, AT; Hutt, AJ; Cowan, DA; Forsling, M				Henry, JA; Fallon, JK; Kicman, AT; Hutt, AJ; Cowan, DA; Forsling, M			Low-dose MDMA ("ecstasy") induces vasopressin secretion	LANCET			English	Article									Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Sch Med, Acad Dept Accident & Emergency Med, London W2 1NY, England; United Med & Dent Sch Guys & St Thomas Hosp, Dept Physiol, London, England; Univ London Kings Coll, Drug Control Ctr, London WC2R 2LS, England; Univ London Kings Coll, Dept Pharm, London WC2R 2LS, England	Imperial College London; University of London; King's College London; University of London; King's College London; University of London; King's College London	Henry, JA (corresponding author), Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Sch Med, Acad Dept Accident & Emergency Med, London W2 1NY, England.		Cowan, David/AAG-2915-2021	Fallon, John/0000-0003-1848-0121; Cowan, David/0000-0001-6407-1113				FABIAN M, 1969, J PHYSIOL-LONDON, V204, P653, DOI 10.1113/jphysiol.1969.sp008937; FORSLING ML, 1985, POSTERIOR PITUITARY, P161; Holden R, 1996, LANCET, V347, P1052, DOI 10.1016/S0140-6736(96)90196-8; IOVINO M, 1985, EUR J PHARMACOL, V113, P99, DOI 10.1016/0014-2999(85)90347-4; MAXWELL DL, 1993, BRIT MED J, V307, P1399, DOI 10.1136/bmj.307.6916.1399	5	99	101	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1784	1784		10.1016/S0140-6736(05)78744-4	http://dx.doi.org/10.1016/S0140-6736(05)78744-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635954				2022-12-28	WOS:000074197600015
J	Thong, MK				Thong, MK			Memorable patients - Down but not out	BRITISH MEDICAL JOURNAL			English	Article									Univ Malaya, Kuala Lumpur 59100, Malaysia	Universiti Malaya	Thong, MK (corresponding author), Univ Malaya, Kuala Lumpur 59100, Malaysia.		Thong, Meow-Keong/B-9960-2010	Thong, Meow-Keong/0000-0002-7288-7910					0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1785	1785		10.1136/bmj.316.7147.1785	http://dx.doi.org/10.1136/bmj.316.7147.1785			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624067	Green Published			2022-12-28	WOS:000074286300026
J	Choy, JH; Kwon, SJ; Park, GS				Choy, JH; Kwon, SJ; Park, GS			High-T-c superconductors in the two-dimensional limit: [(Py-CnH2n+1)(2)HgI4]-Bi2Sr2Cam-1CumOy (m=1 and 2)	SCIENCE			English	Article							INTERCALATION COMPOUNDS; SUPERLATTICES; TEMPERATURE; TRANSITION; SYSTEMS; LAYERS	The free modulation of interlayer distance in a layered high-transition temperature (high-T-c) superconductor is of crucial importance not only for the study of the superconducting mechanism but also for the practical application of high-T-c superconducting materials. Two-dimensional (2D) superconductors were achieved by intercalating a long-chain organic compound into bismuth-based high-T-c cuprates. Although the intercalation of the organic chain increased the interlayer distance remarkably, to tens of angstroms, the superconducting transition temperature of the intercalate was nearly the same as that of the pristine material, suggesting the 2D nature of the high-T-c superconductivity.	Seoul Natl Univ, Coll Nat Sci, Dept Chem, Ctr Mol Catalysis, Seoul 151742, South Korea; Samsung Adv Inst Technol, Suwon 440660, South Korea	Seoul National University (SNU); Samsung	Choy, JH (corresponding author), Seoul Natl Univ, Coll Nat Sci, Dept Chem, Ctr Mol Catalysis, Seoul 151742, South Korea.	jhchoy@plaza.snu.ac.kr		Choy, Jin-Ho/0000-0002-4149-7100				Anderson PW, 1998, SCIENCE, V279, P1196, DOI 10.1126/science.279.5354.1196; ARNEK R, 1976, ACTA CHEM SCAND A, V30, P59, DOI 10.3891/acta.chem.scand.30a-0059; Bae MK, 1996, PHYS REV B, V53, P12416, DOI 10.1103/PhysRevB.53.12416; BANCEL PA, 1981, PHYS REV LETT, V46, P148, DOI 10.1103/PhysRevLett.46.148; CHOY JH, 1994, PHYS REV B, V50, P16631, DOI 10.1103/PhysRevB.50.16631; CHOY JH, 1994, J AM CHEM SOC, V116, P11564, DOI 10.1021/ja00104a045; Choy JH, 1997, J AM CHEM SOC, V119, P1624, DOI 10.1021/ja961993x; CLEM JR, 1990, PHYS REV B, V42, P6209, DOI 10.1103/PhysRevB.42.6209; DISTASIO M, 1990, PHYS REV LETT, V64, P2827, DOI 10.1103/PhysRevLett.64.2827; FENN RH, 1966, ACTA CRYSTALLOGR, V20, P24, DOI 10.1107/S0365110X66000057; GAMBLE FR, 1971, SCIENCE, V174, P493, DOI 10.1126/science.174.4008.493; HARSHMAN DR, 1992, PHYS REV B, V45, P10684, DOI 10.1103/PhysRevB.45.10684; IHM J, 1989, PHYS REV B, V39, P4760, DOI 10.1103/PhysRevB.39.4760; KLEINER R, 1994, PHYS REV B, V49, P1327, DOI 10.1103/PhysRevB.49.1327; KORTER M, 1986, Z ANORG ALLG CHEM, V354, P104; Kosterlitz JM, 1973, J PHYS C SOLID STATE, V6, P1181, DOI 10.1088/0022-3719/6/7/010; Lawrence W.E., 1971, P 12 INT C LOW TEMP, P361; Leggett AJ, 1996, SCIENCE, V274, P587, DOI 10.1126/science.274.5287.587; LI Q, 1990, PHYS REV LETT, V64, P3086, DOI 10.1103/PhysRevLett.64.3086; LIANG G, 1993, PHYS REV B, V47, P1029, DOI 10.1103/PhysRevB.47.1029; Moler KA, 1998, SCIENCE, V279, P1193, DOI 10.1126/science.279.5354.1193; NELSON DR, 1995, NATURE, V375, P356, DOI 10.1038/375356a0; NORTON DP, 1991, PHYS REV LETT, V67, P1358, DOI 10.1103/PhysRevLett.67.1358; PIERSON SW, 1995, PHYS REV LETT, V75, P4674, DOI 10.1103/PhysRevLett.75.4674; Selig H, 1980, ADV INORG CHEM, V23, P289; TERASHIMA T, 1991, PHYS REV LETT, V67, P1362, DOI 10.1103/PhysRevLett.67.1362; TRISCONE JM, 1990, PHYS REV LETT, V64, P804, DOI 10.1103/PhysRevLett.64.804; UEMURA YJ, 1989, PHYS REV LETT, V62, P2317, DOI 10.1103/PhysRevLett.62.2317; WHEATLEY JM, 1988, NATURE, V333, P121, DOI 10.1038/333121a0; XIANG XD, 1990, NATURE, V348, P145, DOI 10.1038/348145a0; XIANG XD, 1991, PHYS REV B, V43, P11496, DOI 10.1103/PhysRevB.43.11496; ZELDOV E, 1995, NATURE, V375, P373, DOI 10.1038/375373a0	33	148	148	1	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1589	1592		10.1126/science.280.5369.1589	http://dx.doi.org/10.1126/science.280.5369.1589			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616119				2022-12-28	WOS:000074061200037
J	Berenson, GS; Srinivasan, SR; Bao, WH; Newman, WP; Tracy, RE; Wattigney, WA				Berenson, GS; Srinivasan, SR; Bao, WH; Newman, WP; Tracy, RE; Wattigney, WA		Bogaulas Heart Study	Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; INSULIN-RESISTANCE; SYNDROME-X; HYPERTENSION; NECROPSY; OBESITY; YOUTH	Background In adults, cardiovascular risk factors reinforce each other in their effect on cardiovascular events. However, information is scant on the relation of multiple risk factors to the extent of asymptomatic atherosclerosis in young people. Methods We performed autopsies on 204 young persons 2 to 39 years of age, who had died from various causes, principally trauma. Data on antemortem risk factors were available for 93 of these persons, who were the focus of this study. We correlated risk factors with the extent of atherosclerosis in the aorta and coronary arteries. Results The extent of fatty streaks and fibrous plaques in the aorta and coronary arteries increased with age. The association between fatty streaks and fibrous plaques was much stronger in the coronary arteries (r=0.60, P<0.001) than in the aorta (r=0.23, P=0.03). Among the cardiovascular risk factors, body-mass index, systolic and diastolic blood pressure, and serum concentrations of total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol, as a group, were strongly associated with the extent of lesions in the aorta and coronary arteries (canonical correlation [a measure of the association between groups of variables]: r=0.70; P<0.001). In addition, cigarette smoking increased the percentage of the intimal surface involved with fibrous plaques in the aorta (1.22 percent in smokers vs. 0.12 percent in nonsmokers, P=0.02) and fatty streaks in the coronary vessels (8.27 percent vs. 2.89 percent, P=0.04). The effect of multiple risk factors on the extent of atherosclerosis was quite evident. Subjects with 0, 1, 2, and 3 or 4 risk factors had, respectively, 19.1 percent, 30.3 percent, 37.9 percent, and 35.0 percent of the intimal surface covered with fatty streaks in the aorta (P for trend=0.01). The comparable figures for the coronary arteries were 1.3 percent, 2.5 percent, 7.9 percent, and 11.0 percent, respectively, for fatty streaks (P for trend=0.01) and 0.6 percent, 0.7 percent, 2.4 percent, and 7.2 percent for collagenous fibrous plaques (P for trend=0.003). Conclusions These findings indicate that as the number of cardiovascular risk factors increases, so does the severity of asymptomatic coronary and aortic atherosclerosis in young people. (C) 1998, Massachusetts Medical Society.	Tulane Univ, Sch Publ Hlth & Trop Med, Tulane Ctr Cardiovasc Hlth, New Orleans, LA 70112 USA; Louisiana State Univ, Med Ctr, Dept Pathol, New Orleans, LA 70112 USA	Tulane University; Louisiana State University System	Berenson, GS (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Tulane Ctr Cardiovasc Hlth, 1501 Canal St,14th Fl, New Orleans, LA 70112 USA.		tracy, richard/L-6072-2019; Hrafnkelsson, Hannes/C-8490-2011; Robles-Sardin, Alma E/M-7714-2015	Robles-Sardin, Alma E/0000-0003-2044-7793	NHLBI NIH HHS [HL-38844] Funding Source: Medline; NICHD NIH HHS [HD-32194] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032194] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038844, U01HL038844] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAO WH, 1994, ARCH INTERN MED, V154, P1842; Bao WH, 1996, CIRCULATION, V93, P54, DOI 10.1161/01.CIR.93.1.54; Berenson G.S., 1986, CAUSATION CARDIOVASC; BERENSON GS, 1992, AM J CARDIOL, V70, P851, DOI 10.1016/0002-9149(92)90726-F; Berenson GS., 1980, CARDIOVASCULAR RISK; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; GUZMAN MA, 1968, LAB INVEST, V18, P479; HAFFNER SM, 1992, DIABETES, V41, P715, DOI 10.2337/diabetes.41.6.715; HUNTER SMD, 1980, PREV MED, V9, P701; KANNEL WB, 1988, AM J CARDIOL, V62, P1109, DOI 10.1016/0002-9149(88)90558-9; KANNEL WB, 1987, NIH PUBL; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; KHOURY P, 1980, AM J EPIDEMIOL, V112, P524, DOI 10.1093/oxfordjournals.aje.a113022; MCGILL HC, 1984, ARTERIOSCLEROSIS, V4, P443, DOI 10.1161/01.ATV.4.5.443; MCGILL HC, 1995, ARTERIOSCL THROM VAS, V15, P2222, DOI 10.1161/01.ATV.15.12.2222; McGill HC, 1997, ARTERIOSCL THROM VAS, V17, P95, DOI 10.1161/01.ATV.17.1.95; MCGILL HC, 1995, ARTERIOSCL THROM VAS, V15, P431, DOI 10.1161/01.ATV.15.4.431; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROBERTS WC, 1990, AM J CARDIOL, V66, P121, DOI 10.1016/0002-9149(90)90751-L; ROBERTS WC, 1989, AM J CARDIOL, V64, P324, DOI 10.1016/0002-9149(89)90528-6; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAS Institute, 1990, SAS US GUID STAT VER; SMOAK CG, 1987, AM J EPIDEMIOL, V125, P364, DOI 10.1093/oxfordjournals.aje.a114543; SOLBERG LA, 1983, ARTERIOSCLEROSIS, V3, P187, DOI 10.1161/01.ATV.3.3.187; Srinivasan SR., 1983, CRC HDB ELECTROPHORE, P185; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; TEJADA C, 1968, LAB INVEST, V18, P509; WEBBER LS, 1979, PREV MED, V8, P407, DOI 10.1016/0091-7435(79)90018-5	30	2673	2791	1	136	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1998	338	23					1650	1656		10.1056/NEJM199806043382302	http://dx.doi.org/10.1056/NEJM199806043382302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR451	9614255				2022-12-28	WOS:000073978000002
J	Watts, DJ; Strogatz, SH				Watts, DJ; Strogatz, SH			Collective dynamics of 'small-world' networks	NATURE			English	Article							PULSE-COUPLED OSCILLATORS; SYNCHRONIZATION; DISEASE; SPREAD; CHAOS	Networks of coupled dynamical systems have been used to model biological oscillators(1-4), Josephson junction arrays(5,6), excitable media(7), neural networks(8-10), spatial games(11), genetic control networks(12) and many other self-organizing systems. Ordinarily, the connection topology is assumed to be either completely regular or completely random. But many biological, technological and social networks lie somewhere between these two extremes. Here we explore simple models of networks that can be tuned through this middle ground: regular networks 'rewired' to introduce increasing amounts of disorder. We find that these systems can be highly clustered, like regular lattices, yet have small characteristic path lengths, like random graphs. We call them 'small-world' networks, by analogy with the small-world phenomenon(13,14) (popularly known as six degrees of separation(15)). The neural network of the worm Caenorhabditis elegans, the power grid of the western United States, and the collaboration graph of film actors are shown to be small-world networks. Models of dynamical systems with small-world coupling display enhanced signal-propagation speed, computational power, and synchronizability. In particular, infectious diseases spread more easily in small-world networks than in regular lattices.	Cornell Univ, Dept Theoret & Appl Mech, Ithaca, NY 14853 USA	Cornell University	Watts, DJ (corresponding author), Columbia Univ, Paul F Lazarsfeld Ctr Social Sci, 812 SIPA Bldg,420 W118 St, New York, NY 10027 USA.		Strogatz, Steven H/A-1641-2014; Xie, Jianjun/D-9838-2012; Watts, Duncan J/J-6483-2012	Strogatz, Steven H/0000-0003-2923-3118; 				ABBOTT LF, 1993, PHYS REV E, V48, P1483, DOI 10.1103/PhysRevE.48.1483; [Anonymous], 1990, 6 DEGREES SEPARATION; [Anonymous], 1992, AYS NEUROANATOMY C E; Axelrod R., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; BLYTHE SP, 1991, MATH BIOSCI, V107, P379, DOI 10.1016/0025-5564(91)90015-B; BOLLABAS B, 1985, RANDOM GRAPHS; BRAIMAN Y, 1995, NATURE, V378, P465, DOI 10.1038/378465a0; Bressloff PC, 1997, PHYS REV LETT, V79, P2791, DOI 10.1103/PhysRevLett.79.2791; COLLINS JJ, 1995, NATURE, V376, P236, DOI 10.1038/376236a0; Das R, 1994, LECT NOTES COMPUT SC, V866, P344; GERHARDT M, 1990, SCIENCE, V247, P1563, DOI 10.1126/science.2321017; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; Hess G, 1996, ECOLOGY, V77, P1617, DOI 10.2307/2265556; HOPFIELD JJ, 1995, P NATL ACAD SCI USA, V92, P6655, DOI 10.1073/pnas.92.15.6655; KAUFFMAN SA, 1969, J THEOR BIOL, V22, P437, DOI 10.1016/0022-5193(69)90015-0; Kochen Manfred, 1989, SMALL WORLD; Kretzschmar M, 1996, MATH BIOSCI, V133, P165, DOI 10.1016/0025-5564(95)00093-3; Kuramoto Y., 1984, CHEM OSCILLATIONS WA; LONGINI IM, 1988, MATH BIOSCI, V90, P367, DOI 10.1016/0025-5564(88)90075-2; MILGRAM S, 1967, PSYCHOL TODAY, V1, P61; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; PHADKE AG, 1988, COMPUTER RELAYING PO; SATTENSPIEL L, 1988, MATH BIOSCI, V90, P341, DOI 10.1016/0025-5564(88)90074-0; STROGATZ SH, 1993, SCI AM, V269, P102, DOI 10.1038/scientificamerican1293-102; Wasserman S., 1994, STRUCTURAL ANAL SOCI, DOI 10.1017/CBO9780511815478; Wiesenfeld K, 1996, PHYSICA B, V222, P315, DOI 10.1016/0921-4526(96)85057-5; Winfree A. T., 1980, GEOMETRY BIOL TIME, DOI 10.1007/978-1-4757-3484-3	27	25946	28035	245	4407	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					440	442		10.1038/30918	http://dx.doi.org/10.1038/30918			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9623998				2022-12-28	WOS:000074020000035
J	Li, DY; Brooke, B; Davis, EC; Mecham, RP; Sorensen, LK; Boak, BB; Eichwald, E; Keating, MT				Li, DY; Brooke, B; Davis, EC; Mecham, RP; Sorensen, LK; Boak, BB; Eichwald, E; Keating, MT			Elastin is an essential determinant of arterial morphogenesis	NATURE			English	Article							ATHEROSCLEROSIS; DISRUPTION; CELLS; GENE	Elastin, the main component of the extracellular matrix of arteries, was thought to have a purely structural role(1). Disruption of elastin was believed to lead to dissection of arteries(2,3), but we showed that mutations in one allele encoding elastin cause a human disease in which arteries are blocked, namely, supravalvular aortic stenosis(4,5). Here we define the role of elastin in arterial development and disease by generating mice that lack elastin. These mice die of an obstructive arterial disease, which results from subendothelial cell proliferation and reorganization of smooth muscle. These cellular changes are similar to those seen in atherosclerosis. However, lack of elastin is not associated with endothelial damage, thrombosis or inflammation, which occur in models of atherosclerosis. Haemodynamic stress is not associated with arterial obstruction in these mice either, as the disease still occurred in arteries that were isolated in organ culture and therefore not subject to haemodynamic stress. Disruption of elastin is enough to induce subendothelial proliferation of smooth muscle and may contribute to obstructive arterial disease. Thus, elastin has an unanticipated regulatory function during arterial development, controlling proliferation of smooth muscle and stabilizing arterial structure.	Univ Utah, Hlth Sci Ctr, Div Cardiol, Salt Lake City, UT 84112 USA; Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84112 USA; Eccles Inst Human Genet, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Washington University (WUSTL); Washington University (WUSTL)	Li, DY (corresponding author), Univ Utah, Hlth Sci Ctr, Div Cardiol, Salt Lake City, UT 84112 USA.		Davis, Elaine/F-3449-2012					Bittar, 1993, ADV MOL CELL BIOL, P133, DOI [10.1016/S1569-2558(08)60201-5, DOI 10.1016/S1569-2558(08)60201-5]; CURRAN ME, 1993, CELL, V73, P159, DOI 10.1016/0092-8674(93)90168-P; DENG CX, 1993, MOL CELL BIOL, V13, P2134, DOI 10.1128/MCB.13.4.2134; EWART AK, 1993, NAT GENET, V5, P11, DOI 10.1038/ng0993-11; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Gibbons GH, 1996, SCIENCE, V272, P689, DOI 10.1126/science.272.5262.689; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Langille BL, 1997, TRENDS CARDIOVAS MED, V7, P111, DOI 10.1016/S1050-1738(97)00005-4; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; OWENS GK, 1995, PHYSIOL REV, V75, P487; PROSSER IW, 1989, AM J PATHOL, V135, P1073; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; TERPIN T, 1987, CAN J PHYSIOL PHARM, V65, P395, DOI 10.1139/y87-066; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; Thompson RW, 1996, CURR OPIN CARDIOL, V11, P504, DOI 10.1097/00001573-199609000-00010	18	561	587	0	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					276	280		10.1038/30522	http://dx.doi.org/10.1038/30522			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607766				2022-12-28	WOS:000073761000056
J	Jemmott, JB; Jemmott, LS; Fong, GT				Jemmott, JB; Jemmott, LS; Fong, GT			Abstinence and safer sex HIV risk-reduction interventions for African American adolescents - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	American-Public-Health-Association Conference	OCT 30-NOV 01, 1996	NEW YORK, NY	Amer Public Hlth Assoc			PREGNANCY PREVENTION PROGRAM; CONDOM-USE INTENTIONS; EDUCATION-PROGRAM; PLANNED BEHAVIOR; SELF-EFFICACY; AIDS; PEER; FAMILY; WOMEN	Context.-African American adolescents are at high risk of contracting sexually transmitted infection with human immunodeficiency virus (HIV), but which behavioral interventions to reduce risk are most effective and who should conduct them is not known. Objective.-To evaluate the effects of abstinence and safer-sex HIV risk-reduction interventions on young inner-city African American adolescents' HIV sexual risk behaviors when implemented by adult facilitators as compared with peer cofacilitators. Design.-Randomized controlled trial with 3-, 6-, and 12-month follow-up. Setting.-Three middle schools serving low-income African American communities in Philadelphia, Pa. Participants.-A total of 659 African American adolescents recruited for a Saturday program. Interventions.-Based on cognitive-behavioral theories and elicitation research, interventions involved 8 1-hour modules implemented by adult facilitators or peer cofacilitators. Abstinence intervention stressed delaying sexual intercourse or reducing its frequency; safer-sex intervention stressed condom use; control intervention concerned health issues unrelated to sexual behavior. Main Outcome Measures.-Self-reported sexual intercourse, condom use, and unprotected sexual intercourse. Results.-Mean age of the enrollees was 11.8 years; 53% were female and 92.6% were still enrolled at 12 months, Abstinence intervention participants were less likely to report having sexual intercourse in the 3 months after intervention than were control group participants (12.5% vs 21.5%, P=.02), but not at 6- or 12-month follow-up (17.2% vs 22.7%, P=.14; 20.0% vs 23.1%, P=.42, respectively). Safer sex intervention participants reported significantly more consistent condom use than did control group participants at 3 months (odds ratio [OR]=3.38; 95% confidence interval [CI], 1.25-9.16) and higher frequency of condom use at all follow ups. Among adolescents who reported sexual experience at baseline, the safer-sex intervention group reported less sexual intercourse in the previous 3 months at 6- and 12-month follow-up than did control and abstinence intervention (adjusted mean days over prior 3 months, 1.34 vs 3.77 and 3.03, respectively; P less than or equal to.01 at 12-month follow-up) and less unprotected intercourse at all follow-ups than did control group (adjusted mean days, 0.04 vs 1.85, respectively, P<.001, at 12-month follow-up). There were no differences in intervention effects with adult facilitators as compared with peer cofacilitators. Conclusion.-Both abstinence and safer-sex interventions can reduce HIV sexual risk behaviors, but safer-sex interventions may be especially effective with sexually experienced adolescents and may have longer-lasting effects.	Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA; Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; Univ Waterloo, Dept Psychol, Waterloo, ON, Canada	Princeton University; University of Pennsylvania; University of Waterloo	Jemmott, JB (corresponding author), Princeton Univ, Dept Psychol, Green Hall, Princeton, NJ 08544 USA.	jemmott@princeton.edu	Fong, Geoffrey T/H-2810-2014; Jemmott, John B/B-3629-2015	Fong, Geoffrey T/0000-0001-9098-6472; Jemmott, John B/0000-0003-2831-8240	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052035] Funding Source: NIH RePORTER; NIMH NIH HHS [R01MH52035] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Ajzen I., 1980, UNDERSTANDING ATTITU; BANDURA A, 1982, AM PSYCHOL, V37, P122, DOI 10.1037/0003-066X.37.2.122; Bandura A., 1986, SOCIAL FDN THOUGHT A; Bandura A, 1994, SOCIAL COGNITIVE THE, P25, DOI DOI 10.1007/978-1-4899-1193-3_3; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BROOK JS, 1977, PSYCHOL REP, V41, P1095, DOI 10.2466/pr0.1977.41.3f.1095; CATANIA JA, 1990, PSYCHOL BULL, V108, P339, DOI 10.1037/0033-2909.108.3.339; CATES W, 1992, FAM PLANN PERSPECT, V24, P75, DOI 10.2307/2135469; *CDCP, 1996, HIV AIDS SURV REP US; *CDCP, 1990, NAT HIV SER SURV SUM; CHRISTOPHER FS, 1990, FAM RELAT, V39, P68, DOI 10.2307/584951; Cohen J., 1983, APPL MULTIPLE REGRES; Cook T.C., 1979, QUASIEXPERIMENTATION; Crowne D.P., 1964, APPROVAL MOTIVE STUD; Dryfoos JG., 1990, ADOLESCENTS RISK PRE; EISENBERG N, 1991, DEV PSYCHOL, V27, P849, DOI 10.1037/0012-1649.27.5.849; Fishbein M.A., 1975, PHILOS RHETORIC; Fisher JD, 1996, HEALTH PSYCHOL, V15, P114, DOI 10.1037/0278-6133.15.2.114; GILLUM RF, 1982, AM HEART J, V104, P839, DOI 10.1016/0002-8703(82)90021-7; HOWARD M, 1990, FAM PLANN PERSPECT, V22, P21, DOI 10.2307/2135434; IBRAHIM M, 1985, HYPERTENSION, V7, P453; JEMMOTT JB, 1992, J ADOLESCENT HEALTH, V13, P512, DOI 10.1016/1054-139X(92)90016-5; JEMMOTT JB, 1992, AM J PUBLIC HEALTH, V82, P372, DOI 10.2105/AJPH.82.3.372; JEMMOTT JB, IN PRESS AM J COMMUN; JEMMOTT LS, 1992, NURS RES, V41, P273; JEMMOTT LS, 1995, BE PROUD BE RESPONSI; JOHNSON JH, 1981, J YOUTH ADOLESCENCE, V10, P169, DOI 10.1007/BF02091743; KANTOR LM, 1992, SIECUS REP, V21, P1; Kauth M R, 1991, AIDS Educ Prev, V3, P207; Kim N, 1997, J ADOLESCENT HEALTH, V20, P204, DOI 10.1016/S1054-139X(96)00169-3; Kirby D, 1997, FAM PLANN PERSPECT, V29, P100, DOI 10.2307/2953331; KIRBY D, 1991, FAM PLANN PERSPECT, V266, P1237; MADDEN TJ, 1992, PERS SOC PSYCHOL B, V18, P3, DOI 10.1177/0146167292181001; MCFARLAND SG, 1985, J PERS SOC PSYCHOL, V49, P1692; *NIH, 1997, NIH CONS STAT, V15; PAGE HS, 1985, NIH PUBLICATION; RICKERT VI, 1991, J ADOLESCENT HEALTH, V12, P38, DOI 10.1016/0197-0070(91)90039-O; ROOSA MW, 1990, FAM RELAT, V39, P363, DOI 10.2307/585214; Rosenthal Robert., 1985, CONTRAST ANAL FOCUSE; ROTHERAMBORUS MJ, 1991, JAMA-J AM MED ASSOC, V266, P1237, DOI 10.1001/jama.266.9.1237; SAMUEL W, 1980, J PERS SOC PSYCHOL, V38, P993, DOI 10.1037/0022-3514.38.6.993; SLAP GB, 1991, J ADOLESCENT HEALTH, V12, P434, DOI 10.1016/1054-139X(91)90020-X; Stanton BF, 1996, ARCH PEDIAT ADOL MED, V150, P363, DOI 10.1001/archpedi.1996.02170290029004; STLAWRENCE JS, 1995, J CONSULT CLIN PSYCH, V63, P221, DOI 10.1037/0022-006X.63.2.221; STPIERRE TL, 1995, FAM RELAT, V44, P69; Sudman Seymour., 1974, RESPONSE EFFECTS SUR; WALTER HJ, 1993, JAMA-J AM MED ASSOC, V270, P725, DOI 10.1001/jama.270.6.725; WINER BJ, 1971, STAT PRINCIPLES EXPE; Young M, 1992, FAMILY LIFE ED, V10, P4	50	531	532	2	59	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1529	1536		10.1001/jama.279.19.1529	http://dx.doi.org/10.1001/jama.279.19.1529			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZN087	9605896				2022-12-28	WOS:000073608100030
J	Chen, GL; Liebermann, RC; Weidner, DJ				Chen, GL; Liebermann, RC; Weidner, DJ			Elasticity of single-crystal MgO to 8 gigapascals and 1600 kelvin	SCIENCE			English	Article							HIGH-PRESSURE; HIGH-TEMPERATURE; MAGNESIUM-OXIDE; EQUATION; STATE; MODULI; MANTLE; VELOCITIES; PARAMETERS; NACL	The cross pressure (P) and temperature (T) dependence of the elastic moduli (C-ij) of single-crystal samples of periclase (MgO) from acoustic wave travel times was measured with ultrasonic interferometry: partial derivative(2)C(11)/partial derivative P partial derivative T = (-1.3 +/- 0.4) x 10(-3) per kelvin; partial derivative(2)C(110)/partial derivative P partial derivative T = (1.7 +/- 0.7) x 10(-3) per kelvin; and partial derivative(2)C(44)/partial derivative P partial derivative T = (-0.2 +/- 0.3) x 10(-3) per kelvin. The elastic anisotropy of MgO decreases with increasing pressure at ambient temperature, but then increases as temperature is increased at high pressure. An.assumption of zero cross pressure and temperature derivatives for the elastic moduli underestimates the elastic anisotropy and overestimates the acoustic velocities of MgO at the extrapolated high-pressure and high-temperature conditions of Earth's mantle.	SUNY Stony Brook, Ctr High Pressure Res, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Mineral Phys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Geosci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Liebermann, RC (corresponding author), SUNY Stony Brook, Ctr High Pressure Res, Stony Brook, NY 11794 USA.							ANDERSON OL, 1995, EQUATIONS STATE SOLI, P57; BIRCH F, 1986, J GEOPHYS RES-SOLID, V91, P4949, DOI 10.1029/JB091iB05p04949; CHEN G, 1996, J GEOPHYS RES, V101, P25; Chen GL, 1996, SCIENCE, V272, P979, DOI 10.1126/science.272.5264.979; CHOPELAS A, 1992, EARTH PLANET SC LETT, V114, P185, DOI 10.1016/0012-821X(92)90160-W; DECKER DL, 1971, J APPL PHYS, V42, P3239, DOI 10.1063/1.1660714; DUFFY TS, 1995, J GEOPHYS RES-SOL EA, V100, P529, DOI 10.1029/94JB02065; DUFFY TS, 1995, PHYS REV LETT, V74, P1371, DOI 10.1103/PhysRevLett.74.1371; DUFFY TS, 1989, J GEOPHYS RES-SOLID, V94, P1895, DOI 10.1029/JB094iB02p01895; FEI Y, 1991, J GEOPHYS RES-SOLID, V96, P2157, DOI 10.1029/90JB02164; ISAAK DG, 1976, J GEOPHYS RES, V81, P2483, DOI 10.1029/JB081i014p02483; ISAAK DG, 1990, J GEOPHYS RES-SOLID, V95, P7055, DOI 10.1029/JB095iB05p07055; ISAAK DG, 1993, PHYS EARTH PLANET IN, V80, P37, DOI 10.1016/0031-9201(93)90071-G; ISAAK DG, 1989, PHYS CHEM MINER, V16, P704; ITA J, 1992, J GEOPHYS RES-SOL EA, V97, P6849, DOI 10.1029/92JB00068; Jackson I., 1982, HIGH PRESSURE RES GE, P93, DOI DOI 10.1007/978-94-009-7867-6_8; Jamieson J. C., 1982, HIGH PRESSURE RES GE, P27, DOI DOI 10.1007/978-94-009-7867-63; Karki BB, 1997, AM MINERAL, V82, P51; KNOCHE R, 1998, HIGH PRESSURE RES PR, P119; KUSABA K, 1993, PURE APPL GEOPHYS, V141, P643, DOI 10.1007/BF00998350; LI B, 1998, HIGH PRESSURE RES PR, P41; Li BS, 1996, PHYS EARTH PLANET IN, V98, P79, DOI 10.1016/S0031-9201(96)03173-1; LIEBERMANN RC, 1996, EOS, V77, pF672; LIEBERMANN RC, REV HIGH PRESSURE SC; LLOYD EC, 1971, NBS SPEC PUBL, V326, P1; NOMURA M, 1982, JPN J APPL PHYS 1, V21, P936, DOI 10.1143/JJAP.21.936; SHEN AH, 1998, HIGH PRESSURE RES PR, P71; SPETZLER H, 1970, J GEOPHYS RES, V75, P2073, DOI 10.1029/JB075i011p02073; SPETZLER HA, 1993, PURE APPL GEOPHYS, V141, P341, DOI 10.1007/BF00998335; TAKAHASHI E, 1987, HIGH PRESSURE RES MI, P427; UTSUMI W, 1998, HIGH PRESSURE RES PR, P327; Vaughan MT, 1993, SHORT COURSE HDB EXP, P95; WANG K, 1995, GEOPHYS RES LETT, V22, P1297, DOI 10.1029/95GL01194; WANG Y, 1998, HIGH PRESSURE RES PR, P35; Weidner D.J., 1992, HIGH PRESSURE RES AP, V67, P13; WEIDNER DJ, 1987, HIGH PRESSURE RES MI, P439; YONEDA A, 1990, J PHYS EARTH, V38, P19, DOI 10.4294/jpe1952.38.19	37	79	83	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1913	1916		10.1126/science.280.5371.1913	http://dx.doi.org/10.1126/science.280.5371.1913			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632384				2022-12-28	WOS:000074323800056
J	Welch, AM; Semlitsch, RD; Gerhardt, HC				Welch, AM; Semlitsch, RD; Gerhardt, HC			Call duration as an indicator of genetic quality in male gray tree frogs	SCIENCE			English	Article							ACOUSTIC CRITERIA; HYLA-VERSICOLOR; FEMALE CHOICE; LIFE-HISTORY; MATE CHOICE; SELECTION; VARIABILITY; BEHAVIOR; GROWTH; BUFO	The "good genes" hypothesis predicts that mating preferences enable females to select mates of superior genetic quality. The genetic consequences of the preference shown by female gray tree frogs for long-duration calls were evaluated by comparing the performance of maternal half-siblings sired by males with different call durations. Offspring of male gray tree frogs that produced long calls showed better performance during larval and juvenile stages than did offspring of males that produced short calls. These data suggest that call duration can function as a reliable indicator of heritable genetic quality.	Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Welch, AM (corresponding author), Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.			Semlitsch, Raymond/0000-0002-7999-5762				BERVEN KA, 1983, AM ZOOL, V23, P85; Falconer DS, 1996, INTRO QUANTITATIVE G; FELLERS GM, 1979, COPEIA, P286, DOI 10.2307/1443416; Gerhardt HC, 1996, BEHAV ECOL, V7, P7, DOI 10.1093/beheco/7.1.7; GERHARDT HC, 1991, ANIM BEHAV, V42, P615, DOI 10.1016/S0003-3472(05)80245-3; GERHARDT HC, 1995, ANIM BEHAV, V50, P1187; Gosner K. L., 1960, Herpetologica, V16, P183; Grafe U, 1997, COPEIA, P356, DOI 10.2307/1447755; HOWARD RD, 1994, EVOLUTION, V48, P1286, DOI 10.1111/j.1558-5646.1994.tb05313.x; Kirkpatrick M, 1997, P NATL ACAD SCI USA, V94, P1282, DOI 10.1073/pnas.94.4.1282; KLUMP GM, 1987, NATURE, V326, P286, DOI 10.1038/326286a0; KRENZ JD, UNPUB; MITCHELL SL, 1990, EVOLUTION, V44, P502, DOI 10.1111/j.1558-5646.1990.tb05935.x; NORRIS K, 1993, NATURE, V362, P537, DOI 10.1038/362537a0; PETRIE M, 1994, NATURE, V371, P598, DOI 10.1038/371598a0; RITKE ME, 1990, J HERPETOL, V24, P135, DOI 10.2307/1564220; RUNKLE LS, 1994, BEHAV ECOL, V5, P318, DOI 10.1093/beheco/5.3.318; Semlitsch RD, 1996, EVOL ECOL, V10, P531, DOI 10.1007/BF01237883; Semlitsch RD, 1997, EVOLUTION, V51, P1249, DOI 10.1111/j.1558-5646.1997.tb03972.x; SEMLITSCH RD, 1994, BEHAV ECOL SOCIOBIOL, V34, P19; Sokal R. R, 1981, BIOMETRY; SULLIVAN BK, 1992, ANIM BEHAV, V44, P733, DOI 10.1016/S0003-3472(05)80299-4; WELLS KD, 1986, BEHAV ECOL SOCIOBIOL, V19, P9, DOI 10.1007/BF00303837; WILBUR HM, 1973, SCIENCE, V182, P1305, DOI 10.1126/science.182.4119.1305; WOODWARD BD, 1986, AM NAT, V128, P58, DOI 10.1086/284539; ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3	26	347	355	2	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1928	1930		10.1126/science.280.5371.1928	http://dx.doi.org/10.1126/science.280.5371.1928			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632389				2022-12-28	WOS:000074323800061
J	Boden, WE; O'Rourke, RA; Crawford, MH; Blaustein, AS; Deedwania, PC; Zoble, RG; Wexler, LF; Kleiger, RE; Pepine, CJ; Ferry, DR; Chow, BK; Lavori, PW				Boden, WE; O'Rourke, RA; Crawford, MH; Blaustein, AS; Deedwania, PC; Zoble, RG; Wexler, LF; Kleiger, RE; Pepine, CJ; Ferry, DR; Chow, BK; Lavori, PW		VANQWISH Trial Investigators	Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BYPASS GRAFT-SURGERY; CLINICAL-TRIALS; SHORT-TERM; MORTALITY; PROGNOSIS; REINFARCTION; EXTENSION; EVOLUTION; DILTIAZEM; ISCHEMIA	Background Non-Q-wave myocardial infarction is usually managed according to an "invasive" strategy (i.e., one of routine coronary angiography followed by myocardial revascularization). Methods We randomly assigned 920 patients to either "invasive" management (462 patients) or "conservative" management, defined as medical therapy and noninvasive testing, with subsequent invasive management if indicated by the development of spontaneous or inducible ischemia (458 patients), within 72 hours of the onset of a non-Q-wave infarction. Death or nonfatal infarction made up the combined primary end point. Results During an average follow-up of 23 months, 152 events (80 deaths and 72 nonfatal infarctions) occurred in 138 patients who had been randomly assigned to the invasive strategy, and 139 events (59 deaths and 80 nonfatal infarctions) in 123 patients assigned to the conservative strategy (P=0.35). Patients assigned to the invasive strategy had worse clinical outcomes during the first year of follow-up. The number of patients with one of the components of the primary end point (death or nonfatal myocardial infarction) and the number who died were significantly higher in the invasive-strategy group at hospital discharge (36 vs. 15 patients, P=0.004, for the primary end point; 21 vs. 6, P=0.007, for death), at one month (48 vs. 26, P=0.072; 23 vs. 9, P=0.021), and at one year (111 vs. 85, P=0.05; 58 vs. 36, P=0.025). Overall mortality during follow-up did not differ significantly between patients assigned to the conservative-strategy group and those assigned to the invasive-strategy group (hazard ratio, 0.72; 95 percent confidence interval, 0.51 to 1.01). Conclusions Most patients with non-Q-wave myocardial infarction do not benefit from routine, early invasive management consisting of coronary angiography and revascularization. A conservative, ischemia-guided initial approach is both safe and effective. (C) 1998, Massachusetts Medical Society.	Vet Affairs Healthcare Network Upstate NY, Med Serv, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Syracuse, NY 13210 USA; Vet Affairs Med Ctr, San Antonio, TX USA; Vet Affairs Med Ctr, Albuquerque, NM USA; Vet Affairs Med Ctr, Houston, TX 77030 USA; Vet Affairs Med Ctr, Fresno, CA USA; James A Haley Vet Adm Med Ctr, Tampa, FL 33612 USA; Vet Affairs Med Ctr, Cincinnati, OH 45267 USA; Washington Univ, Jewish Hosp St Louis, Sch Med, St Louis, MO 63110 USA; Vet Affairs Med Ctr, Gainesville, FL 32608 USA; Jerry L Pettis Mem Vet Adm Med Ctr, Loma Linda, CA 92354 USA; Dept Vet Affairs, Cooperat Studies Program Coordinating Ctr, Palo Alto, CA USA; Vet Affairs Med Ctr, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center; Barnes-Jewish Hospital; Washington University (WUSTL); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Boden, WE (corresponding author), Vet Affairs Healthcare Network Upstate NY, Med Serv, 800 Irving Ave, Syracuse, NY 13210 USA.							BODEN W E, 1988, American Journal of Noninvasive Cardiology, V2, P125; BODEN WE, 1991, AM J CARDIOL, V67, P335, DOI 10.1016/0002-9149(91)90038-M; BODEN WE, 1987, AM J CARDIOL, V59, P782, DOI 10.1016/0002-9149(87)91091-5; BODEN WE, 1990, J CARDIOVASC PHARM, V16, pS55, DOI 10.1097/00005344-199000006-00012; BODEN WE, 1991, CORONARY HEART DIS R, V3, P113; BODEN WE, 1991, PROG CARDIOL, V4, P143; BOSCH X, 1987, CIRCULATION, V75, P988, DOI 10.1161/01.CIR.75.5.988; BRAUNWALD E, 1994, CIRCULATION, V89, P1545; CANNON CP, 1995, AM J CARDIOL, V75, P977, DOI 10.1016/S0002-9149(99)80707-3; CHUNG MK, 1995, AM J CARDIOL, V75, P18, DOI 10.1016/S0002-9149(99)80519-0; COX DR, 1972, J R STAT SOC B, V34, P187; EDWARDS FH, 1994, ANN THORAC SURG, V57, P12, DOI 10.1016/0003-4975(94)90358-1; FEILD DJ, 1987, J AM COLL CARDIOL, V10, P935, DOI 10.1016/S0735-1097(87)80294-2; Ferry DR, 1998, J AM COLL CARDIOL, V31, P312, DOI 10.1016/S0735-1097(97)00486-5; FORCINITO M, 1991, J AM COLL CARDIOL, V18, P1149; Gibson R S, 1988, Curr Probl Cardiol, V13, P9; GIBSON RS, 1986, NEW ENGL J MED, V315, P423, DOI 10.1056/NEJM198608143150704; GIBSON RS, 1996, ATHEROSCLEROSIS CORO, V2, P1097; GOLDBERG RJ, 1987, AM HEART J, V113, P273, DOI 10.1016/0002-8703(87)90265-1; GOLDBERG RJ, 1987, AM HEART J, V114, P1535, DOI 10.1016/0002-8703(87)90580-1; HUEY BL, 1987, J AM COLL CARDIOL, V9, P18, DOI 10.1016/S0735-1097(87)80076-1; Jones RH, 1996, J AM COLL CARDIOL, V28, P1478, DOI 10.1016/S0735-1097(96)00359-2; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLEIGER RE, 1990, AM J CARDIOL, V65, P23, DOI 10.1016/0002-9149(90)90020-2; KLEIN LW, 1986, PROG CARDIOVASC DIS, V29, P205, DOI 10.1016/0033-0620(86)90042-3; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; Krumholz HM, 1997, NEW ENGL J MED, V336, P1522, DOI 10.1056/NEJM199705223362111; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Liebson PR, 1997, PROG CARDIOVASC DIS, V39, P399, DOI 10.1016/S0033-0620(97)80038-2; Madsen JK, 1997, CIRCULATION, V96, P748; Magovern JA, 1996, J AM COLL CARDIOL, V28, P1147, DOI 10.1016/S0735-1097(96)00310-5; MAISEL AS, 1985, CIRCULATION, V71, P211, DOI 10.1161/01.CIR.71.2.211; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; MARMOR A, 1981, AM J CARDIOL, V48, P603, DOI 10.1016/0002-9149(81)90137-5; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; NICOD P, 1989, CIRCULATION, V79, P528, DOI 10.1161/01.CIR.79.3.528; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; RICH MW, 1992, AM J MED, V92, P7, DOI 10.1016/0002-9343(92)90008-Y; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; SCHECHTMAN KB, 1990, J AM COLL CARDIOL, V15, P940, DOI 10.1016/0735-1097(90)90221-A; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; Tu JV, 1997, J AM COLL CARDIOL, V30, P1317, DOI 10.1016/S0735-1097(97)00295-7	45	597	630	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1998	338	25					1785	1792		10.1056/NEJM199806183382501	http://dx.doi.org/10.1056/NEJM199806183382501			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU443	9632444				2022-12-28	WOS:000074197500001
J	Li, P; Zhuo, M				Li, P; Zhuo, M			Silent glutamatergic synapses and nociception in mammalian spinal cord	NATURE			English	Article							LONG-TERM POTENTIATION; NUCLEI RETICULARIS-GIGANTOCELLULARIS; SUBSTANTIA GELATINOSA NEURONS; SUPERFICIAL DORSAL HORN; DESCENDING FACILITATION; PARS-ALPHA; RAT; INFLAMMATION; PLASTICITY; TRANSMISSION	Neurons in the superficial dorsal horn of the spinal cord are important for conveying sensory information from the periphery to the central nervous system(1,2). Some synapses between primary afferent fibres and spinal dorsal horn neurons may be inefficient or silent(3). Ineffective sensory transmission could result from a small postsynaptic current that fails to depolarize the cell to threshold for an action potential or from a cell with a normal postsynaptic current but an increased threshold for action potentials. Here we show that some cells in the superficial dorsal horn of the lumbar spinal cord have silent synapses: they do not respond unless the holding potential is moved from -70 mV to +40 mV. Serotonin (5-hydroxytryptamine, 5-HT), an important neurotransmitter of the raphe-spinal projecting pathway, transforms silent glutamatergic synapses into functional ones. Therefore, transformation of silent glutamatergic synapses may serve as a cellular mechanism for central plasticity in the spinal cord.	Washington Univ, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Zhuo, M (corresponding author), Washington Univ, Dept Anesthesiol, Campus Box 8054, St Louis, MO 63110 USA.		Zhuo, Min/A-2072-2008	Zhuo, Min/0000-0001-9062-3241				BEYER WH, 1968, HDB TABLES PROBABILI; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; FIELDS HL, 1991, ANNU REV NEUROSCI, V14, P219, DOI 10.1146/annurev.neuro.14.1.219; GEBHART GF, 1990, BRAINSTEM MECH BEHAV, P315; HARRIS JA, 1996, NEUROSCIENCE, V14, P7; Hori Y, 1996, J PHYSIOL-LONDON, V492, P867, DOI 10.1113/jphysiol.1996.sp021352; HYLDEN JLK, 1989, PAIN, V37, P229, DOI 10.1016/0304-3959(89)90135-8; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Isaac JTR, 1997, NEURON, V18, P269, DOI 10.1016/S0896-6273(00)80267-6; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KUMAZAWA T, 1978, J COMP NEUROL, V177, P417, DOI 10.1002/cne.901770305; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LIGHT AR, 1979, J COMP NEUROL, V186, P151, DOI 10.1002/cne.901860204; LopezGarcia JA, 1996, EUR J NEUROSCI, V8, P2188, DOI 10.1111/j.1460-9568.1996.tb00740.x; Maccaferri G, 1996, J NEUROSCI, V16, P5334; Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1; MENETREY D, 1982, PAIN, V13, P343, DOI 10.1016/0304-3959(82)90003-3; Paxinos G., 1998, RAT BRAIN STEROTAXIC; RANDIC M, 1993, J NEUROSCI, V13, P5228, DOI 10.1523/JNEUROSCI.13-12-05228.1993; SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/science.270.5237.758; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; TODD AJ, 1994, J NEUROSCI, V14, P774; WALL PD, 1977, PHILOS T R SOC B, V278, P361, DOI 10.1098/rstb.1977.0048; Wu GY, 1996, SCIENCE, V274, P972, DOI 10.1126/science.274.5289.972; YOSHIMURA M, 1990, J PHYSIOL-LONDON, V430, P315, DOI 10.1113/jphysiol.1990.sp018293; Zhuo M, 1997, J NEUROPHYSIOL, V78, P746, DOI 10.1152/jn.1997.78.2.746; ZHUO M, 1991, BRAIN RES, V550, P35, DOI 10.1016/0006-8993(91)90402-H; ZHUO M, 1992, J NEUROPHYSIOL, V67, P1599, DOI 10.1152/jn.1992.67.6.1599	29	212	225	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1998	393	6686					695	698		10.1038/31496	http://dx.doi.org/10.1038/31496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641681				2022-12-28	WOS:000074289600056
J	Wright, J; Walley, J				Wright, J; Walley, J			Health needs assessment - Assessing health needs in developing countries	BRITISH MEDICAL JOURNAL			English	Article									Univ Leeds, Nuffield Inst Hlth, Leeds LS2 9PL, W Yorkshire, England	University of Leeds	Wright, J (corresponding author), Univ Leeds, Nuffield Inst Hlth, Leeds LS2 9PL, W Yorkshire, England.		Wright, John/H-1624-2012; Walley, John D/AAY-1375-2021	Wright, John/0000-0001-9572-7293; Walley, John D/0000-0001-7290-0989				ADAMS L, 1996, REPORT PARTICIPATORY; Barker C, 1996, HEALTH POLICY PLANN, V11, P179, DOI 10.1093/heapol/11.2.179; BOBADILLA JL, 1994, B WORLD HEALTH ORGAN, V72, P653; CHAMBERS R, 1994, WORLD DEV, V22, P1253, DOI 10.1016/0305-750X(94)90003-5; Chambers R., 1992, 311 BRIGHT I DEV STU; Cornwall A, 1995, SOC SCI MED, V41, P1667, DOI 10.1016/0277-9536(95)00127-S; De Koning K, 1996, PARTICIPATORY RES HL; FORD H, 1994, J EPIDEMIOL COMMUN H, V48, P276, DOI 10.1136/jech.48.3.276; FREIRE P, 1968, PEGAGOGY OPPRESSED; MURRAY C, 1996, INVESTING HLTH RES D; Rahman M.A., 1991, ACTION KNOWLEDGE BRE; REYNOLDS J, 1993, PRIMARY HLTH CARE MA; SEAMAN J, 1991, TROP DOCT, V21, P38, DOI 10.1177/00494755910210S109; Vaughan J.P., 1989, MANUAL EPIDEMIOLOGY; *WHO, 1993, RAP EV METH GUID MAT; *WORLD BANK, 1993, WORLD DEV REP 1993 I; WRIGHT J, 1992, BRIT MED J, V305, P1479, DOI 10.1136/bmj.305.6867.1479	17	33	33	2	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1819	+		10.1136/bmj.316.7147.1819	http://dx.doi.org/10.1136/bmj.316.7147.1819			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZV258	9624079	Green Published			2022-12-28	WOS:000074286300036
J	Eudy, JD; Weston, MD; Yao, SF; Hoover, DM; Rehm, HL; Ma-Edmonds, M; Yan, D; Ahmad, I; Cheng, JJ; Ayuso, C; Cremers, C; Davenport, S; Moller, C; Talmadge, CB; Beisel, KW; Tamayo, M; Morton, CC; Swaroop, A; Kimberling, WJ; Sumegi, J				Eudy, JD; Weston, MD; Yao, SF; Hoover, DM; Rehm, HL; Ma-Edmonds, M; Yan, D; Ahmad, I; Cheng, JJ; Ayuso, C; Cremers, C; Davenport, S; Moller, C; Talmadge, CB; Beisel, KW; Tamayo, M; Morton, CC; Swaroop, A; Kimberling, WJ; Sumegi, J			Mutation of a gene encoding a protein with extracellular matrix motifs in usher syndrome type IIa	SCIENCE			English	Article							SYNDROME TYPE-I; ALPORT SYNDROME; LOCALIZATION; IDENTIFICATION; CHROMOSOME-11	Usher syndrome type IIa (OMIM 276901), an autosomal recessive disorder characterized by moderate to severe sensorineural hearing loss and progressive retinitis pigmentosa, maps to the long arm of human chromosome 1q41 between markers AFM268ZD1 and AFM144XF2. Three biologically important mutations in Usher syndrome type IIa patients were identified in a gene (USH2A) isolated from this critical region. The USH2A gene encodes a protein with a predicted size of 171.5 kilodaltons that has laminin epidermal growth factor and fibronectin type III motifs; these motifs are most commonly observed in proteins comprising components of the basal lamina and extracellular matrixes and in cell adhesion molecules.	Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Boys Town Natl Res Hosp, Dept Genet, Omaha, NE 68131 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol, Ann Arbor, MI 48105 USA; Univ Nebraska, Med Ctr, Dept Cell Biol & Anat, Omaha, NE 68198 USA; Fdn Jimenez Diaz, E-28003 Madrid, Spain; Univ Nijmegen, Sint Radboudziekenhuis, NL-6500 NB Nijmegen, Netherlands; Univ Hosp RIL, Ear Nose & Throat Clin, S-58180 Linkoping, Sweden; Univ Javeriana, Unidad Genet Clin, Bogota, Colombia; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet Gynecol & Reprod Biol & Pathol, Boston, MA 02115 USA	University of Nebraska System; University of Nebraska Medical Center; Boys Town National Research Hospital; Harvard University; Harvard Medical School; University of Michigan System; University of Michigan; University of Nebraska System; University of Nebraska Medical Center; Radboud University Nijmegen; Pontificia Universidad Javeriana; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Sumegi, J (corresponding author), Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA.	jsumegi@mail.unmc.edu	Cremers, C.W.R.J./L-4254-2015	Rehm, Heidi L./0000-0002-6025-0015; Tamayo, Martha Lucia/0000-0001-8297-3970; Ayuso, Carmen/0000-0002-9242-7065; Swaroop, Anand/0000-0002-1975-1141	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P01DC001813, R01DC003402] Funding Source: NIH RePORTER; NEI NIH HHS [EY07003] Funding Source: Medline; NIDCD NIH HHS [DC03402, 5PO1 DC01813-05] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BARTSCH U, 1990, J NEUROCYTOL, V19, P550, DOI 10.1007/BF01257243; BOUGHMAN JA, 1983, BRIT J OPHTHALMOL, V67, P449, DOI 10.1136/bjo.67.7.449; Chaib H, 1997, HUM MOL GENET, V6, P27, DOI 10.1093/hmg/6.1.27; DAHL SP, 1993, J MED GENET, V30, P843, DOI 10.1136/jmg.30.10.843; ElAmraoui A, 1996, HUM MOL GENET, V5, P1171, DOI 10.1093/hmg/5.8.1171; EUDY JD, UNPUB; HALLGREN B, 1959, ACTA PSYCHIAT SCAN S, V138; KAPLAN J, 1992, GENOMICS, V14, P979, DOI 10.1016/S0888-7543(05)80120-X; Kimberling W J, 1995, J Am Acad Audiol, V6, P63; KIMBERLING WJ, 1992, GENOMICS, V14, P988, DOI 10.1016/S0888-7543(05)80121-1; KIMBERLING WJ, 1990, GENOMICS, V7, P245, DOI 10.1016/0888-7543(90)90546-7; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; MOCHIZUKI T, 1994, NAT GENET, V8, P77, DOI 10.1038/ng0994-77; OGDEN TE, 1994, RETINA, P58; PIASSA L, 1986, ARCH OPHTHALMOL-CHIC, V1041, P1336; ROBERTSON NG, 1994, GENOMICS, V23, P42, DOI 10.1006/geno.1994.1457; Rosenberg T, 1997, CLIN GENET, V51, P314; SANKILA EM, 1995, HUM MOL GENET, V4, P93, DOI 10.1093/hmg/4.1.93; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; SoussiYanicostas N, 1996, J CELL SCI, V109, P1749; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; Sumegi J, 1996, GENOMICS, V35, P79, DOI 10.1006/geno.1996.0325; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Vielmetter J, 1997, GENOMICS, V41, P414, DOI 10.1006/geno.1997.4688; Wayne S, 1996, HUM MOL GENET, V5, P1689, DOI 10.1093/hmg/5.10.1689; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0	27	291	301	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	1998	280	5370					1753	1757		10.1126/science.280.5370.1753	http://dx.doi.org/10.1126/science.280.5370.1753			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624053				2022-12-28	WOS:000074197800042
J	Schwartz, PJ; Stramba-Badiale, M; Segantini, A; Austoni, P; Bosi, G; Giorgetti, R; Grancini, F; Marni, ED; Perticone, F; Rosti, D; Salice, P				Schwartz, PJ; Stramba-Badiale, M; Segantini, A; Austoni, P; Bosi, G; Giorgetti, R; Grancini, F; Marni, ED; Perticone, F; Rosti, D; Salice, P			Prolongation of the QT interval and the sudden infant death syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VENTRICULAR REPOLARIZATION; CARDIAC REPOLARIZATION; SLEEPING POSITION; INNERVATION; POPULATION; RISK	Background The sudden infant death syndrome (SIDS) is multifactorial in origin, but its causes remain unknown. We previously proposed that prolongation of the QT interval on the electrocardiogram, possibly resulting from a developmental abnormality in cardiac sympathetic innervation, may increase the risk of life-threatening ventricular arrhythmias and contribute to this devastating disorder. We prospectively tested this hypothesis. Methods Between 1976 and 1994, we recorded electrocardiograms on the third or fourth day of life in 34,442 newborns and followed them prospectively for one year. The QT interval was analyzed with and without correction for the heart rate. Results One-year follow-up data were available for 33,034 of the infants. There were 34 deaths, of which 24 were due to SIDS. The infants who died of SIDS had a longer corrected QT interval (QTc) than did the survivors (mean [+/- SD], 435 +/- 45 vs. 400 +/- 20 msec, P < 0.01) and the infants who died from causes other than SIDS (393 +/- 24 msec, P < 0.05). Moreover, 12 of the 24 SIDS victims but none of the other infants had a prolonged QTc (defined as a QTc greater than 440 msec). When the absolute QT interval was determined for similar cardiac-cycle lengths, it was found that 12 of the 24 infants who died of SIDS had a QT value exceeding the 97.5th percentile for the study group as a whole. The odds ratio for SIDS in infants with a prolonged QTc was 41.3 (95 percent confidence interval, 17.3 to 98.4). Conclusions Prolongation of the QT interval in the first week of life is strongly associated with SIDS. Neonatal electrocardiographic screening may permit the early identification of a substantial percentage of infants at risk for SIDS, and the institution of preventive measures may therefore be possible. (C) 1998, Massachusetts Medical Society.	Policlin San Matteo, Ist Ricovero & Cura Carattene Sci, Dept Cardiol, I-27100 Pavia, Italy; Univ Pavia, Dept Pediat, I-27100 Pavia, Italy; Univ Milan, Ctr Fisiol Clin & Ipertens, Milan, Italy; Osped Maggiore, Ist Ricovero & Cura Carattene Sci, Milan, Italy; Osped Niguarda Ca Granda, Cardiol Dept A De Gasperis, Milan, Italy; Univ Ferrara, Inst Pediat, I-44100 Ferrara, Italy; Osped Galmarini, Tradate, Italy; Univ Reggio Calabria, Dept Expt & Clin Cardiol G Salvatore Catanzaro, Catanzaro, Italy; Osped Regina Elena, Milan, Italy	IRCCS Fondazione San Matteo; University of Pavia; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; University of Ferrara; Universita Mediterranea di Reggio Calabria	Schwartz, PJ (corresponding author), Policlin San Matteo, Ist Ricovero & Cura Carattene Sci, Dept Cardiol, Piazzale Golgi 2, I-27100 Pavia, Italy.		Stramba-Badiale, Marco/AAA-6183-2020; Schwartz, Peter J/J-4267-2016; Rosenthal, Eric/I-7469-2012; Perticone, Francesco/I-4260-2017	Schwartz, Peter J/0000-0003-0367-1048; Rosenthal, Eric/0000-0003-3030-9749; Stramba-Badiale, Marco/0000-0001-5900-811X				ALGRA A, 1991, CIRCULATION, V83, P1888, DOI 10.1161/01.CIR.83.6.1888; ALIMURUNG MM, 1950, CIRCULATION, V1, P1329, DOI 10.1161/01.CIR.1.6.1329; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BERGMAN AB, 1970, SUDDEN INFANT DEATH; Butrous G.S., 1989, CLIN ASPECTS VENTRIC; DAVIGNON A, 1980, PEDIATR CARDIOL, V1, P123, DOI 10.1007/BF02083144; DWYER T, 1995, PEDIATR ANN, V24, P350, DOI 10.3928/0090-4481-19950701-06; DWYER T, 1995, JAMA-J AM MED ASSOC, V273, P783, DOI 10.1001/jama.273.10.783; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; Gootman P. M., 1986, DEV NEUROBIOLOGY AUT; HADDAD GG, 1979, PEDIATR RES, V13, P136, DOI 10.1203/00006450-197902000-00010; KELLY DH, 1977, CIRCULATION, V55, P633, DOI 10.1161/01.CIR.55.4.633; MALFATTO G, 1990, CIRC RES, V66, P427, DOI 10.1161/01.RES.66.2.427; MCCAMMON RW, 1961, ACTA PAEDIATR, V50, P3; MERRI M, 1989, CIRCULATION, V80, P1301, DOI 10.1161/01.CIR.80.5.1301; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS3, DOI 10.1111/j.1440-1754.1992.tb02729.x; MONTAGUE TJ, 1984, AM J CARDIOL, V54, P301, DOI 10.1016/0002-9149(84)90187-5; Priori SG, 1997, PACE, V20, P2052, DOI 10.1111/j.1540-8159.1997.tb03626.x; PRIORI SG, IN PRESS CIRCULATION; ROMANO C, 1963, Clin Pediatr (Bologna), V45, P656; SADEH D, 1987, NEW ENGL J MED, V317, P1501, DOI 10.1056/NEJM198712103172404; SCHOUTEN EG, 1991, CIRCULATION, V84, P1516, DOI 10.1161/01.CIR.84.4.1516; SCHWARTZ LZ, 1988, ANN NY ACAD SCI, V533, P132, DOI 10.1111/j.1749-6632.1988.tb37242.x; SCHWARTZ PJ, 1981, REV PERINATAL MED, V4, P475; SCHWARTZ PJ, 1987, CIRCULATION, V75, P677, DOI 10.1161/01.CIR.75.4.677; SCHWARTZ PJ, 1988, ANN NY ACAD SCI, V533, P210, DOI 10.1111/j.1749-6632.1988.tb37250.x; SCHWARTZ PJ, 1982, CIRCULATION, V66, P496, DOI 10.1161/01.CIR.66.3.496; SCHWARTZ PJ, 1978, CIRCULATION, V57, P1074, DOI 10.1161/01.CIR.57.6.1074; SCHWARTZ PJ, 1993, CIRCULATION, V88, P782, DOI 10.1161/01.CIR.88.2.782; SCHWARTZ PJ, 1976, AM J MED, V60, P167, DOI 10.1016/0002-9343(76)90425-3; SCHWARTZ PJ, 1988, ANN NY ACAD SCI, P533; SCHWARTZ PJ, 1990, CARDIAC ELECTROPHYSI, P330; SCHWARTZ PJ, 1985, AM HEART J, V109, P99; Schwartz PJ, 1995, CARDIAC ELECTROPHYSI, P788; SOUTHALL DP, 1986, ARCH DIS CHILD, V61, P327, DOI 10.1136/adc.61.4.327; STEINSCHNEIDER A, 1978, AM J DIS CHILD, V132, P688, DOI 10.1001/archpedi.1978.02120320048011; StrambaBadiale M, 1997, AM HEART J, V134, P406, DOI 10.1016/S0002-8703(97)70074-7; STRAMBABADIALE M, 1995, AM J CARDIOL, V75, P1277, DOI 10.1016/S0002-9149(99)80781-4; STRAMBABADIALE M, 1992, AM J PHYSIOL, V263, pH1514, DOI 10.1152/ajpheart.1992.263.5.H1514; WALSH SZ, 1963, AM HEART J, V66, P36, DOI 10.1016/0002-8703(63)90066-8; WYNN VT, 1992, BRIT HEART J, V67, P84	41	488	511	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1998	338	24					1709	1714		10.1056/NEJM199806113382401	http://dx.doi.org/10.1056/NEJM199806113382401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT654	9624190	Bronze			2022-12-28	WOS:000074109800001
J	Marshall, EG; Spiegelhalter, DJ				Marshall, EG; Spiegelhalter, DJ			Reliability of league tables of in vitro fertilisation clinics: retrospective analysis of live birth rates	BRITISH MEDICAL JOURNAL			English	Article							PERFORMANCE	Objective: To determine to what extent institutions carrying out in vitro fertilisation can reasonably be ranked according to their live birth rates. Design: Retrospective analysis of prospectively collected data on live birth rate after in vitro fertilisation. Setting: 52 clinics in the United Kingdom carrying out in vitro fertilisation over the period April 1994 to March 1995. Main outcome measure: Estimated adjusted live birth rate for each clinic; their rank and its associated uncertainty. Results: There were substantial and significant differences between the live birth rates of the clinics. There was great uncertainty, however, concerning the true ranks, particularly for the smaller clinics. Only one clinic could be confidently ranked in the bottom quarter according to this measure of performance. Many centres had substantial changes in rank between years, even though their live birth rate did not change significantly. Conclusions: Even when there are substantial differences between institutions, ranks are extremely unreliable statistical summaries of performance and change in performance, particularly for smaller institutions. Any performance indicator should always be associated with a measure of sampling variability.	Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England	MRC Biostatistics Unit; University of Cambridge	Spiegelhalter, DJ (corresponding author), Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England.		McKee, Martin/E-6673-2018	McKee, Martin/0000-0002-0121-9683				*CLIN RES AUD GROU, 1995, CLIN OUTC IND 1994; COURSAGET P, 1991, LANCET, V337, P1180, DOI 10.1016/0140-6736(91)92857-X; DILLNER L, 1995, BRIT MED J, V311, P1041, DOI 10.1136/bmj.311.7012.1041; Gilks W. R., 1996, MARKOV CHAIN MONTE C; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P385, DOI 10.2307/2983325; Hii JLK, 1997, J MED ENTOMOL, V34, P193, DOI 10.1093/jmedent/34.2.193; *HUM FERT EMBR AUT, 1995, PAT GUID DI IVF CLIN; *HUM FERT EMBR AUT, 1996, PAT GUID DI IVF CLIN; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; Jordan P, 1997, INT J EPIDEMIOL, V26, P501, DOI 10.1093/ije/26.3.501; LAIRD NM, 1989, J EDUC STAT, V14, P29, DOI 10.2307/1164724; Lilford RJ, 1996, BRIT MED J, V313, P603; McKee M, 1995, Qual Health Care, V4, P5, DOI 10.1136/qshc.4.1.5; *NHS EX, 1995, NHS PERF GUID 1994 1; *NY STAT DEP HLTH, 1996, COR ART BYP SURG NY; Schneider EC, 1996, NEW ENGL J MED, V335, P251, DOI 10.1056/NEJM199607253350406; Spiegelhalter D.J., 1995, BUGS BAYESIAN INFERE; TWEEDLE RL, 1996, LUNG CANCER, V14, P171	18	140	142	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1701	1704		10.1136/bmj.316.7146.1701	http://dx.doi.org/10.1136/bmj.316.7146.1701			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614016	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000074129500016
J	Gmachl, C; Capasso, F; Narimanov, EE; Nockel, JU; Stone, AD; Faist, J; Sivco, DL; Cho, AY				Gmachl, C; Capasso, F; Narimanov, EE; Nockel, JU; Stone, AD; Faist, J; Sivco, DL; Cho, AY			High-power directional emission from microlasers with chaotic resonators	SCIENCE			English	Article							QUANTUM CASCADE LASER; ROOM-TEMPERATURE; STADIUM BILLIARD; MICRODISK LASERS; WAVE-FUNCTIONS; CAVITIES; EIGENFUNCTIONS; SCATTERING; INTERFACE; DYNAMICS	High-power and highly directional semiconductor microcylinder lasers based on an optical resonator with deformed cross section are reported. In the favorable directions of the far-field, a power increase of up to three orders of magnitude over the conventional circularly symmetric lasers was obtained. A "bow-tie"-shaped resonance is responsible for the improved performance of the lasers in the higher range of deformations, in contrast to "whispering-gallery"-type modes of circular and weakly deformed lasers. This resonator design, although demonstrated here in midinfrared quantum-cascade lasers, should be applicable to any laser based on semiconductors or other high-refractive index materials.	Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA; Yale Univ, Dept Appl Phys, New Haven, CT 06520 USA; Max Planck Inst Phys Komplexer Syst, D-01187 Dresden, Germany	Alcatel-Lucent; Lucent Technologies; AT&T; Yale University; Max Planck Society	Capasso, F (corresponding author), Lucent Technol, Bell Labs, 600 Mt Ave, Murray Hill, NJ 07974 USA.	fc@lucent.com	Nockel, Jens U/A-7639-2008; Faist, Jerome/A-7339-2013	Nockel, Jens U/0000-0001-5165-2437; Faist, Jerome/0000-0003-4429-7988				ALT H, 1995, PHYS REV LETT, V74, P62, DOI 10.1103/PhysRevLett.74.62; Baba T, 1997, IEEE J SEL TOP QUANT, V3, P808, DOI 10.1109/2944.640635; Berry M. V., 1981, European Journal of Physics, V2, P91, DOI 10.1088/0143-0807/2/2/006; BERRY MV, 1987, PROC R SOC LON SER-A, V413, P183, DOI 10.1098/rspa.1987.0109; Capasso F, 1997, SOLID STATE COMMUN, V102, P231, DOI 10.1016/S0038-1098(96)00711-9; CHU DY, 1994, APPL PHYS LETT, V65, P3167, DOI 10.1063/1.112470; CROMMIE MF, 1993, SCIENCE, V262, P218, DOI 10.1126/science.262.5131.218; Deng H, 1996, APPL PHYS LETT, V69, P3120, DOI 10.1063/1.116801; Faist J, 1996, APPL PHYS LETT, V69, P2456, DOI 10.1063/1.117496; FAIST J, 1994, SCIENCE, V264, P553, DOI 10.1126/science.264.5158.553; Faist J, 1998, IEEE J QUANTUM ELECT, V34, P336, DOI 10.1109/3.658728; Faist J, 1996, APPL PHYS LETT, V68, P3680, DOI 10.1063/1.115741; GASPARD P, 1989, J CHEM PHYS, V90, P2225, DOI 10.1063/1.456017; Gmachl C, 1997, IEEE J QUANTUM ELECT, V33, P1567, DOI 10.1109/3.622638; GRAF HD, 1992, PHYS REV LETT, V69, P1296, DOI 10.1103/PhysRevLett.69.1296; HASEGAWA H, 1989, PROG THEOR PHYS SUPP, P198, DOI 10.1143/PTPS.98.198; JOHNSON BR, 1993, J OPT SOC AM A, V10, P343, DOI 10.1364/JOSAA.10.000343; KUDROLLI A, 1995, PHYS REV LETT, V75, P822, DOI 10.1103/PhysRevLett.75.822; Lazutkin V.F., 1993, RESULTS MATH RELATED, V24; LEBOEUF P, 1990, J PHYS A-MATH GEN, V23, P1745, DOI 10.1088/0305-4470/23/10/016; LEVI AFJ, 1993, APPL PHYS LETT, V62, P561, DOI 10.1063/1.108911; LEVI AFJ, 1993, APPL PHYS LETT, V62, P2021, DOI 10.1063/1.109492; Li BJ, 1997, IEEE J QUANTUM ELECT, V33, P791, DOI 10.1109/3.572153; Liu H, 1998, OPT LETT, V23, P451, DOI 10.1364/OL.23.000451; MARCUS CM, 1992, PHYS REV LETT, V69, P506, DOI 10.1103/PhysRevLett.69.506; MCCALL SL, 1992, APPL PHYS LETT, V60, P289, DOI 10.1063/1.106688; MILLER WH, 1972, J CHEM PHYS, V56, P38, DOI 10.1063/1.1676877; NOCKEL JU, 1994, OPT LETT, V19, P1693, DOI 10.1364/OL.19.001693; Nockel JU, 1996, OPT LETT, V21, P1609, DOI 10.1364/OL.21.001609; Nockel JU, 1997, NATURE, V385, P45, DOI 10.1038/385045a0; NOCKEL JU, 1995, OPTICAL PROCESSES MI, pCH11; PFEIFFER L, 1991, APPL PHYS LETT, V58, P2258, DOI 10.1063/1.104915; QIAN SX, 1986, SCIENCE, V231, P486, DOI 10.1126/science.231.4737.486; Reichl L.E., 1992, TRANSITION CHAOS CON; Saleh B.E.A., 2007, FUNDAMENTALS PHOTONI, V2nd; Silfvast W.T., 1996, LASER FUNDAMENTALS; SIRTORI C, 1995, APPL PHYS LETT, V66, P3242, DOI 10.1063/1.113391; SIRTORI C, IN PRESS IEEE J QUAN; SRIDHAR S, 1991, PHYS REV LETT, V67, P785, DOI 10.1103/PhysRevLett.67.785; STEIN J, 1992, PHYS REV LETT, V68, P2867, DOI 10.1103/PhysRevLett.68.2867; YAMAMOTO Y, 1993, PHYS TODAY, V46, P66, DOI 10.1063/1.881356; Yokoyama H., 1995, SPONTANEOUS EMISSION	42	646	661	2	137	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	1998	280	5369					1556	1564		10.1126/science.280.5369.1556	http://dx.doi.org/10.1126/science.280.5369.1556			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616111	Green Submitted			2022-12-28	WOS:000074061200029
J	Shann, F				Shann, F			Pneumococcal vaccine: time for another controlled trial	LANCET			English	Editorial Material							RESPIRATORY-TRACT INFECTIONS; PAPUA-NEW-GUINEA; CHILDREN		Royal Childrens Hosp, Intens Care Unit, Melbourne, Vic 3052, Australia	Royal Children's Hospital Melbourne	Shann, F (corresponding author), Royal Childrens Hosp, Intens Care Unit, Flemington Rd, Melbourne, Vic 3052, Australia.		Shann, Frank/C-9510-2011					AABY P, 1995, SOC SCI MED, V41, P673, DOI 10.1016/0277-9536(95)00038-9; Dullforce P, 1998, NAT MED, V4, P88, DOI 10.1038/nm0198-088; Goldblatt D, 1993, Immunodeficiency, V4, P47; Kayhty H, 1996, EMERG INFECT DIS, V2, P289, DOI 10.3201/eid0204.9604; LEHMANN D, 1991, ANN TROP PAEDIATR, V11, P247, DOI 10.1080/02724936.1991.11747510; POMAT WS, 1994, INFECT IMMUN, V62, P1848, DOI 10.1128/IAI.62.5.1848-1853.1994; RILEY ID, 1986, LANCET, V2, P877; TEMPLE K, 1991, PEDIATR INFECT DIS J, V10, P386, DOI 10.1097/00006454-199105000-00008; Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006; *WHO, 1997, TECHN REV GROUP M JU, P32; *WHO, 1995, WORLD HLTH REP 1995, P9; WITT CS, 1991, CLIN EXP IMMUNOL, V83, P219, DOI 10.1111/j.1365-2249.1991.tb05618.x; Woolfson A, 1997, B WORLD HEALTH ORGAN, V75, P453; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	14	19	20	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1600	1601		10.1016/S0140-6736(05)77683-2	http://dx.doi.org/10.1016/S0140-6736(05)77683-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620711				2022-12-28	WOS:000074026600004
J	Clarke, M; Collins, R; Davies, C; Godwin, J; Gray, R; Peto, R				Clarke, M; Collins, R; Davies, C; Godwin, J; Gray, R; Peto, R		Early Breast Cancer Trialists Collaborative Grp	Tamoxifen for early breast cancer: An overview of the randomised trials	LANCET			English	Article							ADJUVANT TAMOXIFEN; THERAPY; TUMORS; WOMEN	Background. There have been many randomised trials of adjuvant tamoxifen among women with early breast cancer, and an updated overview of their results is presented. Methods. In 1995, information was sought on each woman in any randomised trial that began before 1990 of adjuvant tamoxifen versus no tamoxifen before recurrence. Information was obtained and analysed centrally on each of 37000 women in 55 such trials, comprising about 87% of the worldwide evidence. Compared with the previous such overview, this approximately doubles the amount of evidence from trials of about 5 years of tamoxifen and, taking all trials together, on events occurring more than 5 years after randomisation. Findings. Nearly 8000 of the women had a low, or zero, level of the oestrogen-receptor protein (ER) measured in their primary tumour. Among them, the overall effects of tamoxifen appeared to be small, and subsequent analyses of recurrence and total mortality are restricted to the remaining women (18000 with ER-positive tumours, plus nearly 12000 more with untested tumours, of which an estimated 8000 would have been ER-positive). For trials of 1 year, 2 years, and about 5 years of adjuvant tamoxifen, the proportional recurrence reductions produced among these 30000 women during about 10 years of follow-up were 21% (SD 3), 29% (SD 2), and 47% (SD 3), respectively, with a highly significant trend towards greater effect with longer treatment (x(1)(2) = 52.0, 2p < 0.00001). The corresponding proportional mortality reductions were 12% (SD 3), 17% (SD 3), and 26% (SD 4), respectively, and again the test for trend was significant (X-1(2) = 8.8, 2p = 0.003). The absolute improvement in recurrence was greater during the first 5 years, whereas the improvement in survival grew steadily larger throughout the first 10 years. The proportional mortality reductions were similar for women with node-positive and node-negative disease, but the absolute mortality reductions were greater in node-positive women. In the trials of about 5 years of adjuvant tamoxifen the absolute improvements in 10-year survival were 10.9% (SD 2.5) for node-positive (61.4% vs 50.5% survival, 2p < 0.00001) and 5.6% (SD 1.3) for node-negative (78.9% vs 73.3% survival, 2p < 0.00001). These benefits appeared to be largely irrespective of age, menopausal status, daily tamoxifen dose (which was generally 20 mg), and of whether chemotherapy had been given to both groups. In terms of other outcomes among all women studied tie, including those with "ER-poor" tumours), the proportional reductions in contralateral breast cancer were 13% (SD 13), 26% (SD 9), and 47% (SD 9) in the trials of 1, 2, or about 5 years of adjuvant tamoxifen. The incidence of endometrial cancer was approximately doubled in trials of 1 or 2 years of tamoxifen and approximately quadrupled in trials of 5 years of tamoxifen (although the number of cases was small and these ratios were not significantly different from each other). The absolute decrease in contralateral breast cancer was about twice as large as the absolute increase in the incidence of endometrial cancer, Tamoxifen had no apparent effect on the incidence of colorectal cancer or, after exclusion of deaths from breast or endometrial cancer, on any of the other main categories of cause of death (total nearly 2000 such deaths; overall relative risk 0.99 [SD 0.05]). Interpretation. For women with tumours that have been reliably shown to be ER-negative, adjuvant tamoxifen remains a matter for research. However, some years of adjuvant tamoxifen treatment substantially improves the 10-year survival of women with ER-positive tumours and of women whose tumours are of unknown ER status, with the proportional reductions in breast cancer recurrence and in mortality appearing to be largely unaffected by other patient characteristics or treatments.	Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Clarke, M (corresponding author), Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England.		Gnant, Michael/AAN-7054-2020; McLaughlin, John R/E-4577-2013; Boccardo, Francesco Mario/AAF-2654-2019; Harris, Adrian/ABA-3343-2020; Barkmanova, Jaroslava/A-1411-2017	Gnant, Michael/0000-0003-1002-2118; Boccardo, Francesco Mario/0000-0002-5392-4077; Semiglazov, Vladimir/0000-0003-0077-9619; Dunn, Janet/0000-0001-7313-4446; Howell, Anthony/0000-0002-6233-719X; Portnoj, S/0000-0002-8965-5040; Evans, Vaughan/0000-0002-2366-2301; , david/0000-0002-4133-9364; RUBAGOTTI, Alessandra/0000-0002-4009-8829; Harris, Adrian/0000-0003-1376-8409; Smith, David/0000-0002-9465-988X; Coombes, Raoul Charles/0000-0002-4811-1100; Douglas, Pamela/0000-0001-9876-4049; Barkmanova, Jaroslava/0000-0003-1406-7292; Anderson, Stewart/0000-0001-8948-0650; Blomqvist, Carl/0000-0003-3041-1938; Bergh, Jonas/0000-0001-5526-1847				ABE O, 1992, LANCET, V339, P71; ABE O, 1995, NEW ENGL J MED, V333, P1444; Abram P, 1996, J NATL CANCER I, V88, P1834; [Anonymous], 1996, Lancet, V348, P1189; [Anonymous], 1988, NEW ENGL J MED, V319, P1681; [Anonymous], 1992, Lancet, V339, P1; CLARK GM, 1997, P ASCO, V16, P454; Cuzick J, 1996, IARC SCI PUBL, P95; DELOZIER T, 1997, P AN M AM SOC CLIN, V16, P1289; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1; ELWOOD JM, 1980, BRIT J CANCER, V42, P635, DOI 10.1038/bjc.1980.296; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; Gotto AM, 1997, AM J CARDIOL, V79, P1663, DOI 10.1016/S0002-9149(97)00218-X; IARC, 1996, IARC MON EV CARC RIS, P253; KNIGHT WA, 1980, CLIN ENDOCRINOL META, V9, P361, DOI 10.1016/S0300-595X(80)80038-7; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; MCDONALD CC, 1995, BRIT MED J, V311, P977; Parkin DM, 1992, CANC INCIDENCE 5 CON, VVI; Peto R, 1996, J NATL CANCER I, V88, P1791, DOI 10.1093/jnci/88.24.1791; Peto R, 1994, MORTALITY SMOKING DE; Rutqvist LE, 1996, J NATL CANCER I, V88, P1543; RUTQVIST LE, 1995, J NATL CANCER I, V87, P645, DOI 10.1093/jnci/87.9.645; RUTQVIST LE, 1989, INT J RADIAT ONCOL, V16, P629, DOI 10.1016/0360-3016(89)90478-1; Stewart HJ, 1996, BRIT J CANCER, V74, P297, DOI 10.1038/bjc.1996.356; Tormey DC, 1996, JNCI-J NATL CANCER I, V88, P1828, DOI 10.1093/jnci/88.24.1828; WILLIAMS GM, 1993, CARCINOGENESIS, V14, P315	27	3167	3210	1	152	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 16	1998	351	9114					1451	1467						17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605801				2022-12-28	WOS:000073707300007
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Automating a mouse	SCIENCE			English	Editorial Material																		Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1101	1101						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9616082				2022-12-28	WOS:000073663600053
J	Struhl, G; Adachi, A				Struhl, G; Adachi, A			Nuclear access and action of notch in vivo	CELL			English	Article							DEVELOPING DROSOPHILA EYE; EPIDERMAL GROWTH-FACTOR; OF-FUNCTION MUTATIONS; SPLIT COMPLEX GENES; ACTIVATES TRANSCRIPTION; SIGNAL-TRANSDUCTION; RECEPTOR; PROTEIN; EXPRESSION; SUPPRESSOR	The Drosophila Notch (N) gene encodes a conserved single-pass transmembrane receptor that transduces extracellular signals controlling cell fate. Here, we present evidence that the intracellular domain of Notch gains access to the nucleus in response to ligand, possibly through a mechanism involving proteolytic cleavage and release from the remainder of the protein. In addition, our results suggest that signal transduction by Notch depends on the ability of the intracellular domain, particularly the portion containing the CDC10 repeats, to reach the nucleus and to participate in the transcriptional activation of downstream target genes.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Struhl, G (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, Howard Hughes Med Inst, 701 W 168th St, New York, NY 10032 USA.							ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Eastman DS, 1997, MOL CELL BIOL, V17, P5620, DOI 10.1128/MCB.17.9.5620; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FISHER AL, 1998, IN PRESS GENES DEV; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD I, 1998, IN PRESS GENES DEV; HEITZLER P, 1993, DEVELOPMENT, V117, P1113; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KODOYIANNI V, 1992, MOL BIOL CELL, V3, P1199, DOI 10.1091/mbc.3.11.1199; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Roehl H, 1996, EMBO J, V15, P7002, DOI 10.1002/j.1460-2075.1996.tb01092.x; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Wang SW, 1997, DEVELOPMENT, V124, P4435; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	40	630	651	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1998	93	4					649	660		10.1016/S0092-8674(00)81193-9	http://dx.doi.org/10.1016/S0092-8674(00)81193-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604939	hybrid			2022-12-28	WOS:000073722200017
J	Troughton, J				Troughton, J			A memorable patient - It pays to be specific	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1998	316	7148					1889	1889						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632413				2022-12-28	WOS:000074686500030
J	Dryburgh, FJ				Dryburgh, FJ			Patients who make my practice - Known by name	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1801	1801		10.1136/bmj.316.7147.1801	http://dx.doi.org/10.1136/bmj.316.7147.1801			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624071	Green Published			2022-12-28	WOS:000074286300030
J	Shen, HM; Peters, A; Baron, B; Zhu, XD; Storb, U				Shen, HM; Peters, A; Baron, B; Zhu, XD; Storb, U			Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes	SCIENCE			English	Article							IMMUNOGLOBULIN GENES; NUCLEOTIDE-SEQUENCE; INTRON ENHANCER; ELEMENTS; LYMPHOMA; REGION; LOCUS	Immunoglobulin (Ig) genes are hypermutated in B lymphocytes that are the precursors to memory B cells. The mutations are linked to transcription initiation, but non-Ig promoters are permissible for the mutation process; thus, other genes expressed in mutating B cells may also be subject to somatic hypermutation. Significant mutations were not observed in c-MYC, S14, or alpha-fetoprotein (AFP) genes, but BCL-6 was highly mutated in a large proportion of memory B cells of normal individuals. The mutation pattern was similar to that of Ig genes.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60617 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60617 USA; Univ Chicago, Dept Pathol, Chicago, IL 60617 USA; Univ Chicago, Dept Med, Chicago, IL 60617 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	Storb, U (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60617 USA.			zhu, xiangdong/0000-0002-5627-8082	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038649] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38649, GM07183] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; Cline J, 1996, NUCLEIC ACIDS RES, V24, P3546, DOI 10.1093/nar/24.18.3546; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GIBBS PEM, 1987, BIOCHEMISTRY-US, V26, P1332, DOI 10.1021/bi00379a020; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; KLEIN U, 1994, J EXP MED, V180, P1383, DOI 10.1084/jem.180.4.1383; Klotz EL, 1996, J IMMUNOL, V157, P4458; Migliazza A., 1997, Blood, V90, p177A; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MUELLER J, 1995, P NATL ACAD SCI USA, V92, P6577; Newton JS, 1996, EUR J IMMUNOL, V26, P811, DOI 10.1002/eji.1830260413; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; Storb U, 1996, CURR OPIN IMMUNOL, V8, P206, DOI 10.1016/S0952-7915(96)80059-8; Storb U, 1998, CURR TOP MICROBIOL, V229, P11; STORB U, IN PRESS BIOL GERMIN; STORB U, UNPUB; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; TumasBrundage K, 1997, J EXP MED, V185, P239, DOI 10.1084/jem.185.2.239	22	439	444	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1750	1752		10.1126/science.280.5370.1750	http://dx.doi.org/10.1126/science.280.5370.1750			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624052				2022-12-28	WOS:000074197800041
J	Irvine, WM; Bergin, DA; Dickens, JE; Jewitt, D; Lovell, AJ; Matthews, HE; Schloerb, FP; Senay, M				Irvine, WM; Bergin, DA; Dickens, JE; Jewitt, D; Lovell, AJ; Matthews, HE; Schloerb, FP; Senay, M			Chemical processing in the coma as the source of cometary HNC	NATURE			English	Article							ABUNDANCE RATIO; HCN	The discovery of hydrogen isocyanide (HNC) in comet Hyakutake with an abundance (relative to hydrogen cyanide, KCN) similar to that seen in dense interstellar clouds raised the possibility that these molecules might be surviving interstellar material(1). The preservation of material from the Sun's parent molecular cloud would provide important constraints on the processes that took place in the protostellar nebula. But another possibility is that HNC is produced by photochemical processes in the coma, which means that its abundance could not be used as a direct constraint on conditions in the early Solar System. Here we show that the HNC/HCN ratio determined for comet Hale-Bopp varied with heliocentric distance in a way that matches the predictions of models of gas-phase chemical production of HNC in the coma, but cannot be explained if the HNC molecules were coming from the comet's nucleus. We conclude that HNC forms mainly by chemical reactions in the coma, and that such reactions need to be considered when attempting to deduce the composition of the nucleus from observations of the coma.	Univ Massachusetts, Five Coll Radio Astron Observ, Amherst, MA 01003 USA; Smithsonian Astrophys Observ, Cambridge, MA 02138 USA; Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; Natl Res Council Canada, Herzberg Inst Astrophys, Ottawa, ON K1A 0R6, Canada; Joint Astron Ctr, Hilo, HI 96720 USA	University of Massachusetts System; University of Massachusetts Amherst; Harvard University; Smithsonian Institution; University of Hawaii System; National Research Council Canada	Irvine, WM (corresponding author), Univ Massachusetts, Five Coll Radio Astron Observ, 619 LGRC, Amherst, MA 01003 USA.							Bergin EA, 1997, ASTROPHYS J, V486, P316, DOI 10.1086/304510; Biver N, 1997, SCIENCE, V275, P1915, DOI 10.1126/science.275.5308.1915; BIVER N, IN PRESS EARTH MOON; BOCKELEEMORVAN D, 1994, PLANET SPACE SCI, V42, P655, DOI 10.1016/0032-0633(94)90043-4; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; FESTOU MC, 1993, ASTRON ASTROPHYS REV, V5, P37, DOI 10.1007/BF00872923; Fomenkova M. N., 1997, Astronomical Society of the Pacific Conference Series, V122, P415; GOLDSMITH PF, 1986, ASTROPHYS J, V310, P383, DOI 10.1086/164692; GOLDSMITH PF, 1981, ASTROPHYS J, V249, P524, DOI 10.1086/159312; HERBST E, 1978, ASTROPHYS J, V222, P508, DOI 10.1086/156163; HIROTA T, IN PRESS ASTROPHYS J; IRVINE WH, IN PRESS FARADAY DIS, V109; Irvine WM, 1996, NATURE, V383, P418, DOI 10.1038/383418a0; IRVINE WM, 1997, ESA, P277; LOVAS FJ, 1992, J PHYS CHEM REF DATA, V21, P181, DOI 10.1063/1.555920; Lovell AJ, 1998, ASTROPHYS J, V497, pL117, DOI 10.1086/311288; LOVELL AJ, IN PRESS EARTH MOON; Mumma M. J., 1993, PROTOSTARS PLANETS, P1177; Notesco G, 1997, ICARUS, V126, P336, DOI 10.1006/icar.1996.5654; OLOFSSON H, 1982, ASTRON ASTROPHYS, V107, P128; RODGERS SD, IN PRESS ASTROPHYS J; SCHMIDT HU, 1988, COMPUT PHYS COMMUN, V49, P17, DOI 10.1016/0010-4655(88)90214-7; Shiba Y, 1998, J CHEM PHYS, V108, P698, DOI 10.1063/1.475443; TACCONIGARMAN LE, 1990, ASTROPHYS J, V364, P672, DOI 10.1086/169450; WINK J, IN PRESS EARTH MOON; IN PRESS EARTH MOON	26	64	64	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1998	393	6685					547	550		10.1038/31171	http://dx.doi.org/10.1038/31171			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634231				2022-12-28	WOS:000074150100043
J	Glover, DW; Maron, BJ				Glover, DW; Maron, BJ			Profile of preparticipation cardiovascular screening for high school athletes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUDDEN-DEATH; YOUNG-ADULTS; DISEASE; ECHOCARDIOGRAPHY; CARDIOMYOPATHY	Context.-Sudden death in young competitive athletes due to unsuspected cardiovascular disease has heightened concern and interest in the preparticipation screening available to high school athletes in the United States. Objective.-To assess the potential adequacy of the preparticipation screening process for detecting or increasing the suspicion of cardiovascular abnormalities. Design.-Current guidelines and requirements for implementation of preparticipation screening from each of the high school jurisdictions in the 50 states and the District of Columbia were analyzed and compared with the 1996 American Heart Association (AHA) consensus panel guidelines on screening. Outcome Measures.-Items contained on preparticipation screening questionnaires; the examiners designated to perform screening. Results.-Eight states (16%) have no approved history and physical examination questionnaires to guide examiners, including 1 state without a formal screening requirement. Of the remaining 43 states, several items relevant to cardiac-related problems were frequently omitted from the questionnaires, Exertional dyspnea or chest pain, prior limitation from sports, family history of heart disease, or Marian syndrome were included in 0% to 56% of the state forms. Specific cardiovascular items on physical examination were included in forms from only 5% to 37% of states, including documentation of a heart murmur, irregular heart rhythm, peripheral pulses, or stigmata of Marfan syndrome. Seventeen (40%) of 43 states had history and physical questionnaires judged to be most adequate with at least 9 of the 13 AHA recommendations, whereas 12 states (28%) were least adequate with 4 or less of these recommended items. Therefore, a total of 20 (40%) of the 51 states have no approved history and physical examination questionnaires, or formal screening requirement, or forms that were judged to be inadequate. In addition to physicians, 21 states also permit nurses or physician assistants to administer examinations, and 11 states specifically provide for practitioners with limited cardiovascular training (such as chiropractors). Conclusions.-Preparticipation athletic screening for cardiovascular disease with standard history and physical examination, as presently employed in US high schools, is highly dependent on the state-approved questionnaires, which frequently are abbreviated and may be inadequate; is implemented by a variety of health care workers with varying levels of expertise; and may be severely limited in its power to detect potentially lethal cardiovascular abnormalities. These observations should represent an impetus for change and improvement in the preparticipation cardiovascular screening process for high school athletes.	St Lukes Hosp, Ambulatory Care Div, Kansas City, MO USA; Minneapolis Heart Inst Fdn, Minneapolis, MN USA	Saint Luke's Hospital - Missouri; Minneapolis Heart Institute Foundation	Maron, BJ (corresponding author), 920 E 28th St,Suite 40, Minneapolis, MN 55407 USA.							BHARATI S, 1986, J AM COLL CARDIOL, V8, P1096, DOI 10.1016/S0735-1097(86)80387-4; BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; CORRADO D, 1990, AM J MED, V89, P588, DOI 10.1016/0002-9343(90)90176-E; CORRADO D, 1997, CIRCULATION S1, V96, P152; Feinstein RA, 1994, CLIN J SPORT MED, V3, P149; Fuller CM, 1997, MED SCI SPORT EXER, V29, P1131, DOI 10.1097/00005768-199709000-00003; LACORTE MA, 1989, CLIN CARDIOL, V12, P41; LEWIS JF, 1989, AM J CARDIOL, V64, P1029, DOI 10.1016/0002-9149(89)90802-3; Liberthson RR, 1996, NEW ENGL J MED, V334, P1039, DOI 10.1056/NEJM199604183341607; MARON BJ, 1987, J AM COLL CARDIOL, V10, P1214, DOI 10.1016/S0735-1097(87)80121-3; MARON BJ, 1993, NEW ENGL J MED, V329, P55, DOI 10.1056/NEJM199307013290113; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; Maron BJ, 1996, CIRCULATION, V94, P850, DOI 10.1161/01.CIR.94.4.850; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; Maron BJ, 1997, LANCET, V350, P127, DOI 10.1016/S0140-6736(97)01282-8; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; MARON BJ, 1996, CIRCULATION, V94, P388; Maron BJ, 1994, J AM COLL CARDIOL, V24, P845; MARSALESE DL, 1989, J AM COLL CARDIOL, V14, P422, DOI 10.1016/0735-1097(89)90197-6; MURRY PM, 1995, AM J CARDIOL, V76, P849, DOI 10.1016/S0002-9149(99)80244-6; SMITH DM, 1997, PREPARTICIPATION PHY, P1; THIENE G, 1988, NEW ENGL J MED, V318, P129, DOI 10.1056/NEJM198801213180301; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641; WEIDENBENER EJ, 1995, CLIN J SPORT MED, V5, P86, DOI 10.1097/00042752-199504000-00003; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6	25	119	119	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1817	1819		10.1001/jama.279.22.1817	http://dx.doi.org/10.1001/jama.279.22.1817			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR635	9628714				2022-12-28	WOS:000073998500035
J	Mdluli, K; Slayden, RA; Zhu, YQ; Ramaswamy, S; Pan, X; Mead, D; Crane, DD; Musser, JM; Barry, CE				Mdluli, K; Slayden, RA; Zhu, YQ; Ramaswamy, S; Pan, X; Mead, D; Crane, DD; Musser, JM; Barry, CE			Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid	SCIENCE			English	Article							CATALASE-PEROXIDASE GENE; ACYL CARRIER PROTEIN; DRUG-RESISTANCE; CELL-GROWTH; FATTY-ACID; TARGET; INHA; MUTATIONS; KATG; BIOSYNTHESIS	Although isoniazid (isonicotinic acid hydrazide, INH) is widely used for the treatment of tuberculosis, its molecular target has remained elusive. In response to INH treatment, saturated hexacasanoic acid (C26:0) accumulated on a 12-kilodalton acyl carrier protein (AcpM) that normally carried mycolic acid precursors as long as C50. A protein species purified from INH-treated Mycobacterium tuberculosis was shown to consist of a covalent complex of INH, AcpM, and a beta-ketoacyl acyl carrier protein synthase, KasA. Amino acid-altering mutations in the KasA protein were identified in INH-resistant patient isolates that lacked other mutations associated with resistance to this drug.	NIAID, Rocky Mt Labs, Intracellular Parasites Lab, TB Res Unit,NIH, Hamilton, MT 59840 USA; Baylor Coll Med, Dept Pathol, Inst Study Bacterial Pathogenesis, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Baylor College of Medicine	Barry, CE (corresponding author), NIAID, Rocky Mt Labs, Intracellular Parasites Lab, TB Res Unit,NIH, Hamilton, MT 59840 USA.		Barry, Clifton E/ABE-7992-2020; Barry, III, Clifton/H-3839-2012; Slayden, Richard/O-8626-2016; Slayden, Richard/AAV-2582-2021	Barry, Clifton E/0000-0002-2927-270X; Barry, III, Clifton/0000-0002-2927-270X; Slayden, Richard/0000-0001-6857-7277; Slayden, Richard/0000-0001-6857-7277	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000783, R01AI037004] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline; NIAID NIH HHS [AI37004] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; DAVIDSON LA, 1979, ANTIMICROB AGENTS CH, V16, P104, DOI 10.1128/AAC.16.1.104; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HEYM B, 1994, LANCET, V344, P293, DOI 10.1016/S0140-6736(94)91338-2; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; KEATING DH, 1995, J BIOL CHEM, V270, P22229, DOI 10.1074/jbc.270.38.22229; Marttila HJ, 1996, ANTIMICROB AGENTS CH, V40, P2187, DOI 10.1128/AAC.40.9.2187; Mdluli K, 1996, J INFECT DIS, V174, P1085, DOI 10.1093/infdis/174.5.1085; MDLULI K, UNPUB; MIDDLEBROOK G, 1952, AM REV TUBERC PULM, V65, P765; MORRIS S, 1995, J INFECT DIS, V171, P954, DOI 10.1093/infdis/171.4.954; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; OBrien KL, 1996, MOL CELL PROBE, V10, P1, DOI 10.1006/mcpr.1996.0001; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; PRESCOTT DJ, 1972, ADV ENZYMOL RAMB, V36, P269; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; Sacchettini JC, 1996, RES MICROBIOL, V147, P36, DOI 10.1016/0923-2508(96)80201-4; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; SUMMERS RG, 1995, BIOCHEMISTRY-US, V34, P9389, DOI 10.1021/bi00029a015; TAKAYAMA K, 1975, J LIPID RES, V16, P308; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; TAKAYAMA K, 1974, AM REV RESPIR DIS, V110, P43; TAKAYAMA K, 1979, ANTIBIOTICS, V1, P98; Winder F. G., 1982, The biology of the mycobacteria. Volume 1, P353; WINDER F G, 1970, Journal of General Microbiology, V63, P41; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	28	345	364	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1607	1610		10.1126/science.280.5369.1607	http://dx.doi.org/10.1126/science.280.5369.1607			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616124				2022-12-28	WOS:000074061200042
J	Morris, JS; Ohman, A; Dolan, RJ				Morris, JS; Ohman, A; Dolan, RJ			Conscious and unconscious emotional learning in the human amygdala	NATURE			English	Article							BLOOD-FLOW; DISCRIMINATION; RECOGNITION; MECHANISMS; ACTIVATION; EXPRESSION; RESPONSES; IMAGES; FACES	If subjects are shown an angry face as a target visual stimulus for less than forty milliseconds and are then immediately shown an expressionless mask, these subjects report seeing the mask but not the target. However, an aversively conditioned masked target can elicit an emotional response from subjects without being consciously perceived(1,2). Here we study the mechanism of this unconsciously mediated emotional learning. We measured neural activity in volunteer subjects who were presented with two angry faces, one of which, through previous classical conditioning, was associated with a burst of white noise. In half of the trials, the subjects' awareness of the angry faces was prevented by backward masking with a neutral face. A significant neural response was elicited in the right, but not left, amygdala to masked presentations of the conditioned angry face. Unmasked presentations of the same face produced enhanced neural activity in the left, but not right, amygdala. Our results indicate that, first, the human amygdala can discriminate between stimuli solely on the basis of their acquired behavioural significance, and second, this response is lateralized according to the subjects' level of awareness of the stimuli.	Wellcome Dept Cognit Neurol, London WC1N 3BG, England; Karolinska Hosp, Dept Clin Neurosci, Psychiat & Psychol Sect, S-17176 Stockholm, Sweden; Royal Free Hosp, London NW3 2DF, England; UCL Hosp, Sch Med, London NW3 2DF, England	University of London; University College London; Karolinska Institutet; Karolinska University Hospital; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; UCL Medical School	Dolan, RJ (corresponding author), Wellcome Dept Cognit Neurol, Queen Sq, London WC1N 3BG, England.		anand, amit/A-7222-2009	Dolan, Ray/0000-0001-9356-761X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adolphs R, 1997, LEARN MEMORY, V4, P291, DOI 10.1101/lm.4.3.291; Babinsky R, 1993, Behav Neurol, V6, P167, DOI 10.3233/BEN-1993-6310; BECHARA A, 1995, SCIENCE, V269, P1115, DOI 10.1126/science.7652558; Breiter HC, 1996, NEURON, V17, P875, DOI 10.1016/S0896-6273(00)80219-6; Cahill L, 1996, P NATL ACAD SCI USA, V93, P8016, DOI 10.1073/pnas.93.15.8016; DAVIS M, 1992, P255; DEKOSKY ST, 1980, BRAIN LANG, V9, P206, DOI 10.1016/0093-934X(80)90141-8; Ekman P., 1976, PICTURES FACIAL AFFE; Esteves F., 1994, COGNITION EMOTION, V9, P99; Fried I, 1997, NEURON, V18, P753, DOI 10.1016/S0896-6273(00)80315-3; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; GAZZANIGA MS, 1983, ANN NEUROL, V13, P536, DOI 10.1002/ana.410130511; GAZZANIGA MS, 1995, COGNITIVE NEUROSCIEN, P1049; GUR RC, 1994, BRAIN COGNITION, V25, P271, DOI 10.1006/brcg.1994.1036; HUGDAHL K, 1995, NEUROREPORT, V6, P1723, DOI 10.1097/00001756-199509000-00005; Kapp BS, 1984, NEUROPSYCHOLOGY MEMO, P473; KLINGER MR, 1995, J EXP PSYCHOL LEARN, V21, P569, DOI 10.1037/0278-7393.21.3.569; LABAR KS, 1995, J NEUROSCI, V15, P6846; LADAVAS E, 1993, COGNITION EMOTION, V7, P95, DOI 10.1080/02699939308409179; LeDoux J. E., 1996, EMOTIONAL BRAIN; LEONARD CM, 1985, BEHAV BRAIN RES, V15, P159, DOI 10.1016/0166-4328(85)90062-2; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; Morris JS, 1997, P ROY SOC B-BIOL SCI, V264, P769, DOI 10.1098/rspb.1997.0109; OHMAN A, 1994, J ABNORM PSYCHOL, V103, P231, DOI 10.1037/0021-843X.103.2.231; STONE VS, 1995, NEUROPSYCHOLOGIA, V34, P23; WEISKRANTZ L, 1956, J COMP PHYSIOL PSYCH, V49, P381, DOI 10.1037/h0088009; Whalen PJ, 1998, J NEUROSCI, V18, P411; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O; YOUNG AW, 1993, BRAIN, V116, P941, DOI 10.1093/brain/116.4.941	30	1243	1280	1	150	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 4	1998	393	6684					467	470		10.1038/30976	http://dx.doi.org/10.1038/30976			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZR842	9624001	Green Submitted			2022-12-28	WOS:000074020000044
J	Harris, AL				Harris, AL			Are angiostatin and endostatin cures for cancer?	LANCET			English	Editorial Material							SUPPRESSION; DORMANCY		Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund, Oxford OX3 9DS, England	University of Oxford	Harris, AL (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund, Oxford OX3 9DS, England.		Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409				Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Brem S, 1998, Angiogenesis, V2, P9, DOI 10.1023/A:1009068807898; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; Harris Adrian L., 1997, Lancet (North American Edition), V349, P13; Hohenester E, 1998, EMBO J, V17, P1656, DOI 10.1093/emboj/17.6.1656; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; OREILLY MS, 1997, INVEST NEW DRUGS, V1, P5; Pezzella F, 1997, AM J PATHOL, V151, P1417; Sage EH, 1997, TRENDS CELL BIOL, V7, P182; Sim BKL, 1997, CANCER RES, V57, P1329	16	36	42	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1598	1599		10.1016/S0140-6736(98)22022-8	http://dx.doi.org/10.1016/S0140-6736(98)22022-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620709				2022-12-28	WOS:000074026600002
J	Wang, HU; Chen, ZF; Anderson, DJ				Wang, HU; Chen, ZF; Anderson, DJ			Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4	CELL			English	Article							TYROSINE KINASE; NEUREGULIN RECEPTOR; CARDIAC DEVELOPMENT; PROTEIN; LIGAND; VASCULOGENESIS; FAMILY; SWITCH; ROLES; MICE	The vertebrate circulatory system is composed of arteries and veins. The functional and pathological differences between these vessels have been assumed to reflect physiological differences such as oxygenation and blood pressure. Here we show that ephrin-B2, an Eph family transmembrane ligand, marks arterial but not venous endothelial cells from the onset of angiogenesis. Conversely, Eph-B4 a receptor for ephrin-B2, marks veins but not arteries. ephrin-B2 knockout mice display defects in angiogenesis by both arteries and veins in the capillary networks of the head and yolk sac as well as in myocardial trabeculation. These results provide evidence that differences between arteries and veins are in part genetically determined and suggest that reciprocal signaling between these two types of vessels is crucial for morphogenesis of the capillary beds.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Anderson, DJ (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.							ANDRES AC, 1994, ONCOGENE, V9, P1461; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Chen J, 1996, ONCOGENE, V12, P979; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Evans HM, 1909, ANAT REC, V3, P498, DOI 10.1002/ar.1090030903; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Gilbert S., 1997, DEV BIOL; GOTO F, 1993, LAB INVEST, V69, P508; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Holland SJ, 1998, CURR OPIN NEUROBIOL, V8, P117, DOI 10.1016/S0959-4388(98)80015-9; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Kaufman M.H., 1992, ATLAS MOUSE DEV; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Ma QF, 1998, NEURON, V20, P469, DOI 10.1016/S0896-6273(00)80988-5; Martin M, 1997, IN VITRO CELL DEV-AN, V33, P261, DOI 10.1007/s11626-997-0045-y; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sabin F., 1917, CONTRIB EMBRYOL CARN, V6, P61; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schumacher B, 1998, CIRCULATION, V97, P645, DOI 10.1161/01.CIR.97.7.645; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Xu QL, 1995, DEVELOPMENT, V121, P4005; [No title captured]	45	1221	1312	0	35	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					741	753		10.1016/S0092-8674(00)81436-1	http://dx.doi.org/10.1016/S0092-8674(00)81436-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630219	Bronze			2022-12-28	WOS:000073956700011
J	Fawzi, WW; Msamanga, GI; Spiegelman, D; Urassa, EJN; McGrath, N; Mwakagile, D; Antelman, G; Mbise, R; Herrera, G; Kapiga, S; Willett, W; Hunter, DJ				Fawzi, WW; Msamanga, GI; Spiegelman, D; Urassa, EJN; McGrath, N; Mwakagile, D; Antelman, G; Mbise, R; Herrera, G; Kapiga, S; Willett, W; Hunter, DJ		Tanzania Vitam HIV Infect Trial Team	Randomised trial of effects of vitamin supplements on pregnancy outcomes and T cell counts in HIV-1-infected women in Tanzania	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; HIV-INFECTION; INFANT-MORTALITY; TYPE-1 INFECTION; BETA-CAROTENE; BIRTH-WEIGHT; A-DEFICIENCY; MORBIDITY	Background. In HIV-1-infected women, poor micronutrient status has been associated with faster progression of HIV-1 disease and adverse birth outcomes. We assessed the effects of vitamin A and multivitamins on birth outcomes in such women. Methods. In Tanzania, 1075 HIV-1-infected pregnant women at between 12 and 27 weeks' gestation received placebo (n = 267), vitamin A (n = 269), multivitamins excluding vitamin A (n = 269), or multivitamins including vitamin A (n = 270) in a randomised, double-blind, placebo-controlled trial with a 2x2 factorial design. We measured the effects of multivitamins and vitamin A on birth outcomes and counts of T lymphocyte subsets. We did analyses by intention to treat. Results. 30 fetal deaths occurred among women assigned multivitamins compared with 49 among those not on multivitamins (relative risk 0.61 [95% CI 0.39-0.94] p = 0.02). Multivitamin supplementation decreased the risk of low birthweight (< 2500 g) by 44% (0.56 [0.38-0.82] p = 0.003), severe preterm birth (< 34 weeks of gestation) by 39% (0.61 [0.38-0.96] p = 0.03), and small size for gestational age at birth by 43% (0.57 [0.39-0.82] p = 0.002). Vitamin A supplementation had no significant effect on these variables. Multivitamins, but not vitamin A, resulted in a significant. increase in CD4, CD8, and CD3 counts. Interpretation. Multivitamin supplementation is a low-cost way of substantially decreasing adverse pregnancy outcomes and increasing T-cell counts in HIV-l-infected women. The clinical relevance of our findings for vertical transmission and clinical progression of HIV-1 disease is yet to be ascertained.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Muhimbili Univ, Coll Hlth Sci, Dept Community Hlth, Dar Es Salaam, Tanzania; Muhimbili Univ, Coll Hlth Sci, Dept Obstet & Gynecol, Dar Es Salaam, Tanzania; Muhimbili Univ, Coll Hlth Sci, Dept Microbiol & Immunol, Dar Es Salaam, Tanzania; Muhimbili Univ, Coll Hlth Sci, Dept Pediat & Child Hlth, Dar Es Salaam, Tanzania; Muhimbili Univ, Coll Hlth Sci, Dept Epidemiol & Biostat, Dar Es Salaam, Tanzania	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Fawzi, WW (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.			Antelman, Gretchen/0000-0001-7906-9964; McGrath, Nuala/0000-0002-1039-0159; Kapiga, Saidi/0000-0003-1753-4060	FOGARTY INTERNATIONAL CENTER [D43TW000004] Funding Source: NIH RePORTER; FIC NIH HHS [D43 TW00004] Funding Source: Medline; PHS HHS [R01 32257] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAMS EJ, 1995, PEDIATRICS, V96, P451; BEACH RS, 1992, AIDS, V6, P701, DOI 10.1097/00002030-199207000-00013; BRENNER WE, 1993, AM J OBSTET GYNECOL, V168, P1197; COODLEY GO, 1993, J ACQ IMMUN DEF SYND, V6, P272; Coodley GO, 1996, AIDS, V10, P967, DOI 10.1097/00002030-199610090-00006; Dacie J., 1991, PRACTICAL HEMATOLOGY, V7th; DEGRUTTOLA V, 1995, AIDS CLIN TRIALS, P129; DUSHIMIMANA A, 1992, 8 INT C AIDS 3 STD W; FILTEAU SM, 1993, AM J CLIN NUTR, V58, P192, DOI 10.1093/ajcn/58.2.192; Gray RH, 1998, LANCET, V351, P98, DOI 10.1016/S0140-6736(97)09381-1; Lyamuya EF, 1996, J IMMUNOL METHODS, V195, P103, DOI 10.1016/0022-1759(96)00094-4; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; NAIR P, 1993, J ACQ IMMUN DEF SYND, V6, P298; Newell ML, 1997, AIDS, V11, P1859; ROLSCHAU J, 1979, ACTA OBSTET GYN SCAN, V58, P343, DOI 10.3109/00016347909154593; ROTHMAN KJ, 1995, NEW ENGL J MED, V333, P1369, DOI 10.1056/NEJM199511233332101; ROYSTON E, 1982, WORLD HLTH STAT Q, V35, P5; Scholl TO, 1997, AM J EPIDEMIOL, V146, P134, DOI 10.1093/oxfordjournals.aje.a009244; SELIGMANN M, 1994, LANCET, V343, P871; SEMBA RD, 1995, CLIN INFECT DIS, V21, P966, DOI 10.1093/clinids/21.4.966; SEMBA RD, 1993, ARCH INTERN MED, V153, P2149, DOI 10.1001/archinte.153.18.2149; TAHA TE, 1995, INT J EPIDEMIOL, V24, P1022, DOI 10.1093/ije/24.5.1022; Tang AM, 1997, J NUTR, V127, P345, DOI 10.1093/jn/127.2.345; Tang AM, 1996, AM J EPIDEMIOL, V143, P1244, DOI 10.1093/oxfordjournals.aje.a008712; *UNAIDS, 1998, REP GLOB HIV AIDS EP; Urass E J, 1992, J Obstet Gynaecol East Cent Africa, V10, P70; WEI LJ, 1985, BIOMETRIKA, V72, P359	27	324	334	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1477	1482		10.1016/S0140-6736(98)04197-X	http://dx.doi.org/10.1016/S0140-6736(98)04197-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605804				2022-12-28	WOS:000073707300010
J	Sleigh, A; Jackson, S				Sleigh, A; Jackson, S			Public health and public choice: Dammed off at China's Three Gorges?	LANCET			English	Editorial Material									Univ Queensland, Australian Ctr Int & Trop Hlth & Nutr, Brisbane, Qld 4006, Australia; Univ Queensland, Dept Econ, St Lucia, Qld 4067, Australia	University of Queensland; University of Queensland	Sleigh, A (corresponding author), Univ Queensland, Australian Ctr Int & Trop Hlth & Nutr, Brisbane, Qld 4006, Australia.		sleigh, adrian/J-4540-2019	sleigh, adrian/0000-0001-8443-7864				[Anonymous], 1993, PARASITIC DIS WATER; CHEN Y, 1990, ATLAS ECOLOGY ENV 3; DORCEY T, 1997, P WORKSH HELD APR 11; Lei X, 1998, SCIENCE, V280, P24, DOI 10.1126/science.280.5360.24; ZHONG QX, 1987, SCHISTOSOMIASIS ATLA, V1; ZHU N, 1996, GORGES PROJECT RESET; 1994, CHINA HLTH YB; 1996, CHINA STAT YB	8	10	10	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1449	1450		10.1016/S0140-6736(05)78866-8	http://dx.doi.org/10.1016/S0140-6736(05)78866-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605798				2022-12-28	WOS:000073707300004
J	Choi, SK; Lee, JH; Zoll, WL; Merrick, WC; Dever, TE				Choi, SK; Lee, JH; Zoll, WL; Merrick, WC; Dever, TE			Promotion of Met-tRNA(i)(Met) binding to ribosomes by yIF2, a bacterial IF2 homolog in yeast	SCIENCE			English	Article							INITIATION FACTOR-II; SACCHAROMYCES-CEREVISIAE; TRANSLATIONAL-INITIATION; SHUTTLE VECTORS; CHROMOSOME-I; START-SITE; GENE; SEQUENCE; IDENTIFICATION; SELECTION	Delivery of the initiator methionine transfer RNA (Met-tRNA(i)(Met)) to the ribosome is a key step in the initiation of protein synthesis. Previous results have indicated that this step is catalyzed by the structurally dissimilar translation factors in prokaryotes and eukaryotes-initiation factor 2 (IF2) and eukaryotic initiation factor 2 (eIF2), respectively. A bacterial IF2 homolog has been identified in both eukaryotes and archaea. By using a combination of molecular genetic and biochemical studies, the Saccharomyces cerevisiae IF2 homolog is shown to function in general translation initiation by promoting Met-tRNA(i)(Met) binding to ribosomes. Thus, the mechanism of protein synthesis in eukaryotes and prokaryotes is more similar than was previously realized.	NICHHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Case Western Reserve University	Dever, TE (corresponding author), NICHHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA.		Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678	NIGMS NIH HHS [GM08056] Funding Source: Medline; PHS HHS [26796] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS SL, 1975, J BIOL CHEM, V250, P9083; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ASTROM SU, 1993, J MOL BIOL, V233, P43, DOI 10.1006/jmbi.1993.1483; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CIGAN AM, 1988, SCIENCE, V242, P93, DOI 10.1126/science.3051379; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; Dennis PP, 1997, CELL, V89, P1007, DOI 10.1016/S0092-8674(00)80288-3; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; DIEHL BE, 1991, GENETICS, V127, P287; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; HERSHEY JWB, 1991, TRANSLATION EUKARYOT, P353; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Huang HK, 1997, GENE DEV, V11, P2396, DOI 10.1101/gad.11.18.2396; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P224, DOI 10.1073/pnas.95.1.224; LAALAMI S, 1991, J MOL BIOL, V220, P335, DOI 10.1016/0022-2836(91)90017-Z; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; MARTIN TE, 1973, EXP CELL RES, V80, P496, DOI 10.1016/0014-4827(73)90333-9; MARTIN TE, 1970, J BIOL CHEM, V245, P1504; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; Merrick W.C., 1975, J BIOL CHEM, V250, P1107; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; MOEHLE CM, 1991, MOL CELL BIOL, V11, P2723, DOI 10.1128/MCB.11.5.2723; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; SIKORSKI RS, 1989, GENETICS, V122, P19; SUTRAVE P, 1994, GENE, V146, P209, DOI 10.1016/0378-1119(94)90294-1; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; VAMBUTAS A, 1991, EUR J BIOCHEM, V201, P643, DOI 10.1111/j.1432-1033.1991.tb16325.x; WICKNER RB, 1994, METH MOL G, V3, P141; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248	33	112	114	2	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1757	1760		10.1126/science.280.5370.1757	http://dx.doi.org/10.1126/science.280.5370.1757			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624054				2022-12-28	WOS:000074197800043
J	Sweitzer, SM; Hinshaw, JE				Sweitzer, SM; Hinshaw, JE			Dynamin undergoes a GTP-dependent conformational change causing vesiculation	CELL			English	Article							PROTEIN-KINASE-C; MEDIATED ENDOCYTOSIS; ACIDIC PHOSPHOLIPIDS; BINDING-SITE; SH3 DOMAINS; DROSOPHILA; SHIBIRE; IDENTIFICATION; MUTATIONS	The dynamin family of GTPases is essential for receptor-mediated endocytosis and synaptic vesicle recycling, and it has recently been shown to play a role in vesicle formation from the trans-Golgi network. Dynamin is believed to assemble around the necks of clathrin-coated pits and assist in pinching vesicles from the plasma membrane. This role would make dynamin unique among GTPases in its ability to act as a mechanochemical enzyme. Data presented here demonstrate that purified recombinant dynamin binds to a lipid bilayer in a regular pattern to form helical tubes that constrict and vesiculate upon GTP addition. This suggests that dynamin alone is sufficient for the formation of constricted necks of coated pits and supports the hypothesis that dynamin is the force-generating molecule responsible for membrane fission.	NIDDKD, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Sweitzer, SM (corresponding author), NIDDKD, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA.							Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; LIU JP, 1994, J BIOL CHEM, V269, P21043; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; Llorente A, 1998, J CELL BIOL, V140, P553, DOI 10.1083/jcb.140.3.553; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Omata W, 1997, BIOCHEM BIOPH RES CO, V241, P401, DOI 10.1006/bbrc.1997.7810; POODRY CA, 1973, DEV BIOL, V32, P373, DOI 10.1016/0012-1606(73)90248-0; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Roos J, 1997, TRENDS CELL BIOL, V7, P257, DOI 10.1016/S0962-8924(97)01068-4; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; TUMA PL, 1993, J BIOL CHEM, V268, P17240; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; Warnock DE, 1997, MOL BIOL CELL, V8, P2553, DOI 10.1091/mbc.8.12.2553; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	39	526	534	2	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					1021	1029		10.1016/S0092-8674(00)81207-6	http://dx.doi.org/10.1016/S0092-8674(00)81207-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635431	Bronze			2022-12-28	WOS:000074205700013
J	Mullen, F; Adler, C				Mullen, F; Adler, C			Connie Adler, MD - Living rural medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Biographical-Item									George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA; Franklin Mem Hosp, Farmington, ME USA	George Washington University	Mullen, F (corresponding author), Health Affairs, 7500 Old Georgetown Rd,Suite 600, Bethesda, MD 20814 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1833	1836		10.1001/jama.279.22.1833	http://dx.doi.org/10.1001/jama.279.22.1833			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR635	9628720				2022-12-28	WOS:000073998500040
J	Moore, LR; Rocap, G; Chisholm, SW				Moore, LR; Rocap, G; Chisholm, SW			Physiology and molecular phylogeny of coexisting Prochlorococcus ecotypes	NATURE			English	Article							SKELETONEMA-COSTATUM BACILLARIOPHYCEAE; DIVINYL CHLOROPHYLL-A; NORTH-ATLANTIC OCEAN; COMMUNITY STRUCTURE; GENETIC DIVERSITY; SEQUENCE-ANALYSIS; SEA; SYNECHOCOCCUS; PICOPLANKTON; DISTRIBUTIONS	The cyanobacterium Prochlorococcus(1,2) is the dominant oxygenic phototroph in the tropical and subtropical regions of the world's (1,3,4). It can grow at a range of depths over which light oceans intensities can vary by up to 4 orders of magnitude. This broad depth distribution has been hypothesized to stem from the coexistence of genetically different populations adapted for growth at high-and low-light intensities(4-6). Here we report direct evidence supporting this hypothesis, which has been generated by isolating and analysing distinct co-occurring populations of Prochlorococcus at two locations in the North Atlantic. Go-isolates from the same water sample have very different light-dependent physiologies, one growing maximally at light intensities at which the other is completely photoinhibited. Despite this ecotypic differentiation, the co-isolates have 97% similarity in their 16S ribosomal RNA sequences, demonstrating that molecular microdiversity, commonly observed in microbial systems(7-12), can be due to the coexistence of closely related, physiologically distinct populations. The coexistence and distribution of multiple ecotypes permits the survival of the population as a whole over a broader range of environmental conditions than would be possible for a homogeneous population.	MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT Woods Hole Oceanog Inst Joint Program Oceanog, Woods Hole, MA 02543 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Chisholm, SW (corresponding author), MIT, Dept Civil & Environm Engn, 48-425,77 Massachusetts Ave, Cambridge, MA 02139 USA.	chisholm@mit.edu		Rocap, Gabrielle/0000-0001-7253-611X; Moore, Lisa/0000-0002-4114-1518; Chisholm, Sallie/0000-0003-1480-2445				Amann R, 1996, J BACTERIOL, V178, P3496, DOI 10.1128/jb.178.12.3496-3500.1996; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; CAMPBELL L, 1993, DEEP-SEA RES PT I, V40, P2043, DOI 10.1016/0967-0637(93)90044-4; CHISHOLM SW, 1988, NATURE, V334, P340, DOI 10.1038/334340a0; CHISHOLM SW, 1992, ARCH MICROBIOL, V157, P297, DOI 10.1007/BF00245165; DELONG EF, 1994, NATURE, V371, P695, DOI 10.1038/371695a0; FUHRMAN JA, 1993, APPL ENVIRON MICROB, V59, P1294, DOI 10.1128/AEM.59.5.1294-1302.1993; GALLAGHER JC, 1982, J PHYCOL, V18, P148, DOI 10.1111/j.0022-3646.1982.00148.x; GALLAGHER JC, 1980, J PHYCOL, V16, P464; GIOVANNONI SJ, 1990, NATURE, V345, P60, DOI 10.1038/345060a0; GOERICKE R, 1993, MAR ECOL PROG SER, V101, P307, DOI 10.3354/meps101307; JEFFREY SW, 1975, BIOCHEM PHYSIOL PFL, V167, P191, DOI 10.1016/s0015-3796(17)30778-3; Maidak BL, 1997, NUCLEIC ACIDS RES, V25, P109, DOI 10.1093/nar/25.1.109; MOORE LR, 1995, MAR ECOL PROG SER, V116, P259, DOI 10.3354/meps116259; MOORE LR, UNPUB LIMNOL OCEANOG; OLSON RJ, 1988, DEEP-SEA RES, V35, P425, DOI 10.1016/0198-0149(88)90019-2; OLSON RJ, 1990, DEEP-SEA RES, V37, P1033, DOI 10.1016/0198-0149(90)90109-9; PALENIK B, 1994, APPL ENVIRON MICROB, V60, P3212, DOI 10.1128/AEM.60.9.3212-3219.1994; Partensky F, 1996, DEEP-SEA RES PT I, V43, P1191, DOI 10.1016/0967-0637(96)00056-8; PARTENSKY F, 1993, PLANT PHYSIOL, V101, P285, DOI 10.1104/pp.101.1.285; PLATT T, 1980, J MAR RES, V38, P687; Scanlan DJ, 1996, EUR J PHYCOL, V31, P1, DOI 10.1080/09670269600651131; Shimada A, 1996, MAR BIOL, V127, P15, DOI 10.1007/BF00993639; SMITH SW, 1994, COMPUT APPL BIOSCI, V10, P671; Toledo G, 1997, APPL ENVIRON MICROB, V63, P4298, DOI 10.1128/AEM.63.11.4298-4303.1997; Urbach E, 1998, J MOL EVOL, V46, P188, DOI 10.1007/PL00006294; VELDHUIS MJW, 1993, NETH J SEA RES, V31, P135, DOI 10.1016/0077-7579(93)90003-B; WARD DM, 1990, NATURE, V345, P63, DOI 10.1038/345063a0; Waterbury JB, 1986, CAN B FISH AQUAT SCI, V214, P71	29	562	577	3	86	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					464	467		10.1038/30965	http://dx.doi.org/10.1038/30965			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624000				2022-12-28	WOS:000074020000043
J	Schoenberger, SP; Toes, REM; van der Voort, EIH; Offringa, R; Melief, CJM				Schoenberger, SP; Toes, REM; van der Voort, EIH; Offringa, R; Melief, CJM			T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions	NATURE			English	Article							CD40 LIGAND; DENDRITIC CELLS; ANTITUMOR IMMUNITY; DEFICIENT MICE; CLASS-II; ACTIVATION; DISRUPTION; INDUCTION; ANTIGENS; MOLECULE	Although in vivo priming of CD8(+) cytotoxic T lymphocytes (CTLs) generally requires the participation of CD4(+) T-helper lymphocytes(1,2), the nature of the 'help' provided to CTLs is unknown(3). One widely held view is that help for CTLs is mediated by cytokines produced by T-helper cells activated in proximity to the CTL precursor at the surface of an antigen-presenting cell (APC)(4). An alternative theory is that, rather than being directly supplied to the CTL by the helper cell, help is delivered through activation of the APC, which can then prime the CTL directly(5). CD40 and its ligand, CD40L, may activate the APC to allow CTL priming. CD40L is expressed on the surface of activated CD4(+) T-helper cells and is involved in their activation and in the development of their effector functions(6,7). Ligation of CD40 on the surface of APCs such as dendritic cells, macrophages and B cells greatly increases their antigen-presentation and co-stimulatory capacity(8-11). Here we report that signalling through CD40 can replace CD4(+) T-helper cells in priming of helper-dependent CD8(+) CTL responses. Blockade of CD40L inhibits CTL priming; this inhibition is overcome by signalling through CD40. CD40-CD40L interactions are therefore vital in the delivery of T-cell help for CTL priming.	Univ Leiden Hosp, Dept Immunohematol, NL-2333 AZ Leiden, Netherlands; Univ Leiden Hosp, Blood Bank, NL-2333 AZ Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	Schoenberger, SP (corresponding author), Univ Leiden Hosp, Dept Immunohematol, POB 9600, NL-2333 AZ Leiden, Netherlands.	sps@liai.org		Toes, Rene/0000-0002-9618-6414				Bennett SRM, 1997, J EXP MED, V186, P65, DOI 10.1084/jem.186.1.65; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; Grewal IS, 1996, IMMUNOL TODAY, V17, P410, DOI 10.1016/0167-5699(96)10030-X; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; GUERDER S, 1992, J EXP MED, V176, P553, DOI 10.1084/jem.176.2.553; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; HUSMANN LA, 1988, ANN NY ACAD SCI, V532, P158, DOI 10.1111/j.1749-6632.1988.tb36335.x; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; KENNEDY MK, 1994, EUR J IMMUNOL, V24, P116, DOI 10.1002/eji.1830240118; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; Kurts C, 1997, J EXP MED, V186, P239, DOI 10.1084/jem.186.2.239; Mackey MF, 1997, CANCER RES, V57, P2569; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; Noelle RJ, 1996, IMMUNITY, V4, P415, DOI 10.1016/S1074-7613(00)80408-2; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Shinde S, 1996, J IMMUNOL, V157, P2764; SIMPSON E, 1977, IMMUNOL REV, V35, P59, DOI 10.1111/j.1600-065X.1977.tb00235.x; Soong L, 1996, IMMUNITY, V4, P263, DOI 10.1016/S1074-7613(00)80434-3; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Stout RD, 1996, J IMMUNOL, V156, P8; Toes REM, 1996, CANCER RES, V56, P3782; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862	29	1916	2015	2	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 4	1998	393	6684					480	483		10.1038/31002	http://dx.doi.org/10.1038/31002			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624005				2022-12-28	WOS:000074020000048
J	Yu, DR; Miller, R; Bray, PF				Yu, DR; Miller, R; Bray, PF			Through thick and thin	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUSPECTED PULMONARY-EMBOLISM; MOLECULAR-WEIGHT HEPARIN; UNFRACTIONATED HEPARIN; VENOUS THROMBOEMBOLISM; THROMBOSIS; THROMBOCYTOPENIA; FEATURES; ANTIBODY		Johns Hopkins Univ Hosp, Dept Med, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Bray, PF (corresponding author), 720 Rutland Ave,Ross 1015, Baltimore, MD 21205 USA.							ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; BALLEW KA, 1995, CLIN CHEST MED, V16, P295; BELL WR, 1977, AM J MED, V62, P355, DOI 10.1016/0002-9343(77)90832-4; BERGQVIST D, 1985, BRIT J SURG, V72, P105, DOI 10.1002/bjs.1800720211; Decousus H, 1998, NEW ENGL J MED, V338, P409, DOI 10.1056/NEJM199802123380701; GINSBERG JS, 1995, BLOOD, V86, P3685, DOI 10.1182/blood.V86.10.3685.bloodjournal86103685; Ginsberg JS, 1996, NEW ENGL J MED, V335, P1816, DOI 10.1056/NEJM199612123352407; GOLDHABER SZ, 1982, AM J MED, V73, P822, DOI 10.1016/0002-9343(82)90764-1; GOODNOUGH LT, 1983, MEDICINE, V62, P248, DOI 10.1097/00005792-198307000-00004; GREINACHER A, 1992, THROMB HAEMOSTASIS, V67, P545; HANDELAND GF, 1990, EUR J CLIN PHARMACOL, V39, P107, DOI 10.1007/BF00280041; HULL RD, 1994, ARCH INTERN MED, V154, P289, DOI 10.1001/archinte.154.3.289; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; LILIENFELD DE, 1990, CHEST, V98, P1067, DOI 10.1378/chest.98.5.1067; MANGANELLI D, 1995, CHEST, V107, pS25, DOI 10.1378/chest.107.1_Supplement.25S; Meaney JFM, 1997, NEW ENGL J MED, V336, P1422, DOI 10.1056/NEJM199705153362004; PALLA A, 1995, CHEST, V107, pS21, DOI 10.1378/chest.107.1_Supplement.21S; PUTTERMAN C, 1995, NEW ENGL J MED, V333, P1208, DOI 10.1056/NEJM199511023331809; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; Siragusa S, 1996, AM J MED, V100, P269, DOI 10.1016/S0002-9343(97)89484-3; Sirnes PA, 1996, J AM COLL CARDIOL, V28, P1444, DOI 10.1016/S0735-1097(96)00349-X; STAUFFER JL, 1997, CURRENT MED DIAGNOSI, P290; STEIN PD, 1991, CHEST, V100, P598, DOI 10.1378/chest.100.3.598; Stein PD, 1996, CHEST, V109, P233; tenCate JW, 1997, NEW ENGL J MED, V337, P657; vanErkel AR, 1996, RADIOLOGY, V201, P29, DOI 10.1148/radiology.201.1.8816516; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; 1973, CIRCULATION S2, V47, P86	29	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1998	338	23					1684	1687		10.1056/NEJM199806043382308	http://dx.doi.org/10.1056/NEJM199806043382308			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR451	9614261				2022-12-28	WOS:000073978000008
J	Das, S; Sasaki, YF; Rothe, T; Premkumar, LS; Takasu, M; Crandall, JE; Dikkes, P; Conner, DA; Rayudu, PV; Cheung, W; Chen, HSV; Lipton, SA; Nakanishi, N				Das, S; Sasaki, YF; Rothe, T; Premkumar, LS; Takasu, M; Crandall, JE; Dikkes, P; Conner, DA; Rayudu, PV; Cheung, W; Chen, HSV; Lipton, SA; Nakanishi, N			Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A	NATURE			English	Article							LONG-TERM POTENTIATION; DENDRITIC SPINES; REGIONAL EXPRESSION; RAT-BRAIN; CHANNEL; PLASTICITY; CLONING	The NMDA (N-methyl-D-aspartate) subclass of glutamate receptor(1) is essential for the synaptic plasticity thought to underlie learning and memory(2-4) and for synaptic refinement during development(5,6). It is currently believed that the NMDA receptor (NMDAR) is a heteromultimeric channel comprising the ubiquitous NR1 subunit and at least one regionally localized NR2 subunit(7-11). Here we report the characterization of a regulatory NMDAR subunit, NR3A (formerly termed NMDAR-L or chi-1), which is expressed primarily during brain development(12,13) NR3A co-immunoprecipitates with receptor subunits NR1 and NR2 in cerebrocortical extracts. In single-channel recordings from Xenopus oocytes, addition of NR3A to NR1 and NR2 leads to the appearance of a smaller unitary conductance, Genetic knockout of NR3A in mice results in enhanced NMDA responses and increased dendritic spines in early postnatal cerebrocortical neurons. These data suggest that NR3A is involved in the development of synaptic elements by modulating NMDAR activity.	Brigham & Womens Hosp, Cerebrovasc & Neurosci Res Inst, Neurosurg Serv, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA; Eunice Kennedy Shriver Ctr Mental Retardat Inc, Dev Neurosci Div, Waltham, MA 02254 USA; Childrens Hosp, Div Neurosci, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Harvard University; Boston Children's Hospital	Nakanishi, N (corresponding author), Brigham & Womens Hosp, Cerebrovasc & Neurosci Res Inst, Neurosurg Serv, 75 Francis St, Boston, MA 02115 USA.	slipton@rics.bwh.harvard.edu; nnakanis@warren.med.harvard.edu	Sasaki, Yasnory/L-7065-2018; Das, Saumya/R-7644-2019	Sasaki, Yasnory/0000-0003-2614-7038; Posina, Venkata Rayudu/0000-0002-3040-9224; Das, Saumya/0000-0002-4521-4606; Lipton, Stuart/0000-0002-3490-1259				BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Chen HSV, 1997, J PHYSIOL-LONDON, V499, P27, DOI 10.1113/jphysiol.1997.sp021909; CIABARRA AM, 1995, J NEUROSCI, V15, P6498; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; GUSTAFSSON B, 1988, TRENDS NEUROSCI, V11, P156, DOI 10.1016/0166-2236(88)90142-7; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Kossel AH, 1997, J NEUROSCI, V17, P9634; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; McAllister AK, 1996, NEURON, V17, P1057, DOI 10.1016/S0896-6273(00)80239-1; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Papa M, 1996, NEUROSCIENCE, V71, P1005, DOI 10.1016/0306-4522(95)00490-4; Premkumar LS, 1997, J GEN PHYSIOL, V110, P485, DOI 10.1085/jgp.110.5.485; ROGERS SW, 1991, J NEUROSCI, V11, P2713; SEGAL M, 1995, TRENDS NEUROSCI, V18, P468, DOI 10.1016/0166-2236(95)92765-I; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/science.270.5237.758; STERN P, 1994, J PHYSIOL-LONDON, V476, P391, DOI 10.1113/jphysiol.1994.sp020140; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; SUCHER NJ, 1995, J NEUROSCI, V15, P6509; Woolley CS, 1997, J NEUROSCI, V17, P1848; WOOLLEY CS, 1994, J NEUROSCI, V14, P7680	29	473	501	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 28	1998	393	6683					377	381		10.1038/30748	http://dx.doi.org/10.1038/30748			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620802				2022-12-28	WOS:000073883600057
J	Pastuszak, AL; Schuler, L; Speck-Martins, CE; Coelho, KEFA; Cordello, SM; Vargas, F; Brunoni, D; Schwarz, IVD; Larrandaburu, M; Safattle, H; Meloni, VFA; Koren, G				Pastuszak, AL; Schuler, L; Speck-Martins, CE; Coelho, KEFA; Cordello, SM; Vargas, F; Brunoni, D; Schwarz, IVD; Larrandaburu, M; Safattle, H; Meloni, VFA; Koren, G			Use of misoprostol during pregnancy and Mobius syndrome in infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOEBIUS SYNDROME; VASCULAR ETIOLOGY; ILLEGAL ABORTION; BRAZIL; TERATOGENICITY; MIFEPRISTONE; TRIMESTER	Background Patients with upper gastrointestinal ulceration may be treated with misoprostol, but it is not recommended for pregnant women because it may stimulate uterine contractions and cause vaginal bleeding and miscarriage. Recent data from Bra zil, where misoprostol is used orally and vaginally as an abortifacient, have suggested a relation between the use of misoprostol by women in an unsuccessful attempt to terminate pregnancy and Mobius' syndrome (congenital facial paralysis) in their infants. Methods We compared the frequency of misoprostol use during the first trimester by mothers of infants in whom Mobius' syndrome was diagnosed and mothers of infants with neural-tube defects in Brazil. All diagnoses in infants were made between January 16, 1990, and May 31, 1996, by clinical geneticists at seven hospitals who also interviewed the mothers and recorded information about the administration of misoprostol, among other data. Results We identified 96 infants with Mobius' syndrome and matched them with 96 infants with neural-tube defects. The mean age at the time of the diagnosis of Mobius' syndrome was 16 months (range, 0.5 to 78), and the diagnosis of neural-tube defects was made within 1 week of birth in most cases. Among the mothers of the 96 infants with Mobius' syndrome, 47 (49 percent) had used misoprostol in the first trimester of pregnancy, as compared with 3 (3 percent) of the mothers of the 96 infants with neural-tube defects (odds ratio, 29.7; 95 percent confidence interval, 11.6 to 76.0). Twenty of the mothers of the infants with Mobius' syndrome had taken misoprostol only orally (odds ratio, 38.8; 95 percent confidence interval, 9.5 to 159.4), 20 had taken misoprostol both orally and vaginally, 3 had taken the drug vaginally, and 4 did not report how they took the drug. Conclusions Attempted abortion with misoprostol is associated with an increased risk of Mobius' syndrome in infants. (N Engl J Med 1998;338:1881-5.) (C) 1998, Massachusetts Medical Society.	Univ Toronto, Hosp Sick Children, Fetal Diag & Treatment Ctr, Motherisk Program, Toronto, ON M5G 1X8, Canada; Univ Fed Rio Grande Sul, Dept Genet, Porto Alegre, RS, Brazil; Hosp Clin Porto Alegre, Unidade Genet, Porto Alegre, RS, Brazil; Rede Hosp Sarah, Setor Genet, Brasilia, DF, Brazil; Rede Hosp Sarah, Setor Genet, Salvador, BA, Brazil; Hosp Univ Graffre Guinle, Setor Genet, Rio De Janeiro, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Disciplina Genet, Sao Paulo, Brazil; Hosp Serv Publ Estado Sao Paulo, Unidade Citogenet, Sao Paulo, Brazil	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Universidade Federal do Rio Grande do Sul; Universidade Federal de Sao Paulo (UNIFESP); Instituto de Assistencia Medica ao Servidor Publico Estadual (IAMSPE)	Pastuszak, AL (corresponding author), Univ Toronto, Hosp Sick Children, Fetal Diag & Treatment Ctr, Motherisk Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Meloni, Vera/O-8378-2015; SCHULER-FACCINI, LAVINIA/C-8309-2013; Schwartz, Ida/M-1422-2015; Brunoni, Decio/K-3155-2012; Vargas, Fernando/V-1934-2019; SCHULER-FACCINI, LAVINIA/K-2927-2016; Koren, Gideon/AAG-7726-2019	Meloni, Vera/0000-0003-4954-8766; SCHULER-FACCINI, LAVINIA/0000-0002-2428-0460; Schwartz, Ida/0000-0002-7933-6687; SCHULER-FACCINI, LAVINIA/0000-0002-2428-0460; Koren, Gideon/0000-0002-9234-0875				BAIRD DT, 1992, LANCET, V339, P313, DOI 10.1016/0140-6736(92)91392-L; BOND GR, 1994, AM J OBSTET GYNECOL, V171, P561, DOI 10.1016/0002-9378(94)90302-6; CASTILLA EE, 1994, AM J MED GENET, V51, P161, DOI 10.1002/ajmg.1320510217; COELHO HLL, 1993, LANCET, V341, P1261, DOI 10.1016/0140-6736(93)91157-H; COSTA SH, 1993, LANCET, V341, P1258, DOI 10.1016/0140-6736(93)91156-G; COSTA SH, 1993, LANCET, V341, P1486; ESAKI K, 1985, JITCHUKEN ZENRINSHO, V11, P189; ESAKI K, 1985, JITCHUKEN ZENRINSHO, V11, P213; ESAKI K, 1985, JITCHUKEN ZENRINSHO, V11, P167; Fonseca W, 1996, REV SAUDE PUBL, V30, P13, DOI 10.1590/S0034-89101996000100003; Genest D. R., 1994, Teratology, V49, P418; GONZALEZ CH, 1993, AM J MED GENET, V47, P59, DOI 10.1002/ajmg.1320470113; HAUSKNECHT RU, 1995, NEW ENGL J MED, V333, P537, DOI 10.1056/NEJM199508313330901; HOLMES LB, 1995, J PEDIATR-US, V126, P131, DOI 10.1016/S0022-3476(95)70516-3; KUMAR D, 1990, J MED GENET, V27, P122, DOI 10.1136/jmg.27.2.122; LIPSON AH, 1989, TERATOLOGY, V40, P339, DOI 10.1002/tera.1420400406; Lipson AH, 1996, EUR J PEDIATR, V155, P800, DOI 10.1007/BF02002911; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; PAUMGARTTEN FJR, 1995, BRAZ J MED BIOL RES, V28, P355; SCHULER L, 1992, LANCET, V339, P437, DOI 10.1016/0140-6736(92)90131-L; Schuler L., 1997, Teratology, V55, P36; SHEPARD TH, 1995, LANCET, V346, P780, DOI 10.1016/S0140-6736(95)91540-0; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x	24	149	160	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1998	338	26					1881	1885		10.1056/NEJM199806253382604	http://dx.doi.org/10.1056/NEJM199806253382604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV898	9637807				2022-12-28	WOS:000074352800004
J	Chen, CY; Del Gatto-Konczak, F; Wu, ZG; Karin, M				Chen, CY; Del Gatto-Konczak, F; Wu, ZG; Karin, M			Stabilization of interleukin-2 mRNA by the c-Jun NH2-terminal kinase pathway	SCIENCE			English	Article							MESSENGER-RNA DEGRADATION; TUMOR-NECROSIS-FACTOR; AU-RICH ELEMENTS; PROTEIN-KINASE; 3'-UNTRANSLATED REGION; MAP KINASE; GENE-EXPRESSION; ACTIVATION; CELLS; IDENTIFICATION	Signaling pathways that stabilize interleukin-2 (IL-2) messenger RNA (mRNA) in activated T cells were examined. IL-2 mRNA contains at least two cis elements that mediated its stabilization in response to different signals, including activation of c-Jun amino-terminal kinase (JNK). This response was mediated through a cis element encompassing the 5' untranslated region (UTR) and the beginning of the coding region. IL-2 transcripts lacking this 5' element no longer responded to JNK activation but were still responsive to other signals generated during T cell activation, which were probably sensed through the 3' UTR. Thus, multiple elements within IL-2 mRNA modulate its stability in a combinatorial manner, and the JNK pathway controls turnover as well as synthesis of IL-2 mRNA.	Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA.		Del Gatto-Konczak, Fabienne/L-1506-2015					AKAHANE K, 1991, J IMMUNOL, V146, P4190; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chen C., UNPUB; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1028; ELIAS JA, 1990, J IMMUNOL, V145, P161; GUBA SC, 1989, J CLIN INVEST, V84, P1701, DOI 10.1172/JCI114352; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IWAI Y, 1993, J IMMUNOL, V150, P4386; IWAI Y, 1991, J BIOL CHEM, V266, P17959; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KOEFFLER HP, 1988, MOL CELL BIOL, V8, P3432, DOI 10.1128/MCB.8.8.3432; KRAMNIK I, 1993, J IMMUNOL METHODS, V162, P143, DOI 10.1016/0022-1759(93)90379-L; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; McKnight S.L., 1992, TRANSCRIPTIONAL REGU; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHAW J, 1988, J IMMUNOL, V140, P2243; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	41	318	325	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1945	1949		10.1126/science.280.5371.1945	http://dx.doi.org/10.1126/science.280.5371.1945			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632395				2022-12-28	WOS:000074323800067
J	Wyatt, R; Sodroski, J				Wyatt, R; Sodroski, J			The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens	SCIENCE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN MONOCLONAL-ANTIBODY; AMINO-ACID-RESIDUES; INTERCELLULAR-ADHESION MOLECULE-1; TYPE-1 GP120 GLYCOPROTEIN; CD4 BINDING-SITE; HUMAN CELL-LINES; NEUTRALIZING ANTIBODIES; RECEPTOR-BINDING; HTLV-III	The human immunodeficiency virus-type 1 (HIV-1) envelope glycoproteins interact with receptors on the target cell and mediate virus entry by fusing the viral and cell membranes. The structure of the envelope glycoproteins has evolved to fulfill these functions while evading the neutralizing antibody response. An understanding of the viral strategies for immune evasion should guide attempts to improve the immunogenicity of the HIV-1envelope glycoproteins and, ultimately, aid in HIV-1vaccine development.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol AIDS,Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Sodroski, J (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol AIDS,Dept Pathol, Boston, MA 02115 USA.	joseph_sodroski@dfci.harvard.edu			NIAID NIH HHS [AI 31783, AI 39420, AI28691] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039420, R01AI031783, P30AI028691] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; ARENDRUP M, 1992, J ACQ IMMUN DEF SYND, V5, P303; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; Bandres JC, 1998, J VIROL, V72, P2500, DOI 10.1128/JVI.72.3.2500-2504.1998; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BERKOWER I, 1989, J EXP MED, V170, P1681, DOI 10.1084/jem.170.5.1681; BERMAN PW, 1994, AIDS RES HUM RETROV, V10, P585, DOI 10.1089/aid.1994.10.585; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Binley JM, 1996, AIDS RES HUM RETROV, V12, P911, DOI 10.1089/aid.1996.12.911; Bjorndal A, 1997, J VIROL, V71, P7478; BOUHABIB DC, 1994, J VIROL, V68, P6006, DOI 10.1128/JVI.68.9.6006-6013.1994; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; Cantin R, 1997, J VIROL, V71, P1922, DOI 10.1128/JVI.71.3.1922-1930.1997; Cantin R, 1997, BLOOD, V90, P1091, DOI 10.1182/blood.V90.3.1091.1091_1091_1100; Cao J, 1997, J VIROL, V71, P9808, DOI 10.1128/JVI.71.12.9808-9812.1997; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CASTILLETTI C, 1995, AIDS RES HUM RETROV, V11, P547, DOI 10.1089/aid.1995.11.547; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CHOE HR, 1992, J ACQ IMMUN DEF SYND, V5, P204; CLAPHAM PR, 1992, J VIROL, V66, P3531, DOI 10.1128/JVI.66.6.3531-3537.1992; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; CORDONNIER A, 1989, J VIROL, V63, P4464, DOI 10.1128/JVI.63.10.4464-4468.1989; CORDONNIER A, 1989, NATURE, V340, P571, DOI 10.1038/340571a0; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Delahunty MD, 1996, VIROLOGY, V218, P94, DOI 10.1006/viro.1996.0169; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DITZEL HJ, 1995, J IMMUNOL, V154, P893; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; Dumonceaux J, 1998, J VIROL, V72, P512, DOI 10.1128/JVI.72.1.512-519.1998; EARL PL, 1993, AIDS RES HUM RETROV, V9, P589, DOI 10.1089/aid.1993.9.589; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P14742, DOI 10.1073/pnas.94.26.14742; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Fauci AS, 1996, ANN INTERN MED, V124, P654, DOI 10.7326/0003-4819-124-7-199604010-00006; FELSER JM, 1989, VIROLOGY, V170, P566, DOI 10.1016/0042-6822(89)90448-0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fortin JF, 1997, J VIROL, V71, P3588, DOI 10.1128/JVI.71.5.3588-3596.1997; Fortin JF, 1998, J VIROL, V72, P2105, DOI 10.1128/JVI.72.3.2105-2112.1998; Fouts TR, 1997, J VIROL, V71, P2779, DOI 10.1128/JVI.71.4.2779-2785.1997; Frank I, 1996, AIDS, V10, P1611, DOI 10.1097/00002030-199612000-00004; FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; FUNG MSC, 1992, J VIROL, V66, P848, DOI 10.1128/JVI.66.2.848-856.1992; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GEGERFELT A, 1991, VIROLOGY, V185, P162; GNANN JW, 1987, J VIROL, V61, P2639, DOI 10.1128/JVI.61.8.2639-2641.1987; GOMATOS PJ, 1990, J IMMUNOL, V144, P4183; GORNY MK, 1992, J VIROL, V66, P7538, DOI 10.1128/JVI.66.12.7538-7542.1992; GORNY MK, 1994, J VIROL, V68, P8312, DOI 10.1128/JVI.68.12.8312-8320.1994; GUO MML, 1995, AIDS RES HUM RETROV, V11, P1007, DOI 10.1089/aid.1995.11.1007; HAIGWOOD NL, 1992, J VIROL, V66, P172, DOI 10.1128/JVI.66.1.172-182.1992; HELSETH E, 1990, J VIROL, V64, P6314, DOI 10.1128/JVI.64.12.6314-6318.1990; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; HENDERSON LE, 1987, J VIROL, V61, P629, DOI 10.1128/JVI.61.2.629-632.1987; Hill CM, 1997, J VIROL, V71, P6296, DOI 10.1128/JVI.71.9.6296-6304.1997; HO DD, 1991, J VIROL, V65, P489, DOI 10.1128/JVI.65.1.489-493.1991; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; Hosie MJ, 1998, J VIROL, V72, P2097, DOI 10.1128/JVI.72.3.2097-2104.1998; HOXIE JA, 1987, HUM IMMUNOL, V18, P39, DOI 10.1016/0198-8859(87)90111-X; HWANG SS, 1992, SCIENCE, V257, P535, DOI 10.1126/science.1636088; IVANOFF LA, 1991, AIDS RES HUM RETROV, V7, P595, DOI 10.1089/aid.1991.7.595; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; JIANG SB, 1993, BIOCHEM BIOPH RES CO, V195, P533, DOI 10.1006/bbrc.1993.2078; KANG CY, 1993, J IMMUNOL, V151, P449; KANG CY, 1991, P NATL ACAD SCI USA, V88, P6171, DOI 10.1073/pnas.88.14.6171; KARWOWSKA S, 1992, AIDS RES HUM RETROV, V8, P1099, DOI 10.1089/aid.1992.8.1099; KLANIECKI J, 1991, AIDS RES HUM RETROV, V7, P791, DOI 10.1089/aid.1991.7.791; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOITO A, 1994, J VIROL, V68, P2253, DOI 10.1128/JVI.68.4.2253-2259.1994; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; KROWKA JF, 1991, CLIN IMMUNOL IMMUNOP, V59, P53, DOI 10.1016/0090-1229(91)90081-K; KWONG P, IN PRESS J VIROL; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LI JT, 1995, J VIROL, V69, P7061, DOI 10.1128/JVI.69.11.7061-7067.1995; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Martin KA, 1997, SCIENCE, V278, P1470, DOI 10.1126/science.278.5342.1470; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MATTHEWS TJ, 1994, AIDS RES HUM RETROV, V10, P631, DOI 10.1089/aid.1994.10.631; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MCKEATING JA, 1993, J VIROL, V67, P4932, DOI 10.1128/JVI.67.8.4932-4944.1993; MCKEATING JA, 1992, VIROLOGY, V190, P134, DOI 10.1016/0042-6822(92)91199-5; MCKEATING JA, 1991, J VIROL, V65, P852, DOI 10.1128/JVI.65.2.852-860.1991; Moore J P, 1995, AIDS, V9 Suppl A, pS117; MOORE JP, 1993, J VIROL, V67, P6136, DOI 10.1128/JVI.67.10.6136-6151.1993; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; MOORE JP, 1995, J VIROL, V69, P101, DOI 10.1128/JVI.69.1.101-109.1995; MOORE JP, 1994, J VIROL, V68, P469, DOI 10.1128/JVI.68.1.469-484.1994; MOORE JP, 1993, J VIROL, V67, P863, DOI 10.1128/JVI.67.2.863-875.1993; MOORE JP, 1995, J VIROL, V69, P122, DOI 10.1128/JVI.69.1.122-130.1995; Morikita T, 1997, AIDS RES HUM RETROV, V13, P1291, DOI 10.1089/aid.1997.13.1291; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; MYERS G, 1996, HUMAN RETROVIRUSES A; NARA PL, 1990, J VIROL, V64, P3779, DOI 10.1128/JVI.64.8.3779-3791.1990; NARA PL, 1987, J VIROL, V61, P3173, DOI 10.1128/JVI.61.10.3173-3180.1987; OBRIEN WA, 1994, J VIROL, V68, P5264, DOI 10.1128/JVI.68.8.5264-5269.1994; OHNO T, 1991, P NATL ACAD SCI USA, V88, P10726, DOI 10.1073/pnas.88.23.10726; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; PAGE KA, 1992, J VIROL, V66, P524, DOI 10.1128/JVI.66.1.524-533.1992; PALKER TJ, 1987, P NATL ACAD SCI USA, V84, P2479, DOI 10.1073/pnas.84.8.2479; PANTALEO G, 1991, J EXP MED, V173, P511, DOI 10.1084/jem.173.2.511; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; PINTER A, 1989, J VIROL, V63, P2674, DOI 10.1128/JVI.63.6.2674-2679.1989; POLLARD SR, 1992, EMBO J, V11, P585, DOI 10.1002/j.1460-2075.1992.tb05090.x; POSNER MR, 1991, J IMMUNOL, V146, P4325; PROFY AT, 1990, J IMMUNOL, V144, P4641; Reeves JD, 1997, J VIROL, V71, P1453, DOI 10.1128/JVI.71.2.1453-1465.1997; Rizzuto CD, 1997, J VIROL, V71, P4847, DOI 10.1128/JVI.71.6.4847-4851.1997; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; ROBEY WG, 1985, SCIENCE, V228, P593, DOI 10.1126/science.2984774; Rossio JL, 1995, AIDS RES HUM RETROV, V11, P1433, DOI 10.1089/aid.1995.11.1433; RUSCHE JR, 1987, P NATL ACAD SCI USA, V84, P6924, DOI 10.1073/pnas.84.19.6924; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAIFUDDIN M, 1995, J EXP MED, V182, P501, DOI 10.1084/jem.182.2.501; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; SATTENTAU QJ, 1995, J EXP MED, V182, P185, DOI 10.1084/jem.182.1.185; SAWYER LSW, 1994, J VIROL, V68, P1342, DOI 10.1128/JVI.68.3.1342-1349.1994; SCHAAL H, 1995, J VIROL, V69, P3308, DOI 10.1128/JVI.69.6.3308-3314.1995; SCHUTTEN M, 1993, AIDS, V7, P919, DOI 10.1097/00002030-199307000-00003; SHOTTON C, 1995, J VIROL, V69, P222, DOI 10.1128/JVI.69.1.222-230.1995; Shugars DC, 1996, J VIROL, V70, P2982, DOI 10.1128/JVI.70.5.2982-2991.1996; Speck RF, 1997, J VIROL, V71, P7136, DOI 10.1128/JVI.71.9.7136-7139.1997; Stamatatos L, 1997, VIROLOGY, V229, P360, DOI 10.1006/viro.1997.8443; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; STEIMER KS, 1991, SCIENCE, V254, P105, DOI 10.1126/science.1718036; SULLIVAN N, 1993, J VIROL, V67, P3674, DOI 10.1128/JVI.67.6.3674-3679.1993; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; SULLIVAN N, IN PRESS J VIROL; THALI M, 1992, J VIROL, V66, P5635, DOI 10.1128/JVI.66.9.5635-5641.1992; THALI M, 1991, J VIROL, V65, P6188, DOI 10.1128/JVI.65.11.6188-6193.1991; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; TILLEY SA, 1991, RES VIROLOGY, V142, P247, DOI 10.1016/0923-2516(91)90010-Z; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Tsai WP, 1996, VIROLOGY, V226, P205, DOI 10.1006/viro.1996.0648; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WANG JJG, 1986, P NATL ACAD SCI USA, V83, P6159, DOI 10.1073/pnas.83.16.6159; WEISS CD, 1990, J VIROL, V64, P5674, DOI 10.1128/JVI.64.11.5674-5677.1990; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; Willett BJ, 1997, NATURE, V385, P587, DOI 10.1038/385587a0; Willett BJ, 1997, J VIROL, V71, P6407, DOI 10.1128/JVI.71.9.6407-6415.1997; WRIN T, 1994, J ACQ IMMUN DEF SYND, V7, P211; WRIN T, 1995, J VIROL, V69, P39, DOI 10.1128/JVI.69.1.39-48.1995; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1997, J VIROL, V71, P9722, DOI 10.1128/JVI.71.12.9722-9731.1997; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0; Zhang YJ, 1997, VIROLOGY, V238, P254, DOI 10.1006/viro.1997.8812	176	1263	1347	2	156	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1998	280	5371					1884	1888		10.1126/science.280.5371.1884	http://dx.doi.org/10.1126/science.280.5371.1884			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632381				2022-12-28	WOS:000074323800046
J	Link, MS; Wang, PJ; Pandian, NG; Bharati, S; Udelson, JE; Lee, MY; Vecchiotti, MA; VanderBrink, BA; Mirra, G; Maron, BJ; Estes, NAM				Link, MS; Wang, PJ; Pandian, NG; Bharati, S; Udelson, JE; Lee, MY; Vecchiotti, MA; VanderBrink, BA; Mirra, G; Maron, BJ; Estes, NAM			An experimental model of sudden death due to low-energy chest-wall impact (commotio cordis)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BASEBALL; HEART	Background The syndrome of sudden death due to low-energy trauma to the chest wall (commotio cordis) has been described in young sports participants, but the mechanism is unknown. Methods We developed a swine model of commotio cordis in which a low-energy impact to the chest wall was produced by a wooden object the size and weight of a regulation baseball. This projectile was thrust at a velocity of 30 miles (48 km) per hour and was timed to the cardiac cycle. Results We first studied 18 young pigs, 6 subjected to multiple chest impacts and 12 to single impacts. Of the 10 impacts occurring within the window from 30 to 15 msec before the peak of the T wave on the electrocardiogram, 9 produced ventricular fibrillation. Ventricular fibrillation was not produced by impacts at any other time during the cardiac cycle. Of the 10 impacts sustained during the QRS complex, 4 resulted in transient complete heart block. We also studied whether the use of safety baseballs, which are softer than standard ones, would reduce the risk of arrhythmia. A total of 48 additional animals sustained up to three impacts during the T-wave window of vulnerability to ventricular fibrillation with a regulation baseball and safety baseballs of three degrees of hardness. We found that the likelihood of ventricular fibrillation was proportional to the hardness of the ball, with the softest balls associated with the lowest risk (two instances of ventricular fibrillation after 26 impacts, as compared with eight instances after 23 impacts with regulation baseballs). Conclusions This experimental model of commotio cordis closely resembles the clinical profile of this catastrophic event. Whether ventricular fibrillation occurred depended on the precise timing of the impact. Safety baseballs, as compared with regulation balls, may reduce the risk of commotio cordis. (C) 1998, Massachusetts Medical Society.	Tufts Univ, New England Med Ctr, Cardiac Arrhythmia Serv, Boston, MA 02111 USA; EHS Christ Hosp & Med Ctr, Heart Inst Children, Maurice Lev Congenital Heart & Conduct Ctr, Oak Lawn, IL 60453 USA; Minneapolis Heart Inst Fdn, Cardiovasc Res Div, Minneapolis, MN USA	Tufts Medical Center; Tufts University; Minneapolis Heart Institute Foundation	Link, MS (corresponding author), Tufts Univ, New England Med Ctr, Cardiac Arrhythmia Serv, Box 197,750 Washington St, Boston, MA 02111 USA.							ABRUNZO TJ, 1991, AM J DIS CHILD, V145, P1279, DOI 10.1001/archpedi.1991.02160110071023; Adler P, 1996, YOUTH BASEBALL PROTE, P1; BHARATI S, 1991, CHEST, V100, P207, DOI 10.1378/chest.100.1.207; COOPER GJ, 1982, J TRAUMA, V22, P994, DOI 10.1097/00005373-198212000-00004; Dickman Gerald L, 1978, Phys Sportsmed, V6, P85, DOI 10.1080/00913847.1978.11948393; GREEN ED, 1980, ANN EMERG MED, V9, P155, DOI 10.1016/S0196-0644(80)80272-1; HOWE BB, 1968, ACTA ANAT, V71, P13, DOI 10.1159/000143165; Janda DH., 1992, CLIN J SPORT MED, V2, P172; KAPLAN JA, 1993, J TRAUMA, V34, P151, DOI 10.1097/00005373-199301000-00030; KLEBER AG, 1978, CIRC RES, V42, P603, DOI 10.1161/01.RES.42.5.603; KYLE SB, 1996, YOUTH BASEBALL PROTE; LIEDTKE AJ, 1974, AM J PHYSIOL, V226, P377, DOI 10.1152/ajplegacy.1974.226.2.377; LINK MS, IN PRESS CHEST; Maron BJ, 1997, AM J CARDIOL, V79, P840, DOI 10.1016/S0002-9149(96)00887-9; MARON BJ, 1995, NEW ENGL J MED, V333, P337, DOI 10.1056/NEJM199508103330602; MARON BJ, 1997, CIRCULATION S1, V96, P755; Morikawa M, 1996, CLIN CARDIOL, V19, P831; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Viano DC, 1992, CLIN J SPORT MED, V2, P166	19	235	242	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1998	338	25					1805	1811		10.1056/NEJM199806183382504	http://dx.doi.org/10.1056/NEJM199806183382504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU443	9632447	Bronze			2022-12-28	WOS:000074197500004
J	Poulson, J				Poulson, J			Bitter pills to swallow	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Toronto, Fac Med, Toronto, ON M5S 1A1, Canada	University of Toronto	Poulson, J (corresponding author), Univ Toronto, Fac Med, Toronto, ON M5S 1A1, Canada.								0	11	12	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1998	338	25					1844	1846		10.1056/NEJM199806183382512	http://dx.doi.org/10.1056/NEJM199806183382512			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU443	9632455				2022-12-28	WOS:000074197500012
J	Rosenberg, PS; Biggar, RJ				Rosenberg, PS; Biggar, RJ			Trends in HIV incidence among young adults in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INJECTING DRUG-USERS; INCUBATION PERIOD; HOMOSEXUAL MEN; AIDS EPIDEMIC; INFECTION; MORTALITY; AGE	Context.-Behaviors that result in potential exposure to human immunodeficiency virus (HIV) usually begin in adolescence or young adulthood, but trends in HIV incidence in young people remain unclear. Objective.-To estimate trends in HIV incidence in teenagers and young adults. Design and Setting.-Back-calculation of past HIV incidence in persons born between 1960 and 1974 using US national acquired immunodeficiency syndrome (AIDS) incidence data and estimates of the distribution of times between HIV infection and AIDS. Main Outcome Measures.-Incidence and prevalence of HIV in 1988 and 1993 in persons aged 20 and 25 years, respectively, in each of those years. Results.-As of January 1993, about 22 000 men and 11 000 women aged 18 to 22 years were living with HIV infection in the United States. Homosexual contact was the leading route of infection among young men. Heterosexual contact was the leading route of infection among young women. The HIV incidence attributed to homosexual contact or injection drug use decreased among persons aged 20 and 25 years between 1988 and 1993, but HIV incidence attributed to heterosexual contact was stable or increasing. Notably, in men aged 20 and 25 years, HIV prevalence declined by about 50% in white men but was relatively stable in black and Hispanic men. In contrast, HIV prevalence in women aged 20 and 25 years rose by 36% and 45%, respectively, because of increasing heterosexual transmission. Overall, HIV prevalence in persons aged 20 and 25 years declined by only 14% between 1988 and 1993. Conclusions.-In young persons, HIV incidence in homosexual men and injection drug users was slowing by 1993; this favorable trend was offset by increasing heterosexual transmission, especially in minorities.	NCI, Biostat Branch, Bethesda, MD 20892 USA; NCI, Viral Epidemiol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rosenberg, PS (corresponding author), NCI, Biostat Branch, 6130 Execut Blvd,EPN-403, Bethesda, MD 20892 USA.			Rosenberg, Philip/0000-0001-6349-9126	NIAID NIH HHS [U01-AI-35041, U01-AI-35040, U01-AI-35039] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035041, U01AI035039, U01AI035040] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1996, HIV AIDS SURV REP, P1; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P889; CELUM C, 1997, 4 C RETR OPP INF JAN; Centers for Disease Control and Prevention, 1992, MMWR RECOMM REP, V18, P1; Cohen J, 1997, SCIENCE, V275, P615, DOI 10.1126/science.275.5300.615; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; Darby SC, 1996, LANCET, V347, P1573, DOI 10.1016/S0140-6736(96)91073-9; GALAI N, 1995, J ACQ IMMUN DEF SYND, V8, P66; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HENDRIKS JCM, 1993, AIDS, V7, P231, DOI 10.1097/00002030-199302000-00012; HOOVER DR, 1996, 11 INT C AIDS JUL 7; Institute of Medicine, 1997, HIDD EP CONFR SEX TR; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; Karon JM, 1997, J ACQ IMMUN DEF SYND, V16, P116, DOI 10.1097/00042560-199710010-00007; MARIOTTO AB, 1992, AM J EPIDEMIOL, V135, P428, DOI 10.1093/oxfordjournals.aje.a116303; McQuillan GM, 1997, J ACQ IMMUN DEF SYND, V14, P355, DOI 10.1097/00042560-199704010-00008; Munoz A, 1996, STAT MED, V15, P2459, DOI 10.1002/(SICI)1097-0258(19961130)15:22<2459::AID-SIM464>3.0.CO;2-Q; Rosenberg PS, 1998, STAT MED, V17, P155, DOI 10.1002/(SICI)1097-0258(19980130)17:2&lt;155::AID-SIM758&gt;3.0.CO;2-O; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; ROSENBLUM L, 1992, AM J PUBLIC HEALTH, V82, P1495, DOI 10.2105/AJPH.82.11.1495; *US CENS BUR, 1997, OFF STAT; VANHAASTRECHT HJA, 1994, AIDS, V8, P363, DOI 10.1097/00002030-199403000-00011; Wortley PM, 1997, JAMA-J AM MED ASSOC, V278, P911, DOI 10.1001/jama.278.11.911; ZACCARELLI M, 1994, AIDS, V8, P345, DOI 10.1097/00002030-199403000-00008	25	99	100	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1998	279	23					1894	1899		10.1001/jama.279.23.1894	http://dx.doi.org/10.1001/jama.279.23.1894			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT653	9634261	Bronze			2022-12-28	WOS:000074109700037
J	Atkins, S				Atkins, S			A lesson to be learnt - Parenting is not on the medical curriculum	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1838	1838		10.1136/bmj.316.7147.1838	http://dx.doi.org/10.1136/bmj.316.7147.1838			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624099	Green Published			2022-12-28	WOS:000074286300081
J	Brooks, P				Brooks, P			Recent advances - Rheumatology	BRITISH MEDICAL JOURNAL			English	Review							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ARTHRITIS; COMBINATION; THERAPY; METHOTREXATE; SULFASALAZINE; PARACETAMOL; DISEASE; RISK		Univ New S Wales, St Vincents Hosp, Sydney, NSW 2010, Australia	St Vincents Hospital Sydney; University of New South Wales Sydney	Brooks, P (corresponding author), Univ Queensland, Royal Brisbane Hosp, Off Execut Dean Hlth Sci, Herston, Qld 4029, Australia.	P.Brooks@unsw.edu.au						BAHKLE YS, 1996, MEDIATORS INFLAM, V6, P305; Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140-6736(97)01300-7; Bresnihan B., 1997, British Journal of Rheumatology, V36, P105; Campion GV, 1996, ARTHRITIS RHEUM, V39, P1092, DOI 10.1002/art.1780390704; deLeeuw PW, 1996, DRUGS, V51, P179, DOI 10.2165/00003495-199651020-00001; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; EMERY P, 1994, BRIT J RHEUMATOL, V33, P765; Firestein GS, 1997, NEW ENGL J MED, V337, P195, DOI 10.1056/NEJM199707173370310; Fries JF, 1996, ARTHRITIS RHEUM, V39, P616, DOI 10.1002/art.1780390412; FRIES JF, 1990, J RHEUMATOL, V17, P12; HAAGSMA CJ, 1994, BRIT J RHEUMATOL, V33, P1049; HAMILTON JA, 1995, BAILLIERE CLIN RHEUM, V9, P673; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; HENRY D, 1997, P INT C INF SAN FRAN; HUTCHINSON F, 1997, P W HARV RES C SEL C; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MARCH L, 1994, BRIT MED J, V309, P1041, DOI 10.1136/bmj.309.6961.1041; MCKENDRY RJR, 1996, ARTHRITIS RHEUM, V39, P1248; McManus P, 1996, MED J AUSTRALIA, V164, P589, DOI 10.5694/j.1326-5377.1996.tb122200.x; Mottonen T, 1996, ARTHRITIS RHEUM, V39, P996, DOI 10.1002/art.1780390617; MUELLER C, 1996, BR J RHEUMATOL S1, V35, P68; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; SAAG KG, 1994, AM J MED, V96, P115, DOI 10.1016/0002-9343(94)90131-7; SEIDEMAN P, 1993, ACTA ORTHOP SCAND, V64, P285, DOI 10.3109/17453679308993626; SKOLNICK AA, 1997, JAMA-J AM MED ASSOC, V227, P276; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; Tyndall A, 1996, ANN RHEUM DIS, V55, P149, DOI 10.1136/ard.55.3.149; WOLDE ST, 1996, LANCET, V347, P347; Wynne HA, 1996, BRIT J CLIN PHARMACO, V42, P253, DOI 10.1046/j.1365-2125.1996.41420.x	30	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1810	1812		10.1136/bmj.316.7147.1810	http://dx.doi.org/10.1136/bmj.316.7147.1810			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624076	Green Published			2022-12-28	WOS:000074286300033
J	Sirringhaus, H; Tessler, N; Friend, RH				Sirringhaus, H; Tessler, N; Friend, RH			Integrated optoelectronic devices based on conjugated polymers	SCIENCE			English	Article							FIELD-EFFECT TRANSISTORS; THIN-FILM TRANSISTORS; PHYSICS; DIODES; MODEL	An all-polymer semiconductor integrated device is demonstrated with a high-mobility conjugated polymer field-effect transistor (FET) driving a polymer light-emitting diode (LED) of similar size. The FET uses regioregular poly(hexylthiophene). Its performance approaches that of inorganic amorphous silicon FETs, with field-effect mobilities of 0.05 to 0.1 square centimeters per volt second and ON-OFF current ratios of >10(6). The high mobility is attributed to the formation of extended polaron states as a result of local self-organization, in contrast to the variable-range hopping of self-localized polarons found in more disordered polymers. The FET-LED device represents a step toward all-polymer optoelectronic integrated circuits such as active-matrix polymer LED displays.	Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England	University of Cambridge	Sirringhaus, H (corresponding author), Univ Cambridge, Cavendish Lab, Madingley Rd, Cambridge CB3 0HE, England.		Sirringhaus, Henning/ABD-1555-2021; Tessler, Nir/A-9849-2008	Sirringhaus, Henning/0000-0001-9827-6061; Tessler, Nir/0000-0002-5354-3231; Friend, Richard Henry/0000-0001-6565-6308				Bao Z, 1996, APPL PHYS LETT, V69, P4108, DOI 10.1063/1.117834; BRAUN D, 1991, APPL PHYS LETT, V58, P1982, DOI 10.1063/1.105039; BROWN AR, 1995, SCIENCE, V270, P972, DOI 10.1126/science.270.5238.972; Brown AR, 1997, SYNTHETIC MET, V88, P37, DOI 10.1016/S0379-6779(97)80881-8; BURROUGHES JH, 1988, NATURE, V335, P137, DOI 10.1038/335137a0; CHEN TA, 1995, J AM CHEM SOC, V117, P233, DOI 10.1021/ja00106a027; DODABALAPUR A, IN PRESS APPL PHYS L; Greenham N. C., 1995, SOLID STATE PHYS, V49, P1; HOROWITZ G, 1991, J APPL PHYS, V70, P469, DOI 10.1063/1.350250; Horowitz G, 1996, ADV MATER, V8, P52, DOI 10.1002/adma.19960080109; HOURD AC, 1984, PHILOS MAG B, V51, P613; MACKENZIE KD, 1983, APPL PHYS A-MATER, V31, P87, DOI 10.1007/BF00616310; Nelson SF, 1998, APPL PHYS LETT, V72, P1854, DOI 10.1063/1.121205; SHUR M, 1989, J APPL PHYS, V66, P3371, DOI 10.1063/1.344481; SHUR M, 1984, J APPL PHYS, V55, P3831, DOI 10.1063/1.332893; SIRRINGHAUS H, UNPUB; TANG CW, 1996, Patent No. 5550066; Tessler N, 1998, ADV MATER, V10, P64, DOI 10.1002/(SICI)1521-4095(199801)10:1<64::AID-ADMA64>3.0.CO;2-G; Torsi L, 1996, SCIENCE, V272, P1462, DOI 10.1126/science.272.5267.1462; Torsi L, 1998, PHYS REV B, V57, P2271, DOI 10.1103/PhysRevB.57.2271; Wu CC, 1997, IEEE ELECTR DEVICE L, V18, P609, DOI 10.1109/55.644086	21	2542	2632	18	522	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	1998	280	5370					1741	1744		10.1126/science.280.5370.1741	http://dx.doi.org/10.1126/science.280.5370.1741			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624049				2022-12-28	WOS:000074197800038
J	Blaum, JM; Omura, EF				Blaum, JM; Omura, EF			Cutaneous larva migrans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Alabama, Sch Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Blaum, JM (corresponding author), Univ Alabama, Sch Med, Birmingham, AL 35294 USA.								0	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1998	338	24					1733	1733		10.1056/NEJM199806113382405	http://dx.doi.org/10.1056/NEJM199806113382405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT654	9625629				2022-12-28	WOS:000074109800005
J	Blanch, G; Quenby, S; Ballantyne, ES; Gosden, CM; Neilson, JP; Holland, K				Blanch, G; Quenby, S; Ballantyne, ES; Gosden, CM; Neilson, JP; Holland, K			Embryonic abnormalities at medical termination of pregnancy with mifepristone and misoprostol during first trimester: observational study	BRITISH MEDICAL JOURNAL			English	Article									Univ Liverpool, Dept Obstet & Gynaecol, Liverpool L69 3BX, Merseyside, England; Liverpool Womens Hosp, Day Care Abort Unit, Liverpool, Merseyside, England	University of Liverpool; University of Liverpool	Blanch, G (corresponding author), Univ Liverpool, Dept Obstet & Gynaecol, Liverpool L69 3BX, Merseyside, England.			Quenby, Siobhan/0000-0003-3221-5471				Everett C, 1997, BRIT MED J, V315, P32, DOI 10.1136/bmj.315.7099.32; HUME RF, 1994, FETAL DIAGN THER, V9, P239; KLINE J, 1990, EARLY PREGNANCY FAIL, P240; LELAIDIER C, 1993, HUM REPROD, V8, P492, DOI 10.1093/oxfordjournals.humrep.a138078; WALD NJ, 1994, CIBA F SYMP, V181, P192	5	15	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1712	1713		10.1136/bmj.316.7146.1712	http://dx.doi.org/10.1136/bmj.316.7146.1712			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614021	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000074129500023
J	Dunea, G				Dunea, G			Say no to Viagra	BRITISH MEDICAL JOURNAL			English	Editorial Material									Cook Cty Hosp, Chicago, IL 60612 USA	John H Stroger Junior Hospital Cook County	Dunea, G (corresponding author), Cook Cty Hosp, Chicago, IL 60612 USA.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1755	1755		10.1136/bmj.316.7146.1755	http://dx.doi.org/10.1136/bmj.316.7146.1755			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614049	Green Published			2022-12-28	WOS:000074129500088
J	Atkins, C				Atkins, C			God save the child	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1677	1677		10.1001/jama.279.21.1677	http://dx.doi.org/10.1001/jama.279.21.1677			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624008				2022-12-28	WOS:000073878700001
J	Valente, E; Wyatt, SM; Moy, E; Levin, RJ; Griner, PF				Valente, E; Wyatt, SM; Moy, E; Levin, RJ; Griner, PF			Market influences on internal medicine residents' decisions to subspecialize	ANNALS OF INTERNAL MEDICINE			English	Article							CARE SPECIALTY CHOICE; PHYSICIAN WORKFORCE; REFORM; STATE	Background: Managed care reduces the demand for internal medicine subspecialists, but little empirical information is available on how increasing managed care may be affecting residents' training choices. Objective: To determine whether increased managed care penetration into an area where residents train was associated with a decreased likelihood that residents who completed general internal medicine training pursued subspecialty training. Design: Secondary logistic regression analysis of data from the 1993 cohort of general internal medicine residents. Setting: U.S. residency training sites. Participants: 2263 U.S. medical school graduates who completed general internal medicine residency training in 1993. Measurements: The outcome variable (enrollment in subspecialty training) was derived from the Graduate Medical Education Tracking Census of the Association of American Medical Colleges (AAMC). Health maintenance organization (HMO) penetration (possible range, 0.0 to 1.0; higher values indicate greater penetration) was taken from the Interstudy Competitive Edge Database. Individual and medical school covariates were taken from the AAMC's Student and Applicant Information Management System database and the National Institutes of Health Information for Management Planning, Analysis, and Coordination system. The U.S. Census division was included as a control covariate. Results: 980 participants (43%) enrolled in subspecialty training. Logistic regression analyses indicated a nonlinear association between managed care penetration into a training area and the odds of subspecialization. Increasing managed care penetration was associated with decreasing odds of subspecialization when penetration exceeded 0.15. The choice of subspecialty training increased as HMO penetration increased from 0 to 0.15. Conclusions: Local market forces locally influenced the career decisions of internal medicine residents, but the influence was small compared with the effects of age and sex. These results suggest that market forces help to achieve more desirable genera list-to-specialist physician ratios in internal medicine.	Assoc Amer Med Coll, Washington, DC 20037 USA	Association of American Medical Colleges	Valente, E (corresponding author), Assoc Amer Med Coll, 2450 N St NW, Washington, DC 20037 USA.							*ASS AM MED COLL, 1995, AAMC GRAD MED ED TRA; BLAND CJ, 1995, ACAD MED, V70, P620, DOI 10.1097/00001888-199507000-00013; BLANK LL, 1992, ANN INTERN MED, V117, P778; COHEN JJ, 1993, ANN INTERN MED, V119, P1125, DOI 10.7326/0003-4819-119-11-199312010-00010; Colquitt WL, 1996, ACAD MED, V71, P400, DOI 10.1097/00001888-199604000-00023; *COUNC GRAD MED ED, 1992, IMPR ACC HLTH CAR PH; KASSEBAUM DG, 1996, ACAD MED, V71, P197; MARKHAM FW, 1997, JEFFERSON MED COLL H, V10, P7; Meurer LN, 1996, ACAD MED, V71, P68, DOI 10.1097/00001888-199601000-00020; Miller RS, 1996, JAMA-J AM MED ASSOC, V275, P708, DOI 10.1001/jama.275.9.708; Nelson HD, 1998, J GEN INTERN MED, V13, P39, DOI 10.1046/j.1525-1497.1998.00006.x; *NIH EXTR TRENDS, 1995, NIH PUB; *PHYS PAYM REV COM, 1997, CHANG LAB MARK PHYS, P345; RIVO ML, 1993, ANN INTERN MED, V119, P146, DOI 10.7326/0003-4819-119-2-199307150-00009; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; Ruhnke GW, 1997, JAMA-J AM MED ASSOC, V277, P70, DOI 10.1001/jama.277.1.70; Salsberg ES, 1996, JAMA-J AM MED ASSOC, V276, P683, DOI 10.1001/jama.276.9.683; Schwartz AL, 1996, ACAD MED, V71, P15, DOI 10.1097/00001888-199601000-00012; Seifer SD, 1996, JAMA-J AM MED ASSOC, V276, P695, DOI 10.1001/jama.276.9.695; Srinivasan A, 1995, JAMA, V273, P78, DOI 10.1001/jama.273.1.78; *STAT CORP, 1997, STAT STAT SOFTW REL; *US CENS BUR, 1995, CENS 1990 SUMM TAP F; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WHITCOMB ME, 1992, ACAD MED, V67, P587, DOI 10.1097/00001888-199209000-00009; 1996, INTERSTUDY COMPETI 3	25	13	13	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					915	921		10.7326/0003-4819-128-11-199806010-00010	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634431				2022-12-28	WOS:000073808600007
J	Allada, R; White, NE; So, WV; Hall, JC; Rosbash, M				Allada, R; White, NE; So, WV; Hall, JC; Rosbash, M			A mutant Drosophila homolog of mammalian Clock disrupts circadian rhythms and transcription of period and timeless	CELL			English	Article							MESSENGER-RNA LEVELS; GENE-EXPRESSION; SUPRACHIASMATIC NUCLEUS; DIOXIN RECEPTOR; DNA-BINDING; AH RECEPTOR; DARK CYCLES; PROTEIN; MELANOGASTER; BEHAVIOR	We report the identification, characterization, and cloning of a novel Drosophila circadian rhythm gene, dClock. The mutant, initially called Jrk, manifests dominant effects: heterozygous flies have a period alteration and half are arrhythmic, while homozygous flies are uniformly arrhythmic. Furthermore, these flies express low levels of the two clock proteins, PERIOD (PER) and TIMELESS (TIM), due to low per and tim transcription. Mapping and cloning of the Jrk gene indicates that it encodes the Drosophila homolog of mouse Clock. The mutant phenotype results from a premature stop codon that eliminates much of the putative activation domain of this bHLH-PAS transcription factor, thus explaining the dominant features of Jrk. The remarkable sequence conservation strongly supports common clock components present in the common ancestor of Drosophila and mammals.	Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02254 USA; Brandeis Univ, Ctr Biol Timing, NSF, Waltham, MA 02254 USA; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Brandeis University; Howard Hughes Medical Institute; Brandeis University; National Science Foundation (NSF); NSF - Center for Biological Timing; Brandeis University; Harvard University; Brigham & Women's Hospital	Rosbash, M (corresponding author), Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02254 USA.							Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; ARONSON BD, 1994, P NATL ACAD SCI USA, V91, P7683, DOI 10.1073/pnas.91.16.7683; BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; Blackman RK, 1996, BIOTECHNIQUES, V21, P226; Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; ENGELS WR, 1986, FOCUS, V8, P6; EWER J, 1992, J NEUROSCI, V12, P3321; FELDMAN J F, 1973, Genetics, V75, P605; Feldman J.F., 1982, PHOTOCHEM PHOTOBIOL, V7, P319; Gelbart WM, 1998, NUCLEIC ACIDS RES, V26, P85; GRASSO G, 1996, INFO SERV, V77, P94; HAMBLEN M, 1986, J NEUROGENET, V3, P249, DOI 10.3109/01677068609106855; HAMBLENCOYLE M, 1989, J NEUROGENET, V5, P229, DOI 10.3109/01677068909066210; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HARDIN PE, 1994, MOL CELL BIOL, V14, P7211, DOI 10.1128/MCB.14.11.7211; HARTL DL, 1994, P NATL ACAD SCI USA, V91, P6824, DOI 10.1073/pnas.91.15.6824; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Kimmerly W, 1996, GENOME RES, V6, P414, DOI 10.1101/gr.6.5.414; King DP, 1997, GENETICS, V146, P1049; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KONOPKA RJ, 1994, J BIOL RHYTHM, V9, P189, DOI 10.1177/074873049400900303; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; Linden H, 1997, EMBO J, V16, P98, DOI 10.1093/emboj/16.1.98; LIU X, 1991, NEURON, V6, P753, DOI 10.1016/0896-6273(91)90172-V; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Marrus SB, 1996, EMBO J, V15, P6877, DOI 10.1002/j.1460-2075.1996.tb01080.x; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Morris ME, 1998, SCIENCE, V279, P1544, DOI 10.1126/science.279.5356.1544; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; Pollenz RS, 1996, J BIOL CHEM, V271, P30886, DOI 10.1074/jbc.271.48.30886; ROBERTSON LM, 1988, J NEUROSCI, V8, P12; Rouyer F, 1997, EMBO J, V16, P3944, DOI 10.1093/emboj/16.13.3944; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; Rutila JE, 1996, NEURON, V17, P921, DOI 10.1016/S0896-6273(00)80223-8; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Sawyer LA, 1997, SCIENCE, V278, P2117, DOI 10.1126/science.278.5346.2117; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; SMITH RF, 1981, MOL GEN GENET, V183, P243, DOI 10.1007/BF00270625; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; Stanewsky R, 1997, EMBO J, V16, P5006, DOI 10.1093/emboj/16.16.5006; Stanewsky R, 1996, GENETICS, V143, P259; SU LK, 1995, CANCER RES, V55, P2972; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Tut TG, 1997, J CLIN ENDOCR METAB, V82, P3777, DOI 10.1210/jc.82.11.3777; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; ZERR DM, 1990, J NEUROSCI, V10, P2749; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713	74	558	579	2	64	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					791	804		10.1016/S0092-8674(00)81440-3	http://dx.doi.org/10.1016/S0092-8674(00)81440-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630223	Bronze			2022-12-28	WOS:000073956700015
J	Lee, D; Lis, JT				Lee, D; Lis, JT			Transcriptional activation independent of TFIIH kinase and the RNA polymerase II mediator in vivo	NATURE			English	Article							C-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; HSP70 GENE; PHOSPHORYLATION; CTD; HOLOENZYME; YEAST; REQUIREMENT; PROMOTER; ENHANCER	The carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II becomes multiply phosphorylated by protein kinases during early steps in the gene transcription cycle both in vivo(1) and in vitro(2). In yeast, the major CTD kinase is a subunit of the general transcription factor TFIIH, and is encoded by an essential gene, KIN28 (ref. 3). Although the CTD and its phosphorylation are important for transcription(4-6), in vitro studies(7,8) have challenged whether CTD phosphorylation is an absolutely required step. The general importance of CTD phosphorylation by Kin28 for transcription in yeast has been suggested because, for all genes tested, transcription is inhibited at the non-permissive temperature in temperature-sensitive kin28 mutants(9,10). However, using such a mutant and a copper-inducible targeted destruction method, we show here that transcription of certain genes can be highly induced even when cells lack Kin28. We also show that transcription of these Kin28-independent genes is independent of Srb4 and Srb6, critical components of the CTD-associated transcriptional mediator complex(11). These results indicate that there are at least two distinct pathways for transcriptional activation: one is dependent on Kin28 and the mediator complex, and the other is not.	Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	Cornell University	Lis, JT (corresponding author), Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA.							AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BOORSTEIN WR, 1990, J BIOL CHEM, V265, P18912; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Dubois MF, 1997, NUCLEIC ACIDS RES, V25, P694, DOI 10.1093/nar/25.4.694; ELION EA, 1986, MOL CELL BIOL, V6, P2089, DOI 10.1128/MCB.6.6.2089; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; GERBER HP, 1995, NATURE, V374, P60; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316	30	88	88	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1998	393	6683					389	392		10.1038/30770	http://dx.doi.org/10.1038/30770			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620805				2022-12-28	WOS:000073883600060
J	Oksenhendler, E; Cazals-Hatem, D; Schulz, TF; Barateau, V; Grollet, L; Sheldon, J; Clauvel, JP; Sigaux, F; Agbalika, F				Oksenhendler, E; Cazals-Hatem, D; Schulz, TF; Barateau, V; Grollet, L; Sheldon, J; Clauvel, JP; Sigaux, F; Agbalika, F			Transient angiolymphoid hyperplasia and Kaposi's sarcoma after primary infection with human herpesvirus 8 in a patient with human immunodeficiency virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MULTICENTRIC CASTLEMANS-DISEASE; DNA-SEQUENCES; ANTIBODIES; ANTIGENS		Hop St Louis, Dept Immunol & Hematol, Paris, France; Hop St Louis, Dept Pathol, Paris, France; Hop St Louis, Virol Lab, Paris, France; Hop St Louis, Lab Mol Hematol, Paris, France; Univ Liverpool, Dept Med Microbiol & Genitourinary Med, Liverpool L69 3BX, Merseyside, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Liverpool	Oksenhendler, E (corresponding author), Hop St Louis, Serv Immunohematol, 1 Ave Claude Vellefaux, F-75010 Paris, France.		Schulz, Thomas/AAA-1634-2019	Schulz, Thomas/0000-0001-8792-5345; Sheldon, Julie/0000-0002-8240-0010				Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; HEIPEL F, 1997, J VIROL, V71, P4187; KALABRO ML, IN PRESS J HUM VIROL; Kedes DH, 1996, NAT MED, V2, P1041; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Luppi M, 1996, BLOOD, V87, P3903, DOI 10.1182/blood.V87.9.3903.bloodjournal8793903; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Oksenhendler E, 1996, AIDS, V10, P61, DOI 10.1097/00002030-199601000-00009; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sarid R, 1997, NAT MED, V3, P293, DOI 10.1038/nm0397-293; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; SOULIER J, 1995, BLOOD, V86, P1131; Whitby D, 1998, J NATL CANCER I, V90, P395, DOI 10.1093/jnci/90.5.395	23	79	79	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1998	338	22					1585	1590		10.1056/NEJM199805283382204	http://dx.doi.org/10.1056/NEJM199805283382204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ350	9603796				2022-12-28	WOS:000073852400004
J	Schroeter, EH; Kisslinger, JA; Kopan, R				Schroeter, EH; Kisslinger, JA; Kopan, R			Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain	NATURE			English	Article							GOLGI-COMPLEX; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTOR; PROTEINS; CELLS; VIRUS; RBP-J-KAPPA/SU(H); TRANSDUCTION; SUPPRESSOR; EXPRESSION	Notch proteins are ligand-activated transmembrane receptors involved in cell-fate selection throughout development(1-3). No known enzymatic activity is contained within Notch and the molecular mechanism by which it transduces signals across the cell membrane is poorly understood. In many instances, Notch activation results in transcriptional changes in the nucleus through an association with members of the CSL family of DNA-binding proteins (where CSL stands for CBF1, Su(H), Lag-1)(1-4). As Notch is located in the plasma membrane and CSL is a nuclear protein, two models have been proposed to explain how they interact (Fig. I). The first suggests that the two interact transiently at the membrane(1,5-7). The second postulates that Notch is cleaved by a protease, enabling the cleaved fragment to enter the GRAPHICS nucleus(6,8-14). Here we show that signalling by a constitutively active membrane-bound Notch-1 protein requires the proteolytic release of the Notch inh acellular domain (NICD), which interacts preferentially with CSL, Very small amounts of NICD are active, explaining why it is hard to detect in the nucleus in vivo, We also show that it is ligand binding that induces release of NICD.	Washington Univ, Div Dermatol, St Louis, MO 63110 USA; Washington Univ, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Kopan, R (corresponding author), Washington Univ, Div Dermatol, Box 8123,4940 Parkview Pl, St Louis, MO 63110 USA.	kopan@pharmdec.wustl.edu	Kopan, Raphael/AFG-3275-2022; Kopan, Raphael/AAF-1357-2022	Kopan, Raphael/0000-0002-0350-2730				ArtavanisTsakonas S, 1997, NAT GENET, V16, P212, DOI 10.1038/ng0797-212; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Aster JC, 1997, J BIOL CHEM, V272, P11336; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BREDENBEEK PJ, 1993, J VIROL, V67, P6439, DOI 10.1128/JVI.67.11.6439-6446.1993; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Gho M, 1996, DEVELOPMENT, V122, P1673; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kopan R, 1996, CURR OPIN NEUROBIOL, V6, P594, DOI 10.1016/S0959-4388(96)80090-0; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; QUINN P, 1983, J CELL BIOL, V96, P851, DOI 10.1083/jcb.96.3.851; Roehl H, 1996, EMBO J, V15, P7002, DOI 10.1002/j.1460-2075.1996.tb01092.x; Sotillos S, 1997, DEVELOPMENT, V124, P4769; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WEINTRAUB H, 1988, P NATL ACAD SCI USA, V85, P5819, DOI 10.1073/pnas.85.16.5819; Wen CH, 1997, DEVELOPMENT, V124, P4759; Wettstein DA, 1997, DEVELOPMENT, V124, P693	30	1339	1396	1	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 28	1998	393	6683					382	386		10.1038/30756	http://dx.doi.org/10.1038/30756			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620803				2022-12-28	WOS:000073883600058
J	Michaelsson, K; Baron, JA; Farahmand, BY; Johnell, O; Magnusson, C; Persson, PG; Persson, I; Ljunghall, S				Michaelsson, K; Baron, JA; Farahmand, BY; Johnell, O; Magnusson, C; Persson, PG; Persson, I; Ljunghall, S		Swedish Hip Fracture Study Grp	Hormone replacement therapy and risk of hip fracture: population based case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL WOMEN; BONE-DENSITY; ESTROGEN; OSTEOPOROSIS; EPIDEMIOLOGY; PREVENTION; AGE	Objective: To determine the relative risk of hip fracture associated with postmenopausal hormone replacement therapy including the effect of duration and recency of treatment, the addition of progestins, route of administration, and dose. Design: Population based case-control study. Setting: Six counties in Sweden. Subjects: 1327 women aged 50-81 years with hip fracture and 3262 randomly selected controls. Main outcome measure: Use of hormone replacement therapy. Results: Compared with women who had never used hormone replacement therapy, current users had an odds ratio of 0.35 (95 % confidence interval 0.24 to 0.53) for hip fracture and former users had an odds ratio of 0.76 (0.57 to 1.01), For every year of therapy the overall risk decreased by 6% (3% to 9%): 4%, (1% to 8%) for regimens without progestin and 11% (6% to 16%) for those with progestin. Last use between one and five years previously with a duration of use more than five years, was associated with all odds ratio of 0.27 (0.08 to 0.94). After five years without hormone replacement therapy the protective effect was substantially diminished (-7% to 48%). With current use, an initiation of therapy nine or more years after the menopause gave equally strong reduction in risk for hip fracture as an earlier start. Oestrogen treatment with skin patches gave similar risk estimates as oral regimens. Conclusions: Recent use of hormone replacement therapy is required for optimum fracture protection, but therapy can bt started several years after the menopause. The protective effect increases with duration of use, and an oestrogen-sparing effect is achieved when progestins are included in the regimen.	Univ Uppsala Hosp, Dept Orthopaed, S-75185 Uppsala, Sweden; Dartmouth Med Sch, Dept Med, Hanover, NH USA; Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH USA; Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Stockholm Cty Council, Dept Epidemiol, S-17176 Stockholm, Sweden; Malmo Gen Hosp, Dept Orthopaed, S-20502 Malmo, Sweden; Univ Uppsala Hosp, Dept Internal Med, S-75185 Uppsala, Sweden	Uppsala University; Uppsala University Hospital; Dartmouth College; Dartmouth College; Karolinska Institutet; Stockholm County Council; Uppsala University; Uppsala University Hospital	Michaelsson, K (corresponding author), Univ Uppsala Hosp, Dept Orthopaed, S-75185 Uppsala, Sweden.	Karl.Michaelsson@ortopedi.uu.se	Michaelsson, Karl/AAM-9094-2021	Magnusson, Cecilia/0000-0002-8567-6725; Michaelsson, Karl/0000-0003-2815-1217	NINR NIH HHS [NR 1 RO 1 CA58427] Funding Source: Medline	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHRISTIANSEN C, 1985, LANCET, V2, P800; Christiansen C, 1990, Osteoporos Int, V1, P7; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GALLAGHER JC, 1991, AM J MED, V90, P171; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Hammar ML, 1996, OBSTET GYNECOL, V88, P955; HEANEY RP, 1992, J INTERN MED, V231, P169, DOI 10.1111/j.1365-2796.1992.tb00520.x; HILLARD TC, 1991, CALCIFIED TISSUE INT, V49, pS55, DOI 10.1007/BF02555090; HORSMAN A, 1983, NEW ENGL J MED, V309, P1405, DOI 10.1056/NEJM198312083092301; KANIS JA, 1992, BRIT MED J, V305, P1124, DOI 10.1136/bmj.305.6862.1124; KANIS JA, 1992, BONE, V13, pS7, DOI 10.1016/S8756-3282(09)80004-5; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MAXIM P, 1995, OSTEOPOROSIS INT, V5, P23, DOI 10.1007/BF01623654; MELTON LJ, 1987, BONE MINER, V2, P321; MICHAELSSON K, 1995, INT J EPIDEMIOL, V24, P771, DOI 10.1093/ije/24.4.771; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; Naessen T, 1997, AM J OBSTET GYNECOL, V177, P412, DOI 10.1016/S0002-9378(97)70207-2; NILAS L, 1987, J CLIN ENDOCR METAB, V65, P697, DOI 10.1210/jcem-65-4-697; PRIOR JC, 1990, ENDOCR REV, V11, P386, DOI 10.1210/edrv-11-2-386; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; Rizzoli R, 1997, LANCET, V349, pS20, DOI 10.1016/S0140-6736(97)90007-6; Schneider DL, 1997, JAMA-J AM MED ASSOC, V277, P543, DOI 10.1001/jama.277.7.543; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102	28	201	206	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 20	1998	316	7148					1858	1863						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632404				2022-12-28	WOS:000074686500016
J	Kurtzhals, JAL; Adabayeri, V; Goka, BQ; Akanmori, BD; Oliver-Commey, JO; Nkrumah, FK; Behr, C; Hviid, L				Kurtzhals, JAL; Adabayeri, V; Goka, BQ; Akanmori, BD; Oliver-Commey, JO; Nkrumah, FK; Behr, C; Hviid, L			Low plasma concentrations of interleukin 10 in severe malarial anaemia compared with cerebral and uncomplicated malaria	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; PLASMODIUM-FALCIPARUM MALARIA; SERUM LEVELS; BONE-MARROW; IFN-GAMMA; IN-VITRO; CHILDREN; ANEMIA; IL-10; DISEASE	Background Severe anaemia is a major complication of malaria but little is known about its pathogenesis. Experimental models have implicated tumour necrosis factor (TNF) in induction of bone-marow suppression and eythrophagocytosis. Conversely, interleukin 10 (IL-10), which mediates feed-back regulation of TNF, stimulates bone-marrow function in vitro and counteracts anaemia in mice. We investigated the associations of these cytokines with malarial anaemia. Methods We enrolled 175 African children with malaria into two studies in 1995 and 1996. In the first study, children were classified as having severe anaemia (n=10), uncomplicated malaria (n=26), or cerebral anaemia (n=41). In the second study, patients were classified as having cerebral malaria (n=33) or being fully conscious (n=65), and the two groups were subdivided by measured haemoglobin as normal (>110 g/L), moderate anaemia (60-90 g/L), and severe anaemia (<50 g/L). IL-10 and TNF concentrations were measured by ELISA in plasma samples from all patients. Findings IL-10 concentrations were significantly lower in patients with severe anaemia than in all other groups. In 1995, geometric mean plasma IL-10 in patients with severe anaemia was 270 pg/mL (95% CI 152-482) compared with 725 pg/mL (465-1129) in uncomplicated malaria and 966 pg/mL (612-1526) in cerebral malaria (p<0.03). In 1996, fully conscious patients with severe anaemia also had significantly lower IL-10 concentrations than all other groups, including cerebral-malaria patients with severe anaemia and all patients with moderate anaemia (p<0.001). In both studies, TNF concentrations were significantly higher in cerebral malaria than in fully conscious patients (p<0.01). By contrast, the ratio of TNF to IL-10 was significantly higher in fully conscious patients with severe anaemia than in all other groups (p<0.001). Interpretation Our findings identify severe malarial anaemia as a distinct disorder in which insufficient IL-10 response to high TNF concentrations may have a central role.	Noguchi Mem Inst Med Res, Immunol Unit, Legon, Ghana; Korle Bu Teaching Hosp, Dept Child Hlth, Accra, Ghana; Copenhagen Univ Hosp, RHIMA Ctr, Ctr Medlocal Parisitol, Copenhagen, Denmark; Univ Copenhagen, Inst Med Microbiol & Immunol, DK-1168 Copenhagen, Denmark; Inst Pasteur, Unite Immunol Mol Parasites, CNRS, URA 1960, Paris, France	University of Ghana; University of Copenhagen; University of Copenhagen; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Kurtzhals, JAL (corresponding author), Rigshosp, Dept M7641, DK-2200 Copenhagen N, Denmark.	jkcmp@ncs.com.gh	Kurtzhals, Jorgen AL/I-8921-2012; Kurtzhals, Jorgen/Y-3799-2019; Hviid, Lars/G-3705-2012	Kurtzhals, Jorgen/0000-0003-2760-8713; Hviid, Lars/0000-0002-1698-4927				ABDALLA S, 1980, BRIT J HAEMATOL, V46, P171, DOI 10.1111/j.1365-2141.1980.tb05956.x; CLARK IA, 1988, BRIT J HAEMATOL, V70, P99, DOI 10.1111/j.1365-2141.1988.tb02440.x; Clark IA, 1996, ADV PARASIT, V37, P1, DOI 10.1016/S0065-308X(08)60218-3; DAVIS TME, 1990, J CLIN INVEST, V86, P793, DOI 10.1172/JCI114776; ECKWALANGA M, 1994, P NATL ACAD SCI USA, V91, P8097, DOI 10.1073/pnas.91.17.8097; GAZZINELLI RT, 1992, J IMMUNOL, V148, P1792; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; HO M, 1995, J INFECT DIS, V172, P838, DOI 10.1093/infdis/172.3.838; JAKOBSEN PH, 1995, PARASITE IMMUNOL, V17, P223, DOI 10.1111/j.1365-3024.1995.tb01019.x; Jakobsen PH, 1996, CLIN EXP IMMUNOL, V105, P69, DOI 10.1046/j.1365-2249.1996.d01-718.x; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kurtzhals JAL, 1997, BRIT J HAEMATOL, V97, P169, DOI 10.1046/j.1365-2141.1997.82654.x; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; MALEFYT RD, 1991, J EXP MED, V174, P1209; McHugh S, 1996, EUR J IMMUNOL, V26, P1260, DOI 10.1002/eji.1830260612; MOLDAWER LL, 1989, FASEB J, V3, P1637, DOI 10.1096/fasebj.3.5.2784116; MOLYNEUX ME, 1989, Q J MED, V71, P441; Mordmuller BG, 1997, EUR CYTOKINE NETW, V8, P29; MOSMANN T, 1991, IMMUNOL TODAY, V12, P257, DOI 10.1016/0167-5699(91)90121-9; PEYRON F, 1994, CLIN EXP IMMUNOL, V95, P300, DOI 10.1111/j.1365-2249.1994.tb06527.x; PHILLIPS RE, 1992, BAILLIERE CLIN HAEM, V5, P315, DOI 10.1016/S0950-3536(11)80022-3; Pretolani M, 1997, IMMUNOL TODAY, V18, P277, DOI 10.1016/S0167-5699(97)80023-0; RALPH P, 1992, J IMMUNOL, V148, P808; SNOW RW, 1995, PARASITOL TODAY, V11, P188, DOI 10.1016/0169-4758(95)80156-1; TAVERNE J, 1994, IMMUNOLOGY, V82, P397; Tsukahara H, 1997, BLOOD, V90, P473; Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x; VANDERPOLL T, 1994, J EXP MED, V180, P1985, DOI 10.1084/jem.180.5.1985; VANVLASSELAER P, 1994, J CELL BIOL, V124, P569, DOI 10.1083/jcb.124.4.569; VANVLASSELAER P, 1995, CLIN ORTHOP RELAT R, P103; Wang CQ, 1996, J CELL PHYSIOL, V166, P305, DOI 10.1002/(SICI)1097-4652(199602)166:2<305::AID-JCP8>3.0.CO;2-T; Waruiru CM, 1996, T ROY SOC TROP MED H, V90, P152, DOI 10.1016/S0035-9203(96)90120-0; WENISCH C, 1995, J CLIN IMMUNOL, V15, P69, DOI 10.1007/BF01541734; WENISCH C, 1995, CLIN IMMUNOL IMMUNOP, V74, P115, DOI 10.1006/clin.1995.1017; WICKRAMASINGHE SN, 1987, BRIT J HAEMATOL, V66, P295, DOI 10.1111/j.1365-2141.1987.tb06913.x; YAP GS, 1994, INFECT IMMUN, V62, P357, DOI 10.1128/IAI.62.2.357-362.1994	36	248	252	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 13	1998	351	9118					1768	1772		10.1016/S0140-6736(97)09439-7	http://dx.doi.org/10.1016/S0140-6736(97)09439-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635949				2022-12-28	WOS:000074197600010
J	Baylies, MK; Bate, M; Gomez, MR				Baylies, MK; Bate, M; Gomez, MR			Myogenesis: A view from Drosophila	CELL			English	Review							TRANSCRIPTION FACTOR; MUSCLE DEVELOPMENT; EMBRYONIC-DEVELOPMENT; MESODERMAL CELLS; SKELETAL-MUSCLE; TWIST GENE; EMBRYOGENESIS; DIFFERENTIATION; RECEPTOR; PROTEIN		Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	Cornell University; Memorial Sloan Kettering Cancer Center; University of Cambridge	Baylies, MK (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.		Ruiz-Gómez, Mar/K-9266-2014	Ruiz-Gómez, Mar/0000-0002-9024-1400				ABMAYR SM, 1995, TRENDS GENET, V11, P153, DOI 10.1016/S0168-9525(00)89030-7; Abmayr SM, 1998, CURR TOP DEV BIOL, V38, P35; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Azpiazu N, 1996, GENE DEV, V10, P3183, DOI 10.1101/gad.10.24.3183; BAKER R, 1995, DEVELOPMENT, V121, P1387; BATE M, 1991, DEVELOPMENT, V113, P79; BATE M, 1990, DEVELOPMENT, V110, P791; Bate M, 1996, SEMIN CELL DEV BIOL, V7, P103, DOI 10.1006/scdb.1996.0015; BATE M, 1993, CR ACAD SCI III-VIE, V316, P1055; BATE M, 1993, DEV DROSOPHILA METAN, V2, P1013; BAYLIES MK, 1995, DEVELOPMENT, V121, P3829; Baylies MK, 1996, SCIENCE, V272, P1481, DOI 10.1126/science.272.5267.1481; Beiman M, 1996, GENE DEV, V10, P2993, DOI 10.1101/gad.10.23.2993; BERNSTEIN SI, 1993, INT REV CYTOL, V143, P63; Bock E., 1941, WILHELM ROUX ARCH ENTWICKLUNGSMECH ORGAN, V141, P159; BODMER R, 1990, DEVELOPMENT, V110, P661; Borkowski OMD, 1995, DEVELOPMENT, V121, P4183; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; CARMENA A, 1995, GENE DEV, V9, P2373, DOI 10.1101/gad.9.19.2373; Carmena A, 1998, GENE DEV, V12, P304, DOI 10.1101/gad.12.3.304; CHASAN R, 1993, DEV DROSOPHILA MELAN, V1, P387; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; DOHRMANN C, 1990, GENE DEV, V4, P2098, DOI 10.1101/gad.4.12a.2098; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Gisselbrecht S, 1996, GENE DEV, V10, P3003, DOI 10.1101/gad.10.23.3003; Gomez MR, 1997, DEVELOPMENT, V124, P4857; GOMEZ MR, 1997, DEVELOPMENT, V124, P3407; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; Keller CA, 1997, DEV BIOL, V181, P197, DOI 10.1006/dbio.1996.8434; Lawrence PA, 1995, DEVELOPMENT, V121, P4303; LEPTIN M, 1990, DEVELOPMENT, V110, P73; LI L, 1995, DEV BIOL, V121, P1099; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; MAGGERT K, 1995, DEVELOPMENT, V121, P2107; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; RAWIS A, 1997, CELL, V89, P5; Riechmann V, 1997, DEVELOPMENT, V124, P2915; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUSHTON E, 1995, DEVELOPMENT, V121, P1979; STAEHLINGHAMPTO.K, 1994, NATURE, V372, P22; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; TAJBAKHSH S, 1997, GENE DEV, V7, P634; TAYLOR MV, 1995, MECH DEVELOP, V50, P29, DOI 10.1016/0925-4773(94)00323-F; TAYLOR MV, 1995, CURR BIOL, V5, P740, DOI 10.1016/S0960-9822(95)00149-7; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; WU XS, 1995, DEV BIOL, V169, P619, DOI 10.1006/dbio.1995.1174; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; Yin ZZ, 1997, DEVELOPMENT, V124, P4971; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	54	213	220	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					921	927		10.1016/S0092-8674(00)81198-8	http://dx.doi.org/10.1016/S0092-8674(00)81198-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635422	hybrid			2022-12-28	WOS:000074205700004
J	Cole, ST; Brosch, R; Parkhill, J; Garnier, T; Churcher, C; Harris, D; Gordon, SV; Eiglmeier, K; Gas, S; Barry, CE; Tekaia, F; Badcock, K; Basham, D; Brown, D; Chillingworth, T; Connor, R; Davies, R; Devlin, K; Feltwell, T; Gentles, S; Hamlin, N; Holroyd, S; Hornby, T; Jagels, K; Krogh, A; McLean, J; Moule, S; Murphy, L; Oliver, K; Osborne, J; Quail, MA; Rajandream, MA; Rogers, J; Rutter, S; Seeger, K; Skelton, J; Squares, R; Squares, S; Sulston, JE; Taylor, K; Whitehead, S; Barrell, BG				Cole, ST; Brosch, R; Parkhill, J; Garnier, T; Churcher, C; Harris, D; Gordon, SV; Eiglmeier, K; Gas, S; Barry, CE; Tekaia, F; Badcock, K; Basham, D; Brown, D; Chillingworth, T; Connor, R; Davies, R; Devlin, K; Feltwell, T; Gentles, S; Hamlin, N; Holroyd, S; Hornby, T; Jagels, K; Krogh, A; McLean, J; Moule, S; Murphy, L; Oliver, K; Osborne, J; Quail, MA; Rajandream, MA; Rogers, J; Rutter, S; Seeger, K; Skelton, J; Squares, R; Squares, S; Sulston, JE; Taylor, K; Whitehead, S; Barrell, BG			Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence	NATURE			English	Article							ANTIGEN; RESISTANCE; SURVIVAL; LEPRAE; REPEAT; SEARCH; CELLS; GENES; DNA	Countless millions of people have died from tuberculosis, a chronic infectious disease caused by the tubercle bacillus. The complete genome sequence of the best-characterized strain of Mycobacterium tuberculosis, H37Rv, has been determined and analysed in order to improve our understanding of the biology of this slow-growing pathogen and to help the conception of new prophylactic and therapeutic interventions. The genome comprises 4,411,529 base pairs, contains around 4,000 genes, and has a very high guanine + cytosine content that is reflected in the biased amino-acid content of the proteins. M. tuberculosis differs radically from other bacteria in that a very large portion of its coding capacity is devoted to the production of enzymes involved in lipogenesis and lipolysis, and to two new families of glycine-rich proteins with a repetitive structure that may represent a source of antigenic variation.	Sanger Ctr, Hinxton CB10 1SA, England; Inst Pasteur, Unite Genet Mol Bacterienne, F-75724 Paris 15, France; Inst Pasteur, Unite Genet Mol Levures, F-75724 Paris 15, France; NIAID, TB Res Unit, Intracellular Parasites Lab, Rocky Mt Labs,NIH, Hamilton, MT 59840 USA; Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark	Wellcome Trust Sanger Institute; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Technical University of Denmark	Barrell, BG (corresponding author), Sanger Ctr, Wellcome Trust Genome Campus, Hinxton CB10 1SA, England.	stcole@pasteur.fr; barrell@sanger.ac.uk	Azadbakht, Morteza/ABA-2569-2020; Choobkar, Saeed/AAA-3212-2020; Salami, Aysan/AAZ-6730-2020; Barry, Clifton E/ABE-7992-2020; Tekaia, Fredj/H-4553-2012; Parkhill, Julian/G-4703-2011; Barry, III, Clifton/H-3839-2012; Quail, michael/ABE-6131-2020; Brosch, Roland/AAZ-3850-2021; Brosch, Roland/ABB-4108-2021; Krogh, Anders/M-1541-2014	Azadbakht, Morteza/0000-0001-8103-3506; Barry, Clifton E/0000-0002-2927-270X; Parkhill, Julian/0000-0002-7069-5958; Barry, III, Clifton/0000-0002-2927-270X; Brosch, Roland/0000-0003-2587-3863; Gordon, Stephen/0000-0002-4833-5542; Krogh, Anders/0000-0002-5147-6282; Tekaia, Fredj/0000-0003-1934-2396; Murphy, Lee/0000-0001-6467-7449; Davies, Robert/0000-0002-9983-1378	Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000783] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOUZEID C, 1991, INFECT IMMUN, V59, P2712, DOI 10.1128/IAI.59.8.2712-2718.1991; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARRUDA S, 1993, SCIENCE, V261, P1454, DOI 10.1126/science.8367727; Av-Gay Y., 1997, MICROB COMP GENOMICS, V2, P63, DOI DOI 10.1089/OMI.1.1997.2.63; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Bardarov S, 1997, P NATL ACAD SCI USA, V94, P10961, DOI 10.1073/pnas.94.20.10961; BARRY CE, IN PRESS PROG LIPID; BAUMLER AJ, 1994, INFECT IMMUN, V62, P1623; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bloom Barry R., 1994, P531; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; Brennan Patrick J., 1994, P271; Brosch R, 1998, INFECT IMMUN, V66, P2221, DOI 10.1128/IAI.66.5.2221-2229.1998; Chan J, 1994, TUBERCULOSIS PATHOGE, P271; COLE ST, 1995, EUR RESPIR J, V8, pS701; COLE ST, 1994, FEMS MICROBIOL REV, V14, P139, DOI 10.1016/0168-6445(94)90003-5; Cole ST, 1998, NOVART FDN SYMP, V217, P160, DOI 10.1002/0470846526.ch12; Collins DM, 1996, TRENDS MICROBIOL, V4, P426, DOI 10.1016/0966-842X(96)10066-4; FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013; Freiberg C, 1997, NATURE, V387, P394, DOI 10.1038/387394a0; GOBIN J, 1995, P NATL ACAD SCI USA, V92, P5189, DOI 10.1073/pnas.92.11.5189; Greenacre Michael, 1984, THEORY APPL CORRES A; HERMANS PWM, 1992, J BACTERIOL, V174, P4157, DOI 10.1128/jb.174.12.4157-4165.1992; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; KROGH A, 1994, NUCLEIC ACIDS RES, V22, P4768, DOI 10.1093/nar/22.22.4768; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; McMurray AA, 1998, GENOME RES, V8, P562, DOI 10.1101/gr.8.5.562; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; POULET S, 1995, ARCH MICROBIOL, V163, P87, DOI 10.1007/s002030050176; RATLEDGE CR, 1982, BIOL MYCOBACTERIA, P53; Riley M., 1996, ESCHERICHIA COLI SAL, P2118; ROBERTSON BD, 1992, TRENDS GENET, V8, P422, DOI 10.1016/0168-9525(92)90325-X; Smith DR, 1997, GENOME RES, V7, P802, DOI 10.1101/gr.7.8.802; SNIDER DE, 1994, TUBERCULOSIS PATHOGE, P2; SORENSEN AL, 1995, INFECT IMMUN, V63, P1710; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; VEGALOPEZ F, 1993, INFECT IMMUN, V61, P2145; Wheeler Paul R., 1994, P353; YOUNG DB, 1997, NEW GENERATION VACCI, P631	50	6154	10750	16	703	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					537	+		10.1038/31159	http://dx.doi.org/10.1038/31159			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634230	Bronze			2022-12-28	WOS:000074150100041
J	van Poppel, MNM; Koes, BW; van der Ploeg, T; Smid, T; Bouter, LM				van Poppel, MNM; Koes, BW; van der Ploeg, T; Smid, T; Bouter, LM			Lumbar supports and education for the prevention of low back pain in industry - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRUNK MUSCLE STRENGTH; INJURY; BELTS	Context.-Low back pain is a frequent and costly health problem. Prevention of low back pain is important both for the individual patient and from an economic perspective, Objective.-To assess the efficacy of lumbar supports and education in the prevention of low back pain in industry. Design.-A randomized controlled trial with a factorial design, Setting.-The cargo department of an airline company in the Netherlands. Participants.-A total of 312 workers were randomized, of whom 282 were available for the 6-month follow-up. Interventions.-Subjects were randomly assigned to 4 groups: (1) education (lifting instructions) and lumbar support, (2) education, (3) lumbar support, and (4) no intervention. Education consisted of 3 group sessions on lifting techniques with a total duration of 5 hours. Lumbar supports were recommended to be used during working hours for 6 months, Main Outcome Measures.-Low back pain incidence and sick leave because of back pain during the 6-month intervention period. Results.-Compliance with wearing the lumbar support at least half the time was 43%. In the 282 subjects for whom data were available, no statistically significant differences in back pain incidence (48 [36%] of 134 with lumbar support vs 51 [34%] of 148 without, P=.81) or in sick leave because of low back pain (mean, 0.4 days per month with lumbar support vs 0.4 days without, P=.52) were found among the intervention groups. In a subgroup of subjects with low back pain at baseline, lumbar supports reduced the number of days with low back pain per month (median, 1,2 vs 6.5 days per month; P=.03). Conclusions.-Overall, lumbar supports or education did not lead to a reduction in low back pain incidence or sick leave, The results of the subgroup analysis need to be confirmed by future research. Based on our results, the use of education or lumbar supports cannot be recommended in the prevention of low back pain in industry.	Vrije Univ Amsterdam, Fac Med, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands; Vrije Univ Amsterdam, Fac Movement Sci, NL-1081 BT Amsterdam, Netherlands; KLM Royal Dutch Airlines, Dept Hlth Safety & Environm, Schiphol Airport, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	van Poppel, MNM (corresponding author), Vrije Univ Amsterdam, Fac Med, Inst Res Extramural Med, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	mnm.van_poppet.emgo@med.vu.nl	Koes, Bart w/K-4614-2016; Van Poppel, Mireille/AAL-8228-2020	Koes, Bart w/0000-0002-0450-9969; Van Poppel, Mireille/0000-0001-5694-4324; Bouter, Lex/0000-0002-2659-5482				ALEXANDER A, 1995, PROF SAF, V40, P22; Altman D.G., 1991, PRACTICAL STAT MED R; ANDERSON CK, 1993, EFFECTIVENESS USING; ANDERSSON GBJ, 1991, ADULT SPINE PRINCIPL, P107; BARRON BA, 1994, J OCCUP REHABIL, V4, P125, DOI 10.1007/BF02109969; BIERINGSORENSEN F, 1984, SPINE, V9, P106, DOI 10.1097/00007632-198403000-00002; DALTROY LH, 1993, HEALTH EDUC QUART, V20, P43, DOI 10.1177/109019819302000106; Daltroy LH, 1997, NEW ENGL J MED, V337, P322, DOI 10.1056/NEJM199707313370507; Dijkstra A, 1981, FUNKTIONEREN ARBEIDS; DONCHIN M, 1990, SPINE, V15, P1317, DOI 10.1097/00007632-199012000-00015; FELDSTEIN A, 1993, J OCCUP ENVIRON MED, V35, P114, DOI 10.1097/00043764-199302000-00010; FRYMOYER JW, 1991, ORTHOP CLIN N AM, V22, P263; GENAIDY AM, 1995, ERGONOMICS, V38, P996, DOI 10.1080/00140139508925166; HOLMSTROM E, 1992, J SPINAL DISORD, V5, P260, DOI 10.1097/00002517-199209000-00003; HYYTIAINEN K, 1991, SCAND J REHABIL MED, V23, P3; KOES BW, 1994, EUR J PHYS MED REHAB, V4, P86; Kraus, 1996, Int J Occup Environ Health, V2, P264; LAHAD A, 1994, JAMA-J AM MED ASSOC, V272, P1286, DOI 10.1001/jama.272.16.1286; Larson C O, 1992, Qual Life Res, V1, P247, DOI 10.1007/BF00435633; National Institute for Occupational Safety and Health, 1994, DHHS PUBL, V94-113; Oja P., 1995, EUROFIT ADULTS ASSES; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P83; Schulz KF, 1996, BRIT MED J, V312, P742; Thompson L, 1994, Work, V4, P22, DOI 10.3233/WOR-1994-4104; van Poppel MNM, 1997, OCCUP ENVIRON MED, V54, P841, DOI 10.1136/oem.54.12.841; Van Weel C., 1992, FUNCTIONAL STATUS AS; VERSLOOT JM, 1992, SPINE, V17, P22, DOI 10.1097/00007632-199201000-00004; WALSH NE, 1990, AM J PHYS MED REHAB, V69, P245, DOI 10.1097/00002060-199010000-00004; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	30	93	94	1	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1789	1794		10.1001/jama.279.22.1789	http://dx.doi.org/10.1001/jama.279.22.1789			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZR635	9628709	Green Published, Bronze			2022-12-28	WOS:000073998500030
J	Beecham, L				Beecham, L			New members elected to medical advisory committee	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1754	1754						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614048				2022-12-28	WOS:000074129500084
J	Taylor, G				Taylor, G			Underperforming doctors: a postal survey of the northern Deanery	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To discover the perceived size of pool of doctors considered to be underperforming in general practice in the Northern Deanery and to discover whether these perceptions are based on formal assessments. Design: Postal questionnaire. Setting: Area covered by the Northern Deanery. Subjects: Seven health authority directors of primary care, seven secretaries of local medical committees, and 14 chief officers of community health councils. Results: The response rate was 100% for directors of primary care and secretaries of local medical committees and, after one reminder, 92% for chief officers of community health councils. Numbers of doctors perceived to be underperforming ranged from none to over 15 in different health authority areas. Main areas for concern were communication skills, clinical skills, and management skills. Patients' representatives were concerned about lack of power of patients and health authorities and doctors' lack of accountability. Health authorities were concerned about lack of power, identification of underperforming doctors, and doctors' professional loyalty. Local medical committees were concerned about the problem of identifying underperformance. A number of methods were used for identification, and there was no common method applied. Conclusions: The number of doctors thought to be underperforming was small. Work still needs to be done on developing tools that can be used in everyday practice to enable doctors to confirm for themselves, their colleagues, and their patients that they are providing an adequate level of care.	Univ Newcastle Upon Tyne, Postgrad Inst Med & Dent, Newcastle Upon Tyne NE2 4AB, Tyne & Wear, England	Newcastle University - UK	Taylor, G (corresponding author), Univ Newcastle Upon Tyne, Postgrad Inst Med & Dent, Newcastle Upon Tyne NE2 4AB, Tyne & Wear, England.							BRITTEN N, 1995, FAM PRACT, V12, P104, DOI 10.1093/fampra/12.1.104; *DEP HLTH NHS EX, 1997, GMS STAT ENGL WAL; Fink A., 1985, CONDUCT SURVEYS; *GEN MED COUNC, 1997, NEW PERF PROC; *KINGS FUND, 1993, KINGS FUND ORG AUD P; NEWBLE D, 1994, CERTIFICATION RECERT, P184; *NHS EX, 1998, NEW NHS MOD DEP NAT; *ROYAL COLL GEN PR, 1997, RCGP CLIN PRACT EV P; *ROYAL COLL GEN PR, 1997, 50 RCGP	9	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1705	1708		10.1136/bmj.316.7146.1705	http://dx.doi.org/10.1136/bmj.316.7146.1705			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614017	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000074129500018
J	Jones, TW; Porter, P; Sherwin, RS; Davis, EA; O'Leary, P; Frazer, F; Byrne, G; Stick, S; Tamborlane, WV				Jones, TW; Porter, P; Sherwin, RS; Davis, EA; O'Leary, P; Frazer, F; Byrne, G; Stick, S; Tamborlane, WV			Decreased epinephrine responses to hypoglycemia during sleep	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; NOCTURNAL HYPOGLYCEMIA; HORMONAL COUNTERREGULATION; GLUCOSE COUNTERREGULATION; SUBSEQUENT HYPOGLYCEMIA; INSULIN THERAPY; NERVE ACTIVITY; HUMANS	Background In patients with type I diabetes mellitus, hypoglycemia occurs commonly during sleep and is frequently asymptomatic. This raises the question of whether sleep is associated with reduced counterregulatory-hormone responses to hypoglycemia. Methods We studied the counterregulatory-hormone responses to insulin-induced hypoglycemia in eight adolescent patients with type I diabetes and six age-matched normal subjects when they were awake during the day, asleep at night, and awake at night. In each study, the plasma glucose concentration was stabilized for 60 minutes at approximately 100 mg per deciliter (5.6 mmol per liter) and then reduced to 50 mg per deciliter (2.8 mmol per liter) and maintained at that concentration for 40 minutes. Plasma free insulin, epinephrine, norepinephrine, cortisol, and growth hormone were measured frequently during each study. Sleep was monitored by polysomnography. Results The plasma glucose and free insulin concentrations were similar in both groups during all studies. During the studies when the subjects were asleep, no one was awakened during the hypoglycemic phase, but during the final 30 minutes of the studies when the subjects were awake both the patients with diabetes and the normal subjects had symptoms of hypoglycemia. In the patients with diabetes, plasma epinephrine responses to hypoglycemia were blunted when they were asleep (mean [+/-SE] peak plasma epinephrine concentration, 70+/-14 pg per milliliter [382+/-76 pmol per liter]; P=0.3 for the comparison with base line), as compared with when they were awake during the day or night (238+/-39 pg per milliliter [1299+/-213 pmol per liter], P=0.004 for the comparison with base line, and 296+/-60 pg per milliliter [1616+/-327 pmol per liter], P=0.004, respectively). The patients' plasma norepinephrine responses were also reduced during sleep, whereas their plasma cortisol concentrations did not increase and their plasma growth hormone concentrations increased, slightly. The patterns of counterregulatory-hormone responses in the normal subjects were similar. Conclusions Sleep impairs counterregulatory-hormone responses to hypoglycemia in patients with diabetes and normal subject. (C) 1998, Massachusetts Medical Society.	Princess Margaret Hosp Children, Dept Endocrinol & Diabet, Perth, WA 6001, Australia; Princess Margaret Hosp Children, Dept Resp Med, Perth, WA 6001, Australia; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA	University of Western Australia; University of Western Australia; Yale University; Yale University	Jones, TW (corresponding author), Princess Margaret Hosp Children, Dept Endocrinol & Diabet, Box D184, Perth, WA 6001, Australia.		Porter, Paul/R-2362-2018; Stick, Stephen/AAA-5945-2021; Stick, Stephen/GZG-7584-2022; Stick, Stephen/O-5683-2014	Porter, Paul/0000-0001-9051-589X; Stick, Stephen/0000-0002-5386-8482; Davis, Elizabeth/0000-0003-4244-5473; Jones, Timothy/0000-0002-7989-1998; O'Leary, Peter/0000-0001-9375-0801	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00125, RR06020] Funding Source: Medline; PHS HHS [10495] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMIEL SA, 1987, NEW ENGL J MED, V316, P1376, DOI 10.1056/NEJM198705283162205; BENDTSON I, 1993, ACTA ENDOCRINOL-COP, V128, P109, DOI 10.1530/acta.0.1280109; BOLLI G, 1983, DIABETES, V32, P134, DOI 10.2337/diabetes.32.2.134; CADUFF F, 1989, SCHWEIZ MED WSCHR, V119, P9; CRYER PE, 1989, DIABETES, V38, P1193, DOI 10.2337/diabetes.38.9.1193; CRYER PE, 1994, DIABETES CARE, V17, P734, DOI 10.2337/diacare.17.7.734; DAGOGOJACK SE, 1993, J CLIN INVEST, V91, P819, DOI 10.1172/JCI116302; Davis EA, 1997, DIABETES CARE, V20, P22, DOI 10.2337/diacare.20.1.22; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; GALE EAM, 1979, LANCET, V1, P1049; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; HORNYAK M, 1991, BRAIN, V114, P1281, DOI 10.1093/brain/114.3.1281; Kryger M, 1994, PRINCIPLES PRACTICE; Maggs DG, 1997, DIABETES, V46, P70, DOI 10.2337/diabetes.46.1.70; OKADA H, 1991, NEUROLOGY, V41, P1961, DOI 10.1212/WNL.41.12.1961; Porter PA, 1996, ARCH DIS CHILD, V75, P120, DOI 10.1136/adc.75.2.120; SHALWITZ RA, 1990, J PEDIATR-US, V116, P685, DOI 10.1016/S0022-3476(05)82648-4; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIMONSON DC, 1985, ANN INTERN MED, V103, P184, DOI 10.7326/0003-4819-103-2-184; VENEMAN T, 1993, DIABETES, V42, P1233, DOI 10.2337/diabetes.42.9.1233	20	182	182	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1998	338	23					1657	1662		10.1056/NEJM199806043382303	http://dx.doi.org/10.1056/NEJM199806043382303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR451	9614256	Bronze			2022-12-28	WOS:000073978000003
J	Noah, DL; Drenzek, CL; Smith, JS; Krebs, JW; Orciari, L; Shaddock, J; Sanderlin, D; Whitfield, S; Fekadu, M; Olson, JG; Rupprecht, CE; Childs, JE				Noah, DL; Drenzek, CL; Smith, JS; Krebs, JW; Orciari, L; Shaddock, J; Sanderlin, D; Whitfield, S; Fekadu, M; Olson, JG; Rupprecht, CE; Childs, JE			Epidemiology of human rabies in the United States, 1980 to 1996	ANNALS OF INTERNAL MEDICINE			English	Review							SURVEILLANCE	Purpose: To summarize the epidemiologic, diagnostic, and clinical features of the 32 laboratory-confirmed cases of human rabies diagnosed in the United States from 1980 to 1996. Data Sources: Data were obtained from case reports of human rabies submitted to the Centers for Disease Control and Prevention by state or local health authorities. Study Selection: All cases of human rabies reported in the United States from 1980 to 1996 in which infection with rabies virus was confirmed by laboratory studies. Data Extraction: Patients were reviewed for demographic characteristics, exposure history, rabies prophylaxis, clinical presentation, treatment, clinical course, diagnostic laboratory tests, identification of rabies virus variants, and the number of medical personnel or family members who required postexposure prophylaxis after coming in contact with an exposed person. Data Synthesis: 32 cases of human rabies were reported from 20 states. Patients ranged in age from 4 to 82 years and were predominantly male (63%). Most patients (25 of 32) had no definite history of an animal bite or other event associated with rabies virus transmission. Of the 32 cases, 17 (53%) were associated with rabies virus variants found in insectivorous bats, 12 (38%) with variants found in domestic dogs outside the United States, 2 (6%) with variants found in indigenous domestic dogs, and 1 (3%) with a variant found in indigenous skunks. Among the 7 patients with a definite exposure history, 6 cases were attributable to dog bites received in foreign countries and 1 was attributable to a bat bite received in the United States. In 12 of the 32 patients (38%), rabies was not clinically suspected and was diagnosed after death. In the remaining 20 cases (63%), the diagnosis of rabies was considered before death and samples were obtained specifically for laboratory confirmation a median of 7 days (range, 3 to 17 days) after the onset of clinical signs. Of the clinical differences between patients in whom rabies was diagnosed before death and those in whom it was diagnosed after death, the presence of hydrophobia or aerophobia was significantly associated with antemortem diagnosis (odds ratio, 11.0 [95% CI, 1.05 to 273.34]). The median number of medical personnel or familial contacts of the patients who received postexposure prophylaxis was 54 per patient (range, 4 to 179). None of the 32 patients with rabies received postexposure prophylaxis before the onset of clinical disease. Conclusions: In the United States, human rabies is rare, but probably underdiagnosed. Rabies should be included in the differential diagnosis of any case of acute, rapidly progressing encephalitis, even if the patient does not recall being bitten by an animal. In addition to situations involving an animal bite, a scratch from an animal, or contact of mucous membranes with infectious saliva, post-exposure prophylaxis should be considered if the history indicates that a bat was physically present, even if the person is unable to reliably report contact that could have resulted in a bite. Such a situation may arise when a bat bite causes an insignificant wound or the circumstances do not allow recognition of contact, such as when a bat is found in the room of a sleeping person or near a previously unattended child.	Ctr Dis Control & Prevent, Viral & Rickettsial Zoonoses Branch, Atlanta, GA 30333 USA; Ctr Dis Control, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Childs, JE (corresponding author), Ctr Dis Control & Prevent, Viral & Rickettsial Zoonoses Branch, 1600 Clifton Rd,Mailstop G-13, Atlanta, GA 30333 USA.		Rupprecht, Charles/AAI-1544-2020; Childs, James E/B-4002-2012					AFSHAR A, 1979, BRIT VET J, V135, P142, DOI 10.1016/S0007-1935(17)32935-4; ANDERSON LJ, 1984, ANN INTERN MED, V100, P728, DOI 10.7326/0003-4819-100-5-728; [Anonymous], MMWR; CHILDS JE, 1994, EPIDEMIOL INFECT, V113, P501, DOI 10.1017/S0950268800068515; Dean A.G., 1994, EPI INFO VERSION 6 W; FISHBEIN DB, 1991, NATURAL HIST RABIES, P526; HELD JR, 1967, PUBLIC HEALTH REP, V82, P1009, DOI 10.2307/4593183; HELMICK CG, 1983, JAMA-J AM MED ASSOC, V250, P1990, DOI 10.1001/jama.250.15.1990; HELMICK CG, 1987, REV INFECT DIS, V9, P511; Hemachudha T, 1994, Curr Top Microbiol Immunol, V187, P121; Human rabies-Alabama Tennessee and Texas, 1994, MMWR MORB MORTAL WKL, V44, P269; Human rabies-Connecticut, 1995, MMWR MORB MORTAL WKL, V45, P207; Human rabies-Kentucky and Montana, 1996, MMWR MORB MORTAL WKL, V46, P397; Human rabies-Texas and California, 1993, MMWR MORB MORTAL WKL, V43, P93; Krebs JW, 1995, J AM VET MED ASSOC, V207, P1562; KREBS JW, 1993, J AM VET MED ASSOC, V203, P1718; KUNZ T.H., 1994, WALKERS BATS WORLD, P1; NORUSIS MJ, 1993, SPSS WINDOWS 6 0; SMITH JS, 1992, J INFECT DIS, V166, P296, DOI 10.1093/infdis/166.2.296; Smith JS, 1995, SEMIN VIROL, V6, P387, DOI 10.1016/S1044-5773(05)80016-2; SMITH JS, 1991, NEW ENGL J MED, V324, P205, DOI 10.1056/NEJM199101243240401; SMITH JS, 1986, J CLIN MICROBIOL, V24, P573, DOI 10.1128/JCM.24.4.573-580.1986; SMITH JS, 1995, MANUAL CLIN MICROBIO; Smith JS, 1991, NATURAL HIST RABIES, P533; *WHO, 1990, WORKSH RAB CONTR AS; 1985, MMWR MORB MORTAL WKL, V34, P705; 1991, MMWR MORB MORTAL WKL, V40, P1; 1994, MMWR MORB MORTAL WKL, V44, P86; 1989, MMWR MORB MORTAL WKL, V38, P335; 1983, MMWR MORB MORTAL WKL, V32, P159; 1985, MMWR MORB MORTAL WKL, V34, P235; 1996, MMWR MORB MORTAL WKL, V45, P719; 1992, MMWR MORB MORTAL WKL, V41, P461; 1991, MMWR MORB MORTAL WKL, V40, P765; 1995, MMWR MORB MORTAL WKL, V44, P93; 1994, MMWR MORB MORTAL WKL, V43, P455; 1982, MMWR MORB MORTAL WKL, V31, P135; 1984, MMWR MORB MORTAL WKL, V33, P469; 1985, MMWR MORB MORTAL WKL, V34, P700; 1983, MMWR MORB MORTAL WKL, V32, P494; 1981, MMWR MORB MORTAL WKL, V30, P537; 1995, MMWR MORB MORTAL WKL, V44, P625; 1988, MMWR MORB MORTAL WKL, V37, P305; 1995, MMWR MORB MORTAL WKL, V44, P484; 1983, MMWR MORB MORTAL WKL, V32, P78; 1997, MMWR MORB MORTAL WKL, V46, P267; 1993, MMWR MORB MORTAL WKL, V42, P805; 1994, MMWR MORB MORTAL WKL, V43, P773; 1996, MMWR MORB MORTAL WKL, V45, P727; 1984, MMWR MORB MORTAL WKL, V33, P633; 1981, MMWR MORB MORTAL WKL, V30, P343; 1996, MMWR MORB MORTAL WKL, V45, P353; 1991, MMWR MORB MORTAL WKL, V40, P132	53	164	174	1	25	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					922	930		10.7326/0003-4819-128-11-199806010-00012	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00012			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634432				2022-12-28	WOS:000073808600008
J	Astin, JA				Astin, JA			Why patients use alternative medicine - Results of a national study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPLEMENTARY MEDICINE; UNITED-STATES; CARE; PRACTITIONERS; SOMATIZATION; PREVALENCE; THERAPIES; ATTITUDES; BEHAVIORS; DOCTORS	Context.-Research both in the United States and abroad suggests that significant numbers of people are involved with various forms of alternative medicine. However, the reasons for such use are, at present, poorly understood. Objective.-To investigate possible predictors of alternative health care use. Methods.-Three primary hypotheses were tested. People seek out these alternatives because (1) they are dissatisfied in some way with conventional treatment; (2) they see alternative treatments as offering more personal autonomy and control over health care decisions; and (3) the alternatives are seen as more compatible with the patients' values, worldview, or beliefs regarding the nature and meaning of health and illness. Additional predictor variables explored included demographics and health status. Design.-A written survey examining use of alternative health care, health status, values, and attitudes toward conventional medicine. Multiple logistic regression analyses were used in an effort to identify predictors of alternative health care use. Setting and Participants.-A total of 1035 individuals randomly selected from a panel who had agreed to participate in mail surveys and who live throughout the United States. Main Outcome Measure.-Use of alternative medicine within the previous year. Results.-The response rate was 69%. The following variables emerged as predictors of alternative health care use: more education (odds ratio [OR], 1.2; 95% confidence interval [CI], 1.1-1.3); poorer health status (OR, 1.3, 95% CI, 1.1-1.5); a holistic orientation to health (OR, 1.4; 95% CI, 1.1-1.9); having had a transformational experience that changed the person's worldview (OR, 1.8; 95% CI, 1.3-2.5); any of the following health problems: anxiety (OR, 3.1; 95% CI, 1.6-6.0); back problems (OR, 2.3; 95% CI, 1.7-3.2); chronic pain (OR, 2.0; 95% CI, 1.1-3.5); urinary tract problems (OR, 2.2; 95% CI, 1.3-3.5); and classification in a cultural group identifiable by their commitment to environmentalism, commitment to feminism, and interest in spirituality and personal growth psychology (OR, 2.0; 95% CI, 1.4-2.7). Dissatisfaction with conventional medicine did not predict use of alternative medicine. Only 4.4% of those surveyed reported relying primarily on alternative therapies. Conclusion.-Along with being more educated and reporting poorer health status, the majority of alternative medicine users appear to be doing so not so much as a result of being dissatisfied with conventional medicine but largely because they find these health care alternatives to be more congruent with their own values, beliefs, and philosophical orientations toward health and life.	Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, Palo Alto, CA 94304 USA	Stanford University	Astin, JA (corresponding author), Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, 730 Welch Rd, Palo Alto, CA 94304 USA.							AVINA RL, 1978, WESTERN J MED, V128, P366; BARSKY AJ, 1995, JAMA-J AM MED ASSOC, V274, P1931, DOI 10.1001/jama.274.24.1931; Bernstein JH, 1997, SOC SCI MED, V44, P1341, DOI 10.1016/S0277-9536(97)84076-2; BORKAN J, 1994, J FAM PRACTICE, V39, P545; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; CHARLTON BG, 1993, J ROY SOC MED, V86, P125; DEAN K, 1981, SOC SCI MED-MED SOC, V15, P673, DOI 10.1016/0271-7123(81)90091-2; Dimmock S, 1996, CLIN RHEUMATOL, V15, P478, DOI 10.1007/BF02229645; Duggan R M, 1995, Altern Ther Health Med, V1, P28; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Fuller R., 1989, ALTERNATIVE MED AM R; FURNHAM A, 1988, SOC SCI MED, V26, P685, DOI 10.1016/0277-9536(88)90060-3; FURNHAM A, 1993, BRIT J CLIN PSYCHOL, V32, P237, DOI 10.1111/j.2044-8260.1993.tb01051.x; FURNHAM A, 1994, J CLIN PSYCHOL, V50, P458, DOI 10.1002/1097-4679(199405)50:3<458::AID-JCLP2270500318>3.0.CO;2-V; JENSEN P, 1990, ACTA DERM-VENEREOL, V70, P425; KLEINMAN A, 1984, ALTERNATIVE MED POPU; Kraemer HC, 1997, ARCH GEN PSYCHIAT, V54, P337; Kuhn T.S., 1970, STRUCTURE SCI REVOLU, P174; LEVIN JS, 1986, SOC SCI MED, V23, P889, DOI 10.1016/0277-9536(86)90217-0; LIPOWSKI ZJ, 1988, AM J PSYCHIAT, V145, P1358; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; MARQUIS MS, 1983, MED CARE, V21, P821, DOI 10.1097/00005650-198308000-00006; McGuire Meredith, 1988, RITUAL HEALING SUBUR; Millar WJ, 1997, CAN J PUBLIC HEALTH, V88, P154, DOI 10.1007/BF03403879; MURRAY RH, 1992, NEW ENGL J MED, V326, P61, DOI 10.1056/NEJM199201023260113; Ostrow MJ, 1997, J ACQ IMMUN DEF SYND, V15, P115, DOI 10.1097/00042560-199706010-00003; OTHS K, 1994, CULT MED PSYCHIAT, V18, P83, DOI 10.1007/BF01384878; PERKIN MR, 1994, J ROY SOC MED, V87, P523; RAY PH, 1997, AM DEMOGRAPHICS  FEB; RAY PH, IN PRESS CULTURAL CR; RIESMANN F, 1994, SOC POLICY       SPR, P53; SALMON JW, 1984, ALTERNATIVE MED POPU; SUTHERLAND LR, 1994, J CLIN GASTROENTEROL, V19, P194, DOI 10.1097/00004836-199410000-00004; Vincent C, 1996, BRIT J CLIN PSYCHOL, V35, P37, DOI 10.1111/j.2044-8260.1996.tb01160.x	34	1904	1948	9	230	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1548	1553		10.1001/jama.279.19.1548	http://dx.doi.org/10.1001/jama.279.19.1548			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZN087	9605899	Bronze			2022-12-28	WOS:000073608100033
J	Lees, KR				Lees, KR			Does neuroprotection improve stroke outcome?	LANCET			English	Editorial Material							DOUBLE-BLIND; TRIAL		Univ Glasgow, Western Infirm, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Lees, KR (corresponding author), Univ Glasgow, Western Infirm, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland.							Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Bath P, 1997, BRIT MED J, V315, P1167; CANDELISE L, 1995, LANCET, V346, P1509; Davis SM, 1997, LANCET, V349, P32, DOI 10.1016/S0140-6736(05)62166-6; Diener HC, 1998, CEREBROVASC DIS, V8, P172, DOI 10.1159/000015847; Diener HC, 1996, STROKE, V27, P76, DOI 10.1161/01.STR.27.1.76; DONNAN GA, 1995, LANCET, V345, P578; Dyker Alexander G., 1997, Stroke, V28, P233; Grotta J, 1997, STROKE, V28, P2338, DOI 10.1161/01.STR.28.12.2338; Hommel M, 1996, NEW ENGL J MED, V335, P145; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MUIR KW, 1995, STROKE, V26, P1183, DOI 10.1161/01.STR.26.7.1183; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; MUIR KW, 1996, CEREBROVASC DIS, V6; Ronning OM, 1998, STROKE, V29, P58, DOI 10.1161/01.STR.29.1.58; Sandercock P, 1997, LANCET, V349, P1569; Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5; Weir CJ, 1997, BMJ-BRIT MED J, V314, P1303, DOI 10.1136/bmj.314.7090.1303	18	47	47	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 16	1998	351	9114					1447	1448		10.1016/S0140-6736(05)78865-6	http://dx.doi.org/10.1016/S0140-6736(05)78865-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605797				2022-12-28	WOS:000073707300003
J	Karin, M				Karin, M			New twists in gene regulation by glucocorticoid receptor: Is DNA binding dispensable?	CELL			English	Review							NF-KAPPA-B; CELL-DEATH; HORMONE; TRANSCRIPTION; INTERFERENCE; INHIBITION; REPRESSION; APOPTOSIS; ELEMENT; DOMAIN		Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.							AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; Felig P., 1987, ENDOCRINOLOGY METABO, V2nd Ed; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Meister M, 1997, BIOESSAYS, V19, P1019, DOI 10.1002/bies.950191112; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	20	267	286	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					487	490		10.1016/S0092-8674(00)81177-0	http://dx.doi.org/10.1016/S0092-8674(00)81177-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604923	Bronze			2022-12-28	WOS:000073722200001
J	Morrison, J; Wickersham, P				Morrison, J; Wickersham, P			Physicians disciplined by a state medical board	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPAIRED PHYSICIANS; MALPRACTICE; EXPERIENCE; CLAIMS; RISK; CARE	Context.-State medical boards discipline several thousand physicians each year. Although certain subgroups, such as those disciplined for malpractice. substance use, or sexual abuse, have been studied, little is known about disciplined physicians as a group. Objective.-To assess the offenses, contributing factors, and type of discipline of a consecutive series of disciplined physicians. Design.-Case-control study on publicly available data matching 375 disciplined physicians with 2 groups of control physicians, one matched solely by locale, and a second matched for sex, type of practice, and locale. Subjects.-All disciplined physicians publicly reported by the Medical Board of California from October 1995 through April 1997. Main Outcome Measures.-Characteristics of disciplined physicians, offenses leading to discipline, and type of discipline. Results.-A total of 375 physicians licensed by the Medical Board of California (approximately 0.24% per year) were disciplined for 465 offenses. The most frequent causes for discipline were negligence or incompetence (34%), abuse of alcohol or other drugs (14%), inappropriate prescribing practices (11%), inappropriate contact with patients (10%), and fraud (9%). Discipline imposed was revocation of medical license (21%), actual suspension of license (13%), stayed suspension of license (45%), and reprimand (21%). Type of offense was significantly associated with severity of discipline (P=.03). In logistic regression models comparing disciplined physicians with controls matched by locale: board discipline was significantly associated with physicians' sex (odds ratio [OR] for women, 0.44; 95% confidence interval [CI], 0.28-0.70) and involvement in direct patient care (ORI 2.56 95% CI, 1.75-3.75). In the regression model with additional matching criteria, disciplinary action was negatively associated with specialty board certification (OR, 0.42; 95% CI, 0.29-0.60) and positively associated with being in practice more than 20 years (OR, 2.02; 95% CI, 1.39-2.92). Conclusions.-A small but substantial proportion of physicians is disciplined each year for a variety of offenses. Further study of disciplined physicians is necessary to identify physicians at high risk for offenses leading to disciplinary action and to develop effective interventions to prevent these offenses.	Dept Vet Affairs Med Ctr, Coatesville, PA USA; Wyeth Ayerst Res, Dept Clin Biostat, Radnor, PA USA	Pfizer	Morrison, J (corresponding author), VAMC Coatesville, 1400 Black Horse Hill Rd, Coatesville, PA 19320 USA.							Adamson TE, 1997, WESTERN J MED, V166, P37; Agresti A., 1990, CATEGORICAL DATA ANA, pXV; *AM MED ASS, 1996, DIR PHYS US; BISSELL L, 1987, JAMA-J AM MED ASSOC, V257, P2932; BLOOM JD, 1989, WESTERN J MED, V151, P336; BOVBJERG RR, 1994, JAMA-J AM MED ASSOC, V272, P1421, DOI 10.1001/jama.272.18.1421; BRESLOW NE, 1980, CANC RES ANAL CASE C, V1; CHARLES SC, 1992, WESTERN J MED, V157, P433; DONALDSON LJ, 1994, BRIT MED J, V308, P1277, DOI 10.1136/bmj.308.6939.1277; Enbom JA, 1997, AM J OBSTET GYNECOL, V176, P1340, DOI 10.1016/S0002-9378(97)70355-7; *FED STAT MED BOAR, 1997, SUMM 1996 BOARD ACT; GALANTER M, 1990, AM J PSYCHIAT, V147, P64; Gallegos K V, 1988, QRB Qual Rev Bull, V14, P116; Goodwin J, 1994, J Am Med Womens Assoc (1972), V49, P19; Grunfeld Berthold, 1993, Tidsskrift for den Norske Laegeforening, V113, P1744; Jost T S, 1993, Health Matrix Clevel, V3, P309; KOFOED L, 1989, WESTERN J MED, V150, P597; KUSSEROW RP, 1987, JAMA-J AM MED ASSOC, V257, P820; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; *MED BOARD CAL, 1997, 1996 97 ANN REP; POST J, 1991, B NEW YORK ACAD MED, V67, P66; SCHAFFER WA, 1988, NEW ENGL J MED, V318, P356, DOI 10.1056/NEJM198802113180605; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCHWARTZ RP, 1995, J ADDICT DIS, V14, P13, DOI 10.1300/J069v14n02_02; SCHWARTZ WB, 1989, JAMA-J AM MED ASSOC, V262, P1335, DOI 10.1001/jama.262.10.1335; SHORE JH, 1987, JAMA-J AM MED ASSOC, V257, P2931; SLAWSON PF, 1984, AM J PSYCHIAT, V141, P979; TALBOTT GD, 1987, JAMA-J AM MED ASSOC, V257, P2927, DOI 10.1001/jama.257.21.2927; TARAGIN MI, 1992, AM J MED, V93, P537, DOI 10.1016/0002-9343(92)90582-V; *VET ADM, 1986, 6ABA99147 VET ADM	30	135	136	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1998	279	23					1889	1893		10.1001/jama.279.23.1889	http://dx.doi.org/10.1001/jama.279.23.1889			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT653	9634260	Bronze			2022-12-28	WOS:000074109700036
J	Hewson, MG				Hewson, MG			Traditional healers in southern Africa	ANNALS OF INTERNAL MEDICINE			English	Article							CARE	One task of medical anthropologists is to search for similarities and differences among cultural conceptions of illness and healing. This search may identify common, if not universal, characteristics of healing and effective patient care. This paper describes traditional healing practices in southern Africa as related by six traditional healers. Despite the seemingly exotic nature of their practice, the traditional healers' underlying strategies (probing deeply into the psychological, spiritual, and social contexts of illness and using healing ceremonies and natural medicinal preparations) seem to be effective in certain circumstances. Perhaps more important, these strategies can leave both patient and practitioner with a sense of connection and satisfaction. A study of these strategies reveals some general qualities of the healing process that are more apparent in the absence of sophisticated technology.	Cleveland Clin Fdn, Div Educ, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hewson, MG (corresponding author), Cleveland Clin Fdn, Div Educ, 9500 Euclid Ave, Cleveland, OH 44195 USA.							Cassel, 1991, NATURE SUFFERING GOA; Damasio A.R., 2005, DESCARTES ERROR EMOT; Fadiman J. A., 1977, AFR STUD REV, V20, P87, DOI [10.2307/523864, DOI 10.2307/523864]; Frank J. D., 1973, PERSUASION HEALING C; Hewson MG, 1996, J GEN INTERN MED, V11, P481, DOI 10.1007/BF02599044; HEWSON MGA, 1985, ANTHROPOL EDUC QUART, V16, P31, DOI 10.1525/aeq.1985.16.1.05x0849q; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; Kuhn T.S., 1970, STRUCTURE SCI REVOLU, P174; Levenstein J, 1989, COMMUNICATING MED PA; Levin J S, 1997, JAMA, V278, P792, DOI 10.1001/jama.278.9.792; Lincoln Y, 1985, NATURALISTIC ENQUIRY; LIPKING M, 1995, MED INTERVIEW CLIN; MBITI JS, 1969, AFRICAN REL PHILOS; MCCALLUM TG, 1992, WHITE WOMAN WITCHDOC; NGUBANE H, 1992, SOCIAL BASIS HLTH HE; NOVACK DH, 1995, MED INTERVIEW CLIN C; OSLER W, 1910, BMJ-BRIT MED J, V2, P1470; RANTALA E, 1992, BASELINE STUDY HLTH; Sandelowski M, 1991, Image J Nurs Sch, V23, P161, DOI 10.1111/j.1547-5069.1991.tb00662.x; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001; Sharma H.M., 1996, FUNDAMENTALS COMPLEM; Smith RC, 1996, PATIENTS STORY INTEG; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125	23	55	57	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				1029	1034		10.7326/0003-4819-128-12_Part_1-199806150-00014	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00014			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625666				2022-12-28	WOS:000074201300010
J	Rosbash, M				Rosbash, M			Why the rat-1 fibroblast should replace the SCN as the in vitro model of choice	CELL			English	Review							PERIOD GENE-PRODUCT; VISUAL-SYSTEM; DROSOPHILA; EXPRESSION; RHYTHMS; CLOCK; DBP		Brandeis Univ, Dept Biol, Ctr Biol Timing, NSF,Howard Hughes Med Inst, Waltham, MA 02254 USA	Brandeis University; Howard Hughes Medical Institute; National Science Foundation (NSF); NSF - Center for Biological Timing	Rosbash, M (corresponding author), Brandeis Univ, Dept Biol, Ctr Biol Timing, NSF,Howard Hughes Med Inst, Waltham, MA 02254 USA.							Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; BESHARSE JC, 1983, NATURE, V305, P133, DOI 10.1038/305133a0; Campbell SS, 1998, SCIENCE, V279, P396, DOI 10.1126/science.279.5349.396; CZEISLER CA, 1995, NEW ENGL J MED, V332, P6, DOI 10.1056/NEJM199501053320102; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EWER J, 1992, J NEUROSCI, V12, P3321; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; Klein D.C., 1991, SUPRACHIASMATIC NUCL; LIU X, 1988, GENE DEV, V2, P228, DOI 10.1101/gad.2.2.228; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; ZERR DM, 1990, J NEUROSCI, V10, P2749	23	28	28	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					917	919		10.1016/S0092-8674(00)81197-6	http://dx.doi.org/10.1016/S0092-8674(00)81197-6			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635421	Bronze			2022-12-28	WOS:000074205700003
J	Moser, M				Moser, M			Why are physicians not prescribing diuretics more frequently in the management of hypertension?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; ANTIHYPERTENSIVE DRUG-THERAPY; LEFT-VENTRICULAR HYPERTROPHY; FACTOR INTERVENTION TRIAL; DIABETIC-PATIENTS; CARDIAC-ARREST; BETA-BLOCKERS; RISK; LIPOPROTEINS; LIPIDS	Diuretics have again been recommended by the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) as one of the first-choice medications in the management of hypertension. This recommendation is based on the results of numerous randomized, diuretic-based, long-term controlled clinical trials that have demonstrated a reduction in both cerebrovascular and cardiovascular morbidity. Despite this and other national recommendations, the use of diuretics has steadily decreased over the past 15 years. Reasons include heavy promotion of other medications and the perception that diuretics produce adverse metabolic effects and do not reduce coronary heart disease events. Data, however, indicate that (1) changes in glucose and cholesterol metabolism are minor, especially with the smaller doses now being used; (2) cardiovascular morbidity and mortality have been reduced in hypertensive patients, even in those with hyperlipidemia or diabetes, when diuretics are used; and (3) concerns about hypokalemia-induced arrhythmias have been overstated. While special indications exist for other medications in the treatment of hypertension, for example, use of an angiotensin-converting enzyme inhibitor (usually in addition to a diuretic) for a patient with heart failure or diabetic nephropathy, most patients, including those with hyperlipidemia or glucose intolerance, can be effectively treated with a diuretic as initial therapy or as part of a combination regimen, Diuretics should be used more not less frequently; use of diuretics would reduce the number of resistant hypertensive patients.	Yale Univ, Sch Med, New Haven, CT USA	Yale University	Moser, M (corresponding author), 13 Murray Hill Rd, Scarsdale, NY 10583 USA.							AMES RP, 1986, DRUGS, V32, P260, DOI 10.2165/00003495-198632030-00003; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; BLACK HR, 1993, HYPERTENSION, V21, P335; Borhani NO, 1996, JAMA-J AM MED ASSOC, V276, P785, DOI 10.1001/jama.276.10.785; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; EPSTEIN M, 1995, ARCH INTERN MED, V155, P2150, DOI 10.1001/archinte.155.20.2150; Gottdiener JS, 1997, CIRCULATION, V95, P2007, DOI 10.1161/01.CIR.95.8.2007; GREENBERG G, 1984, AM J MED, V76, P45, DOI 10.1016/0002-9343(84)90956-2; Grimm RH, 1997, ARCH INTERN MED, V157, P638, DOI 10.1001/archinte.157.6.638; GURWITZ JH, 1993, ANN INTERN MED, V118, P273, DOI 10.7326/0003-4819-118-4-199302150-00005; HEBERT PR, 1993, ARCH INTERN MED, V153, P578, DOI 10.1001/archinte.153.5.578; HOES AW, 1995, ANN INTERN MED, V123, P481, DOI 10.7326/0003-4819-123-7-199510010-00001; HOLLAND OB, 1981, AM J MED, V70, P762, DOI 10.1016/0002-9343(81)90530-1; HOLLIFIELD JW, 1981, ACTA MED SCAND, P67; HOUSTON MC, 1989, AM HEART J, V117, P911, DOI 10.1016/0002-8703(89)90631-5; *HYP DET FOLL UP P, 1988, JAMA-J AM MED ASSOC, V259, P2118; Kaplan NM, 1996, JAMA-J AM MED ASSOC, V275, P1577, DOI 10.1001/jama.275.20.1577; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; LANGFORD HG, 1986, PROG CARDIOVASC DIS, V29, P29, DOI 10.1016/0033-0620(86)90033-2; LASSER NL, 1984, AM J MED, V76, P52, DOI 10.1016/0002-9343(84)90957-4; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MANOLIO TA, 1995, ARCH INTERN MED, V155, P829, DOI 10.1001/archinte.155.8.829; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MCINNES GT, 1992, J HYPERTENS, V10, P317; MESSERLI FH, 1989, ARCH INTERN MED, V149, P1263, DOI 10.1001/archinte.149.6.1263; MIALL WE, 1983, BMJ-BRIT MED J, V287, P1249; MIDDEKE M, 1987, CLIN CARDIOL, V10, P94, DOI 10.1002/clc.4960100204; MOSER M, 1991, JAMA-J AM MED ASSOC, V265, P498, DOI 10.1001/jama.265.4.498; Moser M, 1996, J AM COLL CARDIOL, V27, P1214, DOI 10.1016/0735-1097(95)00606-0; MOSER M, 1993, CLEV CLIN J MED, V60, P27; MOSER M, 1984, AM HEART J, V107, P616, DOI 10.1016/0002-8703(84)90121-2; MOSER M, 1994, NEW ENGL J MED, V331, P1235; MOSER M, 1991, EUR HEART J, V12, P1034, DOI 10.1093/eurheartj/12.9.1034; MOSER M, 1989, AM HEART J, V118, P1362, DOI 10.1016/0002-8703(89)90059-8; MOSER M, 1992, EUR HEART J, V13, P72, DOI 10.1093/eurheartj/13.suppl_G.72; MOSER M, 1993, DIABETES CARE, V16, P542, DOI 10.2337/diacare.16.2.542; MOSER M, 1979, CHLORTHALIDONE 25 MG, P13; *MRFIT RES GROUP, 1990, JAMA-J AM MED ASSOC, V263, P1765; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; OGILVIE RI, 1993, CAN MED ASSOC J, V149, P575; PAPADEMETRIOU V, 1988, ARCH INTERN MED, V148, P1272, DOI 10.1001/archinte.148.6.1272; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; *ROYAL AUSTR COLL, 1991, HYP DIAGN TREATM MAI; Savage PJ, 1998, ARCH INTERN MED, V158, P741, DOI 10.1001/archinte.158.7.741; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SHAPIRO AP, 1961, NEW ENGL J MED, V265, P1028, DOI 10.1056/NEJM196111232652102; Siegel D, 1997, JAMA-J AM MED ASSOC, V278, P1745, DOI 10.1001/jama.278.21.1745; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; ZANCHETTI A, 1993, BMJ-BRIT MED J, V307, P1541, DOI 10.1136/bmj.307.6918.1541; ZUSMAN RM, 1986, HYPERTENSION, V8, P837, DOI 10.1161/01.HYP.8.10.837	55	74	75	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1813	1816		10.1001/jama.279.22.1813	http://dx.doi.org/10.1001/jama.279.22.1813			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR635	9628713				2022-12-28	WOS:000073998500034
J	Beecham, L				Beecham, L			NHS fraud buster named	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1754	1754						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614048				2022-12-28	WOS:000074129500082
J	Nightingale, SL				Nightingale, SL			Hypersensitivity to chlorhexidine-impregnated medical devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	10	11	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1684	1684		10.1001/jama.279.21.1684	http://dx.doi.org/10.1001/jama.279.21.1684			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624011				2022-12-28	WOS:000073878700005
J	Leeman, E				Leeman, E			Misuse of psychiatric epidemiology	LANCET			English	Editorial Material							NATIONAL-COMORBIDITY-SURVEY; UNITED-STATES; PREVALENCE; DISORDERS		Columbia Univ, Dept Psychiat, New York, NY 10032 USA	Columbia University	Leeman, E (corresponding author), Columbia Univ, Dept Psychiat, New York, NY 10032 USA.							BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; EATON WW, 1984, ARCH GEN PSYCHIAT, V41, P942; FREEDMAN DX, 1984, ARCH GEN PSYCHIAT, V41, P931; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; *PC MENT HLTH, 1978, REP PRES PRES COMM M, V1; Regier DA, 1998, ARCH GEN PSYCHIAT, V55, P109, DOI 10.1001/archpsyc.55.2.109; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; REGIER DA, 1984, ARCH GEN PSYCHIAT, V41, P934; ROBINS LN, 1982, PSYCHOL MED, V12, P855, DOI 10.1017/S0033291700049151; Spitzer RL, 1998, ARCH GEN PSYCHIAT, V55, P120, DOI 10.1001/archpsyc.55.2.120	10	5	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	1998	351	9116					1601	1602		10.1016/S0140-6736(05)77684-4	http://dx.doi.org/10.1016/S0140-6736(05)77684-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZR900	9620712				2022-12-28	WOS:000074026600005
J	Wolffers, I; Adjei, S; van der Drift, R				Wolffers, I; Adjei, S; van der Drift, R			Health research in the tropics	LANCET			English	Editorial Material							NAVRONGO		Vrije Univ Amsterdam, HVS, Fac Med, NL-1081 BT Amsterdam, Netherlands; Minist Hlth, Hlth Res Unit, Accra, Ghana; INP, Bissau, Guinea Bissau	Vrije Universiteit Amsterdam	Wolffers, I (corresponding author), Vrije Univ Amsterdam, HVS, Fac Med, Van de Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.							BINKA FN, 1995, STUD FAMILY PLANN, V26, P121, DOI 10.2307/2137832; BUNDERS JFG, 1997, EUR C RES PARTN SUST; *CENTR SERV KUL, 1995, DIR ORG NAOG MOZ; Chabot J., 1995, AFRICAN PRIMARY HLTH; Cook GC, 1996, BRIT MED J, V312, P1160; Cook GC, 1997, LANCET, V350, P813, DOI 10.1016/S0140-6736(05)62607-4; Cook GC, 1997, T ROY SOC TROP MED H, V91, P372, DOI 10.1016/S0035-9203(97)90244-3; Davis P, 1996, SOC SCI MED, V43, P865, DOI 10.1016/0277-9536(96)00130-X; GAILLARD J, 1995, INT C DON SUPP DEV O; *HLTH RES UN, 1997, WORKSH STRENGTH RES; *HLTH RES UN, 1997, POL GUID STRENGTH RE; *I FORM RECH APPL, 1996, ET REL SECT PRIV; *MIN HLTH, 1992, HLTH RES DEV GHAN FR; Nazzar A, 1995, STUD FAMILY PLANN, V26, P307, DOI 10.2307/2138097; *REP GHAN, 1995, MED TERM HLTH STRAT; ROSE K, 1995, FAMILY REPROD HLTH P; *SNV BEN, 1994, UN MOND MOUV UN VUE; The Commission on Health Research for Development, 1990, HLTH RES ESS LINK EQ; *WHO, 1997, 1 M GLOB FOR HLTH RE; WOLFFERS I, 1997, RES PROGRAMMES D AUG, P8; WOLFFERS I, 1996, METHODOLOGY SOME CHA, P1; 1996, LANCET, V347, P629; 1997, LANCET, V349, P1	23	43	43	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1652	1654		10.1016/S0140-6736(97)10237-9	http://dx.doi.org/10.1016/S0140-6736(97)10237-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620734				2022-12-28	WOS:000074026600038
J	Finzi, D; Siliciano, RF				Finzi, D; Siliciano, RF			Viral dynamics in HIV-1 infection	CELL			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; IN-VIVO; T-CELLS; PERIPHERAL-BLOOD; DENDRITIC CELLS; LYMPHOID-TISSUE; CD4 LYMPHOCYTES; TYPE-1; LATENCY; PLASMA		Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University	Finzi, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI028108, R01AI028108] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28108] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; GARCIABLANCO MA, 1991, SCIENCE, V254, P815, DOI 10.1126/science.1658933; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; Hellerstein MK, 1997, IMMUNITY, V7, P583, DOI 10.1016/S1074-7613(00)80379-9; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; NICHOLSON JKA, 1986, J IMMUNOL, V137, P323; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Perelson AS, 1997, AIDS, V11, pS17; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; POMERANTZ RJ, 1992, J VIROL, V66, P1809, DOI 10.1128/JVI.66.3.1809-1813.1992; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; RABIN RL, 1995, J CLIN INVEST, V95, P2054, DOI 10.1172/JCI117891; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SESHAMMA T, 1992, P NATL ACAD SCI USA, V89, P10663, DOI 10.1073/pnas.89.22.10663; SPINA CA, 1995, J VIROL, V69, P2977, DOI 10.1128/JVI.69.5.2977-2988.1995; SU L, 1995, IMMUNITY, V2, P25, DOI 10.1016/1074-7613(95)90076-4; van Furth R, 1989, Curr Top Pathol, V79, P125; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; ZACK JA, 1988, SCIENCE, V240, P1026, DOI 10.1126/science.2835813; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	54	171	172	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1998	93	5					665	671		10.1016/S0092-8674(00)81427-0	http://dx.doi.org/10.1016/S0092-8674(00)81427-0			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630210	hybrid			2022-12-28	WOS:000073956700002
J	Downs, JR; Clearfield, M; Weis, S; Whitney, E; Shapiro, DR; Beere, PA; Langendorfer, A; Stein, EA; Kruyer, W; Gotto, AM				Downs, JR; Clearfield, M; Weis, S; Whitney, E; Shapiro, DR; Beere, PA; Langendorfer, A; Stein, EA; Kruyer, W; Gotto, AM		AFCAPS TexCAPS Res Grp	Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-DISEASE; SERUM-CHOLESTEROL; CARDIOVASCULAR-DISEASE; BLOOD-INSTITUTE; NATIONAL-HEART; HYPERCHOLESTEROLEMIA; PRAVASTATIN; POPULATION; PROGRAM; PLASMA	Context.-Although cholesterol-reducing treatment has been shown to reduce fatal and nonfatal coronary disease in patients with coronary heart disease (CHD), it is unknown whether benefit from the reduction of low-density lipoprotein cholesterol (LDL-C) in patients without CHD extends to individuals with average serum cholesterol levels, women, and older persons. Objective.-To compare lovastatin with placebo for prevention of the first acute major coronary event in men and women without clinically evident atherosclerotic cardiovascular disease with average total cholesterol (TC) and LDL-C levels and below-average high-density lipoprotein cholesterol (HDL-C) levels. Design.-A randomized, double-blind, placebo-controlled trial. Setting.-Outpatient clinics in Texas. Participants.-A total of 5608 men and 997 women with average TC and LDL-C and below-average HDL-C las characterized by lipid percentiles for an age-and sex-matched cohort without cardiovascular disease from the National Health and Nutrition Examination Survey [NHANES] III). Mean (SD) TC level was 5.71 (0.54) mmol/L (221 [21] mg/dL) (51st percentile), mean (SD) LDL-C level was 3.89 (0.43) mmol/L (150 [17] mg/dL) (60th percentile), mean (SD) HDL-C level was 0.94 (0.14) mmol/L (36 [5] mg/dL) for men and 1.03 (0.14) mmol/L (40 [5] mg/dL) for women (25th and 16th percentiles, respectively), and median (SD) triglyceride levels were 1.78 (0.86) mmol/L (158 [76] mg/dL) (63rd percentile). Intervention.-Lovastatin (20-40 mg daily) or placebo in addition to a low-saturated fat, low-cholesterol diet. Main Outcome Measures.-First acute major coronary event defined as fatal or nonfatal myocardial infarction, unstable angina, or sudden cardiac death. Results.-After an average follow-up of 5.2 years, lovastatin reduced the incidence of first acute major coronary events (183 vs 116 first events; relative risk [RR], 0.63; 95% confidence interval [CI], 0.50-0.79; P<.001), myocardial infarction (95 vs 57 myocardial infarctions; RR, 0.60; 95% CI, 0.43-0.83; P=.002), unstable angina (87 vs 60 first unstable angina events; RR, 0.68; 95% CI, 0.49-0.95; P=.02), coronary revascularization procedures (157 vs 106 procedures; RR, 0.67; 95% CI, 0.52-0.85; P=.001), coronary events (215 vs 163 coronary events; RR, 0.75; 95% CI, 0.61-0.92; P=.006), and cardiovascular events (255 vs 194 cardiovascular events; RR, 0.75; 95% CI, 0.62-0.91; P=.003). Lovastatin (20-40 mg daily) reduced LDL-C by 25% to 2.96 mmol/L (115 mg/dL) and increased HDL-C by 6% to 1.02 mmol/L (39 mg/dL). There were no clinically relevant differences in safety parameters between treatment groups. Conclusions.-Lovastatin reduces the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL-C levels. These findings support the inclusion of HDL-C in risk-factor assess ment, confirm the benefit of LDL-C reduction to a target goal, and suggest the need for reassessment of the National Cholesterol Education Program guidelines regarding pharmacological intervention.	Cornell Univ Med Coll, New York, NY 10021 USA; Wilford Hall USAF Med Ctr, Lackland AFB, San Antonio, TX 78236 USA; Univ N Texas, Hlth Sci Ctr, Ft Worth, TX USA; Heart & Vasc Inst Texas, San Antonio, TX USA; Merck & Co Inc, West Point, PA USA; Metab & Atherosclerosis Res Ctr, Cincinnati, OH USA; Brooks AFB, San Antonio, TX USA	Cornell University; United States Department of Defense; United States Air Force; University of North Texas System; University of North Texas Health Science Center; Merck & Company	Gotto, AM (corresponding author), Cornell Univ Med Coll, 1300 York Ave,Room F105, New York, NY 10021 USA.	dean@mail.med.cornell.edu						BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; CASTELLI WP, 1988, AM J OBSTET GYNECOL, V158, P1553, DOI 10.1016/0002-9378(88)90189-5; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; CLEARFIELD M, UNPUB FORCE TEXAS CO; Downs JR, 1997, AM J CARDIOL, V80, P287, DOI 10.1016/S0002-9149(97)00347-0; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; KANNEL WB, 1995, AM J CARDIOL, V76, pC69, DOI 10.1016/S0002-9149(99)80474-3; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; National Center for Health Statistics, 1996, 3 NAT HLTH NUTR EX S; PEDERSEN TR, 1994, LANCET, V344, P1383; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; WHITNEY EJ, 1992, AM J CARDIOL, V70, P738, DOI 10.1016/0002-9149(92)90551-9	20	4049	4217	0	231	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1998	279	20					1615	1622		10.1001/jama.279.20.1615	http://dx.doi.org/10.1001/jama.279.20.1615			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP489	9613910	Bronze			2022-12-28	WOS:000073758600030
J	Barnes, DE; Bero, LA				Barnes, DE; Bero, LA			Why review articles on the health effects of passive smoking reach different conclusions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ENVIRONMENTAL TOBACCO-SMOKE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; WILLIAMSON DOCUMENTS; HEART-DISEASE; TRIALS; QUALITY; PREGNANCY; ARTHRITIS; CHILDHOOD; EXPOSURE	Objective.-To determine whether the conclusions of review articles on the health effects of passive smoking are associated with article quality, the affiliations of their authors, or other article characteristics. Data Sources.-Review articles published from 1980 to 1995 were identified through electronic searches of MEDLINE and EMBASE and from a database of symposium proceedings on passive smoking. Article Selection.-An article was included if its stated or implied purpose was to review the scientific evidence that passive smoking is associated with 1 or more health outcomes. Articles were excluded if they did not focus specifically on the health effects of passive smoking or if they were not written in English. Data Extraction.-Review article quality was evaluated by 2 independent assessors who were trained, followed a written protocol, had no disclosed conflicts of interest, and were blinded to all study hypotheses and identifying characteristics of articles. Article conclusions were categorized by the 2 assessors and by one of the authors. Author affiliation was classified as either tobacco industry affiliated or not, based on whether the authors were known to have received funding from or participated in activities sponsored by the tobacco industry. Other article characteristics were classified by one of the authors using predefined criteria. Data Synthesis.-A total of 106 reviews were identified. Overall, 37% (39/106) of reviews concluded that passive smoking is not harmful to health; 74% (29/39) of these were written by authors with tobacco industry affiliations. In multiple logistic regression analyses controlling for article quality, peer review status, article topic, and year of publication, the only factor associated with concluding that passive smoking is not harmful was whether an author was affiliated with the tobacco industry (odds ratio, 88.4; 95% confidence interval, 16.4-476.5; P<.001). Conclusions.-The conclusions of review articles are strongly associated with the affiliations of their authors, Authors of review articles should disclose potential financial conflicts of interest, and readers of review articles should consider authors' affiliations when deciding how to judge an article's conclusions.	Univ Calif San Francisco, Sch Med, Inst Hlth Policy Studies, San Francisco, CA 94109 USA; Univ Calif San Francisco, Sch Publ Hlth, Dept Publ Hlth Biol & epidemiol, San Francisco, CA 94109 USA; Univ Calif San Francisco, Sch Pharm, Dept Clin Pharm, San Francisco, CA 94109 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bero, LA (corresponding author), Univ Calif San Francisco, Sch Med, Inst Hlth Policy Studies, 1388 Sutter St,11th Floor, San Francisco, CA 94109 USA.	bero@cardio.ucsf.edu						ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; ARMITAGE AK, 1993, J SMOKING RELATED DI, V4, P27; ASSENDELFT WJJ, 1995, JAMA-J AM MED ASSOC, V274, P1942, DOI 10.1001/jama.274.24.1942; Barnes D E, 1997, Tob Control, V6, P19; Barnes DE, 1996, J HEALTH POLIT POLIC, V21, P515, DOI 10.1215/03616878-21-3-515; BARNES DE, 1995, JAMA-J AM MED ASSOC, V274, P248, DOI 10.1001/jama.274.3.248; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P241, DOI 10.1001/jama.274.3.241; BERO LA, 1994, JAMA-J AM MED ASSOC, V271, P612, DOI 10.1001/jama.271.8.612; BERO LA, 1993, TOB CONTROL, V2, P103; BLAKLEY BW, 1995, OTOLARYNG HEAD NECK, V112, P441; BLAND JM, 1995, INT J EPIDEMIOL, V24, pS7, DOI 10.1093/ije/24.Supplement_1.S7; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; Cho MK, 1996, ANN INTERN MED, V124, P485, DOI 10.7326/0003-4819-124-5-199603010-00004; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; CRAWFORD WA, 1988, ARCH ENVIRON HEALTH, V43, P34, DOI 10.1080/00039896.1988.9934371; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; DIFRANZA JR, 1995, J FAM PRACTICE, V40, P385; DURBIN R, 1993, TOB CONTROL, V2, P8; Glantz S.A., 1996, CIGARETTE PAPERS; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; Hackshaw AK, 1997, BMJ-BRIT MED J, V315, P980, DOI 10.1136/bmj.315.7114.980; HAYNES RB, 1992, BRIT MED J, V304, P330, DOI 10.1136/bmj.304.6823.330; Law MR, 1997, BMJ-BRIT MED J, V315, P973, DOI 10.1136/bmj.315.7114.973; Light R.J., 1984, SUMMING SCI REV RES; MULROW C, 1996, CONDUCT COCHRANE SYS; MULROW CD, 1994, BRIT MED J, V309, P597, DOI 10.1136/bmj.309.6954.597; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; *NAT AC SCI, 1986, ENV TOB SMOK MEAS EX; [Office of Research and Development Office of Health Environmental Assessment United States Environmental Protection Agency], 1992, RESP HLTH EFF PASS S; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P91, DOI 10.1016/0895-4356(91)90205-N; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; ROCHON PA, 1994, JAMA-J AM MED ASSOC, V272, P108, DOI 10.1001/jama.272.2.108; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; RUBIN DH, 1988, YALE J BIOL MED, V61, P401; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SARACEI R, 1986, TOBACCO MAJOR INT HL, P173; SHIMIZU Y, 1990, INDOOR AIR QUALITY, P323; SILAGY CA, 1993, FAM PRACT, V10, P337, DOI 10.1093/fampra/10.3.337; SWAEN GMH, 1988, BRIT J IND MED, V45, P624; TAGER IB, 1989, NEW YORK STATE J MED, V89, P27; TONG S, 1992, DEV MED CHILD NEUROL, V34, P191; TREDANIEL J, 1994, PAEDIATR PERINAT EP, V8, P233, DOI 10.1111/j.1365-3016.1994.tb00455.x; TREDANIEL J, 1994, EUR RESPIR J, V7, P173, DOI 10.1183/09031936.94.07010173; *US DEPT HHS, 1986, HLTH CONS INV SMOK R; WELLS AJ, 1994, J AM COLL CARDIOL, V24, P546, DOI 10.1016/0735-1097(94)90315-8; [No title captured]	48	321	330	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1566	1570		10.1001/jama.279.19.1566	http://dx.doi.org/10.1001/jama.279.19.1566			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN087	9605902				2022-12-28	WOS:000073608100036
J	Booy, R				Booy, R			Getting Hib vaccine to those who need it	LANCET			English	Editorial Material									St Marys Hosp, Dept Paediat, London W2 1NY, England; Inst Child Hlth, Dept Epidemiol & Publ Hlth, London, England	Imperial College London; University of London; University College London	Booy, R (corresponding author), St Marys Hosp, Dept Paediat, Praed St, London W2 1NY, England.		Booy, Robert/D-4188-2011					*GLOB PROGR VACC I, 1998, WKLY EPIDEMIOL REC, V73, P64; Hausdorff WP, 1996, VACCINE, V14, P1179, DOI 10.1016/S0264-410X(96)00024-2; KANE M, 1995, B WORLD HEALTH ORGAN, V73, P529; RUFF TA, 1993, PROGR LIVER DIS, P179; TUDORWILLIAMS G, 1989, ARCH DIS CHILD, V64, P520, DOI 10.1136/adc.64.4.520; WENGER JD, 1997, NEW GENERATION VACCI, P489	6	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1446	1447		10.1016/S0140-6736(98)22020-4	http://dx.doi.org/10.1016/S0140-6736(98)22020-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605796				2022-12-28	WOS:000073707300002
J	Khokhlatchev, AV; Canagarajah, B; Wilsbacher, J; Robinson, M; Atkinson, M; Goldsmith, E; Cobb, MH				Khokhlatchev, AV; Canagarajah, B; Wilsbacher, J; Robinson, M; Atkinson, M; Goldsmith, E; Cobb, MH			Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation	CELL			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; C-JUN; CRYSTAL-STRUCTURE; PC12 CELLS; MITOGEN; TRANSCRIPTION; RECEPTOR; SIGNAL; JNK	The MAP kinase ERK2 is widely involved in eukaryotic signal transduction. Upon activation it translocates to the nucleus of the stimulated cell, where it phosphorylates nuclear targets. We find that nuclear accumulation of microinjected ERK2 depends on its phosphorylation state rather than on its activity or on upstream components of its signaling pathway. Phosphorylated ERK2 forms dimers with phosphorylated and unphosphorylated ERK2 partners. Disruption of dimerization by mutagenesis of ERK2 reduces its ability to accumulate in the nucleus, suggesting that dimerization is essential for its normal ligand-dependent relocalization. The crystal structure of phosphorylated ERK2 reveals the basis for dimerization. Other MAP kinase family members also form dimers. The generality of this behavior suggests that dimerization is part of the mechanism of action of the MAP kinase family.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, Tyler, TX 75710 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.			Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK34128, DK46993] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046993, R01DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CASSEL D, 1982, P NATL ACAD SCI-BIOL, V79, P2231, DOI 10.1073/pnas.79.7.2231; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; CHIYING FH, 1996, P NATL ACAD SCI USA, V93, P10078; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DURSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4185; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Moriguchi T, 1996, Adv Pharmacol, V36, P121, DOI 10.1016/S1054-3589(08)60579-7; NGAI PK, 1991, BIOCHEM J, V280, P805, DOI 10.1042/bj2800805; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; SETH A, 1992, J BIOL CHEM, V267, P24796; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	64	565	603	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					605	615		10.1016/S0092-8674(00)81189-7	http://dx.doi.org/10.1016/S0092-8674(00)81189-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604935	Bronze			2022-12-28	WOS:000073722200013
